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Preface 
Myeloid leukemias have been studied for decades, and considerable progress has been 
made in the elucidation of critical pathogenetic factors including transcription factor
networks and signaling pathways and in the diagnosis and treatment of these
leukemias. However, while the prognosis of a fraction of patients (particularly those
with chronic myeloid leukemia in chronic phase) has improved dramatically with the 
advent of novel rationally designed therapies, the prognosis of many other patients 
(i.e. with most subtypes of acute myeloid leukemia) has not improved to the same
degree and have been compounded by the fact that  molecular targeted therapies are
expensive and are not readily available in all parts of the world. 
The intention of this book is to provide a global scope on these issues. Following an 
open call, authors were invited to propose topics and send in an abstract of the chapter 
they wanted to contribute. After selection of appropriate abstracts, full chapters were 
provided and reviewed. Revised chapters were again reviewed and final chapters 
selected for publication.
The topics of the present book focus on basic mechanisms of leukemogenesis and 
cover the following:
 Chromosomal instability and DNA repair in CML and AML
 Novel BCR-ABL1 fusions
 Mechanisms of resistance to tyrosine kinase inhibitors and strategies how to 
overcome these 
 Novel targets at the cellular and molecular level, including CML stem cells,
proteasome inhibitors, and activators of phosphatases 
 Genetic Alterations and new molecular markers in AML, including Acute
Promyelocytic Leukemia 
 The role of the bone marrow microenvironment and TGFß in the pathogenesis of
AML
 Hematopoietic transcription factors and tumor suppressors, including the Id
proteins, PU.1, Vav1, and p15INK4b 
 Apoptosis and Apoptosis Modulators in Myeloid Leukemia
 Functional Analysis of Leukemogenic Gene Products in Hematopoietic Progenitor
Cells
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 Role of Signaling Pathways in Myeloid Leukemia, including BCR-ABL1 and 
mutant JAK2 
 Epigenetic Changes Associated with Chromosomal Translocation in Leukemia 
 Etiology and Risk factors of AML in Africa 
Each chapter is a sole-standing publication that reflects each author´s interpretation of 
the data. However, the unifying theme is myeloid leukemia.  Thus, the book displays a 
multi-facetted picture of our current understanding of myeloid leukemia 
pathogenesis. In addition, the open access structure of the book will guarantee wide-
spread access even in cases where resources required for subscription to more 
expensive scientific journals or books are limited. We encourage the readers to send 
their comments.  This is an exciting new way of discussing science and to support the 
effort of increasing the alertness and education of patients and physicians all around 
the globe.  
 
Prof. Dr. Steffen Koschmieder 
Department of Medicine (Oncology, Hematology,  
and Stem Cell Transplantation) at the University of Aachen, 
 Germany 
Dr. Utz Krug 
Department of Medicine (Hematology, Oncology, Hemostaseology,  
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BCR-ABL Hits at Mitosis; Implications for 
Chromosomal Instability, Aneuploidy  
and Therapeutic Strategy 
Katarzyna Piwocka, Kamila Wolanin,  
Monika Kusio-Kobialka and Paulina Podszywalow-Bartnicka  
Nencki Institute of Experimental Biology, Polish Academy of Sciences 
Poland 
1. Introduction 
1.1 Genomic and chromosomal instability in CML 
An unstable genome is a common hallmark of nearly all solid tumors and most of leukemias 
in contrast to normal, healthy cells which are able to maintein genome integrity (Negrini et 
al., 2010). Genomic instability could result from changes in chromosome structure and 
number as well as changes on the DNA level. Chromosomal instability (CIN) arises from 
unproper chromosome segregation as well as division defects and leads to aneuploidy 
(Foijer, 2010), whereas accumulation of mutations and DNA alterations usually is an effect 
of the defective repair systems and DNA damage response in cancer cells (Economopoulou 
et al., 2011).  
Chronic myeloid leukemia (CML) cells expressing the BCR-ABL tyrosine kinase have been 
found to accumulate mutations as well as chromosomal abnormalities. One of the first 
indications that CML correlates with additional chromosome changes has been presented in 
1987 (Alimena et al., 1987). Moreover, authors showed that the rate of chromosomal 
anomalies increased during the blastic transformation. In the next years this has been also 
confirmed by other authors (Hagemeijer, 1987; Johansson et al., 2002; Su et al., 1999; 
Suzukawa et al., 1997). Later, random aneuploidy rate between chromosomes 9 and 18 has 
been reported in CML patients – both, untreated as well as upon imatinib therapy (Amiel et 
al., 2006). In broader analysis of CML patients it was found that chromosomal instability 
caused by centrosomal aberrations significantly correlated with the disease progression 
(Giehl et al., 2005). In the chronic phase only one sample out of 18 showed additional 
karyotypic alterations, in contrast to blast crisis where 73% patients (11/16) displayed 
additional karyotype alterations. The observation that CML patients have karyotype 
aberrations was confirmed in other studies where complex chromosomal rearrangements 
(CCR) were investigated (Babicka et al., 2006). By using cytogenetics, the FISH, and 
multicolor FISH (mFISH) methods, a very high level of the genomic instability at the 
chromosomal level, in cells obtained from chronic myeloid leukemia patients was observed.  
Altogether, it was shown that the aberrations associated with the progression of BCR-ABL-
positive CML chronic phase to the aggressive blast crisis include additional chromosomes 
(Ph1, +8, +19), isochromosome 17q (associated with the loss of p53), reciprocal 
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translocations, loss-of-heterozygosity at 14q32, homozygous mutations/deletions of pRb 
and p16/ARF, and mutations in p53 and RAS (Calabretta & Perrotti, 2004). The possible 
mechanisms participating in the BCR-ABL-mediated aneuploidy will be broadly described 
and discussed in the next paragraphs. 
BCR-ABL has been also indicated as a promoter of secondary DNA mutations in CML 
(Burke & Carroll, 2010). This is the effect of the defective DNA damage response and DNA 
repair mechanisms found in CML cells. DNA damage can occur as single-nucleotide 
alterations, single-strand breaks (SSB), or double-strand breaks (DSB). Double-strand breaks 
are proposed to be the most mutagenic, as neither strand remains intact to serve as a 
template for repair. Single-nucleotide alterations are repaired by mismatch repair (MMR) or 
nucleotide excision repair (NER) mechanisms. Single or double-strand breaks are repaired 
by either high-fidelity homologous recombination repair (HRR) or non-homologous end-
joining (NHEJ), when a sister chromatid is not available as a template. The last mechanism is 
error-prone and can lead to short deletions in the repaired strands.  
Data from different laboratories collectively indicate that BCR-ABL promotes dysfunctions 
of nearly all mechanisms participating in the DNA repair. It is known that BCR-ABL cells 
treated with genotoxic agents present higher levels of DNA damage and aberrant repair 
systems, leading to the accumulation of DNA errors (Brady, 2003; Laurent et al., 2003; 
Slupianek et al., 2002). Studies from Skorski’s group clearly showed that expression of BCR-
ABL affects different mechanisms participating in the DNA repair. They found that BCR-
ABL modifies the repair of DNA double-strand breaks (Koptyra et al., 2008; Nowicki et al., 
2004; Slupianek et al., 2006). Briefly, CML cells produced increased rate of DSBs in S and 
G2/M phases of the cell cycle, as a result of oxidative DNA damage caused by BCR-ABL. 
These breaks were repaired, however with a high mutation rate and large deletions, as a 
result of defective HRR and NHEJ repair systems, respectively. Moreover, they found that 
BCR-ABL is able to inhibit both, mismatch repair (MMR) and inhibit apoptosis as well as to 
induce point mutations (Stoklosa et al., 2008). Upon this, CML cells were able to survive 
treatment leading to generation of the O(6)-methylguanine and O(4)-methylthymine 
recognized by the MMR system, however they displayed 15-fold higher mutation frequency 
than parental counterparts.  
Deutsch et al indicated that DNA-PKcs, a protein involved in the NHEJ repair system, may 
be downregulated by BCR-ABL (Deutsch et al., 2001). This decrease was proteasome- and 
tyrosine kinase-dependent, as it was reversed by proteasome as well as tyrosime kinase 
inhibitors. Alternatively, the role of DNA-PKcs has been recently indicated to switch on the 
backup-NHEJ system, which is more error-prone (Poplawski & Blasiak, 2010). It was also 
shown that BCR-ABL upregulates the error-prone DSB repair pathways, particularly single-
strand annealing and non-homologous end-joining due to an increased level of DNA-end-
processing factor CtIP (Salles et al., 2011). Additionally, BCR-ABL also promotes the DNA 
DSB repair by using the highly mutagenic single-strand annealing (SSA) pathway which 
involves single repeats (Fernandes et al., 2009). This required the active Ras and PI3K 
pathways, acting downstream of the Y177 site of BCR-ABL, which is a major regulatory site 
for ROS induction and is necessary for the optimal activation of the PI3K and Ras pathways. 
Moreover, using stromal cell lines authors also showed that the stromal cell-conditioned 
media increased the SSA frequency, measured in K562 cells in the presence or absence of 
imatinib. This supported the hypothesis that microenvironment additionaly promotes 
mutagenesis in CML cells. 
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Altogether, there is no doubt, that defects in DNA repair mechanisms and genomic 
surveillance in CML cells are an effect of the expression of BCR-ABL itself. However, there 
was still an open question, whether occurrence of the genomic instability participates in the 
development of the blast crisis phase (Penserga & Skorski, 2007; Shet et al., 2002). This has 
been strongly indicated to play a significant role in the malignant progression of the disease 
by many authors (Burke & Carroll, 2010; Salleset al., 2011; Skorski, 2008; Skorski, 2011).  
Till now, convincing data was presented and it seems clear, that genetic instability, 
accumulation of mutations and additional chromosomal alterations are the major factors 
involved in the CML progression and resistance to cell death. This leads to an accumulation 
of additional genetic aberrations and changes in gene expression, which result in the 
expansion of differentiation-arrested and increasingly malignant cell clones. Importantly, 
genetic instability of tyrosine kinase refractory cells, including leukemia stem cells (LSCs) 
has also recently been proposed as a reason for their fast transformation leading to the 
generation of additional resistant clones and transformation to a blast phase (Skorski, 2011). 
This mechanism could be responsible for clonal evolution and expansion causing finally 
relapse and malignant progression.  
The current model of blastic transformation proposed recently by Perotti (Perrotti et al., 
2010), indicates that acquiring of additional genetic and epigenetic changes by LSCs or their 
progeny causes leukemia transformation from the chronic phase to the advanced phases. 
This can explain the complexity of the disease progression and blast crisis as well as the 
inability to find common features of cells in blast crisis and specific secondary genetic 
aberrations. Most likely different mutations and aberrations are cumulated to obtain the 
critical point allowing the disease to progress. Thus, it will be very difficult to plan the 
therapeutic strategy against genetically unstable LSCs, resistant to tyrosine kinase inhibitors, 
with the already used agents and probably novel therapies need to be developed. 
2. The role of aberrant divisions in CML cells 
It has been known for more than a century that neoplastic cells could exhibit disturbances of 
the cell division process (Boveri, 1902, 1914). Boveri observed that sea urchin embryos 
manipulated to undergo mitosis in the presence of multipolar spindles produced aneuploid 
progeny and proposed that tumors arise from normal cells becoming aneuploid as a result 
of aberrant mitoses. Boveri’s theory that division errors and aneuploidy could lead to cancer 
development has been revisited during the last decade (Duesberg et al., 2006; Holland & 
Cleveland, 2009; Weaver & Cleveland, 2006).  
Today, it is commonly accepted that aberrant mitoses result in chromosomal instability 
(CIN), leading to the gain or loss of whole or large fragments of chromosomes, which are the 
main form of genomic instability in cancers. As it was mentioned in the previous chapter, it 
is fully convincing that expression of BCR-ABL leads to significant chromosomal 
aberrations. Moreover, these abnormalities increase along with the disease progression, 
participating in the blastic transformation. Below, we present current data concerning the 
role of BCR-ABL-mediated defects in the mechanisms controlling cell division as well as the 
role of BRCA1 in the development of aneuploidy in CML. 
2.1 Centrosomal multiplication 
Centrosomes are small organelles with a crucial role in the formation of bipolar mitotic 
spindle, which is necessary for the accurate segregation of chromosomes (Fukasawa, 2007; 
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translocations, loss-of-heterozygosity at 14q32, homozygous mutations/deletions of pRb 
and p16/ARF, and mutations in p53 and RAS (Calabretta & Perrotti, 2004). The possible 
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by either high-fidelity homologous recombination repair (HRR) or non-homologous end-
joining (NHEJ), when a sister chromatid is not available as a template. The last mechanism is 
error-prone and can lead to short deletions in the repaired strands.  
Data from different laboratories collectively indicate that BCR-ABL promotes dysfunctions 
of nearly all mechanisms participating in the DNA repair. It is known that BCR-ABL cells 
treated with genotoxic agents present higher levels of DNA damage and aberrant repair 
systems, leading to the accumulation of DNA errors (Brady, 2003; Laurent et al., 2003; 
Slupianek et al., 2002). Studies from Skorski’s group clearly showed that expression of BCR-
ABL affects different mechanisms participating in the DNA repair. They found that BCR-
ABL modifies the repair of DNA double-strand breaks (Koptyra et al., 2008; Nowicki et al., 
2004; Slupianek et al., 2006). Briefly, CML cells produced increased rate of DSBs in S and 
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treatment leading to generation of the O(6)-methylguanine and O(4)-methylthymine 
recognized by the MMR system, however they displayed 15-fold higher mutation frequency 
than parental counterparts.  
Deutsch et al indicated that DNA-PKcs, a protein involved in the NHEJ repair system, may 
be downregulated by BCR-ABL (Deutsch et al., 2001). This decrease was proteasome- and 
tyrosine kinase-dependent, as it was reversed by proteasome as well as tyrosime kinase 
inhibitors. Alternatively, the role of DNA-PKcs has been recently indicated to switch on the 
backup-NHEJ system, which is more error-prone (Poplawski & Blasiak, 2010). It was also 
shown that BCR-ABL upregulates the error-prone DSB repair pathways, particularly single-
strand annealing and non-homologous end-joining due to an increased level of DNA-end-
processing factor CtIP (Salles et al., 2011). Additionally, BCR-ABL also promotes the DNA 
DSB repair by using the highly mutagenic single-strand annealing (SSA) pathway which 
involves single repeats (Fernandes et al., 2009). This required the active Ras and PI3K 
pathways, acting downstream of the Y177 site of BCR-ABL, which is a major regulatory site 
for ROS induction and is necessary for the optimal activation of the PI3K and Ras pathways. 
Moreover, using stromal cell lines authors also showed that the stromal cell-conditioned 
media increased the SSA frequency, measured in K562 cells in the presence or absence of 
imatinib. This supported the hypothesis that microenvironment additionaly promotes 
mutagenesis in CML cells. 
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(CIN), leading to the gain or loss of whole or large fragments of chromosomes, which are the 
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is fully convincing that expression of BCR-ABL leads to significant chromosomal 
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Rusan & Rogers, 2009; Tanenbaum & Medema, 2010). Briefly, they are formed by paired 
centrioles surrounded by a protein matrix of pericentriolar material, including pericentrin. 
Their function is to nucleate and anchor microtubules to form an interphase cytoplasmic-
microtubule network and mitotic spindle. During the cell division, each daughter cell 
receives one centrosome, thus the centrosome has to duplicate before the next mitosis. This 
takes place during the S phase and is driven at least partially by the Cdk2-cyclin E complex. 
Coordination of the DNA and centrosome replication is crucial to avoid their 
overduplication. Two mature centrosomes are generated at the late G2 phase and they 
become the spindle poles. It was shown that the DNA damage checkpoint proteins, such as 
ATM, ATR, Chk1 and Chk2 and others also localize at the centrosomes (Zhang et al., 2007). 
It seems that these proteins interact with gamma-tubulin and are involved in the controlling 
of microtubule kinetics during the DNA damage response. It was reported that DNA 
damage leads to centrosome amplification in the G2 phase as a result of cell cycle arrest 
(Inanc et al., 2010). Studies performed by Dodson and colleagues showed the involvement of 
ATM in the centrosome amplification in response to DNA damage, however gene targeting 
of ATM reduced, but did not abrogate completely centrosome amplification (Dodson et al., 
2004). Alternatively, data from lymphoid gamma-irradiated cells showed that neither ATM 
nor ATR kinases are involved in this process, however Chk1-dependent signaling seems to 
be crucial  (Bourke et al., 2007). This issue still needs to be clarified. 
It is commonly accepted that the appearance of supernumerary centrosomes is associated 
with aberrant mitoses and chromosomal instability. Multipolar mitoses, lagging 
chromosomes or multinuclei are observed in cells with overduplicated centrosomes. Cells 
with three centrosomes usually undergo cytokinesis and some of the generated cells are 
viable, however aneuploid. Cells with multipolar (>3) spindles fail to undergo cytokinesis 
and can become polyploid if they are p53-deficient and are able to continue the cell cycle 
(Godinho et al., 2009).  
Centrosome abnormalities are commonly observed in cancers and participate in the 
chromosomal instability and tumorigenesis (Carroll et al., 1999; Duensing & Duensing, 2010; 
Pihan et al., 2001). As mentioned before, mutlipolar mitosis as a result of centrosome 
overduplication can lead to gross chromosome missegregation and cell death. Thus cancer 
cells with supernumerary centrosomes possess the ability to suppress multipolar mitoses 
due to the inactivation, clustering or asymmetric segregation of extra centrosomes (Brinkley, 
2001; Godinhoet al., 2009). This results in the formation of a bipolar, functional, however not 
symmetric mitotic spindle and so called mitotic stability of aneuploid cancer cells. 
Abnormalities in the number of centrosomes were also found in leukemias. It was reported 
that defects in the number of centrosomes caused by the p53 mutation and cyclin E 
overexpression, detected in bladder cancers, led to centrosome amplification and 
chromosomal instability (Kawamura et al., 2004). Moreover, the centrosome aberrations 
were proposed as one of the main factors responsible for aneuploidy in acute myeloid 
leukemia (Kramer et al., 2003; Neben et al., 2003). Studies of CD34+ Ph+ cells isolated from 
chronic myeloid leukemia patients showed that centrosome aberrations correlate with the 
stage of the disease and aneuploidy (Giehl et al., 2005). In these studies freshly isolated cells 
from CML patients, in the chronic phase or blast crisis, were stained for pericentrin and 
gamma-tubulin to analyse the number as well as the structure of centrosomes. Moreover, 
they were studied for additional karyotypic abnormalities. Importantly, a strong correlation 
between the increase of centrosome aberrations, CML progression and blastic 
transformation was found. As centrosome defects were indicated as en early detectable 
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feature of CML, they have been proposed as a cause of karyotype instability and aneuploidy 
in CML progenitor cells as well as a valuable prognostic factor. In the long-term in vitro 
studies, using a cellular model of the chronic phase of CML, authors confirmed, that 
expression of BCR-ABL leads to significant centrosomal hypertrophy visible already after 4 
weeks of BCR-ABL expression (Giehl et al., 2007). This increased upon the next 10 weeks of 
propagation and correlated with the clonal expantion of aneuploid cells. 
We also found, using a mouse cellular model of CML, that the stable expression of low or 
high level of BCR-ABL in mouse progenitor 32D cells leads to the generation of cells with 
supernumerary centrosomes (Wolanin et al., 2010). This was accompanied by increased 
percentage of cells with aberrant mitoses, particularly multipolar spindles, lagging 
chromosomes and multinuclei. The presence of aberrant cells correlated with the level of 
BCR-ABL expression, indicating that the BCR-ABL itself is responsible for these 
abnormalities. Interestingly, Patel and colleagues presented that CML cells have defects in 
the centrosome-centriole cycle (Patel & Gordon, 2009). They showed that p210 (BCR-ABL1) 
and p145 (ABL1) are both, centrosome-associated proteins and form a complex with the 
pericentriolar protein, pericentrin. Numerical and structural centrosomal abnormalities 
were found in CML cell lines and in primary CD34+ cells from CML patients as a result of 
an increased level of separase participating in the abnormalities in the centrosome-centriole 
cycle. They also confirmed the previous data that abnormal centrosome distribution, 
amplification and loss are more evident in the advanced stages of CML. 
Although the tyrosine kinase inhibitors are very potent, selective and successful therapeutic 
agents for treatment of leukemia as well as some solid tumors it can not be neglected that 
some reports indicated that they can lead to centrosome aberrations in cancer as well as 
normal cells (Fabarius et al., 2005; Fabarius et al., 2008; Giehl et al., 2010). This was caused 
by blocking cells in the G1/S transition and the inhibition of cell growth which was 
followed by centrosomal aberrations. This should be taken into consideration with regards 
to the potential side-effects as well as a possible reason of dangerous clonal chromosomal 
abnormalities observed in BCR-ABL-negative progenitor cells under imatinib therapy. 
2.2 Mitotic checkpoint failure 
The spindle assembly checkpoint (SAC) plays a major role in the division control and 
segregation of sister chromatids, preventing occurence of aneuploidy (Chin & Yeong, 2010; 
Kops, 2008; Logarinho & Bousbaa, 2008; Nezi & Musacchio, 2009). SAC proteins, including 
Mad1 (mitotic arrest-deficient protein 1), Mad2, Bub1 (budding uninhibited by 
benzimidazoles 1), BubR1 (Bub1-related kinase 1) and Bub3 are recruited to unattached or 
tensionless kinetochores, forming mitotic checkpoint complex, which inhibits the anaphase 
promoting complex (APC). This protects cells from preearly anaphase entry and unproper 
segregation of chromatids. In physiological conditions the mitotic checkpoint is temporarily 
activated until the mitotic spindle is properly formed, whereas in anticancer therapy it is 
activated upon treatment with a group of microtubule damaging agents, such as taxanes 
and vinca alcaloids. Both interfere with tubulin organization and spindle formation, leading 
to the cell cycle arrest in mitosis and eventually cell death.  
It is known that the complete loss of the mitotic checkpoint function results in embryonic 
lethality, what was shown in Caenorhabditis  elegans (Kitagawa & Rose, 1999) as well as in 
mammalian cells (Michel et al., 2001; Schliekelman et al., 2009). Alternatively, partial loss of 
its function leads to chromosomes missegregation and chromosomal instability (Bharadwaj 
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& Yu, 2004; Ito & Matsumoto, 2010). This was due to the inability to activate the mitotic 
checkpoint and to arrest in mitosis in response to some disturbances. Instead - further 
progression of mitosis eventually leads to aberrant divisions and unproper chromosomes 
segregation. 
Dysfunctions of the mitotic checkpoint were reported in different types of cancers (Baker et 
al., 2005; Bannon & Mc Gee, 2009; Tanaka & Hirota, 2009). They correlated with aneuploidy, 
disease progression and the increase of aggressiveness. Interestingly, similar effects were 
observed in case of the upregulation or decreased expression of mitotic checkpoint 
members. For example, the Mad2 protein has been recently proposed as a critical factor 
leading to aneuploidy in cancers with defects in the Rb and p53 pathways (Schvartzman et 
al., 2011). Authors found that Mad2 expression is repressed by p53 via the Rb pathway, thus 
the cancer cells lacking the Rb protein require Mad2 upregulation leading to chromosomal 
instability and tumor progression in vivo. On the other hand, also Mad2 haplo-insufficiency 
caused chromosomal instability in human cancer cells and murine primary embryonic 
fibroblasts (Michelet al., 2001).  
BubR1 dysfunctions has also been found as a cause of cancer-susceptible disorder mosaic 
variegated aneuploidy (MVA) (Suijkerbuijk et al., 2010). Similarly to Mad2, BubR1 can be 
also overexpressed in cancer, what was shown in hepatocellular carcinoma (HCC) (Liu et 
al., 2009). Authors suggest that BubR1 overexpression, which was found in 45% of patients 
correlated with later stages and was associated with worse prognosis, thus it can be used as 
a potential prognostic factor  for HCC. 
 There were indications that CML cells could have a dysfunctional mitotic checkpoint, as 
their resistance to spindle poisons was reported previously. In the K562 and Lama-84 CML 
cell lines, microtubule disruption caused either by paclitaxel, nocodazole or novel 
microtubule-targeting agent PBOX-6 led to polyploidization without the presence of 
significant apoptosis (Greene et al., 2007). Imatinib treatment minimized the formation of 
polyploid cells and enhanced the apoptotic index upon treatment of CML cells with spindle 
poisons. Resistance to paclitaxel was also shown in K562 cells (Blagosklonny, 2001), but 
mitotic checkpoint competence was not investigated. All these data suggested that BCR-
ABL could somehow affect the response to microtubule disruption; however this issue was 
not discussed by the authors. 
We have shown for the first time that the expression of BCR-ABL in mouse 32D cells 
decreases the expression of SAC proteins, such as Mad2, Bub1, Bub3 and BubR1, as well as 
their mRNA levels, what was estimated by real time RT-PCR (Wolanin et al., 2010). 
Decreased levels of the mitotic checkpoint proteins were associated with dysfunctions in the 
mitotic checkpoint competence observed upon nocodazole and paclitaxel treatment as well 
as resistance to cell death induced by these agents. We found that the inhibition of the BCR-
ABL kinase activity by imatinib reversed the observed phenotype confirming the crucial role 
of BCR-ABL.  
2.3 Aberrant expression of mitotic kinases  
Mitotic kinases have also been implicated in the regulation of the centrosome cycle, spindle 
checkpoint and microtubule-kinetochore attachment, as well as spindle assembly and 
chromosome condensation. The family of Aurora kinases consists of the following proteins: 
Aurora A, B and C. The whole family has serine/threonine kinase activity which modifies 
microtubules during chromosome movement and segregation. Aurora kinases have been 
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found at the centrosomes of interphase cells, at the poles of the bipolar spindle and in the 
midbody of the mitotic apparatus. All three Aurora kinases members are overexpressed in 
many human cancers. This correlated with chromosomal instability and clinically aggressive 
forms of disease (Fu et al., 2007; Meraldi et al., 2004). Aurora A is localized in centrosomes 
and is important for maturation, spindle assembly and metaphase I spindle orientation. It 
has two independent functions in centrosome maturation and asymmetric protein 
localization during mitosis. Ectopic overexpression of Aurora A was shown to induce 
oncogenic transformation (Katayama et al., 2003). Moreover, overexpression of Aurora A 
and aneuploidy have been proposed as predictors of poor outcome in serous ovarian 
carcinoma (Lassus et al., 2011). Also a high level of Aurora B has been reported to promote 
tetraploidy and tumorigenesis in the mouse Xenograft model (Nguyen et al., 2009). 
High expression of Aurora A in leukemia cell lines and freshly isolated leukemia CML cells 
has been presented by Ochi T et al (Ochi et al., 2009). We also showed that the expression of 
BCR-ABL leads to the mislocalization of Aurora A in the chromosomal passenger complex 
(Wolanin et al., 2006). The importance of Aurora A-dependent signaling in CML has been 
shown in studies indicating that Aurora inhibitors seem to be very effective therapeutics for 
CML treatment (Gontarewicz et al., 2008),  what will be discussed by us later. 
Another family of tubulin-associated serine/threonine kinases, Polo-like, has also received 
significant attention regarding its participation in tumorigenesis. As far, in mammalian cells 
four members of this family have been identified (PLK1-4), and each one of them has a 
distinct function. PLK1 is essentially involved in the control of mitotic steps, PLK2 and PLK3 
have been described as potential regulators of the G1 and early S phases of the cell cycle, 
PLK4 as a major centrosome duplication regulator. Polo-like kinase 1 (PLK1) is a key 
regulator of mitosis and participates in regulating this process from its entry to cytokinesis 
(Yuan et al., 2011). Transcription and translation of PLK1 is highly coordinated with cell 
cycle progression. Plk1 mRNA and protein levels begin to accumulate in the S-phase and 
reach a peak at the G2/M transition and then decline upon mitotic exit (Lee et al., 1995). At 
the G2/M phase, PLK1 regulates the Cdk1/Cyclin B1 complex promoting mitotic entry and 
regulating mitotic progression due to regulation of phosphorylation of Cyclin B1, Cdk1, 
Myt1 and Cdc25C. PLK1 also plays a role in centrosome maturation by promoting increased 
recruitment of microtubules to the spindle pole bodies. It also regulates the localization of 
Aurora A to the centrosomes for proper maturation. It is known today that all mitotic 
kinases interplay with each other and form an extensive functional network, thus targeting 
any of them has tremendous consequences for cell physiology (Lens et al., 2010). 
Additionally, it was shown that PLK1 catalysis survivin priming phosphorylation at Ser20, 
what is necessary for survivin-mediated Aurora B docking to the centromere and activation 
(Chu et al., 2010). Expression of the non-phosphorylable survivin mutant prevented Aurora 
B activation and corrected spindle microtubule attachment. We also observed that silencing 
of survivin in CML cells significantly affected CPC function and mitosis as well as proper 
completion of cytokinesis leading to the formation of giant polyploid cells (Wolanin et al., 
2006). PLK1 also regulates the spindle assembly checkpoint (Nezi & Musacchio, 2009) 
probably by phosphorylation of BubR1 and finally, regulates chromosome segregation, 
cytokinesis and mitotic exit. 
PLK1, similarly to other mitotic kinases has been shown to be upregulated in cancers, 
including lymphomas. Studies of a big group of non-Hodgkin’s lymphoma (NHLs) patients 
presented that the level of PLK1 expression was significantly lower in low-grade NHLs than 
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found at the centrosomes of interphase cells, at the poles of the bipolar spindle and in the 
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in high-grade and intermediate-grade NHLs. Moreover, PLK1 has been proposed as a 
valuable marker of proliferating cells, even better than the commonly used Ki67 (Mito et al., 
2005). It was also described that PLK1 is overexpressed in AML cell lines as well as in 
primary cells and its inhibition preferentially targeted lymphoid cells, indicating an 
important role of the PLK1-mediated signaling (Renner et al., 2009). Importantly, healthy 
hematopoietic progenitor CD34+ cells were much less sensitive to growth inhibition caused 
by PLK1 targeting, indicating a high potential of this therapeutic strategy. This observation 
was confirmed by studies performed by Ikezoe and colleagues, who also found PLK1 
overexpressed in a number of human leukemia cell lines and freshly isolated leukemia cells 
from individuals with acute myelogenous leukemia as well as acute lymphoblastic 
leukemia, in comparison with normal bone marrow mononuclear cells (Ikezoe et al., 2009). 
As previously, they indicated PLK1 inhibition as a potent way to inhibit proliferation and 
induce cell death in leukemia cells. Moreover, the functional link between PLK1 and mTOR 
pathway has been shown in AML cells (Renner et al., 2010). Abnormal growth of cells 
overexpressing the active form of PLK1 was reversed by rapamycin, a specific inhibitor of 
the TORC1 complex. This showed a novel aspect of PLK1’s role in leukemia and opened 
new therapeutic possibilities.  
In chronic myeloid leukemia, PLK1was found to be expressed in the phosphorylated form 
in the CML cell line K562 as well as in primary CML cells from patients (Gleixner et al., 
2010). Studies presenting the potential of the PLK1 inhibitors in therapy against CML were 
performed and indicate an important role of PLK1 in CML development and progression. 
They will be discussed in a detailed way in the chapter dedicated to anti-mitotic therapies 
against leukemia. 
3. BCR-ABL-mediated downregulation of BRCA1 
BRCA1, a tumor suppressor isolated in 1994 (Miki et al., 1994) has been implicated in a 
broad range of cellular processes, including DNA repair, cell cycle checkpoint control, cell 
division and gene transcription (Linger & Kruk, 2010; Thompson, 2010; Wu et al., 2010; Yang 
& Xia, 2010). It is a known familiar ovarian and breast cancer-specific tumor suppressor, 
however today it seems that it is involved in the development of other types of cancers as 
well. The protein contains two motifs: a RING domain at the N-terminus and two tandem 
copies of BRCT domain at the C-terminus (Baer, 2001). In vivo it exists in a heterodimeric 
complex with the BRCA1-associated RING domain (BARD1) protein, which resembles 
BRCA1 (Wu et al., 1996).  
The first observation that BRCA1 protein is nearly undetectable in leukemia cells from 
chronic myeloid leukemia (CML) patients has been made by Deutsch et al (Deutsch et al., 
2003). They found a significant downregulation of BRCA1 in primary CD34+ cells obtained 
from both, the chronic phase and the blast crisis patients as well as in cell lines expressing 
BCR-ABL. This was not accompanied by a decrease of the  BRCA1 mRNA, what was studied 
by real-time RT-PCR in one of the investigated cell lines.  
Our group studied the direct influence of BCR-ABL on the BRCA1 expression, using the 
previously mentioned mouse progenitor 32D cell line stably expressing with BCR-ABL, 
particularly in clones, expressing low and high BCR-ABL levels (Fig.1A), (Wolanin et al., 
2010). We found that BCR-ABL expression leads to a strong decrease of BRCA1 at the 
protein level. This was reversed by treatment with imatinib, a specific inhibitor of the BCR-
ABL tyrosine kinase, confirming dependence on the tyrosine kinase activity (Fig. 1B). The 
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lack of a significant decrease of mRNA confirmed the previous observation that BCR-ABL 
affects the posttranscriptional stages of protein expression. Incubation with the proteasome 
inhibitor MG132 did not lead to an increase at the BRCA1 protein level (Fig. 1C), thus 
excluding the possibility that increased degradation is responsible for the protein 
downregulation.  
Recently, it was shown that BCR-ABL interferes with the Fanconi Anemia/BRCA1 pathway, 
thus increasing the predisposition to DNA repair errors and development of centrosomal 
and chromosomal aberrations (Valeri et al., 2010). The interference of BCR-ABL with the 
formation of BRCA1 and FANCD2 nuclear foci was observed in hematopoietic progenitors 
from CML patients. These authors also showed that the ectopic expression of BRCA1 
reverted the generation of aberrant centrosomes induced by BCR-ABL. This suggests, 
however not directly studied, that overexpression of BRCA1 could antagonize also other 
effects of BCR-ABL expression, if they are mediated by BRCA1 downregulation, indeed.  
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Fig. 1. The influence of BCR-ABL expression on the level of the BRCA1 Protein. 
A. Expression of BCR-ABL leads to downregulation of the BRCA1 protein. The level of 
BRCA1 was determined by Western Blot in mouse progenitor 32D cells, control or stably 
expressing BCR-ABL at low (C2 cells) or high (C4 cells) level.  
B. Imatinib treatment leads to upregulation of the BRCA1 protein level in cells expressing 
BCR-ABL. 32D and C4 cells were treated with 0.5 μM imatinib for 1, 2.5 or 4 hours (upper 
panel) or with 0.5 or 5 μM imatinib for 4 and 6 hours (lower panel) followed by estimation 
of the BRCA1 protein level.  
C. BRCA1 downregulation caused by BCR-ABL is not a result of increased proteasomal 
degradation. 32D, C2 and C4 cells were treated with 10 μM proteasome inhibitor MG132 for 
6 hours, followed by determination of the BRCA1 protein level by Western Blot. 
Altogether, there are strong evidences indicating that the decrease of the BRCA1 protein and 
the BRCA1-dependent signaling is caused by BCR-ABL expression and is also specific for 
chronic myeloid leukemia, in addition to other types of tumors. There is a number of 
intracellular processes crucial for cell physiology controlled by BRCA1, including DNA 
damage response as well as activation of the cell cycle checkpoints, chromatin remodelling, 
apoptosis and mitosis. Aberrations in any of them, lead to the accumulation of mutations, 
genomic instability and finally an increased risk of cancerogenesis. Thus, we postulate that 
the decrease of BRCA1 caused by BCR-ABL could have tremendous consequences due to 
defective control of genomic stability. The role of BRCA1 in the regulation of the DNA 
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particularly in clones, expressing low and high BCR-ABL levels (Fig.1A), (Wolanin et al., 
2010). We found that BCR-ABL expression leads to a strong decrease of BRCA1 at the 
protein level. This was reversed by treatment with imatinib, a specific inhibitor of the BCR-
ABL tyrosine kinase, confirming dependence on the tyrosine kinase activity (Fig. 1B). The 
BCR-ABL Hits at Mitosis; Implications for Chromosomal  
Instability, Aneuploidy and Therapeutic Strategy 
 
9 
lack of a significant decrease of mRNA confirmed the previous observation that BCR-ABL 
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excluding the possibility that increased degradation is responsible for the protein 
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the decrease of BRCA1 caused by BCR-ABL could have tremendous consequences due to 
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damage response and cell cycle checkpoint control has been already well explained (Huen et 
al., 2010; Kim & Chen, 2008; Wuet al., 2010; Yang & Xia, 2010; Zhang & Powell, 2005). The 
detailed role of BRCA1 in the regulation of mechanisms participating in the occurence of 
genomic instability as a result of mitosis dysfunctions, referred as a CIN (chromosomal 
instability) will be discussed in the next paragraphs.  
4. The role of BRCA1 in mitosis 
4.1 BRCA1 in the transcriptional regulation 
Currently, there is a lot of evidence suggesting that BRCA1 is involved in the transcriptional 
regulation. This opens a new list of possible interactions with intracellular processes 
(Murray et al., 2007). It has been shown that BRCA1 is a component of the RNA polymerase 
II (pol II) holoenzyme (Scully et al., 1997). Authors developed a purification strategy for the 
mammalian pol II holoenzyme to search for specific transcription factors and they found 
that the wild-type BRCA1 protein was copurified. Moreover, immunopurification of BRCA1 
complexes also contained TFIIF, TFIIE and TFIIH transcription factors, which were 
previously reported to form a complex with the pol II holoenzyme (Maldonado et al., 1996). 
This strongly suggested that one of the BRCA1 functions is to regulate genes expression.  
Unlike many enhancer-specific activators, BRCA1 does not appear to require the specific 
DNA binding domain to stimulate gene transcription, what was shown by investigation of 
the p53-responsive promoter MDM2 (Nadeau et al., 2000). BRCA1 interacts rather with 
multiple transcription factors. Among them we can name ATF1, a member of the cAMP 
response element-binding protein/activating transcription factor (CREB/ATF) family. 
BRCA1 stimulates its transcription from a natural promoter as well as reporter systems 
(Houvras et al., 2000). Moreover, BRCA1 significantly enhanced the transcription of NF-
kappaB target genes due to the binding to p65/RelA, one of the two subunits of the 
transcription factor NF-kappaB (Benezra et al., 2003). Authors suggested that BRCA1 acts as 
a coactivator and proposed a model in which BRCA1 interacts physically with p65/RelA, 
CBP as well as with RNA polymerase II and enhances transcriptional activation of the NF-
kappaB target genes. Additionally, MacLachlan reported that p53 can be stabilized by 
BRCA1 in response to DNA damage and by this selectively transactivated towards genes 
involved in the growth arrest and DNA repair (MacLachlan et al., 2002). The role of BRCA1 
in the regulation of p53-dependent gene expression has been also shown by other groups 
(Ouchi et al., 1998; Zhang et al., 1998).  
BRCA1 is also able to interact with components of the histone deacetylase complex, 
particularly with HDAC1 and HDAC2 (Yarden & Brody, 1999). It was shown to interact in 
vitro and in vivo with the Rb protein as well as with the RB-binding proteins, RBAp46 and 
RBAp48, which are components of the histone deacetylase complexes and are involved in 
chromatin remodelling. Involvement of BRCA1 in chromatin remodelling suggests its 
important role in the regulation of transcription, replication, recombination and others. 
BRCA1-mediated activation of specific genes may result from sequestration of histone 
deacetylases from DNA promoters. It was also reported that BRCA1 interacts with the 
hGCN5/TRAP histone acetyltransferase complex (Oishi et al., 2006), which co-activates the 
transactivation function of BRCA1. 
More recently, BRCA1 has also been shown to play a role in the transcriptional repression 
by ubiquitin-dependent mechanism (Horwitz et al., 2007). It leads to ubiquitination of the 
transcriptional preinitiation complex, thus preventing the stable association of TFIIE and 
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TFIIH transcription factors and blocking the initiation of mRNA synthesis. Amphiregulin 
(AREG) and early growth response-1 (EGR-1) are examples of genes repressed by BRCA1 in 
breast cancers. This phenomen could be broader and may contribute to the BRCA1-
mediated tumor suppression. 
4.2 BRCA1 in the regulation of the mitotic checkpoint  
The role of BRCA1 in the regulation of the mitotic checkpoint has been indicated. BRCA1 
was identified as a mitotic target of the Chk2 kinase in the absence of DNA damage (Stolz et 
al., 2010). Accordingly, loss of BRCA1 or its Chk2-mediated phosphorylation led to defects 
in the spindle formation and chromosomal instability (CIN) due to generation of lagging 
chromosomes and chromosome missegregation. It was shown that MCF-7 cells transfected 
with BRCA1 siRNA display a reduced mitotic index followed by premature cyclin B1 
degradation upon paclitaxel treatment. This suggested that BRCA1 depletion results in the 
inactivation of the spindle checkpoint (Chabalier et al., 2006). They presented that BRCA1 
up-regulates the expression of the protein kinase BubR1, an essential component of the 
functional spindle checkpoint. This indicated that BRCA1 directly influences the expression 
of the mitotic checkpoint components. It was also shown that BRCA1, due to an interaction 
with the transcription factor OCT-1, mediates the transactivation of Mad2 (mitotic arrest 
deficient protein 2) (Wang et al., 2004). The studies of BRCA1 knock-down in human 
prostate and breast cancer cell lines, by using the microarray technique, showed that BRCA1 
depletion caused downregulation of many genes involved in mitosis progression (Bae et al., 
2005). Specifically, mitotic checkpoint components (Bub1, STK6), proteins involved in the 
chromosome segregation and centrosome function as well as cytokinesis (including PLK) 
and finally proteins regulating mitosis entry and progression, such as cyclin B1, Cdc2 and 
Cdc20 were downregulated. 
The influence of BRCA1 on the expression of components of the mitotic checkpoint was also 
confirmed in our studies (Wolanin et al., 2010). We showed that the downregulation of 
BRCA1, caused either by BCR-ABL expression or by gene silencing using siRNA, resulted in 
the downregulation of Mad2 as well as BubR1 and Bub3 gene expression, which all belong 
to the mitotic checkpoint complex and undergo common regulation. Decreased levels of 
these proteins finally led to dysfunctions of the mitotic checkpoint and increased occurence 
of aberrant mitoses and chromosomal instability. Moreover, we observed the increased rate 
of supernumerary centrosomes as well as aberrant divisions in cells expressing BCR-ABL. 
We propose that decrease of the BRCA1 protein caused by BCR-ABL could be an important 
factor participating in the development of genomic instability due to the generation of 
chromosomally unstable cells. We added the regulation of mitotic checkpoint to the 
repertoir of BRCA1-mediated mechanisms participating in the development of aneuploidy 
in CML cells.  
Due to its function in the regulation of mitotic checkpoint competence, BRCA1 has been 
shown to correlate with the sensitivity to spindle poisons (Byrski et al., 2008; Quinn et al., 
2007). As mentioned before, cells ability to activate the mitotic checkpoint is necessary for 
the sensitivity to spindle poisons. BRCA1 downregulation resulted in resistance to 
microtubule damage due to the inability to efficiently activate the mitotic checkpoint, block 
cells in mitosis and induce apoptosis. In our studies, cells expressing BCR-ABL with a 
significantly decreased BRCA1 level were resistant to cell death activated by nocodazole or 
paclitaxel (Wolanin et al., 2010). This was reversed by imatinib treatment, resulting in 
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TFIIH transcription factors and blocking the initiation of mRNA synthesis. Amphiregulin 
(AREG) and early growth response-1 (EGR-1) are examples of genes repressed by BRCA1 in 
breast cancers. This phenomen could be broader and may contribute to the BRCA1-
mediated tumor suppression. 
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chromosomes and chromosome missegregation. It was shown that MCF-7 cells transfected 
with BRCA1 siRNA display a reduced mitotic index followed by premature cyclin B1 
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BRCA1 upregulation. In ovarian cancer it was suggested that BRCA1 can act as a predictive 
marker of response to chemotherapy (Quinn et al., 2009) and dysfunctional BRCA1 resulted 
in resistance to taxanes and other chemotherapeutics. On the other hand, reconstitution of 
BRCA1 into ovarian cancer cells, carrying BRCA1 mutation, reversed the resistance and 
sensitized cells to paclitaxel (Zhou et al., 2003). BRCA1 was also proposed as a predicive 
marker of drug sensitivity in breast cancer treatment (Mullan et al., 2006). As resistance to 
spindle poisons has been reported for CML cells, this supports the previously proposed 
idea, that the overexpression of BRCA1 diminishes some effects of BCR-ABL expression. In 
our opinion, BRCA1 level could serve as a prognostic marker of sensitivity to different 
therapies also those used in leukemias. 
4.3 BRCA1 in the regulation of centrosome number and function 
The first observation that BRCA1 localizes to centrosomes has been made by Hsu et al (Hsu 
& White, 1998), who showed that BRCA1 is associated with centrosomes during mitosis in a 
cell cycle-dependent manner. Moreover, they found that BRCA1 forms a complex with 
gamma-tubulin, which is preferentially associated with the hypophosphorylated form of 
BRCA1. Gamma-tubulin is a crucial component of centrosomes and is responsible for 
nucleation of microtubules. Therefore, this confirmed the idea that BRCA1 could play a role 
in the regulation of centrosome amplification and function and led to the later findings that 
a BF3 domain of BRCA1 (BRCA1 fragment no. 3, amino acids 504-803) is responsible for the 
gamma-tubulin binding (Hsu et al., 2001). Overexpression of the BF3 domain in COS-7 cells 
resulted in the accumulation of mitotic cells with supernumerrary centrosomes and 
abnormal spindles, what is known to lead to aneuploidization.  
The role of BRCA1 in the regulation of centrosome number has been indicated by 
experiments using the mutated forms of BRCA1. Centrosomal amplification was shown in 
mouse embryonic fibroblasts carrying a targeted deletion of exon 11 of BRCA1 (Xu et al., 
1999) and in a BRCA1-mutant breast cancer cell line HCC1937 (Schlegel et al., 2003). What is 
important, Waever et al showed that mouse embryonic fibroblasts carrying different BRCA1 
defects show supernumerary centrosomes and other features similar to human breast cancer 
cells, indicating that the mechanisms are conserved between mice and humans (Weaver et 
al., 2002).  
Moreover, immunohistochemical analysis of 50 samples from breast cancer patients showed 
that numerical centrosome aberrations were signicantly associated with the negative BRCA1 
expression as well as with the BRCA1 germline mutation, whereas there was no significant 
correlation with the centrosome aberrations in size (Shimomura et al., 2009). This suggests 
that BRCA1 plays a role rather in the regulation of centrosome duplication and defects in its 
expression or function result in numerical aberrations. Very recently, direct studies of 14 
different missense mutations in the RING domain of BRCA1 and their influence on the 
control of centrosome number were performed (Kais et al., 2011). Authors showed that only 
2 out of the 14 BRCA1 variant proteins were neutral in the centrosome duplication assay. 
The others were either very effective and resulted in mutated BRCA1 proteins that caused 
centrosome amplification (C24R, C27A, C39Y, H41F, C44F, C47G, M18T and I42V) or had an 
intermediate, however still significant effect on centrosome duplication (I21V, I31M, L52F 
and D67Y). 
Interestingly, we also observed a correlation between the loss of BRCA1 expression and 
increased percentage of cells with supernumerary centrosomes in murine lymphoid cells 
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expressing BCR-ABL oncogene (Wolanin et al., 2010). This was in contrast with the hypothesis 
that BRCA1 defects lead to centrosome amplification in breast cells but not in other types of 
cells (Starita et al., 2004). This idea has been based on the data obtained using the transient 
expression of the BRCA1-inhibiting BIF peptide in nine different cell lines, where four non-
breast cell lines - prostate (PC3), cervix (HeLa), colon (DLD-1) and osteosarcoma (U2OS), did 
not accumulate extra centrosomes. However, lymphoid cells were not included in these 
studies. To date, there were other indications, apart from ours, that the loss or mutation of 
BRCA1 could affect the centrosome number also in other types of cells. Recently, it was shown 
that BCR-ABL intereferes with the Fanconi Anemia (FA)/BRCA pathway and the ectopic 
expression of BRCA1 in CD34+ progenitor cells reversed the appearance of aberrant 
centrosomes, thus confirming our previous observations (Valeri et al., 2010). 
The direct mechanism of BRCA1-mediated control of centrosome number is still not fully 
clear, although the BRCA1-dependent ubiquitination of gamma-tubulin is proposed to be 
involved in the regulation of centrosome function (Staritaet al., 2004). Gamma-tubulin is an 
important protein involved in the initiation of microtubule nucleation by centrosomes. 
Gamma-tubulin’s lysines 48 and 344 have been indicated as crucial in the regulation of 
centrosome duplication and microtubule nucleation function, respectively (Sankaran et al., 
2005). Cells with mutated lysines on gamma-tubulin, unable to be ubiquitinated, were 
characterized by centrosome amplification. On the other hand, the same phenotype was 
observed after inhibition of the enzymatic activity of BRCA1 by transfection of the BRCA1 
(I26A) ligase-defective mutant (Sankaran et al., 2006). Additionally, in vitro experiments 
using Xenopus extracts, purified centrosomes and BRCA1 together with ubiquitination 
factors confirmed that BRCA1 is involved in the microtubule nucleation. It seems that 
BRCA1 controls the centrosome number by preventing reduplication due to ubiquitination 
of lysines of gamma-tubulin, which needs to be phosphorylated to prevent reduplication 
(Ko et al., 2006). Loss of BRCA1 did not affect centrosome duplication in the early S phase 
but rather caused a second round of duplication just prior to mitosis. The model has been 
proposed, in which BRCA1 marks centrosomes as already duplicated via the BRCA1-
mediated ubiqutination of gamma-tubulin (Wong & Stearns, 2003). This issue is still not 
fully clarified, however there is no doubt about the significant role of the BRCA1-mediated 
ubiquitination of gamma-tubulin in this process (Kais & Parvin, 2008). Altogether, this led to 
the conclusion that the E3 ubiquitin ligase activity of BRCA1 is crucial for the effects on the 
biology of centrosomes, and controls centrosome duplication as well as microtubules 
nucleation.  
Recently, it was demonstrated that BRCA1 interacts with centrosomal protein Nlp (ninein-
like protein) (Jin et al., 2009), which is a fast turnover protein and plays a role in the 
centrosome maturation and spindle formation (Casenghi et al., 2005). Authors found that 
Nlp is a BRCA1-associated protein and colocalizes with BRCA1 in different types of cancer 
cells, including HeLa and U2OS cells. Moreover, Nlp expression and stability depends on 
normal cellular BRCA1 function. A variety of different types of cells expressing the mutated 
BRCA1 or silenced for BRCA1 exhibited disrupted Nlp colocalization to centrosomes as well 
as enhanced Nlp degradation. This data was consistent with our observations concerning 
the role of BRCA1 in different types of cancers. The lack of Nlp protein led to centrosome 
amplification, aberrant chromosome segregation, cytokinesis failure and appearance of 
miltinuclei, thus resembling the phenotype upon BRCA1 disruption. Recent studies showed 
that Nlp is recruited by the Aurora B protein and localizes at the midbody during 
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cytokinesis, thus its depletion or increased degradation triggers aborted division and 
subsequently leads to multinucleated phenotypes (Yan et al., 2010). 
Altogether, this data strongly supported the idea that BRCA1 is one of the key elements 
controlling mitosis and the loss of BRCA1 could result in very severe dysfunctions of cell 
division. We propose that this can significantly participate in the generation of aneuploidy, 
CML progression and blastic transformation. A proposed model showing the influence of 
BCR-ABL-mediated downregulation of BRCA1 on the occurrence of genomic instability and 




Decreased expression of 
BRCA1 transcriptional targets
(BubR1, Mad2, Bub1, Bub3, cyclin B1)
Lower mitotic checkpoint 
competence 
High rate of genomic/chromosomal instability 
Increased susceptibility to generate aneuploid clones
Centrosomes 
amplification
Mitotic spindle abnormalities 
Unproper chromosomes segregation
Dysfunctions of DNA 
damage response 
Defective cell cycle  
checkpoints function 
Error-prone DNA repair 
 
 
Fig. 2. Proposed scheme of the mechanisms influenced by BCR-ABL-mediated BRCA1 
downregulation; role in the genomic instability and generation of aneuploid cells. 
5. Therapeutic targeting of mitosis in CML cells 
The effects of the improper control of mitosis in the development and progression of 
leukemias, including chronic myeloid leukemia has been already described above. The 
importance of these processes and their potential as targets for therapy is already obvious. 
In general, looking for new treatment options or combined therapies is still necessary to 
overcome the insensitivity or resistance to tyrosine kinase inhibitors, often developed in 
CML patients. In our opinion, targeting the chromosomal passenger complex and mitotic 
kinases is a very promising trend in the development of novel anti-leukemia therapeutic 
strategies. We will discuss the current data and implications for the future.  
5.1 Chromosomal passenger complex and Aurora kinases  
The chromosomal passenger complex (CPC) is a group of proteins, which are involved in 
the regulation of nearly all stages of mitosis (Vader et al., 2006; Vagnarelli & Earnshaw, 2004; 
Yanet al., 2010). In most organisms, the chromosomal passenger complex is formed by four 
main proteins: Aurora B kinase, INCENP, Survivin and Borealin/Dasra-B (Ruchaud et al., 
2007). Other proteins, like telophase disk 60 kDa (TD-60) have been shown to interact with 
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the CPC proteins and have a typical localization, however they are not members of the core 
complex. The complex undergoes a characteristic scenario of translocations during mitosis – 
they localize at the inner centromeres in prometaphase and metaphase then, at anaphase 
onset, they leave the chromosomes and transfer to the kinetochores at the central spindle to 
finally move to the midbody at cytokinesis. It plays a crucial role in the regulation of 
chromatin condensation, kinetochore function, mitotic checkpoint competence as well as 
cytokinesis (Terada, 2001; Vaderet al., 2006). Very recently it was presented that the 
chromosomal passenger complex is essential for correcting the non-bipolar chromosome 
attachments and for cytokinesis (Becker et al., 2010). To do this, Aurora B and INCENP have 
to be localized to centromeres. This is a very important finding as it indicates the supportive 
role of the CPC complex in case of mitotic checkpoint failure. Moreover, the translocation of 
Aurora B and other CPC proteins from centromeres to the spindle midzone in anaphase is 
necessary to prevent mitotic checkpoint engagement at anaphase (Vazquez-Novelle & 
Petronczki, 2010). 
Members of the CPC complex have been proposed as very potent therapeutic targets. 
Treatment of imatinib-resistant CML cells carrying the T315I mutation with small molecule 
inhibitor, PHA-739358, which selectively targets BCR-ABL and Aurora kinases led to strong 
antiproliferative and apoptotic effects (Gontarewicz et al., 2008). Moreover, this has also 
been observed in CD34+ cells derived from untreated CML patients and from imatinib-
resistant patients in the chronic phase or blast crisis, including those harbouring the T315I 
mutation. Similar effects were obtained by combined treatment of imatinib resistant CML 
cells with vorinostat together with Aurora kinase inhibitor MK-0457 (Dai et al., 2008). 
Effectivity of this combined treatment has been shown against primary CD34+ CML cells, 
murine Ba/F3 cells with various BCR-ABL mutations (T315I, E255K, and M351T), as well as 
in imatinib-resistant K562 cells with BCR-ABL-independent, Lyn-dependent resistance. The 
same combination of therapy was presented also in other studies by Fiskus et al (Fiskus et 
al., 2008). Authors studied different CML cell lines, murine cells expressing BCR-ABL as 
well as primary CML and AML cells and came to the same conclusions. Novel inhibitors of 
Aurora kinases are still investigated in the anti-leukemia therapy of imatinib-resistant cells 
(Fei et al., 2010; Kelly et al., 2010). Usually they are proposed to be used together with 
tyrosine kinase inhibitors, such as imatinib or dasatinib.  
Survivin has been also proposed as a universal target for anticancer therapy (Andersen et 
al., 2007). Several trials are currently undergoing, using different methodologies, from small 
molecule antagonists to immunotherapy (Kanwar et al., 2010). However, the development 
of survivin inhibitors is not as advanced as other therapeutic small inhibitors. It is important 
to point that anti-survivin therapy should be probably combined with other treatments, as it 
is known that survivin depletion uncovers the function of the mitotic as well as post-mitotic 
p53-p21-dependent checkpoints, which protect from polyploidization upon mitosis 
disturbances (Beltrami et al., 2004). In case of cancers with the defective p53 function, 
survivin silencing led to reduced mitotic arrest and enhanced polyploidy, what is a very 
unwanted and dangerous side-effect. Also in our studies, specific depletion of survivin by 
siRNA approach in CML cells with checkpoints defects, resulted in strong polyploidization 
and chromosomal instability (Wolanin et al., 2006). However, when we used a natural 
compound – curcumin, which has been shown as a broadly acting, very potent anticancer 
agent, we found that it affects the CPC proteins and induces mitotic catastrophe, however 
without polyploidization. Curcumin decreased the level of survivin and caused unproper 
localization of Aurora B, leading to perturbances in mitosis and defective cytokinesis.  
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survivin silencing led to reduced mitotic arrest and enhanced polyploidy, what is a very 
unwanted and dangerous side-effect. Also in our studies, specific depletion of survivin by 
siRNA approach in CML cells with checkpoints defects, resulted in strong polyploidization 
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localization of Aurora B, leading to perturbances in mitosis and defective cytokinesis.  
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Thus, the status of the mitotic checkpoint competence as well as p53 should be taken into 
consideration when anti-survivin therapy is proposed. Another natural compound, 16-
hydroxycleroda-3,13-dien-15,16-olide (PL3), one of the clerodane diterpenoid compounds 
isolated from Polyalthia longifolia, induced degradation of Aurora B, mitotic checkpoint 
dysfunctions and finally led to cell death of CML cells, including the T315I-mutated BCR-
ABL+ BA/F3 cells (Lin et al., 2011). Additionally, it reversed the sensitivity to imatinib of 
T315I-mutated CML cells in comparizon to treatment only with imatinib.  
Recently, Aurora inhibitors were indicated as promising agents for acute myeloid and 
chronic myeloid leukemias (Moore et al., 2010). The most promising data was obtained for 
FLT3-mutated AML and imatinib-resistant Ph+ CML, particularly with the T315I mutation. 
Clinical trials investigating these agents have been already initiated (Cheung et al., 2011). 
5.2 Polo-like kinases 
Polo-like kinases are of strong interest according to potential anticancer therapy, as similarly 
to Aurora kinases, they can be targeted with selective small molecule inhibitors (Warner et 
al., 2008). Additionally, many natural compounds with the ability to prevent cancerogenesis, 
such as wortmanin, quercetin, thymoquinone, genistein, indirubin and others, have been 
shown to modulate PLK1 level or activity. It is proposed that naturally occurring PLK1 
inhibitors with low or no toxicity should be considered as interesting agents in prevention 
as well as treatment of cancer (Schmit et al., 2010).  
As described before, PLK1 has been upregulated in different cancers, including leukemias. 
Its inhibition or silencing resulted in cell cycle arrest, decrease of cell viability and induction 
of apoptosis in various cancer cells. Inhibition of PLK1 by different small molecule 
compounds in acute myeloid leukemia (AML) cells led to mitotic accumulation and 
apoptosis (Didier et al., 2008). Comprehensive studies of PLK1 silencing and inhibition 
using the novel selective inhibitor GW843682X in a broad range of different leukemia cell 
lines and primary cells led to the conclusion that PLK1targeting can be a promising strategy 
(Ikezoeet al., 2009). This observation was confirmed by other studies of leukemia primary 
cells (Renneret al., 2009). The potential of PLK1 inhibition to improve the chemotherapy or 
irradiation of resistant leukemia cells has been also investigated in primary patient cells as 
well as in vivo, in mouse Xenograft models of B-lineage ALL studies, with the same 
conclusions (Uckun et al., 2010). Currently, several PLK1 inhibitors are in different phases of 
clinical development for anticancer therapy (Chopra et al., 2010; Schoffski, 2009). Data from 
one of the first clinical trials indicated that the PLK1 inhibitor BI 2536 was well tolerated and 
showed antitumor activity in patients with advanced solid tumors and refractory or 
relapsed AML (Wasch et al., 2010). According to CML, this scheme of therapy was not very 
intensively studied till now, however it also seems to be very potent and prospective. PLK1 
inhibitor BI 2536 in a low, nanomolar concentration was able to induce growth inhibition 
and mitotic arrest followed by apoptosis in CML cells, including cell lines and primary cells 
from patients (Gleixneret al., 2010). Importantly, this agent was very effective not only 
against imatinib-sensitive CML cells, but also imatinib-resistant cells carrying the T315I 
mutation. Treatment with BI2536 together with imatinib or nilotinib showed synergistic 
effect, indicating possibility of a combined therapeutic application.  
6. Final conclusions 
Taken together, it is already clear that BRCA1 due to its multifunctional nature, is one of the 
key molecules controlling mitosis on the different levels of organization. There is no doubt 
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that the decrease of BRCA1 caused by BCR-ABL in CML cells could be a critical factor 
determining the generation of supernumerary centrosomes, aberrant mitotic spindles, 
mitosis and cytokinesis failures, finally leading to aneuploidization. All data presented in 
this review convincingly show that activity of the BCR-ABL kinase is directly responsible for 
the promotion of chromosomally unstable phenotype. As chromosomal instability seems to 
play a crucial role in the disease progression, mitosis is a prospective target for treatment in 
CML. This opens new possibilities for therapeutical intervention based on the targeting 
processes involved in the control of mitosis. It can be an alternative strategy for alone or 
combined treatment of leukemia cells, which developed resistance to imatinib or second-
generation tyrosine kinase inhibitors, such as dasatinib or nilotinib.  
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1. Introduction 
Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome 
(Ph), which is originated by a balanced translocation between chromosomes 9 and 22, that 
is, t(9;22)(q34;q11) results in production of a BCR-ABL1 fusion protein with constitutive Abl 
kinase activity. In experimental models, the expression of said activity causes expansion of 
pluripotent stem cells, preferentially favours myeloid lineage differentiation, and inhibits 
erythroid  differentiation [1,2]. 
The BCR/ABL1 fusion in 22q11 is observed in ~95% of patients with chronic myeloid 
leukemia (CML). The BCR/ABL1 fusion signal on the derivative chromosome 22 is present 
in most CML patients. 
 In 5-10% of cases, this signal is generated by variant rearrangements (variant Ph) that 
involve other genomic regions [3-7]. More than 600 CML cases with variant rearrangements 
have been reported. The breakpoint distribution clearly exhibits a non-random pattern, with 
marked clustering to some chromosome bands, such as 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 
12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13, which suggests that these 
regions may be particularly prone to breakage. In addition, some specific variants are also 
known to be more frecuent, with the two translocations t(3;9;22)(p21;q34;q11) and 
t(17;22)(q25;q11) both having been reported in more than 10 cases [8].  
The occurrence of additional chromosomal aberrations (ACA) in Ph-positive CML is 
strongly associated with disease progression and has been interpreted as a sign of clonal 
evolution as well as chromosomal instability. Mitelman et al. [9] identified +Ph, +8, and 
i(17q) as the most common secondary changes that occur in nearly 90% of the cases with 
additional abnormalities. These three abnormalities were proposed to follow the ‘major 
route’ of clonal evolution, whereas other changes, which evolved more rarely, were 
suggested to follow the ‘minor route’ [9]; the terms ‘major’ and ‘minor’ refer to frequencies 
of the aberrations but not to the  pathogenetic impact. Thus the three major route changes, 
followed by +19, were the most common ACA. Other additional chromosomal 
abnormalities take place in less than 10% of the cases, the most frequent being –Y, +21, +17, 
–7, and –17. On the other hand, no apparent differences in ACA  between CML with 
standard Ph and CML cases with Ph variants are observed. The most common additional 
chromosomal changes are +8 (34%), +Ph (30%), i(17q) (20%), +19 (13%), –Y (8% of 
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(in order of appearance) 
Accelerated and Blastic Phase 
(in order of appearance) 
+Ph classical +Ph classical 
+Ph variant + Ph variant 
+ Ph, +8 +Ph, +8 
+Ph, -Y +Ph, -Y 
+Ph, -21 +Ph, i(17q) 
+8 +19/ +17 /-7 
Complex Karyotype Complex karyotype 
Table 1. Secondary chromosome abnormality patterns in CML patients. 
The chromosome bands frequently involved in secondary structural changes are similar in 
both groups. It is apparent that some chromosome segments are particularly ‘breakprone’: 
1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11–14, 17p11, 17q10, 21q22, and 22q10 when 
breakpoint distribution is observed in CML with standard Ph. 
The ACA are found in various combinations and it has been suggested that i(17q) followed 
by +8 are rather early changes, whereas trisomy 19 is a relatively late one [10,11]. Although 
this temporal order of ACA seems common, exceptions clearly exist. There are several 
examples of Ph-positive CML cases with +8 in all metaphases but i(17q) may also occur in 
only subclones, and Ph-positive CML cases  with a trisomy 19 [12]. Moreover, some 
combinations are more frequent than others. While +8, +Ph, and i(17q) often occur together, 
the combination i(17q),+19 (without +8/+Ph) has only been reported in 2 cases; 
+8,i(17q),+19 (without +Ph) in 16 cases; and i(17q),+19,+Ph (without +8) in 2 cases[12]. Some 
combinations (+8, i(17q); +8,+19; +19,+Ph) are positively associated, while i(17q),+19 and 
i(17q),+Ph are negatively associated according to Hashimoto et al. [13].  
Thus, the selective ACA appearance seems to vary, depending on other aberrations present 
in the combination. Furthermore, available data indicate that the most common secondary 
abnormalities occur in a step-wise, well-ordered manner, with a putative frequent pathway 
which starts with i(17q), then followed by +8 and +Ph, and lastly +19. Since three out of the 
four most frequent ACA involve gains, i.e. +8, +19, and +Ph, thus hyperdiploidy is the most 
common modal number in CML with ACA [14,15]; nearly 50% of the cases have 47–50 
chromosomes. Pseudodiploidy (46 chromosomes with structural abnormalities) is observed 
in almost 40% of the cases, while other modal numbers are uncommon. It is worth bearing 
in mind that the distributions of ploidy levels are not different between CML cases with 
standard Ph and those with variant Ph translocations, which confirms a strong indication 
that there are not any major differences between these two groups when related to 
cytogenetic evolution patterns. Most of the ACA in CML are genomically unbalanced, such 
as trisomies, monosomies, and deletions. In fact, this is common in hematologic 
malignancies, therefore while the primary changes have been proposed as balanced, the 
secondary changes are said to be unbalanced [16]. However, there are some notable 
exceptions in CML, in 10 cases the presence of t(15;17)(q22;q12–21) has been reported [12]. 
Other balanced rearrangements which are characteristically found in acute myeloid 
leukemia (AML) or myelodysplastic syndromes (MDS) and occasionally also found in CML 
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BC include: inv(3)(q21q26)/t(3;3)(q21;q26), t(3;21)(q26;q22), t(7;11)(p15;p15), t(8;21)(q22;q22), 
and inv(16) (p13q22) [12, 18-22].  
Although secondary by definition, these ACA do not behave as ordinary secondary 
changes. Firstly, they are strongly related to quite specific phenotypic features as the 
i(17q) have been associated with marked basophilia and the presence of pseudo Pelger-
Huët neutrophils [4], while other secondary aberrations are not. Secondly, they do not 
normally take place at the same time as other common additional changes, such as +8, 
i(17q), and +Ph, which clearly indicates that they follow a different evolutionary pathway. 
Rather than being secondary changes, they may be seen as second primary changes. It is 
worth noting that the fact that balanced aberrations characteristic of acute lymphoblastic 
leukemia (ALL), such as t(4;11)(q21;q23) and t(8;14)(q24;q32), have, to date, never been 
reported in CML blastic phase [12]. The idea that ALL-associated translocations cannot 
originate during the particular differentiation stage that characterizes the Ph-positive 
stem cell population is a possibility. On the other hand, and equally possible, ALL-
associated translocations may not provide any selective advantage for cells expressing the 
BCR/ABL1 chimeric protein.  
In 60–80% of the cases, ACA precede or accompany blastic phase [14, 15, 23-33], thus there is 
undoubtedly a strong association between secondary changes and transformation. 
Furthermore, early studies of splenic CML transformations give rise to strong support for 
the clinical importance of additional changes, showing that the secondary aberrations 
appeared in the spleen before bone marrow [34-36]. However, the prognostic impact of ACA 
has turned out to be difficult to assess. First, although most studies have reported that lack 
of ACA during blastic phase give rise to a better prognosis [32, 33, 37-41], some investigators 
have not found any prognostic differences between CML blastic phase cases with and 
without secondary changes [23, 30]. Second, it has been debated whether additional changes 
found during chronic phase constitute a dismal prognostic sign, announcing transformation. 
On one hand, as has been repeatedly highlighted, the emergence of new clones does not 
necessarily lead to disease progression and some clones appear only transiently [23, 42, 43]. 
On the other hand, the appearance of new ACA or increment of the clone with additional 
abnormalities has been shown to be  generally associated with clinical deterioration [28, 37, 
44].  
Moreover, Sokal et al. [45] reported that patients’ survival with secondary changes already 
present at the time of diagnosis had a shorter survival rate, but with survival curves for 
those with and without additional changes not diverging until after the 2-year point. Third, 
the number and types of aberrations present during chronic phase and blastic phase may 
also play a role. Quite often the karyotypic changes observed in the chronic phase are single 
events, particularly the loss of the Y chromosome, +8, +Ph, and i(17q) [47], while they are 
multiple and complex in blastic phase [15,31,37,42,46]. The aberrations in i(17q), or other 
changes that result in loss of 17p seem particularly ominous [15,23,25,37,42.47-49]. 
Furthermore, trisomy 8 and +Ph that take place in the blastic phase have been associated 
with poor prognosis [15, 50-52] (table 1). Thus, the prognostic impact of secondary 
abnormalities in CML is complex, heterogeneous, and is probably related to several 
parameters such as time of appearance and specific abnormalities [52]. 
Therefore, response to imatinib on the one hand, and resistance on the other, may also be 
conditioned by different types of ACAs. Enhanced response or resistance to treatment may 
be associated with the occurrence of different cytogenetic or molecular changes which are 
capable of activating the metabolic pathways with different outcomes [53,54]. Several 
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those with and without additional changes not diverging until after the 2-year point. Third, 
the number and types of aberrations present during chronic phase and blastic phase may 
also play a role. Quite often the karyotypic changes observed in the chronic phase are single 
events, particularly the loss of the Y chromosome, +8, +Ph, and i(17q) [47], while they are 
multiple and complex in blastic phase [15,31,37,42,46]. The aberrations in i(17q), or other 
changes that result in loss of 17p seem particularly ominous [15,23,25,37,42.47-49]. 
Furthermore, trisomy 8 and +Ph that take place in the blastic phase have been associated 
with poor prognosis [15, 50-52] (table 1). Thus, the prognostic impact of secondary 
abnormalities in CML is complex, heterogeneous, and is probably related to several 
parameters such as time of appearance and specific abnormalities [52]. 
Therefore, response to imatinib on the one hand, and resistance on the other, may also be 
conditioned by different types of ACAs. Enhanced response or resistance to treatment may 
be associated with the occurrence of different cytogenetic or molecular changes which are 
capable of activating the metabolic pathways with different outcomes [53,54]. Several 
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studies have assessed the impact of ACA on the clinical efficacy of imatinib by assuming 
that these abnormalities may confer BCR/ABL1-independent proliferation and decrease 
sensitivity to imatinib [50-55].   
However, the presence of additional copies of the BCR/ABL1 fusion onto structurally 
abnormal chromosomes has rarely been reported in the chronic or blastic phase of CML 
patients. 
We present two CML patients with additional copies of BCR/ABL1 fusions: the first patient 
with +Ph and BCR/ABL1 extra fusion in chromosome 18 in the blastic phase, and the 
second patient with four BCR/ABL1 fusion signals at diagnosis . 
2. Case report nº 1 
A 34-year-old patient was diagnosed with CML. The hematologic features were: Hb, 96 g; 
WBC, 354x109/L with 2% blasts, 4% basophils; platelets, 716x109/L. Neutrophil alkaline 
phosphatase (NAF) activity was absent. The bone marrow aspirate was hypercellular with 
1% blast cells.  
A cytogenetic study was performed on bone marrow cells and revealed a 
46,XY,t(9;22)(q34;q11) karyotype in all cells analyzed. FISH was performed on chromosome 
preparations using commercially available probe sets (LSI BCR/ABL-ES probe; Vysis, 
Downers Grove, IL) and based on a count of 100 cells (metaphases and interphases). The 
existence of the classic BCR/ABL1 fusion was proved. The patient was treated with 
hydroxyurea and a-interferon, with a satisfactory clinical, but unsatisfactory cytogenetic and 
FISH response , the maximum response reached,  based on a count of 120 cells, was 27/120 
cells with the BCR/ABL1 rearrangement during the 4 year follow-up . A bone marrow 
transplantation could not be performed because no compatible HLA-matched donor was 
available.  
After the aforementioned, 4 years after the initial diagnosis, a decrease of Hb, hematocrit, 
and platelets took place in the peripheral blood: WBC was 4.8x109/L with 38% blasts. Bone 
marrow was hypercellular, with 30% of cells representing the erythroid lineage at all the 
maturation stages, and with intense dyserythropoietic changes: 21% in the myeloid series 
(myeloid/erythroid ratio 5:1.5); 9% in the lymphoplasmocytoid series; and 40% as large 
blasts with fine chromatin in the nucleus, with two nucleoli, and irregularly shaped 
nongranular cytoplasms. Blast cells gave positive histochemical reactions for peroxidise and 
naphthol AS-D chloracetate esterase (inhibited by fluoride) and were periodic acid Schiff 
(PAS) positive as granules. Analysis in bone marrow of more than 100 cells at this time 
revealed that 94% of the cells had two fused BCR/ABL signals: one on the Ph chromosome 
and the other on the short arm of a derivative chromosome 18, detected by metaphase FISH 
analysis with Vysis LSI-BCR/ABL-ES and Cytocell mBCR/ABL probes (Fig. 1). Karyotype 
in bone marrow samples showed one Ph chromosome and one normal chromosome 22, and 
one normal chromosome 18 and another with a deletion of part of its short arm. The 
remaining 6% of cells only had the usual BCR/ABL1 fusion, without any other 
abnormalities.  
The patient was then treated with mitoxantrone and cytarabine without clinical response, 
and later with splenic radiotherapy, which led to an intense pancytopenia; the patient then 
died 4 years 8 months after the initial diagnosis. 
The occurrence of additional chromosome changes is an ominous sign, indicating that 
illness progression is imminent; however, the etiology of blastic transformation is still not 
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completely clear. Erythroblastic transformation of CML has been reported in 10% of patients 
in blastic crisis; nonetheless, this has not been clearly associated to specific chromosome 
aberrations [3-7, 61-66].  
 
 
(a)                                                                 (b) 
Fig. 1. (a) Metaphase cell FISH showing two fusions (a classic one in the Ph chromosome 
and another BCR/ABL fusion in 18p) (arrows), two orange signals (normal and residual 
ABL probe in 9q34), and one green signal (BCR in the normal 22 chromosome) (94% of cells). 
(b) Partial FISH metaphase with DAPI/ FITC showing the three copies of the BCR gene (in 
the Ph chromosome; in 18p, indicated by arrows; and in the normal chromosome 22) (94% of 
more than 100 cells).  
Three cases have been described with additional BCR/ABL1 fusions onto 18p accompanied 
by other chromosome alterations [67, 68], two of which have been reported by the same 
authors [68]. In the case described by Tanaka et al. [67], the blast morphology was not 
specified. Khac et al. [68], however, described two patients with CML in blastic 
transformation with a duplication and transposition of BCR/ABL1 to 18p that presented 
loss of part of its short arm; both patients had erythroblastic transformations, which the 
authors believed to be associated with this particular cytological subtype of disease 
progression in CML. The present case supports the relationship suggested by Khac et al. [68] 
between a tendency for erythroblastic transformation and the presence of extra fused 
BCR/ABL1 onto 18p, as in the patient we described, with a duplication and transposition of 
BCR/ABL1 onto 18p in the majority line (95%) in blastic phase, with no other chromosome 
alterations, together with an increase of red cells, intense dyserythropoietic features and 
PAS in granules leading to a fatal outcome. 
3. Case report nº 2 
A 31-year-old caucasian man, a smoker (10 cigarettes/day) and with a past 
appendectomy, presented with a history of abdominal pain with diarrhea and an abscess 
in the jawbone; he was attended at the Department of Hematology. Clinical examination 
revealed hepatosplenomegaly. Complementary tests revealed leukocytosis in a peripheral 
blood examination. His white blood cell count was 52x109/L, with a peripheral 
monocytosis of 18x109/L and a left shift. The number of platelets was 94x109/L; 
hemoglobin was normal; leukocyte alkaline phosphatase was reduced. In the biochemical 
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studies have assessed the impact of ACA on the clinical efficacy of imatinib by assuming 
that these abnormalities may confer BCR/ABL1-independent proliferation and decrease 
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Downers Grove, IL) and based on a count of 100 cells (metaphases and interphases). The 
existence of the classic BCR/ABL1 fusion was proved. The patient was treated with 
hydroxyurea and a-interferon, with a satisfactory clinical, but unsatisfactory cytogenetic and 
FISH response , the maximum response reached,  based on a count of 120 cells, was 27/120 
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maturation stages, and with intense dyserythropoietic changes: 21% in the myeloid series 
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and the other on the short arm of a derivative chromosome 18, detected by metaphase FISH 
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remaining 6% of cells only had the usual BCR/ABL1 fusion, without any other 
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died 4 years 8 months after the initial diagnosis. 
The occurrence of additional chromosome changes is an ominous sign, indicating that 
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completely clear. Erythroblastic transformation of CML has been reported in 10% of patients 
in blastic crisis; nonetheless, this has not been clearly associated to specific chromosome 
aberrations [3-7, 61-66].  
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Fig. 1. (a) Metaphase cell FISH showing two fusions (a classic one in the Ph chromosome 
and another BCR/ABL fusion in 18p) (arrows), two orange signals (normal and residual 
ABL probe in 9q34), and one green signal (BCR in the normal 22 chromosome) (94% of cells). 
(b) Partial FISH metaphase with DAPI/ FITC showing the three copies of the BCR gene (in 
the Ph chromosome; in 18p, indicated by arrows; and in the normal chromosome 22) (94% of 
more than 100 cells).  
Three cases have been described with additional BCR/ABL1 fusions onto 18p accompanied 
by other chromosome alterations [67, 68], two of which have been reported by the same 
authors [68]. In the case described by Tanaka et al. [67], the blast morphology was not 
specified. Khac et al. [68], however, described two patients with CML in blastic 
transformation with a duplication and transposition of BCR/ABL1 to 18p that presented 
loss of part of its short arm; both patients had erythroblastic transformations, which the 
authors believed to be associated with this particular cytological subtype of disease 
progression in CML. The present case supports the relationship suggested by Khac et al. [68] 
between a tendency for erythroblastic transformation and the presence of extra fused 
BCR/ABL1 onto 18p, as in the patient we described, with a duplication and transposition of 
BCR/ABL1 onto 18p in the majority line (95%) in blastic phase, with no other chromosome 
alterations, together with an increase of red cells, intense dyserythropoietic features and 
PAS in granules leading to a fatal outcome. 
3. Case report nº 2 
A 31-year-old caucasian man, a smoker (10 cigarettes/day) and with a past 
appendectomy, presented with a history of abdominal pain with diarrhea and an abscess 
in the jawbone; he was attended at the Department of Hematology. Clinical examination 
revealed hepatosplenomegaly. Complementary tests revealed leukocytosis in a peripheral 
blood examination. His white blood cell count was 52x109/L, with a peripheral 
monocytosis of 18x109/L and a left shift. The number of platelets was 94x109/L; 
hemoglobin was normal; leukocyte alkaline phosphatase was reduced. In the biochemical 
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study (which included lipids and thyroid hormones) increased HDL, vitamin B12 and uric 
acid were observed; findings of the remaining studies were normal. The 
thoracoabdominal computed tomography scan revealed mild bilateral axillary 
adenopathy, right pleural effusion, hepatomegaly, and periaortic adenopathy; the 
gastroduodenal endoscopy was unremarkable. The patient’s bone marrow was described 
as hypercellular, without visible fat spaces; megakaryocytes were present, normal in both 
number and morphology. The myeloid/erythroid ratio was 20:1. Myeloid precursors were 
high in number and left-shifted, with a relative increase in promyelocytes (7%) and 
eosinophils (6%). The blast percentage was 4%. Erythroid precursors were present in 
normal numbers.  
Cytogenetic analysis with G-banding was performed on chromosomes obtained from 24-
hour bone-marrow cell cultures following the standard procedures. Fluorescence in situ 
hybridization (FISH) was performed on chromosome preparations using a commercially 
available dual-color LSI BCR/ABL-ES probe (Abbott Molecular, Des Plaines, IL) labelled in 
SpectrumGreen and SpectrumOrange, respectively, to detect the BCR/ABL1 
rearrangements in interphase and metaphase nuclei. To identify the chromosomes 9 
correctly, a Vysis whole chromosome paint (WCP 9) was used, labeled in Spectrum- Orange. 
The hybridization was performed according to the manufacturer’s protocols.  
Molecular studies using real-time polymerase chain reaction (RT-PCR) from peripheral 
blood were performed. One microgram of the total RNA was used for cDNA synthesis, and 
later PCR was performed based on a Biomed protocol and using a LightCycler 2.0 [69] 
(Roche Diagnostics, Indianapolis, IN; Mannheim, Germany). A RT-PCR study with a 
fluorescence resonance energy transfer (FRET) probe quantification kit t(9;22) (Roche) that 
detected BCR/ABL1 fusion transcripts resulting from the major and minor breakpoint 
cluster regions (M-BCR and m-BCR) was also performed. The primers used in this kit were 
specifically designed to detect b3a2, b2a2, and e1a2 fusion transcripts, thereby covering 
>95% of the described t(9;22)  translocations. 
At diagnosis, cytogenetic studies indicated the following karyotype:  
46,XY,der(22)t(9;22)(q34;q11.2)[3]/48,XY,+9,t(9;22)(q34;q11.2)x2,+22[40] (figure 2A). 
FISH studies on 167 metaphase and interphase cells revealed the presence of a mosaicism 
formed by three distinct cellular clones at diagnosis. In the major clone, 150/167 cells (90%) 
presented four BCR/ABL1 fusion signals, with two signals on the two chromosomes der(9) 
and the other two signals on the two Ph chromosomes (Fig. 2B and 3). Three chromosomes 9 
were observed with a WCP-9 probe. A sole BCR/ABL1 fusion signal, on chromosome 22, 
was observed in 5/167 cells (3%), and there were no rearrangements in the remaining cells 
analyzed (12/167, or 7%). The FISH technique was performed twice, confirming the results. 
The RT-PCR demonstrated a p210, b3a2 fusion transcript.  
Once the patient was diagnosed as CML, treatment with imatinib was initiated at a dose 
of 400 mg/day. Two months later the patient was asymptomatic and in hematological 
remission. The b3a2 transcripts detected by RT-PCR were at 59%. The patient continued 
with the same imatinib treatment of 400 mg/day. Ten months after beginning therapy,  
a FISH follow-up study performed on a bone marrow sample revealed a cellular 
mosaicism, with partial remission. The initial majority line with four fusions was present 
in only 20/300 cells, only one BCR/ABL1 rearrangement was seen, on chromosome 22, in 
25/300 cells; the remaining 255/300 cells were normal, without any fusion signals. The 
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p210 BCR-ABL1 fusion transcript, identified using RT-PCR (Biomed protocol), decreased 
to 1.66%.  
 
 
Fig. 2. (A) Partial metaphase karyogram shows two derivative chromosomes 9 and two 
derivative chromosomes 22, along with one each of normal chromosomes 9 and 22 in case 
report nº 2 of chronic myeloid leukemia in chronic phase. (B) For the same patient, 
interphase FISH with LSI BCR/ABL-ES probes (Vysis; Abbott Molecular, Des Plaines, IL) 
shows four BCR/ABL1 fusion genes (arrows). Filter: 4’, 6-diamidino-2-phenylindole-
rhodamine-fluoresceinisothiocyanate 
A year after diagnosis, in a routine evaluation, the patient was still asymptomatic and in 
hematological remission. The RT-PCR study performed using FRET probes detected 
BCR/ABL1 transcripts. A quantification analysis (Biomed protocol) performed then was 
negative for p210 (b3a2), but p190 (e1a2) was found at 23.3%. Thus, the original sample was 
analyzed again, in which p190 was also positive. The original imatinib treatment was 
changed to dasatinib at 100 mg/day due to the disappearance of p210 and the presence of 
p190 in 23.3%. 
At diagnosis, the patient in the present case had a karyotype with 48 chromosomes and four 
BCR/ABL1 fusion signals distributed between the two Ph chromosomes and two out of the 
three chromosomes 9 in 90% of all the cells analyzed by FISH. One possible explanation 
could be that the classical BCR/ABL1 fusion occurs initially, followed first by the 
duplication and translocation of the fusion to a derivative 9 chromosome and then by a 
duplication of both Ph chromosomes and 9q+ (the remaining chromosomes were unaltered).  
The possible poor prognostic effect of a BCR/ABL1 fusion located on chromosome 9 has 
been described [4, 5, 61, 70]. Nevertheless, other researchers have reported cases of patients 
with a chimerical BCR/ABL1 fusion gene on chromosome 9 in ~80% of CML samples [62] 
and a double fusion on both chromosomes 9 [71, 72], and the clinical course of the disease 
seemed unaffected by the positional regulation. In the present case, there was only 
hematologic remission after treatment. With regard to treatment with imatinib, additional 
copies of the Ph chromosome have been reported [73, 74]. The development of additional 
chromosomal aberrations (ACA) in Ph negative or Ph+ cells during treatment is a sign of 
clonal evolution and of treatment failure. Patients with ACA more frequently tended to 
have BCR/ABL1 mutations (53% versus 29%) and more resistant mutations (60% versus 38%) 
[75]. The acquisition of ACAs may confer resistance to imatinib mesylate a mechanism for 
imatinib resistance. Therefore, response to imatinib on one hand and resistance on the other 
may also be conditioned by different types of ACAs. Enhanced response or resistance to 
treatment may be associated with the occurrence of different cytogenetic or molecular 
changes that are able to activate metabolic pathways with different outcomes [76-77]. 
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presented four BCR/ABL1 fusion signals, with two signals on the two chromosomes der(9) 
and the other two signals on the two Ph chromosomes (Fig. 2B and 3). Three chromosomes 9 
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Fig. 3. Metaphase FISH with Vysis LSI BCR/ABLeES probes shows four BCR/ABL fusion 
signals (yellow): two signals on the two der(9) chromosomes and two signals on the two 
der(22) chromosomes. The green and orange signals indicate, respectively, the BCR gene on 
the normal chromosome 22 and the ABL gene on the normal chromosome 9.  
In the present case, all the cytogenetic aberrations began to decrease with imatinib 
treatment, and only a small percentage of cells maintained the initial karyotype.  
At the molecular level, the patient showed a p210 and p190 fusion. A p210 decrease 
coincided with an important partial cytogenetical remission of the four BCR/ABL1 fusions. 
During evolution of the disease, the p210 protein disappeared with imatinib as first-line 
treatment, but p190 increased until treatment with dasatinib was started. 
Five months after the start of treatment with dasatinib, RT-PCR showed that p210 remained 
negative and p190 had decreased to 1%. Two years after diagnosis, the patient was still 
clinically asymptomatic and hematologically in remission. New FISH studies, with 200 cells 
analyzed, also showed complete cytogenetic remission. Molecular studies remained 
negative for p210 and positive for p190 in only 0.09%.  
Although interphase FISH is increasingly used for BCR/ABL1 gene rearrangement 
identification in CML, we believe, in agreement with Lim et al. [72] and Primo et al. [79] and  
supported by the present case, that the exact interpretation of any atypical interphase FISH 
pattern is dependent on FISH metaphase studies and molecular breakpoint definition of 
BCR/ABL1 fusion.  
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Fig. 3. Metaphase FISH with Vysis LSI BCR/ABLeES probes shows four BCR/ABL fusion 
signals (yellow): two signals on the two der(9) chromosomes and two signals on the two 
der(22) chromosomes. The green and orange signals indicate, respectively, the BCR gene on 
the normal chromosome 22 and the ABL gene on the normal chromosome 9.  
In the present case, all the cytogenetic aberrations began to decrease with imatinib 
treatment, and only a small percentage of cells maintained the initial karyotype.  
At the molecular level, the patient showed a p210 and p190 fusion. A p210 decrease 
coincided with an important partial cytogenetical remission of the four BCR/ABL1 fusions. 
During evolution of the disease, the p210 protein disappeared with imatinib as first-line 
treatment, but p190 increased until treatment with dasatinib was started. 
Five months after the start of treatment with dasatinib, RT-PCR showed that p210 remained 
negative and p190 had decreased to 1%. Two years after diagnosis, the patient was still 
clinically asymptomatic and hematologically in remission. New FISH studies, with 200 cells 
analyzed, also showed complete cytogenetic remission. Molecular studies remained 
negative for p210 and positive for p190 in only 0.09%.  
Although interphase FISH is increasingly used for BCR/ABL1 gene rearrangement 
identification in CML, we believe, in agreement with Lim et al. [72] and Primo et al. [79] and  
supported by the present case, that the exact interpretation of any atypical interphase FISH 
pattern is dependent on FISH metaphase studies and molecular breakpoint definition of 
BCR/ABL1 fusion.  
4. References 
[1] Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid 
leukemia. Blood. 2000; 96: 3343-3356. 
[2] Era T, Witte ON. Regulated expression of p210 Bcr-Abl during embryonic stem cell 
differentiation stimulates multipotential progenitor expansion and myeloid cell 
fate. Proc Natl Acad Sci U S A. 2000; 97: 1737-1742. 
[3] Sandberg AA. The chromosomes in human cancer and leukemia. 2nd ed. New York: 
Elsevier, 1990. 
[4] Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 
1993; 11(Suppl. 1):11-5. 
 
BCR/ABL1 Extra Fusions in Patients with Chronic Myeloid Leukaemia (CML) 
 
35 
[5] Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerrasio Ade Micheli D, Parziale 
A, Fornaci MN, Martinelli G, Salvatore F. Consistent amounts of acute leukemia-
associated p190 BCR/ABL transcripts are expressed by chronic myelogenous 
leukemia patients at diagnosis. Blood 1996; 87: 1075-80. 
[6] Van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR/ABL 
mRNA is expressed at low levels in p210-positive chronic myeloid and acute 
lymphoblastic leukemias. Blood 1996; 87: 5213-7. 
[7] Brunel V, Sainty D, Costello R, Mozziconacci MJ, Simonetti J, Arnoulet C, Coignet L, 
Bouabdallah R, Gastaut JA, Gabert J, Lafage- Pochitaloff M. Translocation of BCR to  
chromosome 9 in a Philadelphia- negative chronic myeloid leukemia. Cancer Genet 
Cytogenet 1995; 85: 82-4. 
[8] Mitelman F, Johansson B, Mertens F: Recurrent Chromosome Aberrations in Cancer 
(2001). http://cgap.nci.nih.gov/Chromosomes/ RecurrentAberrations. 
[9] Mitelman F, Levan G, Nilsson PG, Brandt L: Non-random karyotypic evolution in 
chronic myeloid leukemia. Int J Cancer 1976; 18: 24– 30. 
[10] Heim S, Mitelman F: Cancer Cytogenetics, ed 2. New York, Wiley-Liss, 1995. 
[11] Prigogina EL, Fleischman EW, Volkova MA, Frenkel MA: Chromosome abnormalities 
and clinical and morphologic manifestations of chronic myeloid leukemia. Hum 
Genet 1978; 41:143–156. 
[12] Mitelman F, Johansson B, Mertens F: Database of Chromosome Aberrations in Cancer 
(2001). http://cgap.nci.nih.gov/Chromosomes/ Mitelman. 
[13]  Hashimoto T, Ohtaki M, Kamada N, Yamamoto H, Munaka M: Application of log-
linear model in inference on karyotypic evolution in chronic myelocytic leukemia. 
Environ Health Perspect 1990; 87: 135–141. 
[14] First International Workshop on Chromosomes in Leukaemia: Chromosomes in Ph1- 
positive chronic granulocytic leukaemia. Br J Haematol 1978; 39: 305–309. 
[15] Ishihara T, Sasaki M, Oshimura M, Kamada N, Yamada K, Okada M, Sakurai M, 
Sugiyama T, Shiraishi Y, Kohno S-I: A summary of cytogenetic studies on 534 cases 
of chronic myelocytic leukemia in Japan. Cancer Genet Cytogenet 1983; 9: 81–92. 
[16] Johansson B, Mertens F, Mitelman F: Primary vs. secondary neoplasia-associated 
chromosomal abnormalities – Balanced rearrangements vs. genomic imbalances? 
Genes Chromosomes Cancer 1996; 16: 155–163. 
[18] Pintado T, Ferro MT, San Roman C, Mayayo M, Larana JG: Clinical correlations of the 
3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with 
preserved or increased platelet production and lack of response to cytotoxic drug 
therapy. Cancer 1985; 55: 535–541. 
[19]  Rubin CM, Larson RA, Bitter MA, Carrino JJ, Le Beau MM, Diaz MO, Rowley JD: 
Association of a chromosomal 3;21 translocation with the blast phase of chronic 
myelogenous leukemia. Blood 1987; 70: 1338–1342. 
[20]  Sato Y, Abe S, Mise K, Sasaki M, Kamada N, Kouda K, Musashi M, Saburi Y, Horikoshi 
A, Minami Y, Miyakuni T, Yokoyama Y, Ishihara Y, Miura Y: Reciprocal 
translocation involving the short arms of chromosomes 7 and 11, t(7p-;11p+), 
associated with myeloid leukaemia with maturation. Blood 1987; 70: 1654–1658. 
[21]  Ferro MT, Steegman JL, Escribano L, Heiurichs B, Parada L, Garcia-Sagredo JM, Resino 
M, Cabello P, San Roman C: Ph-positive chronic myeloid leukemia with 
t(8;21)(q22;q22) in blastic crisis. Cancer Genet Cytogenet 1992; 58: 96–99. 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
36
[22]  Heim S, Egelund Christensen B, Fioretos T, Sörensen A-G, Tinggaard Pedersen N: 
Acute myelomonocytic leukemia with inv(16)(p13q22) complicating Philadelphia 
chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 1992; 59: 
35–38. 
[23]  Bernstein R, Morcom G, Pinto MR, Mendelow B, Dukes I, Penfold G, Bezwoda W: 
Cytogenetic findings in chronic myeloid leukaemia (CML); evaluation of 
karyotype, blast morphology, and survival in the acute phase. Cancer Genet 
Cytogenet 1980; 2: 23–37. 
[24] Tomiyasu T, Sasaki M, Kondo K, Okada M: Chromosome banding studies in 106 cases 
of chronic myelogenous leukemia. Jpn J Hum Genet 1982; 27: 243–258. 
[25] Bernstein R: Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988; 25: 
20–34. 
[26]  Stoll C, Oberling F: Non-random clonal evolution in 45 cases of chronic myeloid 
leukemia. Leuk Res 1978; 3: 61–66. 
[27] Carbonell F, Benitez J, Prieto F, Badia L, Sanchez- Fayos J: Chromosome banding 
patterns in patients with chronic myelocytic leukemia. Cancer Genet Cytogenet 
1982; 7: 287–297. 
[28] Swolin B, Weinfeld A, Westin J, Waldenström J, Magnusson B: Karyotypic evolution in 
Ph-positive chronic myeloid leukemia in relation to management and disease 
progression. Cancer Genet Cytogenet 1985; 18: 65– 79. 
[29] Löwenberg B, Hagemeijer A, Abels J: Detection of the blastic crisis cell clone in chronic 
myeloid leukaemia. Br J Haematol 1985; 59: 27–36. 
[30] Cervantes F, Ballesta F, Mila M, Rozman C: Cytogenetic studies in blast crisis of Ph-
positive chronic granulocytic leukemia: Results and prognostic evaluation in 52 
patients. Cancer Genet Cytogenet 1986; 21: 239–246. 
[31] Krulik M, Smadja N, de Gramont A, Gonzalez- Canali G, Audebert AA, Dray C, 
Brissaud P, Debray J: Sequential karyotype study onPh-positive chronic myelocytic 
leukemia. Significance of additional chromosomal abnormalities during disease 
evolution. Cancer 1987; 60: 974–979. 
[32] 4 Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, 
Freireich EJ: Chronic myelogenous leukaemia in blast crisis. Analysis of 242 
patients. Am J Med 1987; 83: 445–454. 
[33]  Przepiorka D, Thomas ED: Prognostic significance of cytogenetic abnormalities in 
patients with chronic myelogenous leukemia. Bone Marrow Transplant 1988; 3: 
113–119. 
[34] Mitelman F, Brandt L, Nilsson PG: Cytogenetic evidence for splenic origin of blastic 
transformation in chronic myeloid leukaemia. Scand J Haematol 1974;13:87–92. 
[35] Gomez G, Hossfeld DK, Sokal JE: Removal of abnormal clone of leukaemic cells by 
splenectomy. Br Med J 1975; ii: 421–423. 
[36] Mitelman F, Nilsson PG, Brandt L: Abnormal clones resembling those seen in blast 
crisis arising in the spleen in chronic myelocytic leukemia. J Natl Cancer Inst 1975; 
54: 1319– 1321. 
[37] Fleischman EW, Prigogina EL, Volkova MA, Frenkel MA, Zakhartchenko NA, 
Konstantinova LN, Puchkova GP, Balakirev SA: Correlations between the clinical 
course, characteristics of blast cells, and karyotype patterns in chronic myeloid 
leukemia. Hum Genet 1981; 58: 285–293. 
 
BCR/ABL1 Extra Fusions in Patients with Chronic Myeloid Leukaemia (CML) 
 
37 
[38] Swolin B, Weinfeld A, Waldenström J, Westin J: Cytogenetic studies of bone marrow 
and extramedullary tissues and clinical course during metamorphosis of chronic 
myelocytic leukemia. Cancer Genet Cytogenet 1983 ; 9: 197– 209. 
[39]  Alimena G, Dallapiccola B, Gastaldi R, Mandelli F, Brandt L, Mitelman F, Nilsson PG: 
Chromosomal, morphological and clinical correlations in blastic crisis of chronic 
myeloid leukaemia. A study of 69 cases. Scand J Haematol 1982; 28: 103–117. 
[40] 199 Sadamori N, Gomez GA, Sandberg AA: Therapeutic and prognostic value of initial 
chromosomal findings at the blastic phase of Ph1-positive chronic myeloid 
leukemia. Blood 1983; 61: 935–939. 
[41] Muehleck SD, McKenna RW, Arthur DC, Parkin JL, Brunning RD: Transformation of 
chronic myelogenous leukemia: Clinical, morphologic, and cytogenetic features. 
Am J Clin Pathol 1984; 82: 1–14. 
[42] Hagemeijer A, Stenfert Kroeze WF, Abels J: Cytogenetic follow-up of patients with 
nonlymphocytic leukemia I. Philadelphia chromosome- positive chronic myeloid 
leukemia. Cancer Genet Cytogenet 1980; 2: 317–326. 
[43] Watmore AE, Potter AM, Sokol RJ, Wood JK: Value of cytogenetic studies in prediction 
of acute phase CML. Cancer Genet Cytogenet 1985; 14: 293–301. 
[44]  Lilleyman JS, Potter AM, Watmore AE, Cooke P, Sokol RJ, Wood JK: Myeloid 
karyotype and the malignant phase of chronic granulocytic leukaemia. Br J 
Haematol 1978; 39: 317–323. 
[45] Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, Rozman C, 
Carbonell F, Anger B, Heimpel H, Nissen NI, Robertson JE: Prognostic significance 
of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-
positive chronic granulocytic leukemia. Blood 1988; 72: 294–298. 
[46] Gödde-Salz E, Schmitz N, Bruhn H-D: Philadelphia chromosome (Ph) positive chronic 
myelocytic leukemia (CML): Frequency of additional findings. Cancer Genet 
Cytogenet 1985; 14: 313–323. 
[47] Lawler SD, O’Malley F, Lobb DS: Chromosome banding studies in Philadelphia 
chromosome positive myeloid leukaemia. Scand J Haematol 1976; 17: 17–28.  
[48] Majlis A, Smith TL, Talpaz M, O’Brien S, Rios MB, Kantarjian HM: Significance of 
cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996; 
14: 196–203. 
[49]  Borgström GH, Vuopio P, de la Chapelle A: Abnormalities of chromosome No. 17 in 
myeloproliferative disorders. Cancer Genet Cytogenet 1982; 5: 123–135. 
[50]  Olah E, Rak K: Prognostic value of chromosomal findings in the blast phase of Ph1-
positive chronic myeloid leukaemia (CML). Int J Cancer 1981; 27: 287–295. 
[51] Cervantes F, Rozman M, Rosell J, Urbano- Ispizua A, Montserrat E, Rozman C: A study 
of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic 
myelogenous leukaemia. Br J Haematol 1990; 76: 27–32. 
[51] Griesshammer M, Heinze B, Hellmann A, Popp C, Anger B, Heil G, Bangerter M, 
Heimpel H: Chronic myelogenous leukaemia in blast crisis: Retrospective analysis 
of prognostic factors in 90 patients. Ann Hematol 1996; 73: 225–230. 
[52] Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Johansson B, 
Fioretos T, Mitelman F. Acta Haematol. 2002; 107(2): 76-94.  
[53] Hochhaus A, Kreil S, Corbin AS, La Rose´e P, Mu¨ller MC, Lahaye T, Hanfstein B, 
Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
36
[22]  Heim S, Egelund Christensen B, Fioretos T, Sörensen A-G, Tinggaard Pedersen N: 
Acute myelomonocytic leukemia with inv(16)(p13q22) complicating Philadelphia 
chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 1992; 59: 
35–38. 
[23]  Bernstein R, Morcom G, Pinto MR, Mendelow B, Dukes I, Penfold G, Bezwoda W: 
Cytogenetic findings in chronic myeloid leukaemia (CML); evaluation of 
karyotype, blast morphology, and survival in the acute phase. Cancer Genet 
Cytogenet 1980; 2: 23–37. 
[24] Tomiyasu T, Sasaki M, Kondo K, Okada M: Chromosome banding studies in 106 cases 
of chronic myelogenous leukemia. Jpn J Hum Genet 1982; 27: 243–258. 
[25] Bernstein R: Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988; 25: 
20–34. 
[26]  Stoll C, Oberling F: Non-random clonal evolution in 45 cases of chronic myeloid 
leukemia. Leuk Res 1978; 3: 61–66. 
[27] Carbonell F, Benitez J, Prieto F, Badia L, Sanchez- Fayos J: Chromosome banding 
patterns in patients with chronic myelocytic leukemia. Cancer Genet Cytogenet 
1982; 7: 287–297. 
[28] Swolin B, Weinfeld A, Westin J, Waldenström J, Magnusson B: Karyotypic evolution in 
Ph-positive chronic myeloid leukemia in relation to management and disease 
progression. Cancer Genet Cytogenet 1985; 18: 65– 79. 
[29] Löwenberg B, Hagemeijer A, Abels J: Detection of the blastic crisis cell clone in chronic 
myeloid leukaemia. Br J Haematol 1985; 59: 27–36. 
[30] Cervantes F, Ballesta F, Mila M, Rozman C: Cytogenetic studies in blast crisis of Ph-
positive chronic granulocytic leukemia: Results and prognostic evaluation in 52 
patients. Cancer Genet Cytogenet 1986; 21: 239–246. 
[31] Krulik M, Smadja N, de Gramont A, Gonzalez- Canali G, Audebert AA, Dray C, 
Brissaud P, Debray J: Sequential karyotype study onPh-positive chronic myelocytic 
leukemia. Significance of additional chromosomal abnormalities during disease 
evolution. Cancer 1987; 60: 974–979. 
[32] 4 Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, 
Freireich EJ: Chronic myelogenous leukaemia in blast crisis. Analysis of 242 
patients. Am J Med 1987; 83: 445–454. 
[33]  Przepiorka D, Thomas ED: Prognostic significance of cytogenetic abnormalities in 
patients with chronic myelogenous leukemia. Bone Marrow Transplant 1988; 3: 
113–119. 
[34] Mitelman F, Brandt L, Nilsson PG: Cytogenetic evidence for splenic origin of blastic 
transformation in chronic myeloid leukaemia. Scand J Haematol 1974;13:87–92. 
[35] Gomez G, Hossfeld DK, Sokal JE: Removal of abnormal clone of leukaemic cells by 
splenectomy. Br Med J 1975; ii: 421–423. 
[36] Mitelman F, Nilsson PG, Brandt L: Abnormal clones resembling those seen in blast 
crisis arising in the spleen in chronic myelocytic leukemia. J Natl Cancer Inst 1975; 
54: 1319– 1321. 
[37] Fleischman EW, Prigogina EL, Volkova MA, Frenkel MA, Zakhartchenko NA, 
Konstantinova LN, Puchkova GP, Balakirev SA: Correlations between the clinical 
course, characteristics of blast cells, and karyotype patterns in chronic myeloid 
leukemia. Hum Genet 1981; 58: 285–293. 
 
BCR/ABL1 Extra Fusions in Patients with Chronic Myeloid Leukaemia (CML) 
 
37 
[38] Swolin B, Weinfeld A, Waldenström J, Westin J: Cytogenetic studies of bone marrow 
and extramedullary tissues and clinical course during metamorphosis of chronic 
myelocytic leukemia. Cancer Genet Cytogenet 1983 ; 9: 197– 209. 
[39]  Alimena G, Dallapiccola B, Gastaldi R, Mandelli F, Brandt L, Mitelman F, Nilsson PG: 
Chromosomal, morphological and clinical correlations in blastic crisis of chronic 
myeloid leukaemia. A study of 69 cases. Scand J Haematol 1982; 28: 103–117. 
[40] 199 Sadamori N, Gomez GA, Sandberg AA: Therapeutic and prognostic value of initial 
chromosomal findings at the blastic phase of Ph1-positive chronic myeloid 
leukemia. Blood 1983; 61: 935–939. 
[41] Muehleck SD, McKenna RW, Arthur DC, Parkin JL, Brunning RD: Transformation of 
chronic myelogenous leukemia: Clinical, morphologic, and cytogenetic features. 
Am J Clin Pathol 1984; 82: 1–14. 
[42] Hagemeijer A, Stenfert Kroeze WF, Abels J: Cytogenetic follow-up of patients with 
nonlymphocytic leukemia I. Philadelphia chromosome- positive chronic myeloid 
leukemia. Cancer Genet Cytogenet 1980; 2: 317–326. 
[43] Watmore AE, Potter AM, Sokol RJ, Wood JK: Value of cytogenetic studies in prediction 
of acute phase CML. Cancer Genet Cytogenet 1985; 14: 293–301. 
[44]  Lilleyman JS, Potter AM, Watmore AE, Cooke P, Sokol RJ, Wood JK: Myeloid 
karyotype and the malignant phase of chronic granulocytic leukaemia. Br J 
Haematol 1978; 39: 317–323. 
[45] Sokal JE, Gomez GA, Baccarani M, Tura S, Clarkson BD, Cervantes F, Rozman C, 
Carbonell F, Anger B, Heimpel H, Nissen NI, Robertson JE: Prognostic significance 
of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-
positive chronic granulocytic leukemia. Blood 1988; 72: 294–298. 
[46] Gödde-Salz E, Schmitz N, Bruhn H-D: Philadelphia chromosome (Ph) positive chronic 
myelocytic leukemia (CML): Frequency of additional findings. Cancer Genet 
Cytogenet 1985; 14: 313–323. 
[47] Lawler SD, O’Malley F, Lobb DS: Chromosome banding studies in Philadelphia 
chromosome positive myeloid leukaemia. Scand J Haematol 1976; 17: 17–28.  
[48] Majlis A, Smith TL, Talpaz M, O’Brien S, Rios MB, Kantarjian HM: Significance of 
cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996; 
14: 196–203. 
[49]  Borgström GH, Vuopio P, de la Chapelle A: Abnormalities of chromosome No. 17 in 
myeloproliferative disorders. Cancer Genet Cytogenet 1982; 5: 123–135. 
[50]  Olah E, Rak K: Prognostic value of chromosomal findings in the blast phase of Ph1-
positive chronic myeloid leukaemia (CML). Int J Cancer 1981; 27: 287–295. 
[51] Cervantes F, Rozman M, Rosell J, Urbano- Ispizua A, Montserrat E, Rozman C: A study 
of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic 
myelogenous leukaemia. Br J Haematol 1990; 76: 27–32. 
[51] Griesshammer M, Heinze B, Hellmann A, Popp C, Anger B, Heil G, Bangerter M, 
Heimpel H: Chronic myelogenous leukaemia in blast crisis: Retrospective analysis 
of prognostic factors in 90 patients. Ann Hematol 1996; 73: 225–230. 
[52] Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Johansson B, 
Fioretos T, Mitelman F. Acta Haematol. 2002; 107(2): 76-94.  
[53] Hochhaus A, Kreil S, Corbin AS, La Rose´e P, Mu¨ller MC, Lahaye T, Hanfstein B, 
Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
38
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) 
therapy. Leukemia 2002; 16: 2190-6. 
[54] Ossard- Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, Lozach F. 
Duplication of the Ph-chromosome as a possible mechanism of resistance to 
imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet 
Cytogenet 2005; 163: 189-90. 
[55] Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et al. Prognostic significance of 
cytogenetic clonal evolution in patients with chronic myelogenous leukemia on 
imatinib mesylate therapy. Blood. 2003; 101(10): 3794-800. 
[56] Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on 
patients with Philadelphia chromosome- positive chronic myeloid leukemia with 
secondary chromosomal aberrations. Clin Cancer Res. 2003; 9(4): 1333-7. 
[57] O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, et al. Clonal 
evolution and lack of cytogenetic response are adverse prognostic factors for 
hematologic relapse of chronic phase CML patients treated with imatinib mesylate. 
Blood. 2004; 103(2): 451-5. 
[58] O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al. The impact of 
clonal evolution on response to imatinib mesylate (STI571) in accelerated phase 
CML. Blood. 2002; 100 (5): 1628-33. 
[59] Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, et al. Occurrence 
of additional chromosome aberrations in chronic myeloid leukemia patients treated 
with imatinib mesylate. Leukemia. 2003; 17(2): 461-3. 
[60] Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, et al. Influence of 
additional cytogenetic abnormalities on the response and survival in late chronic 
phase chronic myeloid leukemia patients treated with imatinib: long-term results. 
Leuk Lymphoma. 2009; 50(1): 114-8. 
[61] Aurich J, Dastugue N, Duchayne E, Schlaifer D, Rigal-Huguet F, Caballin MR. Location 
of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic 
myeloid leukemia. Genes Chromosomes Cancer 1997; 20: 148-54. 
[62] Macera MJ, Smith LJ, Frankel E, Szabo P, Verma RS. A Philadelphia negative chronic 
myelogenous leukemia with the chimeric BCR/ABL gene on chromosome 9 and 
b3-a2 splice junction. Cancer Genet Cytogenet 1998; 101:143-7. 
[63] Mitelman F, Johansson B, Mertens F (Eds.). Mitelman database of chromosome 
aberrations and gene fusions in cancer. Updated February 2011. Available from 
http://cgap.nci.nih.gov/Chromosomes/Mitelman 
[64] Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of 
chronic myeloid leukemia. Cytogenetic and molecular genetic evolution of chronic 
myeloid leukemia. Acta Haematol. 2002; 107(2): 76-94.  
[65] Jiang DZ, Chen ZM, Lou JY, Wang YG, Liang Y, Jin J. Cytogenetic and molecular 
analysis of 1193 cases with chronic myeloid leukaemia. Zhonghua Xue Ye Xue Za 
Zhi. 2007 Jan; 28(1): 1-5. 
[66] Qiu HR, Miao KR, Qian SX, Wang R, Hong M, Qiao C, Zhang JF, Fan L, Wu HX, Lu H, 
Qiu HX, Chen LJ, Liu P, Zhang SJ, Xu W, Li JY. Cytogenetic analysis of 362 cases of 
chronic myeloid leukaemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb; 17(1): 
27-30. 
 
BCR/ABL1 Extra Fusions in Patients with Chronic Myeloid Leukaemia (CML) 
 
39 
[67] Tanaka K, Arif M, Kyo T, Dohy H, Kamada N. Transposition of duplicated 
chromosomal segment involving fused BCR/ABL gene or ABL oncogene alone in 
chronic myelocytic leukemia and Ph chromosomepositive acute leukemia with 
complex karyotypes. Cancer Genet Cytogenet 2000; 119: 8–14. 
[68] Khac FN, Waill MC, Romana SP, Radford-Weiss I, Busson M, Collonge-Rame MA, 
Ribadeau-Dumas A, Piffaut MC, Daniel MT, Davi F, Merle-Be´ral H, Berger R, 
Arock M. Identical abnormality of the short arm of chromosome 18 in two 
Philadelphia-positive chronic myelocytic leukemia patients with erythroblastic 
transformation, resulting in duplication of BCR/ABL1 fusion. Cancer Genet 
Cytogenet 2002; 138: 22–6. 
[69] Gabert J, Beillard E, Van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, 
Cazzaniga G, Cayuela JM, Cave´ H, Pane F, Aerts JL, De Micheli D, Thirion X, 
Pradel V, Gonza´lez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. 
Standardization and quality control studies of ‘real-time’ quantitative reverse 
transcriptase polymerase chain reaction of fusion gene transcripts for residual 
disease detection in leukemia: a Europe Against Cancer Program. Leukemia 2003; 
17: 2318-57. 
[70] Aurer I, Canaani E, Gale RP. Hypothesis: additional cytogenetic abnormalities and 
progression to acute phase in chronic myelogenous leukemia. Leukemia 1991; 
5:1012e3. 
[71] Michalova´ K, Zemanova´ Z, Bkezinova´ J, Moravcova´ J, Oltova´ A, Sobotka J, Kugl´k 
P, Kozak T, Sindelarova´ L, Jankovska´ M, Obomilova´ A, Sieglova´ Z, Pola´k J, 
Na´dvorn´kova´ S, Haskovec C. Location of the BCR/ABL fusion genes on both 
chromosomes 9q34 in Ph negative chronic myeloid leukemia. Leuk Lymphoma 
2002; 43: 1695-700. 
[72] Lim TH, Tien SL, Lim P, Lim AS. The incidence and patterns of BCR/ABL  
rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ 
hybridisation (FISH). Ann Acad Med Singapore 2005; 34: 533-8. 
[73] Gambacorti-PasseriniCB,GunbyRH, Piazza R,GaliettaA, Rostagno R, Scapozza L. 
Molecular mechanisms of resistance to imatinib in Philadelphia- chromosome-
positive leukaemias. Lancet Oncol 2003; 4: 75-85. 
[74] Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc 
Hematol Educ Program 2003; 2003: 132-52. 
[75] Hochhaus A, Kreil S, Corbin AS, La Rose´e P, Mu¨ller MC, Lahaye T, Hanfstein B, 
Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) 
therapy. Leukemia 2002; 16: 2190-6. 
[76] Ossard- Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, Lozach F. 
Duplication of the Ph-chromosome as a possible mechanism of resistance to 
imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet 
Cytogenet 2005; 163: 189-90. 
[77] Zaccaria A, Testoni N, Valenti AM, Luatti S, Tonelli M, Marzocchi G, Cipriani R, 
Baldazzi C, Giannini B, Stacchini M, Gamberini C, Castagnetti F, Rosti G, Azzena 
A, Cavazzini F, Cianciulli AM, Dalsass A, Donti E, Giugliano E, Gozzetti A, 
Grimoldi MG, Ronconi S, Santoro A, Spedicato F, Zanatta L, Baccarani M; 
GIMEMA Working Party on CML. Chromosome abnormalities additional to the 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
38
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) 
therapy. Leukemia 2002; 16: 2190-6. 
[54] Ossard- Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, Lozach F. 
Duplication of the Ph-chromosome as a possible mechanism of resistance to 
imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet 
Cytogenet 2005; 163: 189-90. 
[55] Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et al. Prognostic significance of 
cytogenetic clonal evolution in patients with chronic myelogenous leukemia on 
imatinib mesylate therapy. Blood. 2003; 101(10): 3794-800. 
[56] Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on 
patients with Philadelphia chromosome- positive chronic myeloid leukemia with 
secondary chromosomal aberrations. Clin Cancer Res. 2003; 9(4): 1333-7. 
[57] O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, et al. Clonal 
evolution and lack of cytogenetic response are adverse prognostic factors for 
hematologic relapse of chronic phase CML patients treated with imatinib mesylate. 
Blood. 2004; 103(2): 451-5. 
[58] O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al. The impact of 
clonal evolution on response to imatinib mesylate (STI571) in accelerated phase 
CML. Blood. 2002; 100 (5): 1628-33. 
[59] Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, et al. Occurrence 
of additional chromosome aberrations in chronic myeloid leukemia patients treated 
with imatinib mesylate. Leukemia. 2003; 17(2): 461-3. 
[60] Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, et al. Influence of 
additional cytogenetic abnormalities on the response and survival in late chronic 
phase chronic myeloid leukemia patients treated with imatinib: long-term results. 
Leuk Lymphoma. 2009; 50(1): 114-8. 
[61] Aurich J, Dastugue N, Duchayne E, Schlaifer D, Rigal-Huguet F, Caballin MR. Location 
of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic 
myeloid leukemia. Genes Chromosomes Cancer 1997; 20: 148-54. 
[62] Macera MJ, Smith LJ, Frankel E, Szabo P, Verma RS. A Philadelphia negative chronic 
myelogenous leukemia with the chimeric BCR/ABL gene on chromosome 9 and 
b3-a2 splice junction. Cancer Genet Cytogenet 1998; 101:143-7. 
[63] Mitelman F, Johansson B, Mertens F (Eds.). Mitelman database of chromosome 
aberrations and gene fusions in cancer. Updated February 2011. Available from 
http://cgap.nci.nih.gov/Chromosomes/Mitelman 
[64] Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of 
chronic myeloid leukemia. Cytogenetic and molecular genetic evolution of chronic 
myeloid leukemia. Acta Haematol. 2002; 107(2): 76-94.  
[65] Jiang DZ, Chen ZM, Lou JY, Wang YG, Liang Y, Jin J. Cytogenetic and molecular 
analysis of 1193 cases with chronic myeloid leukaemia. Zhonghua Xue Ye Xue Za 
Zhi. 2007 Jan; 28(1): 1-5. 
[66] Qiu HR, Miao KR, Qian SX, Wang R, Hong M, Qiao C, Zhang JF, Fan L, Wu HX, Lu H, 
Qiu HX, Chen LJ, Liu P, Zhang SJ, Xu W, Li JY. Cytogenetic analysis of 362 cases of 
chronic myeloid leukaemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb; 17(1): 
27-30. 
 
BCR/ABL1 Extra Fusions in Patients with Chronic Myeloid Leukaemia (CML) 
 
39 
[67] Tanaka K, Arif M, Kyo T, Dohy H, Kamada N. Transposition of duplicated 
chromosomal segment involving fused BCR/ABL gene or ABL oncogene alone in 
chronic myelocytic leukemia and Ph chromosomepositive acute leukemia with 
complex karyotypes. Cancer Genet Cytogenet 2000; 119: 8–14. 
[68] Khac FN, Waill MC, Romana SP, Radford-Weiss I, Busson M, Collonge-Rame MA, 
Ribadeau-Dumas A, Piffaut MC, Daniel MT, Davi F, Merle-Be´ral H, Berger R, 
Arock M. Identical abnormality of the short arm of chromosome 18 in two 
Philadelphia-positive chronic myelocytic leukemia patients with erythroblastic 
transformation, resulting in duplication of BCR/ABL1 fusion. Cancer Genet 
Cytogenet 2002; 138: 22–6. 
[69] Gabert J, Beillard E, Van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, 
Cazzaniga G, Cayuela JM, Cave´ H, Pane F, Aerts JL, De Micheli D, Thirion X, 
Pradel V, Gonza´lez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. 
Standardization and quality control studies of ‘real-time’ quantitative reverse 
transcriptase polymerase chain reaction of fusion gene transcripts for residual 
disease detection in leukemia: a Europe Against Cancer Program. Leukemia 2003; 
17: 2318-57. 
[70] Aurer I, Canaani E, Gale RP. Hypothesis: additional cytogenetic abnormalities and 
progression to acute phase in chronic myelogenous leukemia. Leukemia 1991; 
5:1012e3. 
[71] Michalova´ K, Zemanova´ Z, Bkezinova´ J, Moravcova´ J, Oltova´ A, Sobotka J, Kugl´k 
P, Kozak T, Sindelarova´ L, Jankovska´ M, Obomilova´ A, Sieglova´ Z, Pola´k J, 
Na´dvorn´kova´ S, Haskovec C. Location of the BCR/ABL fusion genes on both 
chromosomes 9q34 in Ph negative chronic myeloid leukemia. Leuk Lymphoma 
2002; 43: 1695-700. 
[72] Lim TH, Tien SL, Lim P, Lim AS. The incidence and patterns of BCR/ABL  
rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ 
hybridisation (FISH). Ann Acad Med Singapore 2005; 34: 533-8. 
[73] Gambacorti-PasseriniCB,GunbyRH, Piazza R,GaliettaA, Rostagno R, Scapozza L. 
Molecular mechanisms of resistance to imatinib in Philadelphia- chromosome-
positive leukaemias. Lancet Oncol 2003; 4: 75-85. 
[74] Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc 
Hematol Educ Program 2003; 2003: 132-52. 
[75] Hochhaus A, Kreil S, Corbin AS, La Rose´e P, Mu¨ller MC, Lahaye T, Hanfstein B, 
Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R. 
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) 
therapy. Leukemia 2002; 16: 2190-6. 
[76] Ossard- Receveur A, Bernheim A, Clausse B, Danglot G, Fauvet D, Leon B, Lozach F. 
Duplication of the Ph-chromosome as a possible mechanism of resistance to 
imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet 
Cytogenet 2005; 163: 189-90. 
[77] Zaccaria A, Testoni N, Valenti AM, Luatti S, Tonelli M, Marzocchi G, Cipriani R, 
Baldazzi C, Giannini B, Stacchini M, Gamberini C, Castagnetti F, Rosti G, Azzena 
A, Cavazzini F, Cianciulli AM, Dalsass A, Donti E, Giugliano E, Gozzetti A, 
Grimoldi MG, Ronconi S, Santoro A, Spedicato F, Zanatta L, Baccarani M; 
GIMEMA Working Party on CML. Chromosome abnormalities additional to the 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
40
Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: 
pathogenetic and prognostic implications. Cancer Genet Cytogenet. 2010 Jun; 199 
(2): 76-80. 
[78] Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le 
Coutre P Impact of additional chromosomal aberrations and BCR-ABL kinase 
domain mutations on the response to nilotinib in Philadelphia chromosome-
positive chronic myeloid leukemia. Haematologica. 2010; 95 (4): 582-8. 
[79] Primo D, Tabernero MD, Rasillo A, Sayague´s JM, Espinosa AB, Chillon MC, Garcia-
Sanz R, Gutierrez N, Giralt M, Hagemeijer A, San Miguel JF, Orfao A. Patterns of 
BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization 
(FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. 
Leukemia 2003; 17:1124-9. 
3 
Causative Factors Involved in Development  
of Resistance to Tyrosine Kinase Inhibition  
and Novel Strategies Designed  
to Override This Resistance 
Ellen Weisberg and James D. Griffin 
Dana Farber Cancer Institute 
USA 
1. Introduction  
This article describes original work performed in our laboratory related to the 
characterization of kinase inhibitors developed to treat myeloid leukemia, as well as 
identified mechanisms that likely contribute to resistance to kinase inhibition. Specifically, 
we provide detailed overviews of the kinase inhibitors nilotinib, used in the treatment of 
chronic myeloid leukemia (CML) and midostaurin, which is currently under investigation in 
late stage clinical trials for the treatment of mutant FLT3-positive acute myeloid leukemia 
(AML). Presented as well is a description of studies investigating strategies that leukemic 
cells employ to escape killing through kinase inhibition, including alterations in the 
expression and composition of targeted proteins and chemoresistance conferred by the bone 
marrow microenvironment. We provide a general overview of kinase inhibitors in 
preclinical and clinical development for CML and AML, and also discuss the use of 
combination therapy as an approach to enhancing the efficacy of tyrosine kinase inhibition 
and reducing the incidence of residual disease. 
2. Development of BCR-ABL inhibitors and combination therapy studies 
geared toward overriding resistance to BCR-ABL inhibition 
Imatinib resistance: Introduction 
The development of resistance in leukemia patients to treatment with targeted tyrosine 
kinase inhibitors is a growing area of concern.  For instance, the ABL inhibitor imatinib 
(STI571) (Druker et al., 1996; Buchdunger et al., 2001), which also inhibits KIT and platelet-
derived growth factor receptor (PDGFR), has proven to be a highly effective, front line 
therapy for CML, a hematopoietic malignancy caused by the product of a reciprocal t(9;22) 
chromosomal translocation, BCR-ABL (Deininger et al., 2000). This targeted therapy has 
changed how newly diagnosed CML patients are treated and has substantially improved 
their prognosis. However, patients in the more advance phases of CML (namely, accelerated 
or blast crisis phase CML patients) often relapse due to drug resistance resulting from the 
emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase 
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domain that reduce sensitivity towards imatinib (Gorre et al., 2001) or amplification of the 
target gene (Weisberg and Griffin, 2000).  
Imatinib resistance and disease relapse in some patients can also be due to BCR-ABL-
independent mechanisms, as exemplified by the small residual pool of BCR-ABL-positive 
quiescent leukemic stem cells existing in CML patients that have achieved complete 
responses after imatinib treatment. This inability of imatinib to completely eradicate 
quiescent leukaemic stem cells occurs despite the high expression of BCR-ABL mRNA and 
protein in these cells (Michor et al., 2005; Roeder et al., 2006; Copland et al., 2006), which 
suggests that these leukemic stem cells are not dependent on BCR-ABL for viability. 
Therefore, a population of BCR-ABL-positive, quiescent stem cells continues to exist after 
imatinib therapy even in patients who have achieved complete responses, and the 
insensitivity of these cells to imatinib is believed to contribute to relapse observed in some 
patients following termination of imatinib treatment. The existence of this quiescent cell 
population is important to consider when attempting development of effective therapies for 
overriding intrinsic kinase inhibitor resistance and resistance due to stromal-mediated 
mechanisms. Such novel treatment approaches must be able to eradicate this cell population 
if maximum clinical benefit and complete disease-free survival is to be achieved.  
Among strategies to override imatinib resistance are the direct targeting of the BCR-ABL 
protein and the targeting of mediators of signaling pathways downstream of BCR-ABL that 
are needed for transformation. Biorational drug design has led to the development of novel 
agents that overcome some forms of imatinib resistance, and impressive results obtained in 
clinical trials have led to rapid FDA approval of second generation compounds that are 
presently used to treat newly diagnosed CML patients. 
BCR-ABL point mutations as a mechanism of imatinib resistance 
Although early studies based on cell line models pointed toward BCR-ABL gene 
amplification and over-expression of BCR-ABL mRNA and protein as contributing to 
imatinib resistance (Weisberg and Griffin, 2000; Mahon et al., 2000; le Coutre et al., 2000), the 
most common mechanism of imatinib resistance was later discovered to be point mutations 
in the BCR-ABL gene that lead to changes in amino acids in the BCR-ABL protein catalytic 
domain. Of the mechanisms considered to be of major importance in the development of 
drug resistance, gene amplification accounts for approximately 10% of relapse in patients, 
whereas mutations in the kinase domain account for 40-90% of relapse in patients. Other 
important mechanisms include mutations or activation of other genes (i.e. Lyn) (Wu et al., 
2008) and the contribution of organic cation transporter 1 or other related drug pumps 
(Engler et al., 2010). Mechanisms of minor importance or uncertain significance include the 
influence of multidrug resistance 1 gene  (Gambacorti-Passerini et al., 2000) and alpha1 
acidic glycoprotein (Mahon et al., 2000).  
BCR-ABL point mutations, which diminish the binding of imatinib to its target, are often 
those that directly or indirectly impair the binding of imatinib to the BCR-ABL protein 
without compromising the function of the ABL tyrosine kinase domain. Point mutations 
that reduce imatinib binding through a direct mechanism are generally positioned around 
the imatinib binding site, and diminish imatinib binding through alterations in amino acid 
side chains or topographical changes that sterically hinder the binding of imatinib. Phe317 
and Thr315 are examples of this type of BCR-ABL point mutation (Cowan-Jacob et al., 2004).  
Point mutations that reduce imatinib binding through an indirect mechanism utilize the 
distinct binding mode of a drug to BCR-ABL. Generally, there are three primary kinase 
Causative Factors Involved in Development of Resistance to Tyrosine Kinase  
Inhibition and Novel Strategies Designed to Override This Resistance 
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inhibitor binding modes that represent main mechanisms for pharmacological inhibition of 
kinase activity (Liu and Gray et al., 2006): 
1. Kinase inhibitor directly competes with ATP in the ATP binding site. Inhibitors of this 
type are known as “Type I” and bind to the “Asp-Phe-Gly (DFG)-in” conformation (the 
“DFG” motif is highly conserved in protein kinases and sits near the beginning, or N-
terminus, of the activation loop) .   
2. Kinase inhibitor engages an adjacent allosteric binding site, typically accessible when 
the activation loop and/or alpha-c helix is folded away from the binding site, which 
leads to kinase inactivation. Inhibitors of this type are known as “Type II” and bind to 
the “DFG-out” conformation. 
3. Kinase inhibitor binds at sites distal from the ATP binding site. 
Imatinib, a “Type II” inhibitor, binds to the catalytically inactive conformation of the ABL 
kinase domain. BCR-ABL point mutations that destabilize the inactive conformations of the 
DFG motif diminish the binding capacity of imatinib, and therefore work through an 
indirect mechanism.  
Over fifty different BCR-ABL point mutations have been identified (Rourmiantsev et al., 
2002; Von Bubnoff et al., 2002; Shah et al., 2002; Hochhaus et al., 2002) and generally fall into 
different categorical regions that include the hinge region (which bridges the C- and N-
terminal lobes of the kinase domain to develop the ATP-binding cleft), A-loop, and P-loop 
(or “nucleotide-binding loop”). The position of the A-loop, which includes amino acids 381-
402, regulates ABL kinase activity. Mutations in the A-loop typically confer moderate 
resistance. In contrast, P-loop mutations, which occur at the binding site for phosphates of 
ATP, include amino acids 244-255 of ABL, are highly imatinib-resistant, and confer a worse 
prognosis than other mutations (Soverini et al., 2005). Point mutations in the ABL kinase 
domain that destabilize the inactive conformations of the P-loop increase the free energy of 
the imatinib-ABL drug-protein complex, and in effect diminish imatinib binding. Gly250, 
Tyr 253, and Glu255 in the P-loop are examples of mutations that reduce imatinib binding 
through an indirect mechanism.  
The vast majority of the BCR-ABL point mutations identified occur infrequently. Mutations 
such as those occurring at residues Thr315, Phe359, Met351, Gly250, Glu255, and Tyr253 
comprise up to 70% of all existing mutations. It is possible that extremely rare levels of BCR-
ABL point mutations pre-exist treatment with imatinib and increase in frequency during 
imatinib therapy (Roche-Lestienne et al., 2002; Hofmann et al., 2003). 
In addition to detection of BCR-ABL point mutations in patients, BCR-ABL point mutations 
characterized as conferring imatinib resistance have been identified through in vitro random 
mutagenesis of BCR-ABL (Shah et al., 2002; Hochhaus et al., 2002). Some identified 
mutations were found to exist distal to the kinase domain, including the Src homology 2 
(SH2) and SH3 domains and N-terminal cap region (Hochhaus et al., 2002; Azam et al., 2003; 
Pluk et al., 2002). 
The detection of a point mutation in the BCR-ABL kinase domain was first reported in 
imatinib-resistant CML patients: three out of nine patients were characterized by BCR-ABL 
gene amplification, while six out of nine patients were characterized by an isoleucine 
substitution in the Thr315 residue located at the periphery of the nucleotide-binding site of 
ABL (also referred to as the “gatekeeper position”) (Gorre et al., 2001).  The Thr315 residue, 
located in the hinge region, participates through a hydroxymethylene side chain in a critical 
H-bond interaction between imatinib and its protein target (Schindler et al., 2000; Manley et 
al., 2002; Nagar et al., 2002). Mutation of threonine to isoleucine confers resistance to 
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terminus, of the activation loop) .   
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the activation loop and/or alpha-c helix is folded away from the binding site, which 
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prognosis than other mutations (Soverini et al., 2005). Point mutations in the ABL kinase 
domain that destabilize the inactive conformations of the P-loop increase the free energy of 
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ABL point mutations pre-exist treatment with imatinib and increase in frequency during 
imatinib therapy (Roche-Lestienne et al., 2002; Hofmann et al., 2003). 
In addition to detection of BCR-ABL point mutations in patients, BCR-ABL point mutations 
characterized as conferring imatinib resistance have been identified through in vitro random 
mutagenesis of BCR-ABL (Shah et al., 2002; Hochhaus et al., 2002). Some identified 
mutations were found to exist distal to the kinase domain, including the Src homology 2 
(SH2) and SH3 domains and N-terminal cap region (Hochhaus et al., 2002; Azam et al., 2003; 
Pluk et al., 2002). 
The detection of a point mutation in the BCR-ABL kinase domain was first reported in 
imatinib-resistant CML patients: three out of nine patients were characterized by BCR-ABL 
gene amplification, while six out of nine patients were characterized by an isoleucine 
substitution in the Thr315 residue located at the periphery of the nucleotide-binding site of 
ABL (also referred to as the “gatekeeper position”) (Gorre et al., 2001).  The Thr315 residue, 
located in the hinge region, participates through a hydroxymethylene side chain in a critical 
H-bond interaction between imatinib and its protein target (Schindler et al., 2000; Manley et 
al., 2002; Nagar et al., 2002). Mutation of threonine to isoleucine confers resistance to 
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imatinib because of direct steric intrusion of the bulky isoleucine side chain, as well as loss 
of the hydrogen-bonding interaction in the ATP-cleft. An independent study of the crystal 
structure of an imatinib analog bound to ABL had shown Thr315 to be critical for the 
binding of imatinib to ABL, and the mutation of threonine to valine at this residue (T315V) 
was observed to confer imatinib resistance (Schindler et al., 2000; Corbin et al., 2002). 
Development of second generation BCR-ABL inhibitors designed to override imatinib resistance 
Nilotinib 
As an approach to overriding imatinib resistance, we characterized and developed the 
phenylaminopyrimidine-based Type II ATP competitive inhibitor, nilotinib (NVP- 
AMN107-NX; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-
3-pyridinyl)-2-pyrimidinyl]amino]benzamide), based on the crystal structures of inhibitors 
complexed with ABL (Cowan-Jacob et al., 2004). As with imatinib, another Type II ATP 
competitive inhibitor, part of nilotinib’s structure binds the ATP binding site, while part of 
its structure binds adjacent to the ATP binding site. Nilotinib was designed to fit into the 
ATP-binding site of BCR-ABL with higher affinity than imatinib, and demonstrates 
significantly higher potency than imatinib in inducing apoptosis of BCR-ABL-expressing 
cells (IC50<10 nM) by directly inhibiting ABL tyrosine kinase (Weisberg et al., 2005). 
Nilotinib also shows activity against a panel of imatinib-resistant BCR-ABL mutants, with 
the exception of T315I, and is effective in preventing the onset of leukemia in a BCR-ABL+ 
leukemic mouse model, and in prolonging the survival of mice harboring imatinib-resistant 
BCR-ABL-expressing cells (Weisberg et al., 2005; O'Hare et al., 2005). Crystallographic 
analysis of nilotinib complexed with ABL shows that, like imatinib, nilotinib binds to the 
inactive conformation of ABL. This suggests that the superior topographical fit to the ABL 
protein, as well as differences in the binding nature of nilotinib to ABL, contribute to the 
higher potency of nilotinib versus imatinib. 
Clinical trial results with nilotinib in imatinib-resistant patients were favorable (Kantarjian 
et al., 2006; le Coutre et al., 2006; Ottmann et al., 2006). A phase III randomized, open-label 
multicenter study was conducted as a direct comparison of imatinib and nilotinib in CML 
patients. Results showed nilotinib to be superior to imatinib in patients with newly 
diagnosed chronic phase CML (Saglio et al., 2010).  On October 29, 2007, the FDA granted 
accelerated approval to nilotinib for use in the treatment of chronic phase and accelerated 
phase Philadelphia chromosome positive (Ph+) CML in adult patients resistant or intolerant 
to prior therapy that included imatinib. On June 17, 2010, the FDA granted accelerated 
approval to nilotinib for treatment of adult patients with newly diagnosed Ph+ CML in 
chronic phase.  
Dasatinib 
Dasatinib (BMS-354825) is a second generation Type I ATP competitive inhibitor of BCR-
ABL that is both a potent ABL inhibitor and a potent Src family kinase inhibitor (Shah et al., 
2004; O'Hare et al., 2005; Burgess et al., 2005; Das et al, 2006; Melnick et al., 2006).  Over-
expression and activation of Src family kinases, such as LYN and HCK, have been shown to 
be associated with imatinib resistance (Donato et al., 2003), which suggests that the 
simultaneous targeting of BCR-ABL and Src family kinases may be effective in overriding 
resistance to imatinib. Unlike imatinib and nilotinib, which bind to the inactive 
conformation of BCR-ABL, dasatinib binds to the active conformation (Tokarski et al., 2006). 
Similar to nilotinib, dasatinib is effective against a number of imatinib-resistant BCR-ABL 
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point mutants, with the notable exception of the T315I gatekeeper mutant (Shah et al., 2004; 
O’Hare et al., 2005; Burgess et al., 2005).  
Dasatinib received accelerated approval by the FDA in June 2006 and the European 
Medicines Agency (EMEA) in November 2006 for treatment of adults in all phase of CML 
with resistance or intolerance to imatinib treatment. This approval was based on positive 
results in early (Phase I and II) clinical trials (Talpaz et al., 2006; Cortes et al., 2007). 
Dasatinib was also approved for treatment of drug-resistant Ph+ acute lymphoblastic 
leukemia (ALL) patients, in which a 190 kDa BCR-ABL protein is expressed resulting from 
an alternative breakpoint in the BCR gene. As with nilotinib, dasatinib has been granted 
FDA approval for therapy of newly diagnosed CML patients (Kantarjian et al, 2010). 
Other BCR-ABL inhibitors 
Dual ABL and Src inhibitors, bosutinib (SKI-606) (Puttini et al., 2006; Golas et al., 2003), 
which is a Type I ATP competitive inhibitor that only occupies the region normally 
occupied by ATP, and INNO-406 (first developed as NS-187) (Kimura et al., 2005), are active 
against a panel of imatinib-resistant BCR-ABL point mutants with the exception of the T315I 
gatekeeper mutant. AZD0530 is another dual ABL and Src inhibitor and Type I ATP 
competitive inhibitor that only weakly inhibits BCR-ABL (Lockton et al., 2005; Hennequin et 
al., 2006).   
Aurora kinase inhibitors, which work through inhibition of the Aurora family of 
serine/threonine kinases, members of which are important for mitotic progression, 
represent another class of second generation inhibitors of BCR-ABL. Examples include 
PHA-739358 (Nerviano Medical Sciences) (Fancelli et al., 2006), which has been tested in 
early clinical trials in patients that relapsed after treatment with imatinib. PHA-739358 is a 
Type I inhibitor that binds the ATP binding site directly. Another example of an Aurora 
kinase inhibitor is MK-0457 (first developed as VX-680), which inhibits the proliferation of 
cells expressing the T315I-BCR-ABL gatekeeper mutant at submicromolar concentrations 
(Carter et al., 2005). MK-0457 has shown activity in some patients harboring the T315I 
mutation (Giles et al., 2007). 
Non-ATP-competitive BCR-ABL inhibitors represent another class of second generation 
BCR-ABL inhibitors that work either via a non-ATP competitive allosteric mechanism or by 
prevention of substrate binding. Examples include ON012380, which shows potent activity 
against BCR-ABL-positive cells (Gumireddy et al., 2005). Compounds of this class make a 
covalent bond to the kinase and act as irreversible inhibitors. One complication is the fact 
that these compounds bind the substrate binding sites of multiple kinases, and therefore are 
very cytotoxic. Consequently, no clinical compound has been derived from this series. Non-
ATP competitive inhibitors are also exemplified by the GNF2 and GNF5 family of inhibitors, 
which bind to the myristate binding site of BCR-ABL and inhibit its activity by stabilizing a 
catalytically less competent conformation of the protein (Adrian et al., 2006; Zhang et al., 
2010). In addition, a type II inhibitor, GNF-7, has been shown to inhibit the T315I mutant in 
vitro and in vivo (Choi et al., 2010).  
As an approach to overriding imatinib resistance, we developed and characterized HG-7-85-
01, which is a Type II ATP competitive inhibitor that opens up a new chemical space in the 
field of kinase inhibitor development (Weisberg et al., 2010a). The structural inspiration for 
HG-7-85-01 is an amalgam of dasatinib and nilotinib, and is mostly utilization of the Type II 
nilotinib binding mode. Part of the structure of HG-7-85-01 binds to the ATP binding site, 
while the other part of its structure binds adjacent to the ATP binding site. In addition to 
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imatinib because of direct steric intrusion of the bulky isoleucine side chain, as well as loss 
of the hydrogen-bonding interaction in the ATP-cleft. An independent study of the crystal 
structure of an imatinib analog bound to ABL had shown Thr315 to be critical for the 
binding of imatinib to ABL, and the mutation of threonine to valine at this residue (T315V) 
was observed to confer imatinib resistance (Schindler et al., 2000; Corbin et al., 2002). 
Development of second generation BCR-ABL inhibitors designed to override imatinib resistance 
Nilotinib 
As an approach to overriding imatinib resistance, we characterized and developed the 
phenylaminopyrimidine-based Type II ATP competitive inhibitor, nilotinib (NVP- 
AMN107-NX; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-
3-pyridinyl)-2-pyrimidinyl]amino]benzamide), based on the crystal structures of inhibitors 
complexed with ABL (Cowan-Jacob et al., 2004). As with imatinib, another Type II ATP 
competitive inhibitor, part of nilotinib’s structure binds the ATP binding site, while part of 
its structure binds adjacent to the ATP binding site. Nilotinib was designed to fit into the 
ATP-binding site of BCR-ABL with higher affinity than imatinib, and demonstrates 
significantly higher potency than imatinib in inducing apoptosis of BCR-ABL-expressing 
cells (IC50<10 nM) by directly inhibiting ABL tyrosine kinase (Weisberg et al., 2005). 
Nilotinib also shows activity against a panel of imatinib-resistant BCR-ABL mutants, with 
the exception of T315I, and is effective in preventing the onset of leukemia in a BCR-ABL+ 
leukemic mouse model, and in prolonging the survival of mice harboring imatinib-resistant 
BCR-ABL-expressing cells (Weisberg et al., 2005; O'Hare et al., 2005). Crystallographic 
analysis of nilotinib complexed with ABL shows that, like imatinib, nilotinib binds to the 
inactive conformation of ABL. This suggests that the superior topographical fit to the ABL 
protein, as well as differences in the binding nature of nilotinib to ABL, contribute to the 
higher potency of nilotinib versus imatinib. 
Clinical trial results with nilotinib in imatinib-resistant patients were favorable (Kantarjian 
et al., 2006; le Coutre et al., 2006; Ottmann et al., 2006). A phase III randomized, open-label 
multicenter study was conducted as a direct comparison of imatinib and nilotinib in CML 
patients. Results showed nilotinib to be superior to imatinib in patients with newly 
diagnosed chronic phase CML (Saglio et al., 2010).  On October 29, 2007, the FDA granted 
accelerated approval to nilotinib for use in the treatment of chronic phase and accelerated 
phase Philadelphia chromosome positive (Ph+) CML in adult patients resistant or intolerant 
to prior therapy that included imatinib. On June 17, 2010, the FDA granted accelerated 
approval to nilotinib for treatment of adult patients with newly diagnosed Ph+ CML in 
chronic phase.  
Dasatinib 
Dasatinib (BMS-354825) is a second generation Type I ATP competitive inhibitor of BCR-
ABL that is both a potent ABL inhibitor and a potent Src family kinase inhibitor (Shah et al., 
2004; O'Hare et al., 2005; Burgess et al., 2005; Das et al, 2006; Melnick et al., 2006).  Over-
expression and activation of Src family kinases, such as LYN and HCK, have been shown to 
be associated with imatinib resistance (Donato et al., 2003), which suggests that the 
simultaneous targeting of BCR-ABL and Src family kinases may be effective in overriding 
resistance to imatinib. Unlike imatinib and nilotinib, which bind to the inactive 
conformation of BCR-ABL, dasatinib binds to the active conformation (Tokarski et al., 2006). 
Similar to nilotinib, dasatinib is effective against a number of imatinib-resistant BCR-ABL 
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point mutants, with the notable exception of the T315I gatekeeper mutant (Shah et al., 2004; 
O’Hare et al., 2005; Burgess et al., 2005).  
Dasatinib received accelerated approval by the FDA in June 2006 and the European 
Medicines Agency (EMEA) in November 2006 for treatment of adults in all phase of CML 
with resistance or intolerance to imatinib treatment. This approval was based on positive 
results in early (Phase I and II) clinical trials (Talpaz et al., 2006; Cortes et al., 2007). 
Dasatinib was also approved for treatment of drug-resistant Ph+ acute lymphoblastic 
leukemia (ALL) patients, in which a 190 kDa BCR-ABL protein is expressed resulting from 
an alternative breakpoint in the BCR gene. As with nilotinib, dasatinib has been granted 
FDA approval for therapy of newly diagnosed CML patients (Kantarjian et al, 2010). 
Other BCR-ABL inhibitors 
Dual ABL and Src inhibitors, bosutinib (SKI-606) (Puttini et al., 2006; Golas et al., 2003), 
which is a Type I ATP competitive inhibitor that only occupies the region normally 
occupied by ATP, and INNO-406 (first developed as NS-187) (Kimura et al., 2005), are active 
against a panel of imatinib-resistant BCR-ABL point mutants with the exception of the T315I 
gatekeeper mutant. AZD0530 is another dual ABL and Src inhibitor and Type I ATP 
competitive inhibitor that only weakly inhibits BCR-ABL (Lockton et al., 2005; Hennequin et 
al., 2006).   
Aurora kinase inhibitors, which work through inhibition of the Aurora family of 
serine/threonine kinases, members of which are important for mitotic progression, 
represent another class of second generation inhibitors of BCR-ABL. Examples include 
PHA-739358 (Nerviano Medical Sciences) (Fancelli et al., 2006), which has been tested in 
early clinical trials in patients that relapsed after treatment with imatinib. PHA-739358 is a 
Type I inhibitor that binds the ATP binding site directly. Another example of an Aurora 
kinase inhibitor is MK-0457 (first developed as VX-680), which inhibits the proliferation of 
cells expressing the T315I-BCR-ABL gatekeeper mutant at submicromolar concentrations 
(Carter et al., 2005). MK-0457 has shown activity in some patients harboring the T315I 
mutation (Giles et al., 2007). 
Non-ATP-competitive BCR-ABL inhibitors represent another class of second generation 
BCR-ABL inhibitors that work either via a non-ATP competitive allosteric mechanism or by 
prevention of substrate binding. Examples include ON012380, which shows potent activity 
against BCR-ABL-positive cells (Gumireddy et al., 2005). Compounds of this class make a 
covalent bond to the kinase and act as irreversible inhibitors. One complication is the fact 
that these compounds bind the substrate binding sites of multiple kinases, and therefore are 
very cytotoxic. Consequently, no clinical compound has been derived from this series. Non-
ATP competitive inhibitors are also exemplified by the GNF2 and GNF5 family of inhibitors, 
which bind to the myristate binding site of BCR-ABL and inhibit its activity by stabilizing a 
catalytically less competent conformation of the protein (Adrian et al., 2006; Zhang et al., 
2010). In addition, a type II inhibitor, GNF-7, has been shown to inhibit the T315I mutant in 
vitro and in vivo (Choi et al., 2010).  
As an approach to overriding imatinib resistance, we developed and characterized HG-7-85-
01, which is a Type II ATP competitive inhibitor that opens up a new chemical space in the 
field of kinase inhibitor development (Weisberg et al., 2010a). The structural inspiration for 
HG-7-85-01 is an amalgam of dasatinib and nilotinib, and is mostly utilization of the Type II 
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inhibiting T315I-BCR-ABL in CML, HG-7-85-01 was observed to inhibit gatekeeper mutants 
of multiple kinases of therapeutic interest including T670I c-Kit and T674I-PDGFRalpha, 
which are clinically observed in gastrointestinal stromal tumor (GIST) and 
hypereosinophilic syndrome (HEL). Despite this broad profile with respect to ‘gatekeeper’ 
mutant kinases, HG-7-85-01 is not a promiscuous inhibitor, and no other inhibitor has been 
reported to possess this biological profile. Demonstration that this multi-gatekeeper mutant 
profile can be achieved is very important to the field because many pharmaceutical 
companies are reluctant to develop inhibitors for drug-resistant mutant kinases as they do 
not believe a sufficient number of patients are likely to benefit. The biological profile of HG-
7-85-01 demonstrates that a single compound could be developed that is capable of 
simultaneously targeting drug-resistant target kinases relevant across a range of 
malignancies. 
Progress is being made toward development of pan-BCR-ABL inhibitors that target all 
identified BCR-ABL point mutants, including T315I-BCR-ABL gatekeeper mutation (the so-
called “third generation” of BCR-ABL inhibitors). However, as the potential for emergence 
of new drug-resistant BCR-ABL point mutations still exists, benefit is likely to be gained 
from further development of BCR-ABL inhibitors displaying higher potency and distinct 
mutagenicity profiles, as well as therapeutic approaches involving administration of more 
than one BCR-ABL inhibitor or combined use of signal transduction inhibitors and BCR-
ABL inhibitors.  
Combination therapy as an approach to overriding resistance to BCR-ABL inhibition 
As it was anticipated that, similar to imatinib, resistance to nilotinib and dasatinib would 
likely also emerge due to arising BCR-ABL point mutations in CML and Ph+ ALL, 
mutagenesis screens were performed to identify nilotinib- and dasatinib-resistant BCR-ABL 
point mutations and showed overlapping but distinct mutagenicity profiles (Von Bubnoff et 
al., 2006; Bradeen et al., 2006; Ray et al., 2007). There has been substantial interest in testing 
the notion that simultaneous or sequential administration of more than one ABL inhibitor 
might delay the onset of emergence of drug-resistant BCR-ABL point mutations. For 
instance, we have shown beneficial paired combinations of imatinib and nilotinib against 
imatinib-resistant CML (Weisberg et al., 2007a). Specifically, we demonstrate the synergistic 
interaction between nilotinib and imatinib against both non-mutated BCR-ABL and 
imatinib-resistant BCR-ABL point mutants. It has been suggested that the differential uptake 
mechanisms for imatinib and nilotinib may contribute to the observed synergy between the 
two agents (White et al., 2006). Alternatively, synergy may be explained by the ability of 
imatinib to increase the intracellular uptake and retention of nilotinib (and therefore its 
overall concentration), possibly through imatinib inhibition of ABCB1-mediated efflux of 
nilotinib (White et al., 2007). The demonstrated synergy between imatinib and nilotinib 
complements other published reports showing synergistic interaction between imatinib and 
the dual Src/Abl inhibitors, dasatinib and AP23848 (O’Hare et al., 2005), as well as 
synergistic interactions between imatinib and a panel of standard chemotherapeutic agents 
(Liu et al., 2002). In addition, combinations of dasatinib and imatinib have proven to be 
effective in diminishing the frequency of occurrence of drug-resistant BCR-ABL mutants, 
with the exception of T315I (Shah et al., 2004; Burgess et al., 2005; Bradeen et al., 2006; 
Talpaz et al., 2006). As improvement of disease-free survival could potentially be achieved 
from combination therapy involving inhibitors from the same or diverse structural classes, 
these studies could serve as a guide for further clinical investigation. 
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Since clonal resistance could potentially be overcome by combining two agents with 
different resistance profiles, we investigated the ability of HG-7-85-01 to positively combine 
with GNF-5, which is unable to potently inhibit T315I as a single agent (Zhang et al., 2010; 
Weisberg et al., 2010c). We demonstrated that combinations of HG-7-85-01 with GNF-5 have 
at least additive effects against both non-mutated BCR-ABL and BCR-ABL T315I in vitro and 
in vivo (Weisberg et al., 2010c).  GNF-5 was also shown to enhance the activity of nilotinib 
against both non-mutated BCR-ABL and T315I-BCR-ABL in vitro and in vivo (Zhang et al., 
2010).  
An important characteristic of leukemia that confers survival advantages is the common 
deregulation of one or more of the three signaling pathways: PI3K/PTEN/Akt/mTOR, 
RAS/Raf/MEK/ERK, and Jak/STAT, each frequently activated by mutations in upstream 
genes.  The redundancy and simultaneous/cross-activation between the three pathways 
warrants consideration of the use of a multi-targeted therapeutic strategy, or the use of more 
than one type of signaling inhibitor. We have shown that the dual PI3K/PDK-1 inhibitor, 
BAG956, has the ability to enhance the inhibitory effects of imatinib and nilotinib, 
respectively, to effectively kill BCR-ABL-expressing cells both in vitro and in vivo (Weisberg 
et al., 2008a). Similarly, enhanced apoptosis of BCR-ABL-positive cells has been found to 
result from treatment with a STAT5 inhibitor and imatinib or nilotinib (Nelson et al., 2011). 
In addition, inhibitors of MAPK and PI3K/Akt signaling have been implicated in up-
regulation of proapoptotic BIM expression (Strasser et al., 2005). This is of potential 
importance with respect to imatinib resistance, as the proapoptotic BH3 domain-only 
protein, BIM, as well as proapoptotic BAD, mediate imatinib-induced apoptosis (Kuroda et 
al., 2006). Of relevance, the BH3 mimetic, ABT-737, overrides imatinib resistance due to loss 
of BIM and BAD (Kuroda et al., 2006). Inhibition of PI3K/Akt signaling also may be of 
potential benefit insofar as stromal-mediated chemoresistance is concerned, as Akt has been 
shown to be involved in leukemic cell survival in the bone marrow microenvironment (Tabe 
et al., 2007).  
3. Development of inhibitors of FLT3, and combination therapy studies 
geared toward overriding resistance to FLT3 inhibition 
Mutant FLT3 as a therapeutic target for AML 
The hematological malignancy, AML, is generally characterized by a block in cellular 
differentiation at different stages and aberrant proliferation of myeloid precursor cells. Early 
models have indicated that two types of mutations are responsible for the development of 
AML: One type of mutation is responsible for blocking terminal differentiation and the 
other type of mutation is responsible for promotion of growth and viability. However, full 
genome sequencing results suggest that up to 20 different mutations initiate AML, and 
disease development is thus likely more complicated than what the two mutation model 
proposes.  
Approximately 30% of AML patients, as well as a portion of ALL patients,  express a 
mutated form of the class III receptor tyrosine kinase, FLT3 (Fms-Like Tyrosine kinase-3; 
STK-1, human Stem Cell Tyrosine Kinase-1; FLK-2, Fetal Liver Kinase-2) (Stirewalt and 
Radich, 2003). The existence of a FLT3 mutation generally translates into a poorer prognosis 
in terms of overall survival and disease-free survival (Mattison et al., 2007). The fact that 
FLT3 mutations are only found in a portion of AML cells suggests that FLT3 mutations may 
be involved in promotion of disease rather than initiation of disease. 
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inhibiting T315I-BCR-ABL in CML, HG-7-85-01 was observed to inhibit gatekeeper mutants 
of multiple kinases of therapeutic interest including T670I c-Kit and T674I-PDGFRalpha, 
which are clinically observed in gastrointestinal stromal tumor (GIST) and 
hypereosinophilic syndrome (HEL). Despite this broad profile with respect to ‘gatekeeper’ 
mutant kinases, HG-7-85-01 is not a promiscuous inhibitor, and no other inhibitor has been 
reported to possess this biological profile. Demonstration that this multi-gatekeeper mutant 
profile can be achieved is very important to the field because many pharmaceutical 
companies are reluctant to develop inhibitors for drug-resistant mutant kinases as they do 
not believe a sufficient number of patients are likely to benefit. The biological profile of HG-
7-85-01 demonstrates that a single compound could be developed that is capable of 
simultaneously targeting drug-resistant target kinases relevant across a range of 
malignancies. 
Progress is being made toward development of pan-BCR-ABL inhibitors that target all 
identified BCR-ABL point mutants, including T315I-BCR-ABL gatekeeper mutation (the so-
called “third generation” of BCR-ABL inhibitors). However, as the potential for emergence 
of new drug-resistant BCR-ABL point mutations still exists, benefit is likely to be gained 
from further development of BCR-ABL inhibitors displaying higher potency and distinct 
mutagenicity profiles, as well as therapeutic approaches involving administration of more 
than one BCR-ABL inhibitor or combined use of signal transduction inhibitors and BCR-
ABL inhibitors.  
Combination therapy as an approach to overriding resistance to BCR-ABL inhibition 
As it was anticipated that, similar to imatinib, resistance to nilotinib and dasatinib would 
likely also emerge due to arising BCR-ABL point mutations in CML and Ph+ ALL, 
mutagenesis screens were performed to identify nilotinib- and dasatinib-resistant BCR-ABL 
point mutations and showed overlapping but distinct mutagenicity profiles (Von Bubnoff et 
al., 2006; Bradeen et al., 2006; Ray et al., 2007). There has been substantial interest in testing 
the notion that simultaneous or sequential administration of more than one ABL inhibitor 
might delay the onset of emergence of drug-resistant BCR-ABL point mutations. For 
instance, we have shown beneficial paired combinations of imatinib and nilotinib against 
imatinib-resistant CML (Weisberg et al., 2007a). Specifically, we demonstrate the synergistic 
interaction between nilotinib and imatinib against both non-mutated BCR-ABL and 
imatinib-resistant BCR-ABL point mutants. It has been suggested that the differential uptake 
mechanisms for imatinib and nilotinib may contribute to the observed synergy between the 
two agents (White et al., 2006). Alternatively, synergy may be explained by the ability of 
imatinib to increase the intracellular uptake and retention of nilotinib (and therefore its 
overall concentration), possibly through imatinib inhibition of ABCB1-mediated efflux of 
nilotinib (White et al., 2007). The demonstrated synergy between imatinib and nilotinib 
complements other published reports showing synergistic interaction between imatinib and 
the dual Src/Abl inhibitors, dasatinib and AP23848 (O’Hare et al., 2005), as well as 
synergistic interactions between imatinib and a panel of standard chemotherapeutic agents 
(Liu et al., 2002). In addition, combinations of dasatinib and imatinib have proven to be 
effective in diminishing the frequency of occurrence of drug-resistant BCR-ABL mutants, 
with the exception of T315I (Shah et al., 2004; Burgess et al., 2005; Bradeen et al., 2006; 
Talpaz et al., 2006). As improvement of disease-free survival could potentially be achieved 
from combination therapy involving inhibitors from the same or diverse structural classes, 
these studies could serve as a guide for further clinical investigation. 
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Approximately 30% of AML patients, as well as a portion of ALL patients,  express a 
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The most prevalent form of constitutively activated FLT3, found in approximately 20-25% of 
AML patients (although in less than 5% of myelodysplastic syndrome patients), occurs as 
internal tandem duplications (ITDs) that are located within the juxtamembrane domain 
(Nakao et al., 1996; Horiike et al., 1997; Kiyoi et al., 1998; Kondo et al., 1999; Rombouts et al., 
2000). This mutation has been shown to cause a rapidly lethal myeloproliferative disorder in 
mice in the absence of a block in differentiation, suggesting that its main role may be to 
cause hyper-proliferation of primitive myeloid cells (Kelly et al., 2002a). Mutant FLT3 is 
believed to interact with additional oncogenes that block differentiation, such as 
AML1/ETO (t(8;21)) PML/RARalpha (t(15;17).) to cause full leukemia development. 
Occurring in approximately 7% of AML cases are gain-of-function FLT3 kinase domain 
point mutations, frequently at position 835 (Yamamoto et al., 2001). Also identified have 
been other kinase domain point mutations, including Y842C (Kindler et al., 2005) and N841I 
(Jiang et al., 2004). An activating point mutation with comparatively weaker transforming 
potential has also been discovered in a stretch of the FLT3 juxtamembrane domain (Reindl et 
al., 2006). 
Inhibitors of mutant FLT3 
There are several FLT3 inhibitors presently in clinical trials, and a number of novel agents 
under preclinical investigation. Unfortunately, the FLT3 inhibitors tested thus far clinically 
induce only partial and transient responses in patients- at best- when used as single agents.  
We identified and developed a small molecule inhibitor, the N-indolo-carbazole 
midostaurin (PKC412; N-benzoylstaurosporin), (Weisberg et al., 2002), a broad-spectrum 
first generation inhibitor that targets constitutively activated mutant FLT3. Other targets of 
midostaurin include (PDGFRbeta), c-KIT and c-FMS (Weisberg et al., 2002).  Midostaurin 
showed high potency against mutant FLT3 as a target in vitro, and progressive leukemia was 
prevented in mice transplanted with marrow transduced with a FLT3-ITD-expressing 
retrovirus (Weisberg et al., 2002).  
In early clinical trials, midostaurin administered in sequential and simultaneous 
combinations with standard chemotherapeutic agents such as daunorubicin and cytarabine 
induction and high-dose cytarabine consolidation yielded clinical responses with transient 
and/or reversible side effects (Stone et al., 2004). Midostaurin is one of several FLT3 
inhibitors presently undergoing clinical testing, and it is currently under investigation in 
late stage clinical trials for AML. 
We have demonstrated the activity of midostaurin against imatinib-resistant GIST 
(Weisberg et al., 2006). Specifically, we demonstrated the potent activity of midostaurin 
against cells expressing two PDGFRalpha mutants associated GIST: the V561D 
juxtamembrane domain mutation and the less imatinib-sensitive D842V kinase domain 
mutation. We also demonstrated the ability of nilotinib to positively combine with either 
imatinib or midostaurin against cells expressing the D842V-PDGFRalpha mutant. Findings 
reported introduce midostaurin as a potential treatment option for mutant PDGFRalpha-
positive GIST and warrant its clinical testing for this disease target. 
Additional multi-targeted inhibitors, such as dasatinib and the biaryl urea compound and 
first-generation inhibitor, sorafenib (BAY 43-9006), have been shown to have activity against 
mutant FLT3 and are under clinical investigation for AML (Auclair et al., 2007; Kancha et al., 
2007; Lierman et al., 2007; Zhang et al., 2008; Metzelder et al., 2009; Guerrouahen et al., 
2010). Other FLT3 inhibitors that have been clinically investigated and which elicited 
transient responses in early phase trials include the indolocarbazole alkaloid and first-
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generation inhibitor, CEP-701 (lestaurtinib) (Levis et al., 2002; Smith et al., 2004; Knapper et 
al., 2006), KW-2449 (Pratz and Levis, 2008; Pratz et al., 2009; Shiotsu et al., 2009), 3-
substituted indolinones SU5416 (Semaxanib) and SU5614 (Yee et al., 2002; Fielder et al., 
2003; Giles et al., 2003; O’Farrell et al., 2004), the indolinone derivative and first-generation 
inhibitor, SU11248 (SU011248, sunitinib) (Fielder et al., 2005; Kancha et al., 2007; O’Farrell et 
al., 2003a,b), and the piperazinyl quinazoline and first-generation inhibitor, MLN518 
(tandutinib; CT53518) (Kelly et al., 2002b; Cheng and Paz, 2008). Among FLT3 inhibitors in 
early development are the N-(4-(3-amino-1H-indazol-4yl)phenyl-N1(2-fluoro-5-
methylphenyl) urea ABT-869 (Albert et al., 2006; Shankar et al., 2007; Zhou et al., 2008), the 
benzimidalzole-quinoline CHIR-258 (TKI258) (Lopes de Menezes et al., 2005), the 
hydroxystyryl-acrylonitrile LS104 (Kasper et al., 2008) and AP24534 (Gozgit et al., 2011).  
AC220 (Chao et al., 2009; Zarrinkar et al., 2009) is a second-generation FLT3 inhibitor that 
exhibits significantly higher potency and selectivity than first-generation inhibitors, and is 
under clinical investigation for mutant FLT3-expressing AML and wild-type FLT3-
harboring AML. A study by Pratz and colleagues suggested, however, that the potency and 
selectivity of agents targeting mutant FLT3 may not, in fact, be the best predictor of clinical 
efficacy (Pratz et al., 2010). In their study, AC220 was found to be the most potent inhibitor 
of several common FLT3 inhibitors tested (including lestaurtinib, midostaurin, sorafenib, 
and sunitinib) and had the highest index of selectivity. However, lestaurtinib- which had the 
lowest index of selectivity- was found to be the most effective when tested against FLT3-
ITD-positive patient samples. Results shown in this study suggested that inhibition of FLT3 
autophosphorylation in a FLT3-ITD specimen does not always induce death.  For example, a 
side-by-side comparison of AC220 and lestaurtinib showed that while both compounds 
fully inhibited FLT3 autophosphorylation and suppressed downstream STAT5 activation in 
one patient sample, only lestaurtinib induced apoptosis. Relapsed AML samples were 
observed to be more sensitive to FLT3 inhibition than diagnostic AML, suggesting that some 
FLT3-ITD AML (i.e. diagnostic) may not be addicted to FLT3 signaling. This study 
suggested that more selective inhibitors, like AC220 may be less effective in the diagnostic 
setting while less selective inhibitors- like lestaurtinib or midostaurin- may be more effective 
at diagnosis.  
Resistance to FLT3 inhibition 
Thus far, none of the FLT3 inhibitors under clinical investigation has elicited a sustained 
clinical response when used as a single agent. As an example, a phase I clinical trial for KW-
2449 showed that FLT3 inhibition in patients occurred only transiently to less than 20% of 
baseline levels (Pratz et al., 2009). It has been suggested that partial and transient FLT3 
inhibition such as this applies to other FLT3 inhibitors in clinical development and may be 
responsible for their limited efficacy (Chu and Small, 2009).  
One putative resistance mechanism related to FLT3 inhibition is dysregulation of signaling 
molecules, such as those associated with the PI3K/Akt and Ras/MEK/MAPK pathways 
(Piloto et al., 2007). Also implicated in drug resistance are aberrant STAT signaling (Zhou et 
al., 2009), the aberrant expression of the STAT5 target gene, PIM (Kim et al., 2005; Kim et al., 
2006), and high levels of phosphoprotein expression of the forkhead transcription factor, 
FOXO3A (Kornblau et al., 2010). Additional mechanisms include up-regulation of anti-
apoptotic proteins (Kohl et al., 2007; Brietenbuecher et al., 2009; Stolzel et al., 2010), up-
regulation of inhibitors of apoptosis proteins, and elevated FLT3 ligand levels (Zhou et al., 
2009). The concentration of FLT3 ligand has been observed to be significantly higher in 
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patients treated with chemotherapy or radiotherapy (Lyman et al., 1995; Wodnar-Filipowicz 
et al., 1996; Zwierzina et al., 1999; Bojko et al., 2002), and this is predicted to impede the 
action of FLT3 inhibitors administered after chemotherapy.  
Another possible resistance mechanism is cytoprotection conferred by the bone marrow 
microenvironment. Indeed, FLT3 inhibition was found to actually enhance the survival of 
CD34+CD38-CD123+ leukemic stem cells and progenitor cells in a “niche-like” in vitro 
microenvironment that was comprised of factors including IL-6, IL-3, stem cell factor (SCF), 
and immobilized fibronectin (Mony et al., 2008).  Small molecule CXCR4 inhibitors may be 
effective in enhancing kinase inhibitor-induced apoptosis of stromal-protected leukemic 
cells, implicating a causal relationship between the chemokine receptor CXCR4 and stroma-
derived factor 1alpha (SDF-1a) interaction and drug-resistant leukemia (Zeng et al., 2006).  
Pre-existing or acquired point mutations in the FLT3 kinase domain that interfere with drug 
binding may also contribute to drug resistance in patients (Cools et al., 2004; Heidel et al., 
2006). 
Point mutations in the FLT3 receptor are generally analogous to point mutations in BCR-
ABL, the most prevalent mechanism of resistance to imatinib. However, there is little 
evidence for the existence of overlapping resistance profiles for FLT3 inhibitors, such as 
those demonstrated for imatinib, dasatinib, and nilotinib with respect to the T315I 
gatekeeper mutation (Von Bubnoff et al., 2006; Bradeen et al., 2006; Ray et al., 2007). Instead, 
non-overlapping mechanisms of resistance between PKC412, sorafenib, and SU5614 were 
found in a screening assay designed to study drug resistance profiles (Von Bubnoff et al., 
2009). For example, SU5614 resistance was characterized predominantly as mutations in the 
D835 residue, while sorafenib resistance was characterized by unique mutations such as 
F691L and point mutations in the Y842 residue (Von Bubnoff et al., 2009). Another study 
confirmed the involvement of acquired mutations, D835N and Y842H, in resistance to 
SU5614 (Bagrintseva et al., 2004). In contrast, PKC412 resistance was characterized by 
mutations in the N676 residue, which was previously identified and characterized in a 
PKC412-resistant AML patient as the sole determinant of drug resistance (Heidel et al., 
2006).  
In addition to non-overlapping mutagenicity profiles between existing FLT3 inhibitors, each 
shows variable activity toward different mutations, for example activation loop mutants 
versus ITD mutations. As an example, sunitinib inhibits ITD and activation loop mutants 
with equal potency, whereas sorafenib is less efficacious toward activation loop mutants 
than ITD (Kancha et al., 2007). PKC412 shows comparable activity against different FLT3 
activation loop mutants, whereas MLN518 shows variable activity (Clark et al., 2004; Barry 
et al., 2007). 
Combination therapy as an approach to treating mutant FLT3-positive disease 
As responses of patients to FLT3 inhibition is generally only partial and transient, there is a 
need for development of novel agents that can either be used effectively alone or combined 
with FLT3 inhibitors to suppress disease progression and prolong lifespan. FLT3 inhibitors 
have been tested in combination with standard chemotherapy agents as an approach to 
assessing the overall efficacy of combined therapies. For example, SU11248, combined with 
cytarabine or daunorubicin, exhibited additive-to-synergistic inhibitory effects on cells 
expressing mutant FLT3 (Yee et al., 2004). Similarly, CEP-701 showed synergy when 
combined with etoposide, mitoxantrone, daunorubicin, and cytarabine (Levis et al., 2004). 
PKC412 demonstrated synergy when combined with vincristine, 4-hydroperoxy-
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cyclophosphamide, etoposide, mitoxantrone, cytarabine, doxorubicin, and idarubicin 
(Mollgard et al., 2008; Furukawa et al., 2007). The sequence of administration of FLT3 
inhibitors and standard chemotherapy appears to often, depending on the FLT3 inhibitor, be 
sequence-dependent, resulting in antagonism when the FLT3 inhibitor is administered prior 
to chemotherapy and resulting in synergy when the FLT3 inhibitor is administered after 
chemotherapy (Pratz and Levis, 2008).  
One strategy geared toward overriding resistance to FLT3 inhibition includes the combined 
use of more than one FLT3 inhibitor, providing their interaction with the FLT3 protein target 
or FLT3 signaling pathway components is distinct enough for the two inhibitors to 
synergize. We demonstrated the potent and selective activity of the novel type II ATP 
competitive inhibitors, HG-7-85-01 and HG-7-86-01, against mutant FLT3, as well as their 
ability to synergize well with standard chemotherapeutic agents or midostaurin (Weisberg 
et al., 2010b). The ability of HG-7-85-01 and HG-7-86-01 to inhibit mutant FLT3, in addition 
to a number of gatekeeper mutants of multiple kinases of therapeutic interest, highlights 
their unique versatility and potential widespread clinical usefulness.  Other potent FLT3 
inhibitors, such as NVP-AST487, have the ability to effectively combine with midostaurin to 
kill drug-sensitive and insensitive mutant FLT3-expressing cells (Weisberg et al., 2008b). The 
ability of two targeted FLT3 inhibitors to synergize may translate into clinical benefit in 
terms of reducing toxicity, as clinical responses achieved with late-stage FLT3 inhibitors like 
midostaurin and CEP-701 depend on combined administration with standard 
chemotherapeutic agents. 
Alternatively, FLT3 inhibitors can be combined with small molecule inhibitors that interact 
with key mediators of major signaling pathways that play a significant role in AML. Cross-
talk between the three main pathways activated by mutant FLT3 (RAS/Raf/MEK/ERK, 
Jak/STAT, and PI3K/PTEN/Akt/mTOR) warrants the development of multi-targeted 
approaches for treatment of mutant FLT3-positive AML  (Brandts et al., 2005; Recher et al., 
2005; Kornblau et al., 2006; Rocnik et al., 2006; Al Shaer et al., 2008). We have shown that 
signaling pathway inhibitors, such as the dual PI3K/PDK-1 inhibitor, BAG956, can 
positively combine with midostaurin against mutant FLT3-positive cells (Weisberg et al., 
2008a). Of relevance, PKC412 and the mTOR inhibitor, rapamycin, synergize against 
PKC412-sensitive and –resistant mutant FLT3-expressing cells (Mohi et al., 2004). The 
rapamycin derivative, RAD001, enhances the anti-leukemic effects of sunitinib (Ikezoe et al., 
2006), as does the MEK1/2 kinase inhibitor, AZD6244 (ARRY-142886) (Nishioka et al., 
2008b). Other agents effective in killing mutant FLT3-expressing cells are heat shock protein 
90 (Hsp90) inhibitors and histone deacetylase inhibitors, which disrupt the major signaling 
pathways (Al Shaer et al., 2008; Nishioka et al., 2008a), and drugs that inhibit farnesyl-
transferase (Mollgard et al., 2008). 
4. Characterization of underlying mechanisms of stroma-mediated 
chemoresistance to tyrosine kinase inhibition  
In addition to identifying and developing potent kinase inhibitors representative of novel 
and unique structural classes with the ability to override drug resistance due to changes in 
the target protein, there is a push toward gaining a better understanding of the mechanisms 
underlying drug resistance in CML and AML as they relate to the leukemic cell 
microenvironment.  Bone marrow is comprised of hematopoietic and stromal cells, in 
addition to other factors including extracellular matrix and blood vessels; growth factors 
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chemoresistance to tyrosine kinase inhibition  
In addition to identifying and developing potent kinase inhibitors representative of novel 
and unique structural classes with the ability to override drug resistance due to changes in 
the target protein, there is a push toward gaining a better understanding of the mechanisms 
underlying drug resistance in CML and AML as they relate to the leukemic cell 
microenvironment.  Bone marrow is comprised of hematopoietic and stromal cells, in 
addition to other factors including extracellular matrix and blood vessels; growth factors 
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and cell:cell interactions (Charbord et al. 1996). Bone marrow stroma and factors derived 
from stroma have been suggested to play a role in the long-term survival and proliferation 
of normal and leukemia cells (Ashley et al., 1994; Bradstock et al., 1996; Rafii et al., 1997; 
Lagneaux et al., 1998, Lagneaux et al., 1999; Konopleva et al., 2002; Litwin et al., 2002). 
Specifically, bone marrow stroma provides signals, such as granulocyte colony-stimulating 
factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and  terminal 
differentiation of hematopoietic stem cells or mediate/support their proliferation (Verfaillie 
et al., 1993; Liesveld et al., 1996; Harrison et al., 1997; Breems et al., 1997; O’Prey et al., 1998; 
Leslie et al., 1998; Shih et al., 1999). SSpenic stroma, as well, has been implicated in enhanced 
survival of both normal and leukemic cells (Shaked et al., 2005; Despars and O’Neill, 2006). 
Clinical trial data with tyrosine kinase inhibitors show that while the peripheral blood of 
patients responds well, bone marrow responds less well. It appears possible that small 
numbers of leukemic CD34+ cells can persist in the marrow microenvironment of leukemia 
patients after years of therapy with kinase inhibitors. Stromal cells have been implicated, as 
they provide viability signals to leukemic cells that protect them from inhibitor effects. 
Indeed, the quantity of leukemic stem cells that rely on stroma to survive is predictive of 
disease outcome (Kumagai et al., 1996).   
We revealed highest tumor burden and residual disease to occur in vivo in stroma-associated 
tissues in imatinib/nilotinib-treated NCr nude mice, suggesting that significant reservoirs 
for tumor growth appear to be tissues that are able to support normal hematopoietic and 
malignant stem cell development (Weisberg et al., 2008c). These studies, which showed a 
pattern of leukemia distribution consistent with what is observed in imatinib- and nilotinib-
treated chronic myeloid leukemia patients, were followed by a more in-depth analysis of 
stroma-leukemia cell interactions that lead to protection of leukemia cells from nilotinib-
induced cytotoxicity. For the latter, we used the human BCR-ABL-positive cell line, KU812F, 
and the human bone marrow stroma cell line, HS-5, to more closely approximate the bone 
marrow-associated cytoprotection observed in drug-treated leukemia patients. Partial 
stromal-mediated protection of BCR-ABL-positive leukemic cells from nilotinib treatment 
involved the cooperative interaction of members of a select panel of stromal-secreted 
viability factors, including IL-6 and GM-CSF (Weisberg et al., 2008c). Similar results were 
observed with mutant FLT3-positive leukemia cells treated with midostaurin in the presence 
of HS-5-stromal-conditioned media versus the same panel of stromal-secreted viability 
factors (Weisberg et al., 2009).  
5. Potentiation of anti-leukemic effects of tyrosine kinase inhibitors by IAP 
inhibition: Implications for use of IAP inhibition to prevent or reduce residual 
disease following tyrosine kinase inhibition  
Deregulated signaling molecules associated with viability/apoptotic signaling represent 
attractive targets for therapeutic intervention, and several strategies have emerged that may 
be effective in preventing drug resistance due to this.  One approach involves combining 
targeted inhibitors with small molecule inhibitors of key components of major signaling 
pathways affecting the viability/expansion of leukemic cells. Accordingly, we have 
developed effective inhibitors of the inhibitor of apoptosis (IAP) family of proteins (Liu et 
al., 2000; Wu et al., 2000), such as LBW242 (Weisberg et al., 2007b), and its structural analog, 
LCL161, which bind to and inhibit multiple IAPs (i.e. XIAP, c-IAP) to enhance the activity of 
different proapoptotic signaling pathways. We have demonstrated the ability of LBW242 to 
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synergize with midostaurin in vivo against progressive mutant FLT3-positive leukemia and 
to override stromal-mediated chemoresistance in vitro (Weisberg et al., 2007b).   
Clinical trial data with midostaurin show that while good responses are achievable in 
mutant FLT3-positive AML patient peripheral blood, patient bone marrow responses are 
more modest. This suggests that stromal cells provide viability signals to AML cells that 
protect the cells from the effects of the selective inhibitor being used. We investigated the 
responsiveness of Ba/F3-FLT3-ITD cells cultured in the presence and absence of WEHI 
(used as a source of IL-3) to the cytotoxic effects of midostaurin, and we found that the 
presence of IL-3 completely protected cells from midostaurin-inhibition of cellular 
proliferation (Weisberg et al., 2007b). In contrast to midostaurin, the IAP inhibitor, LBW242, 
inhibited Ba/F3-FLT3-ITD proliferation in both the absence and the presence of IL-3 
(Weisberg et al., 2007b). Interestingly, LBW242 plus midostaurin inhibited the growth of 
Ba/F3-FLT3-ITD cells cultured in the presence of IL-3 to a greater extent than either agent 
alone; this inhibition was similar to that achieved with co-administration of both agents in 
the absence of IL-3, suggesting that an IAP inhibitor is able to enhance the effects of a FLT3 
inhibitor and override chemoresistance due to provision of viability signals (Weisberg et al., 
2007b).  
In an attempt to more closely model putative stromal-AML cell interactions and stromal-
mediated viability signaling effects on the cytotoxic effects of midostaurin, we tested the 
human stroma cell line, HS-5, in combination with the mutant FLT3 AML line, MOLM-13-luc+ 
(luciferase was used to specifically quantify only the leukemia component in the assay using 
light emission). A confluent layer of HS-5 stromal cells enhanced the growth of MOLM13-luc+ 
cells and was partially protective against the inhibitory effects of midostaurin (Weisberg et al., 
2007b). LBW242 enhanced the cytotoxic effects of midostaurin against MOLM13-luc+ cells in 
the presence of HS-5 human stromal cells, supporting the notion that stromal-mediated 
viability signals may contribute to chemoresistance to FLT3 inhibitors  
(such as midostaurin) observed in marrow, as well as the idea that such resistance may be 
overcome by inclusion of IAP inhibitor treatment (Weisberg et al., 2007b). 
We have also shown the ability of LCL161 to significantly delay disease recurrence in mice 
injected with BCR-ABL-expressing cells and treated for several weeks with a moderate dose 
of nilotinib (Weisberg et al., 2010d).  Specifically, using in vitro models of intrinsic drug 
resistance and stromal-mediated chemoresistance, as well as functional mouse models of 
progressive and residual disease, we showed the ability of the novel IAP inhibitor, LCL161, 
to enhance the cytotoxic effects of tyrosine kinase inhibitors against leukemic disease. 
Importantly, we observed LCL161 to synergize in vivo with nilotinib to reduce leukemia 
burden significantly below the baseline level suppression exhibited by a moderate-to-high 
dose of nilotinib. Our results support the idea of using IAP inhibitors in conjunction with 
targeted tyrosine kinase inhibition to suppress or eradicate progressive and drug-resistant 
or residual disease. Phase I studies in advanced solid tumors are currently ongoing, and 
LCL161 is being considered for testing in clinical trials for leukemia. 
6. Conclusion 
Elucidation of mechanisms of resistance to tyrosine kinase inhibition is critical for the 
optimization of existing therapies and prolongation of patient survival via delaying or 
eradicating the recurrence of disease. For CML, the discovery and characterization of BCR-
ABL point mutations in the kinase target of a number of inhibitors in clinical use has been a 
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survival of both normal and leukemic cells (Shaked et al., 2005; Despars and O’Neill, 2006). 
Clinical trial data with tyrosine kinase inhibitors show that while the peripheral blood of 
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patients after years of therapy with kinase inhibitors. Stromal cells have been implicated, as 
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malignant stem cell development (Weisberg et al., 2008c). These studies, which showed a 
pattern of leukemia distribution consistent with what is observed in imatinib- and nilotinib-
treated chronic myeloid leukemia patients, were followed by a more in-depth analysis of 
stroma-leukemia cell interactions that lead to protection of leukemia cells from nilotinib-
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and the human bone marrow stroma cell line, HS-5, to more closely approximate the bone 
marrow-associated cytoprotection observed in drug-treated leukemia patients. Partial 
stromal-mediated protection of BCR-ABL-positive leukemic cells from nilotinib treatment 
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observed with mutant FLT3-positive leukemia cells treated with midostaurin in the presence 
of HS-5-stromal-conditioned media versus the same panel of stromal-secreted viability 
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Deregulated signaling molecules associated with viability/apoptotic signaling represent 
attractive targets for therapeutic intervention, and several strategies have emerged that may 
be effective in preventing drug resistance due to this.  One approach involves combining 
targeted inhibitors with small molecule inhibitors of key components of major signaling 
pathways affecting the viability/expansion of leukemic cells. Accordingly, we have 
developed effective inhibitors of the inhibitor of apoptosis (IAP) family of proteins (Liu et 
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Clinical trial data with midostaurin show that while good responses are achievable in 
mutant FLT3-positive AML patient peripheral blood, patient bone marrow responses are 
more modest. This suggests that stromal cells provide viability signals to AML cells that 
protect the cells from the effects of the selective inhibitor being used. We investigated the 
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(used as a source of IL-3) to the cytotoxic effects of midostaurin, and we found that the 
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6. Conclusion 
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eradicating the recurrence of disease. For CML, the discovery and characterization of BCR-
ABL point mutations in the kinase target of a number of inhibitors in clinical use has been a 
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tremendous step forward in understanding an important underlying mechanism of drug 
resistance. While second generation BCR-ABL inhibitors, such as nilotinib and dasatinib, 
have proven to be highly effective in the clinic and override imatinib resistance to an extent, 
the existence of highly imatinib-resistant mutants, such as the T315I gatekeeper mutant, is a 
limiting factor. Even for third generation BCR-ABL inhibitors that are able to override T315I, 
the potential exists for the evolution of novel drug-resistant point mutations that impede the 
binding of drug to its target. Thus, there continues to be a need for development of BCR-
ABL inhibitors with high potency and unique mutagenicity profiles, as well as a continued 
need for combination therapy approaches to overriding drug resistance.  
For mutant FLT3-positive AML, due to the only transient and partial effects observed 
clinically with FLT3 inhibitors in late-stage development, there is an urgent need for the 
development of new treatment approaches that could potentially lead to improved clinical 
effectiveness. As with CML, the key to improved patient responsiveness may lie in 
continued development of compounds conferring a higher degree of potency, as well as 
novel combination therapy strategies.  
For both CML and mutant FLT3-positive AML, elucidation of mechanisms of resistance that 
are associated with leukemic cell survival, such as stromal-mediated chemoresistance and 
up-regulation of viability signaling molecules, warrants the investigation of single agent 
activity of pro-apoptotic agents. It also warrants the development of treatment approaches 
that rely on administration of kinase inhibitors combined with other agents targeting 
components of leukemia:stromal cell interactions and stromal-derived viability factors.  
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1. Introduction 
Chronic myelogenous leukemia (CML) is a rare and fatal neoplastic disease clinically 
presented as aberrant accumulation of myeloid cells in bone marrow, blood and spleen. 
CML occurs in 1 to 2 cases per 100,000 people, and is most common in older people with a 
median age at diagnosis of around 65. In the United States of America, there are 3500 to 5000 
new cases per year (Jemal et al., 2010). If untreated, CML naturally progresses from initial 
chronic phase to accelerated phase and blast crisis that resembles acute myeloid leukemia. 
CML is one of the most extensively studied human cancers, and exemplifies that good 
scientific research can lead to successful treatment of a devastating disease.  
In early 1960s, a characteristic small chromosome of CML was identified by Peter Nowell 
and David Hungerford who worked in University of Pennsylvania and Fox Chase Cancer 
Center in Philadelphia, respectively, and was subsequently called the Philadelphia (Ph) 
chromosome (Nowell and Hungerford, 1960; Nowell and Hungerford, 1961). Ph 
chromosome is found in 95% CML patients. In 1973, Janet Rowley identified that Ph 
chromosome was a product of reciprocal translocation of chromosome 9 and 22, the 
t(9;22)(q34;q11) (Rowley, 1973). In early 1980s, the genes involved in translocation were 
identified as proto-oncogene ABL (human homolog of Abelson leukemia virus gene) on 
chromosome 9 that was fused to BCR (break cluster region) on chromosome 22 (Groffen et 
al., 1984), revealing molecular insight of CML. In early 1990s, aberrant tyrosine kinase 
activity of BCR-ABL and its essential roles in transformation of cells were established by 
several groups (Daley et al., 1990; Heisterkamp et al., 1990; Lugo et al., 1990). These 
molecular discoveries provide crucial foundation for drug development for CML treatment. 
In 1996, Brian Druker and colleagues reported the first specific ABL kinase inhibitor 
imatinib mesylate (STI571, CGP 57148, or Gleevec) that effectively inhibited growth of BCR-
ABL positive cells (Druker et al., 1996). In 1998, a phase I clinical trial of imatinib was 
initiated in three centers in the United States (Druker et al., 2001). Imatinib shows 
magnificent effect on bringing CML patients, especially those in chronic phase, into 
remission and improving long-term survival and disease management (Druker et al., 2006), 
and the drug is now the first line treatment for CML. 
However, in contrast to chronic CML, patients at advanced phases (accelerated phase and 
blast crisis) generally have only transient response to imatinib, and relapse quickly 
(Deininger and Druker, 2003). Even for chronic phase patients, imatinib does not eradicate 
the disease and it relapses rapidly if imatinib is discontinued (Michor et al., 2005). Multiple 
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mechanisms, both BCR-ABL dependent and independent, have been described or proposed 
for CML drug resistance, including amplification of BCR-ABL, mutations of BCR-ABL, drug 
pump, leukemia stem cell quiescence, as extensively reviewed before (Apperley, 2007). For 
the scope of this chapter, we will focus on CML acquired resistance, the resistance 
developed after initial remission of the disease, through BCR-ABL genetic mutations.  
2. Acquisition of genetic mutations of CML through drug selection of  
pre-existing mutants 
Charles Sawyers and colleagues first described that acquired resistance to imatinib is 
mediated primarily by BCR-ABL mutations, and to a less extent, by amplification of BCR-
ABL gene and other mechanisms (Gorre et al., 2001; Shah et al., 2002). These mutations 
confer various degree of resistance of CML cells to imatinib. Compiled from published data 
from 2001 to 2007, over 50 unique mutations have been identified in all CML patients, and 
they are mainly located at the BCR-ABL kinase domain (Apperley, 2007). We have updated 
this mutation profile by adding data published from 2008 to 2010 (Chien et al., 2008; Jones et 
al., 2008; Kim et al., 2009; Lewandowski et al., 2009; Markose et al., 2009; Press, 2010). The 
ten most common mutations representing 74% of total mutations (Fig. 1) exhibit similar 
patterns as shown before (Apperley, 2007). T315I remains as the most frequent mutation 
followed by Y253 and E255 mutations. Some minor changes are noticed: G250A/E moves to 
the 4th place ahead of M351T whereas M244V moves to the 10th place.  
The four critical regions of BCR-ABL kinase domain are the prime targets for these 
mutations: T315I mutation for imatinib binding site, mutations on Y253, E255 and G250 for 
ATP binding site or P-loop, mutations on M351, E355 and F359 for catalytic domain and 
mutations on H396 for activation loop (Nagar et al., 2002; Schindler et al., 2000). M244V 
mutation occurs in close proximity to the P-loop and F317 mutations close to imatinib 
binding site. Although it is not functionally clear about the significance of every mutation 
detected, the profile highlights the importance of those high frequency mutations. T315I 
mutant BCR-ABL is resistant to inhibition by the second generation of tyrosine kinase 
inhibitors nilotinib (von Bubnoff et al., 2006; Weisberg et al., 2005) and dasatinib (Shah et al., 
2004), which inhibit most other BCR-ABL mutations. T315I and P-loop mutations are 
associated with reduced survival and poor prognosis in patients (Nicolini et al., 2006). Y253F 
and E255K mutations increase BCR-ABL transformation capability whereas T315I mutation 
affects oncogenicity by altering P-loop phosphorylation (Griswold et al., 2006; Skaggs et al., 
2006).    
Progression of chronic phase to advanced phases may require additional alterations of CML 
genome beyond BCR-ABL (Perrotti et al., 2010). It is perceived that mutation mechanisms 
may be different in chronic phase from that in blast crisis CML cells. We have plotted ten 
most frequent mutations in chronic phase CML (Fig. 1) collected from data published from 
2001 to 2009 (according to Table S2 in Klemm et al., 2009). The ten most common mutations 
representing 78% of total mutations in chronic phase are the same amino acids at the BCR-
ABL kinase domain as seen in the all CML profile. Noticeably, M351T, instead of T315I, 
mutation is the most frequent mutation in chronic CML. It is evident that there is substantial 
increase of T315I mutation and reduction of M244V mutation in all CML profile, suggesting 
T315I is more favored and M244V is less favored towards the advanced phases. In addition, 
the most frequent mutations are clustered more tightly according to the functional regions 
of the kinase domain in all CML profile than in chronic CML profile. Although the above 
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difference may suggest the increased functional selection for drug resistance in advanced 



























































































































































Fig. 1. The top ten mutations of BCR-ABL in all or chronic CML patients 
Upper panel: Ten most frequent mutations in all CML. The profile was created by adding 
344 mutation cases published between 2008 to 2010 to the previously published profile 
(Apperley, 2007). Lower panel: Ten most frequent mutations in chronic CML. The profile 
was created according to the previously compiled data containing 572 total mutation cases 
published from 2001 to 2009 (Klemm et al., 2009).  Mutations in the regions of BCR-ABL 
kinase domain are color-coded: red for imatinib binding site, maroon for ATP binding site, 
green for catalytic domain, fuchsia for activation loop, and light blue for amino acids 
adjacent to those regions.   
Charles Sawyers and colleagues were also among the first to identify mutations of BCR-ABL 
kinase domain in CML patients before imatinib treatment (Roche-Lestienne et al., 2002; Shah 
et al., 2002), and proposed that BCR-ABL mutations in relapsed CML patients upon imatinib 
treatment are a result of selection of pre-existing mutant clones (Shah and Sawyers, 2003). 
This model has been validated by subsequent studies from multiple groups identifying such 
mutations (Ernst et al., 2008; Roche-Lestienne et al., 2003; Willis et al., 2005). Mathematical 
modeling further provides support for rapid expansion of pre-existing mutant clones for fast 
relapse in CML patients (Michor et al., 2005).  However, the rate of BCR-ABL mutations 
found in CML patients prior to imatinib exposure is around 21%, even using high sensitivity 
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ABL kinase domain as seen in the all CML profile. Noticeably, M351T, instead of T315I, 
mutation is the most frequent mutation in chronic CML. It is evident that there is substantial 
increase of T315I mutation and reduction of M244V mutation in all CML profile, suggesting 
T315I is more favored and M244V is less favored towards the advanced phases. In addition, 
the most frequent mutations are clustered more tightly according to the functional regions 
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difference may suggest the increased functional selection for drug resistance in advanced 



























































































































































Fig. 1. The top ten mutations of BCR-ABL in all or chronic CML patients 
Upper panel: Ten most frequent mutations in all CML. The profile was created by adding 
344 mutation cases published between 2008 to 2010 to the previously published profile 
(Apperley, 2007). Lower panel: Ten most frequent mutations in chronic CML. The profile 
was created according to the previously compiled data containing 572 total mutation cases 
published from 2001 to 2009 (Klemm et al., 2009).  Mutations in the regions of BCR-ABL 
kinase domain are color-coded: red for imatinib binding site, maroon for ATP binding site, 
green for catalytic domain, fuchsia for activation loop, and light blue for amino acids 
adjacent to those regions.   
Charles Sawyers and colleagues were also among the first to identify mutations of BCR-ABL 
kinase domain in CML patients before imatinib treatment (Roche-Lestienne et al., 2002; Shah 
et al., 2002), and proposed that BCR-ABL mutations in relapsed CML patients upon imatinib 
treatment are a result of selection of pre-existing mutant clones (Shah and Sawyers, 2003). 
This model has been validated by subsequent studies from multiple groups identifying such 
mutations (Ernst et al., 2008; Roche-Lestienne et al., 2003; Willis et al., 2005). Mathematical 
modeling further provides support for rapid expansion of pre-existing mutant clones for fast 
relapse in CML patients (Michor et al., 2005).  However, the rate of BCR-ABL mutations 
found in CML patients prior to imatinib exposure is around 21%, even using high sensitivity 
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methods for detection (Ernst et al., 2008; Roche-Lestienne et al., 2002; Willis et al., 2005), as 
compared to 40% to 90% in relapsed patients. This difference could be blamed to the 
insufficient sensitivity of detection methods. Alternatively, additional mechanisms for BCR-
ABL mutations may exist and accentuate the mutations.  
3. De novo acquisition of genetic mutations for CML drug resistance 
To address mechanisms of CML acquired resistance, we have recently developed a novel 
tissue culture model using a naïve blast crisis CML cell line KCL-22 (Yuan et al., 2010).  
KCL-22 cells were derived from a female blast crisis CML patient, and were characterized as 
immature undifferentiated cells lacking lymphoid cell characteristics (Kubonishi and 
Miyoshi, 1983). KCL-22 cells are positive for myeloid cell markers including myeloid 
progenitor cell marker CD33. KCL-22 cells harbor two Ph chromosomes but do not have 
detectable BCR-ABL mutations (Yuan et al., 2010). In contrast to resistance of blast crisis 
CML in vivo, most blast crisis CML cell lines in culture are very sensitive to 1 M imatinib 
with exception of KCL-22 (Deininger et al., 1997). Imatinib also kills KCL-22 cells, but it 
requires higher concentrations and takes longer time (Yuan et al., 2010). This unique feature 
of KCL-22 cell line perhaps made us successful in establishing it as a new model for 
acquired resistance of CML in vitro. The key characteristics of this model are summarized as 
follows: 
1. High relevance: KCL-22 cells are incubated with in vivo therapeutic concentrations of 
imatinib, i.e. 2.5 to 10 M. Cells undergo gradually increasing apoptosis for about a 
week followed by re-growing (relapse) with homogenous acquisition of T315I mutation.  
2. Easy to use: KCL-22 cell line is commercially available from German Collection of Cell 
Culture. Cells are easy to grow in standard RPMI 1640 medium supplied with 10% fetal 
bovine serum, and no additional growth factors are needed. One single dose of imatinib 
treatment is sufficient.  
3. Rapid turnaround: Relapse occurs in about two weeks with initial relapsed cells 
microscopically visible as small clusters of enlarged and sometimes irregularly shaped 
cells after around eight days of drug treatment.  
4. High reproducibility: Multiple persons in the lab have used this model and it produces 
highly consistent results among them.   
This model provides a novel tool for us to look into the process of acquisition of BCR-ABL 
mutations on the endogenous BCR-ABL in blast crisis CML cells, and has already provided 
valuable information in our initial study (Yuan et al., 2010) as summarized below. 
1. Acquisition of BCR-ABL mutations does not require pre-existing mutant clones derived 
from the original patient, as clonal cells without an initial mutation can regenerate 
mutations and relapse on imatinib. The mutations do not derive from a fixed 
subpopulation of pre-mutant cells. 
2. Acquisition of BCR-ABL mutations does not provoke additional chromosomal 
rearrangement, is not a result of mutator phenotype of KCL-22 cells, and can not be 
blocked by standard anti-oxidant treatment.   
3. Acquisition of BCR-ABL mutations is a dynamic process influenced by culture and 
environmental conditions. This is supported by several lines of evidence. First, clonal 
KCL-22 cells exhibit great difference for BCR-ABL mutations whereas mutations on 
HPRT gene are relatively stable among clones. Second, clonal KCL-22 cells can acquire 
different single mutations for each clone, suggesting change of mutation hot spots after 
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cloning process. We have identified three clones that can acquire T315I, E255K and 
Y253H mutation, respectively. These three mutations have the highest frequency in 
human patients shown in Fig. 1.  Third, the ability for acquisition of BCR-ABL 
mutations diminishes in parental KCL-22 cells after they are cultured continuously for 
more than 30 passages. Finally, we have found that the quality of fetal bovine serum 
can affect BCR-ABL mutation rate. We routinely use Hyclone characterized fetal bovine 
serum (Cat# SH30071.03) for mutation study, which typically produces consistent 
results among batches. However, when Hyclone serum was compared side by side with 
two other brands of fetal bovine serum, a noticeable reduction of BCR-ABL mutation 













































Fig. 2. Tissue culture conditions affect BCR-ABL mutations 
Comparison of Hyclone characterized fetal bovine serum with two other brands of fetal 
bovine serum. KCL-22 cells were incubated with medium supplied with these sera, 
respectively, for two days, and then seeded onto soft agar for colony formation assay. Left  
panel, 1x106 cells seeded per well with 2.5 M imatinib. Right panel: plating efficiency with 
500 cells seeded per well. Two independent batches of each serum (colored as blue and 
maroon) were tested. 
4. Acquisition of BCR-ABL mutations depends on expression of BCR-ABL, since 
knockdown of BCR-ABL blocks KCL-22 cell relapse and mutations. By over-expression 
of kinase-inactive BCR-ABL, intriguingly, it was found that BCR-ABL kinase activity is 
not absolutely required for acquisition of mutations. 
5. The endogenous BCR-ABL translocation locus significantly influences BCR-ABL 
mutations, as the mutation rate on the endogenous locus is nearly 10 times higher than 
that of the randomly integrated BCR-ABL cDNA as illustrated in Fig. 3. This finding 
reveals a previously unrecognized role of the translocation locus itself in driving BCR-
ABL mutagenesis, suggesting possible involvement of the local epigenome for BCR-
ABL mutations that will be discussed further below.  
Our extensive analyses of BCR-ABL mutations in KCL-22 cells lead to the conclusion that 
mutations can be acquired de novo after imatinib treatment, although precise molecular 
mechanisms are yet to be uncovered.  Such de novo acquisition of mutations may provide an 
alternative mechanism for clinical resistance of CML to tyrosine kinase inhibitors (Fig. 4). 
This is particularly important given that the majority of CML patients at the time of 
diagnosis do not harbor detectable BCR-ABL mutations. De novo acquisition of BCR-ABL 
mutations does not necessarily have to operate exclusively from selection of pre-existing 
mutations. It is anticipated that these two modes of acquisition of BCR-ABL mutations may 
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ABL mutations may exist and accentuate the mutations.  
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KCL-22 cells were derived from a female blast crisis CML patient, and were characterized as 
immature undifferentiated cells lacking lymphoid cell characteristics (Kubonishi and 
Miyoshi, 1983). KCL-22 cells are positive for myeloid cell markers including myeloid 
progenitor cell marker CD33. KCL-22 cells harbor two Ph chromosomes but do not have 
detectable BCR-ABL mutations (Yuan et al., 2010). In contrast to resistance of blast crisis 
CML in vivo, most blast crisis CML cell lines in culture are very sensitive to 1 M imatinib 
with exception of KCL-22 (Deininger et al., 1997). Imatinib also kills KCL-22 cells, but it 
requires higher concentrations and takes longer time (Yuan et al., 2010). This unique feature 
of KCL-22 cell line perhaps made us successful in establishing it as a new model for 
acquired resistance of CML in vitro. The key characteristics of this model are summarized as 
follows: 
1. High relevance: KCL-22 cells are incubated with in vivo therapeutic concentrations of 
imatinib, i.e. 2.5 to 10 M. Cells undergo gradually increasing apoptosis for about a 
week followed by re-growing (relapse) with homogenous acquisition of T315I mutation.  
2. Easy to use: KCL-22 cell line is commercially available from German Collection of Cell 
Culture. Cells are easy to grow in standard RPMI 1640 medium supplied with 10% fetal 
bovine serum, and no additional growth factors are needed. One single dose of imatinib 
treatment is sufficient.  
3. Rapid turnaround: Relapse occurs in about two weeks with initial relapsed cells 
microscopically visible as small clusters of enlarged and sometimes irregularly shaped 
cells after around eight days of drug treatment.  
4. High reproducibility: Multiple persons in the lab have used this model and it produces 
highly consistent results among them.   
This model provides a novel tool for us to look into the process of acquisition of BCR-ABL 
mutations on the endogenous BCR-ABL in blast crisis CML cells, and has already provided 
valuable information in our initial study (Yuan et al., 2010) as summarized below. 
1. Acquisition of BCR-ABL mutations does not require pre-existing mutant clones derived 
from the original patient, as clonal cells without an initial mutation can regenerate 
mutations and relapse on imatinib. The mutations do not derive from a fixed 
subpopulation of pre-mutant cells. 
2. Acquisition of BCR-ABL mutations does not provoke additional chromosomal 
rearrangement, is not a result of mutator phenotype of KCL-22 cells, and can not be 
blocked by standard anti-oxidant treatment.   
3. Acquisition of BCR-ABL mutations is a dynamic process influenced by culture and 
environmental conditions. This is supported by several lines of evidence. First, clonal 
KCL-22 cells exhibit great difference for BCR-ABL mutations whereas mutations on 
HPRT gene are relatively stable among clones. Second, clonal KCL-22 cells can acquire 
different single mutations for each clone, suggesting change of mutation hot spots after 
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cloning process. We have identified three clones that can acquire T315I, E255K and 
Y253H mutation, respectively. These three mutations have the highest frequency in 
human patients shown in Fig. 1.  Third, the ability for acquisition of BCR-ABL 
mutations diminishes in parental KCL-22 cells after they are cultured continuously for 
more than 30 passages. Finally, we have found that the quality of fetal bovine serum 
can affect BCR-ABL mutation rate. We routinely use Hyclone characterized fetal bovine 
serum (Cat# SH30071.03) for mutation study, which typically produces consistent 
results among batches. However, when Hyclone serum was compared side by side with 
two other brands of fetal bovine serum, a noticeable reduction of BCR-ABL mutation 













































Fig. 2. Tissue culture conditions affect BCR-ABL mutations 
Comparison of Hyclone characterized fetal bovine serum with two other brands of fetal 
bovine serum. KCL-22 cells were incubated with medium supplied with these sera, 
respectively, for two days, and then seeded onto soft agar for colony formation assay. Left  
panel, 1x106 cells seeded per well with 2.5 M imatinib. Right panel: plating efficiency with 
500 cells seeded per well. Two independent batches of each serum (colored as blue and 
maroon) were tested. 
4. Acquisition of BCR-ABL mutations depends on expression of BCR-ABL, since 
knockdown of BCR-ABL blocks KCL-22 cell relapse and mutations. By over-expression 
of kinase-inactive BCR-ABL, intriguingly, it was found that BCR-ABL kinase activity is 
not absolutely required for acquisition of mutations. 
5. The endogenous BCR-ABL translocation locus significantly influences BCR-ABL 
mutations, as the mutation rate on the endogenous locus is nearly 10 times higher than 
that of the randomly integrated BCR-ABL cDNA as illustrated in Fig. 3. This finding 
reveals a previously unrecognized role of the translocation locus itself in driving BCR-
ABL mutagenesis, suggesting possible involvement of the local epigenome for BCR-
ABL mutations that will be discussed further below.  
Our extensive analyses of BCR-ABL mutations in KCL-22 cells lead to the conclusion that 
mutations can be acquired de novo after imatinib treatment, although precise molecular 
mechanisms are yet to be uncovered.  Such de novo acquisition of mutations may provide an 
alternative mechanism for clinical resistance of CML to tyrosine kinase inhibitors (Fig. 4). 
This is particularly important given that the majority of CML patients at the time of 
diagnosis do not harbor detectable BCR-ABL mutations. De novo acquisition of BCR-ABL 
mutations does not necessarily have to operate exclusively from selection of pre-existing 
mutations. It is anticipated that these two modes of acquisition of BCR-ABL mutations may 
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work in concert in certain patients leading to even faster relapse on the drug treatment. 
Therefore, we propose that de novo mutation acquisition and selection of pre-existing 































Fig. 3. Mutations on the endogenous BCR-ABL versus integrated BCR-ABL cDNA.  
Left, endogenous BCR-ABL (BA) was amplified by intron primers and integrated BCR-ABL 
was amplified by exon primers for mutation detection. Green for introns, blue for exons, 
asterisk for T315 mutation, and arrows for PCR primers. Right, relative mutation rate was 
the ratio of the number of clones bearing mutated endogenous BA or integrated BA cDNA 
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Fig. 4. Two modes of acquisition of BCR-ABL mutations for CML acquired resistance. 
Clinical relapse of CML on tyrosine kinase may be mediated by selection of pre-existing 
BCR-ABL mutant cells (green), de novo acquisition of BCR-ABL mutations (blue), or the 
combination of both. Non-mutant leukemia cells are in red. Two types of mutation 
acquisition could happen on the same amino acids. 
Although the clinical readout for de novo acquisition and selection of pre-existing mutations 
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management caused by these two modes of mutation acquisition could be different.  
Whereas strong tyrosine kinase inhibitors may be needed to suppress expansion of pre-
existing mutant cells, prevention of de novo mutation acquisition by alternative strategies 
may help block relapse of CML in this category as detailed later.  
4. Search for molecular evidence of de novo acquisition of mutations in 
human CML patients 
So far, de novo acquisition of mutations has not yet been proved in patients. As described 
above, de novo mutation acquisition happens rapidly in the KCL-22 cell model in which early 
relapsed cells are microscopically visible after eight days of imatinib treatment. We have 
further found that mutations may likely form as early as two days after imatinib treatment 
(unpublished data). This rapid generation of mutations may prevent the appropriate use of 
mathematical models (Michor et al., 2005) to effectively distinguish between de novo 
mutation acquisition versus selection of pre-existing mutations. Separation of these two 
modes of mutation acquisition is further confounded by pre-existing mutations that may not 
be detected truly due to insufficient method sensitivity or by non-representative sample 
collection for analysis. It is currently unclear about the molecular signature of de novo 
mutation acquisition in CML patients or how to track this type of mutagenesis. However, 
mutations in clonal KCL-22 cells may provide a clue.      
The mutation hot spots are different in three KCL-22 clones (clone L1 for E255K, clone L7 for 
Y253H and clone Ag 11 for T315I) (Yuan et al., 2010). When the codon changes are examined 
(TAC to CAC for Y253H, GAG to AAG for E255K, and ACT to ATT for T315I), a common 
molecular feature for these three mutations can be easily identified, namely, they are all 
transition mutations. It is important to note that both Y253 and E255 codons can acquire 
either transition or transversion mutation. Since these clonal cells are genetically identical, 
switching mutation hot spot from one transition mutation spot to another transition spot but 
not transversion, indicating that transition mutation is easier to be adapted on the BCR-ABL 
locus for kinase domain mutation. In line with this notion, frequencies for transition 
mutations for both Y253 and E255 codons are significantly higher than their transversion 
counterparts, Y253F and E255V in CML patients (Hochhaus et al., 2002; Press, 2010). 
Importantly, most of high frequency mutations shown in Fig. 1 are transition mutations. 
Further supporting this, a recent study shows that AID (activation-induced cytidine 
deaminase) promotes transition mutations in Ph+ B lymphoid blast crisis CML (Klemm et 
al., 2009). However, AID is activated in B lymphoid CML, but not in myeloid blast crisis 
CML including KCL-22 cells (Klemm et al., 2009), there may be additional mechanisms to 
enhance transitional mutations in myeloid blast crisis CML that makes up about 60% of all 
blast crisis CML (Calabretta and Perrotti, 2004). On the other hand, genetic mutations tend 
to have bias towards transition mutations (Wakeley, 1996). Therefore, additional studies 
including rigorous analysis of clinical samples are needed to explore if transition mutations 
may indeed play a role in de novo acquisition of mutations in CML patients. 
5. Mechanistic basis for integration of de novo mutation acquisition and 
selection of pre-existing mutations for drug resistance 
A key question about de novo acquisition of mutations is how it arises and integrates with 
selection of pre-existing mutations. The selection model for drug resistance is rooted in 
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work in concert in certain patients leading to even faster relapse on the drug treatment. 
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Darwinian genetics, in which mutations can randomly form without providing survival 
advantage until environmental stress is imposed. It has been well recognized that 
mammalian genome is under constant genotoxic assault from intrinsic or extrinsic source, 
and DNA damage contributes significantly to genetic mutations (Friedberg, 2003; Wiseman 
and Halliwell, 1996). Transformation of BCR-ABL in hematopoietic progenitor cells 
increases production of reactive oxygen species (ROS) and DNA damage (Koptyra et al., 
2006). Expression of BCR-ABL alters functions of cellular DNA damage repair machineries, 
especially for double-strand break (DSB) repair, which promotes CML genetic instability 
(Melo and Barnes, 2007). It is reasonable to believe that increased DNA damage and genetic 
instability would predispose CML cells to form mutations prior to drug treatment.  
In the past two decades, significant progresses have been made in the understanding of 
epigenetics and epigenomics for their roles in shaping gene functions, particularly in 
cancer development (Jones and Baylin, 2007). Unlike genetic changes, epigenetic/ 
epigenomic changes are versatile and reversible, which bring dynamics to genetic codes 
and bridge genetic alterations to environmental changes. Epigenomics plays important 
roles in DNA damage repair, best studied for DSB repair. Several chromatin remodeling 
complexes are participated in modifying local chromatin structure to facilitate DNA 
damage repair (Rossetto et al., 2010). Epigenetic regulation of chemoresistance is a 
burgeoning field, and little is understood how it is involved in acquisition of genetic 
mutations for drug resistance.  
We propose the following model as illustrated in Fig.5: Acquisition of BCR-ABL mutation is 
a multi-step process involving at least three core processes: DNA damage initiation, DNA 
damage repair and survival of newly mutated cells. These core processes are bound together 
through local epigenome that may serve as a sensor for stress signals and influence either 
exposure of local DNA to damage, repair process or cell survival. BCR-ABL locus may 
sustain constant DNA damage and repair, and the status of such DNA damage and repair 
determines whether the eventual relapse is mediated by selection of pre-existing mutations 
or de novo acquisition of mutations under stress. 
Based on this model, we predict that under the steady state, the BCR-ABL locus has ongoing 
DNA damage and repair, and most of cells do not harbor mutations because most of DNA 
damage is repaired correctly. Inappropriate repair will lead to low incidence of mutations 
and allow selection of such pre-existing mutations for cell survival and relapse during 
chemotherapy. On the other hand, chemotherapy, including but not limited to imatinib, 
may provide an extrinsic stress signal through epigenome to the locus, which may either 
increase local DNA damage load or interfere functions of repair machineries, accentuating 
the mutagenesis process and resulting in de novo acquisition of mutations. 
The definition of pre-existing mutations or de novo acquisition of mutations is based on the 
readout of DNA sequencing. However, DNA sequencing only detects completed mutations 
but not DNA damage. Therefore, a damaged base undetectable as a mutation by sequencing 
may emerge as a mutation, if it is not repaired on time or is repaired improperly. 
Alternatively, a mutation may emerge as a result of new DNA damage elicited by extrinsic 
stress. Consequently, de novo mutation acquisition would not require a fixed subpopulation 
as we have shown (Yuan et al., 2010), and it would be a dynamic process if environmental 
changes, such as cell growth conditions and nutrients, affect local epigenome and 
subsequently interfere the repair process.  
 





























Fig. 5. An epigenome model for acquisition of BCR-ABL mutations 
Acquisition of BCR-ABL mutations is a multi-step process that is regulated by BCR-ABL 
local epigenome. The epigenome is an important sensor of intrinsic oxidative stress signal 
(green) or extrinsic stress signal (red) including therapeutic or environmental stress, which 
in turn affects DNA damage, repair and cell survival, leading to maturation of genetic 
mutations for acquired resistance of CML. 
6. New opportunities for studying molecular mechanisms of acquired 
resistance 
In the coming years, it is anticipated that some steps of molecular regulation of mutation 
acquisition can be answered using the KCL-22 cell model.  Here we discuss some steps that 
need obvious attention. Understanding these mutagenesis steps may help design new 
strategies to block BCR-ABL mutagenesis.  
1. Regulation of DNA damage initiation. The very origin of mutations, where DNA 
damage is from, remains to be clearly defined. Many chemotherapeutic agents 
deliberately induce DNA damage to kill cancer cells. In contrast, imatinib treatment 
reduces bulk ROS production and DNA damage response measured by H2AX (Yuan 
et al., 2010).  It has been shown that anti-oxidants can inhibit BCR-ABL induced ROS 
production, DNA damage and mutations (Koptyra et al., 2006). However, anti-oxidants 
vitamin E and N-acetylcysteine, even in excessive amount, are unable to block 
acquisition of BCR-ABL mutations in KCL-22 cells (Yuan et al., 2010). There are several 
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Fig. 5. An epigenome model for acquisition of BCR-ABL mutations 
Acquisition of BCR-ABL mutations is a multi-step process that is regulated by BCR-ABL 
local epigenome. The epigenome is an important sensor of intrinsic oxidative stress signal 
(green) or extrinsic stress signal (red) including therapeutic or environmental stress, which 
in turn affects DNA damage, repair and cell survival, leading to maturation of genetic 
mutations for acquired resistance of CML. 
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In the coming years, it is anticipated that some steps of molecular regulation of mutation 
acquisition can be answered using the KCL-22 cell model.  Here we discuss some steps that 
need obvious attention. Understanding these mutagenesis steps may help design new 
strategies to block BCR-ABL mutagenesis.  
1. Regulation of DNA damage initiation. The very origin of mutations, where DNA 
damage is from, remains to be clearly defined. Many chemotherapeutic agents 
deliberately induce DNA damage to kill cancer cells. In contrast, imatinib treatment 
reduces bulk ROS production and DNA damage response measured by H2AX (Yuan 
et al., 2010).  It has been shown that anti-oxidants can inhibit BCR-ABL induced ROS 
production, DNA damage and mutations (Koptyra et al., 2006). However, anti-oxidants 
vitamin E and N-acetylcysteine, even in excessive amount, are unable to block 
acquisition of BCR-ABL mutations in KCL-22 cells (Yuan et al., 2010). There are several 
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possibilities for this observation: these anti-oxidants do not have sufficient potency, the 
DNA damage is too severe to be blocked, the anti-oxidants are inappropriate for the 
type of stress and damage in these cells, and the BCR-ABL locus is not accessible for 
these agents in KCL-22 cells. It is formally possible that there might be other sources of 
DNA damage.  
One interesting but not surprising observation is that after imatinib treatment, ROS level in 
early apoptotic cells surges by more than 100 folds (Yuan et al., 2010) (Fig. 6). This high level 
of ROS may initiate cell death pathway. It is provocative to speculate that mutant cells 
might be derived from rare early apoptotic cells as they somehow abandon apoptosis 
process but sustain substantial DNA damage, which could not be blocked by treatment with 
standard anti-oxidants, and would thus lead to genetic mutations.   
 





























Fig. 6. ROS levels in different apoptotic fractions of KCL-22 cells after imatinib treatment. 
2. Regulation of DNA damage repair. BCR-ABL alters functions of both homologous 
recombination (HR) and non-homologous end joining (NHEJ) repair machineries for 
DSB repair (Melo and Barnes, 2007). NHEJ is the major repair pathway in higher 
eukaryotes (Khanna and Jackson, 2001). NHEJ repair consists of both classic and 
alternative pathways. Classic NHEJ has core components KU70/86 and DNA-PKcs. 
When classic NHEJ is inhibited, alternative NHEJ that is independent of KU70/86 and 
DNA-PKcs will be activated. BCR-ABL inhibits classic NHEJ by degrading the key 
NHEJ factor DNA-PKcs (Deutsch et al., 2001). Recently, it has been found that BCR-
ABL activates alterative NHEJ through upregulation of Werner Syndrome protein 
(WRN) and DNA ligase IIIa in CML cells (Sallmyr et al., 2008). For HR repair, BCR-ABL 
increases expression of RAD51, a central HR factor, which abnormally increases DNA 
repair and enhances CML drug resistance (Slupianek et al., 2001). In addition, BCR-ABL 
expression compromises repair fidelity and increases DNA repair errors in CML cells 
(Nowicki et al., 2004). It will be interesting to determine whether the above mentioned 
repair mechanisms and factors, and perhaps other repair mechanisms, may be involved 
in acquisition of BCR-ABL mutations for acquired resistance to imatinib.  
3. Regulation of survival of emerging mutant cells. The newly relapsed KCL-22 cells 
exhibit morphological enlargement and irregularity with significant increase of G2/M 
fraction (Yuan et al., 2010).  This indicates that newly relapsed cells may likely suffer 
mitotic crisis as they slowly progress through cell cycle. This is perhaps the last and 
critical step for the completion of mutagenesis process to allow full outgrowth of 
mutant cells. Molecular machineries involved in mitotic regulation might play a role in 
survival of newly relapsed CML cells. Among them, Aurora serine/threonine kinases 
are critically involved in regulating mammalian cell division (Keen and Taylor, 2004; 
Early apoptotic
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Marumoto et al., 2005). Aurora A over-expression overrides the mitotic spindle 
assembly checkpoint and promotes cancer cells resistance to chemotherapy (Anand et 
al., 2003). Interestingly, the pan-Aurora kinase inhibitor VX-680  not only inhibits 
Aurora kinases but also suppresses T315I BCR-ABL through distinct structural 
mechanisms (Carter et al., 2005; Young et al., 2006). Another mitotic kinase Polo-like 
kinase 1 (PLK1) is also known to mediate cancer chemoresistance (Luo et al., 2009). It 
remains to be determined if these and other mitotic regulators may play a role in CML 
acquired resistance. 
4. Regulation of epigenome. Epigenome is a central component in our model. Identifying 
epigenetic factors involved in acquired resistance will significantly help us understand 
the dynamic mutation acquisition process. DNA methylation plays an important role in 
genetic mutations (Jones and Baylin, 2002). Methylation of cytosine at CpG sites 
significantly increases C to T transition mutation because of the spontaneous hydrolytic 
deamination of methylated cytosine. Cytosine methylation in gene coding regions is 
associated with mutation hot spots of certain tumor suppressor genes, such as p53, in 
cancer.  
Histone modifications are essential for DSB repair. Within minutes of DSB, histone H2A 
variant H2AX is phosphorylated and recruited to damage foci, which is followed by 
accumulation of DNA repair and chromatin remodeling factors (Rossetto et al., 2010).  
Several types of chromatin remodeling occur on and surround DSB sites. ATP-dependent 
chromatin remodeling complex INO80 is rapidly recruited by H2AX (Downs et al., 2004; 
Morrison et al., 2004; van Attikum et al., 2004). Recruitment of acetyltransferases and 
localized acetylation of histone H3 and H4 helps maintain open chromatin for repair 
(Tamburini and Tyler, 2005). Methylation of histone H4K20 also helps recruitment of repair 
factors through direct protein interaction (Botuyan et al., 2006; Sanders et al., 2004).  When 
repair is completed, local deacetylation mediated by histone deacetylases restores chromatin 
structure. Importantly, the ability to modulate histone acetylation and deacetylation is 
essential for cell viability following HR repair, likely due to its signaling to prevent 
persistent activation of DNA damage checkpoint (Tamburini and Tyler, 2005). In addition, 
class III histone deacetylase SIRT1 is also recruited to DSB sites (O'Hagan et al., 2008) and 
regulates DNA damage response (Oberdoerffer et al., 2008; Yuan et al., 2007).  It would be of 
great interest to define which and how chromatin modifiers response to therapeutic and 
environmental stress signals to mediate DSB repair and BCR-ABL mutagenesis. 
7. Implication of de novo acquisition of genetic mutations in leukemia 
management 
Blocking outgrowth of mutant BCR-ABL clones has clear therapeutic significance, regardless 
how the mutations may be acquired. However, strategies used to overcome resistance may 
be different for pre-exiting mutations and de novo acquired mutations.  The former demands 
more and more potent BCR-ABL inhibitors, which could lead to stronger resistance each 
time. This has been proved with sequential use of kinase inhibitors, resulting in selection of 
compound drug-resistant mutations (Shah et al., 2007). More potent third generation of 
tyrosine kinase inhibitors have been developed (Quintas-Cardama et al., 2010), including 
AP24534 that inhibits all tested BCR-ABL mutations and blocks outgrowth of mutant clones 
(O'Hare et al., 2009). Clinical resistance to the third generation of tyrosine kinase inhibitors 
remains to be determined. 
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Fig. 6. ROS levels in different apoptotic fractions of KCL-22 cells after imatinib treatment. 
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increases expression of RAD51, a central HR factor, which abnormally increases DNA 
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(Nowicki et al., 2004). It will be interesting to determine whether the above mentioned 
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Marumoto et al., 2005). Aurora A over-expression overrides the mitotic spindle 
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al., 2003). Interestingly, the pan-Aurora kinase inhibitor VX-680  not only inhibits 
Aurora kinases but also suppresses T315I BCR-ABL through distinct structural 
mechanisms (Carter et al., 2005; Young et al., 2006). Another mitotic kinase Polo-like 
kinase 1 (PLK1) is also known to mediate cancer chemoresistance (Luo et al., 2009). It 
remains to be determined if these and other mitotic regulators may play a role in CML 
acquired resistance. 
4. Regulation of epigenome. Epigenome is a central component in our model. Identifying 
epigenetic factors involved in acquired resistance will significantly help us understand 
the dynamic mutation acquisition process. DNA methylation plays an important role in 
genetic mutations (Jones and Baylin, 2002). Methylation of cytosine at CpG sites 
significantly increases C to T transition mutation because of the spontaneous hydrolytic 
deamination of methylated cytosine. Cytosine methylation in gene coding regions is 
associated with mutation hot spots of certain tumor suppressor genes, such as p53, in 
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Histone modifications are essential for DSB repair. Within minutes of DSB, histone H2A 
variant H2AX is phosphorylated and recruited to damage foci, which is followed by 
accumulation of DNA repair and chromatin remodeling factors (Rossetto et al., 2010).  
Several types of chromatin remodeling occur on and surround DSB sites. ATP-dependent 
chromatin remodeling complex INO80 is rapidly recruited by H2AX (Downs et al., 2004; 
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localized acetylation of histone H3 and H4 helps maintain open chromatin for repair 
(Tamburini and Tyler, 2005). Methylation of histone H4K20 also helps recruitment of repair 
factors through direct protein interaction (Botuyan et al., 2006; Sanders et al., 2004).  When 
repair is completed, local deacetylation mediated by histone deacetylases restores chromatin 
structure. Importantly, the ability to modulate histone acetylation and deacetylation is 
essential for cell viability following HR repair, likely due to its signaling to prevent 
persistent activation of DNA damage checkpoint (Tamburini and Tyler, 2005). In addition, 
class III histone deacetylase SIRT1 is also recruited to DSB sites (O'Hagan et al., 2008) and 
regulates DNA damage response (Oberdoerffer et al., 2008; Yuan et al., 2007).  It would be of 
great interest to define which and how chromatin modifiers response to therapeutic and 
environmental stress signals to mediate DSB repair and BCR-ABL mutagenesis. 
7. Implication of de novo acquisition of genetic mutations in leukemia 
management 
Blocking outgrowth of mutant BCR-ABL clones has clear therapeutic significance, regardless 
how the mutations may be acquired. However, strategies used to overcome resistance may 
be different for pre-exiting mutations and de novo acquired mutations.  The former demands 
more and more potent BCR-ABL inhibitors, which could lead to stronger resistance each 
time. This has been proved with sequential use of kinase inhibitors, resulting in selection of 
compound drug-resistant mutations (Shah et al., 2007). More potent third generation of 
tyrosine kinase inhibitors have been developed (Quintas-Cardama et al., 2010), including 
AP24534 that inhibits all tested BCR-ABL mutations and blocks outgrowth of mutant clones 
(O'Hare et al., 2009). Clinical resistance to the third generation of tyrosine kinase inhibitors 
remains to be determined. 
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For mutations acquired de novo, however, a prevention strategy may be more appropriate 
and effective to block mutant cells from emergence at the beginning. With better 
understanding of mechanisms of mutations described above, it is expected that a new agent 
may be devised to modulate DNA damage initiation, repair, epigenome remodeling, or 
survival of newly emerged mutant cells, which will prevent CML acquired resistance in 
future. A combination therapy may be adapted with such a new agent and imatinib or other 
tyrosine kinase inhibitors. Alternatively, it is also reasonable to speculate that a multi-target 
agent can be developed to incorporate these features, for example, a drug that both inhibits 
BCR-ABL tyrosine kinase and modulates epigenome. We anticipate different ways to 
overcome resistance depending on which steps and factors the drug would target to block 
mutagenesis. We expect that such a strategy may also have broader implication for 
management of other types of leukemia to overcome drug resistance.     
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Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder of pluripotent 
hematopoietic stem/progenitor cells that has been paradigmatic to our understanding of the 
molecular and cellular basis of human malignancies. It has provided an excellent example of 
how a specific molecular abnormality can be targeted therapeutically to transform a life-
threatening malignancy into a chronic disease. The study of CML has been characterized by 
a number of ‘firsts’. CML was the first malignancy to be: (i) associated with a specific 
chromosomal abnormality, (ii) associated with a specific molecular alteration (BCR-ABL) 
and (iii) successfully treated with a specifically designed targeted therapeutic agent. As such 
it seems natural that CML should be the first human malignancy in which a complete 
medical cure is achieved through the eradication of cancer stem cells. This should be 
realizable through combining the specific targeting of BCR-ABL and CML stem cells. Once 
this has been achieved, the challenge will be to successfully transfer the lessons learned from 
this relatively simple and well-characterized model system to the eradication of cancer stem 
cells in more complex malignancies. 
The treatment of CML has changed dramatically following the introduction into the clinic of 
the tyrosine kinase inhibitor (TKI) imatinib mesylate and second generation TKIs. These 
agents directly target the BCR-ABL oncoprotein product of the constitutively active BCR-
ABL tyrosine kinase. The specific targeting of BCR-ABL induces durable clinical remission 
in a high proportion of chronic phase CML (CP-CML) subjects (5 year survival of 89%) 
(Druker et al, 2006). Although a major molecular response (defined as a 3-log reduction in 
BCR-ABL mutant allele burden) is obtained in many CP-CML patients, only a small number 
attain PCR negativity as determined by the absence of residual BCR-ABL transcripts 
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Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder of pluripotent 
hematopoietic stem/progenitor cells that has been paradigmatic to our understanding of the 
molecular and cellular basis of human malignancies. It has provided an excellent example of 
how a specific molecular abnormality can be targeted therapeutically to transform a life-
threatening malignancy into a chronic disease. The study of CML has been characterized by 
a number of ‘firsts’. CML was the first malignancy to be: (i) associated with a specific 
chromosomal abnormality, (ii) associated with a specific molecular alteration (BCR-ABL) 
and (iii) successfully treated with a specifically designed targeted therapeutic agent. As such 
it seems natural that CML should be the first human malignancy in which a complete 
medical cure is achieved through the eradication of cancer stem cells. This should be 
realizable through combining the specific targeting of BCR-ABL and CML stem cells. Once 
this has been achieved, the challenge will be to successfully transfer the lessons learned from 
this relatively simple and well-characterized model system to the eradication of cancer stem 
cells in more complex malignancies. 
The treatment of CML has changed dramatically following the introduction into the clinic of 
the tyrosine kinase inhibitor (TKI) imatinib mesylate and second generation TKIs. These 
agents directly target the BCR-ABL oncoprotein product of the constitutively active BCR-
ABL tyrosine kinase. The specific targeting of BCR-ABL induces durable clinical remission 
in a high proportion of chronic phase CML (CP-CML) subjects (5 year survival of 89%) 
(Druker et al, 2006). Although a major molecular response (defined as a 3-log reduction in 
BCR-ABL mutant allele burden) is obtained in many CP-CML patients, only a small number 
attain PCR negativity as determined by the absence of residual BCR-ABL transcripts 
(Hughes et al, 2003). This is because TKI therapy does not specifically target or eliminate 
leukemia stem cells (LSCs). Indeed TKI therapy alone is unlikely to ever be curative, as 
following treatment with TKIs LSCs persist in bone marrow (BM) stem cell niches where 
they harbor the potential for relapse. The emergence of resistance to TKI monotherapy 
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through the accumulation of somatic kinase domain mutations that interfere with the 
binding of TKIs to the BCR-ABL ATP-binding site accounts for around 60-90% of relapses 
(O’Hare et al, 2006). There is consequently a significant unmet medical need for more 
effective therapeutic strategies that following effective tumor debulking are able to: (i) 
inhibit the molecular mechanisms responsible for generating the LSC genomic instability 
phenotype, (ii) target the essential components of the stem cell niche and the BM 
microenvironment that generate, protect, and nurture LSCs and (iii) efficiently eradicate 
LSCs. The micro-evolution of TKI resistance in CML is driven by the intrinsic genomic 
instability of the LSC, which in the presence of the selective pressure of drug, results in the 
expansion of a relatively predictable and invariant quasispecies of somatic mutants, which 
have differing degrees of intrinsic and acquired TKI resistance. The frequency of each of 
these clones oscillates with time, with a unitary or oligoclonal set eventually dominating the 
structure of the population and the clinical response to TKI therapy. The spectrum of 
mutants in any individual may be characterized through mutational analysis and 
subsequently used to select the most appropriate TKI therapy. The persistence of LSCs, 
however, allows additional drug-resistant mutants to arise, creating a new repertoire of 
diversity from which the most resistant and fastest growing clones are selected. As a result 
the therapeutic effects of first- and second-line TKI therapy are eventually circumvented. 
Clearly the eradication of the LSCs must form both a necessary and essential component of 
any therapeutic strategies that aim to achieve a deep and sustained molecular and clinical 
response, and ultimately a cure. In what follows we outline a number of approaches to the 
characterization of the CML LSC. The profiling and characterization of the LSC phenotype is 
expected to contribute to the rational design of LSC-targeted therapy, and as such presents 
an opportunity to establish a general paradigm for the development of cancer stem cell-
directed cures for human malignancies.  
2. Clinical and therapeutic challenges in the management of CML  
CML is a clonal, multi-step and multi-lineage myeloproliferative disease that typically 
evolves through three phenotypically and clinically distinct stages (Goldman & Melo, 2003;  
Jiang X. 2007; Savona & Talpaz, 2008; Sloma et al., 2010). The first of these is an indolent 
chronic phase (CP) characterized at the time of diagnosis by the presence of a deregulated 
BCR-ABL+ clone. This expands inappropriately and comes to dominate the population of 
BM progenitor cells, while at the same time continuing to produce phenotypically normal 
mature blood cells. There is, as a result, an excessive output of myeloid precursors and 
mature granulocytes into the BM and peripheral blood (PB). The second stage is an 
accelerated phase (AP) characterized by an incremental increase in the disease burden as 
demonstrated by an increased frequency of leukemic myeloid progenitor/precursor cells. 
The third stage is a rapidly fatal acute blast crisis phase (BC) characterized by increased 
genomic instability, deregulated proliferation and loss of differentiation. BC-CML may be 
categorized as myeloid or lymphoid (pre-B) by the appearance of increased numbers of 
differentiation-arrested blast cells that reflect the growth of sub-clones of early myeloid or 
pre-B cells respectively that have acquired additional somatic mutations (Goldman & Melo, 
2003;  Jiang X. 2007; Savona & Talpaz, 2008; Sloma et al., 2010). The canonical feature of 
CML is the presence in hematopoietic stem cell (HSC) derived progeny of a Philadelphia 
chromosome (Ph+) containing a reciprocal t(9;22)(q34;q11) translocation, which generates a 
clone-specific BCR-ABL fusion oncogene. This encodes a chimeric BCR-ABL oncoprotein 
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that has significantly enhanced and constitutive tyrosine kinase activity, which drives the 
pathogenic features of the disease (Druker et al., 1996; Lugo et al., 1990). It produces a range 
of biochemical changes that impact the growth-factor dependence, turnover, and genomic 
stability of primitive CD34+ leukemic cells, whilst at the same time having little impact on 
their ability to differentiate according to predefined molecular programs (Holyoake et al., 
2002; Jiang et al., 2007b; Penserga & Skorski, 2007; Sloma et al., 2010; Valent, 2008). 
The identification of an invariant molecular genetic alteration (BCR-ABL) in the vast 
majority of cases of CML has facilitated the development of rational targeted therapy 
focused on the selective inhibition of the dysregulated tyrosine kinase activity of the 
encoded BCR-ABL oncoprotein (Druker et al., 1996; Shah et al., 2004; Weisberg et al., 2005). 
Imatinib mesylate (IM, Novartis, Basel, Swizerland) was the first tyrosine inhibitor to be 
developed as a molecular targeted drug (Druker et al., 1996). It is a competitive inhibitor of 
the ATP-binding site of the ABL-kinase domain, and prevents a conformational change of 
the oncoprotein to its active form, resulting in the elimination of most BCR-ABL+ cells 
(Druker et al., 1996). This relatively selective agent (it also recognizes the ATP-binding site 
of the c-Kit and platelet-derived growth factor receptors) has been immensely effective in 
the treatment of subjects with CP-CML (Druker et al., 2006; Druker et al., 2001; Kantarjian et 
al., 2002; O'Brien et al., 2003). Nevertheless, early relapse and the emergence of IM resistance 
are observed in 10-20% of subjects in early CP-CML, and up to 40% of those with advanced 
phase disease including 1-3% of newly diagnosed CML patients that develop sudden blast 
crisis (Apperley, 2007; Deininger et al., 2005; Forrest et al., 2008; Kantarjian et al., 2003; 
O'Hare et al., 2006; Valent, 2008). The inability to successfully discontinue IM therapy 
following at least five years of therapy, the persistence of a reservoir of clonal leukemic stem 
cells following the attainment of a complete molecular response (CMR), and the uncertain 
safety profile of long-term TKI treatment, has led to differing views on the most appropriate 
choice of therapy in CP-CML (Mahon et al., 2010; Ross et al., 2010a; Ross et al., 2010b; 
Rousselot et al., 2007; Sobrinho-Simoes et al., 2010).  Recently, second-line TKIs including 
Dasatinib (DA,Bristol-Myers Squibb, New York, NY, USA) and Nilotinib (NL, Novatis) have 
been licensed for use in this indication and represent alternative therapeutic options either 
first-line or for resistant or intolerant cases. Both drugs have increased potency against the 
BCR-ABL kinase domain mutants most commonly associated with IM resistance. This along 
with their differing spectrums of inhibitory activity across the human kinome, has translated 
into increased clinical efficacy in subjects with IM-resistant disease (Carter et al., 2005; Shah 
et al., 2004; Weisberg et al., 2005). The major cytogenetic response (MCyR) rate following 
therapy with DA or NL in subjects with IM-resistant CP-CML is approximately 60%, with a 
complete cytogenetic response (CCyR) rate of 50% (Hochhaus et al., 2008; Kantarjian et al., 
2007). Two recent Phase 3 randomized trials in subjects with treatment naïve early stage CP-
CML demonstrated that both drugs are more effective than IM at inducing MCyR and major 
molecular (MMR) responses (Kantarjian et al., 2010; Saglio et al., 2010). DA and NL were 
subsequently approved by the U.S. Food and Drug Administration (FDA) as first-line 
therapies in CP-CML. Clinical experience, however, has shown that some subjects 
experience inadequate responses to all existing TKI therapies, or have an initial response but 
then progress rapidly (Kantarjian et al., 2006; Talpaz et al., 2006). As is the case in 60% of 
subjects with IM-resistant disease, the recalcitrant T315I mutation also routinely dominates 
the observed resistance with DA and NL (Apperley, 2007; Goldman, 2007).  As a result these 
agents have no benefit over IM in subjects whose resistance is thought to be mediated 
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principally by T315I somatic mutants. In spite of this, each TKI has a unique spectrum of 
activity with respect to most of the other commonly encountered mutations that confer 
resistance to TKI therapy. Subjects with the V299L, T315A, and F317L/V/I/C mutations, for 
example, are less sensitive to DA (Muller et al., 2009; Soverini et al., 2011; Soverini et al., 
2006), whereas the Y253H, E255K/V and F359V/C/I mutations are less sensitive to 
treatment with NL (Hughes et al., 2009; Soverini et al., 2011). Several third-generation 
tyrosine kinase inhibitors have been developed, including ponatinib (AP24534, ARIAD, 
Cambridge, Massachusetts, US) (O'Hare et al., 2009), which is an orally active multi-targeted 
kinase inhibitor that targets both the wild type and a broad spectrum of mutant forms of 
BCR-ABL. It was specifically designed to inhibit the autophosphorylation of wild-type and 
T315I mutant BCR-ABL and is active against most of the commonly encountered IM-
resistant mutations including G250E, Y253F and E255K (O'Hare et al., 2009). In a phase 1 
study 38 patients with CP-CML, 66% achieved a MCyR and 53% a CCyR. Most significantly, 
a total of 89% (nine subjects) of the subjects harboring a T315I mutation attained a CCyR 
(Santos & Quintas-Cardama, 2011). The effectiveness of long-term therapy with ponatinib in 
IM-resistant patients, however, has yet to be determined. Allogeneic hematopoietic stem cell 
transplantation (allo-HSCT) is currently the only therapeutic option for CML that has 
curative potential. Its use, however, is restricted to subjects of less than 50 years that have a 
suitable donor, and even this highly selected group has a high risk of procedure-related 
morbidity and mortality (Forrest et al., 2008). The salvage rate for subjects with advanced 
phase disease, especially BC-CML, is poor even with allo-HSCT, with the vast majority 
dying as a result of their disease within a few years. There is consequently a significant 
unmet medical need for therapeutic options that prevent the emergence of resistant sub-
clones and that can be administered with curative intent as a result of the selective targeting 
of LSCs. 
3. Properties of CML stem/progenitor cells that generate TKI resistance   
Primitive quiescent CML stem cells are relatively unresponsive to TKIs (Copland et al., 2006; 
Graham et al., 2002; Jorgensen et al., 2007) and possess unique features that predispose them 
to intrinsic and acquired resistance to BCR-ABL targeted therapeutics (Chu et al., 2005; Jiang 
et al., 2007a; Jiang et al., 2007b; Jiang et al., 2007c; Konig et al., 2008; Sorel et al., 2004). 
Evidence further suggests that LSCs are responsible for relapse following the 
discontinuation of IM therapy (Mahon et al., 2010; Ross et al., 2010a; Ross et al., 2010b; 
Rousselot et al., 2007; Sobrinho-Simoes et al., 2010). The elimination of the LSCs responsible 
for disease perpetuation and for the intrinsic and acquired TKI resistance observed in CML 
therefore represents the next logical step in the treatment of CML. An essential component 
of this enterprise, involves the molecular characterization of the CML stem cell phenotype, 
BM microenvironment and the stem niche that foster the origin, development, growth and 
survival of LSCs. 
The relative insensitivity of primitive CML cells to treatment with IM was first reported in a 
quiescent subset of CD34+ CML cells using a carboxy-fluorescein diacetate succinimidyl 
diester (CFSE) staining cell division tracking assay (Graham et al., 2002; Holyoake et al., 
1999). This demonstrated that 3 days of exposure of CML cells in vitro to concentrations of 
IM that were several-fold higher than those achieved in the plasma of subjects treated with 
400 mg IM daily, failed to eliminate most of the primitive quiescent CML cells (Graham et 
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al., 2002). In contrast, cells with replicative competency during the same interval were 
eliminated. A similar insensitivity of this subset of cells to DA and NL has also been 
demonstrated (Copland et al., 2006; Jorgensen et al., 2007). Subsequent studies using assays 
for long-term culture-initiating cells (LTC-ICs) and colony forming assays (CFCs) have  
 
 
Fig. 1. Unique features of CML stem cells promoting their resistance to BCR-ABL-targeted 
therapies. (A) Suspension cultures were initiated with FACS-purified lin-CD34+CD38- and lin-
CD34+CD38+ CML cells and maintained for 3 weeks in the presence or absence of growth 
factors and variable concentrations of imatinib (IM). The differential IM sensitivity of lin-
CD34+CD38- and lin-CD34+CD38+ CML cells to IM in vitro is markedly enhanced under 
growth factor-deprived conditions. (B) BCR-ABL transcript levels relative to BCR were 
measured in RNA isolated from different subsets of cells. Expression of BCR-ABL is highly 
deregulated in lin-CD34+CD38- stem-cell enriched population as compared to their more 
mature progenitor cells (lin-CD34+CD38+) and differentiated cells (lin+CD34-). (C) OCT1, 
ABCB1 and ABCG2 transcript levels relative to GAPDH were measured in different subsets of 
CP-CML and normal BM cells. A reduced level of OCT1 and elevated levels of ABCB1 and 
ABCG2 were detected in lin-CD34+CD38- stem-cell enriched population as compared to their 
more mature progenitor cells. The combination of very low expression of OCT1 (low IM 
uptake), highly elevated expression of ABCB1 and ABCG2 (high efflux of IM and other drugs) 
and elevated expression of BCR-ABL in CML stem cells indicates that their general insensitivity 
to IM and other therapeutics is likely to be explained by multiple abnormal mechanisms.  
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al., 2002). In contrast, cells with replicative competency during the same interval were 
eliminated. A similar insensitivity of this subset of cells to DA and NL has also been 
demonstrated (Copland et al., 2006; Jorgensen et al., 2007). Subsequent studies using assays 
for long-term culture-initiating cells (LTC-ICs) and colony forming assays (CFCs) have  
 
 
Fig. 1. Unique features of CML stem cells promoting their resistance to BCR-ABL-targeted 
therapies. (A) Suspension cultures were initiated with FACS-purified lin-CD34+CD38- and lin-
CD34+CD38+ CML cells and maintained for 3 weeks in the presence or absence of growth 
factors and variable concentrations of imatinib (IM). The differential IM sensitivity of lin-
CD34+CD38- and lin-CD34+CD38+ CML cells to IM in vitro is markedly enhanced under 
growth factor-deprived conditions. (B) BCR-ABL transcript levels relative to BCR were 
measured in RNA isolated from different subsets of cells. Expression of BCR-ABL is highly 
deregulated in lin-CD34+CD38- stem-cell enriched population as compared to their more 
mature progenitor cells (lin-CD34+CD38+) and differentiated cells (lin+CD34-). (C) OCT1, 
ABCB1 and ABCG2 transcript levels relative to GAPDH were measured in different subsets of 
CP-CML and normal BM cells. A reduced level of OCT1 and elevated levels of ABCB1 and 
ABCG2 were detected in lin-CD34+CD38- stem-cell enriched population as compared to their 
more mature progenitor cells. The combination of very low expression of OCT1 (low IM 
uptake), highly elevated expression of ABCB1 and ABCG2 (high efflux of IM and other drugs) 
and elevated expression of BCR-ABL in CML stem cells indicates that their general insensitivity 
to IM and other therapeutics is likely to be explained by multiple abnormal mechanisms.  
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indicated that although IM is able to inhibit the proliferation of primitive CML cells in vitro, 
it does not induce concurrent apoptosis (Holtz et al., 2005; Holtz et al., 2002). We have 
shown that the ability of IM to inhibit primitive CML cells depends on their differentiation 
status (Jiang et al., 2007c). In these experiments, stem cell and progenitor cell enriched CML 
cell fractions (lin-CD34+CD38- and lin-CD34+CD38+ cells, respectively) were isolated and 
cultured in the presence of varying concentrations of IM for a more prolonged period than 
in the earlier studies with primary quiescent CML cells (3 weeks vs. 3 to 12 days). The 
inhibitory effect of IM on the yield of viable cells following a 3 week exposure period was 
found to be much less (~10- to 20-fold) pronounced in cultures initiated with more primitive 
lin-CD34+CD38- CML cells as compared with the more differentiated lin-CD34+CD38+ cells 
(Figure 1A). Taken together, these findings suggest that the most primitive CML cells are 
much less sensitive to IM than the differentiated bulk population. The fact that Ph+CD34+ 
CFCs and LTC-ICs remain detectable in subjects with CML that have achieved 
hematological remission following treatment with IM, suggests that these in vitro findings 
are likely to translate into the clinic (Bhatia et al., 2003; Chu et al., 2005). They are further 
supported by a recent report revealing the presence of BCR-ABL+ cells in LTC-ICs of CML 
patients that have achieved prolonged clinical remission following treatment with either 
interferon-alpha, IM or DA (Chomel et al., 2011). However, whereas most CML cells are 
oncogene addicted and sensitive to TKI treatment, the growth and survival of CML LSCs do 
not appear to be BCR-ABL tyrosine kinase activity dependent (Corbin et al., 2011). This 
suggests that alternative pathways may be active in CML LSCs that drive their proliferation 
and self-renewal in a BCR-ABL independent manner. Combination therapies aimed at 
targeting critical components of these pathways are likely to be of key importance in the 
derivation of a logical CML LSC eradication strategy.  
Other studies have shown that CML stem/progenitor cells have multiple unique features 
that would be expected to contribute to the observed intrinsic and acquired resistance to 
BCR-ABL directed therapeutics (Copland, 2009; Engler et al., 2010; Jiang et al., 2007a; Jiang et 
al., 2007b; Jiang et al., 2007c). These include: (i) elevated levels of BCR-ABL expression and 
kinase activity in CML stem cells as compared with their more mature progeny (Figure 1B) 
in a manner that is cell cycle status independent (Barnes et al., 2005; Copland et al., 2006; 
Jamieson et al., 2004; Jiang et al., 2007b; Jiang et al., 2008; Jiang et al., 2007c), (ii) a 
corresponding reduced (almost undetectable) level of the transporter gene OCT1 that is the 
principal regulator of IM uptake (Figure 1C) (Thomas et al., 2004; White et al., 2006) and 
whose decreased levels would be expected to reduce the ability of cells to take up IM 
(Engler et al., 2010; Jiang et al., 2007c) and (iii) elevated levels of expression of the ABC 
transporter genes ABCB1(MDR) and ABCG2 (Figure 1C) which enhance the cellular efflux of 
IM and other drugs (Jiang et al., 2007c; Jordanides et al., 2006; Lepper et al., 2005). The 
combination of an exceptionally low level of OCT1 expression which impedes cellular IM 
uptake, a highly elevated expression of ABCB1 and ABCG2 which produces a high rate of 
cellular IM efflux, and elevated expression of the BCR-ABL oncogene in CML stem cells, 
indicates that their insensitivity to IM and other therapeutics is in part explained by a 
unique portfolio of protective mechanisms (Jiang et al., 2007b; Jiang et al., 2007c). 
Interestingly studies in a cohort of 30 CML patients have shown that IM-non-responders 
have lower OCT1 transcript levels than IM-responders (Crossman et al., 2005), and that the 
functional activity of the encoded OCT1 protein, as measured by the OCT1-mediated influx 
of IM into primary CML cells, is predictive of the long-term outcome of CP-CML subjects 
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treated with IM (White et al., 2010; White et al., 2006). This suggests that measurement of 
OCT1 expression might provide a useful predictor of the long-term risk of resistance 
acquisition in subjects with IM-treated CML.    
In order to determine whether the unique properties of CD34+ stem/progenitor cells 
derived from treatment-naïve CML patients correlate with the subsequent clinical response 
of the patients to IM therapy, we conducted a retrospective analysis of pre-treatment CD34+ 
PB cells obtained from 25 IM-treated CP-CML subjects with documented clinical outcomes 
(Jiang et al., 2010). Following the isolation of CD34+ cells from pre-treatment samples, we 
measured their in vitro CFC sensitivity to IM, expression levels of BCR-ABL, OCT1, 
ABCB1/MDR, and ABCG2, and the frequency of BCR-ABL tyrosine kinase domain somatic 
mutations. The data were segregated and analyzed according to whether they were from the 
11 clinically defined IM-responders or the 14 IM non-responders. This confirmed the 
reported features of CD34+ CML cells, and identified two further features that differed 
significantly between the two groups. These were the responses of the pre-treatment CFCs 
to IM exposure in vitro (P<0.0001) and the frequency of mutant BCR-ABL transcripts in 
CD34+ cells (P=0.0025) suggesting that these parameters might form the basis of a 
prospective test for the optimization of CP-CML management (Jiang et al., 2010). 
4. Genomic instability and a mutator phenotype as an invariant feature of 
CML LSCs   
The genomic instability of primitive CML cells induced by the presence of the BCR-ABL 
fusion oncogene has long been thought to be a critical feature of CML. However, it is only in 
the last decade that data from CML cell lines and transgenic mice have provided definitive 
evidence that the BCR-ABL oncogene is necessary for the induction of genomic instability in 
hematopoietic cells (Brain et al., 2002; Brain et al., 2003; Canitrot et al., 1999). BCR-ABL is 
able, for example, to induce a mutator phenotype in BCR-ABL transfected murine cells. It 
also produces elevated levels of reactive oxygen species (ROS)-dependent DNA damage as 
compared with non-transfected controls. This damage to genomic DNA is likely to 
contribute to the accumulation of the somatic point mutations found in the ATP-binding site 
of the constitutively expressed BCR-ABL tyrosine kinase, and which are responsible for 
most cases of TKI resistance (Koptyra et al., 2006; Skorski, 2008). Interestingly, the ROS-
dependent mutations in BCR-ABL transfected cells were principally detected in a gene 
encoding the Na+K+ATPase Atp1a1 (Koptyra et al., 2006). Mutant ATP1A1 transcripts 
including those containing point mutations, insertions and deletions have been reported at 
high frequency (15-34%) in CD34+ CML cells rescued from IM nonresponders, a mutational 
rate similar to that observed in the BCR-ABL kinase domain of CML subjects. These 
mutations are not seen in CD34+ BM cells derived from healthy controls (Jiang et al., 2010). 
This and other data suggest that BCR-ABL induces a mutator phenotype, which results in 
the genome-wide instability of primitive CML cells.  
Investigations into the cellular and molecular causes of IM resistance have shown that the 
acquisition of somatic mutations in the BCR-ABL kinase-encoding domain that reduce the 
efficiency of IM binding to the ATP binding site represents the most common mechanism of 
resistance (accounting for 60-80% of relapses) (Deininger et al., 2005; O'Hare et al., 2006; 
Soverini et al., 2011; Valent, 2008). Copy number amplifications of BCR-ABL in contrast are 
rare (<10% of cases) (Gorre et al., 2001; Hochhaus et al., 2002; Tauchi & Ohyashiki, 2004). 
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More than 90 different BCR-ABL kinase domain point mutations have been reported at 
varying frequencies in IM-resistant subjects (Apperley, 2007; Hughes et al., 2006; Shah et al., 
2002; Soverini et al., 2011). Of these 15 specific amino acid substitutions account for more 
than 85% of the mutations at the protein sequence level. The mutations responsible for 66% 
of reported cases, furthermore, have been shown to occur at only six different positions 
(G250E, Y253F/H, E255K/V, T315I, F359V, H396R/P). The T315I mutation, which confers 
resistance to IM, DA and NL, is the most frequently detected mutation in IM-resistant 
patients and is the hardest mutant to treat (Apperley, 2007; Carter et al., 2005; Shah et al., 
2004; Soverini et al., 2011; Weisberg et al., 2005). BCR-ABL kinase domain mutations are 
found in IM-naïve patients but not in the germline of healthy controls, indicating that at 
least some of the mutations are somatically generated prior to the presence of drug 
selection, and that the increased frequency of mutations observed following TKI therapy 
occurs as a result of drug-induced selection and associated clonal expansion (Roche-
Lestienne et al., 2003; Roche-Lestienne et al., 2002; Willis et al., 2005). The somatic mutations 
themselves arise as a consequence of underlying genomic instability, which may reflect 
impaired processes of DNA repair in LSCs. Although some of the mutants are adaptive 
under the selective pressure of drug exposure, the majority diminish in frequency in the 
presence of TKI selection. We and others have demonstrated that the BCR-ABL fusion gene 
in CD34+ leukemic progenitor cells (Chu et al., 2005; Jiang et al., 2010) and CD34+CD38- stem 
cell-enriched cells is itself highly unstable (Jiang et al., 2007a) This is reflected in the 
unusually high frequency of BCR-ABL mutations that accumulate in the CD34+CD38- 
compartment in the presence or absence of IM selection. The rapid acquisition of somatic 
mutations in BCR-ABL is also observed in the progeny of CML cells stimulated to proliferate 
and differentiate in vitro (Figure 2) (Jiang et al., 2007a). The rapid and prolific generation of 
BCR-ABL somatic mutants in primary CML cells in vitro extends recent findings in BCR-
ABL-transduced murine BaF3 cells (von Bubnoff et al., 2005), and adult BM cells (Flamant & 
Turhan, 2005) and indicates that primitive leukemic CML cells have an intrinsically high 
rate of mutation, and a tendency to fix new somatic point mutations irrespective of the 
presence or absence of drug. The nature and timing of these apparently stochastic events 
relative to the size of the primary LSC clone at the time diagnosis and the timing, nature and 
extent of TKI therapy, may to some extent explain the variable clinical responses observed in 
different subjects (Jiang et al., 2007a; Roche-Lestienne et al., 2003; Shah et al., 2002; Sorel et al., 
2004). A recent study shows that CML subjects defined retrospectively as either IM responders 
or IM non-responders display significant differences in the frequency of mutant BCR-ABL 
transcripts present in their pre-treatment CD34+ cells (P=0.0025), with some of the highly 
resistant BCR-ABL kinase domain somatic mutants such as T315I being amplified from the 
CD34+ cells of IM non-responsive subjects (Jiang et al., 2010). Overall this suggests that 
primary CML stem/progenitor cells have a high degree of focal and possibly genome-wide 
instability, emphasizing the importance of taking the properties of these cells into account 
when considering new therapeutic approaches. The unique properties of leukemia 
stem/progenitor cells may, furthermore, help predict individual responses to TKI therapies 
and in so doing improve clinical management by facilitating personalized treatment decisions.   
One approach to targeting the LSC involves defining and inhibiting the generative 
mechanism causal to the observed genomic instability in LSCs. The ROS that are induced by 
BCR-ABL are known to cause many types of DNA damage including double-strand breaks 
(DSBs). It has been shown that the error-prone repair of DSBs by non-homologous end-
joining (NHEJ) may be responsible for at least some of the somatic point mutations observed 
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Fig. 2. CML stem cells are highly unstable and generate a high frequency of BCR-ABL kinase 
domain mutations both in vitro and in vivo.  (A) Suspension cultures were initiated with 
FACS-purified lin-CD34+CD38- stem cell-enriched population and maintained for 3 weeks in 
the presence or absence of growth factors and IM. The cells harvested from the 3-week 
cultures were then assayed for CFCs. Mutational analysis was then performed for the 
detection of BCR-ABL kinase domain mutations in freshly isolated lin-CD34+CD38- cells and 
their CFC progenies. (B) Pre-existing BCR-ABL kinase domain mutations could be detected 
in freshly isolated lin-CD34+CD38- stem cells and new mutations appeared during the 
growth of primitive CML cells in vitro. (C) Chromosomal abnormalities, such as 17 p+, could 
be observed from single colonies generated from the cells present after 3 weeks in culture 
with IM.    
in early CML and also the large deletions seen in later-stage CML. This is supported by 
evidence which suggests that key protein components of the major NHEJ pathway, WRN 
and DNA ligase IIIα that form a molecular complex which is recruited to DSBs, are up-
regulated in CML (Sallmyr et al., 2008). There is also evidence that ROS-induced DSBs are 
repaired, at least to some extent, by single-strand annealing (SSA). This is a rare and very 
unfaithful repair mechanism whose activity has been shown to be stimulated by BCR-ABL. 
Interestingly the activation of this repair mechanism is attenuated by IM therapy (Cramer et 
al., 2008). The presence of multiple alternative error-prone mechanisms for repairing DSBs, 
raises the possibility that the differential recruitment of these alternative repair pathways 
itself evolves as the disease progresses from CP to BC. 
One approach to identifying the generative mechanism that underlies the observed genomic 
instability in CML, is to generate a compendium of BCR-ABL kinase domain somatic 
mutations to determine if the mutator phenotype observed in LSCs is associated with a 
distinct mutational signature. In order to establish whether CML is characterized by a 
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FACS-purified lin-CD34+CD38- stem cell-enriched population and maintained for 3 weeks in 
the presence or absence of growth factors and IM. The cells harvested from the 3-week 
cultures were then assayed for CFCs. Mutational analysis was then performed for the 
detection of BCR-ABL kinase domain mutations in freshly isolated lin-CD34+CD38- cells and 
their CFC progenies. (B) Pre-existing BCR-ABL kinase domain mutations could be detected 
in freshly isolated lin-CD34+CD38- stem cells and new mutations appeared during the 
growth of primitive CML cells in vitro. (C) Chromosomal abnormalities, such as 17 p+, could 
be observed from single colonies generated from the cells present after 3 weeks in culture 
with IM.    
in early CML and also the large deletions seen in later-stage CML. This is supported by 
evidence which suggests that key protein components of the major NHEJ pathway, WRN 
and DNA ligase IIIα that form a molecular complex which is recruited to DSBs, are up-
regulated in CML (Sallmyr et al., 2008). There is also evidence that ROS-induced DSBs are 
repaired, at least to some extent, by single-strand annealing (SSA). This is a rare and very 
unfaithful repair mechanism whose activity has been shown to be stimulated by BCR-ABL. 
Interestingly the activation of this repair mechanism is attenuated by IM therapy (Cramer et 
al., 2008). The presence of multiple alternative error-prone mechanisms for repairing DSBs, 
raises the possibility that the differential recruitment of these alternative repair pathways 
itself evolves as the disease progresses from CP to BC. 
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instability in CML, is to generate a compendium of BCR-ABL kinase domain somatic 
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distinct mutational imprint, we analyzed BCR-ABL tyrosine kinase domain sequence data 
from 15 IM-naïve and 316 IM-resistant CP-CML subjects (Grant et al., 2010). This revealed a 
distinct and non-random distribution of BCR-ABL kinase domain mutations with apparent 
hot spot regions located at codon positions 1 and 2, and several other distinct features that 
are commensurate with the activity of a distinct mutator. These include a propensity for 
transitions relative to unselected regions of the human genome across all codon positions, a 
T-to-C mutational hotspot at codon position 2, a near lack of mutations at codon position 3, 
and an overall under-representation of C-to-T mutations. These results provide evidence for 
the activity of a distinct mutator that is active in LSCs, and it is interesting that the 
frequently observed M244V and D276G mutations arise from T-to-C transitions, both of 
which are predicted consequences of putative CML LSC mutator activity. The clinically 
most problematic mutation, T315I, is interestingly generated by a C-to-T transition, 
indicating the imprint of intense drug-mediated selection. This characteristic mutational 
signature may provide insights into the mechanism that contributes to the observed 
genomic instability in LSCs, and which may act in concert with the error-prone repair of 
DSBs. Candidate mutators include the MYC oncogene, which is known to result in aberrant 
DNA synthesis and which has been shown to be over-expressed in CML subjects at the time 
of diagnosis. Higher expression levels have, furthermore, been shown to correlate with a 
poor clinical response to IM.  Interestingly MYC levels do not directly correlate with BCR-
ABL levels in subjects treated with IM (Albajar et al., 2011). 
5. Strategies for the eradication of leukemic stem cells   
The existence of both intrinsic and acquired resistance to TKIs in CML stem cells has 
prompted considerable interest in identifying multi-targeted therapeutic strategies able to 
combat the emergence of resistant clones by eliminating the LSCs that generate them. It has 
been hypothesized that combination strategies able to target both proliferating and 
primitive quiescent leukemic cells will significantly improve clinical outcomes in CML 
(Jiang X. 2007; Savona & Talpaz, 2008; Sloma et al., 2010). There is no doubt that the 
development of stem cell-directed therapies will be critical to the attainment of prolonged 
remission and ultimately TKI cessation and cure. As expected, the use of molecularly 
targeted agents such as IM results in the elimination of the majority of the more 
differentiated leukemic cells, but leaves primitive stem cells largely untouched. So although 
able to effect a significant initial reduction in leukemic cells of a more mature differentiation 
stage, LSCs eventually repopulate the malignant cell population following or during 
ongoing TKI therapy, generating new resistant mutants that leads to disease persistence and 
clinical recurrence. This situation recapitulates the elimination of rapidly cycling cells and 
sparing of quiescent leukemic stem cells seen in the deployment of conventional 
chemotherapeutics. Whereas monotherapy using agents that directly target LSCs may result 
in only a minimal observable initial response, in the absence of LSCs the leukemia is not 
expected to be maintained or expanded. Most importantly, the micro-evolutionary process 
that continuously and dynamically generates a spectrum of mutant clones will be disabled. 
As a result the disease burden would be expected to decline incrementally, providing 
significantly improved long-term outcomes. Combination with TKIs or other agents that 
target proliferating cells of a more mature phenotype will though continue to be essential for 
debulking. In the situation where resistant clones with BCR-ABL kinase domain mutations 
and/or other critical mutations are already present at high frequency, the simultaneous 
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targeting of the mutant clonal population with a second generation TKI will be necessary if 
molecular cure is to be achieved. This process will be facilitated by the development of new 
and more effective classes of debulking agents. A switch pocket inhibitor DCC-2036, for 
example, has been developed which targets the hydrophobic pockets distant from the 
catalytic region that regulate the transition between the active and inactive state of BCR-
ABL. This drug appears to successfully inhibit the majority of TKI-resistant mutants, 
including the critically important T315I gatekeeper mutation (Chan et al., 2011). DCC-2036 
inhibits the BCR-ABL oncoprotein in both its active and inactive conformation by inducing 
and stabilizing the type II inactive conformation. It is highly effective in suppressing the 
growth of transduced wild-type BCR-ABL murine cells, including cells transduced with the 
T315I mutant both in vitro and in vivo (Chan et al., 2011). A phase I trial of DCC-2036 in IM 
resistant subjects carrying either the T315I mutation or two or more alternative TKI 
mutations is currently underway. However, although useful in the management of TKI-
resistant mutations, DCC-2036 alone is unlikely to target LSCs.  
Global gene expression analysis and transcriptome profiling, including the identification of 
deregulated micro-RNAs (miRs) and the genes they target using next-generation sequencing 
technologies, have been applied in order to facilitate the identification of new molecular 
targets and biomarkers able to predict TKI responsivity in primary CML cells, IM resistant 
cells and BCR-ABL-transduced cells. Several studies have compared the transcriptome of 
CD34+ progenitor cells and CD34+CD38- stem cell-enriched leukemic cells with their healthy 
counterparts. These studies have confirmed the functional relevance of the activation of the 
JAK/STAT, PI3K/AKT, RAS/MAPK and NFκB pathways in LSCs (Janssen et al., 2005; 
Jongen-Lavrencic et al., 2005; Kronenwett et al., 2005; Nowicki et al., 2003; Radich et al., 
2006; Salesse & Verfaillie, 2003; Yong et al., 2006; Zhao et al., 2008). These studies have also 
identified differentially expressed genes that are involved in the regulation of DNA repair, 
cell cycle control, cell adhesion, and homing, as well as genes and transcription factors 
involved in drug metabolism (Diaz-Blanco et al., 2007; Kronenwett et al., 2005; Salesse & 
Verfaillie, 2003; Yong et al., 2006; Zhao et al., 2008). Several miRs and their target genes, 
including miR-203, miR-328 and miR-17-92 cluster, have been shown to regulate BCR-ABL 
and the expression of other genes known to be critical to the generation and maintenance of 
the CML phenotype (Bueno et al., 2008; Eiring et al., 2010; Venturini et al., 2007), indicating 
the potential utility of Micro-RNA profiling in the identification of novel targets for LSC-
directed therapies. Of note, several new potential targets have been identified which 
regulate the maintenance of self-renewal, quiescence and expansion of CML stem and 
progenitor cells. These include promyelocytic leukemia protein (PML), β-Catenin, RNA-
binding proteins (RBPs) and the BMI1 and FOXO transcription factors, suggesting that the 
specific targeting of these proteins in conjunction with TKIs, may help eliminate residual 
CML LSCs (Copland, 2009; Eiring et al., 2008; Hu et al., 2009; Ito et al., 2008; Naka et al., 
2010; Park et al., 2003; Rizo et al., 2010; Zhao et al., 2007). 
The systematic applications of these and other new technologies have resulted in significant 
advances in our understanding of the molecular properties of CML stem and progenitor 
cells. They are also helping to define the nature of the BM microenvironment and stem cell 
niche that support the growth and differentiation of LSCs. The specific targeting of the BM 
microenvironment and stem cell niche represent alternative and indirect strategies for the 
elimination of LSCs (Figure 3). The chemokine receptor CXCR4, for example, which is 
central to stem cell localization and a known chemo-attractant for hematopoietic cells, is 
induced by IM and causes CML cell migration to the BM and promotes the survival of 
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genomic instability in LSCs, and which may act in concert with the error-prone repair of 
DSBs. Candidate mutators include the MYC oncogene, which is known to result in aberrant 
DNA synthesis and which has been shown to be over-expressed in CML subjects at the time 
of diagnosis. Higher expression levels have, furthermore, been shown to correlate with a 
poor clinical response to IM.  Interestingly MYC levels do not directly correlate with BCR-
ABL levels in subjects treated with IM (Albajar et al., 2011). 
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The existence of both intrinsic and acquired resistance to TKIs in CML stem cells has 
prompted considerable interest in identifying multi-targeted therapeutic strategies able to 
combat the emergence of resistant clones by eliminating the LSCs that generate them. It has 
been hypothesized that combination strategies able to target both proliferating and 
primitive quiescent leukemic cells will significantly improve clinical outcomes in CML 
(Jiang X. 2007; Savona & Talpaz, 2008; Sloma et al., 2010). There is no doubt that the 
development of stem cell-directed therapies will be critical to the attainment of prolonged 
remission and ultimately TKI cessation and cure. As expected, the use of molecularly 
targeted agents such as IM results in the elimination of the majority of the more 
differentiated leukemic cells, but leaves primitive stem cells largely untouched. So although 
able to effect a significant initial reduction in leukemic cells of a more mature differentiation 
stage, LSCs eventually repopulate the malignant cell population following or during 
ongoing TKI therapy, generating new resistant mutants that leads to disease persistence and 
clinical recurrence. This situation recapitulates the elimination of rapidly cycling cells and 
sparing of quiescent leukemic stem cells seen in the deployment of conventional 
chemotherapeutics. Whereas monotherapy using agents that directly target LSCs may result 
in only a minimal observable initial response, in the absence of LSCs the leukemia is not 
expected to be maintained or expanded. Most importantly, the micro-evolutionary process 
that continuously and dynamically generates a spectrum of mutant clones will be disabled. 
As a result the disease burden would be expected to decline incrementally, providing 
significantly improved long-term outcomes. Combination with TKIs or other agents that 
target proliferating cells of a more mature phenotype will though continue to be essential for 
debulking. In the situation where resistant clones with BCR-ABL kinase domain mutations 
and/or other critical mutations are already present at high frequency, the simultaneous 
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targeting of the mutant clonal population with a second generation TKI will be necessary if 
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and more effective classes of debulking agents. A switch pocket inhibitor DCC-2036, for 
example, has been developed which targets the hydrophobic pockets distant from the 
catalytic region that regulate the transition between the active and inactive state of BCR-
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including the critically important T315I gatekeeper mutation (Chan et al., 2011). DCC-2036 
inhibits the BCR-ABL oncoprotein in both its active and inactive conformation by inducing 
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growth of transduced wild-type BCR-ABL murine cells, including cells transduced with the 
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resistant subjects carrying either the T315I mutation or two or more alternative TKI 
mutations is currently underway. However, although useful in the management of TKI-
resistant mutations, DCC-2036 alone is unlikely to target LSCs.  
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counterparts. These studies have confirmed the functional relevance of the activation of the 
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including miR-203, miR-328 and miR-17-92 cluster, have been shown to regulate BCR-ABL 
and the expression of other genes known to be critical to the generation and maintenance of 
the CML phenotype (Bueno et al., 2008; Eiring et al., 2010; Venturini et al., 2007), indicating 
the potential utility of Micro-RNA profiling in the identification of novel targets for LSC-
directed therapies. Of note, several new potential targets have been identified which 
regulate the maintenance of self-renewal, quiescence and expansion of CML stem and 
progenitor cells. These include promyelocytic leukemia protein (PML), β-Catenin, RNA-
binding proteins (RBPs) and the BMI1 and FOXO transcription factors, suggesting that the 
specific targeting of these proteins in conjunction with TKIs, may help eliminate residual 
CML LSCs (Copland, 2009; Eiring et al., 2008; Hu et al., 2009; Ito et al., 2008; Naka et al., 
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advances in our understanding of the molecular properties of CML stem and progenitor 
cells. They are also helping to define the nature of the BM microenvironment and stem cell 
niche that support the growth and differentiation of LSCs. The specific targeting of the BM 
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quiescent CML progenitors (Jin et al., 2008). This suggests a possible mechanism of IM 
resistance working through the cross-talk between CML stem/progenitor cells and their BM 
microenvironment niches, and suggests a rationale for the combination of CXCR4 
antagonists with TKIs so as to more effectively eliminate IM-resistant LSCs.  
 
 
Fig. 3. Targeting the CML stem cell.  Schematic diagram of the stem cell compartment and 
stem cell niche, indicating the specific targets of conventional first line TKI drugs, second 
and third generation TKIs, and the opportunities for targeting the CML stem cells either 
directly, or through the targeting and manipulation of the stem cell niche or bone marrow 
microenvironment. 
Components of the sonic hedgehog signalling pathway, including the smoothened 
transmembrane protein (SMO), have similarly been shown to play a critical role in normal 
and leukemic stem cell development, proliferation and self-renewal, including the 
regulation of the epithelial-mesenchymal transition (Varjosalo & Taipale, 2008). Knockdown 
or inhibition of SMO impairs HSC self-renewal and abrogates or delays the appearance of 
CML in several in vitro and in vivo models (Dierks et al., 2008; Zhao et al., 2009). Conversely, 
SMO over-activity has been demonstrated in CML cells, with their proliferation being more 
SMO-dependent than that of healthy HSCs. Clinical trials evaluating the effects of SMO 
pathway antagonists developed by a number of different pharmaceutical companies and the 
relevance of this pathway are currently under way in a range of different malignant 
indications. The combination of NL with the SMO inhibitor LDE225 and DA with PF-
04449913 has been reported as having additive effects on the inhibition of primitive CML 
cells in vitro and in vivo (Mar et al., 2011). Another study indicates that a combination of 
histone deacetylase inhibitors (HDACis, e.g. LAQ824) with IM is effective in targeting 
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quiescent CML stem cells (Figure 3). This study also suggests that an IM/HDAC 
combination inhibits several genes that regulate hematopoietic stem cell maintenance and 
survival (Zhang et al., 2010). Another study demonstrates that the targeting of autophagy, a 
process that allows cells to adapt to environmental stresses, enhances the effects of TKIs in 
BCR-ABL+ cell lines and in primary CML stem and progenitor cells (Bellodi et al., 2009). IM 
induces autophagy in BC-CML cell lines and in primary CML cells, and is associated with 
endoplasmic reticulum (ER) stress that is mechanistically non-overlapping with IM-induced 
apoptosis. Combination treatment with TKIs and inhibitors of autophagy such as 
chloroquine, is more effective in eliminating CML stem and progenitor cells in vitro than 
TKIs or autophagy inhibitors alone (Bellodi et al., 2009). The effectiveness of this 
combination treatment in eliminating primary CML stem and progenitor cells in vivo, 
however, remains to be seen. Other promising therapeutic strategies include the induction 
of protein phosphatase-2A activation by FTY720, which inhibits the survival and self-
renewal of CML progenitor cells (Neviani et al., 2007; Neviani et al., 2005). A 
farnesyltransferase inhibitor (BMS-214662) was also found to target primitive quiescent 
CML cells, indicating a possible role for this class of inhibitors (Copland et al., 2008).  
We have been pursuing a strategy based on the targeting of JAK2 with a view to inhibiting 
the activity of a biologically important multi-molecular complex that we have identified 
comprising AHI-1 (a novel signalling molecule encoded by the Abelson helper integration 
site 1 gene), the BCR-ABL fusion oncoprotein and JAK2 kinase (Zhou et al., 2008).  AHI-1 is 
upregulated in highly enriched populations of CML stem cells in which the levels of BCR-
ABL transcripts are also elevated (Jiang et al., 2004; Jiang et al., 2007c). Interestingly, 
overexpression of AHI-1 confers a growth advantage in vitro and results in leukemia in vivo, 
synergizing with BCR-ABL to enhance these outcomes (Zhou et al., 2008). Conversely, the 
stable suppression of AHI-1 in CD34+ CML cells using small interfering RNA, reduces their 
growth autonomy in vitro. Importantly, this newly defined AHI-1-BCR-ABL-JAK2 molecular 
interaction complex appears to mediate leukemic stem cell transformation and plays an 
important role in the TKI response/resistance of primary CML stem and progenitor cells. 
JAK2 itself is known to interact with the C-terminus of BCR-ABL, and is one of the most 
prominent targets of BCR-ABL in BCR-ABL transformed CML cells (Miyamoto et al., 2001; 
Samanta et al., 2006; Xie et al., 2001). BCR-ABL has also been found to interact with the IL-
3/GM-CSF receptor, which subsequently contributes to the downstream activation of JAK2 
(Wilson-Rawls et al., 1997). Furthermore, in primitive CML cells, BCR-ABL expression 
stimulates the production of IL-3, G-CSF and GM-CSF which, following binding to their 
cognate receptors, further contributes to the CML progenitor cell resistance to TKIs via the 
activation of the JAK2/STAT5 pathway (Jiang et al., 1999; Wang et al., 2007). High STAT5 
levels have also been shown to mediate acquired IM-resistance in CML cells and the STAT5 
inhibitor pimozide was shown to reduce their survival (Nelson et al., 2011; Warsch et al., 
2011). Therefore, targeting the activity of JAK2 could provide an excellent strategy to 
complement the inhibition of BCR-ABL kinase activity in primary CML stem cells (Figure 4). 
Indeed, recent studies have demonstrated that JAK2 inhibitors (TG101209, WP1193) and a 
dual kinase inhibitor of JAK2 and ABL kinases (ON044580) induced apoptosis in IM-
sensitive and IM-resistant CML cell lines (Samanta et al., 2011; Samanta et al., 2010) and that 
treatment with TKIs in combination with TG101209 results in greater inhibition of CML 
stem and progenitor cells as compared to when the same cells are treated with either TKIs or 
TG101209 alone or a combination of TKIs (DeGeer et al., 2010; DeGeer et al., 2009). Several 
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transmembrane protein (SMO), have similarly been shown to play a critical role in normal 
and leukemic stem cell development, proliferation and self-renewal, including the 
regulation of the epithelial-mesenchymal transition (Varjosalo & Taipale, 2008). Knockdown 
or inhibition of SMO impairs HSC self-renewal and abrogates or delays the appearance of 
CML in several in vitro and in vivo models (Dierks et al., 2008; Zhao et al., 2009). Conversely, 
SMO over-activity has been demonstrated in CML cells, with their proliferation being more 
SMO-dependent than that of healthy HSCs. Clinical trials evaluating the effects of SMO 
pathway antagonists developed by a number of different pharmaceutical companies and the 
relevance of this pathway are currently under way in a range of different malignant 
indications. The combination of NL with the SMO inhibitor LDE225 and DA with PF-
04449913 has been reported as having additive effects on the inhibition of primitive CML 
cells in vitro and in vivo (Mar et al., 2011). Another study indicates that a combination of 
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quiescent CML stem cells (Figure 3). This study also suggests that an IM/HDAC 
combination inhibits several genes that regulate hematopoietic stem cell maintenance and 
survival (Zhang et al., 2010). Another study demonstrates that the targeting of autophagy, a 
process that allows cells to adapt to environmental stresses, enhances the effects of TKIs in 
BCR-ABL+ cell lines and in primary CML stem and progenitor cells (Bellodi et al., 2009). IM 
induces autophagy in BC-CML cell lines and in primary CML cells, and is associated with 
endoplasmic reticulum (ER) stress that is mechanistically non-overlapping with IM-induced 
apoptosis. Combination treatment with TKIs and inhibitors of autophagy such as 
chloroquine, is more effective in eliminating CML stem and progenitor cells in vitro than 
TKIs or autophagy inhibitors alone (Bellodi et al., 2009). The effectiveness of this 
combination treatment in eliminating primary CML stem and progenitor cells in vivo, 
however, remains to be seen. Other promising therapeutic strategies include the induction 
of protein phosphatase-2A activation by FTY720, which inhibits the survival and self-
renewal of CML progenitor cells (Neviani et al., 2007; Neviani et al., 2005). A 
farnesyltransferase inhibitor (BMS-214662) was also found to target primitive quiescent 
CML cells, indicating a possible role for this class of inhibitors (Copland et al., 2008).  
We have been pursuing a strategy based on the targeting of JAK2 with a view to inhibiting 
the activity of a biologically important multi-molecular complex that we have identified 
comprising AHI-1 (a novel signalling molecule encoded by the Abelson helper integration 
site 1 gene), the BCR-ABL fusion oncoprotein and JAK2 kinase (Zhou et al., 2008).  AHI-1 is 
upregulated in highly enriched populations of CML stem cells in which the levels of BCR-
ABL transcripts are also elevated (Jiang et al., 2004; Jiang et al., 2007c). Interestingly, 
overexpression of AHI-1 confers a growth advantage in vitro and results in leukemia in vivo, 
synergizing with BCR-ABL to enhance these outcomes (Zhou et al., 2008). Conversely, the 
stable suppression of AHI-1 in CD34+ CML cells using small interfering RNA, reduces their 
growth autonomy in vitro. Importantly, this newly defined AHI-1-BCR-ABL-JAK2 molecular 
interaction complex appears to mediate leukemic stem cell transformation and plays an 
important role in the TKI response/resistance of primary CML stem and progenitor cells. 
JAK2 itself is known to interact with the C-terminus of BCR-ABL, and is one of the most 
prominent targets of BCR-ABL in BCR-ABL transformed CML cells (Miyamoto et al., 2001; 
Samanta et al., 2006; Xie et al., 2001). BCR-ABL has also been found to interact with the IL-
3/GM-CSF receptor, which subsequently contributes to the downstream activation of JAK2 
(Wilson-Rawls et al., 1997). Furthermore, in primitive CML cells, BCR-ABL expression 
stimulates the production of IL-3, G-CSF and GM-CSF which, following binding to their 
cognate receptors, further contributes to the CML progenitor cell resistance to TKIs via the 
activation of the JAK2/STAT5 pathway (Jiang et al., 1999; Wang et al., 2007). High STAT5 
levels have also been shown to mediate acquired IM-resistance in CML cells and the STAT5 
inhibitor pimozide was shown to reduce their survival (Nelson et al., 2011; Warsch et al., 
2011). Therefore, targeting the activity of JAK2 could provide an excellent strategy to 
complement the inhibition of BCR-ABL kinase activity in primary CML stem cells (Figure 4). 
Indeed, recent studies have demonstrated that JAK2 inhibitors (TG101209, WP1193) and a 
dual kinase inhibitor of JAK2 and ABL kinases (ON044580) induced apoptosis in IM-
sensitive and IM-resistant CML cell lines (Samanta et al., 2011; Samanta et al., 2010) and that 
treatment with TKIs in combination with TG101209 results in greater inhibition of CML 
stem and progenitor cells as compared to when the same cells are treated with either TKIs or 
TG101209 alone or a combination of TKIs (DeGeer et al., 2010; DeGeer et al., 2009). Several 
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JAK2 inhibitors with varying degrees of intra-JAK family and intra-kinome selectivity are 
currently in various stages of clinical development. However, the myelosuppressive effects 
of these inhibitors on normal hematopoietic stem/progenitor cells remain a concern. The 
development of highly selective and less toxic (fewer hits across the kinome) JAK2 inhibitors 
in combination with first or second generation TKIs provides an attractive option for the 
specific targeting of LSCs (Figure 3 and 4). The permanent eradication of the leukemia stem 
cell in conjunction with tumor debulking, is expected to result in a functional cure, and in so 
doing to provide the study of CML with its ultimate crowning achievement. Importantly it 
should also provide molecular medicine with a general paradigm for the medical cure of 
cancer through stem cell eradication that with appropriate modifications should be 
applicable to multiple tumor types.   
 
 
Fig. 4. Model of the targeting of the AHI-1-BCR-ABL-JAK2 complex in CML stem cells by 
combination treatment of TKI and JAK2 inhibitors.  Schematic diagram of the AHI-1-BCR-
ABL-JAK2 interaction complex that regulates constitutive activation of BCR-ABL and 
JAK2/STAT5 and results in increased proliferation and a reduced TKI response in CML 
stem and progenitor cells. Targeting both BCR-ABL and JAK2 activities to destabilize this 
protein interaction complex may represent a potential therapeutic option for CML. 
6. Conclusion 
The discovery of tyrosine kinase inhibitors marked a major advance in CML therapy and 
other cancers. Although highly successful, selective tyrosine kinase inhibition has not 
resulted in a functional cure. As CML is driven by genetically unstable pluripotent leukemic 
stem cells, therapeutic approaches that target these cells will be required for definitive 
curative therapies. The systematic characterization of the unique biological properties of 
CML LSCs promises to deliver new insights into the process of malignant transformation 
and disease progression. As it comprises a relatively simple and well-understood model 
system, it is envisaged that the elimination of LSCs in CML will provide a general paradigm 
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1. Introduction  
Chronic Myeloid Leukemia (CML) appears as a consequence of the reciprocal translocation 
between chromosomes 9 and 22 which results in the expression of the Bcr-Abl oncoprotein 
in a hematopoietic stem cell. The tyrosine kinase activity of Bcr-Abl is the direct cause of the 
disease. Therefore, inhibitors of this kinase activity are being used in the treatment of CML. 
Imatinib was the first of such inhibitors and is the first line treatment in CML. However, the 
appearance of Bcr-Abl mutants that are resistant to these inhibitors has emerged as a 
problem in the treatment of CML. Consequently, the search for new drugs or therapeutic 
targets is underway. 
The proteasome is a multiprotein complex where proteins are degraded in a much regulated 
manner. Protein degradation at the proteasome is dependent upon ubiquitylation, which, in 
turn, is mediated by ubiquitin-ligase complexes. By degrading specific proteins, the 
proteasome is involved in cellular processes as important as cell cycle regulation, 
proliferation, differentiation and survival. As such, its activity is also related to the 
transformation of tumor cells. In fact, it has been shown that tumor cells show an increase in 
proteasome activity. Specifically, Bcr-Abl tyrosine kinase activity results in an increase of 
proteasome activity and degradation of some negative regulators of cell cycle progression as 
p27kip1. Therefore, proteasome inhibitors could be an alternative in CML treatment.  
In this chapter, we will discuss the available data suggesting that proteasome inhibition 
could be used in the treatment of CML, including those cases in which Bcr-Abl inhibition is 
not a possibility. 
2. Bcr-Abl and its control of the cell cycle and apoptosis 
In the t(9;22)(q34;q11) translocation found in CML, the bcr (Breakpoint Cluster Region) and 
abl (Abelson Leukemia) genes get fused. As a result, the chimeric tyrosine kinase 
oncoprotein Bcr-Abl is expressed (Ben-Neriah et al., 1986). Unlike c-Abl that shuttles 
between the nucleus and the cytoplasm and whose kinase activity is finely tuned, Bcr-Abl is 
cytoplasmic and its kinase activity is increased and deregulated (Salesse & Verfaillie, 2002). 
Through phosphorylation of different substrates, Bcr-Abl activates different signal 
transduction pathways that participate in the control of cellular proliferation, differentiation, 
migration, adhesion and survival (Afar et al., 1994; Andreu et al., 2005; Bedi et al., 1994; 
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transduction pathways that participate in the control of cellular proliferation, differentiation, 
migration, adhesion and survival (Afar et al., 1994; Andreu et al., 2005; Bedi et al., 1994; 
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Gordon et al., 1987; Horita et al., 2000; Jiang et al., 2000; Puil et al., 1994; Salesse & Verfaillie, 
2003; Sawyers, 1993). 
Several different substrates and partners of Bcr-Abl have been identified so far. Current 
efforts are directed at linking these pathways to the specific pathologic defects that 
characterize CML. These defects include increased proliferation and/or decreased apoptosis 
of a hematopoietic stem cell or progenitor cell (which leads to a massive increase in myeloid 
cell numbers), premature release of immature myeloid cells into the circulation (probably 
due to a defect in adherence of myeloid progenitors to marrow stroma) and genetic 
instability which results in disease progression (Druker, 2008).  
Pathways activated by Bcr-Abl include the Ras-Raf-MAPK, the PI3K/Akt and the 
JAK/STAT pathways. The Ras-Raf-MAPK pathway links Bcr-Abl to the increased 
proliferative rate. The PI3K/Akt pathway induces survival signals through different 
mechanisms such as the Ras-Raf pathway, the phosphorylation of Bad, the induction of Bcl-
xL expression and the inhibition of caspase activity. Besides, it controls the activity of several 
transcription factors involved in the expression of cell cycle regulatory proteins, such as 
FoxO, belonging to the Forkhead family of transcription factors, and NF-κB (Manning & 
Cantley, 2007; Medema et al., 2000). Akt also regulates cell growth through mTOR and the 
control of protein translation and synthesis (Manning & Cantley, 2007). The JAK/STAT 
pathway is also a target of Bcr-Abl kinase activity. Bcr-Abl induces the expression of the 
antiapoptotic protein Bcl-xL through the activation of STAT5, which binds to the promoter 
of the bcl-xL gene, thus increasing survival of Bcr-Abl expressing cells (Horita et al., 2000). 
Bcr-Abl regulates the expression and activity of the cell cycle inhibitor p27kip1 through the 
PI3K/Akt pathway. The inhibition of Bcr-Abl and the inhibition of the PI3K/Akt pathway 
both result in an increase of p27kip1 levels. Bcr-Abl also induces the expression of cyclins D 
and E and the activity of the cyclin E associated kinase Cdk2, resulting in the 
phosphorylation and inactivation of the tumor suppressor Retinoblastoma protein (Rb). 
Consequently, Bcr-Abl expressing cells show a deregulation of one of the main mechanisms 
controlling cell cycle progression along G1 and into S phase (Andreu et al., 2005).  
Therefore, by activating several different signal transduction pathways, Bcr-Abl induces cell 
proliferation and suppresses apoptosis in CML cells. 
3. The proteasome as a therapeutic target 
Protein synthesis and degradation are key mechanisms by which protein levels are 
regulated inside cells. In fact, specific protein degradation has emerged as a very active field 
of research. Two different machineries are involved in this process: the autophagosome 
(which will not be considered in this chapter) and the proteasome. 
3.1 Protein degradation at the proteasome 
The 26S proteasome is a multiprotein complex that can be found in the cytoplasm and in the 
nucleus of eukaryotic cells. It is composed of a catalytic 20S core and two 19S regulatory 
subunits. Proteasome assembly and protein degradation are both ATP dependent (Almond 
& Cohen, 2002; Baumeister et al., 1997; Baumeister et al., 1998). The catalytic core has three 
activities: chymotryptic, tryptic, and post-glutamyl peptide hydrolytic-like activities.The 
regulatory subunits are responsible for substrate recognition and unfolding. The proteasome 
is involved in a wide variety of cellular processes including apoptosis, cell cycle and 
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division, differentiation and development, all of them related directly or indirectly to 
tumoral transformation (DeSalle & Pagano, 2001). 
For a protein to be degraded at the proteasome, it must be labelled with ubiquitin. Ubiquitin 
is a small polypeptide of 76 aminoacids which is highly conserved in all eukaryotes. Protein 
ubiquitylation not only can lead to degradation but is also a mechanism involved in 
intracellular transport. Ubiquitin can be added to proteins as single molecules to one 
(monoubiquitylation) or several (multiubiquitylation) Lysine residues or as polyubiquitin 
chains (polyubiquitylation) using one of several Lysine residues of the ubiquitin molecule to 
form the chain. 
Ubiquitylation requires the sequential activity of three enzymes. The C-terminal Glycine of 
ubiquitin is activated in an ATP dependent process by an E1 ubiquitin-activating enzyme. 
This reaction results in the formation of a thioester covalent linkage between ubiquitin and a 
Cysteine residue in E1. Activated ubiquitin is then transferred to the ubiquitin-conjugating 
enzyme E2 by a trans-esterification reaction. Finally, a ubiquitin-ligase E3 enzyme transfers 
the ubiquitin molecule to the specific target protein to be degraded, thus acting as the 
substrate recognizing enzyme. This conserved ubiquitylation cascade allows for different 
combinations of E1-E2-E3 molecules leading to the recognition, labeling and degradation of 
multiple target proteins (Hershko & Ciechanover, 1998). 
3.2 The proteasome and the cell cycle control 
Along the cell cycle, two different E3 complexes are involved in the degradation of 
regulatory proteins. The SCF complex contains four different subunits: Skp1, Cul1, 
Roc1/Rbx1 and one of several different F-box proteins. This E3 complex is necessary, for 
instance, for the degradation of G1 cyclins, leading to the G1/S transition. G2 cyclins, on the 
other hand, are ubiquitylated by the E3 APC/C (Anaphase Promoting 
Complex/Cyclosome). The APC/C complex is activated by phosphorylation and its activity 
is required for mitosis (Murray, 2004). 
The F-box protein in the SCF complexes interacts with specific substrates targeting them for 
degradation. Interaction with Skp1 requires the conserved F-box region. The substrate that 
is to be degraded needs to be previously phosphorylated. SCF complexes containing the F-
box protein β-Trcp (SCFβ-Trcp) are involved in the degradation of proteins of the NF-κB 
pathway and of β-catenin. Another important F-box protein is Skp2 (S-phase kinase-
interacting protein 2), identified as a protein interacting with cyclin A/Cdk2 complexes 
(Zhang et al., 1995). Many key regulators of the cell cycle, including the cell cycle inhibitor 
p27kip1, are ubiquitylated by SCFSkp2 complexes (Carrano et al., 1999; Sutterluty et al., 1999; 
Tsvetkov et al., 1999). 
The cell cycle inhibitor p27kip1 binds to Cdk2-containing complexes, inhibiting its kinase 
activity and therefore blocking cell cycle progression along G1 and into the S phase. It can 
also bind to cyclin D-containing complexes, where p27kip1 is “sequestered” and maintained 
away from active cyclin E/Cdk2 complexes (Bouchard et al., 1999; Perez-Roger et al., 1999). 
p27kip1 levels in tumors are useful as a prognostic marker. Degradation of p27kip1 at the 
proteasome requires its previous phosphorylation (at Threonine 187) by the same cyclin 
E/Cdk2 complexes it inhibits. Next, the SCFSkp2 complex recognizes the phosphorylated 
protein and labels it with a polyubiquitin chain leading to its degradation (Carrano et al., 
1999; Montagnoli et al., 1999; Nguyen et al., 1999; Perez-Roger et al., 1999; Perez-Roger et al., 
1997; Sheaff et al., 1997; Sutterluty et al., 1999; Tsvetkov et al., 1999; Vlach et al., 1997). 
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division, differentiation and development, all of them related directly or indirectly to 
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For a protein to be degraded at the proteasome, it must be labelled with ubiquitin. Ubiquitin 
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The cell cycle inhibitor p27kip1 binds to Cdk2-containing complexes, inhibiting its kinase 
activity and therefore blocking cell cycle progression along G1 and into the S phase. It can 
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Skp2 expression changes along the cell cycle, being higher in S and G2 and lower in M and 
G1. Induction of Skp2 in the G1-S transition promotes the degradation of p27kip1, allowing 
cell cycle progression (Andreu et al., 2005; Carrano et al., 1999; Marti et al., 1999; Schneider 
et al., 2006; Wirbelauer et al., 2000; Zhang et al., 1995). Skp2 is degraded at the proteasome in 
mitosis, when the APC/C complex becomes active (Wirbelauer et al., 2000). Ectopic 
expression of Skp2 in quiescent cells is sufficient to induce cell cycle entry, making Skp2 a 
potent oncoprotein. In many tumors, the levels of Skp2 and of p27kip1 are inversely 
proportional: low Skp2 correlates with high p27kip1 and slow growing tumors, whereas high 
Skp2 correlates with low p27kip1 and fast growing tumors. 
3.3 Proteasome inhibition: Bortezomib 
The relationship between the ubiquitin-proteasome system (UPS) and the regulation of 
cellular proliferation, differentiation, survival and transformation led to considering the 
proteasome as a suitable target in cancer therapy (Adams, 2004). Proteasome inhibitors 
block protein degradation, causing the accumulation of damaged proteins and inducing the 
heat shock response and cell death (Concannon et al., 2007; Friedman & Xue, 2004).  
Among the several proteasome inhibitors described, Bortezomib has been approved by the 
FDA for treatment of Multiple Myeloma and Mantle Cell Lymphoma (Ocio et al., 2008; 
Perez-Galan et al., 2006). Bortezomib is a dipeptdyl boronic acid that inhibits specifically 
and reversibly the chymotrypsine like activity of the proteasome, thought to be the rate 
limiting step of proteasome degradation (Eldridge & O'Brien, 2010; Jung et al., 2004; 
Richardson et al., 2006).  
Surprisingly, Bortezomib appears to be quite selective against tumor cells. For some reason, 
normal cells seem to be more resistant to proteasome inhibition. One of the molecular effects 
of Bortezomib in several (but not all) cell types is the inhibition of the NF-κB pathway 
involved in suppressing apoptosis and increasing cell survival and resistance to cytotoxic 
agents (Baud & Karin, 2009). Some cases of Multiple Myeloma show an increase in NF-κB 
signaling making them especially sensitive to Bortezomib. Other probably important targets 
of Bortezomib are p53, p21, p27, Bax, Smac/Diablo and p44/42MAPK, all of them involved 
in the regulation of cell proliferation and/or survival (Voorhees et al., 2003). 
4. Inhibition of the proteasome in CML 
Proteasome activity is necessary for all cells to maintain the appropriate balance between 
protein synthesis and degradation. Therefore, proteasome inhibitors have a highly cytotoxic 
effect. However, cancer cells seem to be more sensitive to proteasome inhibition than control 
or normal cells.  
4.1 Bcr-Abl and the proteasome 
Bcr-Abl activity down-regulates the level of the cell cycle inhibitor p27kip1 in different cell 
models expressing Bcr-Abl endogenously (like K562) or exogenously (like Mo7e and BaF/3) 
and in primary CML CD34+ cells. Moreover, exogenous p27kip1 expression partially 
antagonizes the effect of Bcr-Abl on proliferation (Albero et al., 2010; Andreu et al., 2005; 
Bretones et al., 2011; Jonuleit et al., 2000). By inhibiting the tyrosine kinase activity of Bcr-
Abl with Imatinib, the half-life of p27kip1 is increased, meaning that Bcr-Abl induces the 
degradation of p27kip1. At the same time, the expression of Skp2 decreases and when the 
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expression of Skp2 is silenced in Bcr-Abl expressing cells, the levels of p27kip1 increase, 
showing again the inverse relationship between these two proteins. The regulation of p27kip1 
expression by Bcr-Abl depends mainly on the PI3K/Akt pathway. This can be demonstrated 
because when cells are treated with either the Bcr-Abl inhibitor Imatinib or the PI3K 
inhibitor LY294002 the effects are quite similar. These effects are threefold (Fig. 1): first, Akt 
phosphorylates and inactivates FoxO transcription factors, involved in the regulation of 
p27kip1 gene transcription; second, Bcr-Abl induces the expression of Skp2 through the Akt 
pathway, which results in the proteasomal degradation of p27kip1 (Andreu et al., 2005); third, 
Akt also phosphorylates p27kip1 directly, preventing its translocation to the nucleus where it 
inhibits the cyclin/Cdk complexes controlling the cell cycle (Liang et al., 2002). 
 
 
Fig. 1. Bcr-Abl regulation of the level and activity of p27kip1 includes transcriptional 
inhibition, misslocalization and proteasomal degradation. 
Apart from the regulation of key proteins controlling cell cycle progression, there is a direct 
relationship between Bcr-Abl and the proteasome. Exogenous expression of Bcr-Abl in cells 
directly increases the activity of the proteasome and siRNA knock down of Bcr-Abl 
expression in K562 cells is associated with a decrease of all three proteasome activities 
(Crawford et al., 2009). 
As Bcr-Abl regulates the activity of the proteasome and induces the proteasomal 
degradation of several proteins, Bortezomib was proposed as a therapeutic alternative to 
Imatinib, especially in CML cases of Imatinib resistance.  
4.2 Molecular changes in CML cells treated with Bortezomib 
Proteasome inhibition with Bortezomib in Bcr-Abl expressing cell models or primary CD34+ 
cells from CML patients results in a cell cycle inhibition and induction of apoptosis (Albero 
et al., 2010; Gatto et al., 2003; Jagani et al., 2009). Different key regulators are affected by 
Bortezomib leading to the detection of apoptosis markers, such as the activation (cleavage) 
of caspases (3, 8 and 9), or the down-regulation of Bcl-xL and induction of Bim. Among these 
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expression of Skp2 is silenced in Bcr-Abl expressing cells, the levels of p27kip1 increase, 
showing again the inverse relationship between these two proteins. The regulation of p27kip1 
expression by Bcr-Abl depends mainly on the PI3K/Akt pathway. This can be demonstrated 
because when cells are treated with either the Bcr-Abl inhibitor Imatinib or the PI3K 
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key events, Bortezomib treatment reverses the Bcr-Abl suppression of FoxO proteins and 
blocks the activation of NF-κB. 
Although apoptosis induction is a commonplace of Bortezomib treatment, the inhibition of the 
cell cycle can be at the G1/S transition or at the G2/M boundary, depending on the cell 
models used (Albero et al., 2010; Gatto et al., 2003). The cell cycle inhibition at the G1/S 
transition can be explained by the accumulation of p27kip1 in Bortezomib treated cells (Fig. 2). 
This accumulation inhibits the kinase activity of cyclin/Cdk complexes, which results in the 
dephosphorylation (activation) of Rb, blocking the cell cycle at the restriction point by the 
sequestration and inactivation of E2F transcription factors. The dephosphorylation of Rb is 
followed by its caspase-dependent processing and degradation, something associated with the 
induction of apoptosis. As a consequence of the impact on Rb phosphorylation, Bortezomib 
treatment also results in the down-regulation of cyclin A expression (Albero et al., 2010).  
In cell lines derived from CML patients in blast crisis, Bortezomib induces the accumulation 
of IκBα, correlating with a decrease in the NF-κB DNA binding activity in the nucleus at the 
same time (Gatto et al., 2003). However, this effect was only transient and perhaps does not 
explain the cellular effects of Bortezomib. In contrast, in Baf/3-derived cell lines 
exogenously expressing Bcr-Abl, there was no effect of Bortezomib on NF-κB activity 
(Albero et al., 2010). However, in this same study, the non-canonical NF-κB pathway was 
analyzed and the results show that Bortezomib prevents the activation of NF-κB2. This 
protein is activated by proteolysis from a 100 kDa precursor to yield the 52 kDa active form 
in a proteasome dependent manner (Barre & Perkins, 2007). As NF-κB2 is not activated, the 
expression of two of its regulated targets, Skp2 and Myc, is also inhibited (Albero et al., 
2010; Barre & Perkins, 2007; Schneider et al., 2006). This effect, in turn, would reinforce the 
effect of Bortezomib on the accumulation of p27kip1 (Fig. 2) leading to the dephosphorylation 
of Rb and the cell cycle inhibition at the G1/S transition (Albero et al., 2010). 
 
 
Fig. 2. Possible molecular mechanism leading to cell cycle arrest in G1 and apoptosis in CML 
cells treated with Bortezomib, as proposed (Albero et al., 2010). 
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4.3 Effect of Bortezomib on Imatinib resistant CML cells 
As Bortezomib inhibition of the cell cycle and induction of apoptosis is independent of Bcr-
Abl kinase activity it should be effective even in Imatinib resistant cases. Several different 
reports show the effect of Bortezomib on cells resistant to Imatinib, using cell lines 
exogenously expressing wild type and mutant forms of Bcr-Abl, primary CD34+ cells and 
cell lines derived from patients in blast crisis resistant to Imatinib, or CML cell lines selected 
for Imatinib resistance by chronic exposure to the inhibitor. In all these cases, Bortezomib 
induces apoptosis of Bcr-Abl expressing cells regardless of the mutational status of the 
protein, and at concentrations at which control cells are not sensitive (Albero et al., 2010; 
Colado et al., 2008; Crawford et al., 2009; Gatto et al., 2003; Heaney et al., 2010; Jagani et al., 
2009). As these studies include the highly resistant gate keeper mutant T315I, it is clear that 
Bortezomib could be an alternative to Imatinib when this treatment is ineffective. 
Another source of Imatinib resistant cells is the population of primitive, quiescent 
hematopoietic CML stem cells (Graham et al., 2002). During Imatinib treatment, there is an 
initial phase in which Bcr-Abl transcripts decrease rapidly, followed by a second phase in 
which this decrease is slower. This is probably due to the different sensitivity of CML cell 
subpopulations to Imatinib. Differentiated cells are more sensitive to Imatinib, whereas 
primitive CML stem cells are less sensitive to Imatinib. This difference could be due to the 
almost quiescent state of CML stem cells. This subpopulation of cells (Lin-CD34+) 
represents approximately 0.5% of the CD34+ cells but are likely to be responsible for the 
minimal residual disease found in Imatinib treated patients and to relapse if the treatment is 
interrupted. It is estimated that up to 106 lekemia cells may remain in patients with no 
detectable Bcr-Abl transcripts and therefore it is recommended that Imatinib treatment is 
not interrupted (Bhatia et al., 2003; Graham et al., 2002; Holyoake et al., 1999; Holyoake et 
al., 2001; Quintas-Cardama et al., 2009).  
Bortezomib is also effective against the quiescent CML stem cells in different assays (Heaney 
et al., 2010). Bortezomib treatment induces apoptosis of CD34+ cells from chronic phase 
CML patients at diagnosis, with the accumulation of ubiquitylated proteins but with no 
effect on the kinase activity of Bcr-Abl. The primitive CD34+CD38- population that includes 
the quiescent CML stem cells is also sensitive to Bortezomib, which reduces the long-term 
colony formation capability of the cells. Finally, Bortezomib treatment also leads to a 
significant reduction in the engraftment potential of human CD34+ CML cells, although in 
this experiment there were still detectable Bcr-Abl positive cells. However, the effect of 
Bortezomib is not specific for CML cells, as it induces apoptosis also in normal CD34+CD38- 
hematopoietic stem cells (Heaney et al., 2010). 
5. Conclusion 
Imatinib is the first and so far the best example of rational design of anticancer therapeutic 
drugs. However, it is not able to cure and in some cases its efficacy is reduced due to Bcr-
Abl dependent and independent mechanisms of resistance. In this context, the relationship 
between Bcr-Abl and the proteasome is worth exploiting. In fact, the proteasome inhibitor 
Bortezomib has shown its potential in vitro and in animal models. Nevertheless, proteasome 
inhibition is cytotoxic to all cell types. Therefore, the future of Bortezomib and other “non-
specific” inhibitors or drugs may lie in the search for synergies with other “specific” drugs 
aimed to the molecular events characteristic of the tumor. In Chronic Myeloid Leukemia, 
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4.3 Effect of Bortezomib on Imatinib resistant CML cells 
As Bortezomib inhibition of the cell cycle and induction of apoptosis is independent of Bcr-
Abl kinase activity it should be effective even in Imatinib resistant cases. Several different 
reports show the effect of Bortezomib on cells resistant to Imatinib, using cell lines 
exogenously expressing wild type and mutant forms of Bcr-Abl, primary CD34+ cells and 
cell lines derived from patients in blast crisis resistant to Imatinib, or CML cell lines selected 
for Imatinib resistance by chronic exposure to the inhibitor. In all these cases, Bortezomib 
induces apoptosis of Bcr-Abl expressing cells regardless of the mutational status of the 
protein, and at concentrations at which control cells are not sensitive (Albero et al., 2010; 
Colado et al., 2008; Crawford et al., 2009; Gatto et al., 2003; Heaney et al., 2010; Jagani et al., 
2009). As these studies include the highly resistant gate keeper mutant T315I, it is clear that 
Bortezomib could be an alternative to Imatinib when this treatment is ineffective. 
Another source of Imatinib resistant cells is the population of primitive, quiescent 
hematopoietic CML stem cells (Graham et al., 2002). During Imatinib treatment, there is an 
initial phase in which Bcr-Abl transcripts decrease rapidly, followed by a second phase in 
which this decrease is slower. This is probably due to the different sensitivity of CML cell 
subpopulations to Imatinib. Differentiated cells are more sensitive to Imatinib, whereas 
primitive CML stem cells are less sensitive to Imatinib. This difference could be due to the 
almost quiescent state of CML stem cells. This subpopulation of cells (Lin-CD34+) 
represents approximately 0.5% of the CD34+ cells but are likely to be responsible for the 
minimal residual disease found in Imatinib treated patients and to relapse if the treatment is 
interrupted. It is estimated that up to 106 lekemia cells may remain in patients with no 
detectable Bcr-Abl transcripts and therefore it is recommended that Imatinib treatment is 
not interrupted (Bhatia et al., 2003; Graham et al., 2002; Holyoake et al., 1999; Holyoake et 
al., 2001; Quintas-Cardama et al., 2009).  
Bortezomib is also effective against the quiescent CML stem cells in different assays (Heaney 
et al., 2010). Bortezomib treatment induces apoptosis of CD34+ cells from chronic phase 
CML patients at diagnosis, with the accumulation of ubiquitylated proteins but with no 
effect on the kinase activity of Bcr-Abl. The primitive CD34+CD38- population that includes 
the quiescent CML stem cells is also sensitive to Bortezomib, which reduces the long-term 
colony formation capability of the cells. Finally, Bortezomib treatment also leads to a 
significant reduction in the engraftment potential of human CD34+ CML cells, although in 
this experiment there were still detectable Bcr-Abl positive cells. However, the effect of 
Bortezomib is not specific for CML cells, as it induces apoptosis also in normal CD34+CD38- 
hematopoietic stem cells (Heaney et al., 2010). 
5. Conclusion 
Imatinib is the first and so far the best example of rational design of anticancer therapeutic 
drugs. However, it is not able to cure and in some cases its efficacy is reduced due to Bcr-
Abl dependent and independent mechanisms of resistance. In this context, the relationship 
between Bcr-Abl and the proteasome is worth exploiting. In fact, the proteasome inhibitor 
Bortezomib has shown its potential in vitro and in animal models. Nevertheless, proteasome 
inhibition is cytotoxic to all cell types. Therefore, the future of Bortezomib and other “non-
specific” inhibitors or drugs may lie in the search for synergies with other “specific” drugs 
aimed to the molecular events characteristic of the tumor. In Chronic Myeloid Leukemia, 
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inhibiting the proteasome with Bortezomib and inhibiting the kinase activity of Bcr-Abl with 
Imatinib or one of the new compounds may prove the right combination to tackle the 
problems of Bcr-Abl mutations and the Imatinib resistant leukemia stem cell. This could be a 
good starting point for this kind of combined therapies in other tumors where the search for 
a “specific” therapy is still ongoing.  
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1. Introduction 
Myeloid leukemias are characterised by mutation and altered expression of a range of 
tyrosine kinases. Over 90% of chronic myeloid leukemias (CML) harbour the Philadelphia 
chromosome, resulting in expression of the BCR/ABL fusion protein, a constitutively active 
tyrosine kinase that is essential for survival of the CML cells. Acute myeloid leukemia 
(AML) is a heterogeneous disease characterised by mutations and dysregulation of a range 
of tyrosine kinases including the receptors Fms-like tyrosine kinase (Flt-3), c-KIT and 
platelet derived growth factor receptor (PDGFR). Tyrosine kinases represent powerful 
therapeutic targets, as the archetypical example of imatinib has shown for CML. However, 
many patients develop resistance to imatinib and other second generation inhibitors. 
Furthermore, trials of tyrosine kinase inhibitors for AML have thus far proven 
disappointing. Thus novel therapeutic targets are needed in order to improve the survival of 
myeloid leukemia patients. 
Oncogenic tyrosine kinases induce activation of a variety of signaling pathways required for 
the growth and survival of leukemia cells, such as the Ras/MAPK, PI3K/Akt, and 
JAK/STAT pathways. In addition to protein kinases, the rate and duration of protein 
phosphorylation is tightly regulated by the activity of protein phosphatases, and in normal 
cells the reversal of protein phosphorylation by phosphatases is essential for providing the 
fine-tuning of signaling pathways and maintaining a balance in cellular physiology. While 
much of the focus for targeted therapies in leukemia therapy has concentrated on the 
kinases responsible for phosphorylation events, relatively little attention has been given to 
the role that protein phosphatases play. However, research over the past decade has now 
begun to highlight the importance of protein phosphatases in leukemia and their potential 
as targets for novel therapies. In particular, the ser/thr phosphatase PP2A has emerged as 
an important tumor suppressor in myeloid leukemias and strategies aimed at reactivating 
this complex enzyme show great promise for a new generation of leukemia therapies.  
2. Protein phosphorylation in cellular signaling 
Signal transduction via a network of cellular communication pathways enables modulation 
of essential cellular functions such as proliferation, differentiation, survival, adhesion, 
motility and death. Phosphorylation is the most common mechanism for the propagation of 
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intracellular signals. The net phosphorylation state relies on a delicate balance between 
protein kinases, which catalyse phosphate addition, and protein phosphatases, catalysing 
phosphate removal. The role of protein kinases in the cellular signaling pathways 
controlling biological functions has been extensively studied and protein kinases are 
currently the pharmaceutical industry’s second largest drug target (Cohen 2002). In contrast, 
the role of phosphatases in disease has only recently come to the forefront of research.  
Proteins are primarily phosphorylated on Serine (Ser), Threonine (Thr) and Tyrosine (Tyr) 
residues, each accounting for approximately 86, 12 and 2% of the human phosphoproteome 
respectively (Olsen et al. 2006).  Around 2% of the human genome encodes a protein kinase 
gene, totalling 518 genes, of which 428 are known or predicted to phosphorylate Ser or Thr 
residues, and 90 encode protein tyrosine kinases (Alonso et al. 2004; Manning et al. 2002). In 
contrast, the human genome only encodes 147 phosphatase catalytic subunit genes. Of these, 
107 encode a protein tyrosine phosphatase (PTP), a number that is comparable with the 
opposing tyrosine kinase genes (Alonso et al. 2004).  Interestingly, while 98% of 
phosphoprotein sites are Ser and Thr residues, only a handful of the total protein 
phosphatases are specific for these amino acids (Moorhead et al. 2007). The unique way in 
which Ser/Thr phosphatases are regulated explains the difference in the number of Ser/Thr 
phosphatase catalytic subunits compared to PTPs. The evolution of PTPs has developed 
through the addition of discrete modular domains onto a core catalytic domain that define 
the function of the enzyme. In contrast, Ser/Thr phosphatases consist of a relatively simple 
catalytic subunit that reversibly binds to additional regulatory or interacting partner 
proteins which target the complex to specific subcellular locations and substrates, and 
ultimately control their activity. 
3. Classification of protein phosphatases 
Protein phosphatases can be classified into three main classes based on characteristics such 
as sequence, structure and phosphoamino-acid specificity. According to substrate specificity 
the largest phosphatase class is the ser/thr specific phosphoprotein phosphatase (PPP) 
family including PP1, PP2A, PP2B and PP4-PP7. The metallo-protein phosphatase 
dependant (PPM) family, made up mainly of PP2C, also functions against serine and 
threonine residues. Protein tyrosine phosphatases (PTP) form the second group and the 
aspartate-based or dual specificity protein phosphatases (DUSPs) the third. Genetic 
sequencing and analysis maintained these rules of partition, however it has recently been 
shown that particular Ser/Thr phosphatases can also dephosphorylate Tyr residues and 
various enzymes that fall into the dual specificity category based on their genetic sequence 
can selectively function on Ser, Thr, Tyr, phosphoinositides or RNA (Alonso et al. 2004; 
Begley and Dixon 2005). 
4. PTPs in myeloid leukemias 
The role of PTPs in cancer has been recently reviewed (Jiang and Zhang 2008; Julien et al. 
2011; Lopez-Ruiz et al. 2011; Ruela-de-Sousa et al. 2011) and will not be discussed in detail 
here. However it should be noted that PTPs can act as either tumor suppressors or 
oncogenes in both solid tumors and leukaemais. For example, SHP1, a non-receptor PTP, 
displays tumor suppressive properties. SHP1 associates with a number of signaling 
molecules including CD5, the IL-3 receptor, CD22, the B-cell receptor, c-KIT and BCR/ABL 
 
Ser/Thr Phosphatases: The New Frontier for Myeloid Leukemia Therapy? 
 
125 
(Bruecher-Encke et al. 2001; Lorenz et al. 1996; Zhang et al. 2000), and these interactions exert 
primarily inhibitory effects on the signaling pathways. Silencing of the SHP1 gene via 
promotor methylation has been identified as a common event in a range of leukemias and 
lymphomas, and has been suggested as a potential marker for disease progression (Chim et 
al. 2004; Johan et al. 2005; Oka et al. 2002; Zhang et al. 2000). Other PTPs implicated as tumor 
suppressors in myeloid leukemias include PTEN, PTPN2, DEP-1, and DUSP-16. In contrast, 
SHP2 displays oncogenic properties as it promotes growth and survival pathways due to its 
dephosphorylating activity toward negative regulators of the Ras/Erk and PI3K/Akt 
signaling pathways (Neel et al. 2003). Somatic mutations in the SHP2 gene occur in around 
30% of sporadic juvenile myelomonocytic leukemia (JMML) cases (Tartaglia et al. 2003), 6% 
of childhood acute lymphoblastic leukemia (ALL) (Tartaglia et al. 2004) and 5% of AML 
(Bentires-Alj et al. 2004; Tartaglia and Gelb 2005; Tartaglia et al. 2004; Tartaglia et al. 2005). 
Other PTPs with potential oncogenic roles in leukemia include CD45, Cdc25, and DUSP-7. 
5. Ser/Thr phosphatases 
In the early 1980s Ingebritsen and Cohen utilised a number of characteristics of 
phosphatases to pioneer nomenclature classes for the various enzymes (Ingebritsen and 
Cohen 1983a). Biochemical assays, sensitivity to endogenous inhibitors and the limited 
knowledge of substrate specificity at the time were originally used to classify the Ser/Thr 
phosphatases as either type 1 (PP1) or type 2 (PP2). PP1 specifically dephosphorylates the β 
subunit of phosphorylase kinase and is inhibited by nanomolar concentrations of the two 
small heat- and acid-stable proteins, termed inhibitor-1 (I-1) (Nimmo and Cohen 1978) and 
inhibitor-2 (I-2) (Foulkes and Cohen 1980). PP2 phosphatases preferentially 
dephosphorylate the α-subunit of phosphorylase kinase and are insensitive to I-1 and I-2 
(Cohen 1989; Ingebritsen and Cohen 1983a; Ingebritsen and Cohen 1983b). PP2 
phosphatases could in turn be subclassified into three distinct enzymes, PP2A, PP2B, and 
PP2C in a number of ways, but most simply by their metal-ion requirement. PP2A does not 
require a metal ion, however, PP2B and PP2C are Ca2+ and Mg2+ dependent respectively 
(Ingebritsen and Cohen 1983a; Ingebritsen and Cohen 1983b; Moorhead et al. 2007). More 
recently the Ser/Thr phosphatases were re-defined according to their structurally distinct 
gene family as part of the phosphoprotein phosphatase (PPP) family comprising PP1, PP2A, 
PP2B, PP4, PP5, PP6 and PP7 catalytic subunits, or protein phosphatase Mg2+- or Mn2+-
dependent (PPM) family primarily composed of the PP2C catalytic subunit. The majority of 
Ser/Thr phosphatase activity in vivo is accounted for by the PPP family members PP1, 
PP2A and PP2B, together with PP2C of the PPM family (Barford et al. 1998). In the majority 
of cases they operate in hetero-oligomeric complexes interacting with an increasing diversity 
of targeting and regulatory subunits (Gallego and Virshup 2005). 
6. Protein phosphatase 2A (PP2A) 
The past decade has seen a surge in research into the PPP family member, PP2A, most 
notably due to the discoveries indicating its important role as a tumor suppressor. In 
particular PP2A has been implicated as a major player in myeloid leukemias and as a 
potential target for novel therapeutic strategies. In order to study the role of PP2A in 
leukemogenesis, understanding the structure and function of this complex enzyme is 
imperative, and as such is summarised below.  
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6.1 Structure and regulation of PP2A  
PP2A is not a single phosphatase, but essentially encompasses a group of oligomeric 
enzymes consisting of a well conserved catalytic and structural subunit, together with the 
addition of one of a variety of regulatory subunits (Fig. 1). It makes up 1% of total cellular 
proteins and along with PP1, accounts for over 90% of serine/threonine phosphatase 
activity in the cell (Eichhorn et al. 2009). The PP2A core enzyme consists of a structural 
subunit (PP2A-A/PR65) and a catalytic subunit (PP2Ac). In mammals, two distinct genes (α 
and β) encode closely related versions of both the A (Hemmings et al. 1990) and C subunits 
(Arino et al. 1988). A third regulatory subunit (PP2A B) binds to the AC heterodimer, and 
determines both the substrate specificity and cellular localisation of PP2A holoenzyme 
complexes. Three B subunit families have been identified to date: B/B55/PR55 (Mayer et al. 
1991; Strack et al. 1999; Zolnierowicz et al. 1994), B’/B56/PR61 (McCright et al. 1996; 
McCright and Virshup 1995), B”/PR72/130/PR70/48 (Hendrix et al. 1993; Stevens et al. 
2003; Yan et al. 2000). Regulation of PP2A activity is accomplished primarily by members of 
its regulatory subunits. An additional level of regulation is introduced by post-translational 
modification of the catalytic subunit, which can undergo methylation and phosphorylation 
(Janssens et al. 2008), as well as the interaction with a vast array of other cellular and viral 
proteins such as SET, CIP2A and the SV40 small T antigen (Janssens and Goris 2001; Sablina 
and Hahn 2008). The use of specific PP2A inhibitors, PP2A activators and molecular genetics 
tools both in vitro and in vivo have exposed a role for PP2A in cell morphology, cell cycle 
regulation, development and apoptosis.  
 
 
Fig. 1. Schematic of PP2A holoenzymes 
6.2 PP2A in cellular signaling 
PP2A has been implicated in a wide range of cellular signaling pathways, many of which 
are involved in cellular proliferation, apoptosis and differentiation, and as such are 
important in tumorigenesis. Since PP2A is one of the most abundant cellular phosphatases, 
it is not surprising that PP2A can exert opposing roles on similar pathways by acting at 
different levels. Recent work indicates that this substrate specificity is mediated by distinct 
PP2A complexes.  
6.2.1 PP2A and MAPK signaling 
A major function of PP2A is regulation of the MAPK signaling pathway. Interestingly, PP2A 
can exert both inhibitory and activating effects in a context-dependent manner (Fig. 2). PP2A 
acts negatively via the dephosphorylation of MEK (Heriche et al. 1997; Sontag et al. 1993) 
and ERK both in vitro and in mammalian cells (Alessi et al. 1995; Wang et al. 2003; Zhou et al. 
2002). Specific knockdown of B56β and B56γ, but not B55 family subunits in NIH3T3 mouse 
fibroblasts increases basal ERK activation and prolongs ERK signal during stimulation in the 
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absence of pMEK (Fig. 3A)  (Letourneux et al. 2006). More recent evidence indicates that 
PP2A activates Ras-dependent MAPK signaling at the level of Raf-1 and its scaffolding 
protein Kinase Suppressor of Ras-1 (KSR1) (Abraham et al. 2000; Jaumot and Hancock 2001; 
Kubicek et al. 2002; Ory et al. 2003). Dephosphorylation of KSR1 (Ser329) and Raf-1 (Ser259) 
by B55α-containing PP2A complexes induces membrane translocation and increases the 
kinase activity of both proteins in several mammalian cell models, including NIH3T3, COS 
and HEK293 cells (Fig. 3B) (Abraham et al. 2000; Adams et al. 2005; Dougherty et al. 2005; 
Ory et al. 2003). Taken together, these studies provide biochemical mechanisms for how 
PP2A functions as a negative and positive regulator of MAPK signaling, depending on the 
specific regulatory subunit and substrate involved. 
 
 
Fig. 2. Schematic overview of MAPK signaling regulation by PP2A 
A) PP2A holoenzymes containing B56 family members negatively regulate MAPK signaling 
by inactivating MEK and ERK. B) In the inactive state, Raf and KSR1 are phosphorylated on 
Ser259 and Ser329, respectively, and are located within the cytoplasm. Upon stimulation, 
B55-containing PP2A complexes dephosphorylate these residues, which results in protein 
activation and translocation to the plasma membrane. This facilitates the Ras/Raf 
interaction and induces transcriptional activation.  
6.2.2 PP2A and PI3K/Akt signaling 
The normal function of Akt is tightly modulated by phosphorylation events on Thr308 or 
Ser473 (Sarbassov et al. 2005; Vanhaesebroeck and Alessi 2000), and PP2A is the major 
phosphatase targeting these residues in vitro (Borgatti et al. 2003; Ivaska et al. 2002; Resjo et al. 
2002). Over-expression of B55α-containing PP2A holoenzymes in the pro-lymphoid FL5.12 cell 
line substantially dephosphorylates Akt at Thr308 and results in subsequent growth 
suppression (Kuo et al. 2008). Conversely, Aα downregulation impairs Akt phosphorylation in 
neuronal cells, implicating PP2A as a positive regulator of the PI3K/Akt survival signaling 
cascade (Strack et al. 2004). An intriguing study by Andrabi et al. , demonstrated that Akt can 
act as a pro- or anti-apoptotic protein depending on environmental stimuli, and this is 
governed by PP2A (Andrabi et al. 2007). The specific PP2A regulatory subunits controlling this 
apparent switch remain undefined; however, this study reinforces the importance of 
understanding PP2A regulated cell signaling in a context dependent manner.   
6.2.3 PP2A and Wnt/β-catenin signaling 
The function of PP2A in Wnt/β-catenin signaling is similar to its role in the MAPK pathway, 
with individual PP2A subunits exerting either positive or negative effects (Fig. 3). B56 
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family members associate with APC (Seeling et al. 1999; Yamamoto et al. 2001) and axin (Hsu 
et al. 1999; Li et al. 2001)  to impair Wnt signaling; a function that is critical for normal 
dorsal/ventral axis formation in Xenopus development (Li et al. 2001). Further studies 
demonstrate that association of the PP2A PR72 subunit with Naked cuticle is critical for the 
inhibitory function of this protein on the Wnt pathway (Fig. 3A) (Creyghton et al. 2005). 
PP2A is also an important positive regulator of Wnt signaling (Bajpai et al. 2004; Gotz et al. 
2000; Ratcliffe et al. 2000; Willert et al. 1999). Loss of function analysis suggests that B56ε is 
required for Wnt-mediated development in Xenopus embryogenesis (Yang et al. 2003). 
Purified B55α-containing PP2A holoenzymes directly dephosphorylate β-catenin in vitro. 
Accordingly, specific knockdown of B55α in SW480 colon cancer cells significantly elevates 
β-catenin phosphorylation, which induces protein degradation and inhibits the Wnt 
pathway (Zhang et al. 2009). Surprisingly, PR130 opposes the action of PR72 and modulates 
Wnt signal transduction by restricting the ability of Naked to function as a Wnt inhibitor 
(Fig. 4B)  (Creyghton et al. 2006). These studies illustrate an excellent example whereby 
specific PP2A regulatory subunits determine holoenzyme function and provide the fine 
control on important cellular processes.  
6.2.4 PP2A and p53 regulation 
The tumor suppressor, p53, plays a critical role in mediating cellular responses to various 
types of stress, such as DNA damage, by inducing growth arrest or programmed cell death. 
The stability and activity of p53 is regulated by phosphorylation which, under normal 
cellular growth conditions, targets the protein for proteasome-mediated degradation 
(Vogelstein et al. 2000). PP2A B56γ holoenzymes dephosphorylate p53 on Ser37 (Dohoney et 
al. 2004) and Thr55 (Li et al. 2007) following γ radiation;  an event which stabilises p53 in 
response to DNA damage and contributes to apoptosis in mammalian cells. Furthermore, 
ataxia-telangiectasia mutated (ATM) directly phosphorylates and specifically regulates B56γ 
and B56δ. Phosphorylation of B56γ3 at Ser510 after DNA damage increases B56γ-PP2A 
complexes, and directs PP2A phosphatase activity toward p53, activating its tumor-
suppressive functions (Shouse et al. 2010). Conversely, RNAi knockdown of B56γ reduces 
p53 stability and inhibits cell death (Li et al. 2007). B56ε also regulates the p53-dependent 
apoptotic pathway by controlling the stability of p53 protein (Jin et al. 2010). 
Other findings implicate an important role for B56α-containing PP2A complexes in p53 
degradation. One target of p53, cyclin G, recruits B56α into a quaternary complex with the 
E3 ubiquitin ligase, mouse double minute 2 (Mdm2) (Okamoto et al. 1996; Okamoto et al. 
2002). The subsequent dephosphorylation and activation of Mdm2 leads to ubiquitination 
and degradation of p53 (Haupt et al. 1997), thus allowing the cell to proliferate. In this 
context, PP2A serves as a negative regulator. 
6.2.5 PP2A and c-Myc regulation 
PP2A also plays a prominent role in controlling the accumulation of the proto-oncoprotein, 
c-Myc (Yeh et al. 2004). Aberrant regulation of c-Myc has been linked to transformation in 
up to 70% of human tumors; therefore tight control of this protein is crucial for maintaining 
cellular homeostasis (Nesbit et al. 1999). c-Myc stability is regulated, in part, through 
phosphorylation at two residues, Ser62 and Thr58 (Sears et al. 2000). Whilst ERK-mediated 
phosphorylation at Ser62 stabilises c-Myc, specific B56-containing PP2A complexes reverse 
these effects, leading to destabilisation and ubiquitin-mediated degradation (Arnold and 
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Sears 2006). In addition, a novel PP2A-interacting protein, designated cancerous inhibitor of 
PP2A (CIP2A), was found to selectively target the catalytic activity of PP2A-B56α associated 
with c-Myc, and protect c-Myc from Ser62 dephosphorylation. Accordingly, depletion of 
CIP2A results in significantly increased PP2A activity measured from c-Myc 
immunoprecipitates and correlates with c-Myc destabilisation (Junttila et al. 2007). 
Collectively, these results illustrate the dynamic interaction of the PP2A holoenzyme with 
signaling cascades involved in fundamental cellular processes such as proliferation, survival 
and development. The fact that PP2A is involved in both the negative and positive 
regulation of these pathways highlights the exquisite nature of PP2A modulation and 
underscores the importance of investigating specific complexes when determining PP2A 
function. Identification of critical subunits that are aberrantly regulated during 
transformation may ultimately lead to the development of novel treatments for cancer 
patients.   
6.3 PP2A as a tumor suppressor 
The fundamental evidence that implicated PP2A as a tumor suppressor was the discovery 
that okadaic acid, a tumor promoter (Fujiki and Suganuma 2009; Suganuma et al. 1988), 
potently inhibits the phosphatase activity of PP2A (Bialojan and Takai 1988; Haystead et al. 
1989). In addition, the oncogenic polyomavirus middle and small tumor (ST) antigens, along 
with the simian virus 40 (SV40) ST antigen, transforms mammalian cells by inhibiting PP2A 
(Pallas et al. 1990). Transformation of the normal human fibroblast kidney epithelial cell line, 
HEK293, required several key genetic elements; human telomerase catalytic subunit, an 
oncogenic allele of H-Ras, and the SV40 large T (LT) and ST antigens (HEK-TER) (Hahn et al. 
1999). Whilst expression of LT enables the cells to bypass senescence, complete tumor 
formation requires the addition of ST and thus inhibition of PP2A (Yu et al. 2001). 
Accordingly, ST mutants lacking the PP2A binding domain fail to induce tumorigenic 
transformation of HEK-TER cells (Hahn et al. 2002). Structural insights reveal that ST 
interacts with the PP2A-A subunit which overlaps B56 subunit binding site and results in its 
displacement from the core enzyme. Functionally, expression of ST activates Akt signaling 
in human cells in vitro (Rodriguez-Viciana et al. 2006; Yuan et al. 2002; Zhao et al. 2003). 
Taken together, these observations indicate that complete transformation of human cells 
requires the perturbation of PP2A, for example by ST. 
A somewhat confusing aspect of PP2A function in cancer arises because PP2A plays 
important roles in promoting cell cycle progression and cell survival (Li et al. 2002; Lin et al. 
1998; Mayer-Jaekel et al. 1993), which are functions usually associated with tumor initiation 
and progression rather than suppression. Therefore, cellular transformation will most likely 
occur through the disruption of PP2A holoenzymes that normally exert negative regulation 
on oncogenic pathways.  
Whilst some contradiction exists as to the importance of PP2A scaffolding subunits in cancer 
development, several mutations have been identified in spontaneously arising human 
cancers. Notably, somatic alterations of the gene encoding Aβ (PPP2R1B) have been 
detected in up to 8-15% of colon, 15% of lung and 13% of breast cancers (Calin et al. 2000; 
Takagi et al. 2000; Tamaki et al. 2004; Wang et al. 1998). Mutations of the more abundant Aα 
subunit have been observed, albeit at a lower frequency (Calin et al. 2000) and cancer-
associated A subunit mutants exhibit differential defects in binding to the B and C subunits, 
which correlates with impaired PP2A activity (Chen et al. 2005; Ruediger et al. 2001a; 
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which correlates with impaired PP2A activity (Chen et al. 2005; Ruediger et al. 2001a; 
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Ruediger et al. 2001b; Sablina et al. 2007). Even in the absence of mutations, reduced protein 
expression of Aα has been found in 25 out of 58 brain tumors (Colella et al. 2001). Decreased 
levels of Aβ have also been observed in 16 of 32 cancer cell lines derived from human lung, 
colon and breast cancer, as well as primary glioblastoma and B-CLL patient samples 
compared to normal tissue (Kalla et al. 2007; Suzuki and Takahashi 2003; Takagi et al. 2000; 
Zhou et al. 2003). Importantly, Ruediger et al., recently generated knock-in mice with cancer 
associated A mutations, and A knockouts, both of which exhibited increased incidence of 
lung cancer when treated with benzopyrene, thus supporting the role of PP2A as a tumor 
suppressor (Ruediger et al. 2011). 
Pivotal studies using the HEK-TER transformation model demonstrated that suppression of 
B56γ, but not B55α, functionally mimicked the introduction of ST and resulted in partial 
tumorigenic transformation (Chen et al. 2004; Moreno et al. 2004). Moreover, depletion of 
B56γ containing complexes leads to activation of the anti–apoptotic Akt pathway (Chen et al. 
2005). These observations were the first to demonstrate that PP2A complexes containing 
B56γ modulate the phosphorylation of substrates associated with transformation. Loss of 
B56γ has been demonstrated in some human cancers. Decreased expression was identified 
in primary human melanoma samples compared to melanocytic nevi (Deichmann et al. 
2001), and in human lung cancer cell lines where subsequent overexpression of B56γ 
reversed the tumorigenic phenotype (Chen et al. 2004). Reduced transcript levels of B56γ 
have also been documented in patients with aggressive B-CLL compared to those with 
stable disease (Falt et al. 2005). A mutation in B56γ has also been observed in lung cancer, 
and this was shown to disrupt the interaction of B56γ with p53 (Shouse et al. 2010).  In 
contrast, higher expression levels of B56γ1 mRNA were reported in human melanoma cell 
lines compared to normal melanocytes (Francia et al. 1999).  
Recently the HEK293T system was further utilised to systematically examine all PP2A 
regulatory subunits (Sablina et al. 2010). In addition to B56γ, suppression of B56α, 
PR72/PR130, and PTPA (protein phosphatase 2A activator), replaced the expression of ST in 
transformation. Interestingly, the effects on signaling pathways differed depending on the 
regulatory subunit suppressed. Knockdown of B56γ and PTPA, but not B56α or 
PR72/PR130, led to enhanced Akt phosphorylation, while knockdown of B56α, 
PR72/PR130, and PTPA, but not B56γ, resulted in increased c-Myc expression. Moreover, 
suppression of B56γ and PTPA led to increased β-catenin activity, whereas PR72/PR130 
suppression decreased β-catenin activity (Sablina et al. 2010). Overexpression of CIP2A in 
the HEK-TER model can also replace ST in inducing transformation (Junttila et al. 2007), and 
increased CIP2A has been detected in myeloid leukemia patient samples (Wang and Li 
2011), gastric and colon cancer samples (Khanna et al. 2009; Li et al. 2008; Soo Hoo et al. 2002)   
6.4 PP2A in myeloid leukemias  
An emerging body of evidence implicates PP2A as an important tumor suppressor in 
myeloid leukemias (Table 1). In particular, recent work from our laboratory and others 
has revealed a common theme in myeloid leukemias:  inactivation of PP2A by leukemia 
associated tyrosine kinases (Fig. 3). Importantly, PP2A inhibition is essential for 
leukemias driven by these oncogenic tyrosine kinases, as re-activation of PP2A results in 
dephosphorylation, and thus deactivation, of the kinase and subsequent inhibition of 
leukemogenesis. Hence, re-activation of PP2A is an attractive strategy for leukemia 
therapy. 
 




Fig. 3. Model of PP2A inhibition in myeloid leukemias. (A) PP2A activity is inhibited by 
BCR/ABL and oncogenic mutant c-KIT, enabling the activation of signaling pathways 
leading to leukemogenesis. (B) Pharmacological activation of PP2A induces de-activation 
(dephosphorylation) of BCR/ABL and c-KIT, and inhibition of downstream signaling 
pathways, leading to inhibition of leukemogenesis.  
6.4.1 PP2A inhibition in CML 
Functional inactivation of PP2A by BCR/ABL is essential for the development of CML-BC 
and Ph+ ALL, and is thought to result from upregulation of the endogenous PP2A inhibitor 
SET (I2PP2A or TAF-1β) protein (Neviani et al. 2007; Neviani et al. 2005). Although its 
physiological function remains incompletely understood, abnormal expression of SET 
mRNA has been documented in solid tumors and haematological disorders (Carlson et al. 
1998; Fornerod et al. 1995; Li et al. 1996). Expression of BCR/ABL in mouse myeloid 
precursor cells stimulates SET expression and correlates with a loss of PP2A activity 
(Neviani et al. 2005). Conversely, inhibition of BCR/ABL with imatinib treatment 
dramatically reduces SET expression, which results in the restoration of PP2A activity back 
to untransfected levels and results in the dephosphorylation of several substrates which are 
shared by BCR/ABL and PP2A (Neviani et al. 2005). These include STAT5, ERK1/2, Akt, 
BAD and JAK2 (Calabretta and Perrotti 2004; Janssens and Goris 2001). Importantly, 
molecular or pharmacological reactivation of PP2A resulted in growth suppression, 
enhanced apoptosis, restored differentiation, and decreased in vivo leukemogenesis of 
imatinib-sensitive and -resistant BCR/ABL+ cell lines and primary CML-BC cells. 
Furthermore, reactivation of PP2A, by overexpression of PP2AC or 1,9-dideoxyforskolin 
treatment (a cAMP-independent PP2A activator) (see section 6.5.1), reduced the activity and 
expression of BCR/ABL in both imatinib-sensitive and -resistant BCR/ABL cells, suggesting 
that BCR/ABL itself is a target for PP2A activity. Indeed, reactivation of PP2A results in 
PP2AC association with BCR/ABL via the SHP1 tyrosine phosphatase, BCR/ABL 
dephosphorylation, and proteasomal degradation (Neviani et al. 2005). These findings 
establish an important link between an oncogenic kinase and a tumor suppressing 
phosphatase, and indicate that pharmacologic enhancement of PP2A is a powerful 
therapeutic strategy for imatinib-resistant CML. Taken together, these results suggest that 
SET-dependent inhibition of PP2A is required for the transduction of aberrant mitogenic, 
survival and anti-differentiation signals that contribute to the development of CML from the 
chronic phase into blast crisis (Neviani et al. 2005). 
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Table 1. Ser/Thr Phosphatases in Leukaemia 
6.4.2 PP2A inhibition in AML 
Oncogenic c-KIT signaling also requires inhibition of PP2A for leukemogenesis (Roberts et 
al. 2010). c-KIT is a receptor tyrosine kinase that activates similar proliferation, 
differentiation and survival signaling pathways as BCR/ABL, such as the PI3K, ERK and 
JAK/STAT pathways (Linnekin 1999). Gain-of-function c-KIT mutations occur in a range of 
malignancies, including AML, systemic mastocytosis, testicular seminoma, gastrointestinal 
stromal tumors (GIST) and melanomas, making c-KIT an excellent target for anti-cancer 
therapies (Kitamura and Hirota 2004; Masson and Ronnstrand 2009). These mutants induce 
hyperphosphorylation of c-KIT and constitutive activation of downstream signaling 
pathways (Masson and Ronnstrand 2009). Activating c- KIT mutations occur in up to 48% of 
core binding factor-AML (CBF-AML) patients, and are associated with increased relapse 
 
Ser/Thr Phosphatases: The New Frontier for Myeloid Leukemia Therapy? 
 
133 
and reduced survival (Muller et al. 2008). While imatinib has shown remarkable success in 
treating c-KIT+ GIST patients (Demetri et al. 2002), the majority of c-KIT mutations 
expressed in AML patients are intrinsically resistant to imatinib, and as such, many CBF-
AML and systemic mastocytosis patients are unresponsive to imatinib therapy (Cairoli et al. 
2005; Pardanani et al. 2003). Our laboratory has recently shown that myeloid precursor cells 
expressing oncogenic mutant c-KIT receptors display significantly reduced PP2A activity 
compared to c-KIT-negative or WT-c-KIT expressing cells (Roberts et al. 2010). Inhibition of 
PP2A by mutant c-KIT is associated with reduced protein expression of PP2A subunits, 
together with altered expression of the endogenous PP2A inhibitory protein SET. 
Overexpression of PP2A-A caused growth inhibition and apoptosis, suggesting that PP2A 
inhibition is functionally important in c-KIT mediated leukemogenesis. Importantly, 
reactivation of PP2A resulted in dephosphorylation (and hence deactivation) of the mutant 
c-KIT receptor itself, as well as inactivation of downstream signaling proteins required for c-
KIT induced leukemogenesis (e.g. Akt, ERK and STAT5) (Roberts et al. 2010). Furthermore, 
activation of PP2A by the pharmacological agent FTY720, inhibited leukemogenesis driven 
by mutant c-KIT (See section 6.5.2). 
A number of recent studies further support a tumor suppressive role for PP2A in AML. 
Reduced expression of the PP2A-B55α subunit and increased Akt phophorylation in AML 
patient blasts was associated with shorter complete remission (Ruvolo et al. 2011). 
Hyperphosphorylation of PP2Ac, known to inhibit PP2A activity, has been observed in 78% 
of AML patients. This was associated with enhanced expression of PP2A inhibitors SET, 
CIP2A, and/or SET binding protein 1 (SETBP1) (Cristobal et al. 2011). Reduced expression of 
PP2A-A and a number of PP2A regulatory subunits was also observed in a number of 
patients. Increased expression of SETBP1 was also shown to be induced by a novel 
translocation t(12;18)(p13;q12) involving ETV6 in a patient with AML (Cristobal et al. 2010). 
SETBP1 overexpression protected SET from protease cleavage, leading to the formation of a 
SETBP1-SET-PP2A complex that results in PP2A inhibition, promoting proliferation of the 
leukemic cells. SETBP1 was further shown to be overexpressed in over 27% of AML patients 
and correlated with significantly shorter overall survival, in particular in patients over 60 
years (Cristobal et al. 2010). Thus SETBP1 confers a negative prognostic impact and may be a 
predictive factor in any future clinical trials with PP2A activators. Increased expression of 
another PP2A inhibitory protein, CIP2A, has also been observed in diagnosis and relapse 
AML patients compared to patients in remission or healthy controls (Wang and Li 2011). 
6.5 Targeting PP2A for anti-leukemia therapy 
6.5.1 Forskolin  
Forskolin, a diterpene isolated from the roots of Coleus forskohlii, is primarily known to 
stimulate the adenylate cyclase system, which results in elevated levels of cyclic AMP 
(cAMP) and subsequent activation of protein kinase A (PKA) (Seamon and Daly 1981; 
Seamon et al. 1981). The anticancer properties of this compound were initially demonstrated 
through potent inhibition of growth and tumor colonisation of the highly metastatic BL6 
melanoma cell line (Agarwal and Parks 1983). Further studies indicated its potential use 
against ALL (Gutzkow et al. 2002) and CML cell lines (Taetle and Li-en 1984). However, 
more recent findings demonstrate that forskolin also activates PP2A (Feschenko et al. 2002); 
a mechanism which contributes to induction of apoptosis in B-CLL, CML-BC and AML 
patient samples (Cristobal et al. 2011; Moon and Lerner 2003; Neviani et al. 2005). Neviani et 
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al., was the first to highlight the therapeutic relevance of using PP2A-activators to 
specifically target leukemia cells (Neviani et al. 2005). Forskolin inhibited the in vivo 
leukemogenesis of imatinib sensitive and resistant BCR/ABL+ 32Dcl3 cells in mice, 
resulting in significantly prolonged survival. Furthermore, treatment with 1,9-dideoxy-
forskolin, which lacks adenylate cyclase activity, impaired the clonogenic potential of 
BCR/ABL+ 32Dcl3 cells to a similar degree as forskolin, suggesting that the anti-leukaemic 
effects of forskolin and its derivative depends on the induction of PP2A activity rather than 
cAMP . Restoration of PP2A activity with forskolin was also found to inhibit Akt and ERK 
activity, block proliferation and induce caspase-dependant apoptosis in AML cell lines 
(Cristobal et al. 2011; Neviani et al. 2005). Furthermore, forskolin had an additive effect with 
common AML induction therapy drugs Idarubicin and Ara-c (Cristobal et al. 2011).  
6.5.2 FTY720 
FTY720 was first synthesised by structural modifications of myriocin (ISP-1), a fungal 
metabolite isolated from Isaria sinclairii culture broth (Fujita et al. 1994), and is structurally 
similar to sphingosine (Albert et al. 2005; Kiuchi et al. 2005). It is effectively phosphorylated 
in vivo by SphK2 to yield the biologically active FTY720-phosphate (FTY720-P) (Brinkmann 
et al. 2002; Zemann et al. 2006). Interaction of FTY720-P with one of the five known S1P 
receptors induces receptor internalisation and degradation (Graler and Goetzl 2004; 
Matloubian et al. 2004). The S1P signal is required for the migration of lymphocytes from 
secondary lymphoid tissues back into the efferent lymphatics and systemic circulation 
(Cyster 2005; Matloubian et al. 2004) and prolonged S1PR downregulation by FTY720-P 
inhibits the immune response by sequestering functional lymphocytes within secondary 
lymphoid organs (Brinkmann et al. 2002; Mandala et al. 2002). The use of FTY720 as an 
immunomodulator is currently being evaluated in Phase III trials for multiple sclerosis 
(Cohen et al. 2009; Takabe et al. 2008).  
A more recent mechanism of action identified for FTY720 is its activation of purified PP2A 
trimers in vitro (Matsuoka et al. 2003) and as loss of PP2A phosphatase activity contributes to 
the pathophysiology of BCR/ABL-driven leukemias (Neviani et al. 2007) a logical prediction 
would be that restoration of PP2A levels reverses the leukaemic phenotype. Indeed, an 
extensive study has shown that pharmacological reactivation of PP2A with FTY720 inhibits 
the proliferation, enhances apoptosis, restores differentiation and impairs colony formation 
of imatinib-sensitive and –resistant BCR-ABL+ cell lines and CML-BC patient blasts 
(Neviani et al. 2007). Notably, FTY720 promotes BCR/ABL tyrosine dephosphorylation and 
proteolytic degradation, together with reduced phosphorylation of the PP2A targets Akt, 
ERK1/2 and STAT5 (Neviani et al. 2007). Co-treatment with okadaic acid or transduction of 
SV40 ST reverses the enhancement of PP2A activity and restores substrate phosphorylation, 
strongly indicating that FTY720 functions through a PP2A-dependent mechanism.  
Importantly, the in vitro efficacy of FTY720 translated into an in vivo model markedly 
suppressing both imatinib-sensitive (WT) and –resistant (T315I) BCR/ABL+ leukemogenesis 
(Neviani et al. 2007). After 4 weeks of treatment, saline-treated mice contained a large 
number of undifferentiated myeloid cells within the peripheral circulation, representing an 
overt AML phenotype with extensive blast infiltration of distal organs. In contrast, FTY720-
treated mice displayed undetectable levels of BCR/ABL+ cells in the systemic circulation 
and secondary organs. Accordingly, these effects were sustained long term with 80% and 
50% of WT and T315I BCR/ABL+ FTY720-treated mice, respectively, still alive at 27 weeks 
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and showing no signs of leukemia. In contrast, all saline-treated mice were sacrificed 5 
weeks post-tumor cell injection (Neviani et al. 2007). No toxic side effects were observed 
with administration of FTY720, highlighting the safety and therapeutic relevance of utilising 
PP2A-activating drugs in leukemia patients. 
FTY720 also activates PP2A in mutant c-KIT myeloid cells, leading to growth inhibition and 
induction of apoptosis in vitro (Roberts et al. 2010). Activation of PP2A is required for the 
anti-leukaemic effects, as PP2A inhibition with okadaic acid inhibits these effects. FTY720-
induced PP2A activity results in inhibition of c-KIT phosphorylation, and inactivation of 
downstream signaling proteins regulated by both c-KIT and PP2A. Importantly, FTY720 
also inhibited the in vivo tumor growth of mutant c-KIT myeloid cells in a syngeneic mouse 
model (Roberts et al. 2010). Thus FTY720 may also be a useful therapeutic agent for CBF-
AML patients harbouring activating c-KIT mutations. 
7. Other serine/threonine phosphatases in myeloid leukemia 
7.1 PP1 
PP1 activity has been found to alter according to AML blast differentiation. Yamamoto et al., 
found that AML patients with well differentiated leukemia had higher PP1 activity than 
patients with poorly differentiated AML-M1 (Yamamoto et al. 1999). AML blast PP1 activity 
also correlated with patient prognosis where individuals with significantly low PP1 activity 
had lower overall survival than those with high PP1 activity, with a median survival for 
each group of 8 and 27 months respectively (Nishikawa et al. 1994). Thus low PP1 activity 
may be a prognostic indicator of poor prognosis. The functional consequence of low PP1 
activity in AML is not known, however PP1 was recently found to dephosphorylate Akt at 
T405, and PP1 overexpression induced Akt dephosphorylation, promoted cell survival and 
inhibited differentiation (Xiao et al. 2010). PP1 also promotes survival by negative regulation 
of p53 (Li et al. 2006), and is implicated in regulating Wnt/β-catenin (Jiang et al. 2009), TGF-β 
(Shi et al. 2004), and NF-κB (Li et al. 2008) signaling pathways. Luo et al., showed that arsenic 
sulfide, a therapy historically used for treating CML in China, inhibited proliferation and 
induced differentiation of a human APL HL-60 cell line down a monocytic pathway. This 
correlated with increasing PP1 and PP2A activity, and co-treatment with a concentration of 
OA that inhibits both phosphatases suppressed the arsenic sulfide induced differentiation 
(Luo et al. 2006). Furthermore, while the mechanism was unknown at the time, other studies 
had previously shown similar effect in an APL NB4 cell model (Bai and Huang 1998; Lu and 
Wang 2002) and in chronic myeloid leukemia K562 cells (Yin et al. 2004).  These studies 
suggest that PP1 plays a role in the growth inhibition and differentiation of AML, and may 
also provide a useful prognostic tool and/or therapy target. 
7.2 PP2B 
PP2B (calcineurin) is probably best known for its role in immunity where it is activated 
upon T cell receptor stimulation. Indeed, calcineurin is a well established target of 
prophylactic agents used in transplantation, such as Cyclosporin A and FK506, where 
calcineurin inhibition suppresses IL-2 production. Calcineurin was recently implicated as an 
important oncogene in lymphoid leukemias (Medyouf et al. 2007; Medyouf and Ghysdael 
2008; Muller and Rao 2007). Sustained calcineurin activity was observed in human B- and T-
cell lymphomas and in a range of mouse models of lymphoid malignancies. Moreover, 
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al., was the first to highlight the therapeutic relevance of using PP2A-activators to 
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cAMP . Restoration of PP2A activity with forskolin was also found to inhibit Akt and ERK 
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(Cristobal et al. 2011; Neviani et al. 2005). Furthermore, forskolin had an additive effect with 
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metabolite isolated from Isaria sinclairii culture broth (Fujita et al. 1994), and is structurally 
similar to sphingosine (Albert et al. 2005; Kiuchi et al. 2005). It is effectively phosphorylated 
in vivo by SphK2 to yield the biologically active FTY720-phosphate (FTY720-P) (Brinkmann 
et al. 2002; Zemann et al. 2006). Interaction of FTY720-P with one of the five known S1P 
receptors induces receptor internalisation and degradation (Graler and Goetzl 2004; 
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the pathophysiology of BCR/ABL-driven leukemias (Neviani et al. 2007) a logical prediction 
would be that restoration of PP2A levels reverses the leukaemic phenotype. Indeed, an 
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(Neviani et al. 2007). Notably, FTY720 promotes BCR/ABL tyrosine dephosphorylation and 
proteolytic degradation, together with reduced phosphorylation of the PP2A targets Akt, 
ERK1/2 and STAT5 (Neviani et al. 2007). Co-treatment with okadaic acid or transduction of 
SV40 ST reverses the enhancement of PP2A activity and restores substrate phosphorylation, 
strongly indicating that FTY720 functions through a PP2A-dependent mechanism.  
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and secondary organs. Accordingly, these effects were sustained long term with 80% and 
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and showing no signs of leukemia. In contrast, all saline-treated mice were sacrificed 5 
weeks post-tumor cell injection (Neviani et al. 2007). No toxic side effects were observed 
with administration of FTY720, highlighting the safety and therapeutic relevance of utilising 
PP2A-activating drugs in leukemia patients. 
FTY720 also activates PP2A in mutant c-KIT myeloid cells, leading to growth inhibition and 
induction of apoptosis in vitro (Roberts et al. 2010). Activation of PP2A is required for the 
anti-leukaemic effects, as PP2A inhibition with okadaic acid inhibits these effects. FTY720-
induced PP2A activity results in inhibition of c-KIT phosphorylation, and inactivation of 
downstream signaling proteins regulated by both c-KIT and PP2A. Importantly, FTY720 
also inhibited the in vivo tumor growth of mutant c-KIT myeloid cells in a syngeneic mouse 
model (Roberts et al. 2010). Thus FTY720 may also be a useful therapeutic agent for CBF-
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had lower overall survival than those with high PP1 activity, with a median survival for 
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may be a prognostic indicator of poor prognosis. The functional consequence of low PP1 
activity in AML is not known, however PP1 was recently found to dephosphorylate Akt at 
T405, and PP1 overexpression induced Akt dephosphorylation, promoted cell survival and 
inhibited differentiation (Xiao et al. 2010). PP1 also promotes survival by negative regulation 
of p53 (Li et al. 2006), and is implicated in regulating Wnt/β-catenin (Jiang et al. 2009), TGF-β 
(Shi et al. 2004), and NF-κB (Li et al. 2008) signaling pathways. Luo et al., showed that arsenic 
sulfide, a therapy historically used for treating CML in China, inhibited proliferation and 
induced differentiation of a human APL HL-60 cell line down a monocytic pathway. This 
correlated with increasing PP1 and PP2A activity, and co-treatment with a concentration of 
OA that inhibits both phosphatases suppressed the arsenic sulfide induced differentiation 
(Luo et al. 2006). Furthermore, while the mechanism was unknown at the time, other studies 
had previously shown similar effect in an APL NB4 cell model (Bai and Huang 1998; Lu and 
Wang 2002) and in chronic myeloid leukemia K562 cells (Yin et al. 2004).  These studies 
suggest that PP1 plays a role in the growth inhibition and differentiation of AML, and may 
also provide a useful prognostic tool and/or therapy target. 
7.2 PP2B 
PP2B (calcineurin) is probably best known for its role in immunity where it is activated 
upon T cell receptor stimulation. Indeed, calcineurin is a well established target of 
prophylactic agents used in transplantation, such as Cyclosporin A and FK506, where 
calcineurin inhibition suppresses IL-2 production. Calcineurin was recently implicated as an 
important oncogene in lymphoid leukemias (Medyouf et al. 2007; Medyouf and Ghysdael 
2008; Muller and Rao 2007). Sustained calcineurin activity was observed in human B- and T-
cell lymphomas and in a range of mouse models of lymphoid malignancies. Moreover, 
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expression of constitutively active mutant calcineurin favored leukemia progression, while 
treatment with Cyclosporin A or FK506 induced apoptosis of leukemic cells and rapid 
tumor clearance, and significantly improved mouse survival (Medyouf et al. 2007). Thus 
inhibiting calcineurin is a potential therapeutic strategy for lymphoid leukemias. In contrast, 
a specific role for calcineurin in myeloid leukemias has not been reported, however one 
study investigating its activity in AML patients of different FAB subtype found that 
calcineurin activity is relatively low in leukemic blasts arresting at the stage of early 
pluripotent stem cells, and increases during the course of myelomonocytic commitment and 
maturation (Yamamoto et al. 1999).  
7.3 PP2C 
Like PP2B, little information exists regarding the role of PP2C in myeloid leukemia. One 
study revealed it had low expression in AML patient blood cells and its activity and 
expression were relatively constant in various leukemic cell types from AML, ALL, and CLL 
patients (Yamamoto et al. 1999), suggesting it may not play a remarkable role in 
leukemogenesis.  
8. Conclusions 
There is no doubt that PP2A acts as a tumor suppressor in myeloid leukemias, and targeting 
its re-activation, either directly or via inhibition of an endogenous inhibitory protein such as 
SET, is a promising therapeutic strategy. Whether the pre-clinical promise will translate to 
improved survival of myeloid leukemia patients is currently unknown, but clinical trials of 
PP2A activators are eagerly awaited. Emerging studies indicate that other phosphatases 
may also play important roles in myeloid leukemias, and future studies aimed at 
deciphering the molecular mechanisms regulating these phosphatases and their 
downstream targets is sure to identify further targets for novel therapies.   
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1. Introduction  
Janus kinases (JAKs) are a family of receptor-associated tyrosine kinases which are crucial 
for the survival and proliferation of immune and hematopoietic-derived cells. There are four 
mammalian JAKs identified to date: JAK1, JAK2, JAK3 and TYK2 (Lopez et al., 2010). JAKs 
are responsible for mediating the intracellular signaling of numerous growth factors and 
cytokines (Murray et al., 2007 & O’Shea et al., 2002). Once activated JAKs directly 
phosphorylate and activate the transcription factors signal transducers and activators of 
transcriptions (STATs) which transduce JAK signaling by translocating to the nucleus to 
modulate a subset of genes that are critical for cell proliferation and survival (Aaronson et 
al., 2002 & Levy et al., 2002). Dysregulated JAK signaling has been implicated in the 
pathogenesis of several blood-borne cancers but most notably in myeloproliferative 
neoplasms (MPNs) (Nelson et al., 2006; Lucia et al., 2011 & Patnaik et al., 2009). MPNs are 
hematological malignancies defined by the excessive proliferation of one or more myeloid-
derived cells. MPNs are classified into two clinical categories either BCR-ABL-positive 
(BCR-ABL (+)) or BCR-ABL-negative (BCR-ABL (-)) based on the presence of the BCR-ABL 
fusion protein. The major BCR-ABL (-) MPNs include polycythemia vera (PV), essential 
thrombocythemia (ET) and myelofibrosis (MF). The specific pathogenic role that JAK2 has 
in driving some of these MPNs is highlighted by the recent seminal discovery of the 
JAK2V617F mutation (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; & Levine et 
al., 2005). The JAK2V617F mutation is a somatic, gain-of function point mutation which leads 
to constitutive activation of JAK2 and subsequent downstream activation of STATs (Baxter 
et al., 2005 & James et al., 2005). Current data demonstrates that JAK2 is a disease associated 
gene involved in the pathogenesis of BCR-ABL (-) MPNs. However, it remains unclear if 
JAK2 pathway mutations are the primary drivers of sustained disease progression. New 
data is emerging that suggests that targeting the JAK-STAT pathway may have implications 
beyond the treatment of MPN and can be useful for the treatment of other hematological 
and non-hematological cancers. This review will summarize the pathogenic role of JAK-
STAT signaling in BCR-ABL (-) MPNs and introduce the potential broader implications by 
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which JAK-STAT pathway inhibition may have in treating hematological malignancies as 
well as solid tumors.  
2. Janus Kinase Family (JAKs) 
2.1 Function 
Janus kinases are a family of cytoplasmic receptor associated tyrosine kinases responsible 
for integrating the signaling of numerous growth factors and cytokines that are critical for 
hematopoiesis and immune function. There are four JAK family members; JAK1, JAK2, 
JAK3 and TYK2. JAK1, JAK2 and TYK2 are ubiquitously expressed while JAK3 expression is 
restricted to myeloid and lymphoid tissue (Valentino et al., 2006 & Ward et al., 2000 ). 
Various cytokines and growth factor receptors rely on JAKs to propagate their intracellular 
signaling cascades since many of these receptors lack intrinsic kinase activity. JAKs can be 
differentially or coordinately activated in response to various growth factor or cytokine 
stimuli (Murray, 2007). Targeted disruption of individual JAKs have been generated in an 
effort to better understand the biological non-redundant roles that JAKs have in 
development. JAK1 knock-out mice have been generated and present with a perinatal lethal 
phenotype that is characterized by severe defects in lymphopoiesis and neuronal 
development (Rodig et al., 1998). JAK3 mutations in humans have been described in patients 
with severe combined immunodeficiency (SCID), an immune disorder where major defects 
in T- and B- cell development are observed. This clinical phenotype is recapitulated in JAK3 
knock-out models where these mice manifest with SCID-like features characterized by 
impaired lymphocyte production (Nosaka et al., 1995 & Park et al., 2000). TYK2 deficiencies 
although rare have been reported, and these patients usually present with severe dermatitis 
and hyper-IgE syndrome-like symptoms (HIES). Genetic disruption studies involving TYK2 
have presented with severe defects in IL-12 signaling and impaired Th1 and Th2 mediated 
immune responses (Karaghiosoff et al., 2003). Genetic inactivation of JAK2 in mice is 
embryonically lethal due to severe anemia, confirming the critical role that JAK2 is thought 
to have in erythropoiesis (Parganas et al., 1998).  
2.2 Structure  
JAK proteins share seven homologous structural domains (JH1-JH7) each of which elicit 
distinct functional features within JAK proteins. The JAK homology domains consist of the 
C-terminus JH1 domain which is the kinase-active domain, the auto-regulatory JH2 
pseudokinase domain, the SH2-like JH3 domain and the N-terminus FERM (four-point-one, 
ezrin, radixin, and moesin) domain (JH4-JH7). Although the JH3 domain possesses a SH2-
like sequence it is unable to bind and interact with phospho-tyrosine residues and therefore 
its precise function remains unclear while the FERM domain is responsible for mediating 
the interactions of JAKs with their cognate receptors (Huang et al., 2001 & Radtke et al., 
2005). The JH2 pseudokinase domain is a unique structural feature of the JAKs that is 
otherwise absent in other kinase families. The JH2 pseudokinase domain bears high 
sequence identity to the JH1 kinase domain but is devoid of any catalytic activity and is 
thought to act as a regulatory domain through catalytic auto-inhbition (Saharinen et al., 
2000). Moreover, key activating point mutations have been identified in the JH2 
pseudokinase domain of JAK2 that are critically involved in the pathogenesis of some 
myeloproliferative neoplasms (MPNs).  
Role of JAK2 Beyond Myeloproliferative Neoplasms (MPNs): Rationale  




Fig. 1. JAK Protein Domain Structure. The seven homologous JAK domains (JH1-JH7) 
conserved throughout the JAK kinase family.  
2.3 JAK-STAT signaling  
In the absence of ligand, JAKs are pre-associated with receptor monomers, upon ligand 
binding receptor dimerzation ensues leading to trans-phosphorylation and auto-activation 
of JAKs. Once activated, JAKs proceed to phosphorylate specific tyrosine residues within 
the cytoplasmic domains of growth factor receptors creating docking sites for downstream 
mediators of JAK signaling. JAKs can activate classical signaling pathways such as PI-3-
kinase and MAPK but JAKs also directly activate STATs as described above. STATs are 
latent transcription factors that are activated and phosphorylated by JAKs at specific 
tyrosine residues (Darnell J, 1997 & Benekli et al., 2003). Once phosphorylated, STAT 
monomers can then homo/hetero-dimerize through reciprocal Src homology 2 (SH2) 
interactions and translocate to the nucleus to modulate the transcription of key genes which 
promote cell growth and survival.  
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3. Myeloproliferative Neoplasms (MPNs) 
3.1 Clinical biology 
MPNs are hematopoietic malignancies characterized by excessive growth of one or more 
myeloid derived cell lineages such as erythrocytes, platelets and/or granulocytes. MPNs are 
clinically grouped into either BCR-ABL (+) or BCR-ABL (-) based on the presence of the 
BCR-ABL protein, as seen in CML patients. Dysregulated JAK-STAT signaling has been 
implicated in the pathogenesis of these BCR-ABL (-) MPNs. The three most common BCR-
ABL (-) MPNs include polycythemia vera (PV), essential thrombocythemia (ET) and 
idiopathic myelofibrosis (IMF) with an estimated annual cumulative incidence of 130,000 
patients in the United States which translates into an estimated prevalence of 6.2 per 100,000 
cases (Ma et al., 2008; Mesa et al., 1999 & Ania B et al., 1994). The major clinical features of 
PV include uncontrolled growth of multiple myeloid-derived lineages with the dominating 
lineage being erythrocytes which is often reflected by an increased hematocrit and 
splenomegaly, while minor features include trilineage myeloproliferation of the bone 
marrow (Wadleigh & Tefferi, 2010). ET is characterized by an increase in both platelet size 
and number while hematocrit is unchanged. IMF is the most severe of the three MPNs and 
the major clinical criteria for diagnosis usually includes megakaryocytic proliferation 
accompanied by severe fibrosis of the bone marrow or hypercellularity of the bone marrow 
that is characterized by granulocyte proliferation (Wadleigh & Tefferi, 2010). IMF can 
manifest on its own or it can be preceded by PV or ET, post-PV or post-ET IMF has a 
variable evolution rate of roughly 25 evolutions per 1000 patients ET/PV patients 
(Passamonti et al., 2008 & Gangat et al., 2007). Furthermore, each one of these MPNs has the 
potential to progress to acute myelogenous leukemia (AML). In an unselected BCR-ABL (-) 
MPN population the overall leukemic transformation (LT) rate registered at 4.0% with MF 
having the highest transformation rate: 11.4%-MF, 4.3%-PV & 1.75% for ET (Cervantes et al., 
1991). Aberrant tyrosine kinase signaling has been implicated in the pathogenesis in the 
majority of MPNs, most notably with CML where the product of a chromosomal 
translocation results in the production of constitutively active tyrosine kinase known as the 
BCR-ABL (Druker et al., 1996). The discovery of the BCR-ABL tyrosine kinase led to the 
development of the clinically successful small molecule inhibitor, imatinib, which 
predominately targets BCR-ABL in addition to PDGF-R and KIT kinases (O’Brien et al., 
2003). The initial observation that altered tyrosine kinase signaling could single-handedly 
drive the entire pathogenesis of a disease as seen with BCR-ABL and CML hinted at the 
possibility that other altered tyrosine kinase signaling could be involved in the pathogenesis 
of these BCR-ABL (-) MPNs. 
3.2 Pathogenic role of JAK2 in BCR-ABL-negative MPNs 
Mutations in JAK2 have been implicated as a key genetic factor responsible for driving BCR-
ABL (-) MPNs and several lines of evidence highlight this finding. The major hematopoietic 
growth factors erythropoietin (Epo) and thrombopoietin (Tpo) that give rise to the myeloid 
derived cells that often over-populate PV and ET patients such as erythrocytes and platelets 
signal exclusively through JAK2. Loss of heterozygosity (LOH) on chromosome 9, where 
JAK2 is localized is observed in roughly 30% of PV patients (Kralovics et al., 2002), 
moreover, progenitor cells isolated from PV patients have routinely demonstrated an 
increased sensitivity to hematopoietic growth factors such as Epo and Tpo in ex vivo colony 
growth assays. Additionally, multiple animal models involving targeting expression of 
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JAK2 including transgenic and retroviral transduction methods leads to a MPN-like 
phenotype in vivo, further supporting a causal role for JAK2 in the pathogenesis of these 
diseases (Wernig et al., 2006)  
3.3 V617F and other JAK2-associated mutations in MPNs 
In 2005, several independent laboratories identified a unique somatic activating point 
mutation in the JAK2 gene (V617F). The JAK2V617F mutation occurs in the JH2 pseudokinase 
domain of JAK2 in exon 14 at position 617 where a valine is replaced with a phenylalanine 
which leads to constitutive activation of JAK2. The mechanism of activation of the V617F 
mutation is believed to be due to the removal of the auto-inhibitory function of the JH2 
pseudokinase domain present in JAK2. The incidence of the JAK2V617F mutation is highly 
prevalent within the BCR-ABL (-) MPN patient population particularly within PV cohorts 
where more than 95% (Wernig et al., 2006) of PV patients are positive for it while 50% of ET 
and IMF patients are positive for it (Pikman et al, 2006). Although the JAK2V617F mutation 
represents a major genetic event underlying the pathogenesis of these MPNs there is still a 
fraction of PV patients (~5%) and ET/IMF patients (~50%) that present with these MPNs but 
yet are negative for the V617F JAK2 mutation. The existence of V617F-negative MPNs 
highlights the need to identify additional JAK2 signaling components that may be involved 
in the pathogenesis of these V617F-independent MPNs. Several gain-of-function mutations 
comprised of deletions, insertions and frame-shifts have been indentified in exon 12 of JAK2 
in a small subset of V617-negative PV patients (~3%) (Scott et al., 2007). Interestingly, exon 
12 JAK2 mutations are mutually exclusive from V617F JAK2 mutations and to date have 
only been described in V617F-negative PV patients. Expression of exon 12 JAK2 mutations 
results in a PV-like phenotype in vivo that is characterized by erythrocytosis. Alternatively, 
activating point mutations in the thrombopoietin receptor (Tpo-R/c-MPL) have been 
identified in a subset of V617F-negative ET and IMF patients (5-10%). The mechanism of 
action for the MPLW515L mutation is similar to that of the V617F mutation since it also 
results in the removal of an auto-inhibitory sequence thought to be located within the 
transmembrane region of the Tpo receptor which causes spontaneous activation of 
downstream JAK2-STAT signaling (Pikman et al., 2006). The relative frequencies of these 
JAK-related mutations are summarized in figure 3 (Paradanani et al, 2011). The oncogenic 
potential of these mutations in MPN is further highlighted by their ability to induce MPN-
like phenotypes in murine bone marrow reconstitution studies. JAK2V617F expression 
induces a PV-like phenotype that presents with erythrocytosis and splenomegaly while 
(Wernig et al., 2006) MPLW515L promotes a more aggressive MF-like phenotype 
characterized by marked thrombocytopenia and severe fibrosis of the bone marrow (Pikman 
et al., 2006). Collectively, these results highlight a strong selective pressure to activate JAK-
STAT signaling in BCR-ABL-(-) MPNs and thus therapies designed to target the JAK-STAT 
signaling may be beneficial for the treatment of MPN.  
4. JAK inhibitors in clinical development  
Since the discovery of the JAK2V617F mutation in 2004 remarkable scientific progress has 
been made from bench to beside with the first JAK inhibitors being tested in humans by mid 
2007. Currently there are 36 clinical trials in the US underway evaluating various treatments 
for MPNs or investigating the molecular pathobiology underlying MPNs. The current JAK 
inhibitors are typically small molecule ATP competitive inhibitors of both wild-type and  
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Fig. 3. Allele Frequency in IMF Cohort, adapted from Chaligne R, et al. Leukemia (2008). 
Relative mutation frequency in a IMF cohort (n =603), V617F; 58%, MPLW515L; 8.1% and 
MPLW515L/V617F <1% 
mutant JAK enzymes that can be either selective JAK2 inhibitors or non-selective JAK2 
inhibitors with the latter having additional activity against other kinases besides JAK2. 
Initial clinical trials with JAK inhibitors were designed to recruit only IMF patients based on 
the biological severity of IMF compared to ET or PV, however more recently, clinical trials 
have expanded to include testing of JAK inhibitors in both PV and ET cohorts. The most 
advanced JAK inhibitor in the clinic to date is ruxolitinib (INCB018424), a pan-JAK inhibitor 
which demonstrates potent activity against JAK2 and JAK1 (Quintas-Cardama et al., 2010). 
A recent phase I/II trial (n=153) has commenced evaluating ruxolitinib for the treatment of 
IMF. While on ruxolitinib, a significant number of patients demonstrated a favorable clinical 
response including a reduction in spleen size, improvement in constitutional symptoms and 
normalization of pro-inflammatory cytokine levels. The suppression of inflammatory 
cytokines is thought to be linked to the pan inhibitory effects of ruxolitinib on both JAK1 
and JAK2 (Verstovsek et al., 2010). Given the clinical response of ruxolitinib in the treatment 
of IMF, trials have begun to evaluate the safety and efficacy of ruxolitinib in the treatment of 
PV and ET. Interestingly, these clinical responses did not correlate with JAK2V617F status 
and molecular remission of the mutant allele was absent even after two years of continued 
therapy (Verstovsek et al., 2008). The lack of effect on mutant allele burden could be due to 
direct loss of the mutant allele itself also known as “V617F-independence” that is reported 
to occur in some patients throughout the evolution of MPN (Passamonti et al., 2010). 
TG101348 is small molecule inhibitor of JAK 2 in clinical development. Results from a phase 
I/II multicenter study in IMF patients revealed that >45% of patients on TG101348 observed 
a >50% reduction in spleen size which was evident by five months but could be detected 
early two months and more than 70% of patients that presented with elevated white blood 
cell counts prior to treatment normalized (Pardanani et al., 2009). Unlike ruxolinitib, there 
was no significant decrease in serum levels of inflammatory cytokines while on therapy 
although the majority of patients did report a resolution of IMF-associated constitutional 
symptoms.  
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Compound   Company  Indication Phase NCT Trial # 
INCB18424 Incyte PV/ET/MF I/II/III NCT01445769 
TG101348 TargeGen MF I/II NCT00631462 
SB1518 S*BIO PV/ET/MF I/II NCT00745550 
CYT387 YM BIOSCIENCES MF I/II NCT00935987 
AZD1480 Astra Zeneca MF I/II NCT00910728 
LY2784544 Eli Lilly PV/ET/MF I NCT01134120 
BMS-911543 Bristol Myers-Squibb MF I NCT01236352 
Table 1. Current JAK Inhibitors in the Clinic 
5. Implications for targeting JAK-STAT signaling in additional hematological 
cancers and solid tumors 
Activating mutations in JAK2 (V617F and exon 12) in BCR-ABL (-) MPNs appear to be the 
primary mechanism by which these cells preferentially activate JAK-STAT signaling, 
however there are additional mechanisms available for cells to activate JAKs. Cells can also 
undergo chromosomal rearrangements which also lead to constitutive activation of JAKs. 
Chromosomal translocations activate JAKs by causing constitutive dimerization through 
replacement of amino terminal sequences with a fusion partner. In non-MPN hematological 
malignancies such as acute leukemias and lymphomas chromosomal rearrangements 
involving JAK2 represent another mechanism for activating JAK2. There have been seven 
fusion partners identified for JAK2, most of which lead to constitutive activation of JAK2 
signaling, these are summarized in table 2.  
 
    
Fusion Partner  Cancer Oncogenic Reference 
TEL (ETV6) T-ALL, aCML,B-ALL Yes Lacronique, 1997 
PCM1 ALL, aCML Yes Reiter, 2005 
BCR aCML Yes Greisinger, 2005  
SSBP2 B-ALL  Yes Poitras, 2008  
STRN3  ALL  Yes Mullighan, 2009  
PAX5 ALL  No  Bousquet, 2007  
SEC31-A cHL Yes VanRoosbroeck, 2011  
Table 2. Summary of JAK2 fusion partners due to chromosomal translocations involving 
chromosome 9p24. Abbreviations include-: T-ALL = T-cell acute lymphoblastic leukemia, 
aCML= atypical chronic myelogenous leukemia, B-ALL = B-cell acute lymphoblastic 
leukemia, ALL = acute lymphoblastic leukemia and cHL = classic Hodgkin lymphoma.  
5.1 Role of JAK-STAT signaling in non-MPN hematological malignancies 
Evidence is accumulating indicating dysregulated JAK-STAT signaling in various types of 
lymphomas. In classical Hodgkin lymphoma (cHL) and primary mediastinal B cell 
lymphoma (PMBL) several different mechanisms appear to be involved in the preferential 
activation of the JAK-STAT signaling network. An estimated 30% cHL patients and 35%-
45% of PMBL patients (Joos et al., 2003, 2000; Meier et al.,2009) present with genetic gains in 
chromosome band 9p24, the region where JAK2 is localized. Recently, several tumorgenic 
functions have been associated with this amplicon including JAK2-mediated increases in 
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programmed cell death 1 ligand 1 (PD-L1) expression. PD-L1 is also localized to band 9p24 
and therefore cells positive for this genetic gain can also demonstrate increased PD-L1 
expression in addition to elevated JAK 2 content. PD-L1 inhibits antitumor cytotoxic T 
lymphocyte (CTL) responses by activating its cognate inhibitor PD-1 receptor located on T-
cells, therefore PD-L1-/PD-1 interactions can promote tumorgenesis by mediating tumor 
evasiveness. A recent study showed elevated expression of PD-L1 and JAK2 in a subset of 
cHL and PMBL cell lines that were positive for the 9p24 amplicon and went on to show that 
PD-L1 expression could be augmented upon JAK2 inhibition suggesting a regulatory role 
for JAK2 in PD-L1 expression (Green et al., 2010 & Rui et al., 2010). In another study, 
alternative oncogenic functions were implicated for the 9p24 amplicon based on STAT-
independent epigenetic functions of JAK2. In this study, JAK2 was shown to cooperate with 
the epigenetic modifier JMJDC2 in several lymphoma cell lines positive for the 9p24 gain to 
induce epigenetic remodeling of the oncogene MYC locus leading to altered expression of 
MYC (Rui et al., 2010). The cooperative interplay between JAK2 and JMJDC2 was further 
demonstrated when the anti-proliferative effects induced by loss of JMJD2C were 
exaggerated upon JAK inhibition. In addition, inactivating mutations in SOCS-1, a negative 
regulator of JAK-STAT signaling are observed in 40% of cHL patients (Weniger et al., 2006 & 
Mottok et al., 2007). Increased expression of activated STATs, namely STAT 3 and STAT6 
are often observed in cHL patients and this is thought to be due to sustained signaling loops 
perpetuated by chronic IL-13 stimulation (Skinnider et al., 2002) furthermore, loss of STAT3 
or STAT6 in cHL cell lines results in diminished proliferative capacity and induction of 
apoptosis (Baus, 2009 & Kube et al., 2005). To further validate a role for abnormal JAK-STAT 
signaling in lymphoma-type cancers is the more recent study in which an inverse 
relationship between the inhibitory microRNA-135a and JAK2 was observed in cHL 
patients. Interestingly, low levels of miR-135a expression were strongly correlated with 
disease relapse and shorter disease-free survival in a cohort of cHL patients. The regulatory 
role of miR-135a on JAK2 was confirmed when over- expression of miR-135a led to an 
increase in JAK2 expression (25%-55%) in lymphoma cell lines (Navarro et al., 2009).  
5.2 Role of dysregulated JAK-STAT signaling in multiple myeloma 
Altered JAK-STAT signaling has also been implicated in the progression of multiple 
myeloma (MM). MM is an aggressive hematological malignancy characterized by excessive 
proliferation of clonal plasma B-cells that accumulate in the bone marrow (Anderson et al., 
1999). The maintenance of MM is highly dependent on the interaction of myeloma cells with 
resident bone marrow stromal cells (BMSC) both of which secrete various cytokines and 
growth factors that promote myeloma cell growth. IL-6 is recognized as a critical cytokine 
that’s essential for the survival and proliferation of myeloma cells (Bommert et al., 2006). 
Elevated serum levels of IL-6 are frequently observed in MM patients who fail to respond to 
conventional chemotherapies and IL-6 levels also correlate with poor prognosis of MM 
(Niesvizky et al., 1995). IL-6 signals through JAK1/JAK2/TYK2 leading to downstream 
activation of STAT3 to promote proliferation and survival of myeloma cells (Murray et al., 
2007). Interestingly, elevated levels of activated STAT3 have been observed in more than 
50% of myeloma patient samples (Bharti AC et al., 2004). Pre-clinical studies have shown 
that JAK inhibition can induce apoptosis, inhibit proliferation and block constitutive and  
IL-6 induced activation of STAT3 in several MM cell-based models. Furthermore, JAK 
inhibition also enhanced the anti-tumorgenic effects of bortezomib, a current therapy 
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available for MM, in tumor models of myeloma. In summary, JAK inhibition may not be 
sufficient as a mono-therapy for the treatment of MM but studies that combine JAK 
inhibitors with the current treatments available for MM like bortezomib may prove 
beneficial for MM patients. Of note, the pan-JAK inhibitor, INCB18424, currently being 
tested for the treatment of MPN is also being evaluated in a phase I study for the treatment 
of MM.  
5.3 Implications for abnormal JAK-STAT signaling in solid tumors 
Dysregulated JAK-STAT signaling has also been implicated in the pathogenesis of solid 
tumors primarily due to elevated levels of constitutively activated STATs. Among the 
STATs, STAT3 and STAT5 are the most studied and well characterized regarding their 
oncogenic potential. Activated STATs possess multiple oncogenic traits which promote 
tumorgenesis including tumor cell proliferation, induction of anti-apoptotic and immune 
cell responses. A defined role has been established for STAT5 in driving some hematological 
malignancies, including some MPNs where STAT5 expression leads to a MPN-like 
phenotype, while STAT3 appears to be more involved in solid tumor progression (Germain, 
2007). In solid tumors, increased STAT activation is thought to be due to sustained cytokine 
stimulation via autocrine/paracrine signaling loops rather than increased activity in 
upstream activators of STATs such as JAKs. Elevated levels of activated STAT3 are observed 
in multiple solid tumors including breast, prostate, colon, pancreatic, head and neck and 
ovarian cancers (Song et al, 2006 & Frank., 2003) Recently, an extensive profiling study was 
done that identified a subset of solid tumor cell lines that expressed high levels of 
constitutive and IL-6 inducible activated STAT3 and when these cells were treated with 
specific JAK inhibitors both constitutive and inducible STAT3 activation was suppressed 
(Hedvat et al., 2009). In a panel of pancreatic cell lines, elevated activated STAT3 levels were 
found to correlate with gp130 expression, an IL-6 receptor, reinforcing the idea that STAT 
activation in solid tumors is related to sustained cytokine stimulation (Corcoran et al., 2011)  
6. Conclusion 
Emerging clinical data on a variety of JAK2 inhibitors support a role of these agents in the 
symptomatic relief of MPN patients. However, there are still unresolved issues associated 
with these inhibitors including the inability of most inhibitors to reduce the amount of 
mutant allele burden. The numerous mechanisms that blood-derived cancer cells have 
acquired to preferentially activate JAK-STAT signaling (point mutations, translocations & 
chromosomal gains) demonstrates the importance of this pathway in promoting 
hematological malignancies. The use of JAK inhibitors for the treatment of other non-MPN 
hematological cancers such as lymphomas and multiple myelomas are intriguing but 
require additional pre-clinical studies to determine which JAKs underlie these findings. In 
this regard, lymphomas with a high frequency of the 9p24 gain (30%) coupled with the 
recent identification of the novel JAK2-SEC31-A fusion protein implicates a preference for 
these cells to also activate JAK-STAT signaling. In multiple myeloma, a reliance of these cells 
on IL-6 for their survival and growth suggests that these patients could benefit from JAK 
inhibition therapies. For the role of JAK2-STAT signaling in solid tumors, it remains unclear 
of the potential of pathway inhibition but is likely to require rational combination strategies 
with other agents in clinical development to unmask the full therapeutic potential of JAK 
inhibitors.  
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1. Introduction 
Acute myeloid leukemia (AML) is a hematologic malignancy with great variability in the 
pathogenesis, clinical features, and treatment outcomes. Advances in molecular research 
have greatly improved our understanding of the leukemogenesis in AML. A two-hit model 
proposes that the development of AML requires the cooperation between at least two 
classes of gene mutations.(Frohling, et al 2005, Gilliland 2002) Class I mutations, such as 
RAS, FLT3, KIT, PTPN11 and JAK2 mutations, involve genes in the kinase signaling 
pathways leading to cell survival and proliferation and Class II mutations, such as 
t(15;17)/PML-RARA, inv(16)/CBFB-MYH11 and t(8;21)/RUNX1-RUNX1T1 fusions, and 
MLL/PTD, and CEBPA and AML1/RUNX1 mutations, involve transcription factors or 
cofactors resulting in impaired hematopoietic differentiation. In addition to genetic 
abnormalities, increasing evidences show that epigenetic deregulations are also critical to 
the pathogenesis of AML.(Chen, et al 2010) Compatible with these findings, several novel 
mutations involving genes related to epigenetic modifications, such as isocitrate 
dehydrogenase 1 (IDH1), IDH2, ten-eleven translocation 2 (TET2), additional sex comb-like 1 
(ASXL1), and DNA methyltransferase 3A (DNMT3A) were detected in AML recently.(Chou, 
et al 2010b, Delhommeau, et al 2009, Gelsi-Boyer, et al 2009, Ley, et al 2010, Mardis, et al 2009, 
Metzeler, et al 2011) 
Risk-adapted treatment may not only improve the prognosis, but also reduce the toxicity 
from the therapy in patients with AML. In addition to the conventional risk factors, such as 
age, white blood cell (WBC) counts and cytogenetics, molecular genetic alterations, such as 
mutations of NPM1, CEBPA, AML1/RUNX1, WT1, FLT3, TET2, and DNMT3A etc., are also 
important prognostic factors in AML patients. Furthermore, the gene mutations which are 
stable during treatment courses can also be used as biomarkers to monitor minimal residual 
disease (MRD). Herein, we will review the gene mutations in AML and discuss their clinical 
implications.  
2. Class I mutations that lead to cell survival and proliferation  
2.1 FLT3 mutations 
FMS-like tyrosine kinase 3 (FLT3), mapped at 13q12, encodes a receptor tyrosine 
kinase.(Kiyoi, et al 1998) FLT3-internal tandem duplication (FLT3-ITD) mutation, one of the 
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implications.  
2. Class I mutations that lead to cell survival and proliferation  
2.1 FLT3 mutations 
FMS-like tyrosine kinase 3 (FLT3), mapped at 13q12, encodes a receptor tyrosine 
kinase.(Kiyoi, et al 1998) FLT3-internal tandem duplication (FLT3-ITD) mutation, one of the 
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most common mutations in AML, was found by Nakao et al in 1996.(Nakao, et al 1996) The 
mutation occurs as a duplication of nucleotide sequences of variable lengths in exons 14 and 
15, leading to addition of repeated peptide in the juxtamembrane domain in the cytoplasm. 
Another activating FLT3 mutation occurs in tyrosine kinase domain (FLT3-TKD), causing 
point mutations, small deletions or insertions mainly at codon 835 or 836 within the 
activation loop of the second kinase domain.(Bacher, et al 2008, Yamamoto, et al 2001) The 
FLT3 mutant protein constitutively activates the cascade of FLT3 signaling in the absence of 
FLT3 ligand promoting cell proliferation and decreased apoptosis.  
FLT3-ITD occurs in about 25% of adult AML and shows association with normal karyotype 
and NPM1 mutation. The patients with this mutation have higher WBC counts, shorter 
disease-free survival (DFS) and overall survival (OS), and increased relapse rate.(Kottaridis, et 
al 2001, Kottaridis, et al 2002) While mutant size may not be related to prognosis, higher 
mutant levels are associated with higher relapse rate and shorter survival.(Gale, et al 2008) 
Absence of FLT3-ITD combined with NPM1 mutation is regarded as a favorable prognostic 
genotype.(Gale, et al 2008, Schlenk, et al 2008) Up to one third of AML patients with FLT3-ITD 
can lose the mutation at disease relapse, indicating that this mutation is much less stable than 
NPM1 mutation, and is not a good marker for disease monitoring.(Chou, et al 2011b, 
Kottaridis, et al 2002, Palmisano, et al 2007, Shih, et al 2002) FLT3-TKD occurred in about 4%-
10% of AML patients.(Yamamoto, et al 2001, Bacher, et al 2008) AML with this mutation also 
shows specific clinical and biologic features, such as elevated WBC counts at diagnosis, higher 
frequency of normal karyotype and mutations in NPM1, CEBPA, and NRAS. However, the 
prognostic significance is still inconclusive.(Bacher, et al 2008, Whitman, et al 2008)   
2.2 RAS mutations  
The RAS proteins are a large superfamily of low molecular-weight guanine nucleotide-
binding proteins, which are activated by cytokine receptors in response to ligand 
stimulation and therefore control cell proliferation and survival of hematopoietic 
progenitors.(Downward 2003, Reuther and Der 2000, Shields, et al 2000, Wittinghofer 1998) 
Three members of the RAS family, HRAS, KRAS and NRAS, are found to be activated by 
mutations in human cancers.(Bos 1989, Downward 2003) Almost all RAS mutations occur by 
single nucleotide substitutions in codons 12, 13 and 61.(Bos, et al 1987, Farr, et al 1988, Senn, 
et al 1988, Toksoz, et al 1989) NRAS and KRAS mutations are found in approximately 12-30% 
and 9-14%, respectively, of AML patients. In a large cohort study of 2502 AML patients, the 
mutations were found much prevalent in patients with inv(16)/t(16;16) and inv(3)/t(3;3), 
but seldom found in those with t(15;17) and complex karyotype.(Bacher, et al 2006)  
The prognostic relevance of RAS mutation in AML has not been firmly established. Some 
studies showed RAS mutation predicted poor prognosis(De Melo, et al 1997, Kiyoi, et al 
1999, Meshinchi, et al 2003), some showed no impact on clinical outcome,(Bacher, et al 2006, 
Bowen, et al 2005, Radich, et al 1990, Ritter, et al 2004) whereas others found RAS mutations 
were associated with a favorable prognosis.(Coghlan, et al 1994, Neubauer, et al 1994) 
However, higher dose of cytarabine may decrease the relapse rate in RAS-mutated AML 
patients.(Neubauer, et al 2008) 
2.3 KIT mutations 
KIT, a member of type III receptor tyrosine kinase family, is important for the development 
of hematopoietic progenitor cells and also crucial in leukemogenesis.(Blume-Jensen and 
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Hunter 2001, Bowen, et al 2005, Radich, et al 1990) High expression of KIT (CD117) is a 
common finding in AML,(Ikeda, et al 1991, Reuss-Borst, et al 1994) and activation mutations 
of KIT, most commonly affecting exons 8 and 17 can be identified in 20–45% of AML with 
inv (16) and 12.8–46.8% of AML with t(8;21), but infrequently found in other AML 
types.(Beghini, et al 2000, Beghini, et al 2004, Care, et al 2003) Most, though not all, 
studies,(Boissel, et al 2006, Care, et al 2003, Schnittger, et al 2006) showed KIT mutation was 
associated with inferior outcome in the core binding factor (CBF) AML, especially KIT-D816 
mutations in t(8;21)/RUNX1-RUNX1T1–positive AML.  
2.4 JAK2 mutations 
JAK2 is a nonreceptor tyrosine kinase. The JAK2 V617F mutation induces the activation of 
JAK2-STAT5 signal transduction pathway and then substantially alters the proliferation and 
self-renewal of hematopoietic precursors.(Liu, et al 1999, Walz, et al 2006) Although the JAK2 
V617F mutation is a common genetic event in the patients with myeloproliferative 
neoplasms (MPN),(Baxter, et al 2005, Goldman 2005, Kralovics, et al 2005, Levine, et al 2005b) 
it is seldom found (<1%-2%) in de novo AML patients.(Frohling, et al 2006, Illmer, et al 2007, 
Lee, et al 2006, Levine, et al 2005a) Illmer et al showed 3.6% of patients with CBF AML had 
JAK2 V617F mutation and these patients had an aggressive clinical course and poor 
outcome.(Illmer, et al 2007)  
2.5 PTPN 11 mutations 
SHP-2 is encoded by PTPN11 which is located on chromosome 12q24. The protein is a non-
receptor tyrosine phosphatase participating in intracellular signaling elicited by a number of 
growth factors, cytokines, hormones and adhesion molecules.(Neel, et al 2003, Tartaglia, et al 
2004) Germline PTPN11 mutations were first reported by Tartaglia et al in patients afflicted 
with Noonan syndrome.(Tartaglia, et al 2002, Tartaglia, et al 2001) Subsequently, somatic 
PTPN11 mutations were also found in patients with juvenile myelomonocytic leukemia, and 
myelodysplastic syndrome (MDS).(Chen, et al 2006, Loh, et al 2004b, Tartaglia, et al 2003) The 
PTPN11 mutation is not a frequent molecular event (4-5%) in AML.(Hou, et al 2008, Loh, et al 
2004a, Tartaglia, et al 2005) In a study of 272 primary AML patients, we found this gene 
mutation was closely associated with older age, French-American-British (FAB) M4/M5 
subtype, CD14 expression, normal karyotype and NPM1 mutation.(Hou, et al 2008) Loh et al 
and Tartaglia et al revealed that the PTPN11 mutation had no prognostic implication for 
pediatric patients with AML;(Loh, et al 2004a, Tartaglia, et al 2005) however, this mutation 
may be a poor-risk factor for OS in adult AML patients without NPM1 mutations.(Hou, et al 
2008) 
3. Class II mutations that impair hematopoietic differentiation 
3.1 CEBPA mutations 
CCAAT/enhancer binding protein  (C/EBP) is a 42-kDa transcription factor that 
possesses a DNA-binding basic leucine zipper domain (bZIP) in the COOH terminus and 
two transactivation domains TAD 1 and TAD 2 in the NH2 terminus.(Friedman and 
McKnight 1990) As a transcription factor, it plays a crucial role in granulocytic 
differentiation and diminished C/EBP activity contributes to myeloid progenitor 
transformation.(Cammenga, et al 2003, Oelgeschlager, et al 1996, Smith, et al 1996) CEBPA 
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most common mutations in AML, was found by Nakao et al in 1996.(Nakao, et al 1996) The 
mutation occurs as a duplication of nucleotide sequences of variable lengths in exons 14 and 
15, leading to addition of repeated peptide in the juxtamembrane domain in the cytoplasm. 
Another activating FLT3 mutation occurs in tyrosine kinase domain (FLT3-TKD), causing 
point mutations, small deletions or insertions mainly at codon 835 or 836 within the 
activation loop of the second kinase domain.(Bacher, et al 2008, Yamamoto, et al 2001) The 
FLT3 mutant protein constitutively activates the cascade of FLT3 signaling in the absence of 
FLT3 ligand promoting cell proliferation and decreased apoptosis.  
FLT3-ITD occurs in about 25% of adult AML and shows association with normal karyotype 
and NPM1 mutation. The patients with this mutation have higher WBC counts, shorter 
disease-free survival (DFS) and overall survival (OS), and increased relapse rate.(Kottaridis, et 
al 2001, Kottaridis, et al 2002) While mutant size may not be related to prognosis, higher 
mutant levels are associated with higher relapse rate and shorter survival.(Gale, et al 2008) 
Absence of FLT3-ITD combined with NPM1 mutation is regarded as a favorable prognostic 
genotype.(Gale, et al 2008, Schlenk, et al 2008) Up to one third of AML patients with FLT3-ITD 
can lose the mutation at disease relapse, indicating that this mutation is much less stable than 
NPM1 mutation, and is not a good marker for disease monitoring.(Chou, et al 2011b, 
Kottaridis, et al 2002, Palmisano, et al 2007, Shih, et al 2002) FLT3-TKD occurred in about 4%-
10% of AML patients.(Yamamoto, et al 2001, Bacher, et al 2008) AML with this mutation also 
shows specific clinical and biologic features, such as elevated WBC counts at diagnosis, higher 
frequency of normal karyotype and mutations in NPM1, CEBPA, and NRAS. However, the 
prognostic significance is still inconclusive.(Bacher, et al 2008, Whitman, et al 2008)   
2.2 RAS mutations  
The RAS proteins are a large superfamily of low molecular-weight guanine nucleotide-
binding proteins, which are activated by cytokine receptors in response to ligand 
stimulation and therefore control cell proliferation and survival of hematopoietic 
progenitors.(Downward 2003, Reuther and Der 2000, Shields, et al 2000, Wittinghofer 1998) 
Three members of the RAS family, HRAS, KRAS and NRAS, are found to be activated by 
mutations in human cancers.(Bos 1989, Downward 2003) Almost all RAS mutations occur by 
single nucleotide substitutions in codons 12, 13 and 61.(Bos, et al 1987, Farr, et al 1988, Senn, 
et al 1988, Toksoz, et al 1989) NRAS and KRAS mutations are found in approximately 12-30% 
and 9-14%, respectively, of AML patients. In a large cohort study of 2502 AML patients, the 
mutations were found much prevalent in patients with inv(16)/t(16;16) and inv(3)/t(3;3), 
but seldom found in those with t(15;17) and complex karyotype.(Bacher, et al 2006)  
The prognostic relevance of RAS mutation in AML has not been firmly established. Some 
studies showed RAS mutation predicted poor prognosis(De Melo, et al 1997, Kiyoi, et al 
1999, Meshinchi, et al 2003), some showed no impact on clinical outcome,(Bacher, et al 2006, 
Bowen, et al 2005, Radich, et al 1990, Ritter, et al 2004) whereas others found RAS mutations 
were associated with a favorable prognosis.(Coghlan, et al 1994, Neubauer, et al 1994) 
However, higher dose of cytarabine may decrease the relapse rate in RAS-mutated AML 
patients.(Neubauer, et al 2008) 
2.3 KIT mutations 
KIT, a member of type III receptor tyrosine kinase family, is important for the development 
of hematopoietic progenitor cells and also crucial in leukemogenesis.(Blume-Jensen and 
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Hunter 2001, Bowen, et al 2005, Radich, et al 1990) High expression of KIT (CD117) is a 
common finding in AML,(Ikeda, et al 1991, Reuss-Borst, et al 1994) and activation mutations 
of KIT, most commonly affecting exons 8 and 17 can be identified in 20–45% of AML with 
inv (16) and 12.8–46.8% of AML with t(8;21), but infrequently found in other AML 
types.(Beghini, et al 2000, Beghini, et al 2004, Care, et al 2003) Most, though not all, 
studies,(Boissel, et al 2006, Care, et al 2003, Schnittger, et al 2006) showed KIT mutation was 
associated with inferior outcome in the core binding factor (CBF) AML, especially KIT-D816 
mutations in t(8;21)/RUNX1-RUNX1T1–positive AML.  
2.4 JAK2 mutations 
JAK2 is a nonreceptor tyrosine kinase. The JAK2 V617F mutation induces the activation of 
JAK2-STAT5 signal transduction pathway and then substantially alters the proliferation and 
self-renewal of hematopoietic precursors.(Liu, et al 1999, Walz, et al 2006) Although the JAK2 
V617F mutation is a common genetic event in the patients with myeloproliferative 
neoplasms (MPN),(Baxter, et al 2005, Goldman 2005, Kralovics, et al 2005, Levine, et al 2005b) 
it is seldom found (<1%-2%) in de novo AML patients.(Frohling, et al 2006, Illmer, et al 2007, 
Lee, et al 2006, Levine, et al 2005a) Illmer et al showed 3.6% of patients with CBF AML had 
JAK2 V617F mutation and these patients had an aggressive clinical course and poor 
outcome.(Illmer, et al 2007)  
2.5 PTPN 11 mutations 
SHP-2 is encoded by PTPN11 which is located on chromosome 12q24. The protein is a non-
receptor tyrosine phosphatase participating in intracellular signaling elicited by a number of 
growth factors, cytokines, hormones and adhesion molecules.(Neel, et al 2003, Tartaglia, et al 
2004) Germline PTPN11 mutations were first reported by Tartaglia et al in patients afflicted 
with Noonan syndrome.(Tartaglia, et al 2002, Tartaglia, et al 2001) Subsequently, somatic 
PTPN11 mutations were also found in patients with juvenile myelomonocytic leukemia, and 
myelodysplastic syndrome (MDS).(Chen, et al 2006, Loh, et al 2004b, Tartaglia, et al 2003) The 
PTPN11 mutation is not a frequent molecular event (4-5%) in AML.(Hou, et al 2008, Loh, et al 
2004a, Tartaglia, et al 2005) In a study of 272 primary AML patients, we found this gene 
mutation was closely associated with older age, French-American-British (FAB) M4/M5 
subtype, CD14 expression, normal karyotype and NPM1 mutation.(Hou, et al 2008) Loh et al 
and Tartaglia et al revealed that the PTPN11 mutation had no prognostic implication for 
pediatric patients with AML;(Loh, et al 2004a, Tartaglia, et al 2005) however, this mutation 
may be a poor-risk factor for OS in adult AML patients without NPM1 mutations.(Hou, et al 
2008) 
3. Class II mutations that impair hematopoietic differentiation 
3.1 CEBPA mutations 
CCAAT/enhancer binding protein  (C/EBP) is a 42-kDa transcription factor that 
possesses a DNA-binding basic leucine zipper domain (bZIP) in the COOH terminus and 
two transactivation domains TAD 1 and TAD 2 in the NH2 terminus.(Friedman and 
McKnight 1990) As a transcription factor, it plays a crucial role in granulocytic 
differentiation and diminished C/EBP activity contributes to myeloid progenitor 
transformation.(Cammenga, et al 2003, Oelgeschlager, et al 1996, Smith, et al 1996) CEBPA 
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mutations are observed in 7% to 18% of patients with AML.(Frohling, et al 2004, Lin, et al 
2005, Pabst, et al 2001b, Preudhomme, et al 2002) Two major types of CEBPA mutations have 
been identified; one alters COOH terminal bZIP of CEBPA, resulting in decreased DNA-
binding and/or dimerization activity and the other disrupts translation of the C/EBP NH2 
terminus, thereby up-regulates an alternative 30-kDa isoform with dominant-negative effect 
on the full-length wild-type C/EBP.(Koschmieder, et al 2009, Lin, et al 1993, Pabst, et al 
2001b) Most patients with CEBPA mutations harbored biallelic mutations involving both the 
NH2-terminal TAD region and the COOH-terminal bZIP domain.(Hou, et al 2009, Lin, et al 
2005, Pabst, et al 2009, Renneville, et al 2009a) CEBPA mutations occur most frequently in 
patients with FAB subtype M2, and are closely associated with CD7, CD15, CD34, and HLA-
DR expression on the leukemic cells, higher circulatory blasts and normal 
cytogenetics.(Frohling, et al 2004, Lin, et al 2005, Pabst, et al 2001a, Zhang, et al 1997) This 
mutation seems quite stable during AML evolution and may be a potential marker to 
monitor MRD. The fact that none of the AML patients who do not have CEBPA mutations at 
diagnosis acquire the mutation at relapse suggests that this mutation may not play a major 
role in the progression of AML.(Lin, et al 2005, Tiesmeier, et al 2003) Several studies have 
shown mutant CEBPA predicts favorable outcome in AML patients with intermediate or 
normal cytogenetics.(Barjesteh van Waalwijk van Doorn-Khosrovani, et al 2003, Bienz, et al 
2005, Frohling, et al 2004, Preudhomme, et al 2002) The favorable impact of CEBPA 
mutations in the AML patients is only observed in the absence of FLT3/ITD or other 
associated cytogenetic abnormalities.(Renneville, et al 2009a) Moreover, only double CEBPA 
mutations, but not single CEBPA mutation, are associated with better prognosis and define a 
distinct genetic entity.(Dufour, et al 2010, Hou, et al 2009, Pabst, et al 2009, Wouters, et al 
2009)         
3.2 MLL -PTD 
The MLL partial tandem duplication (MLL-PTD) most commonly results from a duplication 
of a genomic region encompassing exon 5 through exon 11/12 and insertion of the 
duplicated segment into intron 4 of the full-length MLL gene.(Caligiuri, et al 1994, 
Schichman, et al 1994, Whitman, et al 2005) The duplication involves a portion of the gene 
corresponding to the amino terminus of the MLL protein which contains the AT hook and a 
region of homology to DNA methyltransferase motifs.(Schichman, et al 1995) The 
mechanism by which MLL-PTD contributes to leukemic phenotype is not clear, but may be 
through silencing of the wild-type MLL by epigenetic mechanisms.(Dimartino and Cleary 
1999, Whitman, et al 2005) This mutation is found in 5-12% of patients with cytogenetically 
normal AML (CN-AML),(Dohner, et al 2002, Munoz, et al 2003, Schnittger, et al 2000, Shiah, 
et al 2002) and up to 54% of AML patients with trisomy 11.(Rege-Cambrin, et al 2005) 
Compared with patients without MLL-PTD, patients with this mutation more often have 
FAB M2 subtype, CD11b expression, wild-type NPM1 and high BAALC expression, but 
lower WBC counts, less frequently extramedullary involvement and FAB M4/M5 subtype at 
diagnosis.(Shiah, et al 2002, Whitman, et al 2007) The presence of MLL-PTD predicts shorter 
remission duration and worse OS;(Dohner, et al 2002, Munoz, et al 2003, Shiah, et al 2002) 
however, more intensive consolidation therapy that includes hematopoietic stem cell 
transplantation (HSCT) during first complete remission (CR) may reverse the poor 
prognosis conferred by this mutation.(Whitman, et al 2007)  
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3.3 AML1/RUNX1  
The AML1/RUNX1 gene(Ito 2008), consisting of 10 exons (exons 1-6, 7A, 7B, 7C and 8), is one 
of the most frequently deregulated genes in leukemia through chromosomal translocations 
and point mutations.(Friedman 2009, Niebuhr, et al 2008, Osato 2004, Yamagata, et al 2005) 
Monoallelic germ-line mutation of the RUNX1 gene occurs in rare cases of familial platelet 
disorder with predisposition to AML (FPD/AML).(Michaud, et al 2002) Acquired RUNX1 
mutation was frequently reported in therapy-related MDS or MDS/AML.(Harada, et al 
2004) The incidence of RUNX1 mutation in AML varies from 2.9% to 46% depending on the 
population selected, the regions of RUNX1 screened, and the methods used.(Dicker, et al 
2007, Preudhomme, et al 2000, Tang, et al 2009) In a large cohort study of 470 adult patients 
with de novo non-M3 AML, we detected RUNX1 mutation in 13.2% of cases. The RUNX1 
mutation is closely associated with older age, immature FAB subtypes (M0/M1) and specific 
cytogenetic abnormalities such as trisomy 8 (+8), +13, or +21.(Dicker, et al 2007, Schnittger, et 
al 2011, Tang, et al 2009) None of the patients with t(8;21), inv(16), t(15;17) or 11q23 
translocation shows RUNX1 mutation.(Tang, et al 2009) One half of RUNX1-mutated 
patients have concurrently other gene mutations, mostly (83.9%) Class I mutations, 
especially FLT3/ITD, FLT3/TKD and N-RAS mutations(Tang, et al 2009) which all result in 
hyperactivation of the receptor tyrosine kinase (RTK)-RAS signalling pathways.(Niimi, et al 
2006) This finding is consistent with the two-hit model of leukemogenesis.(Frohling, et al 
2005, Gilliland 2002) Further, the RUNX1 mutation is mutually exclusive with CEBPA and 
NPM1 mutations, but closely associated with MLL/PTD.(Schnittger, et al 2011, Tang, et al 
2009) The mutation may be lost at relapse in RUNX1-mutated patients, but none of the 
patients who do not harbor RUNX1 mutation at diagnosis acquire novel mutation at 
relapse.(Tang, et al 2009) RUNX1 mutation is an independent poor-risk factor for DFS and 
OS in de novo AML patients.(Gaidzik, et al 2011, Schnittger, et al 2011, Tang, et al 2009) In 
addition, HSCT seems to ameliorate the poor survival impact of RUNX1 
mutations.(Gaidzik, et al 2011, Tang, et al 2009) 
4. Other mutations  
4.1 NPM1 mutations 
NPM1 mutation in AML was first identified by Dr. Falini’s group, who noticed that some 
AML patients’ leukemia cells exhibited aberrant cytoplasmic localization of NPM1 protein, 
which normally located in nucleoli in non-mitotic cells.(Falini, et al 2005) Subsequent 
investigation revealed a tetra-nucleotide insertion near the C-terminal end of the coding 
sequence of NPM1. The most frequent form of mutation is duplication of TCTG (type A, 
c.860_863dupTCTG), resulting in alteration of the peptide sequence from DLWQWRKSL* to 
DLCL AVEEVSLRK*. NPM1 mutation occurs in about 30% of AML, more frequently in 
elder patients,(Falini, et al 2011, Falini, et al 2005) and is highly associated with normal 
karyotype, and FLT3/ITD, but significantly exclusive with CEBPA mutation, favorable 
karyotype, and expression of CD34 and HLA-DR.(Boissel, et al 2005, Chou, et al 2006, 
Dohner, et al 2005, Falini, et al 2005, Schnittger, et al 2005, Suzuki, et al 2005, Verhaak, et al 
2005)  NPM1 mutation generally renders better prognosis,(Falini, et al 2005) especially when 
FLT3-ITD is absent.(Schlenk, et al 2008, Thiede, et al 2006) Further refinement of patient 
groups disclosed 3 groups with distinct prognosis: good (NPM1+/FLT3-ITD-), intermediate 
(NPM1+/FLT3-ITD+ or NPM1-/FLT3-ITD-), and poor (NPM1-/FLT3-ITD+).(Gale, et al 2008) 
NPM1 mutation seems quite consistent with disease status.(Chou, et al 2007, Schnittger, et al 
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mutations are observed in 7% to 18% of patients with AML.(Frohling, et al 2004, Lin, et al 
2005, Pabst, et al 2001b, Preudhomme, et al 2002) Two major types of CEBPA mutations have 
been identified; one alters COOH terminal bZIP of CEBPA, resulting in decreased DNA-
binding and/or dimerization activity and the other disrupts translation of the C/EBP NH2 
terminus, thereby up-regulates an alternative 30-kDa isoform with dominant-negative effect 
on the full-length wild-type C/EBP.(Koschmieder, et al 2009, Lin, et al 1993, Pabst, et al 
2001b) Most patients with CEBPA mutations harbored biallelic mutations involving both the 
NH2-terminal TAD region and the COOH-terminal bZIP domain.(Hou, et al 2009, Lin, et al 
2005, Pabst, et al 2009, Renneville, et al 2009a) CEBPA mutations occur most frequently in 
patients with FAB subtype M2, and are closely associated with CD7, CD15, CD34, and HLA-
DR expression on the leukemic cells, higher circulatory blasts and normal 
cytogenetics.(Frohling, et al 2004, Lin, et al 2005, Pabst, et al 2001a, Zhang, et al 1997) This 
mutation seems quite stable during AML evolution and may be a potential marker to 
monitor MRD. The fact that none of the AML patients who do not have CEBPA mutations at 
diagnosis acquire the mutation at relapse suggests that this mutation may not play a major 
role in the progression of AML.(Lin, et al 2005, Tiesmeier, et al 2003) Several studies have 
shown mutant CEBPA predicts favorable outcome in AML patients with intermediate or 
normal cytogenetics.(Barjesteh van Waalwijk van Doorn-Khosrovani, et al 2003, Bienz, et al 
2005, Frohling, et al 2004, Preudhomme, et al 2002) The favorable impact of CEBPA 
mutations in the AML patients is only observed in the absence of FLT3/ITD or other 
associated cytogenetic abnormalities.(Renneville, et al 2009a) Moreover, only double CEBPA 
mutations, but not single CEBPA mutation, are associated with better prognosis and define a 
distinct genetic entity.(Dufour, et al 2010, Hou, et al 2009, Pabst, et al 2009, Wouters, et al 
2009)         
3.2 MLL -PTD 
The MLL partial tandem duplication (MLL-PTD) most commonly results from a duplication 
of a genomic region encompassing exon 5 through exon 11/12 and insertion of the 
duplicated segment into intron 4 of the full-length MLL gene.(Caligiuri, et al 1994, 
Schichman, et al 1994, Whitman, et al 2005) The duplication involves a portion of the gene 
corresponding to the amino terminus of the MLL protein which contains the AT hook and a 
region of homology to DNA methyltransferase motifs.(Schichman, et al 1995) The 
mechanism by which MLL-PTD contributes to leukemic phenotype is not clear, but may be 
through silencing of the wild-type MLL by epigenetic mechanisms.(Dimartino and Cleary 
1999, Whitman, et al 2005) This mutation is found in 5-12% of patients with cytogenetically 
normal AML (CN-AML),(Dohner, et al 2002, Munoz, et al 2003, Schnittger, et al 2000, Shiah, 
et al 2002) and up to 54% of AML patients with trisomy 11.(Rege-Cambrin, et al 2005) 
Compared with patients without MLL-PTD, patients with this mutation more often have 
FAB M2 subtype, CD11b expression, wild-type NPM1 and high BAALC expression, but 
lower WBC counts, less frequently extramedullary involvement and FAB M4/M5 subtype at 
diagnosis.(Shiah, et al 2002, Whitman, et al 2007) The presence of MLL-PTD predicts shorter 
remission duration and worse OS;(Dohner, et al 2002, Munoz, et al 2003, Shiah, et al 2002) 
however, more intensive consolidation therapy that includes hematopoietic stem cell 
transplantation (HSCT) during first complete remission (CR) may reverse the poor 
prognosis conferred by this mutation.(Whitman, et al 2007)  
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3.3 AML1/RUNX1  
The AML1/RUNX1 gene(Ito 2008), consisting of 10 exons (exons 1-6, 7A, 7B, 7C and 8), is one 
of the most frequently deregulated genes in leukemia through chromosomal translocations 
and point mutations.(Friedman 2009, Niebuhr, et al 2008, Osato 2004, Yamagata, et al 2005) 
Monoallelic germ-line mutation of the RUNX1 gene occurs in rare cases of familial platelet 
disorder with predisposition to AML (FPD/AML).(Michaud, et al 2002) Acquired RUNX1 
mutation was frequently reported in therapy-related MDS or MDS/AML.(Harada, et al 
2004) The incidence of RUNX1 mutation in AML varies from 2.9% to 46% depending on the 
population selected, the regions of RUNX1 screened, and the methods used.(Dicker, et al 
2007, Preudhomme, et al 2000, Tang, et al 2009) In a large cohort study of 470 adult patients 
with de novo non-M3 AML, we detected RUNX1 mutation in 13.2% of cases. The RUNX1 
mutation is closely associated with older age, immature FAB subtypes (M0/M1) and specific 
cytogenetic abnormalities such as trisomy 8 (+8), +13, or +21.(Dicker, et al 2007, Schnittger, et 
al 2011, Tang, et al 2009) None of the patients with t(8;21), inv(16), t(15;17) or 11q23 
translocation shows RUNX1 mutation.(Tang, et al 2009) One half of RUNX1-mutated 
patients have concurrently other gene mutations, mostly (83.9%) Class I mutations, 
especially FLT3/ITD, FLT3/TKD and N-RAS mutations(Tang, et al 2009) which all result in 
hyperactivation of the receptor tyrosine kinase (RTK)-RAS signalling pathways.(Niimi, et al 
2006) This finding is consistent with the two-hit model of leukemogenesis.(Frohling, et al 
2005, Gilliland 2002) Further, the RUNX1 mutation is mutually exclusive with CEBPA and 
NPM1 mutations, but closely associated with MLL/PTD.(Schnittger, et al 2011, Tang, et al 
2009) The mutation may be lost at relapse in RUNX1-mutated patients, but none of the 
patients who do not harbor RUNX1 mutation at diagnosis acquire novel mutation at 
relapse.(Tang, et al 2009) RUNX1 mutation is an independent poor-risk factor for DFS and 
OS in de novo AML patients.(Gaidzik, et al 2011, Schnittger, et al 2011, Tang, et al 2009) In 
addition, HSCT seems to ameliorate the poor survival impact of RUNX1 
mutations.(Gaidzik, et al 2011, Tang, et al 2009) 
4. Other mutations  
4.1 NPM1 mutations 
NPM1 mutation in AML was first identified by Dr. Falini’s group, who noticed that some 
AML patients’ leukemia cells exhibited aberrant cytoplasmic localization of NPM1 protein, 
which normally located in nucleoli in non-mitotic cells.(Falini, et al 2005) Subsequent 
investigation revealed a tetra-nucleotide insertion near the C-terminal end of the coding 
sequence of NPM1. The most frequent form of mutation is duplication of TCTG (type A, 
c.860_863dupTCTG), resulting in alteration of the peptide sequence from DLWQWRKSL* to 
DLCL AVEEVSLRK*. NPM1 mutation occurs in about 30% of AML, more frequently in 
elder patients,(Falini, et al 2011, Falini, et al 2005) and is highly associated with normal 
karyotype, and FLT3/ITD, but significantly exclusive with CEBPA mutation, favorable 
karyotype, and expression of CD34 and HLA-DR.(Boissel, et al 2005, Chou, et al 2006, 
Dohner, et al 2005, Falini, et al 2005, Schnittger, et al 2005, Suzuki, et al 2005, Verhaak, et al 
2005)  NPM1 mutation generally renders better prognosis,(Falini, et al 2005) especially when 
FLT3-ITD is absent.(Schlenk, et al 2008, Thiede, et al 2006) Further refinement of patient 
groups disclosed 3 groups with distinct prognosis: good (NPM1+/FLT3-ITD-), intermediate 
(NPM1+/FLT3-ITD+ or NPM1-/FLT3-ITD-), and poor (NPM1-/FLT3-ITD+).(Gale, et al 2008) 
NPM1 mutation seems quite consistent with disease status.(Chou, et al 2007, Schnittger, et al 
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2009) Serial analyses of NPM1 mutations showed the mutation disappeared at CR, but the 
same mutation usually reappeared at relapse. This feature makes NPM1 mutation an ideal 
marker for MRD monitoring. Studies have shown NPM1 mutant levels reflect disease status, 
predict impending relapse, and bring prognostic implication.(Chou, et al 2007, Gorello, et al 
2006, Kronke, et al 2011, Schnittger, et al 2009) 
4.2 WT1 mutations  
The Wilms’ Tumor 1 (WT1) gene, encoding a zinc-finger transcription factor, is 
physiologically expressed in hematopoietic stem cells and involved in regulation of cellular 
growth and differentiation.(Baird and Simmons 1997, Ellisen, et al 2001) WT1 was initially 
identified as a tumor suppressor gene,(Haber, et al 1990) but was later found to be 
overexpressed in AML as well as other cancers and thus was suggested to be an 
oncogene.(Bergmann, et al 1997, King-Underwood, et al 1996, Miwa, et al 1992) Mutations in 
WT1 gene are found in about 7-13% of CN-AML patients with hotspots in the four Cys-His 
zinc finger domains on exons 7 and 9.(Gaidzik, et al 2009, Hou, et al 2010, King-Underwood, 
et al 1996, Paschka, et al 2008, Virappane, et al 2008) The precise role of WT1 mutations in the 
leukemogenesis remains to be defined. The majority of WT1 mutations are frame-shift 
mutations occurring in exon 7, followed by single amino acid substitutions in exon 9; 
whereas frame-shift mutations in exon 9 are rare. WT1 mutations occur with similar 
frequencies in patients with normal karyotype and those with abnormal cytogenetics.(Hou, 
et al 2010) Chromosomal abnormality t(7;11)(p15;15), a translocation resulting in 
NUP98/HOXA9 fusion, is closely associated with WT1 mutation.(Hou, et al 2010) WT1 
mutations are positively associated with FLT3/ITD and CEBPA mutations.(Gaidzik, et al 
2009, Renneville, et al 2009b) Paschka et al showed patients with WT1 mutations had higher 
expression of ERG and BAALC than patients without.(Paschka, et al 2008) WT1 mutation is 
an independent poor prognostic factor in CN-AML as well as total AML patients.(Hou, et al 
2010, Paschka, et al 2008, Renneville, et al 2009b, Virappane, et al 2008), though different 
results have been reported.(Gaidzik, et al 2009, Santamaria, et al 2009)   
5. Mutations of genes that involve epigenetic modifications 
Different from genetic abnormalities which result in DNA sequence changes, epigenetic 
dysregulation causes aberrant gene expression without alteration of gene sequences.(Baylin 
and Ohm 2006, Chen, et al 2010, Jones and Baylin 2002) Epigenetic regulation includes DNA 
methylation, histone modifications, such as methylation, acetylation and phosphorylation, 
etc, and microRNA expression. (Baylin and Ohm 2006, Chen, et al 2010, Jones and Baylin 
2002) The recent findings that mutations of genes related to epigenetic modifications, such 
as IDH1, IDH2, TET2, ASXL1 and DNMT3A, are detected in AML patients provide new 
insights into mechanisms of epigenetic deregulation in the leukemogenesis.  
5.1 TET2 mutations  
TET2 protein can catalyze the conversion of 5-methylcytosine (5-mC) of DNA to 5-
hydroxymethylcytosine (5-hmC), with ferrous iron and α-ketoglutarate (α-KG) as cofactors, 
indicating a role of TET2 in DNA methylation.(Ito, et al 2010) Mutations of TET2 result in 
global DNA hypermethylation.(Figueroa, et al 2010) TET2 mutation was originally identified 
in myeloid malignancies via single nucleotide polymorphism and comparative genomic-
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hybridization array, which revealed common deletion of this gene in chromosome 
4q.(Delhommeau, et al 2009) Subsequent studies confirmed this mutation in MDS, MPN, 
MDS/MPN, and secondary AML, with frequencies around 10% to 26%, 7% to 13%, 22% to 
58% and 24% to 32%, respectively.(Bacher, et al 2010, Couronne, et al 2010, Flach, et al 2010, 
Jankowska, et al 2009, Kosmider, et al 2009a, Kosmider, et al 2009b, Langemeijer, et al 2009, 
Saint-Martin, et al 2009, Schaub, et al 2010, Smith, et al 2010, Tefferi, et al 2009a, Tefferi, et al 
2009b) TET2 mutation occurs in 18.0% to 23% of CN-AML patients.(Chou, et al 2011a, 
Metzeler, et al 2011) It is closely associated with older age, higher WBC count, but mutually 
exclusive with IDH mutation.(Chou, et al 2011a, Metzeler, et al 2011) In our study of AML 
patients with and without chromosomal abnormalities, TET2 mutation was also found to be 
positively associated with normal karyotype, intermediate-risk cytogenetics, isolated 
trisomy 8, NPM1 mutation, and ASXL1 mutation.(Chou, et al 2011a) In European 
LeukemiaNet (ELN) favorable-risk group (patients with CN-AML with mutated CEBPA 
and/or mutated NPM1 without FLT3-ITD),(Dohner, et al 2010) but not intermediate-1 risk 
group (CN-AML with wild-type CEBPA and wild-type NPM1 and/or FLT3-ITD), TET2-
mutated patients were found to have a lower CR rate, shorter DFS and OS, compared with 
TET2-wild type patients.(Metzeler, et al 2011) However, we did not have the same finding, 
but found that TET2 mutation was an unfavorable prognostic factor in patients with 
intermediate-risk cytogenetics, and its negative impact was further enhanced when the 
mutation was combined with FLT3-ITD, NPM1-wild, or unfavorable genotypes (other than 
ELN favorable-risk group).(Chou, et al 2011a) More studies are needed to clarify the 
prognostic implication of TET2 mutations in AML. 
5.2 IDH mutations  
IDH1 and IDH2 genes encode two isoforms of isocitrate dehydrogenase which catalyzes the 
carboxylation of isocitrate to α-KG. IDH1 and IDH2 mutations were first detected in patients 
with brain tumors.(Parsons, et al 2008) Later, IDH1 mutations (Mardis, et al 2009) and then 
IDH2 mutations were discovered in AML patients, too.(Abbas, et al 2010, Marcucci, et al 
2010, Ward, et al 2010) IDH1 mutations affect arginine residue in position 132 (R132) and 
IDH2 mutations, in R140 and R172 of exon 4. IDH mutations occur at low frequencies (3.6% 
to 5%) in MDS,(Kosmider, et al 2010) and in chronic-phase MPN (about 1.8%)(Pardanani, et 
al 2010), but obviously increased as these diseases progress to AML (7.5% to 
21%),(Kosmider, et al 2010, Pardanani, et al 2010) indicating a role of IDH mutations in 
leukemogenesis. In de novo AML, IDH2 mutations occur more frequently than IDH1 
mutations, with frequencies of 11% vs. 6% in patients younger than 60 years,(Abbas, et al 
2010) 15.4% vs. 7.7% in total patients,(Ward, et al 2010) and 19% vs. 14% in adults with 
normal karyotype.(Marcucci, et al 2010) The underlying mechanism of IDH mutations in the 
leukemogenesis of AML remains to be determined, but several implications of IDH1/2 
mutations in AML have been generated. First, IDH mutations are loss-of-function 
mutations, as mutant IDH proteins show decreased enzyme activities,(Zhao, et al 2009) and 
have dominant-negative effects on wild type IDH upon homodimerization.(Zhao, et al 2009) 
Secondly, IDH mutations are also gain-of-function mutations because the mutant proteins 
can convert α-KG to 2-hydroxyglutarate (2-HG), a metabolite that may contribute to tumor 
growth through activating hypoxia-inducing factor-1α (HIF-1α).(Dang, et al 2009, Reitman, 
et al 2010, Ward, et al 2010) Thirdly, IDH mutations reduce production of α-KG, a cofactor of 
TET2, thus impair catalytic function of TET2 resulting in global DNA hypermethylation, 
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2009) Serial analyses of NPM1 mutations showed the mutation disappeared at CR, but the 
same mutation usually reappeared at relapse. This feature makes NPM1 mutation an ideal 
marker for MRD monitoring. Studies have shown NPM1 mutant levels reflect disease status, 
predict impending relapse, and bring prognostic implication.(Chou, et al 2007, Gorello, et al 
2006, Kronke, et al 2011, Schnittger, et al 2009) 
4.2 WT1 mutations  
The Wilms’ Tumor 1 (WT1) gene, encoding a zinc-finger transcription factor, is 
physiologically expressed in hematopoietic stem cells and involved in regulation of cellular 
growth and differentiation.(Baird and Simmons 1997, Ellisen, et al 2001) WT1 was initially 
identified as a tumor suppressor gene,(Haber, et al 1990) but was later found to be 
overexpressed in AML as well as other cancers and thus was suggested to be an 
oncogene.(Bergmann, et al 1997, King-Underwood, et al 1996, Miwa, et al 1992) Mutations in 
WT1 gene are found in about 7-13% of CN-AML patients with hotspots in the four Cys-His 
zinc finger domains on exons 7 and 9.(Gaidzik, et al 2009, Hou, et al 2010, King-Underwood, 
et al 1996, Paschka, et al 2008, Virappane, et al 2008) The precise role of WT1 mutations in the 
leukemogenesis remains to be defined. The majority of WT1 mutations are frame-shift 
mutations occurring in exon 7, followed by single amino acid substitutions in exon 9; 
whereas frame-shift mutations in exon 9 are rare. WT1 mutations occur with similar 
frequencies in patients with normal karyotype and those with abnormal cytogenetics.(Hou, 
et al 2010) Chromosomal abnormality t(7;11)(p15;15), a translocation resulting in 
NUP98/HOXA9 fusion, is closely associated with WT1 mutation.(Hou, et al 2010) WT1 
mutations are positively associated with FLT3/ITD and CEBPA mutations.(Gaidzik, et al 
2009, Renneville, et al 2009b) Paschka et al showed patients with WT1 mutations had higher 
expression of ERG and BAALC than patients without.(Paschka, et al 2008) WT1 mutation is 
an independent poor prognostic factor in CN-AML as well as total AML patients.(Hou, et al 
2010, Paschka, et al 2008, Renneville, et al 2009b, Virappane, et al 2008), though different 
results have been reported.(Gaidzik, et al 2009, Santamaria, et al 2009)   
5. Mutations of genes that involve epigenetic modifications 
Different from genetic abnormalities which result in DNA sequence changes, epigenetic 
dysregulation causes aberrant gene expression without alteration of gene sequences.(Baylin 
and Ohm 2006, Chen, et al 2010, Jones and Baylin 2002) Epigenetic regulation includes DNA 
methylation, histone modifications, such as methylation, acetylation and phosphorylation, 
etc, and microRNA expression. (Baylin and Ohm 2006, Chen, et al 2010, Jones and Baylin 
2002) The recent findings that mutations of genes related to epigenetic modifications, such 
as IDH1, IDH2, TET2, ASXL1 and DNMT3A, are detected in AML patients provide new 
insights into mechanisms of epigenetic deregulation in the leukemogenesis.  
5.1 TET2 mutations  
TET2 protein can catalyze the conversion of 5-methylcytosine (5-mC) of DNA to 5-
hydroxymethylcytosine (5-hmC), with ferrous iron and α-ketoglutarate (α-KG) as cofactors, 
indicating a role of TET2 in DNA methylation.(Ito, et al 2010) Mutations of TET2 result in 
global DNA hypermethylation.(Figueroa, et al 2010) TET2 mutation was originally identified 
in myeloid malignancies via single nucleotide polymorphism and comparative genomic-
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hybridization array, which revealed common deletion of this gene in chromosome 
4q.(Delhommeau, et al 2009) Subsequent studies confirmed this mutation in MDS, MPN, 
MDS/MPN, and secondary AML, with frequencies around 10% to 26%, 7% to 13%, 22% to 
58% and 24% to 32%, respectively.(Bacher, et al 2010, Couronne, et al 2010, Flach, et al 2010, 
Jankowska, et al 2009, Kosmider, et al 2009a, Kosmider, et al 2009b, Langemeijer, et al 2009, 
Saint-Martin, et al 2009, Schaub, et al 2010, Smith, et al 2010, Tefferi, et al 2009a, Tefferi, et al 
2009b) TET2 mutation occurs in 18.0% to 23% of CN-AML patients.(Chou, et al 2011a, 
Metzeler, et al 2011) It is closely associated with older age, higher WBC count, but mutually 
exclusive with IDH mutation.(Chou, et al 2011a, Metzeler, et al 2011) In our study of AML 
patients with and without chromosomal abnormalities, TET2 mutation was also found to be 
positively associated with normal karyotype, intermediate-risk cytogenetics, isolated 
trisomy 8, NPM1 mutation, and ASXL1 mutation.(Chou, et al 2011a) In European 
LeukemiaNet (ELN) favorable-risk group (patients with CN-AML with mutated CEBPA 
and/or mutated NPM1 without FLT3-ITD),(Dohner, et al 2010) but not intermediate-1 risk 
group (CN-AML with wild-type CEBPA and wild-type NPM1 and/or FLT3-ITD), TET2-
mutated patients were found to have a lower CR rate, shorter DFS and OS, compared with 
TET2-wild type patients.(Metzeler, et al 2011) However, we did not have the same finding, 
but found that TET2 mutation was an unfavorable prognostic factor in patients with 
intermediate-risk cytogenetics, and its negative impact was further enhanced when the 
mutation was combined with FLT3-ITD, NPM1-wild, or unfavorable genotypes (other than 
ELN favorable-risk group).(Chou, et al 2011a) More studies are needed to clarify the 
prognostic implication of TET2 mutations in AML. 
5.2 IDH mutations  
IDH1 and IDH2 genes encode two isoforms of isocitrate dehydrogenase which catalyzes the 
carboxylation of isocitrate to α-KG. IDH1 and IDH2 mutations were first detected in patients 
with brain tumors.(Parsons, et al 2008) Later, IDH1 mutations (Mardis, et al 2009) and then 
IDH2 mutations were discovered in AML patients, too.(Abbas, et al 2010, Marcucci, et al 
2010, Ward, et al 2010) IDH1 mutations affect arginine residue in position 132 (R132) and 
IDH2 mutations, in R140 and R172 of exon 4. IDH mutations occur at low frequencies (3.6% 
to 5%) in MDS,(Kosmider, et al 2010) and in chronic-phase MPN (about 1.8%)(Pardanani, et 
al 2010), but obviously increased as these diseases progress to AML (7.5% to 
21%),(Kosmider, et al 2010, Pardanani, et al 2010) indicating a role of IDH mutations in 
leukemogenesis. In de novo AML, IDH2 mutations occur more frequently than IDH1 
mutations, with frequencies of 11% vs. 6% in patients younger than 60 years,(Abbas, et al 
2010) 15.4% vs. 7.7% in total patients,(Ward, et al 2010) and 19% vs. 14% in adults with 
normal karyotype.(Marcucci, et al 2010) The underlying mechanism of IDH mutations in the 
leukemogenesis of AML remains to be determined, but several implications of IDH1/2 
mutations in AML have been generated. First, IDH mutations are loss-of-function 
mutations, as mutant IDH proteins show decreased enzyme activities,(Zhao, et al 2009) and 
have dominant-negative effects on wild type IDH upon homodimerization.(Zhao, et al 2009) 
Secondly, IDH mutations are also gain-of-function mutations because the mutant proteins 
can convert α-KG to 2-hydroxyglutarate (2-HG), a metabolite that may contribute to tumor 
growth through activating hypoxia-inducing factor-1α (HIF-1α).(Dang, et al 2009, Reitman, 
et al 2010, Ward, et al 2010) Thirdly, IDH mutations reduce production of α-KG, a cofactor of 
TET2, thus impair catalytic function of TET2 resulting in global DNA hypermethylation, 
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similar to the effect of TET2 mutations. 2-HG converted from α-KG in IDH-mutated cells is 
also shown to inhibit TET2-mediated hydroxymethylation of cytosine, indicating 
overlapping effects of these two mutations.(Xu, et al 2011) Compatible with this, IDH and 
TET2 mutations are mutually exclusive in AML patients.(Figueroa, et al 2010, Metzeler, et al 
2011) 
Studies have shown similar clinical features between AML with IDH1 and IDH2 mutations, 
including strong association of both mutations with normal karyotype and isolated 
monosomy 8, but inverse correlation with expression of HLA-DR. However, some 
differences exist. IDH1 mutation shows strong correlation with NPM1 mutation, and FAB 
M1 subtype, but is inversely associated with FAB M4 subtype and expression of CD13 and 
CD14. On the other hand, mutation of IDH2 is associated with higher platelet counts, but is 
inversely correlated with expression of CD34, CD15, CD7, and CD56, and is mutually 
exclusive with WT1 mutation and chromosomal translocations involving CBF. While there is 
no impact of IDH1 mutation on patient survival, multivariate analysis reveals IDH2 
mutation as an independent favorable prognostic factor,(Chou, et al 2010a, Chou, et al 
2011c,) but different results have also been reported.(Marcucci, et al 2010, Thol, et al 2010) 
More intriguing are the differences of clinical presentations between patients with R140 and 
R172 mutations. Compared with IDH2 R140 mutation, IDH2 R172 mutation is associated 
with younger age, lower WBC count and LDH level, and is mutually exclusive with NPM1 
mutation. Recent studies also reported worse prognosis in AML patients bearing IDH2 
R172Q,(Boissel, et al 2010, Marcucci, et al 2010) while IDH2 R140Q, in the contrary, conferred 
a better prognosis.(Green, et al 2010) Why mutations in different isoforms or loci of the same 
gene render distinct clinical and prognostic features remains to be investigated. Serial 
analyses of IDH1/2 mutations at both diagnosis and relapse confirmed high stability of these 
two mutations.(Chou, et al 2010a, Chou, et al 2011c)   
5.3 ASXL1 mutations  
Recently, mutations in exon 12 of Additional sex comb-like 1 (ASXL1) gene were found in 
various types of myeloid malignances, including MDS, MPN, MDS/MPN, and 
AML.(Abdel-Wahab, et al 2010, Boultwood, et al 2010, Carbuccia, et al 2009, Carbuccia, et al 
2010, Gelsi-Boyer, et al 2009) ASXL1, a human homologue of the Additional sex combs (Asx) 
gene of Drosophila, mapped to chromosome 20q11, a region commonly involved in 
cancers.(Fisher, et al 2003) It consists of an N-terminal ASX Homology (ASXH) domain and a 
C-terminal plant homeodomain (PHD) zinc finger region.(Fisher, et al 2003, Fisher, et al 
2006) In human, the exact function of ASXL1 mutation remains to be defined, but it is 
involved in regulation of histone methylation by cooperation with heterochromatin protein-
1 (HP1) to modulate the activity of LSD1, a histone demethylase for H3K4 and H3K9.(Dange 
and Colman 2010, Wang, et al 2009) ASXL1 mutations in exon 12 are found with an 
incidence of 10.8%, 8.9% and 12.9% among total cohort of patients with de novo AML, those 
with normal karyotype and abnormal cytogenetics, respectively.(Chou, et al 2010b)  Most of 
the mutations appear to be either non-sense or frame-shift mutations, leading to disruption 
of the plant hoemodomain (PHD) at the C terminal of ASXL1, which is well conserved 
among different species and can recognize methylated H3K4.(Abdel-Wahab, et al 2010, 
Fisher, et al 2003, Pena, et al 2006, Shi, et al 2006, Wysocka, et al 2006) Up to two thirds of 
mutations occurred at c.1934dupG (an extra G after 1934th nucleotide of the coding sequence 
of ASXL1) causing G646WfsX12 (change of glycine to tryptophan at amino acid 646, with a 
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premature stop codon after another 11 amino acid).(Chou, et al 2010b) The mutation was 
closely associated with older age, male gender, isolated trisomy 8, RUNX1 mutation, and 
expression of HLA-DR and CD34, but inversely associated with t(15;17), complex 
cytogenetics, FLT3-ITD, NPM1 mutations, WT1 mutations, and expression of CD33 and 
CD15.(Chou, et al 2010b) Patients with ASXL1 mutations had a shorter OS than those 
without, but the mutation was not an independent adverse prognostic factor in multivariate 
analysis. Sequential analyses showed that the original ASXL1 mutations could disappear at 
relapse and/or refractory status in some patients.  Moreover, two out of the 109 ASXL1-wild 
patients acquired a novel ASXL1 mutation at relapse.(Chou, et al 2010b) Thus, the ASXL1 
mutation status can change during disease evolution in a few patients.  
5.4 DNMT3A mutations  
By whole genome sequencing on a single patient with normal cytogenetics, Ley and his 
colleagues found a mutation in DNMT3A gene, which encodes the enzyme DNA 
methyltransferase 3A which belongs to the family of DNMTs that catalyze the addition of 
methyl group to cytosine of CpG dinucleotide.(Ley, et al 2010) In this seminal study, 
DNMT3A mutation was detected in 22.1% of AML patients. Most of the mutations occurred 
at R882 amino acid. Others included mis-sense, non-sense and frame-shift mutations. 
Although DNMT3A is directly related to DNA methylation, the real significance of this 
mutation to leukemogenesis remains unknown. First, the wide spreading of mutation spots 
in DNMT3A suggests a loss-of-function mutation, but the remarkable aggregate of mutation 
at R882 implies a gain of function. Reduction of DNA methylation in 182 genomic areas was 
noted in R882 mutation-harboring AML cells, however, the methylation patterns of vast 
majority of cytosine methylation regions are the same as wild type.(Ley, et al 2010)  
DNMT3A mutations are associated with intermediate or normal cytogenetics, higher WBC 
counts, FAB M4/M5 subtypes, and FLT3-ITD, NPM1, and IDH1 mutations but mutually 
exclusive with favorable karyotypes.(Ley, et al 2010, Thol, et al 2011) In our study of 500 
AML patients, DNMT3A mutations were identified in 14% of total patients and 22.9% of 
patients with CN-AML. (Hou, et al 2011) In addition to the findings shown in previous 
reports, (Ley, et al 2010, Thol, et al 2011) we for the first time identified the DNMT3A 
mutation was positively associated with PTPN11 and IDH2 mutations, but negatively 
associated with CEBPA mutation.(Hou, et al 2011) Intriguingly, the majority (97.1%) of the 
DNMT3A-mutated patients showed additional molecular alterations at diagnosis. This 
mutation renders poor OS among all AML patients, patients with a normal karyotype, and 
those with FLT3-ITD.(Hou, et al 2011, Ley, et al 2010, Thol, et al 2011) Importantly, DNMT3A 
mutation is an independent poor prognostic factor. Further, DNMT3A mutation is rather 
stable during disease progression and can be a potential biomarker for monitoring of 
MRD.(Hou, et al 2011)  
6. Gene mutations as markers to monitor Minimal Residual Disease (MRD)  
Since gene mutations are theoretically absent in healthy people and restricted in leukemia 
cells, it is reasonably to monitor MRD by detection of gene mutations. This is an advantage 
of leukemia over solid tumors in that leukemia cells are indigenous to blood and marrow, 
which are easy for access. There are two critical considerations of MRD monitoring by gene 
mutations: one is the stability of the mutations, and the other is the pattern of mutation. An 
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similar to the effect of TET2 mutations. 2-HG converted from α-KG in IDH-mutated cells is 
also shown to inhibit TET2-mediated hydroxymethylation of cytosine, indicating 
overlapping effects of these two mutations.(Xu, et al 2011) Compatible with this, IDH and 
TET2 mutations are mutually exclusive in AML patients.(Figueroa, et al 2010, Metzeler, et al 
2011) 
Studies have shown similar clinical features between AML with IDH1 and IDH2 mutations, 
including strong association of both mutations with normal karyotype and isolated 
monosomy 8, but inverse correlation with expression of HLA-DR. However, some 
differences exist. IDH1 mutation shows strong correlation with NPM1 mutation, and FAB 
M1 subtype, but is inversely associated with FAB M4 subtype and expression of CD13 and 
CD14. On the other hand, mutation of IDH2 is associated with higher platelet counts, but is 
inversely correlated with expression of CD34, CD15, CD7, and CD56, and is mutually 
exclusive with WT1 mutation and chromosomal translocations involving CBF. While there is 
no impact of IDH1 mutation on patient survival, multivariate analysis reveals IDH2 
mutation as an independent favorable prognostic factor,(Chou, et al 2010a, Chou, et al 
2011c,) but different results have also been reported.(Marcucci, et al 2010, Thol, et al 2010) 
More intriguing are the differences of clinical presentations between patients with R140 and 
R172 mutations. Compared with IDH2 R140 mutation, IDH2 R172 mutation is associated 
with younger age, lower WBC count and LDH level, and is mutually exclusive with NPM1 
mutation. Recent studies also reported worse prognosis in AML patients bearing IDH2 
R172Q,(Boissel, et al 2010, Marcucci, et al 2010) while IDH2 R140Q, in the contrary, conferred 
a better prognosis.(Green, et al 2010) Why mutations in different isoforms or loci of the same 
gene render distinct clinical and prognostic features remains to be investigated. Serial 
analyses of IDH1/2 mutations at both diagnosis and relapse confirmed high stability of these 
two mutations.(Chou, et al 2010a, Chou, et al 2011c)   
5.3 ASXL1 mutations  
Recently, mutations in exon 12 of Additional sex comb-like 1 (ASXL1) gene were found in 
various types of myeloid malignances, including MDS, MPN, MDS/MPN, and 
AML.(Abdel-Wahab, et al 2010, Boultwood, et al 2010, Carbuccia, et al 2009, Carbuccia, et al 
2010, Gelsi-Boyer, et al 2009) ASXL1, a human homologue of the Additional sex combs (Asx) 
gene of Drosophila, mapped to chromosome 20q11, a region commonly involved in 
cancers.(Fisher, et al 2003) It consists of an N-terminal ASX Homology (ASXH) domain and a 
C-terminal plant homeodomain (PHD) zinc finger region.(Fisher, et al 2003, Fisher, et al 
2006) In human, the exact function of ASXL1 mutation remains to be defined, but it is 
involved in regulation of histone methylation by cooperation with heterochromatin protein-
1 (HP1) to modulate the activity of LSD1, a histone demethylase for H3K4 and H3K9.(Dange 
and Colman 2010, Wang, et al 2009) ASXL1 mutations in exon 12 are found with an 
incidence of 10.8%, 8.9% and 12.9% among total cohort of patients with de novo AML, those 
with normal karyotype and abnormal cytogenetics, respectively.(Chou, et al 2010b)  Most of 
the mutations appear to be either non-sense or frame-shift mutations, leading to disruption 
of the plant hoemodomain (PHD) at the C terminal of ASXL1, which is well conserved 
among different species and can recognize methylated H3K4.(Abdel-Wahab, et al 2010, 
Fisher, et al 2003, Pena, et al 2006, Shi, et al 2006, Wysocka, et al 2006) Up to two thirds of 
mutations occurred at c.1934dupG (an extra G after 1934th nucleotide of the coding sequence 
of ASXL1) causing G646WfsX12 (change of glycine to tryptophan at amino acid 646, with a 
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premature stop codon after another 11 amino acid).(Chou, et al 2010b) The mutation was 
closely associated with older age, male gender, isolated trisomy 8, RUNX1 mutation, and 
expression of HLA-DR and CD34, but inversely associated with t(15;17), complex 
cytogenetics, FLT3-ITD, NPM1 mutations, WT1 mutations, and expression of CD33 and 
CD15.(Chou, et al 2010b) Patients with ASXL1 mutations had a shorter OS than those 
without, but the mutation was not an independent adverse prognostic factor in multivariate 
analysis. Sequential analyses showed that the original ASXL1 mutations could disappear at 
relapse and/or refractory status in some patients.  Moreover, two out of the 109 ASXL1-wild 
patients acquired a novel ASXL1 mutation at relapse.(Chou, et al 2010b) Thus, the ASXL1 
mutation status can change during disease evolution in a few patients.  
5.4 DNMT3A mutations  
By whole genome sequencing on a single patient with normal cytogenetics, Ley and his 
colleagues found a mutation in DNMT3A gene, which encodes the enzyme DNA 
methyltransferase 3A which belongs to the family of DNMTs that catalyze the addition of 
methyl group to cytosine of CpG dinucleotide.(Ley, et al 2010) In this seminal study, 
DNMT3A mutation was detected in 22.1% of AML patients. Most of the mutations occurred 
at R882 amino acid. Others included mis-sense, non-sense and frame-shift mutations. 
Although DNMT3A is directly related to DNA methylation, the real significance of this 
mutation to leukemogenesis remains unknown. First, the wide spreading of mutation spots 
in DNMT3A suggests a loss-of-function mutation, but the remarkable aggregate of mutation 
at R882 implies a gain of function. Reduction of DNA methylation in 182 genomic areas was 
noted in R882 mutation-harboring AML cells, however, the methylation patterns of vast 
majority of cytosine methylation regions are the same as wild type.(Ley, et al 2010)  
DNMT3A mutations are associated with intermediate or normal cytogenetics, higher WBC 
counts, FAB M4/M5 subtypes, and FLT3-ITD, NPM1, and IDH1 mutations but mutually 
exclusive with favorable karyotypes.(Ley, et al 2010, Thol, et al 2011) In our study of 500 
AML patients, DNMT3A mutations were identified in 14% of total patients and 22.9% of 
patients with CN-AML. (Hou, et al 2011) In addition to the findings shown in previous 
reports, (Ley, et al 2010, Thol, et al 2011) we for the first time identified the DNMT3A 
mutation was positively associated with PTPN11 and IDH2 mutations, but negatively 
associated with CEBPA mutation.(Hou, et al 2011) Intriguingly, the majority (97.1%) of the 
DNMT3A-mutated patients showed additional molecular alterations at diagnosis. This 
mutation renders poor OS among all AML patients, patients with a normal karyotype, and 
those with FLT3-ITD.(Hou, et al 2011, Ley, et al 2010, Thol, et al 2011) Importantly, DNMT3A 
mutation is an independent poor prognostic factor. Further, DNMT3A mutation is rather 
stable during disease progression and can be a potential biomarker for monitoring of 
MRD.(Hou, et al 2011)  
6. Gene mutations as markers to monitor Minimal Residual Disease (MRD)  
Since gene mutations are theoretically absent in healthy people and restricted in leukemia 
cells, it is reasonably to monitor MRD by detection of gene mutations. This is an advantage 
of leukemia over solid tumors in that leukemia cells are indigenous to blood and marrow, 
which are easy for access. There are two critical considerations of MRD monitoring by gene 
mutations: one is the stability of the mutations, and the other is the pattern of mutation. An 
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ideal MRD marker should be very consistent with disease status, while those that may 
disappear after disease evolution are not suitable for this purpose. Also, if the mutation 
appears as a point mutation, probably only qualitative rather than absolute quantitative 
measurement can be achieved because of inevitable background signals due to minimal 
sequence differences between wild-type and mutant alleles. Moreover, if the mutation 
occurs sporadically across the whole coding sequence without a hot spot, the absolute 
quantification techniques (usually fluorescence-based real-time PCR) would become very 
cumbersome. 
Among the mutations in AML, NPM1 mutation is perhaps the most useful and intensively 
studied marker of MRD because this mutation is quite stable, relatively prevalent, highly 
concentrated at a hot spot, and has 4 nucleotide insertion, which can be clearly 
discriminated from the wild-type allele in quantitative real-time PCR.(Chou, et al 2007, 
Schnittger, et al 2009) Studies have shown NPM1 mutant levels reflect disease status, predict 
impending relapse, and bring prognostic implication.(Chou, et al 2007, Gorello, et al 2006, 
Kronke, et al 2011, Schnittger, et al 2009) Another stable marker is IDH mutation. IDH1 and 
IDH2 mutations are stable and highly consistent with disease status.(Chou, et al 2010a, 
Chou, et al 2011c) We have developed a single-tube, highly sensitive and specific PCR 
method to detect all IDH1 mutations at R132 residue.(Chou, et al 2010c) However, the IDH 
mutation is not a good marker for MRD monitoring because the minimal difference between 
the point mutation and normal allele. 
Other gene mutations are not readily applicable in MRD monitoring.  FLT3-ITD is not stable. 
This mutation can disappear at disease relapse in a significant proportion of patients,(Chou, 
et al 2011b, Shih, et al 2002) although this length mutation can be readily and sensitively 
detected by GeneScan-based method.(Stirewalt and Radich 2003) DNMT3A mutation at 
R882, which occurs at a frequency of up to 60% of all DNMT3A mutation, can be a potential 
marker for qualitative assessment of MRD, but awaits for further testing.(Ley, et al 2010, 
Thol, et al 2011, Hou, et al 2011) ASXL1 and TET2 mutations do not have hot spots and are 
not stable during AML evolution.  Other mutations have lower incidences and have not 
been well investigated in MRD monitoring.  
7. Risk-adapted treatment according to gene mutations in AML patients 
The ultimate goal of risk stratification according to molecular alterations is to explore 
personalized therapy, thereby reduce the risk of relapse and treatment-related side effects. 
How to integrate gene mutations into clinical management is a crucial issue. The choice 
between high-dose Cytarabine (HDAC) and allogeneic HSCT as the post-remission therapy 
is traditionally based on the cytogenetic risks and the patients’ condition. The meta-analysis 
showed that allogeneic HSCT resulted in better clinical outcome in younger AML patients 
with intermediate- and unfavorable-risk cytogenetics in first CR.(Cornelissen, et al 2007, 
Koreth, et al 2009) Although allogeneic HSCT reduces the risk of relapse and is a curative 
approach for AML patients, the higher rate of transplantation related morbidity and 
mortality counterbalances its beneficial effect. Thus, allogeneic HSCT is currently 
recommended only in those patients with acceptable benefit-risk ratio. Given that AML is a 
heterogenous disease especially in intermediate-risk cytogenetics and CN-AML, increasing 
understanding of novel molecular genetic markers in AML leukemogenesis can further help 
to reassess the value of HSCT in different prognostic groups.  
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Recently, ELN proposed a new classification to stratify AML patients into different risk 
groups according to cytogenetics and genetic alterations.(Dohner, et al 2010) In addition to 
CBF AML, CN-AML with mutated NPM1 without FLT3-ITD and those with mutated 
CEBPA are categorized as favorable-risk groups; the regimen using repetitive cycles of 
HDAC as postremission therapy is considered beneficial for this group of patients. 
Allogeneic HSCT in first CR is not beneficial for CN-AML patients with mutated NPM1 
without FLT3-ITD,(Schlenk, et al 2008) and probably neither for those with mutated CEBPA. 
Allogeneic HSCT is generally not considered in patients with CBF AML in first CR, but may 
be indicated in those who harbor KIT mutations because such patients did poorly with 
chemotherapy. For the patients with adverse-risk genotype (other than mutated NPM1 
without FLT3/ITD or mutated CEBPA), an allogeneic HSCT from a matched related donor 
or even unrelated donor in first CR is suggested.(Basara, et al 2009, Cornelissen, et al 2007, 
Slovak, et al 2000, Suciu, et al 2003, Tallman, et al 2007) Recent studies showed that allogeneic 
HSCT may be considered in patients with FLT3-ITD even if definite results of prospective 
trials are not available.(Bornhauser, et al 2007, Gale, et al 2005, Schlenk, et al 2008) Besides, 
allogeneic HSCT also ameliorates the poor survival impact of RUNX1 mutations on AML 
patients.(Gaidzik, et al 2011, Tang, et al 2009) The treatment of choice for patients with other 
recently documented poor-risk mutations, such as WT1, TET2 and DNMT3A mutations is 
currently unclear.  
In addition to chemotherapy and transplantation, targeted therapies aiming to specific 
molecular pathway are evolving as an adjunctive treatment in AML patients. FLT3/ITD and 
FLT3/TKD occur in about 20-35% of AML patients. Since FLT3 is a receptor tyrosine kinase 
and promote cancer phenotypes, it is an ideal target for therapy. Several FLT3 inhibitors, 
such as sorafenib, PKC-412 (midostaurin), sunitinib, semaxanib, tandutinib, AC220, KW-
2449, and CEP701 (lestaurtinib) have been used in clinical trials and some effects were 
noticed in relapse/refractory setting.(Levis, et al 2002, Metzelder, et al 2009, Stone, et al 2005, 
Zhang, et al 2008) An ongoing international intergroup trial (10603 RATIFY), incorporating 
midostaurin into induction, consolidation or maintenance setting is currently underway. 
All-trans retinoic acid in combination with chemotherapy was found to be beneficial for 
NPM1-mutated patients (Burnett, et al 2010); however this preliminary result was not 
confirmed by the other study done on younger patients.(Schlenk, et al 2009) Tyrosine kinase 
inhibitor, such as imatinib, might be of clinical value in treatment of patients with KIT 
mutations.(Kindler, et al 2004, Kindler, et al 2003, Kohl, et al 2005) Epigenetic modification 
through demethylation agent azacitidine or decitibine may play a role in the treatment of 
patients with MLL rearrangement,(Altucci and Minucci 2009) and those with genetic 
alterations relating to epigenetic changes, such as TET2 mutations.(Itzykson, et al 2011) 
Besides, recent report demonstrated that inhibition of glutaminase preferentially killed 
IDH1-mutated glial cells, which were more dependent on glutaminolysis pathway to supply 
α-KG, so glutaminase itself could be a potential therapeutical target.(Seltzer, et al 2010) 
Eventually, it may be reasonable to use combinations of molecularly targeted therapies and 
chemotherapy to improve the clinical outcome in AML patients. 
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specialized complex microenvironment, also known as a niche (Scadden et al., 2007; 
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niches work together. Coordination between the osteoblastic and vascular niches regulates 
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marrow (BM). HSCs leave the osteoblastic niche, mobilize to the vascular niche, and enter 
the blood vessel. They subsequently may undergo transendothelial migration from the 
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(Lapidot et al., 2005; Cancelas and Williams, 2006). Within the niche, there are critical 
bidirectional signals that ensure the regulation of normal HSCs (Calvi et al., 2003) and 
maintenance of the quiescent long-term HSC pool (Fleming et al., 2008). The quiescent 
fraction of immunophenotypically defined HSCs has been previously demonstrated to 
correlate with long-term repopulating ability of BM (Passegue et al., 2005) and loss of this 
fraction is associated with inability to sustain serial transplantation, the most stringent in 
vivo assay of self-renewal (Fleming et al., 2008). 
The HM consists of a complex structure of both non-hematopoietic and hematopoietic cells, 
extracellular matrix as well as soluble and membrane bound factors that cooperate to 
support normal hematopoiesis. It was known as early as the 1960s, based on experiments on 
mice, that normal hematopoiesis could not occur without a supportive environment (Russell 
et al., 1979). In vitro studies of the HM over the last several decades have mostly relied on 
the long-term marrow culture system, first reported by Dexter (1977).   
The key component of the HM is mesenchymal stromal cells (MSC). These plastic-adherent 
cells currently described as mesenchymal stem cells are termed multipotent mesenchymal 
stromal cells, while the term mesenchymal stem cell should be reserved for a subset of these 
cells that demonstrate stem cell activity by clearly stated criteria (Horowitz et al., 2005). 
MSCs are primitive cells originating from the mesodermal germ layer and were classically 
described to give rise to connective tissues, skeletal muscle cells, and cells of the vascular 
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could be isolated from BM via inherent adherence to plastic in culture. He defined a 
population of cells as multipotential stromal precursor cells that were spindle-shaped and 
clonogenic in culture conditions, defining them as colony-forming unit fibroblasts. MSCs, in 
the traditional view, should refer to stem cells that are also capable of producing blood cells; 
however, blood cells are actually derived from a distinct cell population called the 
hematopoietic stem cells. This allows classified MSC as nonhematopoietic, multipotential 
stem cells that are capable of differentiating into mesenchymal and non-mesenchymal cell 
lineages (Chamberlain et al., 2007). These cells were able to differentiate into adipocytes, 
chondrocytes, osteocytes, and myoblasts, both in vitro and in vivo. In addition, it has also 
been demonstrated that MSCs are capable of differentiating into cardiomyocytes, neurons, 
and astrocytes in vitro and in vivo (Pittenger et al., 1999; Jori et al., 2005; Beyer Nardi et al., 
2006; Tokcaer-Keskin et al., 2009). By generating functionally distinct cell types and 
structures, MSC play a crucial role in supporting hematopoiesis as key components of the 
HM (Sacchetti et al., 2007). 
Phenotypically MSCs express a number of markers, none of which are specific only to 
MSCs. It is generally agreed that adult human MSCs do not express the hematopoietic 
markers CD45, CD34, CD14, or CD11. They also do not express the costimulatory molecules 
CD80, CD86, or CD40 or the adhesion molecules CD31, CD18, or CD56, but they can express 
CD105 (SH2), CD73 (SH3/4), CD44, CD90 (Thy-1), CD71, and Stro-1 as well as the adhesion 
molecules CD106, CD166, intercellular adhesion molecule, and CD29 (Sordi et al., 2005; 
Chamberlain et al., 2007). Although there are no unique cell surface markers for the 
identification of MSCs, minimal criteria to define human MSC have been published. 
According to such criteria, MSC must be plastic-adherent; and have to express CD105, CD90 
and CD73; they must lack expression of CD45, CD34 and CD14; and they must show in vitro 
differentiation capabilities into osteoblasts, adipocytes and chondroblasts (Horowitz et al., 
2005; Chamberlain et al., 2007). This in vitro system has allowed for the dissection of the 
components of the microenvironment and the study of the complex contact dependent and 
contact independent interactions that occur between the stromal compartment and 
hematopoietic stem cells that regulate stem cell fate decisions.  
Normal hematopoiesis requires complex bidirectional interactions between the HM and 
HSCs. The HM can regulate hematopoiesis by interacting directly with HC and/or by 
secreting regulatory molecules that exert a positive or negative influence on the growth of 
HC. These interactions influence HSC self-renewal. HM controls the formation of blood cells 
through the production and secretion of cytokines, chemokines, and intracellular signals 
initiated by cellular adhesion (Konopleva et al., 2009). Chemokines are a large superfamily 
of small glycoproteins that are required in a various series of biological processes, including 
leukocyte trafficking, hematopoiesis, angiogenesis, and organogenesis. MSCs have the 
ability to migrate into tissues from the circulation, possibly in response to signals that are 
upregulated under injury conditions. Although the mechanisms by which MSCs are 
recruited to tissues and cross the endothelial cell layer are not yet fully understood, it is 
probable that chemokines and their receptors are involved, as they are important factors 
known to control cell migration (Chamberlain et al., 2007).  
CXCL12/stromal cell-derived factor-1alpha (SDF-1α) and its receptor CXCR4 are involved 
in homing of HSC into BM (Abkowitz et al., 2003; Broxmeyer et al., 2005; Morrison and 
Spradling, 2008). Perivascular reticular cells secrete much higher levels of CXCL12 than 
other constitutive sources of CXCL12, such as osteoblasts, fibroblasts, and endothelial cells 
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(Sugiyama et al. 2006). These reticular cells, defined as CXCL12-abundant reticular cells, 
may serve as a transit pathway for shuttling HSC between the osteoblastic and vascular 
niches, where essential but different maintenance signals are provided (Perry and Li, 2007). 
The molecular interactions between HC and MSC involve ligand-receptor relationship 
between adhesion molecules on the surface of HC and stromal cells or between such 
molecules on the cells surface with specific domains within certain extracellular matrix 
molecules. BM engraftment involves subsequent cell-to-cell interactions through the MSC-
produced complex extracellular matrix (ECM) (Zuckerman and Wicha, 1983; Wight et al., 
1986). Vascular cell-adhesion molecule-1 (VCAM-1) or fibronectin is critical for adhesion to 
the MSC (Miyake et al., 1991; Garcia-Gila et al., 2002). One very important type of 
interaction between the MSC and the HSC is the synthesis and presentation by MSC of 
hematopoietic growth factors. Interactions of HSC with stromal elements of BM play a role 
in the egress of mature blood cells from the BM (Chamberlain et al., 2007).   
Whether MSC alterations influence hematological disorders and how such alterations 
contribute to the progression of the disease remains controversial. The molecular 
mechanisms for maintaining quiescence of normal stem cells may also facilitate leukemia 
stem cells (LSC) survival. Whereas LSC share certain features of self-renewal and 
differentiation with HSC, LSC differ in their deregulated proliferation and ability to invade 
and spread. LSC exhibit the capacity for long-term self-renewal (Holyoake et al., 2002; 
Warner et al., 2004; Liesveld et al., 2004) within the BM microenvironment, which is 
required for maintenance of the malignant clone (Braun and Shannon, 2008). LSCs are able 
to generate leukemic blasts, and the leukemic clone is organized as a hierarchy (Zhang et al., 
2003). LSCs may steal the homeostatic mechanisms, take refuge within the HM during 
chemotherapy, and consequently contribute to eventual disease relapse (Warner et al., 2004; 
Lane et al., 2009). Consecutively, LSC are believed to arise through transforming events 
targeting HSC, which allow growth-independent survival and proliferation. MSC are 
capable of promoting the growth, survival and drug resistance of leukemic cells by 
providing the necessary cytokines and cell contact-mediated signals to LSC (Dazzi et al., 
2006; Ramasamy et al., 2007). There is increasing evidence that microenvironment 
alterations may be important and pathogenic in leukemia leading to enhanced stem cell 
mobilization and the creation of alternate niches (Lataillade et al., 2008). Recent data indicate 
that, in parallel with leukemogenic events in the hematopoietic system, the niche is 
converted into an environment with dominant signals favoring cell proliferation and 
growth. In some cases, a combination of these events may be required (Li and Neaves, 2006). 
Therefore, LSC may receive the support of a BM niche for their survival and may in turn 
influence deregulation of the BM niche by their dominant proliferation-promoting signals. 
AML may arise in an abnormal HM, resulting in the generation of multiple populations 
with varying initiation events. Ninomiya et al. (2007) modeled the homing, proliferation, 
and survival sites of human leukemia cells and of cord blood CD34+ cells. The transplanted 
leukemia cells initially localized on the surface of osteoblasts in the epiphysial region and 
then expanded to the inner vascular and diaphysial regions. 8 weeks after transplantation, 
the number of leukemia cells transiently increased by as much as 50%, predominantly in the 
epiphysial region. After administration of high-dose cytarabine, residual leukemia cells 
clustered and adhered to the blood vessels as well as to the endosteum, suggesting that 
leukemia cells receive anti-apoptotic signals not only from osteoblasts but also from 
vascular endothelium (Ninomiya et al., 2007). 
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Several studies have proposed that important quantitative and functional alterations occur 
in MSCs of patients with different hematological disorders (Borojevic et al., 2004; Flores-
Figueroa et al., 2008). In some disorders, such as multiple myeloma, MSC show alterations 
in the expression of some cell adhesion molecules and cytokines, and reduced 
immunosuppressive efficiency (Wallace et al., 2001; Arnulf et al., 2007; Corre et al., 2007). 
Neoplastic plasma cells communicate with the environment through cell/cell contact as well 
cytokines to induce functional changes that support the malignant population (Mitsiades et 
al., 2006; Podar et al., 2007). In myeloproliferative disorders, has been shown, that 
megakaryocytes and macrophages play a principle role in the pathogenesis of the fibrotic 
reaction by secreting PDGF, FGF and TGFα cytokines (Chagraoui et al., 2006). In chronic 
myeloid leukemia (CML), Bhatia (1995) showed that MSC did not provide optimal support 
for normal hematopoietic cells. In contrast, growth of CML cells on CML-derived stroma 
was significantly better, suggesting that the microenvironment in CML was more 
supportive for the malignant clone. Using fluorescent activated cell sorting (FACS) and 
fluorescent in situ hybridization (FISH), it was determined that stromal macrophages were 
all bcr-abl positive and were directly responsible for the selective advantage of clonal bcr-abl 
cells to proliferate through a contact-dependent mechanism (Bhatia et al. 1995). 
Interestingly, other researches estimated that CML-derived MSC do not express the bcr-abl 
gene (Zhao et al., 2006; Jootar et al., 2006). In myelodysplastic syndrome (MDS) MSC show 
alterations in the levels of TNFα (Deeg et al., 2000). Furthermore, the MDS-derived 
monocytes respond abnormally to stromal signals, MDS monocytes fail to upregulate matrix 
metalloproteinase-9 (MMP-9) expression when exposed to stromal signals (Iwata et al., 
2007). MMP-9 has been implicated in the cleavage of SDF1 from the microenvironment and 
may facilitate the egress of HCs from the BM to the peripheral blood (Heissig et al., 2002). In 
the solid tumors, tumor-derived MSC shown acquire aberrant methylation patterns due 
either to direct contact with or via factors secreted by the malignant cells (Hanson et al., 
2006; Fiegl et al., 2006). 
Dysfunction of a BM niche may contribute to leukemogenesis by supplying abundant 
growth factors that promote proliferation and/or inhibit apoptosis (Jones and Wagers, 
2008). MSCs seem to have a relevant role in AML as they prevent spontaneous and induced 
apoptosis and may attenuate chemotherapy-induced cell death. This possibility has been 
confirmed by the finding that co-cultivation of a leukemic cell line with the murine stroma 
cell line MS-5 can block apoptosis (Konopleva et al., 2002). 
The significance role of the HM in initiation of leukemia has been suggested by studies with 
mice deficient in phosphatase and tensin homolog (PTEN) (Yilmaz et al., 2006). PTEN 
deficiency in both HSC and the HM resulted in myeloproliferation that progressed to overt 
leukemia/lymphoma. However, inducible PTEN deletion in HSC in the presence of a wild 
type HM promoted HSC depletion without evidence of myeloproliferation or leukemic 
development. These results suggest that PTEN deficiency in HSC alone is not sufficient for 
malignant transformation. Rupec et al. (2005) reported that activation of NF-kB in 
myelopoietic cells and the absence of its inhibitor IκBα are not sufficient for induction of 
hypergranulopoiesis, but these changes in the non-hematopoietic compartment, such as fetal 
liver, resulted in increased numbers of dysplastic hematopoietic cells with progression into 
secondary AML. These results indicate that non-hematopoietic cells with inactive IκBα can 
initiate premalignant hematopoietic disorder, conceivably via activation of the Notch 
pathway. Additional studies indicate the role of Notch signaling in the interactions of HSC 
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and the HM (Matsuoka et al., 2008) demonstrated that the tumor suppressor Fbxw7, which 
negatively regulates cyclin E, Notch, and c-Myc protein levels, plays a role in maintaining 
HSC quiescence and repressing potential oncogenic activity of HSC. Notably, Notch ligand 
Jagged is expressed by the HSC niche, and Jagged/Notch activation results in increased 
HSC number and niche expansion (Calvi et al., 2003). 
Evidence from research conducted over the last few decades has clearly implicated 
abnormalities of the marrow microenvironment in the pathophysiology of hematologic 
malignancies. Marcondes et al. (2008) demonstrated that MSC derived from patients with 
MDS, in contrast to that from more advanced stages of MDS expressed 14- to 17-fold higher 
levels of IL-32 mRNA than healthy controls, and this constitutive IL-32 expression promoted 
apoptosis in MDS cells, reproducing the inefficient hematopoiesis and extensive apoptosis 
in MDS marrow. These findings indicate that stroma-produced IL-32 could contribute to the 
pathophysiology of MDS, and serve as a therapeutic target. Furthermore, this modified 
microenvironment phenotype was reproduced when the MSC were exposed to TNFα, 
known to be produced at high levels by MDS cells.  
There are significant data to support mechanism, in which the malignant hematopoietic 
clone induces reversible functional changes in the HM that result in improved growth 
conditions for the malignant cells. Gene expression changes occurred in the stroma cell lines, 
HS5 and HS27a, derived from normal marrow in response to TNFα exposure (Stirewalt et 
al., 2008), known to be up-regulated in the bone marrow of patients with MDS. Previous 
experiments showed that interactions between MSC and HSC were required for TNFα to 
trigger apoptosis in hematopoietic cells (Goda et al., 2006).  
Recent discoveries utilizing mouse models have provided the first experimental evidence 
for genetic changes in the HM contributing to or required for leukemogenesis. Raaijmakers 
et al. (2010) using transgenic mice showed that genetic alteration of HM can induce MDS 
with ineffective hematopoiesis and dysmorphic HCs, and with occasional transformation to 
AML. The authors used Dicer1 deletion as a means of altering several gene products in 
subsets of mesenchymal osteolineage cells. Dicer1 is an RNase III endonuclease essential for 
microRNA biogenesis (Bartel, 2004) and RNA processing (Krol et al., 2007), that regulates 
haematopoietic cell fate (Lu et al., 2008). Global repression of microRNA maturation by 
Dicer1 deletion promotes cellular transformation and tumorigenesis (Kumar et al., 2007). 
Raaijmakers et al. (2010) show that deletion of Dicer1 in HM cells of mouse may be sufficient 
to initiate a complex change of homeostasis with similarities to myelodysplasia. The authors 
demonstrated that the ability of HM abnormality to result in the emergence of a clonal 
neoplasm in a cell type of clearly distinct lineage with distinct secondary genetic changes 
(Raaijmakers et al., 2010).  
Previously, Walkley et al (2007a, 2007b) demonstrated that conditional deletion of the 
Retinoblastoma gene (RB) in the BM microenvironment can contribute to the development 
of pre-leukemic myeloproliferative disease in mice. They showed that this was a result of 
interactions between myeloid cells and the microenvironment. The defect had to be present 
in both hematopoietic cells and the microenvironment to initiate disease. Widespread 
inactivation of RB, a central regulator of the cell cycle and a tumor suppressor, resulted in 
extramedullary hematopoiesis and myeloproliferative disease in the murine hematopoietic 
system. However, myeloid-specific loss of RB did not induce myeloproliferative disease or 
HSC abnormalities. Therefore, the myeloproliferative-like disorder in the RB mutants is the 
result of perturbed interactions between hematopoietic cells and the BM microenvironment 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
188 
Several studies have proposed that important quantitative and functional alterations occur 
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and the HM (Matsuoka et al., 2008) demonstrated that the tumor suppressor Fbxw7, which 
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HSC quiescence and repressing potential oncogenic activity of HSC. Notably, Notch ligand 
Jagged is expressed by the HSC niche, and Jagged/Notch activation results in increased 
HSC number and niche expansion (Calvi et al., 2003). 
Evidence from research conducted over the last few decades has clearly implicated 
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MDS, in contrast to that from more advanced stages of MDS expressed 14- to 17-fold higher 
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in MDS marrow. These findings indicate that stroma-produced IL-32 could contribute to the 
pathophysiology of MDS, and serve as a therapeutic target. Furthermore, this modified 
microenvironment phenotype was reproduced when the MSC were exposed to TNFα, 
known to be produced at high levels by MDS cells.  
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conditions for the malignant cells. Gene expression changes occurred in the stroma cell lines, 
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with ineffective hematopoiesis and dysmorphic HCs, and with occasional transformation to 
AML. The authors used Dicer1 deletion as a means of altering several gene products in 
subsets of mesenchymal osteolineage cells. Dicer1 is an RNase III endonuclease essential for 
microRNA biogenesis (Bartel, 2004) and RNA processing (Krol et al., 2007), that regulates 
haematopoietic cell fate (Lu et al., 2008). Global repression of microRNA maturation by 
Dicer1 deletion promotes cellular transformation and tumorigenesis (Kumar et al., 2007). 
Raaijmakers et al. (2010) show that deletion of Dicer1 in HM cells of mouse may be sufficient 
to initiate a complex change of homeostasis with similarities to myelodysplasia. The authors 
demonstrated that the ability of HM abnormality to result in the emergence of a clonal 
neoplasm in a cell type of clearly distinct lineage with distinct secondary genetic changes 
(Raaijmakers et al., 2010).  
Previously, Walkley et al (2007a, 2007b) demonstrated that conditional deletion of the 
Retinoblastoma gene (RB) in the BM microenvironment can contribute to the development 
of pre-leukemic myeloproliferative disease in mice. They showed that this was a result of 
interactions between myeloid cells and the microenvironment. The defect had to be present 
in both hematopoietic cells and the microenvironment to initiate disease. Widespread 
inactivation of RB, a central regulator of the cell cycle and a tumor suppressor, resulted in 
extramedullary hematopoiesis and myeloproliferative disease in the murine hematopoietic 
system. However, myeloid-specific loss of RB did not induce myeloproliferative disease or 
HSC abnormalities. Therefore, the myeloproliferative-like disorder in the RB mutants is the 
result of perturbed interactions between hematopoietic cells and the BM microenvironment 
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(Walkley et al., 2007a). The final model, reported by the same group, may be the most 
compelling. In this report, deletion of the Retinoic Acid Receptor γ (RARγ) in mice resulted 
in a chronic myeloproliferative disorder. Transplant studies revealed that RARγ-
hematopoietic cells functioned normally when transplanted into normal mice. However, 
transplantation of normal hematopoietic cells into the RARγ-microenvironment resulted in a 
myeloproliferative disorder in the transplanted cells. TNFα was implicated in the 
pathogenesis of this MPD as the disorder was partially abrogated when TNFα null stem 
cells were transplanted into the RARγ-microenvironment (Walkley et al., 2007b). These 
studies showed that a defect in HM could be sufficient to generate a myeloproliferative 
disorder.  
Until recently, there has been little evidence to support the role of primary stromal 
abnormalities in the pathogenesis of hematologic neoplasms. Some independent studies 
have documented the existence of genomic alterations in the stroma of leukemia patients 
(Flores-Figueroa et al., 2005; Blau et al., 2007; Lopez-Villar et al., 2009; Klaus et al., 2010). 
Different groups have shown the extensive variability of the aberrations, such as 
hypodiploidy, balanced and unbalanced translocations, whole chromosome gains, and 
deletions. All cytogenetic markers in MSCs never repeated aberrations identified in HCs. 
Since there were no associations between chromosomal aberrations in HCs and MSCs, we 
can state that MSCs were devoid of residue HCs. These findings suggest enhanced genetic 
instability of MSC in leukemia, and indicate the potential involvement of MSC in the 
pathophysiology of these conditions (Blau et al., 2007). Recently, Lopez-Villar et al. (2009) 
reported the presence of cytogenetic aberrations on MSC from MDS patients by array-based 
comparative genomic hybridization and fluorescence in situ hybridization, some of them 
specially linked to a particular MDS subtype, the 5q-syndrome. 
These date indicate that there are significant functional abnormalities, genetic aberrations, 
and epigenetic changes in MSC in leukemia patients. Also of interest are the recent reports 
of abnormalities in the stroma that lead to malignancies of the hematopoietic compartment. 
Although historically, hematologic malignancies are thought to arise from a stem or 
progenitor cell abnormality, there may be groups of patients that have a primary stromal 
defect leading to the hematologic malignancy. Moreover, although a series of genetic and 
epigenetic events in a single cell may be necessary for oncogenesis, they may not be 
sufficient, and a permissive microenvironment has been suggested to be required for frank 
malignancy to emerge (Hanahan and Weinberg, 2007). 
It is known that even years after allogeneic stem cell transplantation (alloSCT), and despite 
successful engraftment of donor-derived hematopoiesis, MSC are in general of host origin 
(Rieger et al., 2005). Some patients after alloSCT do not recover their stem cells despite 
receiving high levels of CD34+ progenitor cells. The presumed basis for this is that the 
preparation regimen has in some way affected the niche, so it no longer has the same 
nurturing capability. It was shown that transplanted HSCs migrate to the endosteal surfaces 
of bone within hours of intravenous injection (Nilsson et al., 1997). Endochondral 
ossification has been shown to be an essential prerequisite for the development of normal 
haematopoiesis in the BM (Zhou et al., 1995), indicating a possible fundamental 
interrelationship of ossification to the mature haematopoietic process in mammals. Recent 
reports have identified that a key cellular component of the HSC niche is cells of the 
osteoblast lineage, the cell type responsible for the formation of bone (Calvi et al., 2003; 
Zhang et al., 2003). Additionally, these studies raise the issue that under transplant 
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conditions, there may be agents that rather than drive hematopoiesis, might affect the 
osteoblast component.  
Understanding the niche has ramifications beyond simple biological interest. Niche biology 
and function has relevance not only in bone marrow transplantation, but in developing 
agents that may impact on the ability to generate a larger number of stem cells or increase 
the efficiency of stem cells to engraft in the transplant setting. By elucidating the role of the 
BM microenvironment in the pathogenesis of hematologic tumors, recent studies have 
provided the framework for identifying and validating novel therapies that target both 
leukemic cells and cells in their surrounding microenvironment (Konopleva et al., 2009). 
Thus in general, treatment strategies have been focused on the eradication of the stem or 
progenitor cell from which the malignancy arose. However, recent evidence suggests that 
focusing therapeutic strategies on the microenvironmental abnormalities can be extremely 
effective. The Imid family of agents has changed the treatment paradigm in diseases such as 
myeloma and MDS and highlighted the importance of targeting the microenvironment 
(Sokol et al., 2007; Melchert and List, 2007).  
If primary stromal defects are identified in humans and implicated in the initiation of 
malignancy, this clearly will have great impact on the treatment strategies offered to 
patients. By explanation the role of the MSC in the pathogenesis of AML, recent studies 
have provided novel therapies that target both leukemic cells and cells of 
microenvironment. Studies of MSC can also aid in potentially modifying the relative 
abundance of normal versus malignant cells in the context of the post chemotherapy setting 
in AML. The underlying molecular mechanisms implicated in stem cell activation and 
homing to the niche will provide important insight into the precise mechanisms involved in 
interactions between leukemic and normal cells that contribute to drug resistance. This 
understanding will provide a framework for the rational combination of agents in clinical 
trials to overcome drug resistance and improve patient outcomes. Detection of alterations in 
MSCs suggests that unstable MSCs may facilitate the expansion of malignant cells. In view 
of these data, alterations in MSCs may be a particular mechanism of leukemogenesis. 
Especially, further understanding of the contribution of the BM niche to the process of 
leukemogenesis may provide new targets aimed at destroying LSC without adversely 
affecting normal stem cell self-renewal.  
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compelling. In this report, deletion of the Retinoic Acid Receptor γ (RARγ) in mice resulted 
in a chronic myeloproliferative disorder. Transplant studies revealed that RARγ-
hematopoietic cells functioned normally when transplanted into normal mice. However, 
transplantation of normal hematopoietic cells into the RARγ-microenvironment resulted in a 
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cells were transplanted into the RARγ-microenvironment (Walkley et al., 2007b). These 
studies showed that a defect in HM could be sufficient to generate a myeloproliferative 
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deletions. All cytogenetic markers in MSCs never repeated aberrations identified in HCs. 
Since there were no associations between chromosomal aberrations in HCs and MSCs, we 
can state that MSCs were devoid of residue HCs. These findings suggest enhanced genetic 
instability of MSC in leukemia, and indicate the potential involvement of MSC in the 
pathophysiology of these conditions (Blau et al., 2007). Recently, Lopez-Villar et al. (2009) 
reported the presence of cytogenetic aberrations on MSC from MDS patients by array-based 
comparative genomic hybridization and fluorescence in situ hybridization, some of them 
specially linked to a particular MDS subtype, the 5q-syndrome. 
These date indicate that there are significant functional abnormalities, genetic aberrations, 
and epigenetic changes in MSC in leukemia patients. Also of interest are the recent reports 
of abnormalities in the stroma that lead to malignancies of the hematopoietic compartment. 
Although historically, hematologic malignancies are thought to arise from a stem or 
progenitor cell abnormality, there may be groups of patients that have a primary stromal 
defect leading to the hematologic malignancy. Moreover, although a series of genetic and 
epigenetic events in a single cell may be necessary for oncogenesis, they may not be 
sufficient, and a permissive microenvironment has been suggested to be required for frank 
malignancy to emerge (Hanahan and Weinberg, 2007). 
It is known that even years after allogeneic stem cell transplantation (alloSCT), and despite 
successful engraftment of donor-derived hematopoiesis, MSC are in general of host origin 
(Rieger et al., 2005). Some patients after alloSCT do not recover their stem cells despite 
receiving high levels of CD34+ progenitor cells. The presumed basis for this is that the 
preparation regimen has in some way affected the niche, so it no longer has the same 
nurturing capability. It was shown that transplanted HSCs migrate to the endosteal surfaces 
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ossification has been shown to be an essential prerequisite for the development of normal 
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interrelationship of ossification to the mature haematopoietic process in mammals. Recent 
reports have identified that a key cellular component of the HSC niche is cells of the 
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in AML. The underlying molecular mechanisms implicated in stem cell activation and 
homing to the niche will provide important insight into the precise mechanisms involved in 
interactions between leukemic and normal cells that contribute to drug resistance. This 
understanding will provide a framework for the rational combination of agents in clinical 
trials to overcome drug resistance and improve patient outcomes. Detection of alterations in 
MSCs suggests that unstable MSCs may facilitate the expansion of malignant cells. In view 
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1. Introduction 
Hematopoiesis is the formation and development of blood cells. In a healthy adult person, 
approximately 1011–1012 new blood cells are produced daily in order to maintain steady state 
levels in the peripheral circulation. Disruption of the steady state may cause the 
development of hematological diseases, such as acute (AML) or chronic myelogenous 
leukemia (CML). All mature blood cells ultimately originate from a rare population of 
primitive pluripotent (multipotential) stem cells. The pluripotent stem cells possess self-
renewal and multi-lineage differentiation potential. The latter process leads to two major 
multipotent progenitors: myeloid progenitors and lymphoid progenitors. The myeloid 
progenitors have the ability to differentiate into mature white cells, erythrocytes, 
megakaryocytes/platelets and mast cells; whereas the lymphoid progenitors cells mainly 
produce mature T, NK, and B lymphocytes. Production of myeloid lineage cells is a highly 
complex process involving the balance between cell proliferation and differentiation, which 
is regulated by growth stimulating or inhibiting signals. Transforming Growth Factor-beta 
(TGFβ) is a pleiotropic growth factor and is one of the major regulators of hematopoiesis 
(Fortunel NO et al. 2000). A major effect of TGFβ on hematopoietic cells is inhibitory (Hu X 
et al 1999, Batard P et al. 2000, Ducos K et al. 2000, Fortunel NO 2000) although its 
stimulatory effect has also been observed in some types of blood cells (Keller JR 1990, 1992). 
Due to its importance in the understanding human diseases including leukemia, over past 
20 years, the mechanisms responsible for TGFβ-induced growth inhibition or stimulation 
have been a major area of investigation and considerable insights into its action mechanisms 
have been learned. This review highlights recent progress in understanding regulatory role 
of TGFβ and its signaling pathways in various types of cells with a focus on human myeloid 
leukemia cells.  
2. Myeloid leukemia and myelogenous leukemia cell lines 
Myeloid leukemia is a type of blood and bone marrow cancers, which includes AML and 
CML. AML is a characterized by the rapid accumulation of abnormal, immature white blood 
cells in both borrow and blood, which is caused by defects in the progenitors and/or stem cells 
population. Unlike AML, myeloid cell differentiation is preserved during the chronic phase of 
CML, a disease which originates from the presence of a genetic abnormality in stem 
cells/progenitors and the nuclei show an abnormal chromosome called the Philadelphia 
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chromosome. In a healthy person, bone marrow makes the blood stem cells and progenitors 
that mature into mature white blood cells, red blood cells and blood platelets.  
In order to simplify the study of leukemia and basic research, a number of human AML cell 
lines were established. These lines provide model systems to study the control of proliferation 
and differentiation in human myelogenous leukemia and, in a broader framework, the controls 
of normal myeloid development. More than 10 leukemic cell lines have been used in our lab to 
study Transforming Growth Factor-β (TGFβ)-mediated cell cycle control and transformed 
events, among which K562 is the first myelogenous leukemia cell line established. The cell line 
was isolated from a 53 year old female CML patient in blast crisis (Lozzio CB and Lozzio BB 
1975). K652 composed of undifferentiated blast cells that are rich in glycophorin and may be 
induced to produce fetal and embryonic hemoglobin in the presence of hemin. The rest nine 
cell lines were isolated from AML patients as described below. MV4-11 cell line was derived 
from blast cells of a 10-year-old male with biphenotypic myelomonocytic leukemia (Lange B et 
al. 1987). This cell line expresses mutated FLT3, a member of the type III receptor tyrosine 
kinase (RTK) family (Quentmeier 2003). KG-1 cell line is composed predominantly of 
myeloblasts and promyelocytes ( Koeffler HP et al. 1978). Recent studies identified a fusion of 
two genes encoding fibroblast growth factor receptors, making this cell line is a good model 
for studying gene fusion-linked leukemia (Gu TL et al. 2006). KG-1a ( Koeffler HP et al. 1980) is 
a subline isolated from KG-1. TF-1 is a growth factor-dependent human cell line that was 
originally isolated from the bone marrow cells of a patient with erythroleukemia (Kitamura T 
et al. 1989). TF-1 cells express a wide range of cytokine receptors and respond to a variety of 
cytokines. Thus, this cell line is a useful tool for studying cytokine signaling network (Rosas M 
et al 2005). TF-1a (Hu X et al. 1998) is growth factor-independent subline isolated from TF-1. A 
unique characteristic of the KG-1 and TF-1 cells is their dependence on colony-stimulating 
factor (CSF) or GM-CSF/IL-3 for proliferation, respectively, whereas KG-1a and TF-1a are 
factor-independent cell lines for their growth, although TF-1a retains its ability to respond to 
several growth factors. HL-60 is a promyelocytic cell line derived from peripheral blood 
leukocytes from a female patient with acute promyelocytic leukemia, which can be induced 
into granulocytes in the presence of DMSO (Gallagher R et al.1979). HL-60 cells differentiate 
into mononuclear phagocytes when exposed to phorbol esters (Xu YZ et al. 2011). HEL is an 
erythroleukemia cell line isolated from the bone marrow cells of a patient (Martin P and 
Papayannopoulou 1982). A mutation in Janus kinase 2 gene (JAK2) in HEL cells was identified 
in 2006 (Quentmeier H et al 2006). Mo7e (Avancd GC et al. 1988) is a subline of the M-07 
human megakaryoblastic leukemia cell line. The cells express platelet glycoprotein-2b-3a. The 
growth of Mo7e is dependent on IL-3 or GM-CSF. U937 is a cell line established from a diffuse 
histiocytic lymphoma of 37 year old male patient (Sundstrom C et al. 1976). A histocyte is a cell 
that is part of the mononuclear phagocytic system that takes part in the immune responses. 
Since U937 displays many monocytic characteristics and has thus served as a model for the 
differentiation of monocytes and macrophage in vitro (Aida J, et al. 2011). This cell line is also a 
good model for induction of apoptosis (Piedfer M et al. 2011).  
3. Effect of TGFβ on the growth of human myeloid leukemia cell lines in 
culture  
Transforming Growth Factor-β (TGF) has three isoforms in mammals: TGFβ1, TGFβ2, and 
TGFβ3. The β1 isoform is the most abundant, universally expressed, which has been 
intensively studied. This review focuses on TGFβ1 unless indicated otherwise. The TGFβ-
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induced biological activities are achieved through the binding of the ligand to its cell surface 
receptor, a serine-threonine kinase complex, known as type I, II, and III (adaptor) receptors. 
TGFβ binds to and activates the type II receptor. Then the type II receptor recruits and 
phosphorylates the type I receptor, which in turn activates Smad family proteins that carry 
signals from the receptors to the nucleus to control transcription of target genes. These gene 
products may stimulate or inhibit cell cycle progression. TGF plays an essential regulatory 
role in the control of hematopoiesis (Fortunel NO et al. 2000). First, the development of 
hematopoietic cells from mesoderm in embryos is regulated by TGFβ signaling. Park et al 
(Park C et al. 2004) demonstrated that BMP-4, a member of TGFβ superfamily, is able to 
induce hematopoietic differentiation from mouse embryonic stem cells. The differentiated 
cells contain all types of myeloid and lymphoid progeny (Olsen AL et al. 2006). Similar roles 
of TGFβ in human hematopoietic stem cells have been reported (Kaufman DS  et al. 2001, 
Chadwick K et al. 2003, Cerdan C et al. 2004). Second, it has also been found that TGF is 
required for maintaining hematopoietic stem/progenitor cells in quiescent states (Batard P 
et al. 2000); in contrast, application of anti-endogenous TGF antibody induces release of 
these cells from G1 phase (Ducos K et al. 2000). In TGFβ-/- mice, enhanced numbers of 
circulating granulocytes, monocytes, platelets, as well as colony forming units, were 
observed (Kulkarni AB et al 1993, Shull MM et al 1992). In addition, inactivation of the TGF 
signaling pathway leads to malignant transformation of early hematopoietic cells (Le 
Bousse-Kerdiles MC et al. 1996). These data indicate that TGFβ is inhibitory to 
hematopoietic cells. However, studies from several groups suggest that the response of 
myeloid stem/progenitor cells to the inhibitory effect of TGFβ appears to be inversely 
correlated with their maturation stage (Sing GK 1988, Keller JR 1990, Ottmann OG & Pellus 
LM 1991, Snoeck H-W 1996). Long-term repopulating stem cells, CD34+ or CD34+/CD38- 
stem/progenitor cells, early myeloid and erythroid progenitors are markedly inhibited in 
the presence of TGF, whereas more differentiated myeloid progenitors forming 
granulocyte-macrophage colonies, and late erythroid progenitors forming CFU-e are less 
inhibited or even stimulated by TGF (Keller JR 1990, 1992, 1994, Fortunel NO 2000, Ruscetti 
FW 2005, Sitnicka E 1996, McNiece IK 1992, Goey H 1989, Morita N 2003, Classen S 2007). 
The inhibitory or stimulatory role by TGFβ in some cases seems to correlate with the 
cytokines used to promote cell growth. TGFβ inhibits SCF-, IL-3- and CSF-1-induced colony 
formation from mouse and human hematopoietic progenitors (McNiece IK 1992, Sitnicka E 
et al 1996). In contrast, TGFβ enhances GM-CSF-induced colony formation derived from 
normal bone marrow cells and Lin- progenitors (Keller JR 1991).  
For leukemia cells, both inhibitory and stimulatory effects have been reported (Tessier N & 
Hoang T 1988, Otten J 2011, Aglietta M 1989, Cashman JD 1992). TGF has been shown to 
inhibit the growth of clonogenic blast cells from patients with acute myeloblastic leukemia 
(AML) (Tessier N & Hoang T 1988). Mutations in the components of TGFβ signal pathways 
may relate to the disease development (Imai Y et al. 2001). In contrast, high expression of 
ALK-1 and ALK-5, two members of TGFβ type I receptors, was reported to be associated 
with AML (Otten J 2011). An inhibitory effect of TGFβ was suggested by the finding of low 
levels of TGFβ type II receptors in CML (Rooke HM 1999) and lymphoid neoplasms (Inman 
GJ et al 2000); whereas, by using TGFβ inhibitors, Naka et al found that TGFβ signal is 
required for maintaining Leukemia Initiating Cells (LIC) by controlling nuclear localization 
of transcription factor, FOXO, in a CML mouse model (Naka K et al. 2010).  
The data described above suggest that TGF has both negative and positive effects on the 
proliferation of normal hematopoietic and leukemia cells. However, some of the data appear 
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chromosome. In a healthy person, bone marrow makes the blood stem cells and progenitors 
that mature into mature white blood cells, red blood cells and blood platelets.  
In order to simplify the study of leukemia and basic research, a number of human AML cell 
lines were established. These lines provide model systems to study the control of proliferation 
and differentiation in human myelogenous leukemia and, in a broader framework, the controls 
of normal myeloid development. More than 10 leukemic cell lines have been used in our lab to 
study Transforming Growth Factor-β (TGFβ)-mediated cell cycle control and transformed 
events, among which K562 is the first myelogenous leukemia cell line established. The cell line 
was isolated from a 53 year old female CML patient in blast crisis (Lozzio CB and Lozzio BB 
1975). K652 composed of undifferentiated blast cells that are rich in glycophorin and may be 
induced to produce fetal and embryonic hemoglobin in the presence of hemin. The rest nine 
cell lines were isolated from AML patients as described below. MV4-11 cell line was derived 
from blast cells of a 10-year-old male with biphenotypic myelomonocytic leukemia (Lange B et 
al. 1987). This cell line expresses mutated FLT3, a member of the type III receptor tyrosine 
kinase (RTK) family (Quentmeier 2003). KG-1 cell line is composed predominantly of 
myeloblasts and promyelocytes ( Koeffler HP et al. 1978). Recent studies identified a fusion of 
two genes encoding fibroblast growth factor receptors, making this cell line is a good model 
for studying gene fusion-linked leukemia (Gu TL et al. 2006). KG-1a ( Koeffler HP et al. 1980) is 
a subline isolated from KG-1. TF-1 is a growth factor-dependent human cell line that was 
originally isolated from the bone marrow cells of a patient with erythroleukemia (Kitamura T 
et al. 1989). TF-1 cells express a wide range of cytokine receptors and respond to a variety of 
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unique characteristic of the KG-1 and TF-1 cells is their dependence on colony-stimulating 
factor (CSF) or GM-CSF/IL-3 for proliferation, respectively, whereas KG-1a and TF-1a are 
factor-independent cell lines for their growth, although TF-1a retains its ability to respond to 
several growth factors. HL-60 is a promyelocytic cell line derived from peripheral blood 
leukocytes from a female patient with acute promyelocytic leukemia, which can be induced 
into granulocytes in the presence of DMSO (Gallagher R et al.1979). HL-60 cells differentiate 
into mononuclear phagocytes when exposed to phorbol esters (Xu YZ et al. 2011). HEL is an 
erythroleukemia cell line isolated from the bone marrow cells of a patient (Martin P and 
Papayannopoulou 1982). A mutation in Janus kinase 2 gene (JAK2) in HEL cells was identified 
in 2006 (Quentmeier H et al 2006). Mo7e (Avancd GC et al. 1988) is a subline of the M-07 
human megakaryoblastic leukemia cell line. The cells express platelet glycoprotein-2b-3a. The 
growth of Mo7e is dependent on IL-3 or GM-CSF. U937 is a cell line established from a diffuse 
histiocytic lymphoma of 37 year old male patient (Sundstrom C et al. 1976). A histocyte is a cell 
that is part of the mononuclear phagocytic system that takes part in the immune responses. 
Since U937 displays many monocytic characteristics and has thus served as a model for the 
differentiation of monocytes and macrophage in vitro (Aida J, et al. 2011). This cell line is also a 
good model for induction of apoptosis (Piedfer M et al. 2011).  
3. Effect of TGFβ on the growth of human myeloid leukemia cell lines in 
culture  
Transforming Growth Factor-β (TGF) has three isoforms in mammals: TGFβ1, TGFβ2, and 
TGFβ3. The β1 isoform is the most abundant, universally expressed, which has been 
intensively studied. This review focuses on TGFβ1 unless indicated otherwise. The TGFβ-
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induced biological activities are achieved through the binding of the ligand to its cell surface 
receptor, a serine-threonine kinase complex, known as type I, II, and III (adaptor) receptors. 
TGFβ binds to and activates the type II receptor. Then the type II receptor recruits and 
phosphorylates the type I receptor, which in turn activates Smad family proteins that carry 
signals from the receptors to the nucleus to control transcription of target genes. These gene 
products may stimulate or inhibit cell cycle progression. TGF plays an essential regulatory 
role in the control of hematopoiesis (Fortunel NO et al. 2000). First, the development of 
hematopoietic cells from mesoderm in embryos is regulated by TGFβ signaling. Park et al 
(Park C et al. 2004) demonstrated that BMP-4, a member of TGFβ superfamily, is able to 
induce hematopoietic differentiation from mouse embryonic stem cells. The differentiated 
cells contain all types of myeloid and lymphoid progeny (Olsen AL et al. 2006). Similar roles 
of TGFβ in human hematopoietic stem cells have been reported (Kaufman DS  et al. 2001, 
Chadwick K et al. 2003, Cerdan C et al. 2004). Second, it has also been found that TGF is 
required for maintaining hematopoietic stem/progenitor cells in quiescent states (Batard P 
et al. 2000); in contrast, application of anti-endogenous TGF antibody induces release of 
these cells from G1 phase (Ducos K et al. 2000). In TGFβ-/- mice, enhanced numbers of 
circulating granulocytes, monocytes, platelets, as well as colony forming units, were 
observed (Kulkarni AB et al 1993, Shull MM et al 1992). In addition, inactivation of the TGF 
signaling pathway leads to malignant transformation of early hematopoietic cells (Le 
Bousse-Kerdiles MC et al. 1996). These data indicate that TGFβ is inhibitory to 
hematopoietic cells. However, studies from several groups suggest that the response of 
myeloid stem/progenitor cells to the inhibitory effect of TGFβ appears to be inversely 
correlated with their maturation stage (Sing GK 1988, Keller JR 1990, Ottmann OG & Pellus 
LM 1991, Snoeck H-W 1996). Long-term repopulating stem cells, CD34+ or CD34+/CD38- 
stem/progenitor cells, early myeloid and erythroid progenitors are markedly inhibited in 
the presence of TGF, whereas more differentiated myeloid progenitors forming 
granulocyte-macrophage colonies, and late erythroid progenitors forming CFU-e are less 
inhibited or even stimulated by TGF (Keller JR 1990, 1992, 1994, Fortunel NO 2000, Ruscetti 
FW 2005, Sitnicka E 1996, McNiece IK 1992, Goey H 1989, Morita N 2003, Classen S 2007). 
The inhibitory or stimulatory role by TGFβ in some cases seems to correlate with the 
cytokines used to promote cell growth. TGFβ inhibits SCF-, IL-3- and CSF-1-induced colony 
formation from mouse and human hematopoietic progenitors (McNiece IK 1992, Sitnicka E 
et al 1996). In contrast, TGFβ enhances GM-CSF-induced colony formation derived from 
normal bone marrow cells and Lin- progenitors (Keller JR 1991).  
For leukemia cells, both inhibitory and stimulatory effects have been reported (Tessier N & 
Hoang T 1988, Otten J 2011, Aglietta M 1989, Cashman JD 1992). TGF has been shown to 
inhibit the growth of clonogenic blast cells from patients with acute myeloblastic leukemia 
(AML) (Tessier N & Hoang T 1988). Mutations in the components of TGFβ signal pathways 
may relate to the disease development (Imai Y et al. 2001). In contrast, high expression of 
ALK-1 and ALK-5, two members of TGFβ type I receptors, was reported to be associated 
with AML (Otten J 2011). An inhibitory effect of TGFβ was suggested by the finding of low 
levels of TGFβ type II receptors in CML (Rooke HM 1999) and lymphoid neoplasms (Inman 
GJ et al 2000); whereas, by using TGFβ inhibitors, Naka et al found that TGFβ signal is 
required for maintaining Leukemia Initiating Cells (LIC) by controlling nuclear localization 
of transcription factor, FOXO, in a CML mouse model (Naka K et al. 2010).  
The data described above suggest that TGF has both negative and positive effects on the 
proliferation of normal hematopoietic and leukemia cells. However, some of the data appear 
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discordant, which may be due to the complexity of the network in vivo. In the presence of 
other growth factors, TGF-induced stimulation or inhibition could be an indirect result or 
affected by other factors. Therefore, using a cell line as a research model may provide a 
direct effect of TGFβ and produce more consistent results. A TGF knock out hematopoietic 
cell line exhibited increased colony formation in response to IL-3, IL-6, and G-CSF (Kim S-J 
& Letterio J 2003), suggesting that TGFβ is inhibitory to the cells. TGF has been reported to 
inhibit proliferation of mouse myeloid leukemic M1 cells and induce adherence of M1 
myeloid leukemia cells to plastic dishes (Okabe-Kado J 1989). In Josk-1 monoblastic 
leukemia cells, dephosphorylation of pRb and inhibition of c-myc were responsible for 
TGF1-induced G1 arrest (Furukawa Y 1992). In U937 cells, it identified that the inhibition 
of the cells by TGF1 was linked to low levels of transcription factors, C-jun, C-fos and Jun B 
(Kanatni Y 1996). In order to delineate the effect of TGF on more myeloid leukemia cell 
lines and to reach a general conclusion, we examined more than 10 human myeloid 
leukemia cell lines, among which MV4-11 and TF-1a are factor-independent but response 
cell lines; TF-1 and Mo7e are factor-dependent cell lines; and KG-1, KG-1a, K562, U937, 
HL60, and HEL are factor-independent and insensitive to any growth factors. We 
demonstrated that TGF is inhibitory for all these human myeloid leukemia cell lines in 
culture, with heterogeneous inhibitory responses being observed (Hu X et al 1999, Hu X & 
Zuckerman KS 2000). Inhibition of TF-1, KG-1, and K562, Mo7e, and HEL by TGFβ has also 
been reported by other groups recently (Moller GM et al. 2007, Koutoulaki A et al 2010, 
Fukuchi Y et al 2001, Kalina U et al. 2001). Our data and some recent discoveries, clearly 
indicate that the responses of the cell lines to TGFβ are not related to the apparent 
differentiation stages of the cells (Hu X et al 1999) but could result from differences in the 
amount of TGF receptors expressed or the degrees of the mutations (Quentmeier et al. 
2003, 2006, Gu TL et al. 2006) in TGFβ signal components in these cells. The mechanisms by 
which TGFβ inhibits hematopoietic cells involves in the regulation of pRb pocket proteins-
E2F complexes, downregulation of a number of cell cycle regulatory molecules, and 
upregulation of p21 (Ducos K et al 2000) and p57 (Scandura JM et al 2004) as described in 
following sections.  
4. Regulation of pRb-E2F complexes in human myeloid leukemia cells 
pRb acts as a signal transducer collecting signals from cell cycle regulatory molecules to 
transcriptional machinery. G1 protein kinases have been reported to modify pRb by 
phosphorylation, thereby promoting cell cycle progression toward DNA replication 
(Suryadinata R et al. 2011, Takaki T et al. 2004). The growth inhibition of human myeloid 
leukemia cells by TGFβ is linked to suppression of pRb phosphorylation on multiple serine 
and threonine residues, including Ser249/Thr252, Thr373, Ser780, Ser795, and Ser807/811 
(Chen P et al. 1989, Mihara K et al. 1989, Hu X et al. 1999). Dephosphorylated pRb interacts 
with E2F transcription factors. E2F-binding sites have been found in the promoters of many 
genes that control cell cycle progression and cell proliferation, thereby E2Fs play a critical 
role in cell growth control (Iaquinta PJ et al. 2007). Previous studies identified that E2F binds 
to the pocket domain of pRB. In E2F1, the pRB-binding domain interacts with the C-
terminus of the E2F molecule. As a consequence of the pRB-E2F interaction, E2F activity is 
repressed. pRB, therefore, exerts its growth suppression function mainly through its 
sequestration of E2F activity. However, one recent report suggests that E2F-1 binding 
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affinity for pRb is not the only determinant of the E2F1 activity (Sahin F and Sladek TL 
2010a). Of the seven E2Fs well documented, E2F1, E2F2, and E2F3 are considered as 
“activator” E2Fs, whereas, E2F4, E2F5, E2F6, and E2F7 are considered to be “repressor” E2Fs 
(Attwooll C et al. 2004, Sahin F and Sladek TL 2010b). pRb and two pRb-related proteins, 
p107 and p130, show a common structure, which are collectively termed the “pocket 
proteins”. E2F1-3 bind to pRb, and E2F5 binds to p130. E2F4 can interact with the all three 
pocket proteins.  
Dephosphorylated pRb preferentially interacts with E2F1-3 (Weinberg RA et al. 1995), and 
the pRb/E2F complexes are found primarily during the G1 phase of the cell cycle (Shirodkar 
S et al. 1992, Schwarz JK et al. 1993), during which time E2F-responsive promoters are 
repressed. The dissociation of the pRb/E2F-repressor complex and liberation of free E2F 
allows for the activation of these promoters (Hiebert SW et al. 1993, Qin X-Q et al. 1995, 
Helin K et al. 1993). It was demonstrated that E2F-1 responsive gene activation was 
inhibited by overexpression of wild-type pRb, but not by a mutant pRb, whereas 
transactivation mediated by mutants of E2F1, which do not bind to pRb, was not affected by 
overexpression of wild-type pRb. Loss of E2F1-3 resulted in an acute cell cycle arrest (Wu L 
et al. 2001). It has been found that Rb gene was often mutated in patients with various 
cancers, whereas p107 and p130 genes appear to be less frequently mutated in human 
cancers, suggesting that pRb is a tumor suppressor, whereas p107 and p130 are not. 
However, recent studies from several labs have shown that p130 and p107 also actively 
involved in E2F-dependent transcription activities. For example, the major E2F complexes in 
quiescent fibroblasts were E2F4-p130. As cells enter the cell cycle, E2F4-p130 was replaced 
by E2F4-p107 and E2F4-pRb (Ikeda M et al. 1996, Moberg K et al. 1996). Subsequent 
investigators, by performing chromatin immunoprecipitation (ChIP) experiments, were able 
to locate E2F complexes in a gene promoter. They have demonstrated that in serum-
deprived cells, predominantly E2F4, p130, and a histone deacetylase (HDAC) are found to 
bind to corresponding E2F-responsive promoters (Rayman JB et al. 2002, Ren B et al. 2002, 
Takahashi Y et al. 2000). Since histones are generally hypoacetylated when a gene is turned 
off, which is regulated by HDAC, the results described above suggest that p130-E2F4 DNA 
binding activity is required for the gene inactivity and for arresting cells in quiescent state. 
As cells progress through mid-G1, E2F4 and p130 are replaced by activators E2F1, 2, and 3. 
Unexpectedly, loss of pRB had no effect on HDAC recruitment to the promoter or pRb was 
not detectable in the promoters containing the E2F responsive site in quiescent cells 
(Rayman JB et al. 2002, Takahashi Y et al. 2000). Thus, these data suggest that pRb may not 
be a primary negative regulator of E2F activity in control of cell cycle progression in these 
cells.  
As indicated in the previous section, TGF dramatically inhibits the growth of several 
human myeloid leukemia cell lines in culture with a maximal growth inhibition being 
observed in MV4-11 cells. We asked how pRb-E2F complexes were regulated in MV4-11 
cells. We found that in actively proliferating MV4-11 cells, p130 and pRb were expressed as 
peptides that migrated in multiple bands in SDS-PAGE, whereas in the cells treated with 
TGFβ, p130 and pRb were dephosphorylated. However, TGFβ did not dephosphrylate p107 
but inhibited expression of the molecule (Hu X et al. 2000). Subsequently, we found that 
TGFβ-treated MV4-11 cells had very low levels of pRb-associated E2F1 and E2F3. The low 
levels of pRb-E2Fs are resulted from a low expression of E2F1 and E2F3 in response to TGF 
that arrested cells in G1 phase. Unexpectedly, proliferating cells without TGFβ contained 
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discordant, which may be due to the complexity of the network in vivo. In the presence of 
other growth factors, TGF-induced stimulation or inhibition could be an indirect result or 
affected by other factors. Therefore, using a cell line as a research model may provide a 
direct effect of TGFβ and produce more consistent results. A TGF knock out hematopoietic 
cell line exhibited increased colony formation in response to IL-3, IL-6, and G-CSF (Kim S-J 
& Letterio J 2003), suggesting that TGFβ is inhibitory to the cells. TGF has been reported to 
inhibit proliferation of mouse myeloid leukemic M1 cells and induce adherence of M1 
myeloid leukemia cells to plastic dishes (Okabe-Kado J 1989). In Josk-1 monoblastic 
leukemia cells, dephosphorylation of pRb and inhibition of c-myc were responsible for 
TGF1-induced G1 arrest (Furukawa Y 1992). In U937 cells, it identified that the inhibition 
of the cells by TGF1 was linked to low levels of transcription factors, C-jun, C-fos and Jun B 
(Kanatni Y 1996). In order to delineate the effect of TGF on more myeloid leukemia cell 
lines and to reach a general conclusion, we examined more than 10 human myeloid 
leukemia cell lines, among which MV4-11 and TF-1a are factor-independent but response 
cell lines; TF-1 and Mo7e are factor-dependent cell lines; and KG-1, KG-1a, K562, U937, 
HL60, and HEL are factor-independent and insensitive to any growth factors. We 
demonstrated that TGF is inhibitory for all these human myeloid leukemia cell lines in 
culture, with heterogeneous inhibitory responses being observed (Hu X et al 1999, Hu X & 
Zuckerman KS 2000). Inhibition of TF-1, KG-1, and K562, Mo7e, and HEL by TGFβ has also 
been reported by other groups recently (Moller GM et al. 2007, Koutoulaki A et al 2010, 
Fukuchi Y et al 2001, Kalina U et al. 2001). Our data and some recent discoveries, clearly 
indicate that the responses of the cell lines to TGFβ are not related to the apparent 
differentiation stages of the cells (Hu X et al 1999) but could result from differences in the 
amount of TGF receptors expressed or the degrees of the mutations (Quentmeier et al. 
2003, 2006, Gu TL et al. 2006) in TGFβ signal components in these cells. The mechanisms by 
which TGFβ inhibits hematopoietic cells involves in the regulation of pRb pocket proteins-
E2F complexes, downregulation of a number of cell cycle regulatory molecules, and 
upregulation of p21 (Ducos K et al 2000) and p57 (Scandura JM et al 2004) as described in 
following sections.  
4. Regulation of pRb-E2F complexes in human myeloid leukemia cells 
pRb acts as a signal transducer collecting signals from cell cycle regulatory molecules to 
transcriptional machinery. G1 protein kinases have been reported to modify pRb by 
phosphorylation, thereby promoting cell cycle progression toward DNA replication 
(Suryadinata R et al. 2011, Takaki T et al. 2004). The growth inhibition of human myeloid 
leukemia cells by TGFβ is linked to suppression of pRb phosphorylation on multiple serine 
and threonine residues, including Ser249/Thr252, Thr373, Ser780, Ser795, and Ser807/811 
(Chen P et al. 1989, Mihara K et al. 1989, Hu X et al. 1999). Dephosphorylated pRb interacts 
with E2F transcription factors. E2F-binding sites have been found in the promoters of many 
genes that control cell cycle progression and cell proliferation, thereby E2Fs play a critical 
role in cell growth control (Iaquinta PJ et al. 2007). Previous studies identified that E2F binds 
to the pocket domain of pRB. In E2F1, the pRB-binding domain interacts with the C-
terminus of the E2F molecule. As a consequence of the pRB-E2F interaction, E2F activity is 
repressed. pRB, therefore, exerts its growth suppression function mainly through its 
sequestration of E2F activity. However, one recent report suggests that E2F-1 binding 
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affinity for pRb is not the only determinant of the E2F1 activity (Sahin F and Sladek TL 
2010a). Of the seven E2Fs well documented, E2F1, E2F2, and E2F3 are considered as 
“activator” E2Fs, whereas, E2F4, E2F5, E2F6, and E2F7 are considered to be “repressor” E2Fs 
(Attwooll C et al. 2004, Sahin F and Sladek TL 2010b). pRb and two pRb-related proteins, 
p107 and p130, show a common structure, which are collectively termed the “pocket 
proteins”. E2F1-3 bind to pRb, and E2F5 binds to p130. E2F4 can interact with the all three 
pocket proteins.  
Dephosphorylated pRb preferentially interacts with E2F1-3 (Weinberg RA et al. 1995), and 
the pRb/E2F complexes are found primarily during the G1 phase of the cell cycle (Shirodkar 
S et al. 1992, Schwarz JK et al. 1993), during which time E2F-responsive promoters are 
repressed. The dissociation of the pRb/E2F-repressor complex and liberation of free E2F 
allows for the activation of these promoters (Hiebert SW et al. 1993, Qin X-Q et al. 1995, 
Helin K et al. 1993). It was demonstrated that E2F-1 responsive gene activation was 
inhibited by overexpression of wild-type pRb, but not by a mutant pRb, whereas 
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substantial quantities of pRb-E2F1 and pRb-E2F3 complexes. In contrast, the cells treated 
with TGFβ (i.e. G1 cells) showed increased levels of pRb-E2F4 and p130-E2F4 and low level 
of p107-E2F4, as detected by immunoprecipitation and Western blotting. Since TGFβ 
treatment inhibited the expression p107 but not E2F4, thus, the low level of p107-E2F4 
complexes is a result of the inhibition of p107. Our data indicate that E2F4 was switched 
from p107 to pRb and p130 when p107 was inhibited in response to TGF treatment. By 
performing electrophoretic gel mobility shift assay (EMSA), we were not able to detect pRb-
E2F4 DNA binding activities either in proliferating cells or in G1 cells but exhibited the 
existence of p107-E2F4 and p130-E2F4 DNA binding complexes in G1 cells. which is 
consistent with the reports from the ChIP experiments described above. Taking together, 
our data suggest that p107 and p130, but not pRb, and the repressor E2F, but not activator 
E2Fs, play a critical role in regulating E2F-responsive gene expression in TGFβ-mediated 
cell cycle control in human myeloid leukemia cells. This conclusion is consistent with 
several studies that have failed to detect pRb at E2F-responsive genes, whereas p107 and 
p130 are readily detectable (Aslanian A 2004, Rayman JB 2002, Takahashi Y 2000, Wells J 
2000). In addition, many cell cycle-regulated E2F targets are depressed in p107-/- and p130-
/- cells but are not depressed in Rb-/- cells (Herrera RE 1996, Hurford  Jr RK 1997, Mulligan 
GJ 1998). It is not clear if traditional activator E2Fs have any significant impact on cell cycle 
progression of MV4-11 cells, because pRb-E2F1 and pRb-E2F3 complexes have been found 
in the proliferating but not in G1 phase cells. Previous studies suggest that pRb may bind 
other regulatory regions of DNA or uses other mechanisms (Sun H et al. 2011), directly or 
indirectly, for its inhibitory function as a tumor repressor. pRb may also have both positive 
or negative role on cell growth, depending on the transcription factors it interacted (Calo E 
et al. 2010).  
5. TGFβ inhibits both G1 and G2 protein kinases in human myeloid leukemia 
cells 
In mammalian cells, the cell cycle progression is regulated by a group of cyclin dependent 
kinases (cdks) and their regulatory subunits in sequential order: cyclin D-cdk4/cdk6 and 
cyclin E-cdk2 complexes act on G1 and G1-S transition, respectively, followed by cyclin A-
cdk2 on S and cyclin B-cdc2 at G2-M transition. TGF is well known to be a negative 
regulator of G1 cyclin/cdk activity in many types of cells. This has been reported to be a 
major mechanism that is responsible for TGF-induced growth inhibition of cells. In 
epithelial and fibroblasts, the negative role of TGFβ includes inhibition of cdk4 and 
disruption of cyclin E-cdk2 assembly (Ewen ME et al. 1993, Koff A et al 1993). Although 
TGFβ is known to be a G1 cdk inhibitor, studies from several groups suggest potential effect 
of TGFβ on G2 checkpoint kinase. For instance, the mouse epithelial cells treated with TGFβ 
expressed a lower level of cdc2 as compared with the cells without TGFβ ( Fautsch MP et al 
1995); in a hepatoma cell line, TGFβ activates cdc2 and cdk2 followed by phosphorylation of 
pRb which in turn triggers apoptosis of the cells (Choi KS et al 1999). A new report 
published in 2008 presented evidence that disruption of Smad 3, a key component of TGFβ-
induced signal pathway, elevated cdk 1(cdc2) activity via upregulating the expression of 
cyclin B. As a result, the uncontrolled cdk1 delayed mitotic progression (Fujita T 2008). In 
human myeloid leukemia cells, we found that inhibition of multiple cdks including cdc2 
and cdc25C is a dominant event in TGFβ-induced growth inhibition of the cells (Hu X et al. 
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2001). Our recent studies, using TF-1 and MV4-11 human myeloid leukemia cells, 
demonstrated that TGF1-induced inhibition of leukemia cell growth is not due solely to 
downregulation of G1 cyclins and cdks but also G2 check point kinases (Hu X 2007). In MV4-
11 cells, TGF caused a rapid and transient dephosphorylation of cdc2 (Tyr15) and cdc25c 
(Ser216), with 60% and 70% inhibition of phosphorylation of the both proteins by 2-3 hours, 
respectively, followed by returning to near normal by 12 hours, and 70-100% inhibitions 
again by 24-72 hours, repectively. The dephosphorylation of cdc2 and cdc25c was followed 
by a dramatic decrease of total cdc25c (100% decrease at 48 and 72 hours) and cylcin B1 and 
cdc2 (70-90% reduction at 24 to 72 hours). Consistent with these data, cdc2 kinase activity, as 
determined by ability to phosphorylate histone H1 and GST-Rb in vitro, was markedly 
reduced in the leukemia cells treated with TGF for 24-48 h. Cyclin B1 and cdc25c were 
degraded in a ubiquitin/26S proteosome assay system in vitro, which suggests strongly that 
ubiquitination and proteasomal degradation may be the key mechanism of degradation that 
leads to block of G2-M transition. The downregulation of cdc2, cdc25c, and cyclin B1 was not 
a result of G1 arrest but a direct effect of TGFβ, because the time required for the inhibition 
of the cells released from G2 is much shorter than the cells released from G1. Using 
immunoprecipitation and Western blotting we detected that the levels of cyclin B1-cdc2 
complexes were much lower in extracts of TGF-treated cells than in control cells. Based on 
our data, we suggest that TGFβ suppresses growth of human myeloid leukemia cells 
through multiple pathways, by inhibiting both G1 and G2 checkpoint kinases. Since the G1 
and G2 checkpoint kinases are able to phosphorylate pRb in proliferating cells, the down 
regulation of G1 and G2 checkpoint kinases would prevent pRb phospharylation, leading to 
G1 arrest. The data also suggest that cdc2, a traditional G2 regulator in mammalian cells, 
may participate in G1 regulation. Fig. 1 illustrates diagrammatically the negative roles of 
TGFβ in the cell cycle control in myeloid leukemic MV4-11 cells.  
 
 
Fig. 1. TGFβ inhibits both G! and G@ cdks in MV4-11 cells 
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6. Dual roles of cdk inhibitors in human myeloid leukemia cells 
It is well known that activity of cdks is counterbalanced by cdk inhibitors (ckis). The cdk 
inhibitors can be classified into two different families: Ink4 (p16, p15, p18 and p19) and 
cip/kip (p21, p27, and p57), based on their structure similarity. Among these cdk inhibitors, 
p27 and p21 have been intensively studied in various types of cells. In quiescent cells or cells 
treated with TGFβ show high level of p27, whereas proliferating cells or cells treated with 
mitogens express low level of p27 (Moller MB 2000). Overexpression of p27 in cultured cells 
arrests the cells in G1 phase and antisense inhibition of p27 reverses cell cycle arrest induced 
by p27 (Coats S et al 1996; Rivard N et al. 1996). In vivo, p27 is a critical regulator of cellular 
proliferation. Mice lacking p27 gene are 15–30% larger than their wild-type or hemizygous 
(p27+/−) littermates (Fero et al. 1996; Kiyokawa et al. 1996). p27 was initially thought to 
interfere with the activities of cyclin D-, E-, and A-dependent kinases. The crystal structure 
of p27 bound to cyclin-cdk2 reveals that a p27 fragment inserts itself within the cdk2 
catalytic site, blocking ATP access (Russo et al., 1996). These data lead to a popular model in 
which anti-proliferative stimuli up-regulate p27, followed by inhibition of cyclinD-cdk4, 
cyclinE-cdk2, cyclin A-cdk2 activities, and by G1 arrest/growth inhibition. Similar to p27, as 
a negative regulator of the cell cycle progression, p21 is thought to bind and inhibit 
cdk2/cyclin E and/or cdk4/cyclin D complexes, thereby arresting cells at the G1 phase. The 
induction of p21 is regulated by the tumor suppressor gene, p53, in response to DNA 
damage.  
The traditional model of p27 or p21 as a cdk inhibitor has been challenged by a number of 
studies from several labs in which p21 or p27 were demonstrated to be required for a 
cdk/cyclin kinase activity or to be a dual player in cell cycle control (Zhang H et al 1994, 
LaBaer et al 1997). It was reported that p21, at low concentration, promotes the assembly of 
active kinase complexes, whereas a high concentration of p21 causes the opposite effect in 
SAOS-2 cells derived from osteosarcoma (LaBaer et al., 1997). In an animal model, it was 
found that low concentration of p21 could promote tumor progression in the presence of 
oncogenic factors (Jones JM 1999). Primary mouse fibroblasts that are p21-/- and p27-/- 
were failed to assemble cylcin D-CDK complexes and were unable to direct cyclin D nuclear 
translocation (Cheng M 1999). Consistent with this report, p27 was demonstrated to be 
essential for mouse mammary gland morphogenesis and function (Muraoka RS et al. 2001); 
an increased level of p21 was found to be parallel with S-phase entry of oligodendrocytes 
(Bansal R et al. 2005). In another report published in the same year, p27 in mouse T cells was 
found to acts as a promoter during the early stage of the cell cycle (Rowell EA et al 2005). In 
addition, it has been reported that in MCF-7 cells, cyclin D1 promotes cellular migration 
through inducing the expression of p27 and by physically associating with p27 to promote 
cellular migration (Li Z et al. 2006). These dual roles of p21 and p27 in non-hematopoietic 
cells are consistent with what we found in human hematopoietic cells a few years ago. By 
using several human myeloid leukemia cell lines as research models, we demonstrated that 
p27 has differential effect on cdk2 and cyclin E activities, which provides supplementary 
information to the evidence of p27 and p21 having dual roles in cell cycle control described 
above (Hu X et al. 2001). Although TGFβ greatly upregulated p27 in both cytosol and 
nucleus in MV4-11 cells, the association of p27 with cylcin E and cdk2 showed different 
patterns with increased amount of cyclin E-p27 and decreased levels of cdk2-p27 being 
detected by Western blot and immunoprecipitation. Surprised, a significant amount of p27 
was found to associate with cdk2 in proliferating cells, which was downregulated in 
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response to TGFβ. The downregulation is a result of inhibition of total cdk2 by TGFβ. 
However, TGF had no effect on the expression of cyclin E. By carrying out p27 
immunodepletion and transfection experiments, we further demonstrated that that at least 
some cdk2 kinase activity is associated with p27 in MV4-11cells. Additional support for this 
possibility was the observation that cells transfected with anti-sense p27 cDNA but not 
empty plasmid, downregulated cdk2 kinase activity by more than 60%. Although p27 also 
may act as an adapter of cyclin E activity, as suggested by expression of cyclin E- p27 
complexes in proliferating MV4-11 cells, p27 mainly acts as an inhibitor of cyclin E activity 
in response to TGF. This is indicated by the fact that TGF1 upregulated cyclin E-
associated p27 and was accompanied by the inhibition of cyclin E-dependent kinase activity. 
Moreover, p27 immunodepletion dramatically upregulated cyclin E-dependent kinase 
activity in TGF1 treated cells. The effect of p27 on cyclin E-dependent kinase activity is 
dose-dependent, with only high concentrations of p27 being inhibitory to cyclin E activity. 
This may explain the observation that immunodepletion of p27 or anti-sense p27 cDNA did 
not significantly increase cyclin E-dependent kinase activity in proliferating MV4-11 cells. 
These results are against the notion that p27 is a negative regulator of cdk2 kinase in vivo, at 
least in these human myeloid leukemia cells. Our data are consistent with previous findings, 
in which cell cycle arrest mediated by TGF remained intact in p27-/- cells (Nakayama et 
al., 1996) and p21 and p27 has dual roles in cell cycle control (Rowell EA et al. 2005, LaBaer 
et al. 1997, Zhang H et al. 1994). The difference is that the negative or positive role of p27 in 
our model is related to the molecules p27 interacted but not the concentrations of p27 as 
reported in the case of p21 (Matsushime et al., 1992). Taken together, we interpret our 
results to suggest that in proliferating cells p27 is associated with cdk2 and cdk4 as an 
adapter. TGF1 downregulates cdk2, cdk4, and D-type cyclins, which leaves p27kip1 free to 
bind and saturate cyclin E, inhibiting cyclin E-cdk2 assembly, rendering cyclin E-dependent 
kinase inactive. By using these two different regulatory mechanisms, TGF1 magnifies its 
cell cycle inhibitory efficiency in human myeloid leukemia cells (Hu X et al 2001).  
7. Conclusion  
New findings in recent years have provided insight into the complex roles and action 
mechanisms of TGFβ in various types of cells. TGFβ exhibits its distinct effect on the growth 
of human myeloid leukemia cells. Although both positive and negative roles of TGFβ in 
hematopoiesis have been reported, the major role of TGFβ appears to be inhibitory with 
heterogeneous responses being observed in human myeloid leukemia cells. The 
heterogeneous responses of the cells to TGFβ are not related to the apparent differentiation 
stages of the cells but could result from differences in the expression of TGF receptors or 
degrees of the mutations in the components of TGFβ signal pathways. TGFβ, a traditional 
G1 cdk inhibitor, represses not only G1 but also G2 protein kinases in human myeloid 
leukemia cells. pRb has been reported to be a tumor suppressor in various types of cells. The 
new studies suggest that p130, whose gene is less mutated in cancer patients, plays a critical 
role in maintaining cells in quiescent status and in TGFβ-mediated growth inhibition. 
Traditionally, p27 and p21 are G1 cdk inhibitors. However, new evidence suggests that p27 
and p21 have both positive and negative effect on G1 cdk activities.  
Based on the data described in this review, it is clear that TGFβ signals have a defined role 
in regulating normal hematopoiesis, and disruption of the signaling components could lead 
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of human myeloid leukemia cells. Although both positive and negative roles of TGFβ in 
hematopoiesis have been reported, the major role of TGFβ appears to be inhibitory with 
heterogeneous responses being observed in human myeloid leukemia cells. The 
heterogeneous responses of the cells to TGFβ are not related to the apparent differentiation 
stages of the cells but could result from differences in the expression of TGF receptors or 
degrees of the mutations in the components of TGFβ signal pathways. TGFβ, a traditional 
G1 cdk inhibitor, represses not only G1 but also G2 protein kinases in human myeloid 
leukemia cells. pRb has been reported to be a tumor suppressor in various types of cells. The 
new studies suggest that p130, whose gene is less mutated in cancer patients, plays a critical 
role in maintaining cells in quiescent status and in TGFβ-mediated growth inhibition. 
Traditionally, p27 and p21 are G1 cdk inhibitors. However, new evidence suggests that p27 
and p21 have both positive and negative effect on G1 cdk activities.  
Based on the data described in this review, it is clear that TGFβ signals have a defined role 
in regulating normal hematopoiesis, and disruption of the signaling components could lead 
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to hematologic malignancies including myeloid leukemia. These are suggested by the 
observations described above: (1) The development of hematopoietic cells from mesoderm 
in embryos is regulated by TGFβ signaling; (2) inactivation of the TGF signaling pathway 
leads to malignant transformation of early hematopoietic cells; (3) abnormal expressions of 
the components of TGF signaling pathway have been found in AML and CML; and (4) a 
number of mutations of genes that encode TGFβ signaling components have been detected 
in several myeloid leukemia cell lines. Thus, the mutated components may be the targets for 
therapeutic strategy of myeloid leukemia in future.  
Although new information on TGFβ and myeloid leukemia have been emerged at an 
incredibly rapid pace, it is unclear whether some information obtained from studies 
performed in vitro mimic a physiological status in vivo. In addition, the detail about dual role 
of cdk inhibitiors and the role of pRb in leukemia transformation are also need to be 
clarified in future.  
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1. Introduction  
1.1 Myelogenous leukemia and the need for novel drug targets 
The successful treatment of myelogenous leukemia depends upon the continuing coordinate 
efforts of the medical and research communities and patients to understand the complex 
nature of leukemia development and progression, and to battle drug resistant cells. Novel 
drug therapies, like Imatinib, have been developed which target the mutant BCR-ABL 
(Breakpoint Cluster Region-Abelson Kinase) protein, and have significantly changed the 
treatment regimens for chronic myelogenous leukemia (CML). However, while Imatinib is 
frequently effective against the majority of the leukemic cells, and patients often undergo 
remission after treatment, these patients also relapse due to a leukemic drug-resistant 
population (Schemionek et al., 2010). In comparison to CML, the treatment for acute 
myelogenous leukemia (AML) is predominantly induction therapy using strong anti-mitotic 
agents, followed by consolidation therapy to kill residual diseased cells (Venditti et al., 
2000). These therapies are not specifically targeted to mutated proteins in the cells, and 
therefore can be more toxic to the patient's normal cells. Researchers have attempted to 
target mutated proteins in AML. However, unlike BCR-ABL, targeting FLT3-ITD (FMS-like 
tyrosine kinase 3-Internal Tandem Duplication) and FLT3-TKD (FMS-like tyrosine kinase 3-
Tyrosine Kinase Domain) mutations have not been as successful as CML-Imatinib therapy 
(Kindler et al., 2010). Therefore, challenges facing patients with AML remain significant, and 
drug-resistant relapses remain a threat.  
1.2 Transcription factor deregulation in myelogenous leukemia 
To identify novel drug targets, researchers will have to gain a better understanding of the 
molecular mechanisms that regulate normal hematopoietic development. Hematopoiesis 
depends upon the activity of transcription factors and their regulators to function at the 
correct time and place during differentiation. Failure to control these processes can lead to 
deregulated proliferation and impaired normal differentiation. Ultimately, these errors can 
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lead to myeloproliferative diseases (MPD), myelodysplastic syndromes (MDS), and chronic 
or acute myelogenous leukemia (Rosenbauer et al., 2005). Current research efforts are 
focused on the molecular mechanism(s) that contribute to transcription factor deregulation 
with a goal of designing better, safer and less toxic therapies, to restore normal 
differentiation or initiate apoptosis of leukemic cell populations. Deregulation can result 
from many different types of mutations including translocations, deletions, and point 
mutations, which can result in loss of function, gain of function, overexpression or 
underexpression. The Id (Inhibitor of DNA Binding) proteins are key downstream 
transcriptional regulators of multiple neoplastic mutations and are deregulated (have 
increased expression) in many types of cancer, and therefore may be good therapeutic 
targets particularly for drug-resistant forms of leukemia. 
2. Id proteins inhibit transcription factors that regulate cell cycle and 
differentiation 
2.1 Tissue specific expression of Id proteins 
The Id proteins belong to a subclass of the helix-loop-helix (HLH) family of proteins. There 
are four family members (Id1, Id2, Id3, Id4), which range in size from 13 to 20 kDa (Figure 1). 
In normal tissues, Id1 and Id3 are ubiquitously expressed; they are detectable throughout 
embryonic development and are present in the bone marrow, testis, kidney, brain, liver and 
spleen. The expression of Id2 and Id4 are more restricted (Riechmann et al., 1994). Id2, is not 
detectable until day 13.5 of fetal liver development. Id2 is most highly expressed in the bone 
 
 
Fig. 1. Schematic representation of the Id family 
Id2, Id3, and Id4 have Cdk2 phosphorylation sites, although only Id2 and Id3 are known to 
be phosphorylated by cyclinA/E-Cdk2.  Cdk2-dependent phosphorylation of Id2 (Hara et 
al., 1997) and Id3 (Deed et al., 1997) inhibits binding to E proteins and Ets transcription 
factors.   Id proteins are ubiquitinated and undergo rapid turnover during the cell cycle 
mediated by ubiquitination and proteosomal degredation, and two different targeting 
mechanisms have been reported.  Id1, Id2, and Id4 have "D box" destruction motifs 
(RxxLxxxN) which is recognized by the anaphase promoting complex (APC) which targets 
the proteins for ubiquitination (Harper et al., 2002; Lasorella et al., 2006).  Degradation of Id1 
and Id3, is mediated by the COP9 signalosome (Berse et al., 2004).   
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marrow, testis and brain. Id4 is expressed during embryogenesis, but is not detectable in the 
fetal liver. Id4 expression is present in the adult bone marrow, testis, kidney, brain, and 
spleen. These data suggest that the Id proteins may be critical during development, as well 
as having important functions in the adult. In this regard, simultaneous deletion of any two 
Id gene family members results in early embryonic lethality, demonstrating that these genes 
are required for development (Fraidenraich et al., 2004). Therefore, in summary, as a family 
the Id proteins are present in many different tissues, and are expressed during early 
development as well as in adult tissues. 
2.2 Id protein function: Regulation of transcription factors and cell cycle regulators 
The Id proteins function by blocking the DNA binding activity of three types of essential 
transcription factors:  (1) The basic Helix-Loop-Helix (bHLH) proteins (E proteins), (2) 
Helix-Turn-Helix ETS transcription factors, and (3) Pax transcription factors (Pax-5 in B 
cells) (Figure 2). In addition, specific members of the Id family decrease the activity of Rb 
tumor suppressors (Iavarone et al., 1994; Lasorella et al., 1996).  
 
 
Fig. 2. Id proteins bind bHLH, ETS, and Pax transcription factors and block their function. 
(A) bHLH, ETS, and Pax factors dimerize and bind to and activate the promoter regions of 
genes essential for differentiation and cell cycle arrest.  
(B) When Id proteins are present, they bind to bHLH, ETS and Pax transcription factors, 
blocking their dimerization and inhibiting their ability to activate transcription. 
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E proteins and regulation of differentiation. The HLH transcription factors are essential for 
regulating the differentiation programs of multiple tissues types. The E proteins, also known 
as "Class A" HLH family members, include E2A (encoding E12 and E47 proteins), HEB, and 
E2-2. E proteins homodimerize or heterodimerize with "Class B" bHLH family members, 
tissue specific proteins such as SCL/tal1 (hematopoiesis), HAND, MyoD, myogenin 
(myogenesis), NeuroD/BETA2 (pancreatic development and neurogenesis), HES-1, and 
MASH-1 (neurogenesis). When dimerized, these bHLH proteins bind to E box consensus 
sequence (CANNTG, where "N" is any nucleotide) through their basic N-terminal regions. 
When Id proteins are present, they bind to the E proteins and disrupt their dimerization 
with the Class B binding partners (Langlands et al., 1997), and block the differentiation of 
muscle, neuronal, pancreatic and hematopoietic cells. The Id proteins homodimerize poorly 
with each other and preferentially bind to the Class A HLH factors (Sun et al., 1991). In 
summary, the effect of Id proteins, prevents or arrests differentiation by blocking the E 
protein transcription activating function in many different cell types. 
E proteins and cell cycle control. The E proteins also induce the expression of cell cycle 
inhibitors, such as p16INK4a and p21Cip1. The cell cycle inhibitors cyclin dependent kinases 
4 and 6 (Cdk4, Cdk6), are necessary for the cell to progress to S phase. Therefore, Id 
proteins inhibit the transcriptional activity of the E proteins, which decrease the 
expression of cell cycle inhibitors, and ultimately results in increased cellular proliferation 
(Alani et al., 2001; Zheng et al., 2004; Prabhu et al., 1997). In support of this, when Id1 is 
knocked-out in mice, mouse embryo fibroblasts that lack Id1 (Id1-/-) undergo premature 
senescence, due in part to increased expression of p16INK4a (Alani et al., 2001). Thus, 
increased expression of Id1 proteins promotes cell proliferation by inhibiting the function 
of E protein transcriptional activity, by blocking their ability to induce the expression of 
key cell cycle inhibitors. 
Regulation of ETS proteins by Ids. The Id proteins also regulate the activity of the ETS (E 
twenty-six) helix-turn-helix family of transcription factors. The ETS proteins comprise one of 
the largest families of transcription factors, and they bind the canonical sequence GGAA/T. 
The ETS proteins are characterized by the presence of the ETS DNA binding domain, and 
the family includes PU.1 (SPI1), Ets1, Ets2, TEL, and TEL2 as well as the ternary complex 
factors (TCF):  Elk1, Elk3 (Net/SAP2), and Elk4 (SAP1). The Id family members interact with 
the ETS protein DNA binding domain, blocking the ability of the ETS proteins to bind DNA, 
and repressing their ability to activate transcription. Id1, Id2 and Id3 have all been shown to 
bind to the TCF proteins Elk-1 and Elk-4, and Id1 and Id3 both suppress the expression of 
the cell cycle inhibitor p27Kip1 by blocking Elk-1's ability to activate transcription (Yates et 
al., 1999; Chassot et al., 2007). As previously described, Ids can decrease p16INK4a protein 
expression by repressing E protein activity, in addition, Id1 has also been shown to reduce 
p16INK4a expression by the inhibiting the activation of its expression by Ets1 and Ets2 (Ohtani 
et al., 2001). Interestingly, the ability of the Id proteins to bind to the ETS transcription 
factors can be inhibited by phosphorylation of the Ids. Within the Id family, only Id2 and 
Id3 undergo phosphorylation, and phosphorylation of these Ids by cyclin A/E-Cdk2 
decreases their ability to bind to ETS proteins (specifically, Elk-1), resulting in cell cycle 
arrest (Stinson et al., 2003). This mechanism may compose part of a normal cell cycle 
regulatory feedback mechanism in cells that permits cell populations to expand and then 
return to a growth arrested state. In summary, Id proteins inhibit the function of the ETS 
proteins, blocking their ability to activate transcription of cell cycle inhibitors, which results 
in increased proliferation.  
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Retinoblastoma (Rb) and p53 tumor suppressors. The retinoblastoma protein (Rb), is an 
important part of normal cell cycle control. When Rb is hypo-phosphorylated, it is active 
and bound to E2F, causing cell cycle arrest by preventing E2F from inducing the expression 
of genes necessary for cell proliferation (Sherr and McCormick, 2002). When Rb is 
phosphorylated by the cyclin dependent kinases (Cdks), it dissociates from E2F, and this 
allows E2F to activate the expression of genes necessary for DNA replication. Rb is 
frequently mutated in many different malignancies, and finding ways to restore Rb function 
remains a goal in cancer research. Interestingly, Id2 alone of the Id family binds to the hypo-
phosphorylated Rb, as well as related proteins p107 and p130 and inhibits their growth 
suppressive activities. The Id proteins do not affect the expression levels or phosphorylation 
state of Rb (Lasorella et al., 1996). However, when Id2 binds in the pocket-binding of Rb site 
it prevents it from arresting the cell cycle (Iavarone et al., 1994; Lasorella et al., 1996). There 
are also reports that Id1 can decrease p53 activity, although it is not known whether this is a 
direct or an indirect effect. The reduction of p53 activity results in decreased PTEN tumor 
suppressor expression, and ultimately results in increased cellular proliferation (Lee et al., 
2009). 
In summary, the Id family of proteins affects both differentiation and cell cycle progression 
by inhibiting the DNA binding activity of the E and ETS protein transcription factors, by 
binding to and disrupting the activity of Rb and related proteins, and by decreasing p53 
activity.  
3. The role of Id proteins in normal myelopoiesis 
3.1 Id protein levels during  myelopoiesis 
Id proteins were first identified in a mouse leukemic cell line in the search for novel factors 
containing HLH domains. Benezra et al. identified the first Id protein in murine 
erythroleukemia (MEL) cells in 1990 (Benezra et al., 1990). They observed that Id1 was 
present in less-differentiated cell types, and found that Id expression decreased after 
differentiation was induced in erythroid, muscle, and endothelial cell lines. Subsequently, 
using a myeloid progenitor cell line, 32DCl3, it was found that endogenous Id1 expression 
rapidly decreased in cells induced to differentiate to neutrophilic granulocytes by 
granulocyte colony stimulating factor (G-CSF), then rose again during the later stages of 
differentiation. Id2 expression also decreased following G-CSF treatment of 32DCl3 cells 
(Leeanansaksiri et al., 2005), as well as in multiple other myeloid cell lines (Ishiguro et al., 
1996). When Id1 concentration was artificially elevated in the 32DCl3 cells, the cells failed to 
differentiate in response to G-CSF (Kreider et al., 1992). Similarly, overexpression of Id1 in 
MEL cells also resulted in a block in differentiation (Shoji et al., 1994). Therefore, in normal 
cells, Id1 expression needs to decrease for a defined period after the induction of 
differentiation. If Id proteins are overexpressed during this phase, the cells do not 
differentiate in spite of the extracellular signals instructing them to mature.  
In mouse bone marrow, moderate levels of Id1 are present in the hematopoietic stem cells 
(HSC) and common lymphoid progenitors (CLP). Id1 expression is increased in the more 
differentiated common myeloid progenitors (CMP), and further increased in the granulocyte 
macrophage progenitors (GMP), however Id1 levels do not increase in megakaryocyte 
erythroid progenitors (MEP). The dynamic levels of Id1 expression during these early stages 
of hematopoiesis suggest that Id1 may regulate cell fate decisions during myeloid, 
erythroid, and lymphoid development (Leeanansaksiri et al., 2005). In support of this 
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Retinoblastoma (Rb) and p53 tumor suppressors. The retinoblastoma protein (Rb), is an 
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allows E2F to activate the expression of genes necessary for DNA replication. Rb is 
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2009). 
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cells, Id1 expression needs to decrease for a defined period after the induction of 
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In mouse bone marrow, moderate levels of Id1 are present in the hematopoietic stem cells 
(HSC) and common lymphoid progenitors (CLP). Id1 expression is increased in the more 
differentiated common myeloid progenitors (CMP), and further increased in the granulocyte 
macrophage progenitors (GMP), however Id1 levels do not increase in megakaryocyte 
erythroid progenitors (MEP). The dynamic levels of Id1 expression during these early stages 
of hematopoiesis suggest that Id1 may regulate cell fate decisions during myeloid, 
erythroid, and lymphoid development (Leeanansaksiri et al., 2005). In support of this 
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hypothesis, culture of mouse bone marrow cells in the presence of interleukin-3 (IL-3) or IL-
3 with stem cell factor (SCF), or GM-CSF, which promote granulocyte and macrophage 
development, all increased Id1 expression. Correspondingly, culture of human CD34+ bone 
marrow cells with myeloid growth factors SCF and IL-3, SCF and macrophage colony 
stimulating factor (M-CSF), SCF and granulocyte macrophage colony stimulating factor 
(GM-CSF), or with GM-CSF alone also induced Id1 expression (Suh et al., 2008). However, 
SCF alone, SCF and erythropoietin (EPO), or SCF and thrombopoietin (TPO), which 
promote erythroid and megakaryocyte development, did not induce Id1 expression in 
murine or human hematopoietic progenitors. Furthermore, initial reports showed that Id2 
expression increases during differentiation of myeloid cells (Ishiguro et al., 1996), although 
the onset of its expression in myelopoiesis is later in hematopoietic development than Id1 
(Cooper et al., 1997). In summary, in normal mouse and human progenitor cells, 
hematopoietic growth factors that promote granulocyte and macrophage development 
induce the expression of Id1. 
3.2 Id protein levels rise in later stages of differentiation   
The study by Kreider et al., which examined Id1 expression during induction of 
differentiation in 32DCl3 cells by G-CSF showed that Id1 levels also increased during 
terminal neutrophil differentiation of 32DCl3 (Kreider et al., 1992). In agreement with this, 
Shoji et al. demonstrated that if Id1 is overexpressed in later stages of myeloid 
differentiation, that Id1 did not block myeloid maturation, as in the early stages of myeloid 
differentiation (Shoji et al., 1994). These reports suggest that Id protein expression may have 
an additional role in terminal myeloid differentiation. This model is supported by studies in 
human CD34+ cord blood cells that show ectopic expression of Id1 can enhance neutrophil 
development; and expression of Id2 accelerates final maturation of eosinophils and 
neutrophils (Buitenhuis et al., 2005). In addition, restoring Id1 expression (along with 
C/EBPα expression) in cells isolated from patients with low-risk myelodysplastic syndrome 
(MDS) restores neutrophil maturation in vitro (Geest et al., 2009). Thus, the expression of the 
Id proteins is biphasic during normal hematopoietic development, appearing first in the 
stem and progenitor stages, decreases during the intermediate developmental stages, and 
then rises again during terminal differentiation. 
3.3 Loss of Id proteins disrupts normal hematopoietic development   
The Id proteins are necessary for proper hematopoietic development, including progenitor 
expansion and fate determination. While Id1 knockout mice are viable and show no overt 
developmental defects, several groups have reported that hematopoietic stem and 
progenitor cells in these mice show impaired development (Yan et al., 1997; Perry et al., 
2007; Suh et al., 2009). Specifically, the hematopoietic stem cells responsible for long term 
engraftment and repopulation (LT-HSC) fail to compete against co-transplanted bone 
marrow cells as well as normal control bone marrow LT-HSC (Jankovic et al., 2007; Perry et 
al., 2007). However, four serial transplantations of Id1-/- bone marrow, without the addition 
of co-transplanted competitor bone marrow, supported equal engraftment and viability of 
the transplant recipients as wild type mouse bone marrow cells, suggesting the intrinsic loss 
of Id1 does not impair the fundamental long-term self-renewal ability of LT-HSC (Suh et al., 
2009). In addition, these studies also showed that the loss of Id1 also significantly alters the 
bone marrow microenvironment, specifically the stromal cells and the hematopoietic 
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growth factors they produce, reducing the amount of SCF and SDF produced, and 
increasing the amount of GM-CSF, G-CSF, and M-CSF produced by the stromal cells (Suh et 
al., 2009). These changes in the stromal microenvironment may explain the myeloid-priming 
effect reported in the Id1-null LT-HSC (Jankovic et al., 2007). In summary, the loss of Id1 can 
disrupt normal hematopoiesis, causing significant changes in the bone marrow 
microenvironment as well as in the hematopoietic stem and progenitor populations.  
While Id1 expression is important for maintenance of the hematopoietic microenvironment, 
and affects the competitive repopulation ability of LT-HSC, Id2 is essential for normal 
hematopoietic development as demonstrated by deletion of Id2 in mouse models. Id2 
knockout mouse models have defects in natural killer (NK) and dendritic cell development, 
as well as impaired lymphopoiesis and erythroid defects (Yokota et al., 1999). Id2 regulates 
fate determination in myeloid development by interaction with the ETS transcription factor 
PU.1. Id2 relieves PU.1 repression of the GATA-1 transcription factor, which shifts 
progenitor cell development from a monocyte/granulocyte differentiation program to an 
erythroid program (Ji et al., 2008). In summary, Id2 is essential for normal hematopoietic 
development and is a key regulatory factor in the fate determination of B and erythroid cell 
development. 
In contrast to its family members Id1 and Id2, the normal physiological role of Id3 appears 
to be regulation of lymphoid development. Specifically Id3 has a major role in supporting 
the proper maturation of B cells, as mice that are Id3 null have defects in B cell proliferation 
and maturation (Pan et al., 1999; Rivera et al., 2000). However, Id3 is not normally expressed 
in myeloid development, nor is Id4 (Ishiguro et al., 1995; Ishiguro et al., 1996). The levels at 
which the Id proteins are expressed in the cells and the stage in differentiation at which they 
are expressed as well as the type of cell in which they are expressed affect how Id proteins 
function "normally" in the cells. Altogether, the Id family of proteins has two functions in 
normal cells:  to regulate the process of fate determination and differentiation, and to control 
cell proliferation.  
4. Id proteins and leukemia 
4.1 Ids and leukemogenesis  
Id proteins have oncogenic properties in myeloid cells. Overexpression of the Id genes is 
associated with malignancy and poor prognosis in many different tissues (Table 1). 
Whether increased expression of Id proteins are a by-product of deregulated growth or are 
causative is still under investigation. Id gene overexpression in cell lines results in 
hyperproliferation and blocked differentiation. For example, Shoji et al., demonstrated that 
Id1 overexpression inhibits differentiation of erythroleukemia cell lines (Shoji et al., 1994) 
and Kreider et al. demonstrated Id1 blocks 32DCl3 myeloid progenitor differentiation 
(Kreider et al., 1992).  
When Id protein expression is deregulated, normal progenitor expansion and differentiation 
becomes unbalanced and shifts towards progenitor hyperproliferation. In the myeloid 
lineage, forced expression of Id1 or Id2 can impair monocyte, granulocyte, and erythroid 
maturation (Jen et al., 1996; Kreider et al., 1992; Leeanansaksiri et al., 2005; Lister et al., 1995). 
Furthermore, in mouse bone marrow cells, overexpression of either Id1 or Id3 can 
immortalize growth factor-dependent hematopoietic progenitors in vitro, resulting in cells 
with an AML-like morphology. Immunophenotypic and gene expression analyses of these 
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2007; Suh et al., 2009). Specifically, the hematopoietic stem cells responsible for long term 
engraftment and repopulation (LT-HSC) fail to compete against co-transplanted bone 
marrow cells as well as normal control bone marrow LT-HSC (Jankovic et al., 2007; Perry et 
al., 2007). However, four serial transplantations of Id1-/- bone marrow, without the addition 
of co-transplanted competitor bone marrow, supported equal engraftment and viability of 
the transplant recipients as wild type mouse bone marrow cells, suggesting the intrinsic loss 
of Id1 does not impair the fundamental long-term self-renewal ability of LT-HSC (Suh et al., 
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growth factors they produce, reducing the amount of SCF and SDF produced, and 
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In contrast to its family members Id1 and Id2, the normal physiological role of Id3 appears 
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the proper maturation of B cells, as mice that are Id3 null have defects in B cell proliferation 
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which the Id proteins are expressed in the cells and the stage in differentiation at which they 
are expressed as well as the type of cell in which they are expressed affect how Id proteins 
function "normally" in the cells. Altogether, the Id family of proteins has two functions in 
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Member Tumor Type Reference 
   
Id1, Id3 Glioblastoma, Medulloblastoma, Neuroblastoma (Lyden et al., 1999) 
Id1, Id2, Id3 Pancreatic Cancer 
(Kleeff et al., 1998; 
Maruyama et al., 
1999) 
Id1, Id2, Id3, 
Id4 Testicular Seminoma (Sablitzky et al., 1998) 
Id1 Thyroid Cancer (Kebebew et al., 2000, 2003) 
Id1, Id2, Id3 Squamous Cell Carcinoma 
(Hu et al., 2001; 
Langlands et al., 
2000; Nishimine et 
al., 2003; Wang et al., 
2002) 
Id1 Breast Cancer 
(Lin et al., 2000; 
Schoppmann et al., 
2003) 
Id1 Endometrial Cancer (Takai et al., 2001) 
Id1 Cervical Cancer (Schindl et al., 2001) 
Id1 Melanoma (Polsky et al., 2001) 
Id2 Neuroblastoma (Lasorella et al., 2002; Lasorella et al., 2000) 
Id2 Ewing Sarcoma 
(Fukuma et al., 2003; 
Nishimori et al., 
2002) 
Id1, Id2, Id3 Astrocytic Tumor (Vandeputte et al., 2002) 
Id1 Basal Cell Carcinoma (Chaturvedi et al., 2003) 
Id1, Id2, Id3 Colorectal Carcinoma (Norton, 2000; Wilson et al., 2001) 
Id1 Hepatocellular Carcinoma (Lee et al., 2003) 
Id1 Kaposi's Sarcoma (Tang et al., 2003) 
Id1 Ovarian Cancer (Schindl et al., 2003) 
Id1 Prostate Cancer (Ouyang et al., 2002) 
Id1 AML subsets (Suh et al., 2008; Tang et al., 2009) 
Table 1. Id Protein Expression in Cancer 
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immortalized cells suggest they are developmentally arrested at the CMP/GMP phase of 
maturation (Suh et al., 2008). The bone marrow cells immortalized by Id1 overexpression 
showed decreased levels of p15INK, p16INK4a, p19ARF and p21Cip1 during culture (Suh et al., 
2008), indicating that Id1 expression reduced the expression of multiple cell cycle inhibitors 
to cause increased growth in deregulated myelopoiesis.  
These results showed that overexpression of Id1 immortalized normal bone marrow cells in 
vitro, and led researchers to investigate if deregulated Id1 expression cells would cause a 
myeloproliferative disease in vivo. Transplantation of Id1 overexpressing mouse HSPC 
resulted in the development of a myeloproliferative disease in mice, causing the animals to 
become moribund within a year. Complete blood cell counts showed the mice had 
monocytosis, and low levels of hemoglobin and hematocrit, as well as the presence of cells 
with leukemic-blast morphology. Pathology revealed that the mice had myeloid and 
erythroid hyperplasia in their bone marrow and spleens which lead to splenomegaly (Suh et 
al., 2008). Therefore, overexpression of Id1 is sufficient to immortalize mouse progenitor 
cells in vitro, and leads to a lethal myeloproliferative disease in vivo. 
Similar to Id1, overexpression of Id2 has also been shown to cause the development of 
leukemia in mouse models. Transgenic overexpression of Id2 in mouse models leads to a 
block in lymphoid differentiation, aberrant apoptosis, and development of T cell lymphoma 
(Morrow et al., 1999). Id2 also blocks differentiation in human cells, specifically, ectopic 
expression of Id2 in human CD34+ myeloid progenitor cells inhibits the acquisition of 
monocyte characteristics, suggesting that Id2 can block myeloid as well as lymphoid 
differentiation (Heinz et al., 2006). It is important to note, that the effects of Id1 or Id2 
overexpression depend upon the developmental stage and lineage in which overexpression 
occurs. In summary, overexpression of both Id1 and Id2 can block differentiation, over-ride 
senescence, and lead to the development of myelo- and lymphoproliferative disease, and 
ultimately leukemogenesis.  
Increased Id1 and Id2 expression is associated with human AML. The finding that Ids 
immortalize primary mouse bone marrow cells in vitro, and promote MPD in vivo, led 
investigators to ask if Id expression levels are elevated in myelogenous leukemia. A 
microarray performed on 285 AML patient samples demonstrated an increase in Id1 and Id2 
in AML subsets (Suh et al., 2008). Specifically, 17.5% of the mRNA samples from AML patients 
had increased Id1 expression, and 19.2% had increased Id2 mRNA levels. Surprisingly, most of 
the patients with elevated Id1 and Id2 levels had a normal karyotype, and were evenly 
distributed across the French-American-British (FAB) subtype classifications: M0-M6. 61% and 
50% of patients with 5q and/or 7q deletion and 28 and 22%of patients with t(15;17) showed 
increased expression of Id1 and Id2, suggesting that elevated Id expression levels contribute to 
a block in granulocyte development. Seventy-eight patients had high levels of FLT3-ITD 
mutations, and 23 of those (29%) had elevated levels of Id1 expression. Twenty-three patients 
had EVI1 deregulation, of which 8 patients (35%) had increased Id1 expression. Id2 expression 
was found in patients with deregulated NRAS (30%), KRAS (44%), C/EBPα (6%) and EVI1 
(30%) expression. Altogether, the analysis suggests that Id gene expression may be induced 
downstream of multiple signal transduction pathways of activated oncogenes. A separate 
analysis of a different cohort of AML samples showed that patients with the highest levels of 
Id1 had a poor prognosis compared to those with lower levels of Id1 (Tang et al., 2009). The 
causes of Id1 and Id2 overexpression in AML are still under investigation. Thus, elevated 
levels of Id gene expression could be used diagnostically to elucidate the severity and 
prognosis of AML patients. 
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Expression of Id1 and Id2 are increased by known leukemic oncogenes. It is possible that 
in many cases Id1 and Id2 mRNA levels increase due to mutations in upstream regulatory 
pathways. Id1 is a downstream target of multiple leukemia-associated oncogenic tyrosine 
kinases, including BCR-ABL and FLT3-ITD (Tam et al., 2008). In addition, the JAK2V617F—
STAT5, and AML-ETO mutations can also increase Id1 expression (Cammenga et al., 2003; 
Wood et al., 2009). PLZF and the PLZF translocation products, associated with APL (acute 
promyelocytic leukemia), activate Id1 and Id3 expression (Bernardo et al., 2007; Doulatov et 
al., 2009; Rice et al., 2009). In addition, overexpression of HOXA9 and HOXA10, both of 
which are associated with myeloid hyperplasia, directly activate expression of Id2 (Nagel et 
al., 2010). Furthermore, viruses also induce Id expression, for example, Id1 is upregulated by 
Epstein-Barr viral protein LMP1 (NH) (Li et al., 2004). Therefore, the Id proteins are likely to 
be part of the mechanism by which several of the known oncogenic mutations impair 
growth control. 
Id2 has both oncogenic and tumor suppressor properties. Interestingly, although Id2 has 
been shown to be upregulated in AML patient samples (as described above), Id2 may have 
have both oncogenic and tumor suppressor properties. Specifically, there are data 
demonstrating that the loss of Id2 in vivo results in the development of a lethal 
myeloproliferative disorder (Ko et al., 2008). This effect was seen in Id2 knockout mice 
backcrossed onto a C57Bl/6 background, but not in 129/sv Id2 knockout, although the 
reasons for this difference are not yet known. Altogether, the data suggest that Id2 is 
important for functional hematopoiesis, but that its function as an oncogene or as a tumor 
suppressor depend upon the cellular environment in which it is expressed. 
Id1 causes genomic instability. Of the Id family of proteins, overexpression of Id1 is most 
consistently reported as associated with oncogenesis. A possible explanation for this may be 
that Id1 has been associated with genomic instability. Interestingly, it was shown that Id1 
contributes to the acquisition of secondary mutations by causing centrosome abnormalities. 
One mechanism by which this been shown to occur is by Id1 binding to the S5A protein. 
Loss of S5A has been associated with mitotic defects resulting in abnormal chromosome 
segregation (Szlanka et al., 2003). When Id1 is overexpressed it interacts with S5A, and this 
interaction causes overduplication of the centrosomes (Hasskarl et al., 2004; Hasskarl et al., 
2008). Leukemogenic translocation mutations such as BCR-ABL can induce genomic 
instability (Dierov et al., 2009). Based on the data showing that BCR-ABL can induce 
expression of Id1, it is possible that part of the mechanism by which BCR-ABL causes 
genomic instability is by inducing overexpression of Id1 (Dierov et al., 2009). Thus, the 
presence of overexpressed Id1 can not only block differentiation and override senescence; it 
can actively contribute to the acquisition of additional mutations. 
Id family overexpression is associated with disruption of apoptosis. In addition to causing 
genomic instability, another mechanism by which cancer cells survive is by avoiding 
programmed cell death. Multiple reports have shown that Id1, Id2, and Id3 can influence 
apoptosis. However, whether the Id proteins behave as pro-apoptotic or anti-apoptotic 
factors depends upon the the cell context. Transgenic expression of Id1 in developing T cells 
in a mouse model resulted in a large percentage of the developing thymocytes to undergo 
apoptosis. The authors of the study speculated that this was because the thymocytes were 
blocked in maturation and apoptosis was initiated during the process of V(D)J 
recombination (Kim et al., 1999). Interestingly, lymphomas developed from the surviving 
thymocytes, suggesting that overexpression of Id1 alone did not drive apoptosis. In 
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addition, Id1 overexpression in prostate cancer cells actually protects malignant cells from 
apoptosis (Ling et al., 2003; Wong et al., 2004). Furthermore, decreasing the activity of the Id 
proteins promotes cell cycle arrest and apoptosis in both breast and ovarian cancer cells 
(Mern et al., 2010a; Mern et al., 2010b). In summary, the Id proteins can have variable affects 
on apoptosis, depending upon the developmental stage and microenvironment of the cell. 
Id4 functions as a tumor suppressor in myeloid leukemia. Id4 is interesting because of 
reports that suggest it may function not as an oncogene, but as a tumor suppressor in 
leukemia (in contrast to its siblings). Methylation of the Id4 promoter is associated with poor 
prognosis in high risk MDS patients, who have a greater probability of developing leukemia 
(Wang et al., 2010b). In addition, high risk myelodysplastic patients whose Id4 promoters 
are methylated have an increased risk of leukemic transformation, an obersvation which 
would support for the use of demethylating agents in MDS/AML treatment (Chen et al., 
2011; Wang et al., 2010b). Id4 methylation also correlates with CML progression. 
Specifically, Id4 is un-methylated in the chronic phase of CML, but is frequently methylated 
in patients in the accelerated and blast crisis stages (Wang et al., 2010a).  
Reports also show that Id4 promoter is methylated in AML cell lines and in AML primary 
patient samples (Yu et al., 2005). This study also demonstrated that Id4 promoter 
methylation resulted in decreased Id4 mRNA expression. At the same time, the role of Id4 
as a tumor suppressor in myelodysplasia appears to be cell type specific, as Id4 
overexpression increases the proliferation of other cell types (breast cancer) (Dell'Orso et al., 
2010). Therefore, of all of the Id family members, Id4 is the only one that is consistently 
reported to be a tumor suppressor in myeloid cells, although how it functions 
mechanistically in that role is not yet understood. 
4.2 Ids and drug resistance in leukemia 
Altogether, the reports described above suggest a strong link between Id expression levels 
and malignancy. It is possible, therefore, that Ids may be part of a mechanism that helps 
the malignant cells evade standard chemotherapeutic treatments. A search of the Gene 
Expression Omnibus (GEO; (Barrett and Edgar, 2006)) database reveals studies, which 
show a correlation between increased Id expression and drug resistance in AML and CML 
cell lines. Specifically, these analyses show that Id1 expression is increased in cytarabine 
resistant AML cell lines (Figure 3A)(GDS 1907), and that Id1 is also increased in 
cyclophosphamide resistant CML (Figure 3B) (GDS2729) (Bao et al., 2007). In addition, Id3 
mRNA levels are increased in cyclophosphamide resistant CML lines (Figure 3C) 
(GDS2729) (Bao et al., 2007). Altogether, these analyses indicate that high levels of Id1 
and/or Id3 expression may correlate with a drug resistant phenotype in myelogenous 
leukemia. 
These analyses agree with many other studies that show Id1 functions as an anti-apoptotic 
factor in cancerous cells from non-hematopoietic tissues. Id1 expression has been shown to 
prevent malignant cells from undergoing programmed cell death when treated with 
chemotherapeutic agents (Summarized in (Zhang et al., 2007)). Decreasing Id1 expression 
with Id1-targeted siRNA restored drug sensitivity in many of these malignant cell lines, 
however, it has not yet been tested in hematopoietic cells (Zhang et al., 2007). In summary, 
the data from these studies suggest that high levels of Id1 expression may be indicative of 
drug resistance in leukemic cells, or may possibly be part of the mechanism underlying 
drug resistance, which will likely be a focus of future studies with both AML and CML. 
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Fig. 3. Increased Id levels associated with drug resistance in leukemic cell lines 
(A) Id1 mRNA expression is increased in cytarabine resistant AML cell lines (GDS 1907);  
(B) Id1 is also increased in cyclophosphamide resistant CML (GDS2729), and (C) Id3 mRNA 
is increased in cyclophosphamide resistant CML lines (GDS2729) 
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4.3 Ids and Leukemia Initiating Cells 
The results shown above lead to the question of whether or not the Ids might be expressed 
in the "Leukemia Initiating Cell" (LIC) population that is resistant to drug treatment. These 
quiescent leukemic stem cells have been termed the "Holy Grail of Leukemia Therapy" 
(Misaghian et al., 2009). However, identifying and understanding the regulation of these 
cells depends on a better understanding of normal transcription factors in stem cells; and 
how they may be deregulated, and become leukemia stem cells (Rosenbauer et al. 2005).  
The process of normal stem-cell self-renewal must be tightly regulated to prevent the 
creation of leukemic stem cells. Therefore, the proteins that regulate the HSC self-renewal 
process are currently under intense investigation. E proteins maintain the stem cell pool and 
promote myeloid progenitor differentiation, and because Id proteins control E protein 
function, variations in Id protein levels can significantly affect HSC self-renewal (Semerad et 
al., 2009). In support of this concept, Id proteins were shown to have a role in maintaining 
the self-renewal capacity of stem cells. Specifically, BMP induction of Id proteins suppresses 
differentiation and sustains ES cell self-renewal in collaboration with STAT3 (Ying et al., 
2003). In addition, in glioma cancer stem cells, decreasing expression of Id1 and Id3 
effectively targeted and reduced the malignant stem cell population (Anido et al., 2010). 
There are also reports that loss of Id1 significantly decreases hematopoietic stem cell 
function, although reports vary on whether this is an environmental effect or a result of 
changes in the bone marrow microenvironment (Jankovic et al., 2007; Perry et al., 2007; Suh 
et al., 2009). In addition, it has been observed that loss of Id2 significantly decreases the 
long-term self-renewal capacity of hematopoietic stem cells (Ming Ji et al., unpublished). All 
of these studies suggest that Id genes contribute to the control of self-renewal of normal 
HSC and deregulation of the Id proteins may contribute to the generation of leukemic stem 
cells. Future studies will likely focus on this important aspect of Id protein function, as they 
may provide a novel approach to target leukemic stem cells. 
5. Id proteins and the bone marrow microenvironment 
Chemotherapy-resistant human leukemia stem cells home to and engraft within the bone-
marrow endosteal region (Ishikawa et al., 2007), and reports indicate that the Id proteins 
may also have an effect on this microenvironment. As previously described, the loss of Id1 
in the bone marrow niche leads to increased progenitor cycling caused by a change in the 
cytokine milieu (Suh et al., 2009). Thus, Id genes may additionally contribute to the initiation 
or progression of AML by affecting the stromal cells that constitute the hematopoietic niche. 
Interestingly, in addition to affecting the local cytokine milieu, the Ids regulate the 
fundamental structure of the bones by controlling osteoblast and osteoclast activity. For 
example, ectopic Id4 expression promotes osteoblast differentiation and was suggested as a 
possible preventative treatment for senile osteoporosis (Tokuzawa et al., 2010). Id1, Id2, and 
Id3 are all upregulated in response to BMP9 treatment of mesenchymal progenitor cells (via 
Smad4), which results in increased proliferation and a block in differentiation of osteogenic 
progenitors (Peng et al., 2004). In addition, Id proteins have been shown to regulate 
osteogenic transcription factor activity (Ogata and Noda, 1991; Tamura and Noda, 1994; 
Zhang et al., 2008). Id2, and Id4 genes also regulate adipogenesis by regulating the 
proliferation pre-adipoctye progenitors and their ability to undergo differentiation (Murad 
et al., 2010; Park et al., 2008). Altogether, these results suggest that the Id family members 
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not only regulate hematopoietic growth factor expression, but the fundamental structure of 
the niche itself.  
6. Targeting Id proteins 
The identification of Id1 as a common downstream effector of oncogenic mutations such as 
BCR-ABL and FLT3-ITD in CML and AML, as well as their upreglation in multiple types of 
cancer, suggest that the Id proteins represent potential targets for therapeutic intervention 
(Suh et al., 2008; Tam et al., 2008). Inhibiting Id1 protein expression in human induced 
pluripotential stem cells using with small inhibitory RNAs (siRNA) increases differentiation 
into committed progenitors suggesting that decreasing Id expression can support cell 
maturation (Hong et al., 2011). To date, there are three novel inhibitors of Id function 
currently under investigation. 
6.1 Peptide conjugated antisense oligonucleotides 
Henke et al. generated an anti-sense oligonucleotide that is covalently coupled to an 
"address-peptide," Id1-PCAO (peptide-conjugated anti-sense oligonucleotide) (Henke et al., 
2008). The peptide used in this study was designed specifically to target endothelial cells; 
however, other targeting peptides are available and could be linked to the Id1 anti-sense 
molecule to direct the anti-sense molecule to hematopoietic cells. While the Id1-PCAO 
strategy has not been tested in hematopoietic cells, it is a feasible approach for use in the 
hematopoietic malignancies. Targeting peptides have been identified which home to bone 
marrow and bind primitive hematopoietic stem cells (Nowakowski et al., 2004). The benefit 
of this procedure would be that it does not require the use of any viral transduction 
procedures, and the targeting peptide should limit potential toxicity by localizing the anti-
sense molecule to the diseased area. 
6.2 Peptide aptamer 
Another small molecule which has recently been developed is a peptide that binds both Id1 
and Id3. Mern et al. identified a peptide aptamer (a short peptide), Id1/Id3-PA7, from a 
randomized combinatorial expression library using yeast and mammalian two-hybrid 
systems. When the aptamer is fused to a "cell-penetrating protein transduction domain" or 
PTD (truncated VP22 ORF), and tested on ovarian cancer cell lines, it causes increased 
expression of p16INK4a, and it induced apoptosis (as indicated by PARP cleavage)  (Mern et 
al., 2010a). The aptamer colocalized with Id1 and Id3 staining based on 
immunohistochemistry, suggesting that its effects result from its direct interaction with Id1 
and/or Id3. To date, the authors have tested this molecule on ovarian and breast cancer cell 
lines in vitro and demonstrated growth inhibition, but have not yet examined its effects on 
normal cells nor in hematopoiesis (Mern et al., 2010a; Mern et al., 2010b).  
6.3 Dominant interfering molecule 13I  
In an effort to better understand the rules of HLH protein interaction, Ciarapica and 
collegues screened a phage display library to identify and isolate mutant domains with 
could interfere with HLH domain interactions. They discovered a dominant interfering 
HLH domain, 13I, which selectively binds to Ids (Id1, Id2, Id3) as opposed to their E protein 
HLH binding partners, and also impairs complex formation with Rb (Id2). Expression of 13I 
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in a human embryonic kidney cell line (293) and in neuroblastoma cell lines restored the 
ability of the E protein E47 to bind and activate the promoters of cell cycle inhibitors. In 
addition, 13I was also able to induce differentiation in neuroblastoma cells suggesting it can 
over-ride both the cell cycle promotion and differentiation blocking functions of the Id 
proteins (Ciarapica et al., 2009). To date, 13I has not yet been tested on normal or 
hematopoietic cells.  
Each of these inhibitors represents a hopeful step forward to reducing aberrant Id levels and 
restoring proper differentiation to hyperproliferative cells. The attractive feature of the Ids 
as potential therapeutic targets is that their expression does not need to be completely 
reduced, just suppressed to low enough levels to restore differentiation, as seen in normal 
tissues. 
7. Summary 
In summary, the Id proteins are potential targets in myelogenous leukemia. Much of the 
work that has gone into characterizing this family of small proteins indicates that if the 
expression of Id1, Id2, and Id3 is maintained at high levels in progenitor cells, and if their 
expression is not reduced at the correct time during maturation or differentiation that this 
could contribute to hyperplasia or neoplasia. Currently there are three targeting molecules 
available that are undergoing testing at the basic research level.  
The discovery of novel mediators of oncogenesis, and biomarkers for disease identification 
and progression, such as the Id family of proteins, will contribute to the design of better 
drugs and more effective therapies for myelogenous leukemia. 
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currently under investigation. 
6.1 Peptide conjugated antisense oligonucleotides 
Henke et al. generated an anti-sense oligonucleotide that is covalently coupled to an 
"address-peptide," Id1-PCAO (peptide-conjugated anti-sense oligonucleotide) (Henke et al., 
2008). The peptide used in this study was designed specifically to target endothelial cells; 
however, other targeting peptides are available and could be linked to the Id1 anti-sense 
molecule to direct the anti-sense molecule to hematopoietic cells. While the Id1-PCAO 
strategy has not been tested in hematopoietic cells, it is a feasible approach for use in the 
hematopoietic malignancies. Targeting peptides have been identified which home to bone 
marrow and bind primitive hematopoietic stem cells (Nowakowski et al., 2004). The benefit 
of this procedure would be that it does not require the use of any viral transduction 
procedures, and the targeting peptide should limit potential toxicity by localizing the anti-
sense molecule to the diseased area. 
6.2 Peptide aptamer 
Another small molecule which has recently been developed is a peptide that binds both Id1 
and Id3. Mern et al. identified a peptide aptamer (a short peptide), Id1/Id3-PA7, from a 
randomized combinatorial expression library using yeast and mammalian two-hybrid 
systems. When the aptamer is fused to a "cell-penetrating protein transduction domain" or 
PTD (truncated VP22 ORF), and tested on ovarian cancer cell lines, it causes increased 
expression of p16INK4a, and it induced apoptosis (as indicated by PARP cleavage)  (Mern et 
al., 2010a). The aptamer colocalized with Id1 and Id3 staining based on 
immunohistochemistry, suggesting that its effects result from its direct interaction with Id1 
and/or Id3. To date, the authors have tested this molecule on ovarian and breast cancer cell 
lines in vitro and demonstrated growth inhibition, but have not yet examined its effects on 
normal cells nor in hematopoiesis (Mern et al., 2010a; Mern et al., 2010b).  
6.3 Dominant interfering molecule 13I  
In an effort to better understand the rules of HLH protein interaction, Ciarapica and 
collegues screened a phage display library to identify and isolate mutant domains with 
could interfere with HLH domain interactions. They discovered a dominant interfering 
HLH domain, 13I, which selectively binds to Ids (Id1, Id2, Id3) as opposed to their E protein 
HLH binding partners, and also impairs complex formation with Rb (Id2). Expression of 13I 
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in a human embryonic kidney cell line (293) and in neuroblastoma cell lines restored the 
ability of the E protein E47 to bind and activate the promoters of cell cycle inhibitors. In 
addition, 13I was also able to induce differentiation in neuroblastoma cells suggesting it can 
over-ride both the cell cycle promotion and differentiation blocking functions of the Id 
proteins (Ciarapica et al., 2009). To date, 13I has not yet been tested on normal or 
hematopoietic cells.  
Each of these inhibitors represents a hopeful step forward to reducing aberrant Id levels and 
restoring proper differentiation to hyperproliferative cells. The attractive feature of the Ids 
as potential therapeutic targets is that their expression does not need to be completely 
reduced, just suppressed to low enough levels to restore differentiation, as seen in normal 
tissues. 
7. Summary 
In summary, the Id proteins are potential targets in myelogenous leukemia. Much of the 
work that has gone into characterizing this family of small proteins indicates that if the 
expression of Id1, Id2, and Id3 is maintained at high levels in progenitor cells, and if their 
expression is not reduced at the correct time during maturation or differentiation that this 
could contribute to hyperplasia or neoplasia. Currently there are three targeting molecules 
available that are undergoing testing at the basic research level.  
The discovery of novel mediators of oncogenesis, and biomarkers for disease identification 
and progression, such as the Id family of proteins, will contribute to the design of better 
drugs and more effective therapies for myelogenous leukemia. 
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1. Introduction 
PU.1 is a member of the Ezb transformation-specific sequence (Ets) family of transcription 
factors, and is expressed in granulocytic, monocytic and B-lymphoid cells (Chen et al., 
1995b; Klemsz et al., 1990). PU.1 expression levels increase during the differentiation of 
granulocytes (Chen et al., 1995b). PU.1-deficient mice exhibit defects in the development of 
neutrophils, macrophages and B cells (McKercher et al., 1996; Scott et al., 1994). Therefore, 
PU.1 is indispensable for myeloid differentiation during normal hematopoiesis. Moreover, 
mice carrying hypomorphic PU.1 alleles that reduce PU.1 expression to 20% of its normal 
levels were reported to develop acute myeloid leukemia (AML) (Rosenbauer et al., 2004), 
suggesting that disruption of the function of this transcription factor plays a pivotal role in 
myeloid leukemia biology through the control of numerous target genes. Binding sites for 
PU.1 are found on almost all myeloid-specific promoters. Notable target genes are receptors 
for the cytokines, macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating 
factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) (Hohaus et al., 
1995; Smith et al., 1996; Zhang et al., 1994), the characteristic antigens CD11b/CD18 
(Rosmarin et al., 1995), primary granule enzymes (Iwama et al., 1998) and the transcription 
factors c-Jun and JunB (Steidl et al., 2006). In addition, a transcriptional repressor function of 
PU.1 toward a certain set of genes has been demonstrated. Although the importance of the 
PU.1 function as a positive regulator of these myeloid genes has been widely examined and 
reviewed, studies on the role of PU.1 as a transcriptional repressor are relatively scarce. The 
author’s group and others demonstrated that loss of PU.1 function resulted in upregulation 
of several drug-resistance or growth-regulating genes, including metallothionein (MT), 
vimentin (VIM), c-myc and Flt3, through disruption of the transcriptional repressor function 
(Imoto et al., 2010; Inomata et al., 2006; Iseki et al., 2009). This review summarizes the 
current understanding of the molecular functions of PU.1. Moreover, this review has a 
particular focus on the transcriptional function of PU.1 as an activator as well as a repressor. 
Furthermore, the role of PU.1 in the biology of myeloid leukemia is discussed. 
2. PU.1, a member of the ETS transcription factor family 
The Ets family of transcription factors is so named because the first gene was identified in 
the E26 avian retrovirus. Ets factors constitute a relatively large gene family, with 27 
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members encoded by the human genome (Sharrocks, 2001). As precisely reviewed by 
Oikawa and Yamada (Oikawa & Yamada, 2003), Ets family proteins can be divided into 
several subfamilies on the basis of their structural compositions and the similarities in their 
DNA-binding Ets domains. Most of them have the Ets domains in their C-terminal regions. 
However, several Ets family proteins, such as the ternary complex factor (TCF) subfamily 
members, have the Ets domains in their N-terminal regions. In addition, besides the 
conserved Ets domain, a subset of Ets family proteins (e.g. Ets-1, Ets-2, ERG, TEL) have 
another evolutionarily conserved domain called the pointed domain at their N-terminal 
regions, which forms a helix-loop-helix (HLH) structure for protein-protein interactions 
(Oikawa & Yamada, 2003). PU.1 is the most distantly related member of the Ets family 
proteins having only about 40% identity with Ets-1 in its DNA-binding domain (Oikawa & 
Yamada, 2003).  
3. Structure of PU.1 
Spi-1, the gene name for PU.1, was first identified by Moreau-Gachelin and colleagues as the 
product of a gene targeted by recurrent insertions of the Spleen Focus Forming Virus (SFFV) 
in Friend’s erythroleukemia. An important and unusual feature of the genomic locus Spi-1 
for SFFV proviral integration is that rearrangements caused by SFFV integration were found 
in 95% of the erythroid tumors examined (Moreau-Gachelin et al., 1988). They subsequently 
isolated PU.1 (for purine-rich box 1) as a factor that binds to a purine-rich motif in the MHC 
class II gene promoter. Basically, monomeric PU.1 binds to the consensus DNA site 5’-
AAAG(A/C/G)GGAAG-3’ via its C-terminal Ets domain and activates transcription via its 
N-terminal glutamine-rich and acidic domains (Klemsz et al., 1990) (Figure 1).  
 
 
Fig. 1. Schematic presentation of PU.1 and its interacting partners. Proteins involved in 
transcription are shown in ovals, with transcriptional repressors shown in light gray and 
basic transcription factors shown in dark gray.  
PU.1 is encoded by the Spi-1 (sfpi1) gene located on chromosome 11 in humans 
(chromosome 2 in mice). PU.1 transcripts are 1333 nucleotides long and are produced from 
the splicing of five exons (Kastner & Chan, 2008). The PU.1 protein is 272 amino acids long 
(predicted MW: 31 kDa). The structure of PU.1 is shown in Figure 1. The DNA-binding Ets 
domain shows sequence similarity with other members of the Ets family and is contained 
within amino acids 171–267 of the C-terminus (Klemsz et al., 1990). The Ets domain 
 
PU.1, a Versatile Transcription Factor and a Suppressor of Myeloid Leukemia  
 
241 
corresponds to the DNA-binding domain and recognizes sequences harboring the core 
GGAA motif. This domain is also involved in the protein-protein interactions between PU.1 
and other factors such as GATA-1 (Nerlov et al., 2000), c-Jun (Behre et al., 1999), Runx 1 or 
C/EBP (Petrovick et al., 1998).  
The activation domain of PU.1 is located within the N-terminus and consists of several 
regions rich in either acidic amino acids or glutamines (designated the Gln-rich domain) 
(Klemsz & Maki, 1996). The activation domain at the N-terminal 75 amino acids of PU.1 has 
been shown to interact in vitro with the basal transcription factor IID (TFIID) and the tumor 
suppressor retinoblastoma (Rb) protein (Hagemeier et al., 1993). Yamamoto et al. 
(Yamamoto et al., 1999) previously found that this transcriptional activation domain of 
amino acids 74–122 binds to a transcriptional coactivator, cAMP response element-binding 
protein (CREB)-binding protein (CBP). CBP potentiated PU.1-mediated transcription of a 
reporter gene driven by multimerized PU.1-binding sites, suggesting that CBP functions as a 
coactivator for PU.1 (Yamamoto et al., 1999). A region from amino acids 118–160, which has 
large numbers of prolines, glutamic acids, serines and threonines, is called the PEST domain 
(Klemsz & Maki, 1996). This domain plays important roles in the protein-protein 
interactions, particularly those with interferon (IFN) consensus sequence-binding protein 
(ICSBP, also called IFN regulatory factor-8) (Nakano et al., 2005). 
The C-terminal region of PU.1 has been reported to interact with the leucine zipper 
transcription factor CCAAT/enhancer-binding protein (C/EBP) , DNA-binding protein 
HMG I/Y, multifunctional phosphatase MKP-1 and chaperone protein HSP90 (Nagulapalli 
et al., 1995) as well as the basic transcription factor TATA box-binding protein (TBP) 
(Kihara-Negishi et al., 2001). 
The PU.1 protein is also the target of phosphorylation events, notably on serine 148, which 
are regulated by various extracellular signals and play critical roles in modifying the activity 
of this factor (Joo et al., 2004). These aspects will be discussed later in section 7. 
4. Role of PU.1 in normal hematopoiesis, especially in the myeloid lineage, 
through the regulation of its target genes 
As described in the introduction, PU.1 is expressed in B-lymphoid, granulocytic and 
monocytic cells (Chen et al., 1995b; Klemsz et al., 1990). PU.1 expression levels increase 
during the differentiation of granulocytes (Chen et al., 1995b). PU.1-deficient mice exhibit 
defects in the development of neutrophils, macrophages and B cells, although the generation 
of erythroid and megakaryocytic cells is intact (McKercher et al., 1996; Scott et al., 1994).  
In the erythroid lineage, the expression of PU.1 is downregulated during terminal 
differentiation of murine erythroleukemia (MEL) cells by treatment with dimethylsulfoxide 
(Hensold et al., 1996). Enforced expression of PU.1 in MEL cells inhibits erythroid 
differentiation (Oikawa et al., 1999; Yamada et al., 2001). In contrast to the lack of PU.1 
expression in the myelomonocytic lineage, which results in impairment of the 
differentiation, overexpression of PU.1 results in erythroid differentiation blockade. 
Expression of PU.1 is observed in CD34+ hematopoietic progenitors and differentiation 
commitment toward the myeloid and lymphoid lineages appears to be determined by the 
expression levels of PU.1, since high PU.1 levels promote macrophage differentiation and 
relatively low PU.1 levels induce B-cell differentiation (DeKoter & Singh, 2000).  
Collectively, PU.1 functions in multiple hematopoietic lineages including myeloid, 
lymphoid and erythroid cells. Many reviews describing the roles of PU.1 in hematopoiesis 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
240 
members encoded by the human genome (Sharrocks, 2001). As precisely reviewed by 
Oikawa and Yamada (Oikawa & Yamada, 2003), Ets family proteins can be divided into 
several subfamilies on the basis of their structural compositions and the similarities in their 
DNA-binding Ets domains. Most of them have the Ets domains in their C-terminal regions. 
However, several Ets family proteins, such as the ternary complex factor (TCF) subfamily 
members, have the Ets domains in their N-terminal regions. In addition, besides the 
conserved Ets domain, a subset of Ets family proteins (e.g. Ets-1, Ets-2, ERG, TEL) have 
another evolutionarily conserved domain called the pointed domain at their N-terminal 
regions, which forms a helix-loop-helix (HLH) structure for protein-protein interactions 
(Oikawa & Yamada, 2003). PU.1 is the most distantly related member of the Ets family 
proteins having only about 40% identity with Ets-1 in its DNA-binding domain (Oikawa & 
Yamada, 2003).  
3. Structure of PU.1 
Spi-1, the gene name for PU.1, was first identified by Moreau-Gachelin and colleagues as the 
product of a gene targeted by recurrent insertions of the Spleen Focus Forming Virus (SFFV) 
in Friend’s erythroleukemia. An important and unusual feature of the genomic locus Spi-1 
for SFFV proviral integration is that rearrangements caused by SFFV integration were found 
in 95% of the erythroid tumors examined (Moreau-Gachelin et al., 1988). They subsequently 
isolated PU.1 (for purine-rich box 1) as a factor that binds to a purine-rich motif in the MHC 
class II gene promoter. Basically, monomeric PU.1 binds to the consensus DNA site 5’-
AAAG(A/C/G)GGAAG-3’ via its C-terminal Ets domain and activates transcription via its 
N-terminal glutamine-rich and acidic domains (Klemsz et al., 1990) (Figure 1).  
 
 
Fig. 1. Schematic presentation of PU.1 and its interacting partners. Proteins involved in 
transcription are shown in ovals, with transcriptional repressors shown in light gray and 
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corresponds to the DNA-binding domain and recognizes sequences harboring the core 
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suppressor retinoblastoma (Rb) protein (Hagemeier et al., 1993). Yamamoto et al. 
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(ICSBP, also called IFN regulatory factor-8) (Nakano et al., 2005). 
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differentiation (Oikawa et al., 1999; Yamada et al., 2001). In contrast to the lack of PU.1 
expression in the myelomonocytic lineage, which results in impairment of the 
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lymphoid and erythroid cells. Many reviews describing the roles of PU.1 in hematopoiesis 
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have been published (Gallant & Gilkeson, 2006; Kastner & Chan, 2008; Oikawa et al., 1999; 
Oikawa & Yamada, 2003). Therefore, this section of the present review particularly focuses 
on the roles of PU.1 in myeloid lineage development through the regulation of its target 
genes.  
Early myeloid differentiation is controlled by PU.1 and other families of transcription factors, 
such as C/EBPs, AML1/Runx1, retinoic acid receptor  (RAR), c-Myb and others (Friedman, 
2002). C/EBP and C/EBP knockout mice also have defects in the development of mature 
macrophages and neutrophils (Yamanaka et al., 1997; Zhang et al., 1999). Hence, PU.1, as well 
as the C/EBP family members, is a critical master regulator for the determination of the 
developmental pathway toward the myeloid lineage in hematopoietic cells.  
 
Gene Level of regulation References 
M-CSFR Promoter (Zhang et al., 1994) (Li et al., 2005) 
GM-CSFR Promoter (Hohaus et al., 1995) 
G-CSFR Promoter (Smith et al., 1996) 
CD11b Promoter (Chen et al., 1993) 
CD18 Promoter (Rosmarin et al., 1995) (Bottinger et al., 1994) 
MPO Enhancer (Ford et al., 1996) 
NE Enhancer (Nuchprayoon et al., 1999) 
NE Promoter (Oelgeschlager et al., 1996) 
PR3 Promoter (Sturrock et al., 1996) 
Lysozyme Enhancer (Ahne & Stratling, 1994) 
gp91phox  Promoter (Suzuki et al., 1998) 
p47phox Promoter (Li et al., 1997) 
c-Jun Unknown (Steidl et al., 2006) 
JunB Promoter (Steidl et al., 2006) 
PU.1 Promoter (Chen et al., 1995a) 
Table 1. PU.1 target genes play crucial roles in myeloid lineage development 
Binding sites for PU.1 are found on almost all myeloid-specific promoters. A large collection 
of PU.1-dependent promoters have been identified, which control an array of genes 
encoding predominantly growth factor receptors, adhesion molecules and characteristic 
enzymes. Notable target genes are receptors for cytokines, adhesion molecules, primary 
granule enzymes and transcription factors.  
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The M-CSF receptor (M-CSFR) (Zhang et al., 1994), GM-CSF receptor  (GM-CSFR) 
(Hohaus et al., 1995) and G-CSF receptor (G-CSFR) (Smith et al., 1996) gene promoters 
were reported to be directly regulated by PU.1. These promoters are regulated by PU.1 in 
combination with C/EBP (Hohaus et al., 1995; Li et al., 2005; Smith et al., 1996). By 
employing sense or antisense PU.1 expression, Celada et al. (Celada et al., 1996) showed 
that PU.1 is necessary for M-CSF-dependent proliferation of macrophages, through the 
control of M-CSFR expression. Another group demonstrated that PU.1-deficient myeloid 
progenitors can proliferate in vitro in response to the multilineage cytokines interleukin 
(IL)-3, IL-6 and stem cell factor, but are unresponsive to the myeloid-specific cytokines 
GM-CSF, G-CSF and M-CSF (DeKoter et al., 1998). Expression of M-CSFR or G-CSFR in 
PU.1-deficient marrow cells did not rescue myeloid development, indicating that PU.1 is 
required beyond the induction of these cytokine receptors (DeKoter et al., 1998; Henkel et 
al., 1999).  
The CD11b (or macrophage-1 antigen; MAC-1) leukocyte integrin subunit exists on the 
surface of human granulocytes and monocytes/macrophages coupled with the CD18 () 
subunit in a heterodimer. This heterodimer mediates multifaceted adherence reactivity of 
these myeloid cells, including the ability to adhere to endothelial cells (Arnaout, 1990). 
The CD11b promoter was reported to be positively regulated by both Sp1 and PU.1 (Chen 
et al., 1993). CD18 promoter activity is also regulated by PU.1 (Bottinger et al., 1994; 
Rosmarin et al., 1995). Consistently, CD11b/CD18 are undetectable on the surfaces of cells 
lacking PU.1 (Henkel et al., 1996; Olson et al., 1995). These molecules are from the 2 
integrin chain, otherwise known as complement receptor 3 (CR3) (Ehlers, 2000). The 
CD11b subunit of CR3 promotes phagocytosis and macrophage migration by binding to 
extracellular matrix proteins, coagulation proteins and a variety of microbial antigens 
(Ehlers, 2000). 
Primary granule enzymes are a group of serine proteases or closely related molecules found 
in cells of the granulocyte series. PU.1-deficient myeloid promoters lack or exhibit low 
expression of primary granule enzymes, including myeloperoxidase (MPO), neutrophil 
elastase (NE), proteinase 3 (PR3) and lysozyme (Iwama et al., 1998). Ford et al. (Ford et al., 
1996) demonstrated that the MPO upstream enhancer is accessible in multipotent cell 
chromatin, but functionally incompetent before granulocyte commitment. Multipotent cells 
contain both PU.1 and C/EBP as enhancer-binding activities. It was reported that a 220-bp 
portion of the second intron of the PR3 gene, which contains an Sp1 consensus site flanked 
by two Ets family consensus sequences that bind PU.1, functions as an enhancer of NE 
expression (Nuchprayoon et al., 1999). In addition, PU.1 cooperates with C/EBP  and c-
Myb to regulate the NE promoter (Oelgeschlager et al., 1996). PR3 expression has also been 
shown to be regulated by PU.1 (Sturrock et al., 1996). PU.1-deficient neutrophils do not 
express secondary granule components, including collagenase, lysozyme and lactoferrin, 
and have limited ability to ingest and kill bacteria (Anderson et al., 1998; Iwama et al., 1998). 
The activity of the lysozyme gene enhancer was demonstrated to be controlled by PU.1 in 
avian macrophages (Ahne & Stratling, 1994). In addition, the expression of gp91phox and 
p47phox, which are both components of nicotinamide adenine dinucleotide phosphate 
(NADPH) phagocyte oxidase, is positively regulated by PU.1 (Li et al., 1997; Suzuki et al., 
1998). 
In addition to these myeloid-specific genes, several transcription factors play crucial roles in 
the phenotype of PU.1-deficient mice. Steidl et al. (Steidl et al., 2006) examined the 
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have been published (Gallant & Gilkeson, 2006; Kastner & Chan, 2008; Oikawa et al., 1999; 
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The M-CSF receptor (M-CSFR) (Zhang et al., 1994), GM-CSF receptor  (GM-CSFR) 
(Hohaus et al., 1995) and G-CSF receptor (G-CSFR) (Smith et al., 1996) gene promoters 
were reported to be directly regulated by PU.1. These promoters are regulated by PU.1 in 
combination with C/EBP (Hohaus et al., 1995; Li et al., 2005; Smith et al., 1996). By 
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that PU.1 is necessary for M-CSF-dependent proliferation of macrophages, through the 
control of M-CSFR expression. Another group demonstrated that PU.1-deficient myeloid 
progenitors can proliferate in vitro in response to the multilineage cytokines interleukin 
(IL)-3, IL-6 and stem cell factor, but are unresponsive to the myeloid-specific cytokines 
GM-CSF, G-CSF and M-CSF (DeKoter et al., 1998). Expression of M-CSFR or G-CSFR in 
PU.1-deficient marrow cells did not rescue myeloid development, indicating that PU.1 is 
required beyond the induction of these cytokine receptors (DeKoter et al., 1998; Henkel et 
al., 1999).  
The CD11b (or macrophage-1 antigen; MAC-1) leukocyte integrin subunit exists on the 
surface of human granulocytes and monocytes/macrophages coupled with the CD18 () 
subunit in a heterodimer. This heterodimer mediates multifaceted adherence reactivity of 
these myeloid cells, including the ability to adhere to endothelial cells (Arnaout, 1990). 
The CD11b promoter was reported to be positively regulated by both Sp1 and PU.1 (Chen 
et al., 1993). CD18 promoter activity is also regulated by PU.1 (Bottinger et al., 1994; 
Rosmarin et al., 1995). Consistently, CD11b/CD18 are undetectable on the surfaces of cells 
lacking PU.1 (Henkel et al., 1996; Olson et al., 1995). These molecules are from the 2 
integrin chain, otherwise known as complement receptor 3 (CR3) (Ehlers, 2000). The 
CD11b subunit of CR3 promotes phagocytosis and macrophage migration by binding to 
extracellular matrix proteins, coagulation proteins and a variety of microbial antigens 
(Ehlers, 2000). 
Primary granule enzymes are a group of serine proteases or closely related molecules found 
in cells of the granulocyte series. PU.1-deficient myeloid promoters lack or exhibit low 
expression of primary granule enzymes, including myeloperoxidase (MPO), neutrophil 
elastase (NE), proteinase 3 (PR3) and lysozyme (Iwama et al., 1998). Ford et al. (Ford et al., 
1996) demonstrated that the MPO upstream enhancer is accessible in multipotent cell 
chromatin, but functionally incompetent before granulocyte commitment. Multipotent cells 
contain both PU.1 and C/EBP as enhancer-binding activities. It was reported that a 220-bp 
portion of the second intron of the PR3 gene, which contains an Sp1 consensus site flanked 
by two Ets family consensus sequences that bind PU.1, functions as an enhancer of NE 
expression (Nuchprayoon et al., 1999). In addition, PU.1 cooperates with C/EBP  and c-
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p47phox, which are both components of nicotinamide adenine dinucleotide phosphate 
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In addition to these myeloid-specific genes, several transcription factors play crucial roles in 
the phenotype of PU.1-deficient mice. Steidl et al. (Steidl et al., 2006) examined the 
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transcriptome of preleukemic hematopoietic stem cells (HSCs) from mice in which PU.1 was 
knocked down to identify transcriptional changes. They demonstrated that the transcription 
factors c-Jun and JunB were among the top downregulated targets. They concluded that the 
decreased levels of c-Jun and especially JunB contribute to the development of PU.1 
knockdown-induced AML by blocking differentiation and increasing self-renewal. It was 
previously reported that PU.1 autoregulates its expression in myeloid cells (Chen et al., 
1995a). However, autoregulation by PU.1 remains uncertain, since the expression of GFP 
reporters driven by the endogenous PU.1 promoter remains high in PU.1-null hematopoietic 
cells (Back et al., 2005; Dakic et al., 2005). 
 
 
Fig. 2. PU.1 as a transcriptional activator. The known myeloid promoters regulated by a set 
of transcription factors in combination with PU.1 are depicted. 
Table 1 shows a list of myeloid genes that are known to be positively regulated by PU.1. 
Collectively, PU.1 plays a pivotal role in myeloid development through the regulation of 
cytokines, receptors, transcription factors and various myeloid specific genes.  
The majority of the PU.1-dependent promoters in the myeloid lineage share several 
structural features, including a PU.1-binding site close to the site(s) of transcriptional 
initiation, no TATA box and a cluster of binding sites for Sp1 and members of the C/EBP or 
core-binding factor (CBF) families (Fisher & Scott, 1998; Tenen et al., 1997). A schematic 
layout of the transcription factors binding to the proximal promoter regions is shown in 
Figure 2. The G-CSFR, M-CSFR and GM-CSFR promoters are regulated by PU.1 and 
C/EBPs, whereas the CD11b and NE promoters are regulated by PU.1 in combination with 
Sp1. 
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In contrast to PU.1 or C/EBPs, the other transcription factors are widely expressed outside 
of the hematopoietic system, indicating that myeloid-specific expression may be principally 
caused by PU.1 or unique combinations of adjoining transcription factors working in concert 
with PU.1 (Fisher & Scott., 1998). In this group of myeloid promoters, as depicted in Figure 
2, binding of PU.1 close to the start point of transcription may facilitate recruitment to the 
TFIID complex and promote the binding of adjoining transcription factors. TFIID is a 
protein complex consisting of TBP and a set of TBP-associated factors (TAFs) (Pugh, 1996). 
Binding of TFIID to the promoter region is the first step in the assembly process that forms 
the transcription initiation complex. Not only does the N-terminal of PU.1 interact with 
TFIID, but its C-terminal was reported to interact with TBP (Kihara-Negishi et al., 2001) 
(Figures 1 and 2). Even though PU.1 may make the initial contact with TFIID, other 
transcriptional factors (e.g. C/EBPs, Sp1) are likely to help stabilize the TFIID complex 
through TAF interactions. The PU.1-initiated cooperative stabilization of TFIID may be 
sufficient to evoke myeloid-specific expression for this group of genes. 
5. Regulation of PU.1 
As described in the previous section, expression of PU.1 is critical for hematopoiesis. 
Therefore, the regulatory mechanisms of PU.1 expression have been extensively studied. To 
date, most aspects of PU.1 regulation have been explained by invoking two regulatory 
elements, the promoter and an upstream regulatory element (URE) at –14 kb upstream of 
the transcription start site of the Spi-1 gene encoding PU.1. 
The Spi-1 promoter contains octamer-binding sites that affect B cell expression (Chen et al., 
1996). As described in the previous section, PU.1 was demonstrated to bind to its own 
promoter to regulate itself in myeloid cells (Chen et al., 1995a). Spi-1 promoter activity can 
also be directed in myeloid cells by C/EBP and AP-1 (Cai et al., 2008) (Figure 3). Although 
the promoter alone cannot drive reporter expression in a chromatin context, a search for 
added regulatory function yielded the conserved URE at around –14 kb, reported to be a 
myeloid-specific enhancer, that enhanced the promoter activity in a myeloid cell line (Li et 
al., 2001). Huang et al. (Huang et al., 2008) demonstrated that AML1/Runx1 binds to 
functionally important sites within the URE and regulates PU.1 expression at both 
embryonic and adult stages of development. As described later in section 8, NF-B was 
reported to regulate PU.1 through a novel site within the upstream URE (Bonadies et al., 
2010). Zarnegar et al. (Zarnegar et al., 2010) recently uncovered a set of conserved cis-
regulatory regions for Spi-1. One is a novel enhancer (–10 kb) that can amplify myeloid cell-
specific expression of PU.1. The other is a separate pro-T-cell-specific silencer element (–9 
kb). The enhancer element at –9 kb functions as a weak silencer in myeloid cells. The 
schematic layout is presented in Figure 3. Using a combination of transgenic studies, global 
chromatin assays and detailed molecular analyses, Leddin et al. (Leddin et al., 2011) 
presented evidence that PU.1 is regulated by a novel mechanism involving crosstalk 
between different cis-elements together with lineage-restricted autoregulation. They 
revealed that myeloid progenitors express C/EBP, which binds to the URE and induces 
activation of an enhancer at –12 kb to allow the formation of a second PU.1 autoregulatory 
loop and binding of additional PU.1 driven-transcription factors, such as early growth 
response 2 (EGR2). In this model, PU.1 regulates its expression in B cells and macrophages 
by differently associating with cell type-specific transcription factors at one of its cis-
regulatory elements to establish differential activity patterns at other elements.  
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Other mechanisms underlying the regulation of PU.1 expression have been demonstrated. 
Ebralidze et al. (Ebralidze et al., 2008) identified naturally occurring antisense transcripts 
overlapping the PU.1 coding region. They demonstrated that noncoding antisense RNAs are 
regulated by shared evolutionarily conserved cis-regulatory elements, and further showed 
that antisense RNAs inhibit PU.1 expression by modulating RNA translation. Vigorito et al. 
(Vigorito et al., 2007) carried out gene expression profiling of activated B cells and validated 
PU.1 as a direct target of microRNA-155 (miR-155)-mediated inhibition. Using mouse bone 
marrow (BM) cells, Hu et al. (Hu et al., 2010) revealed HOXA9-mediated upregulation, 
which is frequently observed in AML, of miR-155 in fractionated bone marrow progenitors. 
Furthermore, they revealed that ectopic expression of miR-155 resulted in a decrease in PU.1 
protein (Hu et al., 2010). These findings suggest that the expression of PU.1 is controlled 
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6. PU.1 suppressive targets 
Stiedl et al. (Steidl et al., 2006) revealed that ~21,500 of 45,000 transcripts were expressed in 
PU.1-knockdown HSCs, among which 225 transcripts were downregulated and 97 were 
upregulated in PU.1-knockdown HSCs. These findings indicate that PU.1 not only activates 
but also represses a substantial number of genes in HSCs. Consistent with this notion, 
several PU.1 suppressive targets have been identified and reported to date. Table 2 shows a 
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Borras et al. (Borras et al., 1995) first identified PU.1 as a transcriptional repressor. They 
examined the ability of PU.1 to regulate the expression of the major histocompatibility complex 
I-Ab gene. Their results indicated that PU.1 represses I-Ab expression, possibly by binding to 
a PU.1 box that is located between the Y-box and the transcription start site (Borras et al., 
1995). The c-myc promoter (–138 to +517) was found to be a target for downregulation by 
PU.1 in a dose-dependent manner by luciferase assays (Kihara-Negishi et al., 2001). These 
authors also found that the c-fos, SV-40, -actin and PCNA promoters are suppressed by 
expression of PU.1, without binding to a PU.1-binding site. They further showed that the c-
myc minimal promoter including a TATA box is sufficient to exert PU.1 repression. Using 
luciferase assays, they demonstrated that a restricted region of PU.1 including the PEST 
domain is responsible for PU.1-mediated transcriptional repression. They clearly 
demonstrated that C-terminal amino acids 101–272 of PU.1 formed a complex with mSin3A 
and HDAC1 in vivo (Kihara-Negishi et al., 2001) (Figure 1). By affinity purification assays, 
Suzuki et al. (Suzuki et al., 2003) found that PU.1 bound directly to methyl-CpG-binding 
protein (MeCP) 2 via the C-terminal Ets domain. They revealed that MeCP2 was integrated 
into the PU.1–mSin3A–HDAC complex. The same group clearly revealed an interaction 
between PU.1 and DNA methyltransferase (Dnmt) 3a and Dnmt3b via the Ets domain 
(Suzuki et al., 2006). They further showed that the CpG sites in the p16(INK4A) promoter 
were methylated by PU.1 overexpression in NIH3T3 cells, accompanied by downregulation 
of p16 (INK4A) gene expression (Suzuki et al., 2006). Moreover, hematopoietic precursor 
cells expressing PU.1 showed downregulation of the c-Myb protein levels. Transient 
expression of PU.1 in cotransfection assays in different cell lines resulted in inhibition of c-
myb promoter activity through the PU.1-binding site (Bellon et al., 1997).  
 
Gene Level of regulation References 
Major histocompatibility 
complex I-Ab Promoter (Borras et al., 1995) 
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c-Myb Promoter (Bellon et al., 1997) 
CD11c Promoter (Lopez-Rodriguez & Corbi, 1997) 
MT-1s, VIM Promoter (Imoto et al., 2010) 
Annexin 1 Unknown (Iseki et al., 2009)  
Flt3 Promoter (Inomata et al., 2006) 
Table 2. Suppressive gene targets regulated by PU.1 
It was reported that PU.1 negatively regulates the CD11c integrin gene promoter through 
recognition of the PU.1-binding site at the major transcriptional start site (Lopez-Rodriguez 
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& Corbi, 1997). The inhibitory action of PU.1 on CD11c is in contrast to its positive 
regulatory effect on the other integrin-related CD11b/CD18 gene promoters (Rosmarin et al., 
1995), as described in section 4. The opposite changes in CD11b and CD11c expression that 
take place in extravasating and maturing blood monocytes (Prieto et al., 1994) might be 
explained by the differential actions of PU.1 on the regulatory regions of the CD11b and 
CD11c genes. 
The author’s group recently revealed that MT-1 and VIM gene expression is directly 
regulated by PU.1 (Imoto et al., 2010). The MT proteins comprise a group of low molecular 
weight cysteine-rich intracellular proteins that can be activated by a variety of stimuli, 
including metal ions, oxidative stress, cytokines, glucocorticoids and growth factors 
(Cherian et al., 2003). MT was reported to be a potential negative regulator of apoptosis 
(Shimoda et al., 2003). VIM is a cytoskeletal protein that belongs to the intermediate filament 
family (Lazarides, 1982). VIM suppresses the apoptotic effect of chemotherapeutic treatment 
(Belichenko et al., 2001). These findings imply that induced expression of MT, as well as 
VIM, may function in anti-apoptosis mechanisms in leukemia cells. We demonstrated that 
MeCP2 and PU.1 bind to the CpG-rich regions in the MT-1 and VIM promoters. Bisulfite 
sequencing analyses of the PU.1-bound regions of these promoters revealed that the 
proportions of methylated CpG sites are tightly correlated with the PU.1 expression levels 
(Imoto et al., 2010). Importantly, the mRNA expression levels of the MT-1 and VIM genes 
were inversely correlated with PU.1 mRNA expression in 43 primary AML specimens (MT-
1G: R=–0.50, p<0.001; MT-1A: R=–0.58, p<0.0005; VIM: R=–0.39, p<0.01) (Imoto et al., 2010).  
The author’s group also demonstrated an inverse correlation between the mRNA expression 
of Annexin 1 and PU.1 in AML specimens (Iseki et al., 2009). In addition, the author and 
colleagues have reported that the Flt3 gene promoter is suppressed by overexpression of 
PU.1, and that there is a significant negative correlation between FLT3 and PU.1 (r=–0.43, 
p<0.05) (Inomata et al., 2006). Therefore, PU.1 downregulation, which is important in the 
pathogenesis of AML as described in section 8, may impact on the overexpression of FLT3, 
which is frequently observed in AML, leading to activation of the FLT3 pathway (Ozeki  et 
al., 2004; Takahashi, 2011). 
Together with these findings, PU.1 represses several genes through its epigenetic activity 
under certain circumstances. The repression of PU.1 is directed in at least two ways. The 
author’s group demonstrated that PU.1 binds to the methylated CpG-rich region with 
MeCP2, where no consensus PU.1-binding sites were found (Imoto et al., 2010). The other 
way is direct binding of PU.1 to PU.1-binding sites, as demonstrated in the promoters of the 
CD11c, p16 (INK4A), major histocompatibility complex I-Ab, c-myb and other genes (Borras et 
al., 1995; Lopez-Rodriguez & Corbi, 1997; Suzuki et al., 2006). In addition, some suppressive 
target genes of PU.1 may be indirect effects (e.g. Iseki et al., 2009), because direct binding to 
their promoters has not been demonstrated. A schematic layout of the complex of PU.1 and 
its corepressors binding to these promoters is shown in Figure 4.  
7. Putative regulatory mechanisms for PU.1 as a transcriptional activator or 
repressor 
As mentioned above, Kihara-Negishi et al. (Kihara-Negishi et al., 2001) showed a direct 
interaction of PU.1 with mSin3A. On the other hand, the same group previously 
demonstrated a direct interaction of PU.1 with the transcriptional coactivator CBP, which 
 




Fig. 4. PU.1 as a transcriptional repressor. This is a schematic picture about the hypothetical 
formation of the PU.1 repressor complexes, because some of these informations are putative. 
Since the Flt3 gene promoter has a CpG-rich region without a functional PU.1-binding site 
(Inomata et al., 2006), Flt3 may be classified into the upper group, although direct binding of 
PU.1 to the Flt3 gene promoter has not been examined.  
enhances the transcriptional activity of PU.1 (Yamamoto et al., 1999). Of particular interest is 
the regulatory mechanism of the selection of the interacting partners, CBP and mSin3A-
HDAC, which possess opposite functions in the regulation of gene expression. 
Posttranslational modification of PU.1, such as phosphorylation or acetylation, may be 
involved in the preferential recruitment of coactivators or corepressors. 
In general, the expression of PU.1 is usually unaffected by most stimuli that regulate gene 
activation and its expression levels remain relatively constant (Yordy & Muise-Helmericks 
2000). PU.1 is primarily regulated post-transcriptionally by phosphorylation (Lloberas et 
al., 1999; Yordy & Muise-Helmericks, 2000). PU.1 is potentially phosphorylated on five 
separate serine residues (Ser41, Ser45, Ser132, Ser133 and Ser148) and is an in vitro 
substrate for casein kinase II (CKII) (Lodie et al., 1997). Lodie et al. (Lodie et al., 1997) 
revealed that lipopolysaccharide stimulation induces phosphorylation of PU.1 at Ser148 
(Figure 1), located within a CKII consensus motif, which increases the transactivation 
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function of PU.1. PU.1 is also phosphorylated at Ser142 by stimulation of IL-3-induced 
p38 MAPK-mediated pathways (Wang et al., 2003). Mutation of Ser142 to alanine 
attenuates the IL-3-enhanced transactivation activity of PU.1. In contrast, Breig et al. (Breig 
et al., 2010) recently described that Ser41, but not Ser148, is necessary for Spi-1/PU.1-
mediated repression of hemoglobin expression in Friend erythroleukemia cells. 
Phosphorylation of critical residues in PU.1 may switch the function of this transcription 
factor from an activator to a repressor. Kihara-Negishi et al. (Kihara-Negishi et al., 2005) 
examined whether acetylation regulates the physical and functional activities of PU.1 in 
MEL cells. They found that PU.1 is acetylated in vivo and that its repressor activity is 
reduced when the putative acetylation motifs in the Ets domain are mutated. The mutant 
cooperates with the coactivator CBP, similar to the case for wild-type PU.1, but shows 
insufficient cooperation with the corepressor mSin3A, which binds to the Ets domain of 
PU.1. These observations are summarized in Table 3.  
The modifications of each functional domain (as depicted in Figure 1), which are required 
for transcriptional activation or repression, may result in the dissociation of cofactors, 
leading to changes in the transcriptional ability of PU.1. 
However, a question still remains. As described in the previous section, in a same-cell 
population like HSCs (Steidl et al., 2006), some genes are suppressed while other genes are 
upregulated by PU.1. How are these genes differently regulated even in the same cells? It is 
possible that the context of the promoter may be important, and that promoter-specific 
cofactors may modify PU.1 and regulate the activity of this protein. These mechanisms 
remain to be elucidated in future studies. 
 
Table 3. List of the post-translational modifications of PU.1 
Site Cells Responsible Signaling Effect Ref. 
Ser41, Ser45, 
Ser132, Ser133 


















Phosphorylation of Ser 
142 increases 
transactivation of PU.1, 
resulted in the 




Ser 41 Friend erythro- leukemia cells 
PI3 kinase 
/Akt 
Ser 41 is responsible for 
the PU.1 mediated 
repression, and 
phosphorylation of this 
site impairs its 












The repressor activity 
of PU.1 was impaired 
by mutations of both 
two acetylation motifs 
(Kihara 
-Negishi 
et al.,  
2005) 
 
PU.1, a Versatile Transcription Factor and a Suppressor of Myeloid Leukemia  
 
251 
8. Role of PU.1 in the pathogenesis of AML 
For many years, it has been known that irradiated mice frequently develop AML after a long 
latent period, and that nearly all of their tumors contain an interstitial deletion in one copy 
of chromosome 2 that includes the PU.1 gene (Hayata et al., 1983; Silver et al., 1999; 
Trakhtenbrot et al., 1988). Subsequent studies revealed that mice with -irradiation-induced 
myeloid leukemia acquired both a deletion in one copy of chromosome 2 and a point 
mutation in the ETS domain of PU.1, which impaired DNA binding of the other PU.1 allele 
(Cook et al., 2004; Suraweera et al., 2005). These single amino acid substitutions were shown 
to alter the function of PU.1 by reducing its transactivation activity. Grisolano et al 
(Grisolano et al., 1997) previously showed that 10–20% of transgenic mice expressing PML-
RAR in their early myeloid cells develop acute promyelocytic leukemia (APL) after a long 
latent period. The penetrance of APL development increases substantially when RAR-PML 
is coexpressed in early myeloid cells (Pollock et al., 1999) or when young mice are 
sublethally irradiated (Walter et al., 2004). In both scenarios, the vast majority of APL 
tumors contain a large (>20 Mb) interstitial deletion in one copy of chromosome 2 that 
invariably includes the PU.1 gene (Walter et al., 2004; Zimonjic et al., 2000). These data 
strongly suggest that PU.1 acts in a similar manner to a tumor suppressor in myeloid 
progenitors, and that deletion of one allele, followed by a reduction in the function of the 
other allele, is relevant for AML pathogenesis. Indeed, PU.1 is expressed at low levels in 
most cases of human AML (Steidl et al., 2006). 
PU.1 expression and/or function appear to be suppressed by several leukemogenic fusion 
products, such as RUNX1-ETO (Vangala et al., 2003), FLT3-ITD (Mizuki et al., 2003) and 
PML-RAR (Mueller et al., 2006a). Following these initial reports of suppressed PU.1 
function in human AML, the leukemic potential of tumor progenitors with critically reduced 
PU.1 function has been illustrated by a series of mouse models. The level of PU.1 expression 
is critical for specifying cell fate and, if perturbed, even modest decreases in PU.1 can lead to 
leukemias and lymphomas (DeKoter & Singh, 2000a; Rosenbauer et al., 2004). Mice with an 
engineered deletion of the URE of PU.1 show decreased PU.1 expression and subsequently 
develop AML, through suppression of the AP-1 transcription factors JunB and c-Jun, by 
blocking differentiation and increasing self-renewal as described in the previous section. 
However, while these observations indicate that low but detectable amounts of PU.1 might 
favor the malignant potential of leukemic cells, this view was challenged by a report 
suggesting that complete loss of PU.1 can also lead to AML (Metcalf et al., 2006). 
As described in section 5, the URE is important for the regulation of PU.1. Several reports 
have described associations between genetic abnormalities of this region and AML biology. 
In an analysis of 209 AML patient specimens, Steidl et al. (Steidl et al., 2007) revealed that a 
distal single nucleotide polymorphism (SNP) alters the long-range regulation of the PU.1 
gene in AML. The homozygous SNP within a highly conserved distal enhancer element in 
humans, which is 2.4-fold more frequent in AML with a complex karyotype (24.3%) than in 
AML with a normal karyotype (10.0%), leads to decreased enhancer activity and reduces 
PU.1 expression in myeloid progenitors in a development-dependent manner (Steidl et al., 
2007). Bonadies et al. (Bonadies et al., 2010a) examined the URE sequence in 120 AML 
patients. They identified one AML patient with heterozygous loss of the entire URE 
sequence with markedly reduced PU.1 expression. The link between PU.1 URE mutations 
and AML pathogenesis might be explained by another model. The same group also 
identified NF-B as an activator of PU.1 expression through a novel site within the upstream 
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function of PU.1. PU.1 is also phosphorylated at Ser142 by stimulation of IL-3-induced 
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PU.1 expression in myeloid progenitors in a development-dependent manner (Steidl et al., 
2007). Bonadies et al. (Bonadies et al., 2010a) examined the URE sequence in 120 AML 
patients. They identified one AML patient with heterozygous loss of the entire URE 
sequence with markedly reduced PU.1 expression. The link between PU.1 URE mutations 
and AML pathogenesis might be explained by another model. The same group also 
identified NF-B as an activator of PU.1 expression through a novel site within the upstream 
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URE (Bonadies et al., 2010b). They found sequence variations of this particular NF-B site in 
four of 120 AML patients. These variant NF-B sequences failed to mediate activation of 
PU.1, and AML patients with such variant sequences had suppressed PU.1 mRNA 
expression. These findings suggest that the change of a single base pair in a distal element 
critically affects the regulation of the tumor suppressor gene PU.1, thereby contributing to 
the development of AML. 
Mutations of PU.1 have previously been examined by several groups. Mueller et al. (Mueller 
et al., 2002; Mueller et al., 2003) identified 10 mutant alleles of the PU.1 gene in 9 of 126 AML 
patients. However, these findings could not be confirmed in two subsequent studies. 
Vegesna et al. (Vegesna et al., 2002) analyzed 381 samples of hematopoietic and solid 
malignancies, including 60 cases of de novo AML and 60 cases of myelodysplastic syndromes 
(MDS), and were not able to identify PU.1 coding region mutations. Similarly, Lamandin et 
al. (Lamandin et al., 2002) failed to detect PU.1 gene mutations in 77 primary AML samples. 
Collectively, direct genetic inactivation of the PU.1 gene in myeloid leukemia has only been 
found in very rare cases. Although there is no doubt that a reduction in PU.1 expression 
plays a very important role in the pathogenesis of AML, its mutations in human myeloid 
leukemia biology remain unclear. 
9. Perspectives and conclusions 
The author has summarized the recent advances in the molecular biology of the PU.1 
transcription factor, with a focus on its functions as both a transcriptional activator and 
repressor. In addition, the role of PU.1 in AML biology has been described. 
In 2009, inactivating mutations of the Ten-Eleven-Translocation oncogene family member 2 
(TET2) gene were identified in about 15% of patients with various myeloid malignancies, 
such as MDS (19%), myeloproliferative disorders (12%), secondary AML (24%) and chronic 
myelomonocytic leukemia (22%) (Delhommeau et al., 2009). TET2 can convert 5-
methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) (Ko et al., 2010), which is 
hypothesized to be an intermediate in the demethylation of DNA. Ko et al. (Ko et al., 2010) 
demonstrated that disruption of TET2 enzymatic activity favors myeloid tumorigenesis. 
Consistent with this observation, it was reported that Dnmt3a mutations were detected in 62 of 
281 (22.1%) AML patients (Ley et al., 2010). These mutations were highly enriched in a group 
of patients with an intermediate-risk cytogenetic profile, as well as in FLT3 receptor mutations 
(25 of 61 (41.0%) patients; p<0.003) (Ley et al., 2010). Walter et al. (Walter et al., 2011) also 
described relatively frequent mutations of Dnmt3a in MDS. They performed sequencing in 
patients with MDS and identified 13 heterozygous mutations with predicted translational 
consequences in 12 of 150 (8.0%) patients. Yan et al. (Yan et al., 2011) discovered mutations in 
DNMT3a in 23 of 112 (20.5%) cases with the M5 subtype of AML. The DNMT mutants showed 
reduced enzymatic activity or aberrant affinity for histone H3 in vitro. Notably, there were 
alterations in the DNA methylation patterns and/or gene expression profiles, such as HOXB 
genes, in samples with DNMT3a mutations compared with those without such mutations (Yan 
et al., 2011). These recent findings strongly suggest a link between recurrent genetic alterations 
and aberrant DNA methylation status in myeloid malignancies. 
As shown in Figures 1 and 4, PU.1 interacts with DNMT3a and DNMT3b (Suzuki et al., 
2006) and suppresses its target genes through Dnmt activity (Imoto et al., 2010; Suzuki et al., 
2006). Since the expression of DNMT3s is constant in AML specimens (Ley et al., 2010), it is 
tempting to speculate that DNMT3a mutations exert their leukemogenic potential, at least in 
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part, by functional impairment of PU.1 epigenetic activities as a transcriptional repressor, 
mainly through downregulation of its expression. It is possible that this may also play an 
important role in AML pathogenesis (Figure 5). 
 
 
Fig. 5. Putative mechanisms of deregulated PU.1 repressor activity in AML. A, Normal cells. 
B, AML cells. A reduction in PU.1 expression (left panel), as well as mutations in Dnmt3a 
(right panel), result in aberrant target gene expression, which plays a role in the 
pathogenesis of AML. 
Collectively, not only deregulation of proper myeloid-specific gene expression by 
downregulation of PU.1, but also insufficient recruitment of such epigenetic factors may 
play important roles in leukemia pathogenesis. Further clarification of the functions of this 
versatile transcription factor, with a particular focus on its function as a transcriptional 
repressor, may reveal the molecular biology of myeloid leukemia. 
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1. Introduction  
Acute promyelocytic leukemia (APL) is the M3 subtype of acute myeloid leukemia (AML), 
characterized by aberrant hyperproliferation of progenitors originally committed to 
terminal differentiation into granulocytes but blocked at the promyelocytic stage. Although 
clinical studies have introduced treatments employing arsenic trioxide, anthracyclines and 
anti-CD33 monoclonal antibodies, all-trans retinoic acid (ATRA)-based therapy represents, 
until today, the standard cure of APL patients (Lo-Coco & Ammatuna, 2006; Tallman, 2007). 
ATRA treatment of APL constitutes, at present, the only example of successful 
differentiation therapy of a human cancer, in which tumor cells are induced to complete 
their maturation to neutrophils. Studies on both APL blasts and APL-derived cell lines have 
elucidated that ATRA acts throughout a complex network that includes the degradation of 
the PML/RAR fusion protein and the activation of RAR-mediated gene transcription 
(Breitman et al., 1980; Lanotte et al., 1991; Yang et al., 2003). In addition, it has been reported 
that ATRA- and phorbol 12-myristate 13-acetate (PMA)-mediated differentiation of human 
myeloid leukemia cell lines results in changes of their sensitivity to chemotherapeutic drugs, 
suggesting that advantages in the cure of APL and other malignancies could be obtained by 
combining differentiating agents and conventional anticancer drugs (Jasek et al., 2008; 
Kogan, 2009; Nasr et al., 2008).   
Even if the mechanism by which ATRA interacts with its receptor located on specific DNA 
sequences is well known, the events mediated by the ATRA target genes, able to elicit the 
integrated signaling networks that promote maturation of tumoral promyelocytes, have not  
been fully clarified and are currently under study to also identify specific molecular targets 
for new therapies of APL.  
One of the proteins up-regulated by ATRA in APL-derived cells and that resulted chiefly 
involved in the maturation program of tumoral promyelocytes is Vav1, the sole member of 
the Vav family of proteins physiologically expressed only in haematopoietic cells, where it 
works as an important signal transducer in immune response (Katzav, 2009; Tybulewicz, 
2005). Relevant insights into the function of Vav1 in hematopoietic cells have been provided 
by studies with knockout mice, demonstrating that the targeted down-modulation of Vav1 
compromises maturation of both lymphoid and myeloid cells (Zhang et al., 1994). In 
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particular, a severe impairment of IL-2 production and calcium mobilization in response to 
external stimuli has been found in T and B cells (Fujikawa et al., 2003; Haubert & 
Weckbecker, 2010) and the defective motility observed in the Vav1-/- neutrophils, 
concomitant with the decrease in migration, has been demonstrated to reduce the capacity 
for an innate immune response (Phillipson et al., 2009). Vav1 has a critical role also in 
regulating the acquisition by macrophages of maturation-related competence, as 
demonstrated by the smaller adhesive area, the reduced motility and the lower migration 
speed of macrophages from Vav1-deficient mice (Hall et al., 2006; Wells et al., 2005). More 
recently, Vav1 activity has been demonstrated to be required specifically for SDF1α-
dependent perivascular homing and subsequent engraftment of hematopoietic stem cells 
(Sanchez-Aguilera et al., 2011). In both lymphoid and myeloid cells, Vav1 is involved in the 
dynamic regulation of the filamentous actin cytoskeleton, critical to numerous physical 
cellular processes, including adhesion, migration and phagocytosis (Cougoule et al., 2006; 
Stricker et al., 2010).  
Vav1 contains an array of structural motifs that enable it to play a role in several distinct cell 
functions, like cytoskeletal reorganization and regulation of gene expression during 
proliferation, maturation, and apoptosis of hematopoietic cells (Clevenger et al., 1995; 
Fischer et al., 1998; Kong et al., 1998). The Vav1 domains include a DH region which exhibits 
a GDP/GTP exchange activity for the RhoA, Rac1 and CDC42 small GTPases, a PH domain 
interacting with phosphoinositides, two SH3 domains and one SH2 domain mediating 
protein-protein interactions, a CH domain that functions as an actin-binding motif and an 
AC region that contains 3 regulatory tyrosines. Vav1 also possesses 2 putative nuclear 
localization signals, indicative for a role of the protein also inside the nuclear compartment 
(Bustelo, 2001).  
In both myeloid and lymphoid cells, the best known function of Vav proteins is the 
guanosine exchange factor (GEF) for small G proteins which is modulated, at variance with 
the other exchange factors for Rho/Rac in humans, by phosphorylation on tyrosine residues 
(Bustelo, 2002). However, some functions of Vav1 in hematopoietic cells are independent of 
its GEF activity and are attributed to its ability to interact with a number of signalling 
molecules, in both cytoplasm and nucleus. In particular, inside the nuclear compartment 
Vav1 seems to play its most intriguing role as part of transcriptionally active complexes 
(Houlard et al., 2002) and by interacting with components of the DNA-dependent protein 
kinase complex as well as with hnRNP proteins (Romero et al., 1996, 1998). 
In addition to the role played in the acquisition of a mature phenotype by normal 
hematopoietic cells, Vav1 has been found to promote the agonist-induced completion of the 
differentiation program of tumoral myeloid precursors. In cell lines  derived from APL patiens 
treated with differentiating agents Vav1 plays indeed multiple roles aimed to regulate 
different aspects of maturation along the neutrophilic and the monocytic/macrophagic 
lineages. Since Vav1 may be recruited by various differentiating agents and plays a central role 
in the completion of the differentiation program of leukemic promyelocytes along diverse 
hematopoietic lineages, it might be considered a common target for developing new 
therapeutic strategies for the different subtypes of myeloid leukemias.  
2. Vav1 and netrophil-like phenotypical maturation    
Promyelocytes derived from APL, which are blocked at different steps of their neutrophil 
differentiation, contain levels of Vav1 variably lower than those found in mature 
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neutrophils. Treatments with differentiating doses of ATRA induce a significant increase of 
Vav1 expression in primary blasts obtained from the bone marrow of APL patients as well 
as in the APL-derived cell lines HL-60 and NB4. A similar increase of Vav1 is observed 
when normal CD34+ hematopoietic progenitors are treated with a cytokine cocktail 
promoting granulocytic differentiation, clearly indicating that an adequate expression of 
Vav1 has to be achieved along with neutrophil maturation of both normal precursors and 
poorly differentiated neoplastic cells (Bertagnolo et al., 2005). These evidence, obtained in a 
variety of normal and neoplastic  cells under different experimental conditions, ascribe to 
Vav1 the potential role of a ubiquitous key player in the path leading myeloid precursors to 
acquire the mature phenotype of differentiated neutrophils.  
The issue of whether the increase of Vav1 observed in differentiation of tumoral 
promyelocytes is merely designed to the function of the protein in mature cells or, more 
intriguingly, it is functionally relevant to the maturation mechanism, has been addressed by 
studies in which the expression of Vav1 was forcedly modulated. The experiments have 
been performed in ATRA treated HL-60 and NB4 cells, which are blocked at different levels 
of granulocytic differentiation, and thus constitute models well suited to better understand 
the role of Vav1 in the maturation process. As a consequence of Vav1 over-expression 
during ATRA treatment of both cell lines, the expression of the myeloid surface marker 
CD11b increases, indicating that Vav1 supports the role of ATRA in regulating the 
maturation process. On the other hand, the sole over-expression of Vav1 is capable to 
significantly induce the expression of CD11b only in HL-60 cells, that, compared to NB4 
cells, are blocked to a less differentiated stage (Bertagnolo et al., 2005). This suggests the 
existence of a direct and ATRA-independent role of Vav1 in regulating the expression of 
CD11b, at least in cells that are blocked at early stages of the neutrophilic maturation.   
Neutrophils radically change in shape during development and functional life (Sanchez & 
Wangh, 1999). Accordingly, profound rearrangements of the cell morphology take place 
throughout differentiation of myeloid precursors along the granulocytic lineage, and the 
nucleus is the cell compartment that undergoes the biggest architectural changes by a 
mechanism still largely unknown. Modifications of the nuclear shape constitute one of the 
markers of neutrophil maturation of tumoral promyelocytes and are particularly evident 
after treatment with ATRA of HL-60 cells, according to the notion that this cell type is 
blocked at an early stage of maturation. On the other hand, the sole over-expression of Vav1 
is unable to induce nuclear modifications in both HL-60 and NB4 cells, indicating that other 
ATRA-induced events are required to regulate the maturation-related rearrangements of cell 
morphology (Bertagnolo et al, 2005).  
The use of siRNAs specific for Vav1 unequivocally demonstrates that Vav1 is not 
dispensable for the progression of tumoral promyelocytes along the granulocytic lineage. In 
fact, the down-modulation of Vav1 expression during ATRA treatment of both HL-60 and 
NB4 cells counteracts the agonist-induced increase of CD11b expression and prevents  the 
maturation-related modifications of cell/nucleus morphology, definitely assigning to Vav1 
a crucial role in regulating phenotypical maturation of APL-derived cells (Bertagnolo et al, 
2005, 2008).    
2.1 Tyrosine phosphorylation of Vav1  
In parallel with the increase of Vav1 expression, ATRA treatment of HL-60 and NB4 cells 
also induces Vav1 tyrosine phosphorylation. Since, in the whole cell, the rise of the 
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phosphosphorylation level is almost proportional to the increase in total Vav1 amount, 
ATRA seems to ensure to differentiating cells the achievement of an adequate amount of 
tyrosine phosphorylated Vav1, according with the functions of Vav1 in mature neutrophils. 
On the other hand, the accumulation of tyrosine-phosphorylated Vav1 inside the nuclear 
compartment seems to be a distinctive feature of the differentiation process induced by 
ATRA in APL-derived cells (Bertagnolo et al., 2005). In fact, a progressive increase of 
tyrosine phosphorylated Vav1 inside the nucleus accompanies the agonist-induced 
maturation (Bertagnolo et al., 1998), indicative of a specific role of tyrosine phosphorylated 
Vav1 inside the nuclear compartment. The tyrosine phosphorylation level of nuclear Vav1 
reaches a maximum in ATRA-treated NB4 cells, which constitute the cell model with the 
most advanced level of neutrophil maturation among APL-derived precursors (Bertagnolo 
et al., 2005), clearly correlating tyrosine phosphorylated Vav1 with the maturation-related 
events that occur inside the nuclear compartment and opening the question of which 
kinase/s is/are involved in this process. 
In both myeloid and lymphoid cells, Vav1 is phosphorylated in tyrosine/s by receptors with 
intrinsic tyrosine kinase activity or by membrane and/or cytoplasmic tyrosine kinases of the 
Syk/Zap70, Src and Jak families (Bustelo, 2002). More recently, also the c-Abl kinase has 
been reported to be specifically involved in regulating the activity of Vav1 in integrin-
mediated neutrophil adhesion (Cui et al., 2009). Recruitment and phosphorylation of Vav1 
depend on its ability to interact with a number of signalling proteins by means of its various 
domains. In particular, the interaction between the SH2 domain of Vav1 and 
phosphorylated proteins is thought to serve for recruitment of activated kinases, which in 
turn can phosphorylate Vav1 (Bustelo, 2002). The Syk/ZAP-70 family of tyrosine kinases 
constitutes an example of proteins that contain two SH2 domains, a tandem sequence that 
might confer high specificity in tyrosine kinase- mediated signalling. In addition, both ZAP-
70 and Syk contain a consensus binding sequence for the Vav1 SH2 domain that seems to be 
critical for antigen receptor-mediated signal transduction (Ottinger et al., 1998). 
Experiments performed with HL-60 cells have demonstrated the association of tyrosine 
phosphorylated Syk with the Vav1-SH2 domain, in both whole cell and nuclear 
compartment, as a consequence of ATRA treatment (Bertagnolo et al., 2001). These data are 
in agreement with the notion that activation of Syk occurs in differentiating HL-60 cells (Qin 
& Yamamura, 1997) and mature neutrophils, in which it regulates migration (Schymeinsky 
et al., 2006) and the formation of lamellipodia during phagocytosis (Shi et al., 2006). While in 
whole HL-60 cells the Vav1/Syk association takes place regardless of their phosphorylation 
level and of ATRA treatment, the formation of Vav1/Syk complexes inside the nuclear 
compartment strongly increases during the differentiation process, suggesting a specific role 
for this tyrosine kinase in the nucleus. The role of Syk in phosphorylating Vav1 has been 
demonstrated by means of in vitro assays (Bertagnolo et al., 2001) and confirmed by the use 
of a pharmacological model of Syk inhibition, in which both HL-60 and NB4 cells were 
treated with Piceatannol (Bertagnolo et al., 2001, 2008), a tyrosine kinase inhibitor with a 
reported selectivity for Syk (Law et al, 1999; Seow et al., 2002).  
The Syk-dependent tyrosine phosphorylation of Vav1 during the ATRA-induced phenotypical 
differentiation is not relevant for the expression of the surface marker CD11b, as indicated by 
the use of Piceatannol in both HL-60 and NB4 cells, but seems to play a crucial role in 
regulating the reorganization of cell architecture.  In fact, when Piceatannol is administered in 
combination with ATRA, the modifications of nuclear morphology typical of granulocytic 
differentiation are almost completely abrogated, similarly to what observed when the 
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expression of Vav1 is down-modulated during the differentiation treatment (Bertagnolo et al., 
2008). However, since Piceatannol fails to abrogate completely the ATRA-induced tyrosine 
phosphorylation of Vav1 in both HL-60 and NB4 cells (Bertagnolo et al., 2008), other kinase/s, 
in addition to Syk, are probably recruited by ATRA in these cell models.  
The results from these inhibition studies support the hypothesized action model that 
requires tyrosine phosphorylated Vav1 in maturation of tumoral myeloid precursors. 
Nevertheless, the issue needs further investigations, in order to identify the kinase/s 
involved. In fact, by extending the analysis to other tyrosine kinase inhibitors, it has been 
found that PP1 and AG490, inhibitors of Src and Jak tyrosine kinase families, respectively, 
did not affect to any significant extent the tyrosine phosphorylation of Vav1 (Bertagnolo et 
al., 2004), leaving open the question of which other tyrosine kinases, in addition to Syk, 
phosphorylate Vav1 during maturation of tumoral promyelocytes.  
2.1.1 Participation to protein complexes with signaling molecules  
In addition to the obvious interaction with tyrosine kinases, the optimal phosphorylation of 
Vav1 seems to require the association with adaptor molecules that facilitate the spatial 
proximity between Vav1 and the upstream kinases. These associations also depend on the 
tyrosine phosphorylation of the involved proteins and often require the engagement of either 
the SH3 or the SH2 domains of Vav1 as interacting motifs (Bustelo, 2002). In this context, SLP-
76, an adaptor protein predominantly expressed in T cells and myeloid cells and which is a 
substrate for ZAP-70 and Syk tyrosine kinases, has been reported to associate, via tyrosine-
phosphorylated residues in its NH2-terminal domain, with the SH2 domain of Vav1 after 
ligation of the T-cell antigen receptor (Tuosto et al., 1996; Pauker & Barda-Saad,, 2011). SLP-76 
was also described as an important adaptor molecule that is regulated by Syk in C-reactive 
protein-stimulated platelets (Gross et. al, 1999) and that plays a critical role in FcRI-mediated 
activation of mast cells in vivo and in vitro (Pivniouk et al., 1999).  
Some of the Vav1-interacting molecules play a role in down modulation of Vav1 signals. A 
potential negative regulator of Vav1 is Cbl, which down-modulates Syk/ZAP-70 and other 
protein tyrosine kinases (Lupher et al., 1999). Cbl associates with Vav1 upon T-cell receptor 
stimulation of primary murine lymphocytes and Jurkat T cells. This interaction appears to 
require the whole SH3-SH2-SH3 COOH-terminal domain of Vav1 and a proline-rich 
sequence of Cbl and seems to inhibit the Vav1-dependent signal transduction (Bustelo et al., 
1997). Very recently, Chiang & Hodes (2011) have demonstrated a role of Cbl in repressing 
signaling events that can mediate thymic differentiation in the absence of Vav1, since Cbl 
inactivation rescued defective T cell development in Vav1-/- mice.  
The molecules involved in the recruitment and phosphorylation of Vav1 during the ATRA-
dependent granulocytic differentiation of tumoral promyelocytes were investigated in HL-
60 cells by using GST-fusion NH2-terminal and COOH-terminal Vav1-SH3 and GST-fusion 
Vav1-SH3-SH2-SH3 proteins. One of the proteins interacting with Vav1 in HL-60 cells is the 
adaptor molecule Cbl, present only in the cytoplasm and strongly phosphorylated in 
response to ATRA treatment. The Vav1/Cbl interaction in HL-60 cells occurs also in control 
conditions and requires the entire SH3-SH2-SH3 domain of Vav1 (Bertagnolo et al., 2001). 
The adaptor protein SLP-76 has been also identified as a phosphorylated protein interacting 
with the SH3-SH2-SH3 fragment of Vav1 in both cells and nuclei of HL-60 after ATRA 
treatment. Similarly to Cbl, SLP-76 associates with Vav1 also in control conditions, without 
quantitative changes due to the differentiation process. Vav1-associated SLP-76 was more 
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phosphosphorylation level is almost proportional to the increase in total Vav1 amount, 
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tyrosine phosphorylated Vav1, according with the functions of Vav1 in mature neutrophils. 
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maturation (Bertagnolo et al., 1998), indicative of a specific role of tyrosine phosphorylated 
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critical for antigen receptor-mediated signal transduction (Ottinger et al., 1998). 
Experiments performed with HL-60 cells have demonstrated the association of tyrosine 
phosphorylated Syk with the Vav1-SH2 domain, in both whole cell and nuclear 
compartment, as a consequence of ATRA treatment (Bertagnolo et al., 2001). These data are 
in agreement with the notion that activation of Syk occurs in differentiating HL-60 cells (Qin 
& Yamamura, 1997) and mature neutrophils, in which it regulates migration (Schymeinsky 
et al., 2006) and the formation of lamellipodia during phagocytosis (Shi et al., 2006). While in 
whole HL-60 cells the Vav1/Syk association takes place regardless of their phosphorylation 
level and of ATRA treatment, the formation of Vav1/Syk complexes inside the nuclear 
compartment strongly increases during the differentiation process, suggesting a specific role 
for this tyrosine kinase in the nucleus. The role of Syk in phosphorylating Vav1 has been 
demonstrated by means of in vitro assays (Bertagnolo et al., 2001) and confirmed by the use 
of a pharmacological model of Syk inhibition, in which both HL-60 and NB4 cells were 
treated with Piceatannol (Bertagnolo et al., 2001, 2008), a tyrosine kinase inhibitor with a 
reported selectivity for Syk (Law et al, 1999; Seow et al., 2002).  
The Syk-dependent tyrosine phosphorylation of Vav1 during the ATRA-induced phenotypical 
differentiation is not relevant for the expression of the surface marker CD11b, as indicated by 
the use of Piceatannol in both HL-60 and NB4 cells, but seems to play a crucial role in 
regulating the reorganization of cell architecture.  In fact, when Piceatannol is administered in 
combination with ATRA, the modifications of nuclear morphology typical of granulocytic 
differentiation are almost completely abrogated, similarly to what observed when the 
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expression of Vav1 is down-modulated during the differentiation treatment (Bertagnolo et al., 
2008). However, since Piceatannol fails to abrogate completely the ATRA-induced tyrosine 
phosphorylation of Vav1 in both HL-60 and NB4 cells (Bertagnolo et al., 2008), other kinase/s, 
in addition to Syk, are probably recruited by ATRA in these cell models.  
The results from these inhibition studies support the hypothesized action model that 
requires tyrosine phosphorylated Vav1 in maturation of tumoral myeloid precursors. 
Nevertheless, the issue needs further investigations, in order to identify the kinase/s 
involved. In fact, by extending the analysis to other tyrosine kinase inhibitors, it has been 
found that PP1 and AG490, inhibitors of Src and Jak tyrosine kinase families, respectively, 
did not affect to any significant extent the tyrosine phosphorylation of Vav1 (Bertagnolo et 
al., 2004), leaving open the question of which other tyrosine kinases, in addition to Syk, 
phosphorylate Vav1 during maturation of tumoral promyelocytes.  
2.1.1 Participation to protein complexes with signaling molecules  
In addition to the obvious interaction with tyrosine kinases, the optimal phosphorylation of 
Vav1 seems to require the association with adaptor molecules that facilitate the spatial 
proximity between Vav1 and the upstream kinases. These associations also depend on the 
tyrosine phosphorylation of the involved proteins and often require the engagement of either 
the SH3 or the SH2 domains of Vav1 as interacting motifs (Bustelo, 2002). In this context, SLP-
76, an adaptor protein predominantly expressed in T cells and myeloid cells and which is a 
substrate for ZAP-70 and Syk tyrosine kinases, has been reported to associate, via tyrosine-
phosphorylated residues in its NH2-terminal domain, with the SH2 domain of Vav1 after 
ligation of the T-cell antigen receptor (Tuosto et al., 1996; Pauker & Barda-Saad,, 2011). SLP-76 
was also described as an important adaptor molecule that is regulated by Syk in C-reactive 
protein-stimulated platelets (Gross et. al, 1999) and that plays a critical role in FcRI-mediated 
activation of mast cells in vivo and in vitro (Pivniouk et al., 1999).  
Some of the Vav1-interacting molecules play a role in down modulation of Vav1 signals. A 
potential negative regulator of Vav1 is Cbl, which down-modulates Syk/ZAP-70 and other 
protein tyrosine kinases (Lupher et al., 1999). Cbl associates with Vav1 upon T-cell receptor 
stimulation of primary murine lymphocytes and Jurkat T cells. This interaction appears to 
require the whole SH3-SH2-SH3 COOH-terminal domain of Vav1 and a proline-rich 
sequence of Cbl and seems to inhibit the Vav1-dependent signal transduction (Bustelo et al., 
1997). Very recently, Chiang & Hodes (2011) have demonstrated a role of Cbl in repressing 
signaling events that can mediate thymic differentiation in the absence of Vav1, since Cbl 
inactivation rescued defective T cell development in Vav1-/- mice.  
The molecules involved in the recruitment and phosphorylation of Vav1 during the ATRA-
dependent granulocytic differentiation of tumoral promyelocytes were investigated in HL-
60 cells by using GST-fusion NH2-terminal and COOH-terminal Vav1-SH3 and GST-fusion 
Vav1-SH3-SH2-SH3 proteins. One of the proteins interacting with Vav1 in HL-60 cells is the 
adaptor molecule Cbl, present only in the cytoplasm and strongly phosphorylated in 
response to ATRA treatment. The Vav1/Cbl interaction in HL-60 cells occurs also in control 
conditions and requires the entire SH3-SH2-SH3 domain of Vav1 (Bertagnolo et al., 2001). 
The adaptor protein SLP-76 has been also identified as a phosphorylated protein interacting 
with the SH3-SH2-SH3 fragment of Vav1 in both cells and nuclei of HL-60 after ATRA 
treatment. Similarly to Cbl, SLP-76 associates with Vav1 also in control conditions, without 
quantitative changes due to the differentiation process. Vav1-associated SLP-76 was more 
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abundant in nuclei than in whole cell lysates, indicating a preferential association into the 
nucleus of these two molecules, in contrast with an exclusive cytoplasmic distribution of 
Vav1/Cbl complexes (Bertagnolo et al., 2001). 
The interaction of Vav1 with Cbl and SLP-76 in HL-60 cells may be correlated to the 
transmembrane signaling mediated by CD38, an early biomarker of ATRA-induced 
differentiation in the HL-60 cell line, in which it may play a causal role in myeloid 
differentiation (Lamkin et al., 2006). A correlation between Vav1 and CD38-activated 
signaling has been recently demonstrated by experiments in which the expression of a 
cytosolic deletion mutant of CD38 caused failure to up-regulate ATRA-induced proteins 
such as CD11b, Vav1 and Fgr, this latter able to phosphorylate Vav1 after ATRA treatment 
of HL-60 cells (Congleton et al., 2011).  
Exclusive of the ATRA treatment of HL-60 seems to be the compartmentalized association 
between Vav1 and interacting proteins during ATRA treatment, since Cbl/Vav1 complexes 
are located in the cytoplasm while SLP-76/Vav1 complexes reside in the inner nuclear 
compartment. This suggests that Vav1 is recruited by one or more signal transduction 
cascades, starting from cell membrane and directed to the nucleus and involving the two 
adaptor proteins Cbl and SLP-76, which may then discretely regulate the amount of Vav1 in 
the cytoplasmic and nuclear compartments (Fig. 1). 
The Vav1-associated protein complexes identified in HL-60 cells also contain the tyrosine 
kinase Syk. In particular, Vav1/Cbl/Syk complexes have been found in cytoplasm whereas 
Vav1/SLP-76/Syk complexes have been demonstrated inside the nuclear compartment. 
These associations are present in control conditions and result strongly increased after 
ATRA treatment (Bertagnolo et al., 2001). This suggests that, during the maturation of APL-
derived myeloid precursors, a sequence of signals originated from membrane receptors and 
directed to the nuclear compartment is ended to regulate the amount of tyrosine 
phosphorylated Vav1 inside the nucleus (Fig. 1) and that this pathway may involve the 
negative regulation of Cbl on Vav1 activity.  
In both cells and nuclei of HL-60 cells, other signalling molecules associate with Vav1 as a 
consequence of ATRA treatment. They include the 1 isoform of PI-PLC and the p85 
regulatory subunit of PI3K. In particular, ATRA treatment increases the binding of tyrosine-
phosphorylated Vav1 to both N-terminal and C-terminal SH2 domains of p85 (Bertagnolo et 
al., 1998). Since Vav1 is the only member of the Vav1/PLC-1/PI3K complex to possess a 
nuclear localization sequence (Bustelo, 2001), it is conceivable that Vav1 is directly involved 
in regulating the amount of PLC-1 and PI3K inside the nuclear compartment. 
2.1.2 Phosphorylation of Vav1 on Tyr745  
Vav1 contains 31 tyrosine residues whose phosphorylation was originally investigated 
almost exclusively in relation to the function of Vav1 as a GEF. A crucial role in this context 
seems to be played by Tyr174 in both lymphoid and myeloid cells, even if other mechanisms 
have emerged in the last few years as regulators of Vav1 GEF activity, and recent data 
suggest that Tyr174 is coversely involved in roles of Vav1 not mediated by GEF activity 
(Katzav, 2009).  In addition to Tyr174, other conserved residues, Tyr142 and Tyr160, have 
been described to be phosphorylated in activated Vav1. It has also been suggested that 
phosphorylation of the tyrosines located inside the acidic region of Vav1 may allow Tyr142, 
Tyr160, and Tyr174 to become docking sites for kinases, which can then phosphorylate 
additional tyrosine residues in Vav proteins (Miletic et al., 2006; Yu et al., 2010). Recently, 
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several of the tyrosine residues at the carboxyl terminus of Vav1 have been shown to be 
phosphorylated in cancer cells, raising the possibility that also these tyrosine residues play 
an important role in Vav1 function (Lazer et al., 2010).  
The residue Tyr174, phosphorylated by members of Syk/Zap70 and Src tyrosine kinase 
families, plays a central role in regulating GEF activity of Vav1 in mature  neutrophils, 
including 2 integrin-mediated neutrophil migration in vitro and neutrophil recruitment 
during the inflammatory response in vivo (Schymeinsky  et al., 2006). In APL-derived cells, 
ATRA induces the phosphorylation of Tyr174 in NB4 but not in HL-60 cells and 
independently of the activity of Syk (Bertagnolo et al., 2011). Both cytofluorimetrical analysis 
of CD11b expression and migration assays on NB4 cells over-expressing the Tyr174Phe-
mutated Vav1 have ruled out any relevant role for this tyrosine residue in supporting the 
activity of ATRA in this cell line (Bertagnolo et al., 2010). Since phosphorylation of Tyr174 in 
neutrophils has been mainly associated to the GEF activity of Vav1 in mature cells, these 
findings suggest that the ATRA-induced phosphorylation of Tyr174 occurs in parallel with 
differentiation and may constitute a marker of the acquisition of a mature phenotype. This 
hypothesis is confirmed by the failure of ATRA in inducing the phosphorylation of Tyr174 in 
HL-60 cells, that reach indeed only a partially differentiatiated phenotype (Bertagnolo et al., 
2011). 
Since the phosphorylation of Vav1 on the Tyr174 residue seems unrelated to the path by 
which tyrosine phosphorylated Vav1 affects the ATRA-induced maturation of APL-derived 
cells, proteomic studies have been undertaken to identify other tyrosine residues 
phosphorylated after ATRA treament in both HL-60 and NB4 cells. Mass spectra analysis 
performed on Vav1 immunoprecipitated from NB4 whole cells identified Tyr745 as an 
ATRA-induced phosphorylated residue, within a highly conserved Vav1 sequence. The 
analysis of maturation-related features in differentiating NB4 cells over-expressing the 
Tyr745Phe-mutated form of Vav1 have clearly shown that phosphorylation of this tyrosine 
residue is crucial in regulating CD11b expression as well as in promoting the acquisition of 
migratory capabilities (Bertagnolo et al., 2010). Even if Tyr745 has never been correlated 
with the known roles of Vav1, multiple sequence alignment analysis of proteins from 
different species indicates that this is a highly conserved aminoacid, likely involved in 
physiological roles of Vav1.   
Inhibition studies have ruled out the role of Syk in phosphorylating Tyr745 as a 
consequence of ATRA treatment and, at present, no data are available about the involved 
tyrosine kinase. This is in part due to the fact that analysis performed with softwares 
designed to predict cell signaling interactions using short sequence motifs failed to 
recognize the Tyr745 of Vav1 as a putative phosphorylation site by the known tyrosine 
kinases. However, some tyrosine residues of Vav1 are not surface exposed and/or may be 
involved in intramolecular interactions, thereby precluding their tyrosine phosphorylation 
and impairing their recognition by the data base analysis. Since Tyr745 is located inside a 
short helix on the SH2 domain of Vav1, its phosphorylation could be an event secondary to 
phosphorylation of other tyrosine residues, which may induce conformational changes of 
Vav1 allowing Tyr745 to become accessible to a specific tyrosine kinase.    
2.1.3 GEF activity  
The best known function of tyrosine phosphorylated Vav1 is a catalytic role as a GEF 
towards the Rho family of GTPases, in which Tyr174 is crucial. Tyr174 lies within an α-helix 
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abundant in nuclei than in whole cell lysates, indicating a preferential association into the 
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transmembrane signaling mediated by CD38, an early biomarker of ATRA-induced 
differentiation in the HL-60 cell line, in which it may play a causal role in myeloid 
differentiation (Lamkin et al., 2006). A correlation between Vav1 and CD38-activated 
signaling has been recently demonstrated by experiments in which the expression of a 
cytosolic deletion mutant of CD38 caused failure to up-regulate ATRA-induced proteins 
such as CD11b, Vav1 and Fgr, this latter able to phosphorylate Vav1 after ATRA treatment 
of HL-60 cells (Congleton et al., 2011).  
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The Vav1-associated protein complexes identified in HL-60 cells also contain the tyrosine 
kinase Syk. In particular, Vav1/Cbl/Syk complexes have been found in cytoplasm whereas 
Vav1/SLP-76/Syk complexes have been demonstrated inside the nuclear compartment. 
These associations are present in control conditions and result strongly increased after 
ATRA treatment (Bertagnolo et al., 2001). This suggests that, during the maturation of APL-
derived myeloid precursors, a sequence of signals originated from membrane receptors and 
directed to the nuclear compartment is ended to regulate the amount of tyrosine 
phosphorylated Vav1 inside the nucleus (Fig. 1) and that this pathway may involve the 
negative regulation of Cbl on Vav1 activity.  
In both cells and nuclei of HL-60 cells, other signalling molecules associate with Vav1 as a 
consequence of ATRA treatment. They include the 1 isoform of PI-PLC and the p85 
regulatory subunit of PI3K. In particular, ATRA treatment increases the binding of tyrosine-
phosphorylated Vav1 to both N-terminal and C-terminal SH2 domains of p85 (Bertagnolo et 
al., 1998). Since Vav1 is the only member of the Vav1/PLC-1/PI3K complex to possess a 
nuclear localization sequence (Bustelo, 2001), it is conceivable that Vav1 is directly involved 
in regulating the amount of PLC-1 and PI3K inside the nuclear compartment. 
2.1.2 Phosphorylation of Vav1 on Tyr745  
Vav1 contains 31 tyrosine residues whose phosphorylation was originally investigated 
almost exclusively in relation to the function of Vav1 as a GEF. A crucial role in this context 
seems to be played by Tyr174 in both lymphoid and myeloid cells, even if other mechanisms 
have emerged in the last few years as regulators of Vav1 GEF activity, and recent data 
suggest that Tyr174 is coversely involved in roles of Vav1 not mediated by GEF activity 
(Katzav, 2009).  In addition to Tyr174, other conserved residues, Tyr142 and Tyr160, have 
been described to be phosphorylated in activated Vav1. It has also been suggested that 
phosphorylation of the tyrosines located inside the acidic region of Vav1 may allow Tyr142, 
Tyr160, and Tyr174 to become docking sites for kinases, which can then phosphorylate 
additional tyrosine residues in Vav proteins (Miletic et al., 2006; Yu et al., 2010). Recently, 
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several of the tyrosine residues at the carboxyl terminus of Vav1 have been shown to be 
phosphorylated in cancer cells, raising the possibility that also these tyrosine residues play 
an important role in Vav1 function (Lazer et al., 2010).  
The residue Tyr174, phosphorylated by members of Syk/Zap70 and Src tyrosine kinase 
families, plays a central role in regulating GEF activity of Vav1 in mature  neutrophils, 
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ATRA induces the phosphorylation of Tyr174 in NB4 but not in HL-60 cells and 
independently of the activity of Syk (Bertagnolo et al., 2011). Both cytofluorimetrical analysis 
of CD11b expression and migration assays on NB4 cells over-expressing the Tyr174Phe-
mutated Vav1 have ruled out any relevant role for this tyrosine residue in supporting the 
activity of ATRA in this cell line (Bertagnolo et al., 2010). Since phosphorylation of Tyr174 in 
neutrophils has been mainly associated to the GEF activity of Vav1 in mature cells, these 
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recognize the Tyr745 of Vav1 as a putative phosphorylation site by the known tyrosine 
kinases. However, some tyrosine residues of Vav1 are not surface exposed and/or may be 
involved in intramolecular interactions, thereby precluding their tyrosine phosphorylation 
and impairing their recognition by the data base analysis. Since Tyr745 is located inside a 
short helix on the SH2 domain of Vav1, its phosphorylation could be an event secondary to 
phosphorylation of other tyrosine residues, which may induce conformational changes of 
Vav1 allowing Tyr745 to become accessible to a specific tyrosine kinase.    
2.1.3 GEF activity  
The best known function of tyrosine phosphorylated Vav1 is a catalytic role as a GEF 
towards the Rho family of GTPases, in which Tyr174 is crucial. Tyr174 lies within an α-helix 
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and binds directly with the GTPase interaction pocket of the DH domain, blocking access to 
substrate and inhibiting Vav1 GEF activity. Phosphorylation releases Tyr174 from the 
binding pocket, relieving the auto-inhibition (Bustelo et al., 2001). The activity of the DH 
domain is also regulated by the CH domain, as deletion of this domain results in 
constitutively active GEF activity. It has been suggested that the Vav1 CH domain can bind 
to the C1 region, occluding the DH domain and blocking access to GTPases. CH–C1 
interaction apparently stabilizes the inhibitory Tyr174–DH interaction. In addition, the PH 
domain regulates Vav1 catalytic activity by interaction with two inositol lipids: 
phosphatidylinositol 4, 5- bisphosphate (PIP2) and phosphatidylinositol 3, 4, 5-trisphosphate 
(PIP3). Whereas the binding of PIP3 moderately enhances the in vitro GEF activity of Vav1, 
binding to PIP2 has an inhibitory effect. Consistent with this model, Vav1 carrying a single 
mutation in its PH domain is constitutively active and induces cytoskeleton rearrangements 
as a consequence of Rac activation. Deletions of C1 domain or mutations that disrupt its 
structural integrity inhibit Vav1 GEF activity. High resolution X-ray structure of DH–PH–C1 
domains suggests that PH and C1 domains contribute to GEF activity by stabilizing the DH 
domain structure and not through direct contacts with GTPases (Bustelo, 2002).  
GEF activity of Vav1 has long been regarded as the key for transferring the signal from 
activated receptors to the cytoskeleton. Among the molecules constituting the cytoskeleton 
architecture, actin seems to be a preferred target of the Vav1-dependent GEF activity.  
Several partners are involved in the pathway by which Vav1 affects actin cytoskeleton. It 
has been reported that Vav1 is a preferential exchange factor for Rac1, which in turn may 
activate phosphatidylinositol-4-phosphate (PIP) 5-kinase which phosphorylates PIP to PIP2. 
PIP2 may function as an activator of actin-binding proteins, like talin and vinculin, that 
attach the cytoskeleton to the cell membrane. Another potential target for the GEF activity of 
Vav1, Cdc42, may activate the WASP protein, a key mediator of actin polymerization 
(Hornstein et al., 2004). Finally, Vav1-activated small G proteins play an essential role in 
regulating actin cytoskeleton dynamics by also interacting with the p21-activated serine-
threonine kinase (PAK) family of actin-regulatory enzymes (Daniels & Bokoch, 1999). 
In both lymphoid and myeloid cells, like other proteins with a GEF activity, Vav1 mediates a 
number of cytoskeletal-associated cellular processes, being an essential part of the molecular 
link connecting activated receptors to the actin cytoskeleton. A consistent number of studies 
(reviewed in Hornstein et al., 2004) have reported the role of Vav1 in the formation of 
immunological synapse and in phagocytosis of T cells. In non adherent neutrophils, 
stimulation of chemoattractant receptors induces a complex sequence of events: actin 
reorganization, shape changes, development of polarity and reversible adhesion, all 
culminating in chemotaxis. The complex signaling mechanisms that regulate neutrophil 
migration are well studied, and Vav1 appears to be a major point of the inhibitory crosstalk 
between adhesion receptors and cytokine receptors (Gakidis et al., 2004). In particular, the 
activity of Vav1 as GEF for Rac2 is inhibited in adherent cells, as a possible consequence of 
the activation by adhesion of one or more tyrosine phosphatases responsible of 
dephosphorylating Vav1. On the other hand, experiments performed with Vav1-/- mice 
have demonstrated that motility and mobilization into peripheral blood induced in 
neutrophils by FMLP are significantly reduced, as well as the generation of filamentous 
actin (Kim et al., 2003). Studies performed in a rat model have demonstrated that the M-
CSF-induced chemotaxis of bone marrow macrophages is initiated by the 3-
phosphoinositide-dependent GEF activity of Vav1 on Rac (Vedham et al., 2005). 
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In APL-derived HL-60 cells, ATRA treatment induces an increase of total GEF activity, not 
attributable to Vav1, as  deduced by in vitro assays on Ras/Rac small G proteins performed 
on Vav1 immunoprecipitated from both whole cells and isolated nuclei (Bertagnolo et al., 
2001). This implies that, in this cell model, the Syk-dependent tyrosine phosphorylation of 
Vav1 is not ended to regulate its GEF activity and that alternative pathways have to be 
considered to explain the mechanism by which Vav1 affects the organization of cytoskeleton 
and nucleoskeleton during  maturation of tumoral promyelocytes. 
2.2 GEF-independent activity of phosphorylated Vav1  
2.2.1 Regulation of actin cytoskeleton  
In addition to act as a GEF, Vav1 may mediate actin reorganization through other, GEF-
independent mechanisms. The presence in its structure of a number of tyrosines and 
domains potentially involved in protein-protein interactions suggests for Vav1 a role in 
actin polymerization as an adapter protein that links signaling and cytoskeletal molecules. 
In T cells, Vav1 binds constitutively Talin and Vinculin, anchoring the actin cytoskeleton to 
the plasma membrane, and the cytoskeletal protein Zyxin (Hornstein et al., 2004). In the 
same cell model, a direct link between Vav1 and dynamin 2 (Dyn2), a component of the 
cytoskeletal regulators, has also been demonstrated (Gomez et al., 2005).  
A mechanism by means of which tyrosine-phosphorylated Vav1 regulates cytoskeleton of 
ATRA-treated tumoral promyelocytes, identified in HL-60 cells, implies the interaction of 
Vav1 with the p85 regulatory subunit of PI3K. Studies aimed to establish the functional 
meaning of this interaction have demonstrated that, in maturating myeloid precursors, PI3K 
activity closely depends on its association with tyrosine phosphorylated Vav1 and that 
when Vav1/PI3K interaction and/or PI3K activity are abrogated, the phenotypic 
differentiation of ATRA-treated HL-60 is compromised (Bertagnolo et al., 1999, 2004). These 
evidence assign to Vav1/PI3K interaction a prominent function in the regulation of 
cytoskeleton alternative to the described role of 3-phosphoinositides on GEF activity of Vav1 
(Han et al., 1998). 
Also actin participates in the ATRA-induced protein complexes containing Vav1 and PI3K 
in HL-60 cells. Remarkably, when the association between Vav1 and PI3K is inhibited, the 
formation of PI3K/actin complexes is reduced, suggesting that the interaction of PI3K with 
Vav1 is essential for its association with actin (Bertagnolo et al., 2004). Since the recovery of 
3-phosphoinositides is strongly reduced when the Vav1-dependent PI3K/actin interaction is 
abrogated, it can be concluded that Vav1 regulates the physical contact of PI3K with their 
cytoskeleton-associated substrates. These observations suggest that in addition to playing a 
regulatory role in Vav1 activation, PI3K activity may itself be regulated by Vav1.  
PI3K is likely to play essential roles in granulocytic differentiation of tumoral myeloid 
precursors, considering that both down-modulation of its expression and pharmacological 
inhibition of its activity during ATRA treatment significantly reduce the tendency of HL-60 
cells to acquire the differentiated phenotype (Bertagnolo et al., 1999). The response to ATRA 
and the downstream effects of PI3K observed during the induced differentiation support the 
notion that PI3K is recruited in the path controling cytoskeleton in mature granulocytes. In 
fact, PI3K is activated in response to chemotactic factors in murine and human neutrophils 
(Cicchetti et al., 2002; Niggli & Keller, 1997; Stephens et al., 2002) in which newly produced 
PIP3 is involved in determining the localization and possibly the crosslinking/stabilization of 
actin filaments (Chen et al., 2003; Hannigan et al., 2002; Wang et al., 2002). In vitro experiments 
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have demonstrated that PI3K may affect actin-related modifications of cytoskeleton also by 
directly affecting PAK kinase activity (Menard & Mattingly, 2004). PI3K has a more general 
influence on cytoskeleton by determining the amount of the inositol-containing lipids, that 
have  emerged as major players in regulating actin assembly at several levels and with 
different mechanisms, including the direct interaction with cytoskeletal proteins, such as 
vinculin and gelsolin (Janmey et al., 1999, Takenawa & Itoh, 2001). 
 
 
Fig. 1. Schematic representation of the recruitment and phosphorylation of Vav1 in ATRA-
treated promyelocytes. 
Since, in ATRA-treated promyelocytes, both PI3K activity and the modifications of the 
nucleus architecture depend on the formation of Vav1/PI3K complexes, Vav1 may be 
important for targeting PI3K to its nuclear substrates. The association of Vav1 with other 
lipid modifying enzymes, including specific PI-PLC isoforms (Bertagnolo et al., 1998;), 
suggests a more general role of Vav1 in determining the composition of the actin-associated 
phosphoinositide pool and, ultimately, in regulating actin polymerization in differentiating 
HL-60 cells. 
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2.2.2 Regulation of gene expression  
Microarray analysis performed on APL-derived cell lines has identified several genes whose 
expression is modified by ATRA treatment, including genes for a  number of cytokines, in 
turn involved in the differentiative program of tumoral promyelocytes (Hsu et al., 1999; 
Visani et al., 1996). As a consequence of ATRA administration, tyrosine-phosphorylated 
Vav1 accumulates inside the nuclear compartment of APL-derived cells and becomes 
involved in the changes of nuclear morphology. Since local reorganization of nuclear 
architecture is required for both transcription and post-transcriptional events, it is 
conceivable that Vav1 plays a role in regulating ATRA-related gene expression.  
An array analysis performed on HL-60 cells focussed on genes coding for cytokines and 
cytokine receptors indicates that the inhibition of the Syk-dependent tyrosine-
phosphorylation of Vav1 during ATRA treatment prevents the ATRA-induced expression of 
8 genes (Bertagnolo et al., 2005). Among them, the thymosin beta-10 (TMSB10) gene has 
been found, encoding for a small G-actin binding protein that induces depolymerization of 
intracellular F-actin pools and thus deeply affects actin architecture (Liu et al., 2004; Rho et 
al., 2004). Tyrosine-phosphorylated Vav1 is also involved in regulating the ATRA-induced 
expression of the gene for Notch homolog, that codifies for a molecule playing a role in 
mediating cell fate decisions during hematopoiesis (Ohishi et al., 2003) and whose signaling 
might be necessary for the proliferation and survival of AML cells, possibly through the 
maintenance of the expression of c-Myc and Bcl2, as well as the phosphorylation of the Rb 
protein (Li et al., 2010). The involvement of Vav1 in regulating ATRA-dependent expression 
of cytokines and/or growth factors has been ascertained by silencing Vav1 during ATRA 
admistration, further confirming that the increase of Vav1 expression is not an 
epiphenomenon but constitutes a key event able to actually promote the granulocytic 
maturation of tumoral myeloid precursors. 
The evidence that Vav1 has a role in regulating ATRA-dependent gene expression in APL-
derived cells suggests the participation of Vav1 to transcriptional complexes activated by 
ATRA, also considering that, in both myeloid and lymphoid cells, Vav1 seems to be 
involved in regulating DNA transcription, by direct interaction with, or as a facilitator of, 
transcription factors (Katzav, 2004). In particular, Vav1 regulates Nuclear Factor of 
Activated T-cells (NFAT), Activator Protein-1 (AP-1) and Nuclear Factor κB (NF-κB) in T-
cells in response to TCR stimulation, and exerts a specific role in regulating the CREB-
dependent gene transcription (Haubert & Weckbecker, 2010; Schneider & Rudd, 2008).  
Direct evidence for the presence of Vav1 as a component of an active transcriptional 
complex has been reported by Houlard et al. (2002) demonstrating the participation of Vav1 
in complexes with NFAT and NF-kB-like, as facilitator of their transcriptional activity. 
In APL-derived cells, nuclear Vav1 associates with PU.1 (Brugnoli et al., 2010), a 
transcription factor induced by ATRA and able to play a crucial role in the completion of 
granulocytic differentiation of APL-derived myeloid precursors (Mueller et al., 2006). In 
particular, the down-modulation of PU.1 by means of specific siRNAs has allowed to 
establish that, like in other tumoral myeloid precursors (Denkinger et al., 2002), PU.1 
regulates the expression of Vav1 induced by ATRA in NB4 cells (Brugnoli et al., 2010).  
In AML-derived myeloid precursors, PU.l represents a major determinant of the myeloid 
expression of CD11b (Kastner & Chan, 2008; Pahl et al., 1993), an integrin receptor whose 
surface expression increases concurrently with CD11b mRNA levels during myeloid 
differentiation of APL-derived cell lines (Barber et al., 2008). Chromatin 
immunoprecipitation (ChIP) experiments performed on NB4 cells treated with ATRA have 
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demonstrated that PU.1 is recruited to its consensus sequence within the CD11b promoter 
(Brugnoli et al., 2010). Since the over-expression of PU.1 might influence phenotype and 
restore differentiation of primary myeloid leukemic blasts (Durual et al., 2007), and its 
silencing counteracts the ATRA ability to induce the expression of the granulocytic marker 
CD11b (Mueller et al., 2006), PU.1 may be used by ATRA to promote CD11b expression 
during the late stages of the maturation of APL-derived cells. This is confirmed by in vitro 
experiments demonstrating the formation of PU.1-containing complexes on the CD11b 
promoter (Brugnoli et al., 2010). 
 
 
Fig. 2. Schematic representation of the involvement of Vav1 in regulating gene expression in 
differentiating promyelocytes. 
Also Vav1 is recruited to the PU.1 consensus sequence on the CD11b promoter in untreated 
NB4 cells. ATRA treatment, by inducing an increase in Syk-dependent tyrosine 
phosphorylation of Vav1, displaces this protein from existing molecular complexes on the 
CD11b promoter. Accordingly, the specific inhibition of Syk activity is accompanied by the 
appearance of a Vav1-containing complex (Brugnoli et al., 2010). The participation of Vav1 
to molecular complexes including PU.1 has been ruled out by EMSA experiments. On the 
other hand, both expression and tyrosine phosphorylation levels of Vav1 seem to play a role 
in regulating the formation of PU.1-containing complexes. In fact, when the amount of Vav1 
is forcedly reduced or its tyrosine phosphorylation is inhibited during the differentiation 
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2010). It is then conceivable that Vav1, and in particular tyrosine-phosphorylated Vav1, 
regulates the recruitment of PU.1 to its consensus sequence on the CD11b promoter region 
and, possibly, the expression of this surface antigen. 
3. Vav1 and protein expression  
Proteome analysis currently provides the opportunity to identify global changes in gene 
expression by directly measuring protein amount. A number of recent studies have used 
this approach to evaluate protein expression during differentiation/apoptosis induced by 
different agonists in APL-derived cells. In particular, it has been reported that ATRA 
modulates the expression level of structural and signal transduction proteins as well as of 
molecules involved in the different phases of protein synthesis (Dong et al, 2006; Harris et 
al., 2004; Wan et al., 2001; Wang et al., 2004;).  
On the basis of the evidence that inside the nucleus of a number of different cell lines, 
including APL-derived cells, Vav1 participates to molecular complexes with DNA-related 
proteins (Brugnoli et al., 2010; Houlard et al., 2002; Romero et al., 1998) a more general role 
of Vav1 in regulating events ended to control protein expression can be hypothesized. 2D 
electrophoresis followed by mass spectrometry have established that, in both HL-60 and 
NB4 cells, the down-modulation of Vav1 abrogates the capacity of ATRA of modulating the 
expression of proteins associated to cytoskeleton and involved in proliferation and of 
apoptosis-related proteins, as well as of molecules implicated in metabolism, synthesis, 
folding and degradation of proteins (Bertagnolo et al., 2008). The majority of the identified 
proteins are affected by Vav1 down-modulation only in one of the two analyzed cell lines, 
according to the notion that HL-60 and NB4 cells, even if both derived from patients with 
APL, show peculiar genotypic and phenotypic profiles (Barber et al., 2008). Interestingly, in 
NB4 cells, the lack of Vav1 affects the ATRA-dependent expression of the Splicing factor, 
arg/ser rich 3 (Sfrs3), a member of SR proteins, known as non-snRNP splicing factors, that 
may affect both constitutive and alternative splicing of mRNA (Sanford et al., 2005). This 
evidence further supports the role of Vav1 in regulating the ATRA-dependent gene 
expression.   
Some of the identified proteins are differentially expressed, as a consequence of Vav1-down-
modulation during ATRA treatment, in both cell lines, suggesting that they may constitute a 
common part of the signalling activated by ATRA in APL-derived promyelocytes. Notably, 
this group of proteins includes the  isoform of the 14-3-3 family of proteins, specifically 
involved in the caspase networks (Liou et al., 2007). The increased expression of 14-3-3 in 
both HL-60 and NB4 cells when Vav1 is down-modulated during ATRA treatment suggests 
that the amount of Vav1 may be critical in determining the mechanism of caspase activation 
in APL.  
Vav1 also affects the ATRA-dependent expression of -enolase, a multifunction protein 
involved in glycolysis and up-regulated in the sera of a number of cancer patients, in which 
it seems to have a role in tumorigenesis (Zou et al., 2005). -enolase is expressed at high 
levels in most AML subtypes in which it might contribute to the adverse evolution of the 
disease (Lopez-Pedrera et al., 2006). Since down-modulation of Vav1 during ATRA 
treatment of APL-derived cells reduces the expression of -enolase (Bertagnolo et al., 2008), 
it has been suggested that Vav1 promotes the differentiation of tumoral promyelocytes by 
also targeting metabolic pathways.  
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The proteasome component “splice isoform 2 subunit 3” is down-modulated as well in 
HL-60 and NB4 cells under the same experimental conditions (Bertagnolo et al., 2008). Since 
proteasome is the major cellular proteolytic machinery responsible for degradation of 
normal and damaged proteins (Von Mikecz, 2006), Vav1 may also be involved in regulating 
protein degradation during ATRA dependent maturation of tumoral promyelocytes. 
Also the component of microtubules -tubulin is affected by down-modulation of Vav1 
during ATRA treatment (Bertagnolo et al., 2008), indicating that Vav1, in addition to 
regulate cytoskeleton reorganization, takes part to the profound architectural changes of 
differentiating promyelocytes by regulating the expression of cytoskeleton components.  
4. Vav1 and monocytic/macrophagic differentiation 
The human promyelocytic leukemia cell lines HL-60 and NB4 can be differentiated either 
toward neutrophils by ATRA or to monocytes/macrophages by PMA (Murao et al., 1983; 
Song & Norman, 1998). PMA is a stable analogue of 2, 3-diacylglycerol that induces, even if 
with dynamics not identical in HL-60 and NB4 cells, morphological and functional changes 
related to monocyte maturation, accompanied by a loss of proliferative capacity (Jasek et al., 
2008). Immunochemical and immunocytochemical analysis demonstrate that the expression 
of Vav1 increases also during the PMA-induced acquisition of a monocyte-like phenotype of 
HL-60 and NB4 cells (Bertagnolo et al., 2011). This is consistent with the notion that also 
mature monocytes express Vav1 and that proper amounts of the protein are necessary for 
their inflammation related functions (Bhavsar et al., 2009; Hall et al., 2006). In the same cell 
types, PMA also induces a relevant increase of tyrosine phosphorylation of Vav1. On the 
other hand, and in constrast to what observed in the ATRA-treatment of the same cell line, 
no role for Syk was demonstrated in this event (Bertagnolo et al., 2011), consistent with the 
notion that, at least in HL-60 cells, Syk might exert a narrower role, restricted to directing 
cells toward granulocyte differentiation (Qin & Yamamura, 1997). In both HL-60 and NB4 
cells, PMA induces a relevant increase of tyrosine phosphorylation of Vav1 on the Tyr174 
residue (Bertagnolo et al., 2011), according to the GEF role played by Vav1 in myeloid cells. 
These results are also in agreement with other data indicating that, in macrophage-like 
differentiated HL-60 cells, the activity of Syk is ended to regulate the roles played by mature 
cells in immune response, including their complement-mediated phagocytosis, in which the 
kinase regulates both actin dynamics and the Vav1-RhoA activation pathway (Shi et al., 
2006). 
Also in differentiation of APL-derived cells to monocytes/macrophages, a crucial role for 
Vav1 in determining the acquisition of maturation-related features has been demonstrated 
by silencing the expression of Vav1 induced by PMA (Bertagnolo et al., 2011). Under these 
conditions, the expression of CD11b, which is induced by PMA and constitutes a marker 
also for monocyte differentiation, is significantly reduced, similarly to what demonstrated 
during the treatment with ATRA of HL-60 and NB4 cells (Bertagnolo et al. 2011). This 
suggests that, in differentiating APL-derived cells, Vav1 plays a role in regulating the 
expression of the CD11b surface antigen regardless the agonist employed and the 
maturation lineage. Since in NB4 cells treated with ATRA Vav1 is recuited to protein/DNA 
complexes on the CD11b promoter (Brugnoli et al., 2010), it can be speculated that Vav1 
plays a specific role in driving the expression of CD11b as part of the transcriptional 
machinery also during the differentiation of NB4 cells along the monocytic/macrophagic 
lineage. 
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Also cell adhesion is affected by down-modulation of Vav1 during PMA treatment of HL-60 
and NB4 cells, in terms of both number of adherent cells and of adhesion area of cells that 
remain attached to the flask bottom. These results are in agreement with the data obtained 
with macrophages from Vav1_/_ mice, showing a smaller adhesive area or a decreased 
adhesion efficiency (Wells et al., 2005).  
4.1 Regulation of actin  
As above reported, the main known functional role of tyrosine phosphorylated Vav1 is to 
regulate cytoskeleton reorganization, a phenomenon at the basis of both adhesion and 
migration of monocytes/macrophages. Vav1 regulates cell architecture not only by means of 
its GEF activity but also by interacting with proteins in turn involved in cytoskeleton 
reorganization. In addition, in both HL-60 and NB4 cells, Vav1 affects the ATRA-induced 
expression of the microtubule component -tubulin.  
Contrarily to what observed during granulocytic differentiation, Vav1 down-modulation 
does not have any effect on expression and architectural organization of -tubulin during 
PMA-induced monocytic/macrophagic maturation of NB4 cells (Bertagnolo et al., 2011). 
This indicates that, during the maturation process of APL-derived cells, Vav1 exerts an 
agonist- and lineage-specific role in regulating -tubulin. From a more general point of 
view, concerning microtubule organization, it can be speculated that the role of Vav1 is 
restricted to the control of the motility of mature cells, as also suggested by the evidence that 
changes in microtubule dynamics contribute to the reduced migration speed of Vav1_/_ 
macrophages in response to CSF-1 (Wells et al., 2005). 
In living cells, the F-actin cytoskeleton encompasses a variety of different structures that are 
essential for many different aspects of cell physiology. In particular, dynamic modulation of 
the filamentous actin cytoskeleton is critical to numerous physical cellular processes, 
including adhesion, migration and phagocytosis, all requiring precise regulation of cell 
shape  (Stricker et al., 2010). Recent data demonstrate that Vav proteins, including Vav1, are 
required for actin cytoskeleton reorganization during migration of macrophages, by 
coupling RhoA and Rac1 activity to adhesion receptors (Bhavsar et al., 2009). Also in ATRA-
induced maturation of cells derived from APL Vav1 seems to regulate actin organization.  
In HL-60 and NB4 cells treated with PMA, an unprecedented involvement of Vav1 in 
regulating the increase of actin expression has been shown very recently (Bertagnolo et al., 
2011), that constitutes a further confirmation that Vav1, besides being involved in the 
formation of filaments, takes part to cytoskeleton reorganization as a modulator of protein 
expression. 
The modifications of cell shape in the different cell processes seem to be regulated by the 
existence of the F-actin cortex, a thin, membrane-bound F-actin network (Stricker et al., 
2010). Defective actin-cap formation has been found in lymphocytes from a Vav-deficient 
mice, clearly correlating Vav1 activity with the regulation of cell shape (Holsinger et al., 
1998). Furthermore, a recent work in which adhesive micropatterned surfaces have been 
used to control the overall shape of fibroblasts, has demonstrated that the shape of the 
nucleus is tightly regulated through a perinuclear actin cap, which is located above and 
around the interphase nucleus (Khatau et al., 2009). A wide variety of contractile F-actin 
networks with different architectures and polarity have also been found near cell adhesion 
surfaces, correlated with the migratory capability of adherent cells (Stricker et al., 2010). By 
means of confocal analysis of PMA-treated adherent NB4 cells, it has been demonstrated the 
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existence of an agonist-induced F-actin network, in which F-actin colocalyzes with Vav1, 
that sharply defines the cytoplasmatic cell border, accumulates inside thin and long cell 
processes and surrounds the nuclear compartment (Bertagnolo et al., 2011). Since the 
existence of cytoplasmatic processes in PMA-treated adherent cells are indicative of 
migratory activity (Stricker et al., 2010), Vav1/F-actin co-localization in cytoplasm 
protrusions is suggestive of a synergy of the two molecules in controling cell motility. This 
is in agreement with the role described for Vav proteins in the maintenance of normal 
morphology and migratory behaviour in macrophages (Bhavsar et al., 2009). The strong  
Vav1/F-actin co-localization observed at the nuclear periphery and, in particular, in the 
region above the nucleus, suggests that the two proteins may cooperate in regulating the 
shape of the nucleus through an actin filament structure similar to the perinuclear actin cap 
described by Khatau et al. (2009). On the other hand, the role of Vav1 in modulating cell 
adhesion of PMA-treated cells seems to be related to its ability to regulate expression of 
integrins, like CD11b, rather than to a direct effect on actin-based cytoskeleton. 
5. Conclusion 
The present review focuses on the role of the multidomain protein Vav1 in promoting and 
sustaining the completion of the differentiation program of tumoral promyelocytes. Vav1 is 
a key protein in the ATRA- and PMA-induced maturation of APL-derived cells, since either 
its down-modulation or over-expression respectively prevents or potentiates the ability of 
these agonists to induce the acquisition of a mature phenotype. Alternatively to the best 
known function of Vav1 as a GEF for small G proteins, ended to regulate cell shape by 
affecting actin assembly, other mechanisms by which Vav1 affects myeloid differentiation 
have been described, reflecting the great interactive and regulatory potential of Vav1, which 
make the full understanding of its functions a very difficult, yet fascinating story.   
An example of the complex role played by Vav1 during myeloid differentiation of APL-
derived cells is the interaction of Vav1 with various lipid-modifying enzymes ended to 
regulate the pool of phosphoinositides associated to cytoskeleton. The resulting 
modifications of actin cytoskeleton contribute to the changes of cellular and nuclear shape 
occurring in differentiating tumoral promyelocytes (Fig. 3).  
The participation of Vav1 to molecular complexes with other adaptor proteins differently 
distributed in the cytoplasm and in the nucleus suggests the existence of a signal sequence 
originated from membrane receptors and directed to the nuclear compartment. Inside the 
nucleus of APL-derived cells, Vav1 seems to play its most intriguing role by regulating the 
expression of CD11b, a surface marker of both granulocyte and monocyte differentiation, 
and of a number of ATRA-modulated proteins (Fig. 3). The nuclear issue assumes thus great 
relevance, confering to Vav1 compartimentalized strategic roles in regulating the maturation 
process of tumoral promyelocytes. 
The bulk of the studies reviewed here are mostly concerned with two cell lines, HL-60 and 
NB4, derived from APL patients, driven to achieve differentiation by treatment with drugs 
of the retinoids or phorbol esters families. Even though a better understanding of the 
functional engagement of Vav1 will be required before converting scientific achievements 
into clinical advances, Vav1 might be considered a common target for developing new 
therapeutic strategies for the different subtypes of myeloid leukemias.  
In addition, it can be speculated that the identified pathways involving Vav1 are of more 
general interest and may be potentially extended also outside the 
haemopoietic/immunological systems. 
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Fig. 3. Overall role of Vav1 in regulating maturation of APL-derived promyelocytes. 
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1. Introduction 
p15INK4b expression is lost in a striking 80% of all patients suffering from acute myeloid 
leukemia (AML). Specific inactivation of the gene by aberrant promoter hypermethylation is 
also detected in about 50% of patients diagnosed with myelodysplastic syndromes (MDS) 
and almost 60% of patients with myeloproliferative disorders (MPD). More importantly, a 
strong correlation between the methylation levels of p15INK4b and poor prognosis is now 
well established in these patients. Hypermethylation levels also provide a marker for 
subsequent transformation and progression of the disease to a more aggressive phenotype. 
These clinical observations establish the repression of p15INK4b expression by promoter 
hypermethylation as the most prevalent genetic abnormality in myeloid leukemia. The 
p15INK4b gene (also referred to as CDKN2B and MTS2) encodes a 15kDa cyclin dependent 
kinase inhibitor (CDKI).  Specific and preferential epigenetic targeting of p15INK4b for 
silencing over other CDKIs such as p16INK4a and p21WAF/CIP in AML, MDS and MPD 
patients strongly supports a role for this protein as a tumor suppressor in hematological 
malignancies of the myeloid lineage.  
This chapter provides a review of the literature outlining the high prevalence of p15INK4b 
loss of expression in human myeloid malignancies, as well as the latest research carried out 
in mice which supports a role for p15Ink4b as a tumor suppressor. It also focuses on the well 
established function of p15INK4b in the control of the cell cycle, as well as its role during 
early and late myeloid cells development. Finally, this chapter discusses the multiple 
mechanisms by which p15INK4b is silenced and presents a few examples of clinical studies 
of drugs that target p15INK4b for re-expression. These include treatments for reversing 
aberrant DNA methylation, and are currently being tested and used for the therapy of MDS 
and AML. 
2. Role of p15INK4b in myeloid malignancies 
2.1 Inactivation in human AML and MDS 
p15INK4b silencing by promoter hypermethylation occurs almost exclusively in cancers of 
the hematopoietic system, and is observed in acute leukemias of myeloid (AML) and 
lymphoid (ALL) origins (Drexler, 1998). Aberrant hypermethylation occurs at the gene’s 
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CpG islands which extend throughout the promoter region, exon 1 and part of intron 1 
(Herman et al., 1996). DNA methylation is the addition of methyl groups on cytosine bases 
on the DNA molecules of mammalian cells which affects gene expression (Deaton et al., 
2011).  Methylation is carried out by the enzymes DNA methyltransferases (DNMT) which 
catalyze the reaction converting cytosine to 5-methylcytosine (Bird et al., 2002).  In the 
earlier studies DNA methylation was assessed by southern blotting and methylation-
specific PCR technique and more recently by more sensitive assays including bisulfate 
pyrosequencing and genome-wide sequencing methods (Deaton et al., 2011).  
Despite the broad clinical diversity of AML, with more than a hundred cytogenetic 
alterations described (Vardiman et al., 2002; Trost et al., 2006), aberrant methylation of 
p15INK4b has been reported in up to 80% of patients with primary and secondary AML. 
Hypermethylation levels have been shown to correlate with a reduction in the mRNA and 
the protein expression levels of p15INK4b (Cameron et al., 1999; Matsuno et al., 2005). 
Furthermore, density of the methylation has been shown to vary greatly between and within 
AML patients and its levels closely correlate with the degree of transcriptional repression 
(Aggerholm et al., 1999, Cameron et al., 1999). AML classification into ten different subtypes 
was originally defined by the French-American-British (FAB) cooperative group (Bennett et 
al., 1976, 1985). Numerous studies have been conducted to assess the methylation levels of 
p15INK4b on samples of patients with AML across the different FAB subtypes (Herman et 
al., 1996, 1997; Aggerholm et al., 1999; Guo et al., 2000; Chim et al., 2001a, 2001b; 
Christiansen et al., 2003; Garcia-Manero et al., 2003; Teofili et al., 2003; Shimamoto et al., 
2005). In patients with adult and childhood AML, hypermethylation of p15INK4b in cells 
isolated from bone marrow and peripheral blood is observed in nearly all morphological 
FAB subtypes. Higher frequencies are generally observed in the M1, M2, M3 and M4 
subtypes than in the M5, M6 or M7 subtypes and are found to occur in the vast majority of 
the patients’ leukemic cells (Aggerholm et al., 1999; Wong et al., 2000; Shimamoto et al., 
2005; Tsellou et al., 2005). In patients with therapy-induced AML (t-AML), aberrant 
methylation of p15INK4b (in over 90% of patients) is found to be independent from the 
patient’s type of previous therapy which ranges from alkylating agents, topoisomerase II 
inhibitors to radiotherapy (Christiansen et al., 2003).  
A similar pattern of aberrant methylation is also well documented in patients with MDS 
(Uchida et al., 1997; Quesnel et al., 1998; Aoki et al., 2000; Tien et al., 2001; Christiansen et al., 
2003; Teofili et al., 2003). The FAB classification system for MDS is mainly based on the 
percentage of blast cells in the bone marrow and the peripheral blood and the degree of 
cytopenia (Bennet et al., 1982). Methylation levels have also been shown to increase during 
follow-up and in conversion to overt AML (Tien et al., 2001, Christiansen et al., 2003). 
Importantly, aberrant DNA methylation of p15INK4b was found to be one of the most 
dominant molecular events in MDS progression to AML (Jiang et al., 2009). Similar to AML, 
cytogenetics of MDS is also a crucial factor in the prognosis and development of the disease 
(Haase et al., 2007). The World Health Organization (WHO) classification system for 
myeloid neoplasms was developed and takes into consideration both morphology and 
cytogenetic abnormalities (Harris et al., 2000). In MDS patients, methylation of p15INK4b is 
associated with an increased percentage of immature myeloblasts in the bone marrow 
(Christiansen et al., 2003). The presence of DNA hypermethylation at the p15INK4b 
promoter is found predominantly in high risk MDS patients with increased levels being 
reported in the subtypes characterized by advanced stages of the disease such as refractory 
anemia with excess blasts (RAEB). Reduced levels are reported in patients with the early 
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stages of MDS such as refractory anemia (RA) and refractory anemia with ringed 
sideroblasts (RARS) (Uchida et al., 1997; Christiansen et al., 2003). However, more recently, 
it was found that even in patients with the RARS subtype, which falls within the lower risk 
of MDS, p15INK4b was found to be the most frequently methylated gene (>20% of cases) of 
25 known tumor suppressors that were evaluated in the study (Valencia et al., 2011). 
Although most studies have been conducted in MDS in adults, comparable levels of 
aberrant methylation patterns have been observed in pediatric MDS patients as well 
(Hasegawa et al., 2005), and a similar correlation with the disease subtypes has been 
established (Rodrigues et al., 2010).  
In chronic myelomonocytic leukemia (CMML), aberrant methylation of p15INK4b is found 
in about 60% of cases and is associated with a high proportion of blastic transformation 
(Tessema et al., 2003). CMML is a disease that was originally categorized under 
myelodysplastic disorders, but is now classified by the WHO as a disorder that bridges 
MDS with myeloproliferative features (Harris et al., 1999). In these patients, genomic 
sequencing techniques have revealed that hypermethylation spans a wide area in the 5’ 
region of the gene and is correlated with reduced expression of the mRNA levels. High 
variability between and within individual patients, consistent with observations in AML 
patients, were also reported (Tessema et al., 2003, Aggerholm et al., 1999, Cameron et al., 
1999). In the pediatric form of the disease, juvenile myelomonocytic leukemia (JMML), 
p15INK4b hypermethylation is found to be a less frequent, however, still significant event 
(17% of cases) (Hasegawa et al., 2005). 
With regards to cytogenetic abnormalities, p15INK4b methylation levels have been found to 
occur at higher frequencies in AML/MDS patients with an unfavorable karyotype (Wong et 
al., 2000; Galm et al., 2005; Shimamoto et al., 2005; Markus et al., 2007). Cases with 
unmethylated or low levels of hypermethylated p15INK4b were associated with normal 
karyotype or with those karyotypic abnormalities that are associated with a favorable 
prognosis (Wong et al., 2000; Markus et al., 2007). Studies have consistently reported an 
increased tendency for p15INK4b hypermethylation in unfavorable cytogenetics (Shimamoto 
et al., 2005). These results suggest interplay between p15INK4b loss of expression and the 
frequent chromosomal translocations, inversions and deletions observed in AML and MDS. 
The mechanisms underlying p15INK4b hypermethylation are not completely understood, 
but a few theories involving maintaining and de-novo DNA methylation through action of 
DNA methyltransferases (DNMT), as well as histone modification pathways have been 
suggested to play a role (Paul et al., 2010). Specifically in t-AML and therapy-induced MDS 
(t-MDS), deletion or loss of chromosome arm 7q, which is the most common cytogenetic 
abnormality in those categories, has been found to be closely associated with 
hypermethylation of p15INK4b (Christiansen et al., 2003). 
p15INK4b is now used as an independent prognosticator in AML and MDS (Chim et al., 
2001b; Teofili et al., 2003; Christiansen et al., 2003; Shimamoto et al., 2005; Chim et al., 2006). 
In the many categories of the diseases, aberrant p15INK4b methylation levels have been 
associated with a generally poor prognosis. In studies that monitor patients across all AML 
FAB subtypes, patients without p15INK4b hypermethylation at diagnosis had increased 
complete remission rates which also correlated with increased survival times (Shimamoto et 
al., 2005; Deneberg et al., 2010). Consistent with these observations, in APL patients, 
abnormal p15INK4b methylation was associated with a shorter disease-free survival (DFS) 
period and a higher incidence of relapse during the 5-year follow up period (Teofili et al., 
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2003).  In the relapsed patients, the p15INK4b hypermethylation levels remained persistent 
following treatment. In contrast, the patients without detectable hypermethylation 
displayed prolonged survival (Chim et al., 2001b). Additionally, as previously stated, 
patients with MDS with high methylation levels at diagnosis had a significantly higher 
chance of the disease progressing to AML (Tien et al., 2001; Jiang et al., 2009). It was also 
reported that in early stage of MDS, the p15INK4b hypermethylation is a negative risk factor 
for patients, closely correlating with leukemic transformation (Aggerholm et al., 2006). The 
same correlation has been shown in patients with t-MDS, in which methylation resulted in 
significantly shorter survival (Christiansen et al., 2003). A recent study showed that the high 
levels of methylation in lower risk MDS categories suggest a poor prognosis in those 
patients as well (Valencia et al, 2011). In JMML p15INK4b hypermethylation was associated 
with reduced overall survival rates and higher relapse of the disease following 
hematopoietic stem cell transplantation (Olk-Batz et al., 2011). All these results suggest that 
lack of p15INK4b expression, mediated by promoter hypermethylation, not only affects the 
prognosis in patients with AML and MDS, but can be used to predict the outcome of the 
diseases. 
The studies described above confirm that aberrant hypermethylation levels of p15INK4b 
have important prognostic implications for clinical monitoring in MDS and assessment of 
risk of progression into AML. However, its potential use as a biomarker in leukemia 
excluded estimation of minimal residual disease in patients who have achieved clinical 
remission, and its implications in terms of subsequent relapse. A study aiming at addressing 
this issue, evaluated p15INK4b methylation levels in AML patients in complete clinical 
remission (Agrawal et al., 2007). The study reported that even in remission, leukemia 
patients that harbored a significant amount of methylation in the bone marrow cells had a 
higher risk for leukemia relapse. Moreover, the time of disease-free survival was found to be 
significantly reduced in correlation with the amount of residual hypermethylation of the 
p15Ink4b gene. Concurrently, low levels of p15INK4b methylation during complete remission 
were associated with reduced relapse rates during the 12 month follow-up. It was suggested 
that analysis of p15INK4b methylation levels during clinical remission can be potentially 
used as a prognosticator for the occurrence of relapse (Agrawal et al., 2007).  
In recent years, it has been suggested in a number of studies that DNA methylation of 
p15INK4b could also help predict response to therapy (Grovdal et al., 2007; Shen et al., 2009). 
Grövdal et al. (2007) studied DNA methylation patterns in older patients with high risk 
MDS and AML following MDS. Patients were treated with conventional induction therapy. 
Methylation levels of p15INK4b, E-cadherin, and HIC1 (hypermethylated in cancer 1), were 
assessed prior to initiation of treatment. Abnormal levels of methylation of p15INK4b alone 
did not correlate with decreased complete remission (CR), but all patients with all three 
genes methylated did not achieve CR. Another study, in which patients with MDS and AML 
were treated with the DNA methyltransferase inhibitor 5-azacytidine (5-aza-C), reported 
consistent results with these observations (Raj et al., 2007; Tran et al., 2011). Patients with 
levels exceeding 24% methylation in the p15Ink4b promoter region did not respond to 
treatment (Raj et al., 2007). The possibility of using methylation of p15INK4b as an indicator 
for treatment outcome is still under investigation. However, results suggest that studying 
p15INK4b methylation density in conjunction with other altered genes at diagnosis and 
monitoring its levels following treatment might have predictive information with respect to 
the patient’s response to treatment. 
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Although hypermethylation is the most common mode of inactivation of p15INK4b in 
myeloid neoplasms, other silencing mechanisms have also been described. In AML with 
chromosome 16 inversion (inv16), the overall p15INK4b methylation levels are found to be 
very low and almost comparable to levels in normal patients. However, expression of the 
gene is severely suppressed. In this type of AML, the inversion (16) results in a fusion 
protein between the core binding factor (CBFβ) and the smooth myosin heavy chain gene 
(SMMHC). This chimeric transcription factor CBFβ-SMMHC binds directly to the promoter 
of p15INK4b and represses its expression (Markus et al., 2007). These results further 
emphasize an important role of p15INK4b silencing in leukemogenesis of the myeloid 
lineage, and suggest, that in the absence of a repressive epigenetic event, other mechanisms 
may result in inhibition of p15INK4b expression (Markus et al., 2007). 
2.2 Inactivation in other types of human leukemias 
In B and T cell acute lymphoblastic leukemias (B-ALL, T-ALL), p15INK4b hypermethylation 
as well as deletion of the entire 9p21 locus which includes p15INK4b, p16INK4a and ARF 
genes has been reported (Roussel, 1999; Ruas et al., 1998).  Homozygous deletions of 
p16INK4a and p15INK4b are found in approximately 30% of childhood acute lymphoblastic 
leukemia at first presentation, with striking rates in T-ALL (60 to 80%), and lower rates in B-
cell precursor ALL (5 to 20%) (Drexler HG, 1998; Chim et al., 2001a). Further studies have 
analyzed methylation levels of the two genes in these disease categories specifically in terms 
of overall survival and absence of relapse at 6 years of follow-up.  p15INK4b and p16INK4a 
methylation levels were found to occur at similar rates (35%) in adults and children with 
mature B-ALL (Graf-Einsiedel et al., 2002). Deletion of the entire locus was observed in 12% 
and 30% of children and adults, respectively. Interestingly, results show that deletion is 
associated with poor overall survival (OS) in adults only, but not in children (Van Zutven et 
al., 2005; Mirebeau et al., 2006; Kim et al., 2009). Furthermore, it did not affect the type of 
relapse or DFS time in children. In untreated adult patients with precursor B-ALL, high 
methylation levels of p15INK4b (found in 43% of patients) were significantly associated with 
decreased DFS at 4 years (Hoshino et al., 2002). Recent methylation profiles in 95 children 
with ALL supported older studies showing that methylation of p15INK4b occurred 
predominantly in T-ALL as opposed to B-ALL, and p15INK4b is one of the most commonly 
methylated genes among the 14 genes analyzed (Takeuchi et al., 2011). A clear correlation 
between increased methylation and prognoses in T-ALL has not been established.  
2.3 p15Ink4b as a tumor suppressor in mice 
To define the role of p15INK4b as a tumor suppressor in AML, mouse models have been 
developed and characterized (Latres et al., 2000; Wolff et al., 2003a, 2004; Bies et al., 2010). 
These have provided strong experimental evidence to support the hypothesis that loss of 
p15INK4b function plays an important role in the development of myeloid leukemia.  
A p15Ink4b-/- mouse model was first described by Latres et al.  (2000). Mice were generated 
by genetic targeting with elimination of the second coding exon of the p15Ink4b gene. 
Knockout mice were viable, fertile, and did not exhibit any behavioral abnormalities. Mouse 
embryonic fibroblasts were found to have a higher proliferation rate and plating efficiency 
when compared to their wild type counterparts. More importantly, they were more 
susceptible to transformation with c-myc and ras oncogenes, confirming the reported results 
that p15Ink4b participates in the tumor suppressor activity triggered after inappropriate 
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2003).  In the relapsed patients, the p15INK4b hypermethylation levels remained persistent 
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Grövdal et al. (2007) studied DNA methylation patterns in older patients with high risk 
MDS and AML following MDS. Patients were treated with conventional induction therapy. 
Methylation levels of p15INK4b, E-cadherin, and HIC1 (hypermethylated in cancer 1), were 
assessed prior to initiation of treatment. Abnormal levels of methylation of p15INK4b alone 
did not correlate with decreased complete remission (CR), but all patients with all three 
genes methylated did not achieve CR. Another study, in which patients with MDS and AML 
were treated with the DNA methyltransferase inhibitor 5-azacytidine (5-aza-C), reported 
consistent results with these observations (Raj et al., 2007; Tran et al., 2011). Patients with 
levels exceeding 24% methylation in the p15Ink4b promoter region did not respond to 
treatment (Raj et al., 2007). The possibility of using methylation of p15INK4b as an indicator 
for treatment outcome is still under investigation. However, results suggest that studying 
p15INK4b methylation density in conjunction with other altered genes at diagnosis and 
monitoring its levels following treatment might have predictive information with respect to 
the patient’s response to treatment. 
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oncogenic ras activation of the Raf-Mek-Erk pathway (Malumbres et al., 2000). However, 
with respect to AML, deleting p15Ink4b did not result in leukemogenesis in these mice. Of 
note, extramedullary hematopoiesis and lymphoid hyperplasia in the spleen were observed 
in mice aged less than 9 months and resulted in death of over 75% of the mice at an older 
age. Taken together, these experimental results were the first to suggest that p15Ink4b might 
be playing a tumor suppressor role in AML (Latres et al., 2000). 
A role for p15Ink4b in myeloid neoplasia in mice was first supported by the finding that 
retrovirus-induced AML had hypermethylation of the CpG promoter region of the p15Ink4b 
gene. Based upon this, further mouse models were developed to determine if loss of 
p15Ink4b increases susceptibility to myeloid leukemia when additional oncogenic events 
were provided by retroviral insertional mutagenesis.  For these studies, a specific retrovirus 
with a broad tropism and the capability of inducing a high incidence of myeloid leukemia 
was constructed (Wolff et al., 2003b and 2004). It consists of a recombinant virus 
incorporating Moloney murine leukemia virus (Mo-MuLV) sequences, and regulatory LTR 
sequences of retrovirus 4070A. The recombinant virus, named MOL4070LTR, combines the 
capacity of 4070A to accelerate myeloid disease with the wide tropism of Mo-MuLV, and 
successfully produced myeloid disease when inoculated intraperitoneally into wild-type 
FVB and BALB/c mice as neonates (Wolff et al., 2003b). The p15Ink4b knockout mice were 
developed using the same targeting vector as described by Latres et al. (2000), and 
MOL4070LTR was inoculated into neonates. While there was no incidence of disease in 
control wild-type mice (p15Ink4b+/+), a significant percentage of heterozygous mice 
(p15Ink4b+/-) developed myeloid leukemia within a year. Surprisingly, a smaller percentage 
of homozygous knockout mice (p15Ink4b-/-) developed myeloid tumors (Wolff et al., 2003a). 
Further experiments demonstrated that in heterozygous p15Ink4b+/- mice, the second 
remaining p15Ink4b allele was actually hypermethylated, with a reduction of its mRNA 
expression. This data supported the fact that p15Ink4b functions as a tumor suppressor for 
myeloid leukemia, however, it was difficult to explain why mice heterozygous for the null 
allele were more susceptible than homozygous null mice. One explanation might be that in 
the homozygous null mice, p15Ink4b is lost in all the tissues and loss of expression in one 
tissue may have compensating effects on loss in another tissue. 
A new mouse system in which deletion of the gene is restricted to the myeloid lineage was 
developed to mimic more closely myeloid lineage disease in man (Bies et al., 2010).  The 
mouse strain utilizes a Cre-loxP system for conditional deletion of the p15Ink4b gene 
through action of Cre recombinase exclusively expressed in blood cells of the myeloid 
lineage (Clausen et al., 1999). In this model, Cre recombinase specifically recognizes loxP 
sites to mediate efficient excision of exon 2 of the p15Ink4b gene in myeloid cells. In order to 
monitor disease development in mice with targeted p15Ink4b deletion (p15Ink4bfl/fl 
LysMcre), white cell counts were performed in circulating blood from targeted and wild-
type animals from different age groups. Interestingly, p15Ink4bfl/flLysMcre mice showed a 
significant increase in the number of circulating monocytes compared to control mice 
(p15Ink4bwt/wtLysMcre), whereas neutrophils, lymphocytes, platelets and red blood cell 
counts were not affected. Monocytosis remained in targeted mice beyond 8 months of age, 
while wild-type mice showed a marked decrease in monocytes resulting in an even greater 
significance in the statistical comparisons (Figure 3A). Expansion of myelomonocytic cells in 
the bone marrow (BM) of p15Ink4bfl/flLysMcre mice was also observed. Analysis of BM cells 
for the cell surface markers Gr-1, Mac-1 and c-Kit revealed that BM cells from 
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p15Ink4bfl/flLysMcre mice had a significant increase in both mature myeloid (Gr-1+/Mac-1+) 
and monocytic (Gr-1-/lo/Mac-1+) cells. This increase correlated with a significantly higher 
proportion of immature myeloid (Mac-1+/lo/c-Kit+) cells in the BM. Inactivation of p15Ink4b 
in myeloid cells promoted a mild preleukemic myeloproliferative-like disease (Bies et al., 
2010). A small percentage of the targeted mice spontaneously progressed to a form of 
leukemia featuring an increased number of mature circulating myeloid cells in the 
peripheral blood, as well as an increase in the number of progenitors in the BM. The disease 
observed in mice most closely resembled an advanced form of CMML (Bies et al., 2010). 
However, the disease did not progress to an acute form of leukemia over the period of 15 
months in any of the mice. These results were in agreement with studies carried on in the 
embryonal p15Ink4b-/- mice, and suggested that inactivation of the p15Ink4b gene without 
an additional genetic/epigenetic hit is not sufficient to cause acute leukemia. Retrovirus-
induced mutagenesis in p15Ink4bfl/flLysMcre mice was used to identify genetic changes that  
 
 
Fig. 1. Cell cycle regulation by the CDKI families. CDKs are switched on and off at different 
times during the cell cycle; the cyclins Ds-dependent kinases 4 and 6, and CDK2/cyclin E, 
CDK2/cyclin A regulate G1 progression and entry into the S phase. CDK1/cyclin B 
regulates entry and exit from mitosis. The CDK/cyclin complexes phosphorylate pRb to 
allow for the transcription of genes under the control of E2Fs which include factors 
necessary for cell cycle progression. CIP/KIP family members of CDKI can be either 
activators or inhibitors of cyclin/CDK assembly (Sherr & Roberts, 1999). 
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could cooperate with the loss of p15Ink4b in leukemia development. Mice inoculated with 
the MOL4070LTR retrovirus were monitored for 15 months for signs of disease. Control 
mice developed leukemia with low penetrance, whereas the incidence of retrovirus-induced 
leukemia was statistically highly significant for the p15Ink4bfl/flLysMcre animals. 
Additionally, phenotypic analyses of tumor cells demonstrated a strong bias towards the 
development of AML in the knockout animals. Myeloid–specific inactivation of p15Ink4b 
results in retrovirus-induced development of tumors mostly monocytic (F4/80+, 
F4/80+/Mac1+) and myelomonocytic (F4/80+/Mac1+/Gr-1+), whereas there was an equal 
distribution of lymphoid and monocytic tumors in the control mice (Figure 3B). Results 
generated using this model complement the embryonal p15nk4b-/- studies and demonstrate 
an active role for p15Ink4b silencing in promoting the establishment of preleukemic 
conditions.  These results also provided strong experimental evidence that p15Ink4b 
functions as a tumor suppressor for myeloid leukemia development (Bies et al., 2010). 
3. Conventional and novel functions of p15INK4b 
3.1 p15INK4B as a regulator of the cell cycle  
p15INK4b belongs to the INK4 family of cyclin-dependent kinases inhibitors (CDKIs). The 
family comprises three other members – p16INK4a, p18INK4c and p19INK4d and is one of 
two families of CDKIs that have been identified and defined based on their structure and CDK 
specificities. INK4 proteins all show a high and exclusive specificity towards the activity of 
cyclin-dependent kinase 4 (CDK 4) and cyclin-dependent kinase 6 (CDK6) during the early 
and mid-G1 phase of the cell cycle (Sherr & Roberts, 1999).  The cell cycle is comprised of 4 
phases, G1, S, G2 (also referred to as interphase), and M phase (mitosis). Entrance of cells from 
the quiescent G0/G1 phase into cycle is governed by the actions of kinases CDK4/CDK6 and 
CDK2 that are activated by cyclins Ds and Es, respectively (Figure 1).  
During the transition to S phase, CDKs hyperphosphorylate pRb causing its dissociation 
from the nuclear transcription factors E2Fs. E2Fs regulate the transcription of genes which 
are required for the completion of the cell cycle and include cyclins A and E, thymidine 
synthetase and PCNA (Korenjak & Brehm, 2005). Throughout the S, G2 and M phases, pRb 
is kept in a hyperphosphorylated state by an orchestrated mechanism that involves 
sequential activities of multiple cyclins/CDKs (Sherr & Roberts, 1999). INK4 proteins inhibit 
CDKs/cyclin Ds complexes and, therefore, function in G1-S checkpoint control. When INK4 
proteins block formation of these complexes, the pRb is in a hypophosphorylated, active 
state and interacts with E2F to inhibit its function (Korenjak & Brehm, 2005). Structural 
studies have demonstrated that INK4 proteins perform their inhibitory activity by allosteric 
competition with cyclins Ds to bind CDK4 and CDK6. CDK4/6-INK4s protein complexes 
have reduced affinity toward the D-type cyclins (Jeffrey et al., 2000; Yuan et al 2000). 
p15INK4b and p16INK4a are tandemly linked on human chromosome 9p21 within a 40kb 
DNA region, whereas p18INK4c and p19INK4d are located in the chromosomal regions 
1p32.3 and 19p13.2, respectively. The 9p21 chromosomal locus is referred to as the 
INK4/ARF locus has been tightly linked to the formation of many types of tumors (Nobori et 
al., 1994). In addition to p15INK4b and p16INK4a, it also encodes a third gene called p14ARF, 
originally identified as an alternative transcript of p16INK4a (Figure 2). p14ARF is 
transcribed from exon 1β and exons 2 and 3 of p16INK4a, but using a different reading frame 
(Figure 2). The p14ARF protein (p19Arf in mouse) is immunologically and functionally 
unrelated to the p16INK4a protein; they are not considered to be isoforms and do not share 
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sequence homology or overlapping roles in the cell (Ozenne et al., 2010; Sherr CJ, 2006).  
Furthermore, p14ARF bears little or no structural similarities with the INK4 family 
members, and is unable to bind or inhibit CDKs. It is not considered to be part of the INK4 
family of inhibitors, but it still participates in the negative regulation of the cell cycle by 
antagonizing the effects of MDM2, a ubiquitin ligase that targets the tumor suppressor 
protein p53 for degradation by the 26S proteasome (Ruas et al., 1998).  
 
 
Fig. 2. 9p21 chromosomal locus showing the promoters and exons that are involved in the 
transcription of p15INK4b, p14ARF and p16INK4a genes. The CpG island is depicted for the 
p15INK4b gene only and extends throughout the promoter region, exon 1 and part of intron 
1 (Herman et al., 1996).  
INK4 family members are highly conserved among species, with over 90% identity between 
the human and the corresponding mouse proteins. In human, the four proteins share 
roughly 40% sequence homology with each other and have a very closely related structure, 
characterized by the presence of ankyrin motif tandem repeats. Four ankyrin repeats are 
found in p15INK4b and p16INK4a, and five repeats in p18INK4c and p19INK4d (Yuan et 
al., 2000). Ankyrin motif repeats consist of a helix-loop-helix structure that promotes 
protein-protein interaction (Li et al., 1999).  Structural studies involving programmed 
mutations and generation of chimeric proteins have revealed that the third ankyrin repeat is 
necessary for the interaction with CDK4 and CDK6, and is responsible for the inhibitory 
activity of these CDKIs.  Crystallography work on the CDK6 bound p16INK4a, p18INK4c 
and p19INK4d suggested that the INK4 proteins bind to one side of the catalytic cleft, 
opposite to the cyclin binding site, and that binding and recognition are mediated mostly 
via hydrogen bonds (Brotherton et al., 1998; Noh et al., 1999; Russo et al., 1998). INK4 
proteins were found not to interfere with the cyclin binding site which is consistent with the 
presence of INK4s/cyclin Ds/CDK4 or CDK6 ternary complexes.  When bound in the 
absence of cyclin D, they cause a conformation switch in CDK4 and CDK6 which distorts the 
cyclin and the ATP-binding sites leading to rapid recycling of unbound D-type cyclins by 
the ubiquitin-dependent 26S proteasome. The specificity towards CDK 4 and CDK6 was 
found to be due primarily to the critical residues involved in the hydrogen bonds with INK4 
proteins which are conserved exclusively in CDK4 and CDK6, but not in the other CDKs 
(Russo et al., 1998). Interestingly, several of the residues necessary for recognition and 
binding have been reported to be mutated in cancer (Li et al., 1999). 
The structural similarities observed between the INK4 proteins are consistent with the 
shared biological and biochemical properties of these molecules. However, the expression 
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could cooperate with the loss of p15Ink4b in leukemia development. Mice inoculated with 
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sequence homology or overlapping roles in the cell (Ozenne et al., 2010; Sherr CJ, 2006).  
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protein p53 for degradation by the 26S proteasome (Ruas et al., 1998).  
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pattern of each of the human INK4 proteins appears to be highly specific to the cell type and 
tissue localization, as well as the differentiation stage of the cells (Shwaller et al., 1997; 
Thullberg et al., 2000). For instance, in normal hematopoietic cells, the expression of 
p15INK4b is shown to be lineage restricted, and is mainly detected in monocytes and 
lymphocytes, but not in any of the erythroid precursors (Teofili et al., 1998). Myeloid-
restricted expression of p15INK4b is observed in peripheral blood and bone marrow and its 
levels are reported to be increased during megakaryocyte and monocyte/macrophage 
differentiation (Furukawa et al., 2000; Teofili et al., 2001; Haviernik et al., 2003). 
p15INK4b, in particular, is an important downstream effector of anti-proliferative signaling 
by the transforming growth factor- β1 (TGF-β1) (Hannon & Beach, 1994). In different human 
and mouse cell lines, treatment with this negative growth factor, as well as interleukin 6 (IL-
6) or Interferon β (IFN- β) leads to G0/G1 cell cycle arrest (Schmidt et al., 2004; Haviernik et 
al., 2003). Treatment with TGF-β1 induces a significant increase in the transcription levels of 
p15INK4b, but also induces a major increase in p15INK4b protein stability (Sandhu et al., 
1997). Following treatment with TGF-β1, p15INK4b-CDK4/6 complexes are more abundant 
compared to the Cyclin D-Cdk4 complexes indicating strong inhibitor activity (Sandhu et 
al., 1997). In contrast to p15INK4b, whose expression is absent in hematopoietic stem cells, 
but increases as the cells mature along the myeloid lineage, p16INK4a is highly expressed in 
hematopoietic stem cells, and down-regulated with differentiation of all lineages (Furukawa 
et al., 2000). p18INK4c is found to be the most homogeneously and abundantly expressed 
member of the family, whereas p19INK4d is the most restricted, and its expression is limited 
to lymphoid cell, epithelial cells, seminiferous tubes and adrenal gland cells (Thullberg et 
al., 2000). The differential expression patterns of the INK4 proteins, suggest non-
overlapping physiological functions. 
Despite their common function in regulation of the cell cycle, the four members are found to 
be differentially involved in tumorigenesis. Mouse knock-out models along with genetic 
screenings of human tumors and gene expression profiling of cell lines have been used to 
help elucidate the role of these cell cycle inhibitors in the establishment and progression of 
cancer (Cánepa et al., 2007). In concordance with the molecular analysis of human tumor 
tissues, mice deficient in different Ink4 proteins display an increased susceptibility to the 
development of various types of tumors with variable penetrance.  p16INK4a is a family 
member that has a prominent role in carcinomas of the pancreas and the bladder, 
glioblastomas, leukemias and melanomas among others. Its expression is lost by several 
mechanisms including point mutations, small deletion and epigenetic modifications which 
have been reported in thousands of human cancers (Serrano et al., 1996; Krimpenfort et al., 
2001). On the other hand, as previously described, p15INK4b is noted to be silenced 
primarily by an epigenetic mechanism in human cancers, and loss of its expression through 
hypermethylation of its promoter region is well documented in hematologic neoplasms in 
particular (Drexler HG, 1998; Roussel, 1999).  In these types of cancers, inactivation of 
p15INK4b has been reported in the absence of aberrant modification or deletion of p16INK4a.  
In contrast with p15INK4b and p16INK4a, p18INK4c was originally found to play a more 
limited role as a human tumor suppressor, and p19INK4d is not thought to be involved in 
the pathogenesis of cancer (Thullberg et al., 2000). p18Ink4c-null mice are viable but display 
an unusual phenotype with pronounced gigantism, lymphomas and more importantly 
pituitary hyperplasia (Franklin et al., 1998).  Later examination of these mice revealed that 
p18Ink4c is a haploinsufficient tumor suppressor for spontaneous and carcinogen-induced 
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pituitary tumors and lymphomas (Bai et al., 2003). Loss of p16Ink4a expression was shown 
to be a necessary event in conjunction with loss of p18Ink4c for the mice to develop 
aggressive advanced stages of pituitary carcinoma (Morishita et al., 2004). Furthermore, it is 
now clear that p18INK4c is a tumor suppressor in human glioblastoma multiform and 
hepatocellular carcinoma (Solomon, 2008a and 2008b). Interestingly, studies in mice 
deficient for p19Ink4d have not revealed increased susceptibility to any cancer or other 
proliferative diseases, suggesting a limited or nonexistent role in carcinogenesis (Buchold et 
al. 2007, Zindy et al, 2000).  
Although these cell cycle regulators exhibit overlapping and surely compensatory activities 
mainly due to their structural similarities (Krimpenfort et al., 2007), their temporal and 
tissue-restricted expression patterns as well as their differential involvement in the 
pathogenesis of human cancers clearly suggest that they can harbor specific and distinct 
functions during development.  
3.2 Function as a regulator of cell fate during early myelopoiesis 
The strikingly high prevalence of p15INK4b loss of expression during the development of 
myeloid disease in human patients has triggered scientists to explore alternate functions for 
this CDKI.  As a cell cycle regulator, p15INK4b was suggested to be one of the players 
determining the fine balances in differentiation and proliferation of myeloid cells. To test 
this hypothesis, the previously described p15Ink4b germline knockout mice as well as 
murine transplant models were used.  Results revealed a novel role for the protein during 
early and late stages of myeloid cells development (Rosu-Myles et al., 2007, 2008).  
Myelopoiesis is the process by which an undifferentiated progenitor cell gives rise to mature 
differentiated functional myeloid cells. The process takes place in the bone marrow and is 
driven by a pool of hematopoietic cytokines that have different binding specificities to cell 
surface markers in a stage and lineage dependent manner. Committed progenitors with a 
restricted myeloid lineage fate arise from earlier common myeloid progenitor cells (CMP), 
who themselves originate from hematopoietic stem cells (HSC) (Akashi et al. 2000).  
In p15Ink4b knockout mice (p15Ink4b-/-), loss of p15Ink4b was found to favor the 
differentiation of CMPs into granulocyte macrophage progenitors (GMP) which results in an 
imbalance between the erythroid and myeloid compartments (Rosu-Myles et al 2007). This 
defect was in the bipotent differentiation capacity of the CMP, and did not affect the 
frequency of early long-term HSCs, or their ability to self-renew and proliferate. Therefore, 
this finding differs from the traditional role of p15Ink4b in regulating the cell cycle. As 
shown in Figure 3A, the increased number of myeloid progenitors was found to occur at the 
expense of differentiation of CMPs towards the erythroid progenitors .Furthermore, 
competitive repopulating assays have shown that the defect is intrinsic to the cells. Loss of 
p15Ink4b provided a competitive advantage over the wild-type cells within the myeloid 
compartment (Rosu-Myles et al., 2007).  
Interestingly, an earlier study carried out in p18Ink4c-/- mice, had shown that this CDKI also 
impacts cell fate but targets a different cell type. Deletion of p18Ink4c was found to result in 
a long-term engraftment advantage in HSCs. The observed effects were not due to increased 
proliferation capacity of the cells, but rather to an enhanced potential of self-renewal of 
these cells as opposed to differentiation. This lead to an efficient expansion of HSCs as well 
as hematopoietic progenitor pools, which fully retained their multi-lineage differentiation 
potential (Yuan et al., 2004).  
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3.3 Function in cell cycle arrest in late myeloid cell development 
In addition to its hypothesized role in cell fate decision of early myeloid progenitors, 
p15Ink4b is implicated during the late stages of myelopoiesis. In this case its role appears to 
be the induction of cell-cycle arrest. p15Ink4b expression has been shown to increase 
specifically during myeloid differentiation in vivo both in human bone marrow and 
peripheral blood cells (Teofili et al. 2000); and in vitro, in murine M1 myeloblastic cells 
which undergo monocytic differentiation following treatment with IL-6 (Schmidt et al 2004).  
 
 
Fig. 3. The loss of p15Ink4b in myeloid lineage results in: A. Imbalance in the myeloid 
progenitor pools and nonreactive monocytosis; B. Increased incidence of the retrovirus-
induced leukemia with preference toward the myeloid phenotype. 
 
p15INK4b, a Tumor Suppressor in Acute Myeloid Leukemia 
 
301 
The M1 leukemia cell line, does not express p53, proliferates autonomously and is often 
used as a model for monocytic differentiation. When terminal differentiation is induced in 
these cells, upregulation of p15Ink4b expression is accompanied by inhibition of Cdk4 
kinase activity as well as by a decrease in levels of phosphorylated Rb (Bergh et al., 1999). 
Furthermore, over-expression of p15Ink4b in M1 cells causes cell cycle arrest in the G1 
phase, providing additional evidence for the implication of the protein in maturation and 
cell cycle inhibition of late stage progenitors (Haviernik et al., 2003). This function is further 
supported by studies in human CD34+ hematopoietic progenitor cells. When expression of 
p15INK4b is triggered, higher levels of the protein are associated with transcriptional 
upregulation of genes known to induce myeloid differentiation, such as the colony 
stimulating factor 1 receptor gene (c-fms), the myeloperoxidase gene (mpo) and lactoferrin 
(lf), among others (Furukawa et al 2000). Overexpression of p15INK4b is also linked with a 
dramatic decrease in early blast progenitor populations and an increase in the numbers of 
cells that adopt a myeloid morphology (Teofili et al., 2000). 
This data suggests that p15INK4b has functions during both the early and late stages of 
myelopoiesis; in early progenitors, p15Ink4b influences cell fate by altering the balance 
between myeloid and erythroid progenitors, whereas during late myelopoiesis, p15INK4b 
appears to be causing withdrawal from the cell-cycle in response to cytokines. 
4. Targeting p15INK4b for re-expression in AML and MDS 
The reversible nature of epigenetic alterations makes them very attractive therapeutic 
targets for AML and MDS. In the case of p15INK4b, these epigenetic alterations consist of 
DNA methylation as well as chromatin remodeling by post-transcriptional histone 
modifications. Studying the association of p15INK4b promoter DNA methylation with 
histone modifications revealed important insight into the interplay of these two types of 
epigenetic mechanisms (Paul et al., 2010). Histones undergo post-transcriptional 
modifications that target primarily the N-terminal tail regions, and involve the attachment 
of phospho, acetyl, methyl, ribosyl, and small ubiquitin-like modifier or ubiquitin groups on 
the side chains of the different amino acids residues of histone molecules (Biancotto et al., 
2010). Acetylation and de-acetylation of lysine residues are catalyzed by two groups of 
enzymes with opposing actions: histone acetyltransferases (HAT) and histone deacetylases 
(HDAC) (Jenuwein & Allis, 2001), whereas histone methyltransferases (HMT), and histone 
demethylases (HDM) control the balance of histone methylations. Similar to DNA 
methylation, histone modifications are fully biochemically reversible, result in changes in 
the protein structure and affect the affinity of histone tails to DNA molecules (Varier & 
Timmers, 2011). Paul et al. (2010) found that in AML cell lines with aberrant p15INK4b DNA 
hypermethylation, the histone 3 trimethylated at lysine 4 (H3K4me3), which is a 
transcriptional activation mark, was at lower levels than in AML cell lines without 
hypermethylation.  Interestingly, irrespective of the methylation status of p15INK4b, this 
study also reported the presence of the repressive mark H3K27me3 (histone 3 trimethylated 
at lysine 27) at the 9p21 locus. Human AML blasts with hypermethylation of p15INK4b were 
similarly found to have H3K27me3, but lacked H3K4me3 at the gene.  
The tight collaboration of the different epigenetic alterations in silencing the p15INK4b gene 
makes combinatorial therapeutics a promising approach for its reexpression. Importantly, 
removal of methyl groups from hypermethylated CpG clusters associated with the gene 
promoter reverses the inhibitory effects and restores normal gene expression (Jones & 
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DNA methylation as well as chromatin remodeling by post-transcriptional histone 
modifications. Studying the association of p15INK4b promoter DNA methylation with 
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epigenetic mechanisms (Paul et al., 2010). Histones undergo post-transcriptional 
modifications that target primarily the N-terminal tail regions, and involve the attachment 
of phospho, acetyl, methyl, ribosyl, and small ubiquitin-like modifier or ubiquitin groups on 
the side chains of the different amino acids residues of histone molecules (Biancotto et al., 
2010). Acetylation and de-acetylation of lysine residues are catalyzed by two groups of 
enzymes with opposing actions: histone acetyltransferases (HAT) and histone deacetylases 
(HDAC) (Jenuwein & Allis, 2001), whereas histone methyltransferases (HMT), and histone 
demethylases (HDM) control the balance of histone methylations. Similar to DNA 
methylation, histone modifications are fully biochemically reversible, result in changes in 
the protein structure and affect the affinity of histone tails to DNA molecules (Varier & 
Timmers, 2011). Paul et al. (2010) found that in AML cell lines with aberrant p15INK4b DNA 
hypermethylation, the histone 3 trimethylated at lysine 4 (H3K4me3), which is a 
transcriptional activation mark, was at lower levels than in AML cell lines without 
hypermethylation.  Interestingly, irrespective of the methylation status of p15INK4b, this 
study also reported the presence of the repressive mark H3K27me3 (histone 3 trimethylated 
at lysine 27) at the 9p21 locus. Human AML blasts with hypermethylation of p15INK4b were 
similarly found to have H3K27me3, but lacked H3K4me3 at the gene.  
The tight collaboration of the different epigenetic alterations in silencing the p15INK4b gene 
makes combinatorial therapeutics a promising approach for its reexpression. Importantly, 
removal of methyl groups from hypermethylated CpG clusters associated with the gene 
promoter reverses the inhibitory effects and restores normal gene expression (Jones & 
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Baylin, 2002). The DNMT inhibitor 5-azacytidine (5-aza-C) and its analogue 5-aza-
deoxycytidine (5-aza-dC, Decitabine) are powerful hypomethylating agents that are used in 
the therapy of high-risk MDS and AML. It has been demonstrated that they can lead to the 
reversal of hypermethylation and subsequent reexpression of the p15INK4b gene in patients 
with MDS (Daskalakis et al., 2002; Farinha et al., 2004; Gore et al., 2006; Santos et al., 2010). It 
was shown that treatment of patient blasts with hypomethylating agent Decitabine also 
affects histone modifications. Paul et al. (2010) provided evidence that the levels of 
H3K4me3 increased with retention of H3K27me3, thus inducing a state of bivalency.  The 
use of other HMT inhibitors such as 3-Deazaneplanocin A (DZNep) have been reported to 
successfully decrease global DNA methylation levels, but not to induce re-expression of 
specific genes including p15INK4b (Flotho et al., 2009; Miranda et al., 2009). 
HDAC inhibitors such as Trichostatin A (TSA) have been used for targeting of histone 
acetylations. In the case of AML samples with p15INK4b hypermethylation, it was shown 
that TSA treatment alone is insufficient to increase p15INK4b expression levels (Scott et al., 
2007; Paul et al., 2010). However, studies that incorporated the use of both HDAC and 
DNMT inhibitors have proven successful at inducing higher levels of p15INK4b expression 
(Cameron et al., 1999; Scott et al., 2007; Paul et al., 2010). 
5. Conclusion 
p15INK4b is a CDK inhibitor whose expression is lost in a very high proportion of patients 
with MDS and AML. This implicates an important role for the loss of the protein expression 
in the development of myeloid disease in humans. Its role in myeloid leukemogenesis as a 
tumor suppressor is now confirmed by research carried out in several mouse models.  In 
addition to its role in inhibiting CDKs to arrest the cell cycle during late myeloid 
development, it is now known to affect cell fate decisions during early myelopoiesis. In 
myeloid progenitors, loss of p15Ink4b results in an imbalance in the progenitor pools, and 
favors the expansion of GMPs at the expense of MEPs. Importantly, when deleted in the 
cells of the myeloid lineage only, mice develop nonreactive monocytosis and are strongly 
predisposed to succumb to retrovirus-induced leukemia, especially of myeloid origin. These 
results validate a tight link between loss of p15INK4b and human myeloid neoplasia.  
Clinical observations that associate p15INK4b demethylation and re-expression with 
improved prognosis and survival, further stress the importance of this gene in AML and 
MDS treatment.  
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Acute leukemia is characterized by abnormal proliferation, inhibition of differentiation and 
expansion of leukemic cells blocked at the early stage of hematopoiesis. Acute myeloid 
leukemia (AML) is a malignant hematological disease of hematopoietic precursor cells of 
non-lymphoid lineage. Recent insights into the molecular mechanisms of AML are 
challenging the traditional diagnostic classification, prognostic significance and clinical 
practice of this hematological disorder.  
1.1 Concept and classification 
AML is a clinically heterogeneous disorder with distinct clinical and biological features. 
Until the 1970s, diagnosis was based on morphological examination of bone marrow and 
peripheral blood samples. In 1976, French, American, and British hematologists (the FAB 
group) defined six subgroups of AML morphological variants (Bennett et al., French-
American-British Cooperative Group [FAB], 1976). This classification allowed us to identify 
several types of AML:  M1-M6. Blastic populations were identified using standard staining 
techniques and consequently classified depending on reactivity to certain cytochemicals, 
namely, myeloperoxidase and Sudan black B (markers of myeloid differentiation) and 
nonspecific esterase reactions such as alpha-naphthyl acetate esterase and alpha-naphthyl 
butyrate esterase  (for monocytic lineage). Later on, this group identified two new types of 
AML (M0 and M7) according to cytochemical and inmunophenotypical features (Bennett et 
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Acute leukemia is characterized by abnormal proliferation, inhibition of differentiation and 
expansion of leukemic cells blocked at the early stage of hematopoiesis. Acute myeloid 
leukemia (AML) is a malignant hematological disease of hematopoietic precursor cells of 
non-lymphoid lineage. Recent insights into the molecular mechanisms of AML are 
challenging the traditional diagnostic classification, prognostic significance and clinical 
practice of this hematological disorder.  
1.1 Concept and classification 
AML is a clinically heterogeneous disorder with distinct clinical and biological features. 
Until the 1970s, diagnosis was based on morphological examination of bone marrow and 
peripheral blood samples. In 1976, French, American, and British hematologists (the FAB 
group) defined six subgroups of AML morphological variants (Bennett et al., French-
American-British Cooperative Group [FAB], 1976). This classification allowed us to identify 
several types of AML:  M1-M6. Blastic populations were identified using standard staining 
techniques and consequently classified depending on reactivity to certain cytochemicals, 
namely, myeloperoxidase and Sudan black B (markers of myeloid differentiation) and 
nonspecific esterase reactions such as alpha-naphthyl acetate esterase and alpha-naphthyl 
butyrate esterase  (for monocytic lineage). Later on, this group identified two new types of 
AML (M0 and M7) according to cytochemical and inmunophenotypical features (Bennett et 
al., FAB, 1985). Over the past decade, refinement in the diagnosis of subtypes of AML and 
advances in therapeutic approaches have improved the outlook for patients with AML 
(Döhner et al., 2010).  
 




M0: AML minimally differentiated 
M1: AML without maturation 
M2: AML with maturation 
M3: Acute promyelocytic leukemia  
M4: Acute myelomonocytic leukemia 
M5: Acute monoblastic leukemia 
M6: Acute erythroleukemia 
M7: Acute megakaryoblastic leukemia 
Table 1. FAB classification of acute myeloid leukemia (AML). 
Since several specific cytogenetic and genetic abnormalities in AML are associated with a 
characteristic morphology and have distinctive clinical behavior (Harris et al., World Health 
Organization [WHO], 1999). The World Health Organization (WHO), classification of 
myeloid neoplasms and acute leukemias integrates genetic, clinical data, and morphological 
features. 
Three prognostic groups have been described classically according to cytogenetic findings. 
The favorable prognostic group includes the following chromosomal abnormalities:  
t(15;17), t(8;21) and inv(16). Normal karyotype and cytogenetic abnormalities not classified 
as favorable or adverse comprise the intermediate group. The adverse prognosis group 
includes patients with complex karyotype, del (5q), 5 or 7 monosomy, 3q abnormalities and 
t(6;9) (Dohner et al., 2010). 
Recently the WHO published a revised and updated edition of the 1998 WHO classification 
where the importance of gene mutations as diagnostic and prognostic markers in myeloid 
neoplasms was acknowledged. This group recommended that fluorescence in situ 
hybridization (FISH), reverse transcriptase–polymerase chain reaction (RT-PCR) and 
mutational status studies should be guided through clinical, laboratory, and morphologic 
information. Mutational studies for mutated NPM1, CEBPA, FLT3, KIT, WT1, and MLL are 
recommended in all cytogenetically normal AML. Table 2 lists the major subgroups of AML 
in the WHO classification (WHO, 2009). 
The genes involved in the pathogenesis of leukemia are normal genes (proto-oncogenes) 
with either structural alterations or deregulated expression patterns, which generates in turn 
a novel gene (an oncogene) whose protein product acts on the host cell to enhance 
malignancy-related characteristics. Oncogene activation and the loss of tumor-suppressor 
genes are consistently associated with some types of leukemia (Cline, 1994). Some of the 
molecular alterations involved in the pathogenesis of AML are: translocations, mutations 
and overexpression of normal genes, which often characterizes a particular subtype of AML. 
Therefore, there are also activating mutations which lead to increased proliferation or 
survival, or both, of haematopoietic progenitor cells through the stimulation of tyrosine 
kinases such as FLT3 or RAS family members. These are considered class I mutations 
(Haferlach et al., 2007; Schlenk et al., 2008). Class II mutations interfere with transcription 
and lead to a maturation arrest either through a direct alteration of transcription factors due 
to gene fusions (CBF-leukemias or PML-RARA positive leukemia) or by indirect 
interference with transcription (MLL-rearrangements). Cytogenetic and molecular analysis 
of leukemic blasts, provide critical diagnostic, therapeutic and prognostic information.  
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Acute myeloid leukemia with recurrent genetic abnormalities
 AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
 APL with t(15;17)(q22;q12); PML-RARA 
 AML with t(9;11)(p22;q23); MLLT3-MLL 
 AML with t(6;9)(p23;q34); DEK-NUP214 
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
 Provisional entity: AML with mutated NPM1 
 Provisional entity: AML with mutated CEBPA 
Acute myeloid leukemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukemia, not otherwise specified 
 AML with minimal differentiation 
 AML without maturation 
 AML with maturation 
 Acute myelomonocytic leukemia 
 Acute monoblastic/monocytic leukemia 
 Acute erythroid leukemia 
  Pure erythroid leukemia 
  Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
 Transient abnormal myelopoiesis 
 Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm
Table 2. WHO classification of acute myeloid leukemia and related neoplasms. 
1.2 Molecular markers 
1.2.1 Useful at diagnosis and to evaluate Minimal Residual Disease (MRD) 
Molecular techniques allow us to diagnose and classify AML, establishing groups of 
patients with different disease behaviour and prognosis.  In the same way, the development 
of more specific therapies and the application of risk-adjusted therapeutic approaches have 
been made possible. Disease relapse can be favored by persistent low numbers of leukemic 
cells undetectable by conventional techniques. Monitoring of AML patients has given rise to 
a higher insight into the effectiveness of treatment. At diagnosis, some types of myeloid 
leukemias display a molecular change that might be useful as a marker of neoplastic disease 
and MRD (Hilden et al., 1995; Nakao et al., 1996; Foroni et al., 1999; Lo Coco et al., 1999a). 
Specific molecular alterations of certain hematologic malignancies are useful in the detection 
of MRD. Translocations are the most widely involved chromosomal abnormalities in AML. 
These can give rise to an altered function or activity of oncogenes located at or near the 
translocated breakpoint. The first molecular cytogenetic marker described in AML was  
t(15;17), which originates a single morphologic phenotype (hyper- or micro-granular 
French-American-British [FAB] AML-M3 acute myeloid leukemia) (Bernstein et al., 1980). 
This rearrangement disappears with complete remission and is able to predict a relapse very 
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accurately. The presence of this translocation or its fusion gene (PML/ RAR) is thus a 
detectable tumor marker in leukemic cells, which allows assessment of the molecular 
response to therapy in AML-M3 patients (Lo Coco et al., 1999b). RUNX1-RUNX1T1 and 
CBF-MYH11 are other genetic alterations less likely to predict relapse, since they may 
persist even when complete remission (CR) has been achieved. However, the applicability of 
this strategy has been limited to those leukemia subsets characterized by genetic markers. 
Recent interest has focused on identifying new molecular markers that might prove 
significant in the diagnosis and follow-up of MRD in AML patients. In recent years, a 
variety ot potential molecular markers have been identified (see table 2 and table 3) (Radich 
& Thomson, 1997; Inoue et al., 1994; Kreuzer et al., 2001; Alberta et al., 2003; Lin et al., 2005; 
Gilliland & Griffin, 2002; Morishita et al., 1992).  
 
Involvement of transcription 















PML-RARA 10-15% Favorable FLT3 (40%) Yes
MLL mutation 10-30% Poor - Yes
CEBPA mutation 15-20% Favorable if biallelic - Yes 
AML1 mutation 1-20% Poor FLT3 (in 20% M0) Yes 
Activating mutations
FLT3-ITD  
mutation 28-34% Poor  Possible 
FLT3-TKD 
mutation 20-30% Controversial CBF, NPM1  
c-KIT mutation 6-48% Poor CBF-leukemias Yes




NPM1 mutation 35% Favorable (without FLT3) FLT3 Yes 
BAALC 
overexpression 65% Poor - Possible 
EVI-1 
overexpression 10-22% Poor - Possible 
WT1 
overexpression 10-15% Poor - Yes 
DNMT3A 
mutation 20% Poor FLT3-ITD - 
IDH1/2 mutation 15% Controversial NPM1, FLT3-ITD -
Table 3. Molecular markers in AML: prevalence, prognostic, associated mutations, genetic 
alterations and utility in MDR. 
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1.2.2 Genetic alterations with prognosis value 
In recent years, the availability of new genetic and molecular prognostic markers in AML 
has grown considerably. This is particularly important in the case of patients with normal 
cytogenetics who comprise the largest subgroup of AML patients (approximately 45%) 
where many new prognostic factors have been identified. These include gene mutations in 
FLT3 (Fms-like tyrosine kinase 3; generally FLT3-ITD has been associated with significantly 
worse survival (Sheikhha et al, 2003)), NPM1 (nucleophosmin 1) and CEBPA (CCAAT 
enhancer-binding protein-α; generally favorable in cases of biallelic mutations) and gene 
overexpression as BAALC, WT1, EVI1 and MN1 (Foran, 2010).  
Identifying alterations in these genes might provide independent prognostic value in 
predicting the outcome of acute leukemia, as in the case of the NPM1 mutation gene, which 
is a relatively frequent abnormality in AML patients and is useful in detecting MRD (Falini 
et al., 2007). 
2. Detailed description of molecular markers 
Next, we will describe the most common molecular markers in AML.  
2.1 Core Binding Factor (CBF) 
Leukemias affecting CBF are characterized by rearrangements of genes that code for 
components of the heterodimeric transcription factor CBF, which plays an essential role in 
haematopoiesis (Gabert et al., 2006). CBF complex is a heterodimer composed of RUNX1 
(also called AML1) and CBF and is the target of at least three common transloctions in 
AML: t(8;21)/RUNX1-RUNX1T1, t(3;21)/RUNX1-EVI1 and inv(16) or t(16;16) resulting in 
CBF-MYH11. Rearrangements of AML1 and CBFB with other genes lead to chimeric 
proteins that disrupt the CBF complex, suppressing the activation of transcription.  
2.1.1 AML1 (RUNX1) rearrangements 
AML1, also called, RUNX1, is normally expressed in all hematopoietic lineages and 
regulates the expression of several genes specifically linked to hematopoiesis, including the 
granulocyte colony-stimulating factor receptor, interleukin 3, T-cell receptor, and 
myeloperoxidase (MPO) genes. The AML1 gene (on 21q22) is one of the genes most 
frequently deregulated in leukemias, generally through translocations that produce chimeric 
messenger RNA. Chimeric protein AML1-ETO (RUNX1-RUNX1T1) results from the 
t(8;21)(q22;q22) involving the AMLI gene on chromosome 21 and the ETO gene on 
chromosome 8. This rearrangement is detected in approximately 8% of AML cases in 
children and young adults. RUNX1-RUNX1T1 is a marker for favourable outcome and an 
important PCR target for MRD detection. Most patients achieve a CR after induction 
therapy and those patients benefit most from a postremission therapy with high-dose 
cytarabin (Bloomfield et al., 1998; Perea et al., 2006). Hence, this marker permits to single out 
a relatively small subgroup of patients who are more likely to relapse (Gabert et al., 2003). 
RUNX1-RUNX1T1 is also frequently associated with c-kit mutations which determine an 
adverse outcome within this group of patients with favorable prognosis. In addition, the 
loss of Y chromosome in male patients with t(8;21) leukemia is a negative prognostic factor 
for the overall survival (Schlenk et al., 2004). While the molecular diagnosis is performed by 
qualitative and quantitative Real Time RT-PCR (QRT-PCR), MRD monitoring is performed 
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by quantitative QRT-PCR. The rare balanced t(3;21)(q26;q22) was described in AML, mainly 
after treatment with topoisomerase II inhibitors. This translocation fuses the AML1 gene on 
21q22 and the EVI-1 gene on 3q26 resulting in t(3;21)(q26;q22). This translocation is 
associated with higher WBC and platelets counts but is not, however, predictive for relapse-
free or overall survival (Preudhomme et al., 2000; Meyers et al., 1993; Lutghart et al., 2010). 
2.1.2 AML1 mutations 
AML1 mutations can be found in de novo leukemia, particularly subtypes FAB M0 and M7, 
as well as in patients with trisomy 21 and myelodysplastic syndromes. Testing for mutations 
can be performed By real time PCR or PCR-single stranded conformational polymorphism 
(SSCP). A multivariate analysis carried out by Schnittger et al., showed an independent 
unfavourable prognostic significance of AML1 (or RUNX1) mutations for overall survival 
(Schnittger et al., 2011). 
2.1.3 CBFb-MYH11 
Inv(16)(p13;q22) or t(16;16)(p13;q22) are among the most frequent recurring chromosomal 
rearrangements detected in AML, generally observed in cases showing myelomonocytic 
differentiation and having abnormal bone marrow eosinophils (M4 Eo AML in the French 
American British (FAB) classification). Inv(16)(p13;q22) is found in approximately 10-12% of 
cases of AML. It can occur in all age groups but is predominantly seen in younger patients. 
This rearrangement results in the disruption of the myosin heavy chain (MYH) gene at 16p13 
and the core binding factor (CBF) gene at 16q22 (FAB, 1976). Ten different CBF-MYH11 
transcripts have been reported, but the frequency of each transcript is variable. CBFB-MYH11 
positive patients are considered to have a favourable prognosis. This rearrangement is 
frequently associated with c-kit and FLT3 mutations which worsen the prognosis. Quantitative 
QRT-PCR allows monitoring of CR (Gabert et al., 2003; Perea et al., 2005). 
2.1.4 CEBPA 
The CCAAT/enhancer binding alpha protein (C/EBP) is the founding member of a family 
of related leucine zipper transcription factors. Mutations in CEBPA are found in 5-14% of 
AML and have been associated with a relatively favourable outcome only in biallelic 
mutations of this gene. There are two main classes of mutation situated at the N- terminal or   
 
 
Fig. 1. Schematic representation of CEBPA (by Smith, 2004). 
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C-terminal basic leucine zipper (bZIP) regions (Figure 1). The latter affect both DNA binding 
and homo and heterodimerization with other CEBP-proteins. The former introduce a 
premature stoppage of the translation of the p42 CEBPA protein, preserving a p30 isoform, 
which was shown to inhibit DNA binding and transactivation by C/EBPpCEBPA 
mutations are exclusively related to the intermediate risk group karyotype AML. CEBPA 
insertion, deletions and point mutations are detected usually by DNA sequencing (Wouters 
et al., 2009; Pabst et al., 2001; Fuchs et al., 2008).  
2.2 PML-RAR 
Acute promyelocytic leukemia is a distinct subtype of AML (AML-M3) according to the FAB 
classification. AML-M3 is characterized by t(15;17) that involves the retinoic acid receptor a 
(RAR) gene on chromosome 17 and the promyelocytic leukemia gene (PML) on 
chromosome 15. At the molecular level, t(15;17) results in a hybrid PML/ RAR gene, which 
is easily identified by reverse transcriptase-polymerase chain reaction (RT-PCR).  This test 
provides a rapid and refined diagnosis. The usefulness of minimal residual disease 
monitoring during follow up (Lo Coco et al., 1992; Lo Coco et al., 1999a) has been well 
established. The different breakpoints within the PML gene cluster can be located in three 
regions: bcr1, 2 and 3. 
The assessment of remission status at the molecular level by RT-PCR of PML-RAR 
represents a significant clinical advance with respect to other poorly sensitive methods 
(morphology, karyotype). The treatment of this disease (arsenicals, liposomal ATRA, other 
retinoid derivatives, etc) needs to be assessed taking into account the response at the RT-
PCR level. The detection of residual PML-RAR transcripts during clinical remission 
predicts subsequent hematologic relapse. This determines the need for additional treatment 
given the benefits of anticipating salvage therapy in AML-M3. Figure 3 shows the 
statistically significant difference between patients treated for molecular relapse and the 
historical series treated for hematologic relapse (Lo Coco et al., 1999b). 
 
 
Fig. 2. Kaplan-Meier estimates of overall survival from relapse in patients treated at the time 
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by quantitative QRT-PCR. The rare balanced t(3;21)(q26;q22) was described in AML, mainly 
after treatment with topoisomerase II inhibitors. This translocation fuses the AML1 gene on 
21q22 and the EVI-1 gene on 3q26 resulting in t(3;21)(q26;q22). This translocation is 
associated with higher WBC and platelets counts but is not, however, predictive for relapse-
free or overall survival (Preudhomme et al., 2000; Meyers et al., 1993; Lutghart et al., 2010). 
2.1.2 AML1 mutations 
AML1 mutations can be found in de novo leukemia, particularly subtypes FAB M0 and M7, 
as well as in patients with trisomy 21 and myelodysplastic syndromes. Testing for mutations 
can be performed By real time PCR or PCR-single stranded conformational polymorphism 
(SSCP). A multivariate analysis carried out by Schnittger et al., showed an independent 
unfavourable prognostic significance of AML1 (or RUNX1) mutations for overall survival 
(Schnittger et al., 2011). 
2.1.3 CBFb-MYH11 
Inv(16)(p13;q22) or t(16;16)(p13;q22) are among the most frequent recurring chromosomal 
rearrangements detected in AML, generally observed in cases showing myelomonocytic 
differentiation and having abnormal bone marrow eosinophils (M4 Eo AML in the French 
American British (FAB) classification). Inv(16)(p13;q22) is found in approximately 10-12% of 
cases of AML. It can occur in all age groups but is predominantly seen in younger patients. 
This rearrangement results in the disruption of the myosin heavy chain (MYH) gene at 16p13 
and the core binding factor (CBF) gene at 16q22 (FAB, 1976). Ten different CBF-MYH11 
transcripts have been reported, but the frequency of each transcript is variable. CBFB-MYH11 
positive patients are considered to have a favourable prognosis. This rearrangement is 
frequently associated with c-kit and FLT3 mutations which worsen the prognosis. Quantitative 
QRT-PCR allows monitoring of CR (Gabert et al., 2003; Perea et al., 2005). 
2.1.4 CEBPA 
The CCAAT/enhancer binding alpha protein (C/EBP) is the founding member of a family 
of related leucine zipper transcription factors. Mutations in CEBPA are found in 5-14% of 
AML and have been associated with a relatively favourable outcome only in biallelic 
mutations of this gene. There are two main classes of mutation situated at the N- terminal or   
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C-terminal basic leucine zipper (bZIP) regions (Figure 1). The latter affect both DNA binding 
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features of acute promyelocytic leukemia, in particular with high WBC counts. Also, FLT3 
mutations, especially ITD, can adversely affect overall survival and disease-free survival in 
PML-RAR-positive AML (Beitinjaneh et al., 2010). However, in a large series of 739 
patients with acute promyelocytic leukemia treated with ATRA and anthracycline-based 
chemotherapy, we were unable to demonstrate an independent prognostic value of FLT3 
mutations (Barragan et al., 2011).  
2.3 DEK-CAN 
AML defined by t(6;9) is a relatively rare disease, associated with specific clinical and 
morphological features (Garcon et al., 2005). Especially in young adults, the leukemic phase 
can be preceded by dysplastic features, conferring a bad prognosis. Morphological findings 
usually correlate with FAB M2 (60%), M4 (30%), or Ml (von Lindern et al., 1990). A chimeric 
protein is generated, resulting from the fusion between DEK and the 30- terminus of the 
CAN gene, also known as NUP214 (von Lindern et al., 1990). DEK is a component of 
metazoan chromatin capable of modifying the structure of DNA by introducing supercoils. 
CAN is a nuclear pore complex protein implicated in nucleocytoplasmic trafficking.  The 
CAN gene is also involved in several fusion transcripts described in acute leukemia other 
than DEK in t(6;9)(p23;q34) AML, such as the SET gene and recently with ABL in T-cell 
acute lymphoblastic leukaemia (ALL). The DEK-CAN transcript can be used as a marker of 
t(6;9) AML which can be sensitively monitored by the polymerase chain reaction. This offers 
a great advantage in the diagnosis, monitoring of response to chemotherapy, and detection 
of minimal residual disease after bone marrow transplantation (von Lindern et al., 1992). 
DEK-CAN is related with an adverse prognosis (Dohner et al., 2010). 
2.4 NPM1 
NPM1 gene is located in 5q35 and encodes a phosphoprotein, nucleophosmin, which moves 
between the nucleus and the cytoplasm. The gene product is thought to be involved in 
several processes including regulation of the ARF/p53 pathway. Mutations in exon 12 in 
this gene are associated with AML with normal karyotype (50%) and especially correlate 
with monocytic leukemias. Patients with NPM1 mutations have a significantly higher rate of 
complete remissions (CRs) after standard induction chemotherapy except for cases 
associated with internal tandem duplications mutations of FLT3 (Falini et al., 2007; Gale et 
al., 2008). Gale et al. (2008) identified 3 prognostic groups among the NPM1+ AML patients: 
good in those with only a NPM1 mutation and absence of a FLT3-ITD; intermediate in those 
with either absence of FLT3-ITD or NPM1 mutations or mutations in both genes; and poor 
in those with only FLT3-ITD. Monitoring can be performed by quantitative PCR (Schnittger 
et al., 2009). In our group, the incidence of NPM1 mutation was 30% (17 of 55 patients with 
AML), being this prevalence similar to that found for FLT3-ITD in the same population (29 
%). The 17 NPM1+ AML patients were distributed as follows: eight M1-M2 (47.1 %), four 
M4-M5 (23.5%), and five not labelled (29.4 %) because cytogenetic studies were not 
informative due to several reasons.  64.7% of the NPM1+ patients had a normal karyotype, 
while 5.8% of them had cytogenetic anomalies. FLT3-ITD mutations were found in 41.2 % of 
the NPM1+ AML cases. In contrast to what has been described in the literature our group 
did not find a higher incidence of M4 or M5 subtypes (Thiede et al., 2002). In our case, a 
higher incidence of M1 and M2 subtypes was detected (Table 4). However the differences 
are most likely attributable to the small sample size of our cohort as compared to the Thiede 
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cohort. The global mortality was analyzed disregarding risk factors, with a mortality of 67 % 
in the NPM1+/FLT3-ITD- group standing in clear contrast to a 100% death rate in the 
NPM1+/FLT3-ITD+ group (Lopez Jorge et al., 2006). This was confirmed in another study 
where we analysed the incidence and prognostic relevance of CD34/CD7/DR surface 
markers in a group of forty two NPM1positive patients and related it to FLT3-ITD 
mutations. We found that 84% of the NPM1 positive patients had normal karyotypes. 
Mutations in FLT3-ITD were detected in 23.8% of the NPM1+ patients. The screening for 
this mutation could be very useful in the future as patients with normal karyotype and 
expression of this molecular marker is included in a better prognostic subgroup (Gomez 
Casares et al., 2009; Dohner et al., 2010). 
 
 Nº patients NPM1+ NPM1- 
Patients (%) 55 17 (30.9) 38(69) 
Median (range age) (years) 60 (18-95) 58 (18-82) 60 (19-95) 




















































































FLT3-ITD+ (%) 16 (29) 7(41.2) 9(23.6) 
Table 4. Cytogenetics and demographic characteristics in a group of 55 AML patients (Lopez 
Jorge et al., 2006). 
2.5 c-KIT 
KIT is a proto-oncogene located on chromosome band 4q11-12 and encodes a 145-kDa 
transmembrane glycoprotein member of the type III receptor tyrosine kinase family. Ligand 
independent activation of KIT results from mutations in the extracellular portion of the 
receptor (exon 8), transmembrane and juxtamembrane domains (exons 10 and 11, 
respectively), and activation loop of the tyrosine kinase domain (exon 17). c-KIT mutations 
have been found in a variable but relatively high frequency (up to 50%) in patients with CBF 
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cohort. The global mortality was analyzed disregarding risk factors, with a mortality of 67 % 
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AML, including both t(8;21) and the other major type of CBF AML inv(16)(p13q22) or 
t(16;16)(p13;q22). This appears to confer a quite unfavourable prognosis with higher relapse 
risk (associated to inv(16) or t(8;21)). An adverse effect on OS in AML with inv(16) has been 
described, particularly those that occur in exon 17 (Paschka et al., 2006). Such patients may 
warrant more aggressive or alternative therapy. The presence of the c-KIT mutation would 
be also important because it provides a target for novel tyrosine kinase inhibitor (TKI) 
therapy (Pollard et al., 2010).  
2.6 FLT3 
Flt3 is a member of the class III tyrosine kinase receptor family that includes the c-kit, c-fms, 
and PDGF receptors. The Flt3 receptor is preferentially expressed on hematopoietic stem 
cells and mediates stem cell differentiation and proliferation. Interaction of the Flt3 receptor 
with Flt3 ligand causes receptor dimerization, leading to the activation of the receptor 
tyrosine kinase and receptor autophosphorylation. The phosphorylated Flt3 transduces 
activation signals through associations with various cytoplasmic proteins, including ras 
GTPase-activating protein, phospholipase C, and Src family tyrosine kinases. Activation of 
the Flt3 receptor by ligand-dependent phosphorylation induces cellular proliferation via 
activation of cytoplasmic mediators. Thus, constitutive activation of the Flt3 pathway may 
lead to disease proliferation and may block cellular apoptotic response to conventional 
chemotherapy. An internal tandem duplication of the juxtamembrane (JM) domain-coding 
sequence of the FLT3 (FLT3-IT) gene on chromosome 13 has been identified in a group of 
patients with AML. Constitutive activation of the Flt3 receptor tyrosine kinase, either by 
internal tandem duplication (ITD) mutations of the juxtamembrane domain or point 
mutations clustering in the second tyrosine kinase domain (TKD mutations as D835), has 
been found in 20% to 30% of patients with AML and in 30% to 45% of patients with normal 
karyotype (reviewed by Stirewalt and Radich (2003)). ITD mutations have been associated 
with an increased risk of treatment failure after conventional chemotherapy (overall 
survival and disease-free survival were worse for ITD positive patients versus FLT3 
wildtype patients), whereas the prognostic relevance of FLT3 point mutations is less evident 
(D835 mutants did not appear to have a worse median overal suvival or disease-free 
survival compared with the wildtype group) (Sheikhha et al., 2003). Recently, Spassov et al 
analyzed for WT1 and FLT3-internal tandem duplication (FLT3-ITD) expression in 30 
samples of AML patients and determined that high WT1 expression correlated with the 
presence of FLT3-ITD (P = 0·014) and with a lower rate of complete remissions (P = 0·023) 
(Spassov et al., 2011). The detection of both molecular markers (WT1 and FLT3-ITD) may be 
helpful in defining high risk AML patients that need special therapeutic strategies. 
 Several studies described that a higher mutational load as determined by calculation of 
FLT3-ITD/FLT3 wildtype ratio indicates a worse prognosis in mutation carriers. Therefore, it 
was suggested that not the FLT3-ITD per se, but more likely loss of heterozygosity is 
associated with the unfavorable outcome in FLT3-ITD mutated AML (Meshinchi et al., 2001; 
Yanada et al., 2005; Thiede et al., 2002; Schnittger et al., 2011). 
2.7 EVI1 overexpression 
The ectopic viral integration site 1 (EVI1), located in chromosome 3q26, has been recognized 
in the last years as one of the most aggressive oncogenes associated to human leukemia 
(Gröschel et al., 2010). The inappropriate expression of EVI1 in hematopoietic cells has been 
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implicated in the development or progress of myeloid disorders (Lugthart et al., 2008). 
Previous studies, applying microarray technology, indicate that high levels of EVI1 
expression are detected in 10% -22% of patients with AML (Barjesteh et al., 2003). Although 
the higher expression of EVI1 gene was clearly associated with myeloid malignancies, is not 
restricted to this group. It is noteworthy that overexpression of EVI1 was also observed in 
13.8% of patients with acute lymphoid leukemia. The correlation between overexpression of 
EVI1 in bone marrow and poor outcome in AML is a frequent issue of discussion in the 
literature (Lugthart et al., 2008; Luzardo et al., 2007).  
We analyzed the incidence of EVI1 overexpression in haematological malignancies and its 
value as a prognostic factor. EVI1 overexpression (EVI1+) was examined by RT-PCR in bone 
marrow and/or peripheral blood samples of 113 AML patients at diagnosis and during 
follow-up. We found that 23.8% of AML overexpressed EVI1, as established by our 
previously determined cut-off point. Correlation with FAB subtypes stands as follows: 2M0, 
1 M1,3 M2, 6 M4, 7 M5, 1 M6, 4 secondary AML and 3 not labeled. Survival curves in the 
AML group didn´t show any significant differences in overall survival and disease free 
survival when comparing EVI1+ to EVI1- populations. In AML samples a greater than 
expected incidence of EVI1 expression was observed (22.8% vs 11% previously described). 
When survival curves were analyzed in the AML group with ages ranging from 14 to 60 
years, all of them treated with similar chemotherapy schemes, no significant difference was 
observed. However, a recent collaboration with other groups, showed that EVI1 
overexpression is a poor prognostic marker in patients <65 years in an independent large 
cohort, and showed that the total absence of EVI1 expression has a prognostic impact in the 
outcome of acute myeloid leukemia patients (Vazquez et al.,2011). 
2.8 BAALC AND MN1 
The Brain and Acute Leukemia Cytoplasmic (BAALC), human gene located on chromosome 
8q22.3, has also been found to be an important adverse prognostic factor if overexpressed in 
normal karyotype AML, suggesting a role for BAALC overexpression in acute leukemia. 
This gene is highly conserved in mammals. Normally, BAALC is almost exclusively 
expressed in neuroectoderm-derived tissues. Though little is known about the biological 
function of BAALC, it is highly expressed in hematopoietic precursor cells as well as 
leukemic blasts and is down-regulated during differentiation. BAALC has been postulated 
to play its role in the cytoskeleton network due to its cellular location. BAALC expression is 
an independent adverse prognostic factor and is associated with a specific gene-expression 
profile. Recent studies revealed the prognostic impact of BAALC expression in AML and 
also as a marker in minimal residual disease. Currently, determination of BAALC 
expression is performed by qualitative and quantitative real-time PCR, although the lack of 
validation or standardization studies limits its utility (Tanner et al., 2001; Gregory et al., 
2009; Baldus et al., 2003;  Najima et al., 2010).  
The meningioma 1 (MN1) gene is localized on human chromosome 22.  MN1 overexpression 
is a prognostic marker in patients with AML with normal karyotype characterized by an 
intermediate prognosis. Patients with high MN1 expression had a significantly worse 
prognosis (the overall survival was shorter and relapse rate was higher in this group 
compared to low MN1 expression group). High MN1 expression has as well been associated 
with other AML characteristics like inv(16) or overexpression of EVI-1 (Heuser et al, 2007). 
In addition, MN1 is able to induce myeloid leukemias in a murine model (Heuser et al, 
2011). This suggested that MN1 may play a functional role in the pathogenesis of AML. 
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We performed a retrospective analysis of MN1 expression in a group of 49 AML patients with 
a mean age of 52 years (43 de novo AML and 6 secondary AML). In order to analyze response 
to chemotherapy, overall survival and correlation to other molecular markers (NPM1, FLT3-
ITD, EVI1 and BAALC), patients were further classified into three groups depending on 
prognosis (favourable with 11 patients, intermediate with 25 and poor with 12). We analysed 
by real-time PCR the expression of MN1 in patients samples. We used as positive control of 
expression RNA of KG1 cell line that overexpress MN1. The incidence of MN1 overespression 
was 65.3%. The study showed that MN1 overexpression correlated to BAALC expression. We 
did not find relation with other markers, such as EVI-1, NPM-1 and FLT3. MN1 and BAALC 
overexpression have been associated to induction treatment refractoriness. However, due to 
the limited sample size in our series, determining whether MN1 or BAALC were actually 
involved with refractoriness was not possible. The 2-year overall survival was 52% and 53% 
for MN1 overexpressed and MN1  not overexpressed patients respectively. The 5-year overall 
survival was 52% and 42% respectively, showing no significant differences. Survival analysis 
for the intermediate risk AML group did not show significant differences either. MN1 
overexpression was not associated with a worse prognosis in any of the studied patients, 
probably due to a small sample size (Rodriguez et al., 2010). 
2.9 WT1 
The Wilms' tumor locus was identified as a tumor suppressor gene, which is inactivated in 
Wilms' tumor, a pediatric kidney cancer. This protein, displaying characteristic features of a 
transcription factor, and with an expression restricted to kidney and haematopoetic cells, was 
called Wilms' tumor gene 1 (WT1). This gene is located on chromosome 11p13 and encodes a 
zinc-finger transcription factor influencing the expression of several growth factors and their 
corresponding receptors. It is also known to be involved in the early stage of hematological cell 
differentiation. Aberrant expression may be one mechanism by which the normal function of 
WT1 is disrupted. However, the exact role of WT1 in hematopoiesis and leukemogenesis still 
remains unclear. The abundant overexpression of WT1 in leukemia creates a very attractive 
target for quantitative MRD studies in AML, especially in those samples with no specific 
fusion gene available. The method used to determine the expression of WT1 gene is the RT-
PCR, which will reveal its value as a marker to detect minimal residual disease (Keilholz et al., 
2005; Weisser et al., 2005; Inoue et al., 1994; Garg et al., 2003).  
Mutations of the coding region (most frequenly in 7 and 9 exons) of the WT1 gene have also 
been described and occur in 10–15% of AML (figure 3). Gaidzik et al. concluded that WT1 
mutation as a single molecular marker did not have an impact on outcome. On the other 
hand, Hou et al. demostrated that WT1 mutations disappeared in WT1-mutated studied 
patients who achieved complete remission, suggesting its potential use as MRD marker 
(Gaidzik et al., 2009; Hou et al., 2010).  
 
 
Fig. 3. Structure of the WT1 gene and localization of the 87 mutations identified by Gaidzik 
et al. 
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2.10 MLL rearrangement and MLL-PTD 
The MLL (mixed lineage leukemia) gene located at 11q23, is fused to a variety of partner 
genes through chromosomal translocations in acute leukemias. Up to now, more than 40 
different MLL partner genes have been identified. MLL gene contains 100 kb of DNA, but 
nearly all breakpoints are clustered within a 8.3 kb region. Molecular analysis shows that 
fusion of the amino terminus of MLL to the carboxy terminus of partner genes generates 
the critical leukemogenic fusion proteins. Abnormalities of the mixed-lineage leukemia 
(MLL) gene can be detected in de novo acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) as well as in therapy-related AML, particularly after 
treatment with DNA topoisomerase II inhibitors (generally less than 5–10% of patients 
carried this rearrangements).The most common translocation involving 11q23 in acute 
myeloid leukemia (AML) is t(9;11)(p22;q23), which results in the generation of a fusion 
transcript of MLL-AF. The other common translocations involving 11q23 in AML are 
t(6;11)(q27;q23), t(10;11)(p12;q23), t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3); these 
translocations result in the generation of fusion transcripts MLL-AF6, MLL-AF10, MLL-
ELL or MLL-ENL, respectively. In AML, MLL-AF9 has generally been associated with a 
more favourable outcome although this finding is controversial. This rearrangement is 
related to a superior event-free and overall survival as compared to patients with other 
chromosomal abnormalities or with no detectable rearrangements (Dimartino et al., 1999; 
Balgobind et al., 2005). In contrast, the other traslocation involving Cr 11q23 are asociated 
with poor prognostic in more cases (Dimartino et al., 1999; Balgobind et al., 2005). 
t(9;11)(p22;q23) is classified as intermediate and t(v;11)(v;q23) as adverse prognostic 
group (Döhner et al., 2010). Therefore, detection and identification of the different types of 
MLL rearrangements is of clinical importance. A recent study indicated that quantification 
by RQ-PCR of the fusion gene transcript levels at diagnosis may be of prognostic 
relevance (Shih et al., 2006; Jansen et al., 2005). One type of MLL rearrangement not 
detectable by classic cytogenetic is the partial tandem duplication of MLL (MLL-PTD). 
This rearrangement results most commonly from a duplication of a genomic region 
encompassing either MLL exons 5 through 11 or MLL exons 5 through 12 that is inserted 
into intron 4 of a full-length MLL gene, thus fusing introns 11 or 12 with intron 4. At a 
transcriptional level, this results in a unique in-frame fusion of exons 11 or 12 upstream of 
exon 5. In adult de novo AML with a normal karyotype, the presence of the MLL-PTD has 
been associated with a worse prognosis (ie, shorter duration of remission) when 
compared with normal karyotype AML without the MLL-PTD (Whitman et al., 2005). 
2.11 Other molecular markers in research: Renin expression 
There have been reports of experimental findings that relate the renin-angiotensin system 
(RAS) with hematopoiesis. Some studies have identified RAS components located in the 
bone marrow (Haznedaroglu & Buyukasik, 1997) that might functionally affect cellular 
proliferation and differentiation in physiological or pathological states (Huckle & Earp, 
1994; Comte et al., 1997). It has been demonstrated that the RAS component renin is 
expressed in the bone marrow microenvironment as well as in hematopoietic cells (Abali et 
al., 2002). Bone marrow blast cells of some types of AML (M4 and M5 FAB types) express 
renin (Wulf et al., 1998), however no expression has been detected in normal bone marrow 
from healthy donors (Gómez Casares et al., 2002).  Our group also detected renin expression 
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in AML patients, but it did not relate to monocytic dififerentiation or to the existence of 
other cytogenetic risk markers (Gómez Casares et al., 2002). Moreover,  renin expression has 
been found to be related to disease activity, disappearing with AML remission and 
returning with relapse (De la Iglesia et al., 2006).   
We did not found statistically significant differences in the outcome between renin-positive 
and renin-negative patients (De la Iglesia et al., 2006).   
 
 
Fig. 4. Renin:glucuronidase ratios vs clinical state of the quantified patients. *This data 
belong to third relapse, CR and fourth relapse, respectively. **This patient did not reach CR, 
continuing the positivity of the renin gene expression. ***Patient 28 in morphological CR 
was presented with 1% blasts in BM that later disappeared (De la Iglesia et al., 2006).   
 
 
Fig. 5. (a) Overall survival of renin-positive and renin-negative patients with AML. Kaplan-
Meier plot showing the correlation between overall survival and renin expression in AML 
patients. (b)Disease-free survival of renin-positive and renin-negative patients with AML. 
Kaplan-Meier plot showing the correlation between disease-free survival and renin 
expression in AML patients. (De la Iglesia et al., 2006).   
Renin expression is related to undifferentiated phenotypic cell lines (K562, KU812), since 
no expression of the renin gene was found in cellular lines that showed a highly 
differentiated phenotype like HL60 and U937 (Gómez Casares et al., 2002). ACE inhibitors 
(captopril and trandolapril) and AT1 receptor blocker (losartan) produce a stop in 
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proliferation  in K562 cells with captopril (C) 10 mM and trandolapril (T) 2 mM (figure 6a) 
as well as an increase in the apoptotic rate in renin positive leukemia cell lines (K562) after 
the treatment with captopril (data not shown) and trandolapril (figure 6b) (De la Iglesia et 







Fig. 6. (a) Proliferation in K562 after the treatment with captopril (C) and trandolapril (T). (b) 
C-myc gene expression in K562 after the treatment with the same drugs. (c) Apoptosis 
determined by annexin V binding in K562 and K562 transfected with bcl-2 and bcl-x (Kbcl2 
and Kbclx) cells treated with 1mM trandolapril (T) (De la Iglesia et al., 2009). All 
experiments were performed in triplicate. 
The leukaemogenic role of renin gene expression and the implicated molecular pathways 
have not yet been elucidated but it may offer novel therapeutic approaches in pathological 
or neoplastic conditions (Haznedaroglu & Öztürk, 2003). 
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The AML embraces very heterogeneous entities with different clinical behaviours. Some of 
these leukemias have certain chromosomal alterations that are related to specific 
morphological and clinical subtypes. Their identification has had great impact on different 
management aspects of these diseases, either from the standpoint of diagnosis, prognosis or 
development of a treatment plan tailored to the risk of relapse. This has been largely 
possible thanks to the application of molecular biology studies, which have provided a 
better and deeper understanding of the pathogenesis of leukemia. 
The genetic alterations that occur at different stages fall into two broad groups: those that 
activate signal transduction as c-KIT and FLT3 (type I) and those which alter transcription 
factors such as CBF, RAR-, CEBPA and NPM1 (type II). These two groups work together in 
leukemogenesis, being very frequent the coexistence of alterations of the two groups in the 
same patient. 
The knowledge of these molecular markers helps us to classify patients within certain 
prognostic groups.  In this way, in patients with normal cytogenetics, it is very important to 
know if there is a mutation of the FLT3 gene as well as its kind (ITD or TKD), because this 
information is of great relevance in order to select the appropriate treatment scheme. 
Moreover, the overexpression of the genes BAALC (under OS, DFS), MN1 (induction failure 
in patients with normal karyotype) or EVI1 (adverse impact) has been shown to have 
prognostic significance in AML. 
In a laboratory setting there are different ways to classify leukemias. One of them is the 
rationale showed in the figure 5. According to the cytogenetic or molecular biology at 
diagnosis, it is possible to perform different determinations which will allow us to classify 
the patients within a favourable or unfavourable prognostic group. AML patients are 
classified at the time of diagnosis into three different prognostic groups based on their 
cytogenetic profiles. 
There are plenty of algorithms which allow us to classify patients into different prognostic 
groups. They are undergoing continuous changes with the enrichment of new data. If we 
are in the presence of a CBF leukemia (by showing RUNX1-RUNXT1 or inv (16)), mutational 
analysis of c-kit should be performed, as this mutation translates into a higher risk of 
relapse. In patients with AML with normal karyotype, we recommend to analyze for FLT3-
ITD first, as FLT-ITD3 is a well-known adverse prognostic factor. We then recommend 
screening for NPM1 mutations as a next step, because it is another mutation with clinical 
relevance of this subgroup of patients in the absence of FLT3-ITD. Then, given the 
favourable prognosis of NK-AML with biallelic CEBPA mutation, we recommend a CEBPA 
mutational analysis in those patients non-carriers of FLT3-ITD or NPM1. Also,  FLT3-TKD 
an others mutations can be analyze in a context of clinical trials, even though there is no 
prognostic relevance. 
There after, it is possible to perform other studies such as the detection of mutations in 
MLL/AF9 or BAALC, MN1 and EVI1 gene overexpression in order to make a better 
stratification of the prognosis. Besides working with prognostic and follow up markers with 
a recognized utility, we are also carrying out experimental work with new, not yet validated 
markers which will probably help us in the follow up, prognosis, classification and 
monitoring of AML patients. Renin, EVI1 and WT1 would be markers applicable to AML 
patients, especially in those with normal karyotype where they will facilitate the monitoring 
of minimal residual disease.  
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inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 






Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 












inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
-5 or del(5q); -7; abnl(17p); complex karyotype 
 
Table 5. Standardized reporting for correlation of cytogenetic and molecular genetic data in 
AML with clinical data (Döhner. European LeukemiaNet , 2010) 
In recent past, treatments had an empirical basis, lack of specificity and, therefore, limited 
effectiveness combined with high toxicity. The treatment of AML pioneered the search for 
specific therapies with the use of ATRA in APL. Currently, the ultimate goal of the 
understanding and classification of molecular aberrations in every AML subtype is to 
design a targeted therapy, which will reduce the risk of relapse and treatment side effects. 
That is because the future of AML therapy should be in the search and development of 
drugs that are directed against specific molecular or fusion proteins aberrations. On the 
other hand, due to the interaction between different molecular aberrations that arise in 
AML, the design of these new drugs has to be focused on the combined inhibition of several 
signalling pathways to achieve maximum clinical benefit. 
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inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
t(6;9)(p23;q34); DEK-NUP214 
t(v;11)(v;q23); MLL rearranged 
-5 or del(5q); -7; abnl(17p); complex karyotype 
 
Table 5. Standardized reporting for correlation of cytogenetic and molecular genetic data in 
AML with clinical data (Döhner. European LeukemiaNet , 2010) 
In recent past, treatments had an empirical basis, lack of specificity and, therefore, limited 
effectiveness combined with high toxicity. The treatment of AML pioneered the search for 
specific therapies with the use of ATRA in APL. Currently, the ultimate goal of the 
understanding and classification of molecular aberrations in every AML subtype is to 
design a targeted therapy, which will reduce the risk of relapse and treatment side effects. 
That is because the future of AML therapy should be in the search and development of 
drugs that are directed against specific molecular or fusion proteins aberrations. On the 
other hand, due to the interaction between different molecular aberrations that arise in 
AML, the design of these new drugs has to be focused on the combined inhibition of several 
signalling pathways to achieve maximum clinical benefit. 
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1. Introduction 
One major limitation in the development of effective and targeted cancer therapies is the 
incomplete understanding of the molecular mechanisms driving malignant cell growth and 
the resistance of residual cancer stem cells to standard therapies, such as chemotherapy 
and radiation. Consequently, numerous attempts have been made to elucidate the molecular 
circuits initiating and perpetuating malignant cell transformation.  
Among the different cancer entities, leukemias harbor only a few mutations and therefore 
represent a good model system for the study of oncogenesis. The cloning and subsequent 
analysis of leukemia-associated gene products have strongly facilitated the understanding 
of their biological function and the development of appropriate model systems. In early 
experiments, leukemia-associated oncogenes were ectopically expressed in fibroblasts, a cell 
type which is not optimal for modeling leukemia initiation and progression. Later, the 
development of cell separation methods for murine and human hematopoietic precursor 
cells allowed for the isolation of specific target cells, in large quantities and with high cell 
population purity (Belvedere et al., 1999). Together with the utilization of retroviral 
expression vectors, which enable stable integration and expression of a transgene of choice, 
these cell isolation procedures represent a significant methodological improvement for 
leukemia modeling approaches in the hematopoietic tissue. With these technologies in hand, 
the genetic lesions of leukemia can be better modeled in the appropriate cell compartment. 
By performing cell biology experiments and tumor sample deep sequencing it became clear 
that both solid tumors and hematological malignancies depend on multiple oncogenic 
alterations to ultimately result in cellular transformation (Hanahan & Weinberg, 2000, 2011; 
Kinzler & Vogelstein, 1996). Additionally, the overall number of mutated genes in solid 
tumors was found to be higher than in leukemias. These observations resulted in the 
formulation of the multi-hit model of tumorigenesis. Initiating mutations induce stem cell 
expansion and survival, thereby allowing for the occurrence of additional genetic alterations 
that result in the progression of malignant transformation. The later stages of this process 
are characterized by uncontrolled proliferation with overgrowth of the ´healthy´ cell 
compartment and metastasis, in the case of solid tumors. This multi-hit cancer model has 
been well described for colon cancer by Kenneth W. Kinzler and Bert Vogelstein (Kinzler & 
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Vogelstein, 1996). Similarly, it has been suggested for hematopoietic malignancies, that only 
a concerted signaling network resulting from the activity of several activated oncogenes 
leads to full transformation of preleukemic cell clones. However, the exact chronological 
order of these genetic events and the causality of their mutual cooperation are hardly 
understood (Schuringa et al., 2010).  
Myeloid leukemia represents a well-depicted tumor entity in terms of molecular pathogenesis. 
It is characterized by an uncontrolled proliferation behavior based on the aberrant self-renewal 
capacity of the myeloid progenitor cell compartment including the erythroid, monocytic and 
granulocytic lineages. Depending on the morphology and genetics of the cells and its clinical 
progression, myeloid leukemia is classified as either acute myeloid leukemia (AML) or chronic 
myeloid leukemia (CML). AML is distinguished by the rapid proliferation of immature 
myeloid progenitor cells, which overgrow the normal hematopoietic cells. AML is the most 
common acute leukemia, which predominantly affects adults. Its incidence strongly increases 
with age, with a median age at diagnosis of 65 years, suggesting that several oncogenic events 
are required for the onset and progression of the disease (Estey & Dohner, 2006). If left 
untreated, the disease proceeds rapidly and is typically fatal within weeks or months. To date, 
numerous AML-specific fusion genes and mutations have been described (Look, 1997). 
Chromosomal translocations and mutations involving the AML1 gene are amongst the most 
common alterations found in AML (Schnittger et al., 2011). AML1 is an essential transcription 
factor that controls the myeloid cell differentiation of progenitor cells into mature blood cells. 
Both point mutations and chromosomal translocations, such as t(8;21) and t(3;21), disrupt the 
physiological function of AML1 and hinder the normal maturation process of the progenitor 
cells (Niebuhr et al., 2008). IIn addition, mutations of the receptor tyrosine kinase, c-kit, are 
frequently detected in these cells and seem to be associated with poor prognosis due to their 
correlation with higher relapse rates after chemotherapy (Boissel et al., 2006; Paschka et al., 
2006). Mutations of the nucleophosmin (NPM1) gene are also frequently observed in AML. 
This gene is involved in multiple cellular processes including protein shuttling between the 
nucleus and cytoplasm, RNA biogenesis, cell cycle control and transcriptional regulation. It is 
also described as a cellular stress sensor associated with the p53-dependent apoptosis pathway 
(Grisendi et al., 2006). Commonly identified NPM1 mutations render this protein mislocalized 
to the cytoplasm. The oncogenic mechanisms behind this phenomenon are currently under 
intense investigation (Falini et al., 2010; Falini et al., 2007). Among the mutated kinases in 
AML, mutations of the FLT3 cytokine receptor gene are common and are associated with poor 
prognosis (Gilliland & Griffin, 2002; Meshinchi et al., 2001). Hyperactive FLT3 induces a strong 
intracellular signal transduction response, mainly by activating STAT5, a latent transcription 
factor important for self-renewal and proliferation of hematopoietic progenitors. For this 
leukemia entity, FLT3-inhibitors blocking its kinase activity are currently being tested in 
clinical trials (Wiernik, 2010). Isocitrate dehydrogenases, IDH1 and IDH2, represent genes that 
were recently identified to be frequently mutated in AML with adverse prognosis in 
cytogenetically normal leukemias (Mardis et al., 2009; Paschka et al., 2010). Mutations in IDH 
genes have also been found in human brain tumors, including gliomas. Interestingly, the 
accumulation of an intracellular metabolite, 2-hydroxyglutarate, was discovered in these 
tumor cells (Dang et al., 2009). This so-called ‘oncometabolite’ alters the genome-wide histone 
and DNA methylation patterns, thereby exerting oncogenic activity (Xu et al., 2011). 
Chronic myeloid leukemia is characterized by the increased proliferation rate of mature 
granulocytes and their precursors. The course of disease can be divided into three phases: 
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the chronic phase, the accelerated phase and the acute phase with typical features of AML 
(Sawyers, 1999). The t(9;22) chromosomal translocation, also called the Philadelphia 
chromosome, which generates the fusion protein BCR/ABL, is frequently observed in 
CML patient samples. The BCR-portion of the fusion protein triggers multimerization of 
the ABL portion, thereby locking the ABL kinase into a hyperactive state. BCR/ABL 
multimers induce constitutive intracellular proliferation and survival signaling, thereby 
triggering the development of leukemia (Hoelbl et al., 2010; Melo & Barnes, 2007). Over 
the last years, a breakthrough in the treatment of CML was achieved with the 
development of the ABL-kinase inhibitor, imatinib (Sawyers et al., 2002). BCR/ABL 
positive CML patients are now treated with one of several targeted, first-line therapies, 
including imatinib, dasatinib, and nilotinib, which have dramatically increased patient 
survival rates to nearly 90% since the advent of these therapies. These kinase inhibitors 
specifically inhibit the oncogenic tyrosine kinase activity of BCR/ABL. For the first time, 
an inhibitor has been developed that targets a driving oncogene with high efficiency, 
which is currently used in many clinical trials (Garcia-Manero et al., 2003). Later, it was 
found that imatinib also targets c-kit, a receptor tyrosine kinase frequently mutated in 
gastrointestinal stromal tumors (GIST), thereby widening the application spectrum of 
imatinib to include solid tumors (Demetri, 2002). Currently, large efforts are being made 
in the development of specific inhibitors for other oncoproteins. The elucidation of the 
molecular mechanisms controlling the process of leukemic transformation represents a 
prerequisite for the development of targeted oncogene inhibitors designed to improve 
current therapeutic strategies for myeloid leukemias.  
For both acute and chronic myeloid leukemia, ‘leukemia stem cells’ are most likely the 
origin of disease and are probably responsible for recurrence after chemotherapy (Trumpp 
& Wiestler, 2008). These leukemia stem cells share common features with normal stem cells. 
They are described as dormant or slowly cycling cells with an increased self-renewal 
capacity and a resistance to chemotherapeutic drugs. It has been proposed that they reside 
in the bone marrow niches and can fully regenerate the leukemia after standard 
chemotherapy. Perturbed self-renewal programs of leukemia stem cells represent a major 
problem for leukemia therapy. Even in BCR/ABL positive CML, for which a specific 
oncogene inhibitor is available, CML stem cells are resistant to imatinib treatment 
(Holyoake et al., 1999). Therefore, lifelong treatment of CML patients with tyrosine kinase 
inhibitors is necessary (Corbin et al., 2011; Diamond & Melo, 2011). 
Most of the current understandings of leukemogenic fusion genes and mutations have 
resulted from overexpression experiments using either cell line models or primary murine 
and human hematopoietic stem cells, both in vitro and in vivo. In these studies, leukemic 
gene products were usually expressed with the help of retroviral expression vectors 
resulting in ectopic and stable expression. This represents a convenient experimental 
strategy to model leukemia in mammalian hematopoietic stem and progenitor cells. The 
following sections will recapitulate the different retroviral expression vector systems used 
for modeling leukemia development and will summarize exemplary results acquired from 
studies of both the murine and human progenitor cell systems.  
2. Retroviral vector systems and expression cassettes 
When modeling leukemia in the mammalian hematopoietic system, there are two major 
strategies used to express a leukemia-associated gene product. The creation of knock-in or 
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transgenic mice enables robust transgene expression in vivo. However, transgene expression 
is usually not restricted to a certain tissue and permanent oncogene expression often causes 
delirious side effects, e.g. embryonic lethality, thereby impeding accurate analysis. 
Alternatively, genes can be delivered by retroviral vectors directly into the hematopoietic 
system via bone marrow transplantation of hematopoietic progenitors, transduced with the 
gene of interest (GOI). Gene marking of few cells also more precisely resembles leukemia 
development from a single cell clone. In addition, this method provides the advantage of 
rapid testing of numerous gene expression constructs in contrast to the time-consuming 
gene-manipulation of mice. Therefore, gamma-retroviral and lentiviral expression vector 
systems represent attractive and efficient techniques for the stable expression of a gene of 
interest in hematopoietic progenitor cells. Retroviruses are enveloped RNA viruses. Viral 
RNA is linear, single-stranded and approximately 7-12 kb in size. The common 
characteristic of retroviruses is their strategy of replication: the viral RNA is reverse 
transcribed into linear double-stranded DNA followed by its integration into the genome of 
the cell (Coffin et al., 2007). The most commonly used delivery system is the gamma-
retroviral vector system. These vectors are derived from the Moloney murine leukemia virus 
(Mo-MLV) genome (Kohn et al., 1987). The murine stem cell virus (MSCV) expression vector 
is one of the most frequently employed vector systems, as it enables stable and high 
transgene expression in virtually all cell types (Hawley et al., 1994). This vector is available 
with several marker genes, such as the enhanced green fluorescent protein (eGFP) and 
derivatives thereof, which are co-expressed via the internal ribosomal entry site (IRES) 
elements. One of the disadvantages of gamma-retroviral vectors is their inability to target 
non-dividing cells. Successful cell transduction is completely dependent on the breakdown 
of the nuclear membrane during mitosis (Roe et al., 1993). In contrast, lentiviral vectors, 
which are mostly derived from the HIV-1 genome, are able to integrate into both dividing 
and non-dividing cells (Lewis et al., 1992; Lewis & Emerman, 1994). Compared with 
gamma-retroviral vectors, lentiviral vectors have the capacity to incorporate larger 
transgenes, up to 10 kilobases, although vector titers decrease when using larger inserts 
(Matrai et al., 2010). The integration of retroviral vectors into the cell genome results in the 
stable and permanent expression of the transgene, which is transferred to all daughter cells 
during cell division. Therefore, retrovirally transduced oncogene expressing cells resemble 
cancer cells in that they pass their oncogenic alterations down to all progeny. However, 
during integration into the genome there is a risk of insertional mutagenesis (Baum, 2007). 
This must be kept in mind while analyzing the potential oncogenic effects of a transgene 
delivered by retroviral vectors. In general, gamma-retro as well as lentiviral vectors 
integrate into transcriptional units. Gamma-retroviruses tend to integrate either upstream or 
downstream of the start of transcriptional units (Wu et al., 2003), while lentiviral vectors 
integrate randomly within a transcriptional unit (Naldini et al., 2006). During retroviral 
integration into the genome of a cell, there is a risk of proto-oncogene activation close to the 
integration site of the vector driven by either the enhancer element or the promoter 
sequences present in the U3 region of the viral long terminal repeats (LTRs). Deletion of the 
U3 region within the LTRs and the insertion of an internal enhancer/promoter result in the 
formation of self-inactivating (SIN) vectors with the reduced risk of cellular oncogene 
activation (Yu et al., 1986). Retroviral particle production and transduction procedures 
represent convenient routine methods, which can be carried out in any laboratory with the 
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appropriate laboratory biosafety level. For safety reasons, genes required for the assembly 
of the viral particles, gag, pol and env, are expressed from separate, so-called helper 
plasmids. In contrast to the expression vector, which codes for the gene of interest, the 
helper plasmids do not contain coding sequences for the packaging signal. Therefore, 
transcribed RNAs from the helper plasmids are not incorporated into the virus particle. 
With these replication defective retroviral particles, only a single round of transduction is 
possible. Thus, the risk of generating replication competent virus particles during 
production is greatly reduced. Retroviral transduction efficacy can be improved by 
concentrating the viral particles via ultracentrifugation (Kanbe & Zhang, 2004; Naldini et 
al., 1996). Gamma-retroviral particles can be preloaded onto RetroNectin-coated surfaces. 
RetroNectin, a recombinant peptide consisting of a mixture of fragments of the fibronectin 
molecule, co-localizes the viral particles and target cells into close proximity, thereby 
strongly increasing the efficiency of transduction (Hanenberg et al., 1996). A standard 
protocol for routine gamma-retroviral particle production and transduction of suspension 
cells is provided in Table 1. Expression of the gene of interest is usually coupled to the 
expression of a marker gene. This allows for immediate determination of the viral 
transduction efficacy as well as for the identification of transduced cells for the 
measurement of proliferation, differentiation and cell death. EGFP is the most commonly 
used marker protein, which exhibits a bright green fluorescence after laser excitation at 
488 nm. Enrichment of vector-transduced fluorescent-labeled cells can be performed by 
fluorescence activated cell sorting (FACS). The usage of drug-selectable marker genes, 
such as neomycin and puromycin, represents another method used to obtain pure 
populations of transduced cells. Cellular expression of more than one transgene by 
retroviral vectors can be accomplished by a variety of strategies (Figure 1).  
The inclusion of an internal promoter allows for the expression of a second transgene 
when one transgene is expressed from the vector 5´-LTR. However, this approach also 
carries the risk of promoter interference with the vector LTR during retroviral particle 
production, thereby reducing vector titers and expression levels of the GOI (de Felipe et 
al., 1999). Another commonly employed strategy is the expression of two separate genes 
from one single transcript using the IRES element derived from the picornavirus 
(Gallardo et al., 1997). The IRES element allows for the initiation of mRNA translation in a 
5’ cap-independent manner (Mountford & Smith, 1995). However, expression levels of the 
two genes usually differ significantly. Typically, the gene located downstream is 
expressed at a level ten times lower than that of the other gene (Mizuguchi et al., 2000). 
The gene of interest and the marker gene can be fused to increase their stability and to 
allow for expression from one promoter. However, fusing two transgenes can result in 
functional restriction of the proteins caused by the fusion. Therefore, a short, flexible 
linker should be used to connect the proteins (Robinson & Sauer, 1998). Repeats of small 
side chain amino acids, such as glycine, serine and alanine, are well suited for the creation 
of linker sequences. The expression of two separate transgenes in equimolar amounts can 
be accomplished using self-cleaving 2A peptides, originating from the foot-and-mouth 
disease virus (Ryan et al., 1991). The 2A peptide sequence disrupts the peptide bond 
formation via a ribosomal skip mechanism, which releases the polypeptide from the 
translational complex and allows the production of the downstream translation product 
(Donnelly et al., 2001).  
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 For retroviral vector particle production subconfluent (80%) 
adherent cell lines (e.g. HEK293T, HeLA) are co-transfected with 
the retroviral expression construct and the appropriate helper 
plasmids 
 6 hours (or overnight) after transfection, exchange the appropriate 
medium for the target cells 
 24 hours later, harvest the viral supernatant: centrifuge the viral 
supernatant at 1.500 rpm to pellet cell debris and filtrate the 
supernatant (0.22 m filter) 
 Virus supernatant is ready for transduction or can be stored at –
80°C for several months 




 One day before transduction (at least 6 hours), add 500 µl 
RetroNectin (RN) solution (50 µg/ml) to each well of a 24-well 
plate (non-tissue culture treated) and incubate overnight at room 
temperature 
 The next day, discard the RN solution (reusable up to 8 times), add 
1 ml stop solution (1xPBS+2% BSA) and incubate for 30 minutes at 
room temperature  
 Discard the stop solution, rinse 1x with HBSS solution and 1x with 
1xPBS 
 Coated plates are ready for virus preload (RN coated plates can be 
stored in 4°C with PBS) 
Step 3:  
Preload of 
viral particles 
 Quickly defrost the virus supernatant and dilute as necessary 
 Discard the 1xPBS and add the viral supernatant with the 
appropriate multiplicities of infection (MOI) 
 Centrifuge at 3000 rpm at 4°C for 20-25 minutes 
 Discard the viral supernatant and repeat the preload at least 3 
times, each with the appropriate volume (minimum: 500 l) 
Step 4:  
Transduction 
of target cells 
 Remove the remaining viral supernatant before adding the cells 
 Count the cells and dilute the cells to a concentration of 7.5x105 
cells/ml in the appropriate culture medium  
 Add 500 µl (minimum) cell suspension to each well and incubate 
at 37°C and 5% CO2 for at least 8 hours (or overnight) 
 Optional: The addition of protamine sulfate (4 µg/ml) might 
increase the transduction efficiency 
 Prepare a second RN coated 24-well plate and repeat the preload 
and transduction procedure for a second, third or fourth 
transduction (max. 2 transductions per day) 
 8 hours after the final transduction, exchange the medium and 
transfer the transduced cells into a fresh tissue-coated 24-well plate 
without RN 
 Optional: Wash the plate 3x with 1x PBS to collect the remaining 
cells from the plate  
Table 1. Vector particle production and transduction standard protocol for suspension cells 
with gamma-retroviral vectors. 
 




Fig. 1. Retroviral co-expression vector constructs, including eGFP as a marker gene. The 
depicted co-expression vectors are based on a standard 5’-LTR driven retroviral expression 
vector (top). 2A elements allow for co-expression of several GOI at equimolar levels. For 
intracellular stabilization, the GOI can be fused to eGFP. An internal promoter, e.g. the CMV 
promoter, drives GOI 2 expression independently of GOI 1. LTR, long terminal repeats; 
GOI, gene of interest; IRES, internal ribosomal entry site; 2A, 2A peptide sequence; eGFP, 
enhanced green fluorescent protein; CMV, cytomegalovirus. 
In the context of the MSCV-based retroviral vectors, it has been shown that coupling four 
transgenes via three different 2A peptide cleavage sequences can generate four separate 
proteins both in vitro and in vivo. One restriction with this system is that the small remaining 
2A-tag at the N-terminal end of the protein may potentially affect protein function 
(Szymczak et al., 2004). Therefore, proper cleavage and function of the individual proteins 
should be carefully verified. Table 2 summarizes the advantages and disadvantages of the 
different expression cassettes used for the co-expression of two genes of interest.  
The lentiviral gene ontology (LeGO) vectors represent a useful collection of state-of-the-art 
expression vectors for functional gene analysis. These vectors contain the retroviral 
enhancer/promoter of the spleen focus-forming virus, which has a broad and high 
expression pattern. LeGO expression vectors are available with a wide spectrum of different 
fluorescent markers, e.g. Cerulean, eGFP, tdTomato and mCherry, which are expressed in 
combination with the gene of interest via IRES elements. LeGO vectors that contain 
fluorescent marker genes linked via 2A peptides to different drug-selectable genes, e.g. 
blasticidin, hygromycin, neomycin, puromycin or zeocin, are also available. Furthermore, 
the expression cassettes of these LeGO vectors are flanked by loxP sites, which allows for 
displacement of the transgene after introduction of the CRE recombinase (Weber, 2007; 
Weber et al., 2008; Weber et al., 2010). 
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 Prepare a second RN coated 24-well plate and repeat the preload 
and transduction procedure for a second, third or fourth 
transduction (max. 2 transductions per day) 
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with gamma-retroviral vectors. 
 




Fig. 1. Retroviral co-expression vector constructs, including eGFP as a marker gene. The 
depicted co-expression vectors are based on a standard 5’-LTR driven retroviral expression 
vector (top). 2A elements allow for co-expression of several GOI at equimolar levels. For 
intracellular stabilization, the GOI can be fused to eGFP. An internal promoter, e.g. the CMV 
promoter, drives GOI 2 expression independently of GOI 1. LTR, long terminal repeats; 
GOI, gene of interest; IRES, internal ribosomal entry site; 2A, 2A peptide sequence; eGFP, 
enhanced green fluorescent protein; CMV, cytomegalovirus. 
In the context of the MSCV-based retroviral vectors, it has been shown that coupling four 
transgenes via three different 2A peptide cleavage sequences can generate four separate 
proteins both in vitro and in vivo. One restriction with this system is that the small remaining 
2A-tag at the N-terminal end of the protein may potentially affect protein function 
(Szymczak et al., 2004). Therefore, proper cleavage and function of the individual proteins 
should be carefully verified. Table 2 summarizes the advantages and disadvantages of the 
different expression cassettes used for the co-expression of two genes of interest.  
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Table 2. Overview of expression cassette elements for co-expression of two genes of interest. 
To accurately characterize oncogene activity it is important to have the ability to selectively 
induce and terminate oncogene expression. This is particularly important if the delivered 
gene product is toxic at high concentrations. The regulation of gene expression can be 
achieved by using the tetracycline-controlled transactivator (tTA)-responsive promoter (Tet-
system), a prokaryotic inducible promoter system that is also applicable to mammalian cells 
(Gossen & Bujard, 1992). The Tet system comprises two components: one component that 
drives expression of the transactivator (tTA) and a second component that contains the 
(tTA)-responsive promoter element for transgene expression. In the first developed tet-off 
system, the transactivator binds to the promoter in the absence of tetracycline. The addition 
of tetracycline inhibits its binding, thereby resulting in inhibition of transgene expression 
(Gossen et al., 1995). To avoid constant tetracycline supplementation, a reverse system (‘tet-
on’ system) allows for transgene expression only in the presence of doxycycline, a 
tetracycline derivate (Gossen et al., 1995). Traditionally, transactivator and promoter 
components had to be introduced by two separate transduction steps to obtain inducible 
gene expression. The development of an ‘all-in-one’ vector system circumvents this 
complication. In this system, all components required for tet-regulated transgene expression 
have been inserted as a bidirectional expression cassette (Heinz et al., 2011). Another means 
of intracellular oncogene dosage control is the regulation at the protein level. With this type 
of expression control, the gene of interest can be fused to a small destabilizing domain, 
thereby mediating the intracellular destruction of the protein by targeting it for proteasomal 
degradation. Degradation of the fusion protein can be specifically blocked by cell 
membrane-permeable small molecules, which bind to and inhibit the destabilizing domain 
mediated degradation, thereby resulting in the accumulation of the expressed transgene 
(Banaszynski et al., 2006). 
3. Murine progenitor cells 
Murine hematopoietic stem and progenitor cells have been well characterized. To study 
these cell types, progenitor cells can be simply isolated from the bone marrow. After femora 
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and tibia preparation, bone marrow cells can be harvested by flushing the bones. Further 
purification of hematopoietic progenitor cells is typically carried out by ‘lineage depletion’. 
Using this method, differentiated ‘lineage positive’ cells, such as monocytes and 
macrophages, T- and B- cells, erythrocytes and granulocytes, are separated from their 
committed precursors, the ‘lineage negative’ fraction. Freshly isolated, complete bone 
marrow suspension cells are incubated with a mixture of magnetically labeled antibodies 
against cell surface markers for mature blood cells, typically B220, CD4, CD8, Gr-1, Mac-1 
and Ter-119. Separation of the lineage negative progenitor cell fraction is performed by 
passing the labeled and non-labeled cells through magnetic columns (Challen et al., 2009).  
Amongst all vertebrates, the murine hematopoietic system is the best characterized. For the 
subdivision of stem and progenitor cell populations, the LSK- and SLAM-markers have 
become widely accepted. LSK (lin-, Sca1+, c-kit+) cells lack the markers of mature blood cells 
and simultaneously express high levels of the stem cell markers, Sca1 and c-kit. As little as 
one hundred LSK cells have been shown to be sufficient for the long-term multilineage 
repopulation of lethally irradiated recipient mice (Okada et al., 1992). The LSK cell 
compartment can be further separated into hematopoietic stem cells (HSCs) and multipotent 
progenitors (MPPs) depending on their diverse expression pattern of the family of ‘signaling 
lymphocyte activation molecule’ (SLAM) receptors (Kiel et al., 2005). The SLAM cell surface 
marker, CD150, is exclusively expressed on HSCs, whereas CD244 is expressed by 
transiently reconstituting MPPs. CD34 and Flt3 expression patterns further allow for the 
discrimination between long term-HSC (LT-HSCs; CD34-/Flt3-) and short term HSCs (ST-
HSCs; CD34+/Flt3+) (Adolfsson et al., 2001; Osawa et al., 1996). ST-HSCs have a reduced 
self-renewal capacity for a restricted time compared with the life-long self-renewal capacity 
of LT-HSCs (Adolfsson et al., 2001; Morrison & Weissman, 1994; Yang et al., 2005). Because 
the murine hematopoietic system has been well characterized, with precisely classified and 
characterized stem and progenitor cell compartments, and simple precursor cell purification 
procedures have been established and optimized, murine hematopoietic progenitor cells are 
well suited for the functional analysis of oncogenic fusion genes and mutations associated 
with leukemia development.  
The cell transforming activity of a given leukemia-associated oncogene can be measured by 
performing an in vitro colony forming unit (CFU) assay. This assay allows for the 
quantification of colony forming progenitors and their iterative replating capacity. 
Hematopoietic progenitor cells expressing the gene of interest are plated in methylcellulose 
at low density. In general, normal progenitor cells only form colonies in the first round of 
plating. However, oncogene-expressing cells are able to confer serial replating capacity for 
several rounds of plating. For example, cells expressing the t(8;21) translocation product, 
AML1/ETO, are able to confer serial replating for up to 13 rounds of plating (Rhoades et al., 
2000). Transgene expressing murine progenitor cells can also be cultivated in liquid 
suspension cultures. Here, cytokines such as IL3, IL6 and SCF must be supplemented 
continuously. Under these ex vivo cultivation parameters specific for cell differentiation, 
proliferation and apoptosis can be measured under various cell culture conditions, such as 
serum or cytokine deprivation and hypoxic conditions, which imitate the hypoxic niches of 
the bone marrow.  
Gene modified precursor cells can be further examined in vivo in a mouse transplantation 
model. In this case, immediately after retroviral gene transfer, lineage depleted bone 
marrow cells stably expressing the oncogene of interest are transplanted into lethally 
irradiated syngeneic recipient mice. The transplantation is performed by injection of gene-
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gene product is toxic at high concentrations. The regulation of gene expression can be 
achieved by using the tetracycline-controlled transactivator (tTA)-responsive promoter (Tet-
system), a prokaryotic inducible promoter system that is also applicable to mammalian cells 
(Gossen & Bujard, 1992). The Tet system comprises two components: one component that 
drives expression of the transactivator (tTA) and a second component that contains the 
(tTA)-responsive promoter element for transgene expression. In the first developed tet-off 
system, the transactivator binds to the promoter in the absence of tetracycline. The addition 
of tetracycline inhibits its binding, thereby resulting in inhibition of transgene expression 
(Gossen et al., 1995). To avoid constant tetracycline supplementation, a reverse system (‘tet-
on’ system) allows for transgene expression only in the presence of doxycycline, a 
tetracycline derivate (Gossen et al., 1995). Traditionally, transactivator and promoter 
components had to be introduced by two separate transduction steps to obtain inducible 
gene expression. The development of an ‘all-in-one’ vector system circumvents this 
complication. In this system, all components required for tet-regulated transgene expression 
have been inserted as a bidirectional expression cassette (Heinz et al., 2011). Another means 
of intracellular oncogene dosage control is the regulation at the protein level. With this type 
of expression control, the gene of interest can be fused to a small destabilizing domain, 
thereby mediating the intracellular destruction of the protein by targeting it for proteasomal 
degradation. Degradation of the fusion protein can be specifically blocked by cell 
membrane-permeable small molecules, which bind to and inhibit the destabilizing domain 
mediated degradation, thereby resulting in the accumulation of the expressed transgene 
(Banaszynski et al., 2006). 
3. Murine progenitor cells 
Murine hematopoietic stem and progenitor cells have been well characterized. To study 
these cell types, progenitor cells can be simply isolated from the bone marrow. After femora 
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and tibia preparation, bone marrow cells can be harvested by flushing the bones. Further 
purification of hematopoietic progenitor cells is typically carried out by ‘lineage depletion’. 
Using this method, differentiated ‘lineage positive’ cells, such as monocytes and 
macrophages, T- and B- cells, erythrocytes and granulocytes, are separated from their 
committed precursors, the ‘lineage negative’ fraction. Freshly isolated, complete bone 
marrow suspension cells are incubated with a mixture of magnetically labeled antibodies 
against cell surface markers for mature blood cells, typically B220, CD4, CD8, Gr-1, Mac-1 
and Ter-119. Separation of the lineage negative progenitor cell fraction is performed by 
passing the labeled and non-labeled cells through magnetic columns (Challen et al., 2009).  
Amongst all vertebrates, the murine hematopoietic system is the best characterized. For the 
subdivision of stem and progenitor cell populations, the LSK- and SLAM-markers have 
become widely accepted. LSK (lin-, Sca1+, c-kit+) cells lack the markers of mature blood cells 
and simultaneously express high levels of the stem cell markers, Sca1 and c-kit. As little as 
one hundred LSK cells have been shown to be sufficient for the long-term multilineage 
repopulation of lethally irradiated recipient mice (Okada et al., 1992). The LSK cell 
compartment can be further separated into hematopoietic stem cells (HSCs) and multipotent 
progenitors (MPPs) depending on their diverse expression pattern of the family of ‘signaling 
lymphocyte activation molecule’ (SLAM) receptors (Kiel et al., 2005). The SLAM cell surface 
marker, CD150, is exclusively expressed on HSCs, whereas CD244 is expressed by 
transiently reconstituting MPPs. CD34 and Flt3 expression patterns further allow for the 
discrimination between long term-HSC (LT-HSCs; CD34-/Flt3-) and short term HSCs (ST-
HSCs; CD34+/Flt3+) (Adolfsson et al., 2001; Osawa et al., 1996). ST-HSCs have a reduced 
self-renewal capacity for a restricted time compared with the life-long self-renewal capacity 
of LT-HSCs (Adolfsson et al., 2001; Morrison & Weissman, 1994; Yang et al., 2005). Because 
the murine hematopoietic system has been well characterized, with precisely classified and 
characterized stem and progenitor cell compartments, and simple precursor cell purification 
procedures have been established and optimized, murine hematopoietic progenitor cells are 
well suited for the functional analysis of oncogenic fusion genes and mutations associated 
with leukemia development.  
The cell transforming activity of a given leukemia-associated oncogene can be measured by 
performing an in vitro colony forming unit (CFU) assay. This assay allows for the 
quantification of colony forming progenitors and their iterative replating capacity. 
Hematopoietic progenitor cells expressing the gene of interest are plated in methylcellulose 
at low density. In general, normal progenitor cells only form colonies in the first round of 
plating. However, oncogene-expressing cells are able to confer serial replating capacity for 
several rounds of plating. For example, cells expressing the t(8;21) translocation product, 
AML1/ETO, are able to confer serial replating for up to 13 rounds of plating (Rhoades et al., 
2000). Transgene expressing murine progenitor cells can also be cultivated in liquid 
suspension cultures. Here, cytokines such as IL3, IL6 and SCF must be supplemented 
continuously. Under these ex vivo cultivation parameters specific for cell differentiation, 
proliferation and apoptosis can be measured under various cell culture conditions, such as 
serum or cytokine deprivation and hypoxic conditions, which imitate the hypoxic niches of 
the bone marrow.  
Gene modified precursor cells can be further examined in vivo in a mouse transplantation 
model. In this case, immediately after retroviral gene transfer, lineage depleted bone 
marrow cells stably expressing the oncogene of interest are transplanted into lethally 
irradiated syngeneic recipient mice. The transplantation is performed by injection of gene-
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modified cells into the tail vein or the retro-orbital sinus of recipient mice (Larochelle et al., 
1995). For successful hematopoietic rescue, transplanted cells must reach the appropriate 
milieu in the bone marrow niches, which supports their proliferation and differentiation; 
this cell migration process is referred to as ‘homing’ (Szilvassy et al., 1999). To analyze 
disease progression in mice following the transplantation of progenitor cells body weight 
and blood profile values must be documented carefully over time. If transplanted mice 
develop any symptoms of leukemia, e.g. sudden body weight reduction, increasing 
peripheral leukocyte counts or poor general health conditions, they should be sacrificed and 
analyzed. Blood cells isolated from the periphery, spleen and bone marrow compartment 
can be studied separately. Flow cytometric analysis conveniently allows for the detection of 
oncogene expressing blood cells by discerning the expression of the fluorescence marker 
proteins. Gene marked cells can be examined for cellular differentiation (CD differentiation 
marker), the proliferation/cell cycle profile and apoptosis by AnnexinV-staining, for 
example. FACS based methods allow for the parallel analysis of transduced and non-
transduced cells, using the latter as the internal experimental control. Transgene expression 
of leukemic cells must be analyzed by RT-PCR and western immunoblotting, which assesses 
mRNA and protein levels, respectively. There are highly specific antibodies that can detect 
epitope-tagged oncoproteins, e.g. Ha- or Flag-tagged proteins, even at very low expression 
levels (Terpe, 2003). To exclude the potential oncogenic effects of vector-mediated 
insertional mutagenesis, clonality and integration site analysis must be performed carefully. 
The oncogene activity of the expressed transgene can be accurately validated by analyzing 
the downstream signal transduction pathways of the cell. For example, phosphorylated 
STAT5 and CRKL are regarded as downstream indicators of oncogenic BCR/ABL signaling. 
Bone marrow and spleen, which are the target organs of leukemic origin, and peripheral 
blood must be analyzed for the presence of immature blast cells. This can be carried out by 
conventional blood smear and flow cytometric analysis. For organ histology, samples of 
each organ, including the spleen, liver, lymph nodes and thymus, are transferred into 
paraffin, sectioned and examined. Hematoxylin and eosin are the most commonly used 
staining solutions in histology for light microscopical analysis. A final validation of the 
leukemia must be demonstrated by re-transplantating the leukemic blood cells into 
secondary lethally irradiated recipient mice. In these secondary transplanted mice, leukemia 
onset should appear much earlier than in primary recipients. In 2002, Kogan et al published 
the ‘Bethesda proposals for the classification of hematopoietic neoplasms in mice’ (Kogan et 
al., 2002). As with the World Health Organization (WHO) classification of human disorders, 
theses proposals utilize morphologic, immunophenotypic, clinical, biological and genetic 
characteristics to classify neoplasms.  
Both methods, the colony-forming assay and the mouse transplantation model are 
commonly used techniques for the investigation of the transforming potential of oncogenes 
in leukemia (Figure 2).  
The following examples illustrate both the genetic and biochemical approaches utilizing 
murine hematopoietic progenitor cells for leukemia modeling.  
The acute promyelocytic leukemia (APL) associated t(15;17) translocation product, 
PML/RAR, is one of the most studied fusion proteins associated with AML (Puccetti & 
Ruthardt, 2004). In the clinical setting, APL patients not only respond well to ‘all trans 
retinoic acid’ (ATRA) therapy, which has been well documented (Huang et al., 1988), but 
also benefit from treatment with arsenic trioxide (Chen et al., 1997), which exerts a profound 
anti-cancer effect by inducing the degradation of the PML/RAR oncoprotein. Retroviral 
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expression of PML/RAR in murine progenitor cells efficiently induces leukemia 
development in transplanted lethally irradiated recipient mice (Minucci et al., 2002). The 
efficacy of arsenic trioxide and ATRA has been recapitulated in PML/RAR mouse models 
displaying the impressive anti-leukemia effects of both substances (Rego et al., 2000). 
Furthermore, in transplantation models based on ATRA-resistant APL cell lines, treatment 
with arsenic trioxide significantly decreases tumor formation (Kinjo et al., 2000). Zhang et al 
have further showed that arsenic trioxide functions by directly binding to PML/RAR. The 
researchers identified cysteine residues within the PML portion that are directly bound by 
arsenic trioxide, which triggered SUMOylation and subsequent degradation of the 
oncoprotein (Zhang et al., 2010).  
 
 
Fig. 2. Functional analysis of gene-modified murine/human hematopoietic progenitor cells. 
Experimental procedures include cloning of the retroviral expression vector, viral particle 
production, hematopoietic progenitor cell isolation, transduction and functional analysis in 
methylcellulose assays, liquid cultures and murine syngeneic or xenogeneic mouse 
transplantation models. GOI, gene of interest; MSCV, murine stem cell virus; LTR, long 
terminal repeats; lin-, lineage negative. 
Other reports have described that oncogene expression experiments involving murine 
progenitor cells supported the clinical finding reporting a highly leukemogenic splice 
variant of the familiar AML1/ETO fusion gene resulting from the translocation t(8;21). 
Several groups have shown that the full length AML1/ETO protein does not lead to the 
development of leukemia when transplanting LSK bone marrow cells expressing 
AML1/ETO into syngeneic mice (de Guzman et al., 2002). However, in similar 
transplantation experiments performed by Yan and colleagues, one mouse developed 
leukemia 14 weeks after bone marrow transplantation. Further analysis showed that a C-
terminal truncated AML1/ETO protein was expressed in this mouse due to a one-base pair 
insertion into the full length AML1/ETO gene. Subsequently, the cloning and creation of 
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mice expressing the truncated protein by transplantation of transduced progenitor cells 
again revealed a rapid leukemia development (Yan et al., 2004). Consequently, these results 
led to the investigation and identification of a naturally occurring splice variant of 
AML1/ETO in t(8;21) patients by sophisticated gene expression analysis of patient material. 
This splice variant, termed AML1/ETO9A, is almost structurally identical to the truncated 
form expressed in the leukemic mouse. Expression of this newly discovered splice isoform 
in mice also induced rapid leukemia development (Yan et al., 2006). In conclusion, these 
oncogene expression experiments using murine progenitor cells led to the clinical 
identification of a potent oncogenic AML1/ETO splice variant. Further experiments must be 
performed to understand whether the AML1/ETO splice isoform is the driving oncogene in 
human t(8;21) leukemia cells. 
The usage of oncogene expressing vectors has also facilitated the understanding of the 
protein domain structure-function relationship. Biophysical and biochemical experiments 
have been used to identify highly conserved domains within several oncoproteins, which 
might represent valuable target structures for molecular intervention. This has been 
demonstrated with the AML1/ETO fusion protein. Here, a central region, the nervy 
homology region 2 (NHR2), was found to play an essential role in the leukemogenic activity 
of the fusion protein. Analysis of the crystal structure revealed a tetrameric formation that is 
essential for the serial colony formation capacity of murine progenitor cells in 
methylcellulose assays (Liu et al., 2006). By performing additional bioinformatic molecular 
modeling analyses, five amino acids were identified within the large NHR2 tetramer-
interface that are important for oligomer formation. Substitution of these critical residues led 
to the conversion of tetramers into dimers with the complete loss of the transforming 
abilities of AML1/ETO. Transplantation of retroviral infected murine bone marrow cells 
expressing the AML1/ETO protein harboring these five substitutions showed that these 
amino acids play a critical role in transformation, as the mice failed to develop leukemia. 
Interestingly, the identified amino acids are clustered in one region at the top of the NHR2 
dimer surface, thereby representing a potential target site for molecular intervention 
(Wichmann et al., 2010). These findings, which reveal the molecular determinants of 
oncogene activity, are the result of a productive combination of bioinformatics, biochemical 
and cell-biological analyses. Furthermore, proof of concept of oncogene targeting was 
demonstrated using a synthetic oligomerization domain. This domain was integrated into 
the AML1/ETO fusion gene, thereby replacing the NHR2 tetramer domain. Specific 
inhibitors that disrupt the oligomerization of this synthetic domain within AML1/ETO 
completely blocked the replating capacity of retrovirally transduced AML1/ETO expressing 
murine progenitor cells (Kwok et al., 2009).  
By expressing leukemia fusion genes in murine cells, one can assess exactly which gene 
product from a balanced translocation, which often generates two different reciprocal fusion 
genes, is responsible for driving the leukemic activity. Bursen and colleagues have reported 
interesting findings regarding the function of the reciprocal fusion proteins, AF4/MLL and 
MLL/AF4, which are generated by the chromosomal translocation t(4;11) in high-risk infant 
acute mixed lineage leukemia. They analyzed the leukemia-inducing capacity of these two 
fusion genes in mice by transplantation of retrovirally transduced Lin-/Sca1+ cells 
expressing either one or both of the reciprocal fusion genes. They could show that 
expression of AF4/MLL alone was sufficient to promote leukemia development, while the 
reciprocal translocation, MLL/AF4, completely lacked leukemogenic potential (Bursen et al., 
2010).  
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4. The human CD34+ progenitor cell system 
Human blood progenitor cells are characterized by the high expression levels of the cell 
surface marker CD34 and the absence of CD38 expression (CD34+/CD38-). CD34 is a 
member of the single-pass transmembrane sialomucin protein family, which is expressed in 
early hematopoietic and vascular-associated tissues; however, little is known about its exact 
biological function (Furness & McNagny, 2006). There are a variety of ways to obtain 
hematopoietic CD34+ cells from the human body. The cells can be isolated from the 
peripheral blood by leukapheresis after stimulation and mobilization of the bone marrow 
precursors with G-CSF (granulocytic colony stimulating factor). Bone marrow aspiration 
represents the classical but invasive isolation method, which also allows for the isolation of 
large numbers of CD34+ cells. A third option involves the usage of placental derived cord 
blood cells of which the quality/stemness and engraftment potential are superior to that of 
adult CD34+ stem cells (Hao et al., 1995). The efficient enrichment of human hematopoietic 
CD34+ cells can be achieved by immunomagnetic cell sorting, which represents a standard 
and convenient method in laboratory work (Clarke & Davies, 2001). Magnetic labeled CD34-
antibodies are used to recover high-purity populations of CD34+ cells by passing cells 
through magnetic columns. Isolated CD34+ cells can then be used for clinical and 
experimental purposes. For transgene expression studies, the cells can be manipulated by 
retroviral transduction immediately after recovery or after a short pre-cultivation in a 
cytokine cocktail, which usually contains IL-3, IL6 and SCF for cell cycle activation. Like the 
murine system, transduced human CD34+ cells can be propagated in vitro in 
methylcellulose assays for colony formation as well as in long-term liquid cultures used to 
assess self-renewal and proliferation/expansion capacities (Figure 1). Furthermore, human 
CD34+ cells expressing leukemic gene products can be transplanted into severe combined 
immunodeficient (NOD/SCID) mice (xenotransplants). Additionally, the NOG (NOD/Shi-
scid/IL-2Rγnull) mice accept heterologous transplanted cells more easily than any other type 
of immunodeficient nude or NOD/SCID mice. Therefore, the NOG mouse system is a 
highly efficient recipient model for the engraftment, proliferation and differentiation of 
human cells (Ito et al., 2002). 
The transformation of human cells requires additional genetic alterations when compared 
with their murine counterparts (Hahn et al., 1999; Rangarajan & Weinberg, 2003). This is 
reflected by the observation that singular expression of several oncogenes induces leukemia 
in the murine system but fails to transform human CD34+ cells in the NOD/SCID 
humanized leukemia mouse model. Further evidence of this concept has been demonstrated 
by gene expression analysis of healthy individuals. Here, oncogenes such as BCR/ABL and 
AML1/ETO have been frequently detected in individuals completely lacking any sign of 
disease (Song et al., 2011). As CD34+ cells represent the human hematopoietic 
stem/progenitor cell population, these cells can be regarded as appropriate target cells used 
to study the biological effects of oncogenes in human leukemia development. 
The following passages provide an overview of recent experiments addressing the 
leukemogenic activity of several myeloid leukemia associated oncogenes expressed alone or 
in combination in human hematopoietic CD34+ progenitor cells. In all cases, genes were 
delivered using gamma-retroviral vectors co-expressing the marker genes eGFP or dNGFR 
(truncated nerve growth factor receptor), which allowed for the convenient detection of 
gene-modified cells by FACS analysis. 
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mice expressing the truncated protein by transplantation of transduced progenitor cells 
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Grignani et al have reported that ectopic expression of PML/RAR in human CD34+ ex vivo 
cultures rapidly induced the cellular differentiation of progenitor cells towards the 
promyelocytic stage, followed by a block in further terminal differentiation into 
granulocytes, which resembled typical features of primary human acute promyelocytic 
leukemia (Grignani et al., 2000). In cytokine deprived liquid cultures, PML/RAR 
expressing cells survived and continued to expand, whereas control cells stopped 
proliferation and died by apoptosis. The terminal differentiation block induced by 
PML/RAR could be overcome by treatment with ATRA, a drug that has dramatically 
improved the overall survival of APL patients. They further demonstrated that a mutation 
of the N-CoR repressor binding interface within the PML portion of the fusion protein 
completely disrupted the observed biological effects, thereby suggesting that N-CoR 
triggered transcriptional repression is an essential prerequisite for PML/RAR oncogene 
activity in human hematopoietic progenitor cells.  
Among the AML oncogenes, hyperactive tyrosine kinases play a major role in disease 
development and have gathered much attention since the kinase inhibitor imatinib has been 
proven to be highly beneficial for BCR/ABL positive CML patients (Druker et al., 1996; 
Sawyers et al., 2002; Brandts et al., 2007). Chung and colleagues retrovirally expressed a 
related constitutive active tyrosine kinase, FLT3-ITD, which is frequently found in AML 
patient samples associated with poor prognosis (Gilliland & Griffin, 2002). Stable expression 
of FLT3-ITD conferred a strong short-term proliferative signal in human CD34+ cells with 
enhanced erythropoiesis for two weeks after transduction ex vivo. The cells were blocked in 
terminal differentiation and colony formation was enhanced when compared with control 
cells. These effects could be partially substituted by expression of a constitutive active 
STAT5 mutant, a major downstream target of the hyperactive FLT3-ITD kinase. Moreover, 
FLT3-ITD triggered effects that could be blocked via inhibition with the FLT3-inhibitor 
tyrphostin (Chung et al., 2005). Despite these significant effects, FLT3-ITD transgene-
expressing CD34+ cells are neither able to expand further in ex vivo cultures nor able to 
induce leukemia in the NOD/SCID mouse transplantation model.  
Stable ectopic expression of several leukemogenic fusion genes resulting from chromosomal 
translocations leads to enhanced ex vivo CD34+ cell expansion for up to several months 
(Abdul-Nabi et al., 2010). This has previously been shown for the t(8;21) associated fusion 
protein AML1/ETO, which is capable of expanding human CD34+ cells ex vivo for several 
months with a cumulative cell expansion of more than 1015-fold. Retroviral expression of 
AML1/ETO resulted in a sustained proliferation potential using a cytokine cocktail that 
included IL3, IL6, SCF, FLT3, GM-CSF, TPO and EPO, all at low concentrations. The cells 
display the typical differentiation block as observed in myeloid blast cells and grow out 
from a mixed culture of transduced and non-transduced cells. Even after several weeks in ex 
vivo culture, the cells are capable of colony formation in methylcellulose assays and, more 
importantly, of engraftment into immunodeficient NOD/SCID mice (Mulloy et al., 2003; 
Mulloy et al., 2002). Phenotypically, a subpopulation of the cells continues to express CD34, 
while the majority of the cells express the myeloid specific markers CD13 and CD33, in the 
absence of erythroid markers. Continuous expansion of the cells completely depends on the 
CD34+ subgroup. Erythroid differentiation was shown to be blocked by the AML1/ETO 
fusion protein via direct inhibition of GATA1 transcription factor activity (Choi et al., 2006). 
However, expression of AML1/ETO does not lead to leukemia development in transplanted 
immunodeficient NOD/SCID mice, suggesting that additional genetic hits must occur for 
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full-blown AML development. Similar results were obtained from analysis of the inv(16) 
fusion protein CBFB/MYH11. Expression of this fusion gene also caused enhanced 
proliferation and expansion of CD34+ cells over several months with retention of the 
engraftment potential in NOD/SCID mice. However, as also observed with AML1/ETO, 
transplanted mice do not develop leukemia (Wunderlich et al., 2006). Therefore, both 
oncogenes confer a preleukemic status and subsequent alterations are required for the 
transition to overt leukemia. 
To decipher the genetic signature of AML, Abdul-Nabi and colleagues have assessed 
various AML-associated fusion proteins for their ability to enhance CD34+ cell expansion ex 
vivo and subsequently analyzed their gene expression profiles (Abdul-Nabi et al., 2010). In 
this study, experiments were also performed with gamma-retroviral vectors expressing the 
fusion genes AML1/ETO, PML/RAR, MLL/AF9 and NUP98/HOXA9 together with 
eGFP. To identify key target genes responsible for the expansion of CD34+ cells the authors 
performed gene array analysis of FACS-sorted eGFP+ cells expressing the indicated 
oncogenes, which identifies the induced and repressed target genes during the ex vivo 
selection process. One interesting candidate gene that was shown to be specifically 
upregulated due to both AML1/ETO and PML/RAR expression was the p53-inhibiting 
molecule MDM2. The authors could further show that activation of the gatekeeper protein 
p53, by blocking the MDM2-p53 protein-protein interaction with the small molecule 
compound Nutlin-3, was sufficient to completely block AML1/ETO induced selection and 
expansion of CD34+ progenitor cells. Therefore, Nutlin-3 is proposed to function as an 
inhibitor for AML1/ETO positive leukemias by reactivating p53 and consecutively 
eliminating the leukemic cells via the induction of apoptosis. Two independent groups have 
shown that retroviral expression of the NUP98/HOXA9 fusion gene, which is found in 
myelodysplastic syndrome (MDS) and AML patients, resulted in a similar outgrowth of 
transgene expressing cells with maintenance of self-renewal potential ex vivo and increased 
engraftment capacity in NOD/SCID mice (Chung et al., 2006; Takeda et al., 2006). This 
outgrowth was accompanied by high levels of HOX gene expression, a typical feature for 
this leukemia entity.  
Regardless of their remarkable ex vivo cell expansion properties, the AML associated gene 
products described above, PML/RAR, FLT3-ITD, NUP98/HOXA9 and AML1/ETO, were 
not able to independently induce leukemia in transplanted NOD/SCID mice. Therefore, it is 
likely that additional genetic alterations are required for full cellular transformation in AML. 
In this regard it was shown that oncogenic RAS signaling, triggered by N-RasG12D 
overexpression, does increase AML1/ETO engraftment capacity in NOD/SCID mice but is 
still not sufficient to overcome the leukemia onset defect in the NOD/SCID mouse model 
(Chou et al., 2011).  
Interestingly, MLL rearrangements are typically found in aggressive infant or therapy 
related leukemias (Aplan, 2006). In contrast to AML derived gene products, ectopic 
expression of either MLL/AF9 or MLL/ENL mixed-lineage leukemia fusion genes, as a 
single genetic event, results in the development of myeloid or lymphoid leukemias in the 
NOD/SCID mouse model approximately 100 days after transplantation (Barabe et al., 2007; 
Wei et al., 2008). Morphological analysis has revealed that AML and B-ALL leukemias are 
associated with both MLL rearrangements. Remarkably, ex vivo expanded cells gave rise to 
leukemia in NOD/SCID mice, even after 70 days of in vitro culture prior to transplantation 
in sublethally irradiated mice. The reasons for the striking differences between AML and 
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MLL fusion genes in their ability to induce leukemia onset in NOD/SCID mice are 
completely unknown. A direct comparison of deregulated genes may reveal which 
additional pathways are activated in MLL leukemic human CD34+ cells. 
Recently, a report was published describing a true oncogenic cooperativeness in human 
CD34+ cell expansion and leukemia induction in NOD/SCID mice (Rizo et al., 2010). The 
authors convincingly have shown that retroviral co-expression of the CML associated 
oncogene, BCR/ABL, and the polycomb ring finger oncogene, BMI1, leads to leukemia 
induction within 4-5 months after transplantation. The isolated human leukemia cells were 
re-transplantable into secondary recipient mice, which induced leukemia with a shortened 
latency. In vitro, the co-expression of both oncogenes in human CD34+ cells allowed for the 
establishment of myeloid and lymphoid long-term cultures with self-renewing properties. 
This report also describes a series of valuable cell culture methods for in vitro analysis of 
CD34+ cell proliferation and self-renewal. Finally, the authors have demonstrated that 
retroviral introduction of BMI1 into primary leukemia cells from CML chronic-phase 
patients elevated the proliferative capacity and self-renewal properties of the leukemia cells, 
while shRNA knockdown of BMI1 in blast crisis CML cells completely blocked their 
proliferation potential. These results highlight BMI1 as an attractive molecular target for 
blast crisis CML cells, which is especially important given the rates of BCR/ABL positive 
leukemic stem cell resistance to kinase inhibitors such as imatinib (Corbin et al., 2011). 
However, the exact molecular mechanisms of BCR/ABL and BMI1 oncogenic co-operation 
have to be addressed in further studies. 
In conclusion, human CD34+ blood progenitor cells represent a powerful cell biology tool 
used for the analysis of leukemogenic gene product activity. Methods of isolation and 
purification of CD34+ cells have significantly improved and are broadly available for 
researchers. The cells can be propagated ex vivo and oncogene activity can be analyzed for a 
wide range of biological parameters, including differentiation, proliferation, self-renewal, 
senescence and apoptosis, using standard cell biology methods. CD34+ suspension cells can 
be cultured ex vivo as liquid cultures or on stromal layer cells. With the possibility to 
transplant these cells into sublethally irradiated NOD/SCID mice this is an ideal model 
system to study the function of human leukemia-associated oncogenes. 
5. Conclusions 
Powerful retroviral expression vectors and standardized enrichment technologies, which are 
used for the isolation of hematopoietic precursor cells from the murine and human bone 
marrow compartment, efficiently enabled the accurate modeling of leukemia initiation and 
progression in the appropriate cell compartment. Currently available expression vectors 
allow for the simultaneous expression of several genes, including oncogenes, marker genes 
for detection and selection genes used to isolate modified cells, which represent practical 
tools for modeling leukemia progression in hematopoietic cells. Among the introduced 
strategies, the humanized mouse model based on human CD34+ precursor cell 
transplantation into NOD/SCID mice represents a credible model system to study human 
leukemia. As described here, the expression of single oncogenes such as BCR/ABL and 
AML1/ETO, which are primarily found in older patients, does not lead to leukemia 
development, implying that disease develops as a result of secondary mutations. In contrast, 
the expression of several MLL fusion proteins, which are typically found in younger 
patients, was found to be sufficient to trigger leukemia development with high penetrance. 
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In total, these approaches will lead to a better understanding of the genetic alterations that 
are required for the onset of cellular transformation. Furthermore, these studies have the 
potential to propel the development of effective drugs designed to eradicate leukemia cells. 
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MLL fusion genes in their ability to induce leukemia onset in NOD/SCID mice are 
completely unknown. A direct comparison of deregulated genes may reveal which 
additional pathways are activated in MLL leukemic human CD34+ cells. 
Recently, a report was published describing a true oncogenic cooperativeness in human 
CD34+ cell expansion and leukemia induction in NOD/SCID mice (Rizo et al., 2010). The 
authors convincingly have shown that retroviral co-expression of the CML associated 
oncogene, BCR/ABL, and the polycomb ring finger oncogene, BMI1, leads to leukemia 
induction within 4-5 months after transplantation. The isolated human leukemia cells were 
re-transplantable into secondary recipient mice, which induced leukemia with a shortened 
latency. In vitro, the co-expression of both oncogenes in human CD34+ cells allowed for the 
establishment of myeloid and lymphoid long-term cultures with self-renewing properties. 
This report also describes a series of valuable cell culture methods for in vitro analysis of 
CD34+ cell proliferation and self-renewal. Finally, the authors have demonstrated that 
retroviral introduction of BMI1 into primary leukemia cells from CML chronic-phase 
patients elevated the proliferative capacity and self-renewal properties of the leukemia cells, 
while shRNA knockdown of BMI1 in blast crisis CML cells completely blocked their 
proliferation potential. These results highlight BMI1 as an attractive molecular target for 
blast crisis CML cells, which is especially important given the rates of BCR/ABL positive 
leukemic stem cell resistance to kinase inhibitors such as imatinib (Corbin et al., 2011). 
However, the exact molecular mechanisms of BCR/ABL and BMI1 oncogenic co-operation 
have to be addressed in further studies. 
In conclusion, human CD34+ blood progenitor cells represent a powerful cell biology tool 
used for the analysis of leukemogenic gene product activity. Methods of isolation and 
purification of CD34+ cells have significantly improved and are broadly available for 
researchers. The cells can be propagated ex vivo and oncogene activity can be analyzed for a 
wide range of biological parameters, including differentiation, proliferation, self-renewal, 
senescence and apoptosis, using standard cell biology methods. CD34+ suspension cells can 
be cultured ex vivo as liquid cultures or on stromal layer cells. With the possibility to 
transplant these cells into sublethally irradiated NOD/SCID mice this is an ideal model 
system to study the function of human leukemia-associated oncogenes. 
5. Conclusions 
Powerful retroviral expression vectors and standardized enrichment technologies, which are 
used for the isolation of hematopoietic precursor cells from the murine and human bone 
marrow compartment, efficiently enabled the accurate modeling of leukemia initiation and 
progression in the appropriate cell compartment. Currently available expression vectors 
allow for the simultaneous expression of several genes, including oncogenes, marker genes 
for detection and selection genes used to isolate modified cells, which represent practical 
tools for modeling leukemia progression in hematopoietic cells. Among the introduced 
strategies, the humanized mouse model based on human CD34+ precursor cell 
transplantation into NOD/SCID mice represents a credible model system to study human 
leukemia. As described here, the expression of single oncogenes such as BCR/ABL and 
AML1/ETO, which are primarily found in older patients, does not lead to leukemia 
development, implying that disease develops as a result of secondary mutations. In contrast, 
the expression of several MLL fusion proteins, which are typically found in younger 
patients, was found to be sufficient to trigger leukemia development with high penetrance. 
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In total, these approaches will lead to a better understanding of the genetic alterations that 
are required for the onset of cellular transformation. Furthermore, these studies have the 
potential to propel the development of effective drugs designed to eradicate leukemia cells. 
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1. Introduction 
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) 
characterized by a severe bleeding tendency, accumulation of abnormal promyelocytes in 
the bone marrow and a reciprocal t(15;17) chromosomal translocation that fuses the gene 
encoding the promyelocytic leukemia protein (PML) to that encoding retinoic acid receptor 
alpha (RARA) (de Thé & Chen, 2010). During the past 30 years two therapeutic drugs have 
been introduced into the clinic that have dramatically improved the treatment outcome of 
this disease (Wang & Chen, 2008). The first of these components was all-trans retinoic acid 
(ATRA), a vitamin A derivative that significantly increased clinical remission and improved 
the 5-years disease-free survival rates from below 40% to more than 80% (Huang et al., 1988). 
The second drug was arsenic trioxide (ATO), a component that was discovered to be 
remarkably effective in treating APL as a single agent (Sun et al., 1992). Today, most 
hospitals employ ATRA in combination with chemotherapy as frontline therapy, while ATO 
is being used for refractory or relapsed patients. Recent clinical studies have also revealed a 
positive synergistic effect between the two drugs, suggesting that future therapy of newly 
diagnosed patients may involve a combination of the two reagents (Estey et al., 2006; Hu et 
al., 2009; Shen et al., 2004; Wang et al., 2004). 
The success of using ATRA and ATO in APL therapy appears to be linked to the ability of 
these drugs to interact with the fusion oncoprotein PML/RARA, which is produced by the 
APL-associated t(15;17) translocation, and that causes the disease. ATRA contacts a ligand 
binding domain present within the RARA moiety of this chimeric protein and promotes 
differentiation of APL cells along the granulocyte linage (Huang et al., 1988). ATO, on the 
other hand, has recently been shown to bind one or more cysteine rich motifs within the 
PML protein (Jeanne et al., 2010; Zhang et al., 2010) and contributes to the cure of APL 
through a mechanism that involves eradication of leukemic-initiating cells (LICs) (Nasr et 
al., 2008; Ito et al., 2008; Zheng et al., 2007).  
Due to the success of using ATRA and ATO in the clinic, and because of the ability of these 
drugs to promote clinical remission through a direct contact with PML/RARA, APL has 
become one of the most attractive model diseases for the development of targeted cancer 
therapy. The APL cure offers a proof of principle that a cancer can be cured through 
targeted inactivation of an oncoprotein, and it provides a rationale for the development of 
novel therapeutic strategies that target fusion oncoproteins produced by chromosomal 
translocations. In this chapter we will summarize the current knowledge of the biological 
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al., 2008; Ito et al., 2008; Zheng et al., 2007).  
Due to the success of using ATRA and ATO in the clinic, and because of the ability of these 
drugs to promote clinical remission through a direct contact with PML/RARA, APL has 
become one of the most attractive model diseases for the development of targeted cancer 
therapy. The APL cure offers a proof of principle that a cancer can be cured through 
targeted inactivation of an oncoprotein, and it provides a rationale for the development of 
novel therapeutic strategies that target fusion oncoproteins produced by chromosomal 
translocations. In this chapter we will summarize the current knowledge of the biological 
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properties of PML, RARA and PML/RARA with particular emphasis on tumorigenesis in 
APL patients and the molecular mechanisms that underlie the response to ATRA and ATO.  
2. APL treatment – a historical perspective  
2.1 The discovery of ATRA-based APL therapy 
APL was first characterized as a distinct clinical entity in 1957 (Hillestad, 1957). Throughout 
the 1950s and 1960s, this disease had a 100% mortality rate and no effective treatment 
options. In 1973, chemotherapy by the topoisomerase inhibitor daunorubicin was shown to 
have some curative effect, yielding a complete remission (CR) rate of 55% (Bernard et al., 
1973), and in the early eighties induction therapy based on anthracyclins (daunorubicin, 
idarubicin among others) and the nucleocide analogue cytosine arabinoside (Ara-C) was 
found to yield CR rates of up to 80% in newly diagnosed patients (Cunningham et al., 1989; 
Sanz et al., 1988). However, the patients frequently suffered from one of the inherent 
drawbacks with induction therapy, namely the release of coagulation factors from dead 
leukemic cells, causing severe bleedings and increased risk of fatal outcome (Cordonnier et 
al., 1985; Drapkin et al., 1978; Ruggero et al., 1977). Consequently, most APL patients 
required intensive platelet and fibrinogen support, and based on the criterion of 5-years 
disease-free survival (DFS), only 35-45% of the cases were cured (Fenaux et al., 2007). The 
focus on APL therapy changed in 1978, as it became clear that leukemic cells undergo 
terminal differentiation upon treatment with differentiating-inducing agents, such as ATRA, 
Ara-C and 13-cis retinoic acid (Breitman et al., 1981; Degos et al., 1985; Gold et al., 1983; 
Koeffler et al., 1985; Sachs, 1978). Such differentiation therapy showed an advantage over 
induction therapy, with respect to incidences of severe bleedings, and led to reduced 
mortality rates. In 1985, the first attempt to treat APL patients with ATRA was made with 
promising results, but the percentage of patients with 5-years DFS was still relatively low 
(less than 50%) (Huang et al., 1987; Huang et al., 1988). Subsequently, optimization trials, 
combining ATRA with chemotherapy, raised the CR rates up to 90-95% and the 5-years DFS 
to 86% (Wang & Chen, 2008). In addition, the combination of ATRA and chemotherapy, 
which currently represents standard frontline APL therapy, helped reducing retinoic acid 
syndrome (RAS), a potentially fatal side effect caused by induction therapy and manifested 
in a burst of inflammatory cytokines released from malignant promyelocytes (de Botton et 
al., 2003; Fenaux et al., 1999; Sanz et al., 1999; Tallman et al., 1997).  
2.2 The discovery of ATO-based APL therapy 
Arsenic, in the form of arsenic trioxide (ATO), was first described as an agent that possesses 
antileukemic properties in the year 1878. In this study, Fowler’s solution, a solution of ATO 
in potassium bicarbonate, was shown to dramatically reduce the number of white blood 
cells in a patient with chronic myelogenous leukemia (CML) (Cutler & Bradford, 1878). 
Subsequently, this remedy was used as a primary antileukemic agent until the discovery of 
radiation therapy in the early 20th century (Forkner & Scott, 1931; Kwong & Todd, 1997). In 
the 1970s, ATO reappeared as a therapeutic agent for APL as Chinese researchers showed 
that ailing-1, a mixture of ATO and crude herbal extracts, was effective in the treatment of 
both de novo as well as relapsed cases (Shen et al., 1997; Sun et al., 1992; Zhang et al., 1996). 
Additional clinical studies showed that ATO, as a single agent, caused complete remission 
in up to 90% of patients and reduced the relapse rate for high risk patients (Niu et al., 1999; 
Shen et al., 1997). A research group in the United States confirmed these preliminary studies 
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and further showed that ATO treatment induced partial differentiation of leukemic cells, 
caspase activation and subsequently apoptosis (Soignet et al., 1998).  
2.3 Present and future APL therapy 
Currently, ATRA in combination with chemotherapy is being employed as frontline therapy 
for APL, whereas ATO primarily is being used for treatment of cases that are resistant to 
ATRA or patients suffering from frequent relapses. However, several clinical trials are now 
assessing the synergistic effect of combining ATRA and ATO with and without 
chemotherapy. These trials are conducted mainly on the basis of successful studies in animal 
models, showing a positive effect of ATRA/ATO combinations in APL mice (Jing et al., 2001; 
Lallemand-Breitenbach et al., 1999). The main conclusion so far from the ongoing clinical 
studies is that newly diagnosed patients are likely to benefit from ATRA/ATO combination 
treatment in addition to low-dose chemotherapy (Estey et al., 2006; Hu et al., 2009; Shen et al., 
2004; Wang et al., 2004).  
3. The mechanism of PML, RARA and PML/RARA 
3.1 The role of PML/RARA in APL pathogenesis  
The molecular hallmark of APL is the t(15;17) chromosomal translocation that expresses the 
fusion oncoprotein PML/RARA. While this genetic aberration is identified in more than 
97% of all APL cases, the remaining patients diagnosed with this disease harbor variant 
translocations that all involve the RARA gene in fusion with alternative partners such as the 
genes encoding promyelocytic leukemia zinc finger (PLZF) (Chen et al., 1993), 
nucleophosmin (NPM) (Redner et al., 1996), nuclear matrix associated (NUMA) (Wells et al., 
1997), or signal transducer and activator of transcription 5b (STAT5B) (Arnould et al., 1999). 
The most compelling evidence that PML/RARA alone can contribute directly to APL 
development comes from studies in mice showing that expression of this oncoprotein as a 
transgene leads to development of an APL–like disease. However, these experiments also 
show that a relatively long latency period is required prior to onset of disease, suggesting 
the involvement of acquired genetic aberrations in addition to the t(15;17) translocation 
(Brown et al., 1997; Grisolano et al., 1997).  
3.2 The function of PML 
The first component of the PML/RARA fusion, the PML protein, is a tumor suppressor 
(Bernardi et al., 2006; Salomoni & Pandolfi, 2002; Trotman et al., 2006) that functions in 
multiple cellular processes, including apoptosis (Wang et al., 1998), differentiation (Ito et al., 
2008), DNA repair (Bøe et al., 2006; Dellaire et al., 2006a), senescence (Ferbeyre et al., 2000; 
Pearson et al., 2000), angiogenesis (Bernardi et al., 2006) and virus defence (Everett & Maul, 
1994). The human PML gene is located on chromosome 15, consists of nine exons and 
produces several alternatively spliced protein isoforms designated PML I through VII. All of 
these PML variants contain an identical tripartite (TRIM) motif in their N-terminal region, 
and a C-terminus that varies due to alternative splicing (Borden, 2002; Fagioli et al., 1992; 
Jensen et al., 2001; Jul-Larsen et al., 2010; Reymond et al., 2001). The TRIM motif, which 
comprises a RING finger, two B-boxes and a predicted coiled coil domain, has been shown 
to be important for PML multimerization, a feature responsible for one of the most striking 
properties of this protein, namely the ability to generate nuclear structures termed PML 
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properties of PML, RARA and PML/RARA with particular emphasis on tumorigenesis in 
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which currently represents standard frontline APL therapy, helped reducing retinoic acid 
syndrome (RAS), a potentially fatal side effect caused by induction therapy and manifested 
in a burst of inflammatory cytokines released from malignant promyelocytes (de Botton et 
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2.2 The discovery of ATO-based APL therapy 
Arsenic, in the form of arsenic trioxide (ATO), was first described as an agent that possesses 
antileukemic properties in the year 1878. In this study, Fowler’s solution, a solution of ATO 
in potassium bicarbonate, was shown to dramatically reduce the number of white blood 
cells in a patient with chronic myelogenous leukemia (CML) (Cutler & Bradford, 1878). 
Subsequently, this remedy was used as a primary antileukemic agent until the discovery of 
radiation therapy in the early 20th century (Forkner & Scott, 1931; Kwong & Todd, 1997). In 
the 1970s, ATO reappeared as a therapeutic agent for APL as Chinese researchers showed 
that ailing-1, a mixture of ATO and crude herbal extracts, was effective in the treatment of 
both de novo as well as relapsed cases (Shen et al., 1997; Sun et al., 1992; Zhang et al., 1996). 
Additional clinical studies showed that ATO, as a single agent, caused complete remission 
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and further showed that ATO treatment induced partial differentiation of leukemic cells, 
caspase activation and subsequently apoptosis (Soignet et al., 1998).  
2.3 Present and future APL therapy 
Currently, ATRA in combination with chemotherapy is being employed as frontline therapy 
for APL, whereas ATO primarily is being used for treatment of cases that are resistant to 
ATRA or patients suffering from frequent relapses. However, several clinical trials are now 
assessing the synergistic effect of combining ATRA and ATO with and without 
chemotherapy. These trials are conducted mainly on the basis of successful studies in animal 
models, showing a positive effect of ATRA/ATO combinations in APL mice (Jing et al., 2001; 
Lallemand-Breitenbach et al., 1999). The main conclusion so far from the ongoing clinical 
studies is that newly diagnosed patients are likely to benefit from ATRA/ATO combination 
treatment in addition to low-dose chemotherapy (Estey et al., 2006; Hu et al., 2009; Shen et al., 
2004; Wang et al., 2004).  
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The molecular hallmark of APL is the t(15;17) chromosomal translocation that expresses the 
fusion oncoprotein PML/RARA. While this genetic aberration is identified in more than 
97% of all APL cases, the remaining patients diagnosed with this disease harbor variant 
translocations that all involve the RARA gene in fusion with alternative partners such as the 
genes encoding promyelocytic leukemia zinc finger (PLZF) (Chen et al., 1993), 
nucleophosmin (NPM) (Redner et al., 1996), nuclear matrix associated (NUMA) (Wells et al., 
1997), or signal transducer and activator of transcription 5b (STAT5B) (Arnould et al., 1999). 
The most compelling evidence that PML/RARA alone can contribute directly to APL 
development comes from studies in mice showing that expression of this oncoprotein as a 
transgene leads to development of an APL–like disease. However, these experiments also 
show that a relatively long latency period is required prior to onset of disease, suggesting 
the involvement of acquired genetic aberrations in addition to the t(15;17) translocation 
(Brown et al., 1997; Grisolano et al., 1997).  
3.2 The function of PML 
The first component of the PML/RARA fusion, the PML protein, is a tumor suppressor 
(Bernardi et al., 2006; Salomoni & Pandolfi, 2002; Trotman et al., 2006) that functions in 
multiple cellular processes, including apoptosis (Wang et al., 1998), differentiation (Ito et al., 
2008), DNA repair (Bøe et al., 2006; Dellaire et al., 2006a), senescence (Ferbeyre et al., 2000; 
Pearson et al., 2000), angiogenesis (Bernardi et al., 2006) and virus defence (Everett & Maul, 
1994). The human PML gene is located on chromosome 15, consists of nine exons and 
produces several alternatively spliced protein isoforms designated PML I through VII. All of 
these PML variants contain an identical tripartite (TRIM) motif in their N-terminal region, 
and a C-terminus that varies due to alternative splicing (Borden, 2002; Fagioli et al., 1992; 
Jensen et al., 2001; Jul-Larsen et al., 2010; Reymond et al., 2001). The TRIM motif, which 
comprises a RING finger, two B-boxes and a predicted coiled coil domain, has been shown 
to be important for PML multimerization, a feature responsible for one of the most striking 
properties of this protein, namely the ability to generate nuclear structures termed PML 
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nuclear bodies (PML NBs) (Lallemand-Breitenbach & de The, 2010). These bodies are highly 
dynamic and change their morphology and biochemical composition in a cell cycle-
dependent manner. For example, during entry into mitosis, several PML NB resident 
components, including Daxx, Sp100 and SUMO, are lost concomitant with formation of 
PML NB aggregates called mitotic assemblies of PML proteins (MAPPs), whereas transition 
from mitosis to G1-phase coincides with exclusion of PML NBs from the progeny nuclei and 
complex formation with nucleoporins and microtubule filaments to form cytoplasmic 
assemblies of PML and nucleoporins (CyPNs) (Chen et al., 2008; Dellaire et al., 2006b; Jul-
Larsen et al., 2009). Although, PML NBs have the capacity to recruit a large number of 
different protein components, PML is the only protein so far that has been shown to be 
required for their formation. For this reason, it is widely assumed that the ability to 
assemble these cellular compartments represents an integral part of PML biogenesis. It still 
remains, however, to clearly define the molecular mechanism involved in PML NB assembly 
and function. 
3.3 The function of RARA 
The second fusion partner, RARA, is a ligand binding transcription factor that contains a 
DNA binding motif in its central region and a retinoid binding domain at the C-terminus. 
To generate an active protein complex, this nuclear receptor forms a heterodimer with the 
RXR family of transcription factors. Upon direct binding to a RA responsive element (RARE) 
within the regulatory region of a target gene, RARA/RXR complexes promote 
transcriptional silencing by recruiting co-repressor proteins such as NCOR1, SMRT and 
histone deacetylase to the promoter-binding complexes. In the presence of physiological 
concentrations of ligand (i.e. retinoids), a conformational change occurs within the 
RARA/RXR heterodimer that leads to dissociation of co-repressors and concomitant 
recruitment of histone acetylases and components of the basic transcription machinery, thus 
transforming the protein complex from a gene silencer to a gene activator (Bastien & 
Rochette-Egly, 2004). RARA regulates several genes involved in myeloid progenitor cell 
differentiation, including c-myc (Bentley & Groudine, 1986; Gowda et al., 1986), C/EBPβ 
(Duprez et al., 2003), C/EBP (Park et al., 1999) and PU.1 (Mueller et al., 2006), suggesting an 
important role of this protein in blood cell maturation.  
3.4 The function of PML/RARA 
Upon fusion between PML and RARA, the variable C-terminus of the PML protein is lost, 
whereas the constant N-terminal TRIM motif generally remains intact. In the case of RARA, 
fusion to PML leads to loss of the first 50 to 60 N-terminal amino acids, a deletion that does 
not appear to affect the DNA and ligand binding activities of this protein (de Thé et al., 
1991). Thus, PML/RARA retains the powerful protein-protein interaction domain of the 
PML protein, whereas the variable isoform-specific region is replaced by the trans-activating 
functions of RARA (Fig. 1.).  
One of the gained PML/RARA functions that is thought to contribute largely to APL 
development is the ability of this chimeric protein to form stable transcription repression 
complexes that are irresponsive to physiological concentrations of retinoids. As a 
consequence, gene promoters that are targeted by PML/RARA become constitutively 
repressed, an observation that has led to the general assumption that this oncoprotein 
causes a block in blood cell differentiation through transcriptional inhibition of key genes 
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involved in hematopoietic maturation. Consistent with a role in gene repression, 
PML/RARA has also been shown to recruit the histone methyl transferase SUV39H1 
(Carbone et al., 2006), members of the polycomb repressive complex 2 (PRC2) (Villa et al., 
2007) and DNA methyltransferases (DNMTs) (Di Croce et al., 2002), proteins that are 
known to induce a repressive chromatin structure. In addition to increased repressor 
activity, the PML/RARA fusion also appears to possess a considerable expanded 
repertoire of target genes compared to the normal RARA protein. This notion is 
supported by in vitro binding studies showing that PML/RARA has a broader and more 
relaxed DNA binding specificity compared to RARA (Hauksdottir & Privalsky, 2001; 
Kamashev et al., 2004), and by a genome wide screen revealing a wide range of 
PML/RARA target genes (Hoemme et al., 2008). The altered DNA binding and 
transcription repression properties of PML/RARA are partially due to the ability of this 
chimeric protein to form homodimeres through protein-protein interactions mediated by 
the TRIM motif of PML (Jansen et al., 1995; Perez et al., 1993). In addition, this chimeric 
protein has also been shown to form functional complexes with other transcription factors 
such as RXR and Daxx, a feature that may further contribute to the expanded promoter 
binding capacity (Zeisig et al., 2007; Zhu et al., 2005; Zhu et al., 2007).  
PML/RARA is also thought to contribute to malignant transformation and development of 
APL through inhibition of PML tumor suppressor functions. A dominant negative effect of 
PML/RARA on this protein is evident by studies demonstrating disruption of nuclear PML 
bodies into a dispersed microspeckled pattern in cells expressing this oncoprotein (Dyck et 
al., 1994; Koken et al., 1994; Weis et al., 1994). Interestingly, while disruption of PML NBs by 
PML/RARA in the nucleus is evident, this oncoprotein readily assembles into MAPPS and 
CyPNs, the mitotic and cytoplasmic versions of PML NBs, respectively (Jul-Larsen et al., 
2009). The disruption of PML NBs in the nucleus may reflect the role of this oncoprotein in 
repression of gene activity. 
 
 
Fig. 1. Structural organization of PML, RARA and PML/RARA. PML contains a RING 
domain (R), two B boxes (B), a coiled coil (CC) and a variable C-terminus. RARA consists of 
six regulatory domains (A-F), of which domain C and E harbor the DNA binding domain 
(DBD) and the ligand binding domain (LBD), respectively. The t (15;17) translocation 
produces PML/RARA, which retains the N-terminal PML motifs as well as RARA DNA 
and ligand binding activity. Arrows indicate protein breakpoints. 
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nuclear bodies (PML NBs) (Lallemand-Breitenbach & de The, 2010). These bodies are highly 
dynamic and change their morphology and biochemical composition in a cell cycle-
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complex formation with nucleoporins and microtubule filaments to form cytoplasmic 
assemblies of PML and nucleoporins (CyPNs) (Chen et al., 2008; Dellaire et al., 2006b; Jul-
Larsen et al., 2009). Although, PML NBs have the capacity to recruit a large number of 
different protein components, PML is the only protein so far that has been shown to be 
required for their formation. For this reason, it is widely assumed that the ability to 
assemble these cellular compartments represents an integral part of PML biogenesis. It still 
remains, however, to clearly define the molecular mechanism involved in PML NB assembly 
and function. 
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The second fusion partner, RARA, is a ligand binding transcription factor that contains a 
DNA binding motif in its central region and a retinoid binding domain at the C-terminus. 
To generate an active protein complex, this nuclear receptor forms a heterodimer with the 
RXR family of transcription factors. Upon direct binding to a RA responsive element (RARE) 
within the regulatory region of a target gene, RARA/RXR complexes promote 
transcriptional silencing by recruiting co-repressor proteins such as NCOR1, SMRT and 
histone deacetylase to the promoter-binding complexes. In the presence of physiological 
concentrations of ligand (i.e. retinoids), a conformational change occurs within the 
RARA/RXR heterodimer that leads to dissociation of co-repressors and concomitant 
recruitment of histone acetylases and components of the basic transcription machinery, thus 
transforming the protein complex from a gene silencer to a gene activator (Bastien & 
Rochette-Egly, 2004). RARA regulates several genes involved in myeloid progenitor cell 
differentiation, including c-myc (Bentley & Groudine, 1986; Gowda et al., 1986), C/EBPβ 
(Duprez et al., 2003), C/EBP (Park et al., 1999) and PU.1 (Mueller et al., 2006), suggesting an 
important role of this protein in blood cell maturation.  
3.4 The function of PML/RARA 
Upon fusion between PML and RARA, the variable C-terminus of the PML protein is lost, 
whereas the constant N-terminal TRIM motif generally remains intact. In the case of RARA, 
fusion to PML leads to loss of the first 50 to 60 N-terminal amino acids, a deletion that does 
not appear to affect the DNA and ligand binding activities of this protein (de Thé et al., 
1991). Thus, PML/RARA retains the powerful protein-protein interaction domain of the 
PML protein, whereas the variable isoform-specific region is replaced by the trans-activating 
functions of RARA (Fig. 1.).  
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consequence, gene promoters that are targeted by PML/RARA become constitutively 
repressed, an observation that has led to the general assumption that this oncoprotein 
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Acute Promyelocytic Leukemia: A Model Disease for Targeted Cancer Therapy 
 
367 
involved in hematopoietic maturation. Consistent with a role in gene repression, 
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(Carbone et al., 2006), members of the polycomb repressive complex 2 (PRC2) (Villa et al., 
2007) and DNA methyltransferases (DNMTs) (Di Croce et al., 2002), proteins that are 
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repertoire of target genes compared to the normal RARA protein. This notion is 
supported by in vitro binding studies showing that PML/RARA has a broader and more 
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PML/RARA on this protein is evident by studies demonstrating disruption of nuclear PML 
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domain (R), two B boxes (B), a coiled coil (CC) and a variable C-terminus. RARA consists of 
six regulatory domains (A-F), of which domain C and E harbor the DNA binding domain 
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While PML/RARA is constantly expressed in more than 97% of all APL patients, the 
reciprocal fusion protein RARA/PML, which contains the N-terminus of RARA and 
variable lengths of the PML C-terminus, is identified in only 70-80% of the cases (Alcalay et 
al., 1992; Grimwade et al., 1996). Not much is known about the role of this protein in the 
pathogenesis of APL. However, one study has described a possible link between 
RARA/PML fusion gene deletions and resistance to ATRA-based therapy (Subramaniyam 
et al., 2006). 
4. The mechanism of ATRA and ATO-mediated APL therapy  
4.1 The mechanism of ATRA-based APL therapy 
Phenotypically, pharmacological concentrations of ATRA lead to effective differentiation of 
immature APL cells to terminally differentiated granulocytes. From a therapeutic point of 
view this may be beneficial since the immature malignant cells progress from being highly 
proliferative and long-lived to arrested and short-lived. In addition, in vitro cell culture 
experiments have shown that ATRA-induced differentiation also coincides with activation 
of apoptosis (Altucci et al., 2001; Grignani et al., 1998; Martin et al., 1990). The relative 
contribution of apoptotic cell death versus increased turnover of mature granulocytes to 
ATRA-induced clearance of tumorigenic cells is not clear. Although ATRA appears to be 
highly effective in clearing the bulk of proliferative tumor cells, a residual population of 
cells with detectable t(15;17) translocation almost invariably persist following treatment 
with this reagent alone, a feature that probably explains the additional need for 
chemotherapy in order to achieve complete remission (Chen et al., 1991; Chomienne et al., 
1990; Huang et al., 1988; Zhu et al., 1995). 
At the molecular level, therapeutic doses of ATRA reverse the differentiation block caused 
by PML/RARA through a direct interaction with the ligand binding site present on the 
RARA moiety. As for normal RARA, the ligand-receptor interaction induces a change in the 
PML/RARA protein structural conformation, which leads to release of transcription 
repressors and subsequent activation of the basal transcription machinery. Coincident with 
transcription activation, ATRA also induces recruitment of the proteasome to the ligand 
binding transcription activation domain AF2 of RARA, and subsequent proteasome-
dependent degradation (Kopf et al., 2000; Zhu et al., 1999). A protein that has been proposed 
to participate in this pathway is the ubiquitin-activating enzyme E1-like (UBE1L) protein, 
which itself represents one of the ATRA-induced proteins (Kitareewan et al., 2002). ATRA-
mediated degradation appears to affect RARA and PML/RARA equally well and may be 
functionally linked to transcription activation, since mutations in RARA that impairs its 
DNA binding activity also inhibits ATRA-mediated catabolism (Zhu et al., 1999). The 
relative contribution of transcriptional activation, differentiation and degradation on 
therapy remains to be fully elucidated.  
4.2 The mechanism of ATO-based APL therapy 
Compared to ATRA, ATO has a more limited ability to induce terminal differentiation of 
APL cells. In vitro studies using cultured cells have revealed a dose-dependent effect of this 
drug on differentiation and apoptosis (Chen et al., 1997). At high concentrations (0.5-2.0 µM) 
ATO induced cell death by apoptosis, while at low concentrations (0.1-0.25 µM) this drug 
caused partial differentiation of APL cells along the granulocyte linage (Cai et al., 2000; Chen 
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et al., 1997). The results from these experiments appear to be in good agreement with studies 
demonstrating ATO-induced partial differentiation and apoptosis in APL patients or animal 
models, where the effective serum concentrations of ATO generally ranges from 0.1 to 1.0 
µM (Chen et al., 1997; Lallemand-Breitenbach et al., 1999). Interestingly, ATO-mediated 
differentiation has been shown to become dramatically enhanced in the presence of cyclic 
adenosine monophosphate (cAMP). The mechanism responsible for this synergistic effect 
was proposed to be the combined effect of ATO-induced PML/RARA degradation and 
cAMP-mediated inhibition of cell cycle progression (Guillemin et al., 2002; Zhu et al., 2002). 
At the molecular level, ATO exerts its therapeutic effect on APL in part by initiating a 
cascade of biochemical alterations that primarily affect the PML moiety of PML/RARA. 
Firstly, the presence of arsenic in the cell culture medium has been shown to increase PML 
and PML/RARA multimerization, an effect that is manifested by decreased solubility of 
these proteins upon preparation of cell lysates and reduced mobility within PML NBs as 
determined by analysis of GFP-tagged PML in living cells (Jeanne et al., 2010; Zhang et al., 
2010). Concomitant with increased aggregation, PML becomes extensively SUMOylated on 
at least three different lysine residues. All of the three different SUMO isoforms, including 
SUMO1, 2 and 3, appear to participate in this reaction, and both mono and poly-
SUMOylation events have been reported (Lallemand-Breitenbach et al., 2001; Lallemand-
Breitenbach et al., 2008; Muller et al., 1998; Tatham et al., 2008). Subsequent to SUMOylation, 
a protein called RNF4 binds SUMOylated residues on PML in order to catalyze poly-
ubiquitination, a modification that directs PML and PML/RARA to the proteasome for 
degradation (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). Recently, a direct 
interaction between PML and ATO, that potentially triggers this SUMO-mediated 
degradation pathway, was mapped to cysteine residues located in the TRIM and B-box 
motifs of PML (Jeanne et al., 2010; Zhang et al., 2010). 
In addition to affecting differentiation of leukemic cells, recent studies have also implicated 
ATO in clearance of leukemic-initiating cells (LICs), a small population of malignantly 
transformed cells with stem cell characteristics that frequently are refractory to cancer 
therapeutic drugs. Consistent with this, PML/RARA expression has been reported to 
support properties of self-renewal of LICs (Wojiski et al., 2009), and certain characteristics of 
promyelocytic phenotypes provide the basic properties for the development of APL-
initiating LICs (Guibal et al., 2009). Furthermore, a recent study demonstrated LIC clearance 
in association with ATO-induced PML/RARA degradation by a mechanism that appeared 
to be uncoupled from the observed cell differentiation (Nasr et al., 2008; Shao et al., 1998). In 
addition, ATO has been reported to cause increased proliferation of LICs in a chronic 
myelogenous mouse model, hence sensitizing otherwise therapy-insensitive leukemic cells 
to Ara-C-based treatment (Ito et al., 2008; Ito et al., 2009).  
The proapoptotic activity of ATO is not specific for APL cells (Akao et al., 1998; Bachleitner-
Hofmann et al., 2001; Ishitsuka et al., 1998; Perkins et al., 2000; Rousselot et al., 1999; Wang et 
al., 1996; Zhang et al., 1998; Zheng et al., 1999), although non-APL tumor cells have been 
shown to be less sensitive to this drug (Huang et al., 1999). ATO induces apoptosis by 
downregulation of the antiapoptotic protein Bcl-2, leading to a disturbance in the regulated 
balance between pro- and antiapoptotic proteins (Akao et al., 1998; Chen et al., 1996; Zhang 
et al., 1998). In addition, ATO increases radioactive oxygen species (ROS) production in 
malignant cells. As a consequence, this drug leads to disruption of the mitochondrial 
membrane potential, followed by cytochrome c release, caspase activation and subsequent 
apoptotic cell death (Jing et al., 1999).  
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4.3 The synergy between ATRA and ATO 
While ATRA and ATO on their own are known to be effective in curing APL, it is also 
becoming increasingly clear that treatment regiments based on a combination of the two 
drugs leads to a quicker clinical remission, a more effective clearance of leukemic cells and a 
significantly longer period of relapse free survival (Estey et al., 2006; Hu et al., 2009; Shen et 
al., 2004; Wang et al., 2004). This synergistic effect may result due to the ability of both these 
drugs to cause PML/RARA degradation, a parameter that appears to be critical for the 
success of APL therapy. In addition, the combined effect of ATO and ATRA may also result 
due to the ability of the two agents to act on separate targets, both of which are important 
for disease remission. For example, ATO may be effective in eradicating self-renewable LICs 
through stimulated PML/RARA degradation, while ATRA represents a more effective 
differentiating agent, and hence may lead to a more complete clearance of undifferentiated 
APL cells.  
5. Therapy-induced degradation of PML/RARA  
ATRA and ATO-induced therapy of APL may be connected to the ability of these drugs to 
induce PML/RARA catabolism (Fig. 2.). In agreement with this, reduced PML/RARA 
expression can be observed in both ATRA and ATO-treated cells, and the two drugs 
synergize both for their ability to induce oncoprotein degradation as well as for their 
capacity to promote clinical remission (Hu et al., 2009; Nasr et al., 2008; Shen et al., 2004). An 
important role of protein degradation for effective APL therapy is also supported by 
experiments in mice. For example, treatment of an APL mouse model with the proteasome 
inhibitor bortezomid led to reduced degradation of PML/RARA and concomitant resistance 
to ATRA and ATO-based therapy (Nasr et al., 2008). In addition, PML/RARA mutated in 
critical SUMOylation target sites, were found to be more resistant to ATO-mediated 
degradation compared to unmodified PML/RARA (Lallemand-Breitenbach et al., 2001; 
Lallemand-Breitenbach et al., 2008). 
In addition to proteasome-dependent degradation induced by ATRA and ATO, 
PML/RARA has also been shown to be amenable for degradation by the lysosome-
dependent degradation pathway autophagy (Isakson et al., 2010; Klionsky, 2007). This 
degradation mechanism appears to play a major role both for basal turnover as well as for 
therapy-induced catabolism of PML/RARA. Indeed, pharmacological inhibitors of 
autophagy were found to completely prevent ATRA and ATO-stimulated degradation of 
PML/RARA expressed in the APL cell line NB4 (Isakson et al., 2010). In contrast to 
proteasome-dependent degradation, autophagy-mediated proteolyses of PML/RARA 
appears to be independent of a direct interaction between the drugs and the target protein. 
Instead, ATRA and ATO seem to stimulate autophagy in APL cells primarily through a 
mechanism that involves the mammalian target of rapamycin (mTOR) and Unc-51-like 
kinase 1 (ULK1) (Bøe & Simonsen, 2010; Isakson et al., 2010). Furthermore, PML/RARA is 
highly aggregation prone and therefore a good substrate for this degradation pathway 
(Isakson et al., 2010; Lallemand-Breitenbach et al., 2001). Aggregates of PML/RARA may 
form during the process of protein synthesis. In agreement with this, synthesis of 
PML/RARA has been shown to be associated with endoplasmatic reticulum stress, a feature 
indicative of aberrant folding during protein synthesis (Khan et al., 2004).  
 




Fig. 2. Schematic overview of the four main ATRA and ATO-mediated PML/RARA 
degradation pathways: 1. ATO-induced proteasome-dependent degradation,  
2. ATRA-induced caspase cleavage, 3. ATRA-induced proteasome-dependent degradation, 
4. ATRA/ATO-induced autophagy-mediated degradation. 
Two different types of proteases have also been implicated in PML/RARA proteolysis. First, 
PML/RARA has been shown to be susceptible to a caspase 3-like activity expressed in APL 
cells and that becomes induced by the presence of ATRA (Nervi et al., 1998). The second 
protease shown to be involved is neutrophil elastase, a myeloid specific serine protease that 
is maximally expressed in promyelocytes (Lane & Ley, 2003). The contribution of this 
protease to APL development is unclear since one study showed enhanced penetrance of 
PML/RARA in a neutrophil elastase defective mice (Lane & Ley, 2003), while another 
demonstrated decreased tumorigenesis in a mouse model expressing a neutrophil elastase 
cleavage defective PML/RARA protein (Uy et al., 2010).  
PML turnover has also been shown to be regulated by a pathway that involves direct 
phosphorylation by the casein kinase 2 (CK2) and subsequent ubiquitin-mediated 
degradation, a mechanism that was proposed to cause decreased PML tumor suppressor 
activity in lung cancer (Scaglioni et al., 2006). However, the significance of CK2-mediated 
PML phosphorylation in PML/RARA degradation and APL pathogenesis has not been 
elucidated.  
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6. The mechanism of APL therapy resistance 
The second most common translocation associated with APL, the t(11;17) translocation that 
expresses PLZF/RARA fusion instead of PML/RARA, is generally insensitive to ATRA and 
ATO-based therapy (Chen et al., 1993; Licht et al., 1995). The poor response of these patients 
to ATO add support to studies showing that this drug primarily target PML, which is absent 
in PLZF/RARA. In the case of the poor response to ATRA, on the other hand, the 
underlying mechanism has been hypothesized to be due to enhanced co-repressor activity 
conferred by the PLZF moiety of the PLZF-RARA fusion (Grignani et al., 1998; He et al., 
1998; Lin et al., 1998). However, the notion that PLZF/RARA is irresponsive to ATRA 
stimulation has been contradicted in more recent studies demonstrating ATRA-induced 
gene expression and differentiation also in PLZF/RARA expressing APL cells (Nasr et al., 
2008; Petti et al., 2002; Rice et al., 2009). Thus, further work is needed in order to fully 
understand the mechanism underlying the insensitivity of PLZF/RARA positive APL cells 
to ATRA.  
Resistance to ATRA-mediated therapy is also seen in APL patients that have relapsed 
following the first clinical remission. Such acquired resistance may be caused by a number 
of different physiological factors, including increased catabolism, reduced cellular uptake, 
or increased cytoplasmic sequestration of the therapeutic drugs (Freemantle et al., 2003; 
Gallagher, 2002). In addition, in vitro cell culture experiments, using the APL cell line NB4, 
have revealed mutations within the PML/RARA gene of subclones with acquired resistance 
to ATRA. Interestingly, several of these mutations were found clustered at/or near the 
ligand binding domain of RARA leading to defects in ATRA binding. Since these mutants 
generally retain their capacity to form complex with RXR and to bind DNA, they have been 
suggested to act as dominant inhibitors of wild type RARA (Duprez et al., 2000; Kitamura et 
al., 1997; Nason-Burchenal et al., 1998; Rosenauer et al., 1996; Shao et al., 1997). Mutations in 
PML/RARA have also been identified in a subset of ATRA-relapsed patients, and these 
mutations were found to be variably associated with inactivation of ATRA binding (Ding et 
al., 1998; Gallagher et al., 2006; Imaizumi et al., 1998; Marasca et al., 1999; Takayama et al., 
2001; Zhou et al., 2002). Interestingly, one study identified mutations within the intact PML 
locus of APL patients with ATRA-resistance and poor prognosis (Gurrieri et al., 2004). 
Recently, PML/RARA mutations have also been discovered in two APL cases with poor 
response to ATO (Goto et al., 2011). In both cases, the mutations were located within the 
second B-box motif of the PML protein. Since the amino acids affected by these mutations 
were close to a cysteine-rich region, previously proposed to bind ATO (Jeanne et al., 2010), 
the authors of this paper hypothesized that these mutations may affect interactions between 
this drug and PML/RARA. Alternatively, the mutated protein may have defects in 
oligomerization, since the B-box domains are known to function in PML multimerization. 
Combined, the PML/RARA mutations that have been identified in ATRA and/or  
ATO–resistant APL cells support the notion that these drugs interact with separate moieties 
of the fusion protein to induce clinical remission. 
7. Perspectives  
During the past 30 years, APL has progressed from a deadly disease to a highly curable 
malignancy. In addition, the advances that have been made in understanding the pathology 
and cure of APL at the molecular level have led to the emergence of a highly attractive 
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model disease for the development of targeted cancer therapy. For example, the case of APL 
clearly demonstrates the therapeutic effectiveness of targeting a defined oncoprotein, and 
since recurrent translocations and expression of fusion oncoproteins similar to that of 
PML/RARA is a common trait also among other types of cancers (including leukemias and 
sarcomas), a large number of malignancies, in addition to APL, may benefit from similar 
targeted therapies. Thus, it will be important to continue identifying therapeutic concepts 
that contribute to the success of APL therapy and to modulate these concepts for treatment 
of other cancers.  
Since both ATRA and ATO have been shown to exert their therapeutic effects through 
interactions with specific regions of the PML/RARA oncoprotein, it may be assumed that 
these drugs will be effective only against APL. However, one should also keep in mind that 
the ability of ATRA and ATO to mediate cure of APL is regarded as a rather fortuitous 
discovery and not merely as a result of rational therapeutic design. For this reason, these 
drugs are likely to have other yet unidentified cellular targets, beside the APL-associated 
fusion portion, that are important for effective treatment. Evidence for this comes from one 
of the studies mentioned above showing that both ATRA and ATO-stimulated autophagic 
degradation of PML/RARA through a mTOR-dependent pathway that does not seem to 
involve direct interactions between drugs and the oncoprotein (Isakson et al., 2010). In 
addition, it is also becoming increasingly clear that ATO has the potential to cure a subset of 
cancers that don't express PML/RARA. For example, induced clearance of LICs has been 
demonstrated both in PML/RARA positive as well as PML/RARA negative leukemic cells 
(Ito et al., 2008; Nasr et al., 2008). Furthermore, a phase II clinical study was recently 
published that showed promising results of using ATO in combination with interferon 
alpha and zidovudine for treatment of patients with chronic adult T cell leukemia (Kchour et 
al., 2009), and finally, this drug was found to sensitize glucocorticoid-resistant acute 
lymphoblastic leukemia cells to dexamethasone (Bornhauser et al., 2007). Thus, it is likely 
that APL for many years to come will continue to represent an important model disease for 
targeted and non-targeted effects of ATRA and ATO, while increased understanding of the 
molecular pathways involved may lead to discoveries of new therapies that are applicable 
for other types of cancers.  
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malignancy. In addition, the advances that have been made in understanding the pathology 
and cure of APL at the molecular level have led to the emergence of a highly attractive 
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model disease for the development of targeted cancer therapy. For example, the case of APL 
clearly demonstrates the therapeutic effectiveness of targeting a defined oncoprotein, and 
since recurrent translocations and expression of fusion oncoproteins similar to that of 
PML/RARA is a common trait also among other types of cancers (including leukemias and 
sarcomas), a large number of malignancies, in addition to APL, may benefit from similar 
targeted therapies. Thus, it will be important to continue identifying therapeutic concepts 
that contribute to the success of APL therapy and to modulate these concepts for treatment 
of other cancers.  
Since both ATRA and ATO have been shown to exert their therapeutic effects through 
interactions with specific regions of the PML/RARA oncoprotein, it may be assumed that 
these drugs will be effective only against APL. However, one should also keep in mind that 
the ability of ATRA and ATO to mediate cure of APL is regarded as a rather fortuitous 
discovery and not merely as a result of rational therapeutic design. For this reason, these 
drugs are likely to have other yet unidentified cellular targets, beside the APL-associated 
fusion portion, that are important for effective treatment. Evidence for this comes from one 
of the studies mentioned above showing that both ATRA and ATO-stimulated autophagic 
degradation of PML/RARA through a mTOR-dependent pathway that does not seem to 
involve direct interactions between drugs and the oncoprotein (Isakson et al., 2010). In 
addition, it is also becoming increasingly clear that ATO has the potential to cure a subset of 
cancers that don't express PML/RARA. For example, induced clearance of LICs has been 
demonstrated both in PML/RARA positive as well as PML/RARA negative leukemic cells 
(Ito et al., 2008; Nasr et al., 2008). Furthermore, a phase II clinical study was recently 
published that showed promising results of using ATO in combination with interferon 
alpha and zidovudine for treatment of patients with chronic adult T cell leukemia (Kchour et 
al., 2009), and finally, this drug was found to sensitize glucocorticoid-resistant acute 
lymphoblastic leukemia cells to dexamethasone (Bornhauser et al., 2007). Thus, it is likely 
that APL for many years to come will continue to represent an important model disease for 
targeted and non-targeted effects of ATRA and ATO, while increased understanding of the 
molecular pathways involved may lead to discoveries of new therapies that are applicable 
for other types of cancers.  
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1. Introduction 
Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a clonal 
hemopoietic disorder that is frequently associated with genetic instability characterized 
by a diversity of chromosomal and molecular abnormalities. There are a lot of reports that 
show that human cancer can be initiated by DNA damage caused by ultraviolet (UV), 
ionizing radiation, and environmental chemical agents. Many genes encode proteins that 
function to protect cells against genetic instability through numerous mechanisms, 
including deoxyribonucleic acid (DNA) repair pathways and protection against oxidative 
stress.  
DNA repair pathways play an important role in maintaining the integrity of the genome, 
and it is obvious that defects in repair pathways are involved in many different types of 
diseases, including leukemia and cancer (Seedhouse, 2002). 
DNA damage repair and cell-cycle checkpoints are the most important defense mechanisms 
against mutagenic exposures. The most important DNA-repair pathways in human cells are: 
direct repair, base excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR), Double Strand Break Repair (DSB repair) and translesion DNA synthesis (TLS). 
Each pathway repairs a different type of lession (D'Andrea, 2010). The NER pathway mainly 
removes bulky distortions in the shape of the DNA double helix. The BER pathway is 
responsible for removal of oxidized DNA bases that may arise endogenously or from 
exogenous agents. The DSB pathway is responsible for repairing double-strand breaks 
caused by a variety of exposures, including ionizing radiation. There are two distinct and 
complementary pathways for DSB repair-namely, homologous recombination (HR) and 
nonhomologous end joining (NHEJ). 
Recent studies have suggested that DNA damage was related to the pathogenesis of some 
diseases such as AML. Therefore, some DNA repair genes may be involved in AML 
susceptibility (Allan, 2004; Kuptsova, 2007; Seedhouse, 2002, 2004; Voso, 2007). 
Exposure to carcinogenic and genotoxic compounds causes DNA damage, and the cells 
have developed multiple DNA repair pathways to protect themselves from different types 
of DNA damage. 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
384 
Zhu, J., Zhou, J., Peres, L., Riaucoux, F., Honore, N., Kogan, S. & de The, H. (2005). A 
sumoylation site in PML/RARA is essential for leukemic transformation. Cancer 
Cell 7, 143-153. 
Zhu, J., Nasr, R., Peres, L. & other authors (2007). RXR is an essential component of the 
oncogenic PML/RARA complex in vivo. Cancer Cell 12, 23-35. 
Zhu, Q., Zhang, J. W., Zhu, H. Q. & other authors (2002). Synergic effects of arsenic trioxide 
and cAMP during acute promyelocytic leukemia cell maturation subtends a novel 
signaling cross-talk. Blood 99, 1014-1022. 
19 
The Association of the DNA Repair  
Genes with Acute Myeloid Leukemia:  
The Susceptibility and the  
Outcome After Therapy  
Claudia Bănescu, Carmen Duicu and Minodora Dobreanu  
Univ Med & Pharm Tg-Mures  
România 
1. Introduction 
Acute myeloid leukemia (AML), the most common acute leukemia in adults, is a clonal 
hemopoietic disorder that is frequently associated with genetic instability characterized 
by a diversity of chromosomal and molecular abnormalities. There are a lot of reports that 
show that human cancer can be initiated by DNA damage caused by ultraviolet (UV), 
ionizing radiation, and environmental chemical agents. Many genes encode proteins that 
function to protect cells against genetic instability through numerous mechanisms, 
including deoxyribonucleic acid (DNA) repair pathways and protection against oxidative 
stress.  
DNA repair pathways play an important role in maintaining the integrity of the genome, 
and it is obvious that defects in repair pathways are involved in many different types of 
diseases, including leukemia and cancer (Seedhouse, 2002). 
DNA damage repair and cell-cycle checkpoints are the most important defense mechanisms 
against mutagenic exposures. The most important DNA-repair pathways in human cells are: 
direct repair, base excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR), Double Strand Break Repair (DSB repair) and translesion DNA synthesis (TLS). 
Each pathway repairs a different type of lession (D'Andrea, 2010). The NER pathway mainly 
removes bulky distortions in the shape of the DNA double helix. The BER pathway is 
responsible for removal of oxidized DNA bases that may arise endogenously or from 
exogenous agents. The DSB pathway is responsible for repairing double-strand breaks 
caused by a variety of exposures, including ionizing radiation. There are two distinct and 
complementary pathways for DSB repair-namely, homologous recombination (HR) and 
nonhomologous end joining (NHEJ). 
Recent studies have suggested that DNA damage was related to the pathogenesis of some 
diseases such as AML. Therefore, some DNA repair genes may be involved in AML 
susceptibility (Allan, 2004; Kuptsova, 2007; Seedhouse, 2002, 2004; Voso, 2007). 
Exposure to carcinogenic and genotoxic compounds causes DNA damage, and the cells 
have developed multiple DNA repair pathways to protect themselves from different types 
of DNA damage. 
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Polymorphisms in DNA repair genes, including those involved in base excision repair 
(BER), nucleotide excision repair, mismatch repair and double strand break repair have been 
implicated in carcinogenesis. Common polymorphisms in DNA repair genes may alter 
protein function and an individual’s capacity to repair damaged DNA. Deficits in repair 
capacity may lead to genetic instability and tumorigenesis. 
Studies have noted associations between risk of de novo AML and DNA repair gene 
polymorphisms (Matullo et al., 2006; Seedhouse et al., 2004). Increased risk of therapy-
related AML was also linked to several gene polymorphisms in base excision repair (BER; 
XRCC1 Arg399Gln), nucleotide excision repair (NER; XPD Lys751Gln), and DSB repair 
(RAD51 G135C and XRCC3 Thr241Met) pathways (Allan et al. 2004; Seedhouse et al., 2002, 
2004)  and may be linked to secondary AML etiology through failure to recognize or excise 
accumulated DNA lesions. 
2. Mechanism of DNA repair 
DNA damage response pathways, some of the genes known to participate in each of these 
pathways, their modes of action are summarized in Table 1. These categories are not 
exclusive; there may be functional overlap between repair systems. For example, certain 
types of base damage can be repaired by base excision repair, nucleotide excision repair or 
homologous recombinational repair. 
DNA repair genes may also have great implications in the therapeutic outcome of certain 
cancer treatments. Most antileukemic drugs interact with target cell DNA and exert their 
cytotoxic effects preferentially in replicating cells. In addition to the primary DNA lesions, 
secondary DNA alterations induced in the course of repair processes also contribute to the 
cytotoxic effects of DNA-reactive agents (Rajewsky &Müller, 2005). 
Although there are several reports on associations between polymorphisms in DNA repair 
genes and cancer risk (Goode et al., 2002), fewer studies have been conducted to evaluate 
relationships between DNA repair gene polymorphisms and response to treatment. 
2.1 Direct repair mechanism  
This is the simplest repair mechanism compared to other repair system regarding number of 
molecules involved. It is an enzyme-catalyzed process used to correct the most frequent 
cause of point mutations in humans. 
In direct repair mechanisms, the lesion is removed or reversed by a single step reaction 
restoring the local sequence to its original state. There are several direct repair enzymes, 
each having a different substrate. For example, O6- methyl guanine DNA methyltransferase 
(O6-MT, the product of the MGMT gene) repairs the alkylation damage. MGMT is important 
in the repair of alkylation damage. The alkyl group from the lesion is transferred to a 
cysteine residue in the active site of MGMT (Hazra et al., 1997). In 20% of human tumor cell 
lines the MGMT activity is decreased and the sensivity to alkylating agent is increased 
(Sancar, 1995), but there are few data which suggest that mutations in the MGMT gene 
contribute to cancer (Wang L et al, 1997; Yu Z et al, 1999). 
The functional status of the O6-MT pathway may be important in patients treated with 
alkylating agents, for O6-methylation of guanine appears to be an important effect of some 
members of that class of drugs (Kaina & Christmann, 2002). High levels of O6-MT are often 
found in AML blasts, which are thereby rendered resistant to certain alkylators (Gerson & 
Trey, 1988). 
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Pathway Function Genes Involved References 
Direct Repair 
Mechanism 
Reverses damage to 
restore DNA integrity. 
DNA photolyase, 
 O6-MGMT 




Repair of damaged 
bases or single-strand 
DNA breaks 
OGG1, XRCC1, 
APE1, PARP,   
Chaudhry, 2007; 
Yu et al., 1999; 




Excision of a variety of 
helix-distorting DNA 
lesions 
XPA, XPB, XPC, 
XPD, XPE, XPF, 
XPG, RAD23, TFIIH, 
RPA1, RPA2, RPA3, 
PCNA  
Kang et al., 2011; 
Reardon & 
Sancar, 2005;  
Yu et al., 1999 
Mismatch Repair 
(MMR) 






PCNA, RPA  
Jiricny, 2006; 
Martin et al., 2010; 
Papouli et al., 
2004;  




Repair of double 








Li & Heyer, 2008; 





Repair of double 
strand DNA breaks 
XRCC4, XRCC5, 
XRCC6, XRCC7,  
LIG4,  XLF,  
Burma et al., 2006; 
Shrivastav  




Bypass of DNA 
adducts during DNA 
replication 
 
POLK, POLI, POLZ, 
REV7, REV1, POLH,  
Lehmann, 2006 
Table 1. DNA Damage Response Pathways 
2.2 Base Excision Repair 
Base excision repair (BER) is the predominant DNA damage repair pathway for the 
processing of small base lesions, derived from ionizing radiation (Chen et al., 2010), 
oxidation, hydrolysis, or deamination and alkylation damages. The repair system involves 
three steps: removal of damaged bases from DNA by DNA glycosylases, then formed abasic 
site is removed and finally gap is filled by DNA polymerase. 
In BER, the removal of a single modified base from one DNA strand is performed by DNA 
glycosylases, specialized enzymes. Some of these glycosylases show pronounced lesion 
specificity, others recognize multiple, and structurally different damaged bases. The 
apurinic/apyrimidinic (AP) site left behind after cleavage of the N-glycosylic bond is 
hydrolyzed by an AP endonuclease, and the 5'-deoxyribose phosphate is excised by a 
phosphodiesterase. The resulting single-nucleotide gap is then filled by polymerase β and 
ligated. Alternatives to this common BER pathway include the excision of a short 
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oligonucleotide patch containing the AP site and filling of the gap by polymerase δ or ε. 
Base alterations caused by a large variety of agents and processes (e.g. spontaneous 
deamination, ionizing radiation, alkylating agents, DNA replication errors) are processed by 
BER. A common feature of the DNA lesions recognized by BER glycosylases is that they do 
not significantly distort the DNA helix (Yu, 2009). 
Common single-nucleotide polymorphisms (SNPs) in the 8-oxoguanine glycosylase 1 
(OGG1), X-ray repair cross-complementing group1 (XRCC1), and the apyrimidinic 
endonuclease-endonuclease 1 (APE1) genes in the BER pathway have been studied for their 
influences in induction of DNA damage (Chen et al., 2010). 
XRCC1 
X-ray repair cross-complementing group 1 (XRCC1) is required for repairing single-strand 
breaks and damaged bases in DNA. The XRCC1 protein interacts with DNA polymerase β, 
DNA ligase III and polyadenosine diphosphate-ribose polymerases (PARP) involved in 
excision and recombinational repair pathways (Cardecott, 2003). The XRCC1 has no known 
enzymatic activity (Thompson et al., 1990) and participates as a scaffold protein in both 
single-strand break repair and base excision repair activities. The human XRCC1 gene is 
located on chromosome 19q13.2 which contains 17 exons and encodes a protein of consisting 
633 amino acids (Lindahl & Wood, 1999). More than 60 validated single-nucleotide XRCC1 
polymorphisms are known. The most studied single nucleotide polymorphisms are 
Arg194Trp on exon 6, Arg280His on exon 9, and Arg399Gln on exon 10. All these 
polymorphisms were studied with association to different types of cancer. 
The presences of the variant (399Gln and 194Trp) alleles have been shown to be associated 
with measurable reduced DNA repair capacity and increased risk of several types of cancers 
(Dufloth et al., 2005; Goode et al., 2002; Hu et al., 2005; Hung et al., 2005). In our study 
involving 43 patients with acute leukemia and 40 controls, for XRCC1 Arg194Trp and 
Arg399Gln polymorphism, we observed the relationship of XRCC1 polymorphisms with 
acute myeloid leukemia (our own unpublished data). Our cases with a codon 194 Trp/Trp 
homozygous variant as well as the heterozygous Arg/Trp variant had an increased risk of 
AML with a greater risk in the case of the homozygous codon 194 Trp/Trp allele (OR=2.28, 
95% for Trp/Trp). There was a significantly high risk of AML among patients who were 
carriers of the variant allele 399Gln (OR=2.45, 95% for Gln/Gln and OR=1.90, 95% for 
Arg/Gln).  
A study by Seedhouse et al. (2002) reported that the presence of at least one XRCC1 399Gln 
allele indicated a protective effect for the allele in controls compared with patients with 
AML, particularly therapy-related AML (t-AML) (odds ratio OR=0.44; 95% confidence 
interval CI=0.20~0.93). According to the same study patients who develop AML as a result 
of therapy for a primary malignancy are more likely to have the wild-type XRCC1 399 
arginine allele. El-Din et al. (2010) reported that XRCC1 gene polymorphism is important in 
the pathogenesis of de novo AML. El-Din et al. (2010) observed that AML patients 
expressing XRCC1 Arg194Trp polymorphism are at high risk of developing AML; in 
addition, a significant risk in the development of AML was observed when XRCC1 
Arg399Gln polymorphism was present. In a study of 372 patients with acute myeloid 
leukemia, Kuptsova et al. (2007) reported no significant associations between XRCC1 
polymorphisms and treatment outcomes. 
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The human 8-oxoguanine DNA glycosylase 1 (hOGG1) encoded by the hOGG1 gene can 
remove 8-hydroxy-2-deoxyguanine (8-OHdG) from damaged DNA as a part of the base 
excision repair pathway (Kohno et al., 1998). The hOGG1 gene is located on chromosome 
3p26.2 (Kohno et al., 1998). Although, several polymorphisms in the hOGG1 gene have been 
described, the most commonly studied polymorphism is an amino acid change from serine 
to cysteine at codon 326 (Ser326Cys). Several studies have reported that Ser326Cys 
polymorphism in OGG1 gene may increase susceptibility to for bladder (Arizono et al., 
2008), lung (Park et al., 2004), oesophageal (Xing et al., 2001), gallbladder and gastric 
(Tsukino et al., 2004) cancer development. 
Liddiard et al (2010) provided a study about the importance of 8-oxoguanine in AML 
including the genotyping of 174 AML patients for the hOGG1 Ser326Cys polymorphism. 
Using Affymetrix microarrays they showed that the prevalence rate of hOGG1 expression 
was 33% and correlated strongly with adverse cytogenetics. hOGG1-expressing patients had 
a worse relapse-free survival and overall survival and an increased risk of relapse at 5-years 
of follow-up. According to Liddiard et al. (2010) hOGG1 is an important prognostic marker 
that could be used to sub-stratify AML patients to predict those likely to fail conventional 
chemotherapies and those likely to benefit from novel therapeutic approaches that modulate 
DNA repair activity. In a recent study Stanczyk et al. (2011) have demonstrated that 
Cys/Cys variant of the OGG1 Ser326Cys polymorphism may increase the risk of ALL 
(OR=5.36, P<0.001). 
APE1 
The human apurinic/apyrimidinic endonuclease (APE1) plays a central role in the base 
excision repair pathway, which is the primary mechanism for the repair of DNA damage 
caused by oxidation and alkylation. The APE1 gene is located on chromosome 14q11.2–
q12 and contains five exons. A total of 18 polymorphisms in APE1 have been reported, 
but the most extensively studied polymorphism is Asp148Glu (Gu et al., 2009). The 
damaged bases of purine and pyrimidine are recognized and excised by specific DNA 
glycosylases, leaving abasic sites. Apurinic/apyrimidinic endonuclease then incise the 
DNA 5' to the abasic sites; further repair proceeds to short-patch (when the gap is only 
one nucleotide) or long-patch (when the gap is two or more nucleotides) subpathways of 
base excision repair (Lo et al., 2009). In a hospital-based matched case-control study with 
730 lung cancer cases and 730 cancer-free controls Lo et al. (2009)  found that the -656T>G 
variant in the APE1 promoter was associated with a significantly decreased risk for lung 
cancer. In a study of 320 pediatric patients with acute leukemia, Krajinovic et al. (2002) 
reported no significant associations between polymorphic APE1 148Glu and XRCC1 
194Trp variants and event-free survival. Ji et al. (2020) performed a meta-analysis to 
explore the association between the APE1 Asn148Glu gene polymorphisms and lung 
cancer risk. They suggested that the APE1 T1349G (Asp148Glu) polymorphism was not 
associated with lung cancer risk among Asians or Caucasians. But, the APE1 G allele was 
an increased risk factor for developing lung cancer among smokers. Pre-clinical and 
clinical data indicate a role for APE1 in the pathogenesis of cancer and in resistance to 
DNA-interactive drugs, particularly monofunctional alkylators and antimetabolites 
(Wilson & Simeonov, 2010). 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
388 
oligonucleotide patch containing the AP site and filling of the gap by polymerase δ or ε. 
Base alterations caused by a large variety of agents and processes (e.g. spontaneous 
deamination, ionizing radiation, alkylating agents, DNA replication errors) are processed by 
BER. A common feature of the DNA lesions recognized by BER glycosylases is that they do 
not significantly distort the DNA helix (Yu, 2009). 
Common single-nucleotide polymorphisms (SNPs) in the 8-oxoguanine glycosylase 1 
(OGG1), X-ray repair cross-complementing group1 (XRCC1), and the apyrimidinic 
endonuclease-endonuclease 1 (APE1) genes in the BER pathway have been studied for their 
influences in induction of DNA damage (Chen et al., 2010). 
XRCC1 
X-ray repair cross-complementing group 1 (XRCC1) is required for repairing single-strand 
breaks and damaged bases in DNA. The XRCC1 protein interacts with DNA polymerase β, 
DNA ligase III and polyadenosine diphosphate-ribose polymerases (PARP) involved in 
excision and recombinational repair pathways (Cardecott, 2003). The XRCC1 has no known 
enzymatic activity (Thompson et al., 1990) and participates as a scaffold protein in both 
single-strand break repair and base excision repair activities. The human XRCC1 gene is 
located on chromosome 19q13.2 which contains 17 exons and encodes a protein of consisting 
633 amino acids (Lindahl & Wood, 1999). More than 60 validated single-nucleotide XRCC1 
polymorphisms are known. The most studied single nucleotide polymorphisms are 
Arg194Trp on exon 6, Arg280His on exon 9, and Arg399Gln on exon 10. All these 
polymorphisms were studied with association to different types of cancer. 
The presences of the variant (399Gln and 194Trp) alleles have been shown to be associated 
with measurable reduced DNA repair capacity and increased risk of several types of cancers 
(Dufloth et al., 2005; Goode et al., 2002; Hu et al., 2005; Hung et al., 2005). In our study 
involving 43 patients with acute leukemia and 40 controls, for XRCC1 Arg194Trp and 
Arg399Gln polymorphism, we observed the relationship of XRCC1 polymorphisms with 
acute myeloid leukemia (our own unpublished data). Our cases with a codon 194 Trp/Trp 
homozygous variant as well as the heterozygous Arg/Trp variant had an increased risk of 
AML with a greater risk in the case of the homozygous codon 194 Trp/Trp allele (OR=2.28, 
95% for Trp/Trp). There was a significantly high risk of AML among patients who were 
carriers of the variant allele 399Gln (OR=2.45, 95% for Gln/Gln and OR=1.90, 95% for 
Arg/Gln).  
A study by Seedhouse et al. (2002) reported that the presence of at least one XRCC1 399Gln 
allele indicated a protective effect for the allele in controls compared with patients with 
AML, particularly therapy-related AML (t-AML) (odds ratio OR=0.44; 95% confidence 
interval CI=0.20~0.93). According to the same study patients who develop AML as a result 
of therapy for a primary malignancy are more likely to have the wild-type XRCC1 399 
arginine allele. El-Din et al. (2010) reported that XRCC1 gene polymorphism is important in 
the pathogenesis of de novo AML. El-Din et al. (2010) observed that AML patients 
expressing XRCC1 Arg194Trp polymorphism are at high risk of developing AML; in 
addition, a significant risk in the development of AML was observed when XRCC1 
Arg399Gln polymorphism was present. In a study of 372 patients with acute myeloid 
leukemia, Kuptsova et al. (2007) reported no significant associations between XRCC1 
polymorphisms and treatment outcomes. 
The Association of the DNA Repair Genes with Acute Myeloid Leukemia:  




The human 8-oxoguanine DNA glycosylase 1 (hOGG1) encoded by the hOGG1 gene can 
remove 8-hydroxy-2-deoxyguanine (8-OHdG) from damaged DNA as a part of the base 
excision repair pathway (Kohno et al., 1998). The hOGG1 gene is located on chromosome 
3p26.2 (Kohno et al., 1998). Although, several polymorphisms in the hOGG1 gene have been 
described, the most commonly studied polymorphism is an amino acid change from serine 
to cysteine at codon 326 (Ser326Cys). Several studies have reported that Ser326Cys 
polymorphism in OGG1 gene may increase susceptibility to for bladder (Arizono et al., 
2008), lung (Park et al., 2004), oesophageal (Xing et al., 2001), gallbladder and gastric 
(Tsukino et al., 2004) cancer development. 
Liddiard et al (2010) provided a study about the importance of 8-oxoguanine in AML 
including the genotyping of 174 AML patients for the hOGG1 Ser326Cys polymorphism. 
Using Affymetrix microarrays they showed that the prevalence rate of hOGG1 expression 
was 33% and correlated strongly with adverse cytogenetics. hOGG1-expressing patients had 
a worse relapse-free survival and overall survival and an increased risk of relapse at 5-years 
of follow-up. According to Liddiard et al. (2010) hOGG1 is an important prognostic marker 
that could be used to sub-stratify AML patients to predict those likely to fail conventional 
chemotherapies and those likely to benefit from novel therapeutic approaches that modulate 
DNA repair activity. In a recent study Stanczyk et al. (2011) have demonstrated that 
Cys/Cys variant of the OGG1 Ser326Cys polymorphism may increase the risk of ALL 
(OR=5.36, P<0.001). 
APE1 
The human apurinic/apyrimidinic endonuclease (APE1) plays a central role in the base 
excision repair pathway, which is the primary mechanism for the repair of DNA damage 
caused by oxidation and alkylation. The APE1 gene is located on chromosome 14q11.2–
q12 and contains five exons. A total of 18 polymorphisms in APE1 have been reported, 
but the most extensively studied polymorphism is Asp148Glu (Gu et al., 2009). The 
damaged bases of purine and pyrimidine are recognized and excised by specific DNA 
glycosylases, leaving abasic sites. Apurinic/apyrimidinic endonuclease then incise the 
DNA 5' to the abasic sites; further repair proceeds to short-patch (when the gap is only 
one nucleotide) or long-patch (when the gap is two or more nucleotides) subpathways of 
base excision repair (Lo et al., 2009). In a hospital-based matched case-control study with 
730 lung cancer cases and 730 cancer-free controls Lo et al. (2009)  found that the -656T>G 
variant in the APE1 promoter was associated with a significantly decreased risk for lung 
cancer. In a study of 320 pediatric patients with acute leukemia, Krajinovic et al. (2002) 
reported no significant associations between polymorphic APE1 148Glu and XRCC1 
194Trp variants and event-free survival. Ji et al. (2020) performed a meta-analysis to 
explore the association between the APE1 Asn148Glu gene polymorphisms and lung 
cancer risk. They suggested that the APE1 T1349G (Asp148Glu) polymorphism was not 
associated with lung cancer risk among Asians or Caucasians. But, the APE1 G allele was 
an increased risk factor for developing lung cancer among smokers. Pre-clinical and 
clinical data indicate a role for APE1 in the pathogenesis of cancer and in resistance to 
DNA-interactive drugs, particularly monofunctional alkylators and antimetabolites 
(Wilson & Simeonov, 2010). 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
390 
2.3 Nucleotide Excision Repair 
Nucleotide excision repair is the most studied DNA repair system in humans (de Laat et al., 
1999). The NER pathway is responsible for repair of bulky distortions in the shape of the 
DNA double helix such as chemical adducts, pyrimidine dimers, and cross-links caused by 
endogenous and environmental lesions (Riedl et al., 2003; van der Wees et al., 2007; Wood, 
1989). This pathway may also be important in conferring resistance to chemotherapeutic 
agents such as platinum-based chemotherapy (Kennedy & D'Andrea, 2006).  
NER has five stages: recognition of the bulky damage which distorts the DNA helix; 
hydrolyzing a phosphodiester bond in the deoxyribose backbone on the 5' side of the lesion; 
excising the damage; filling in the resultant gap using the information from the 
complementary strand; closing the nicked DNA to generate intact strand (Yasbin, 2002). 
NER can be divided into two subpathways (Transcription coupled NER and Global genomic 
NER) that differ only in their recognition of helix-distorting DNA damage (Hanawalt, 2002). 
Global genome repair is a slow process of inspecting the entire genome for damage 
(Kennedy & D'Andrea AD, 2006). Transcription-coupled repair is more rapid, highly 
specific and efficient and repairs DNA damage that blocks the progression of RNA 
polymerase II. 
The actual repair mechanism appears to be identical in transcription-coupled and in global-
genome repair. However, the damage recognition in global-genome repair does not involve 
the RNA polymerase, but is performed by the XPC and HHR23 proteins. Following lesion 
recognition, however, both repair systems use TFIIH components such as XPB and XPD, as 
well as the single-strand binding protein RPA and the XPA protein to fully unwind and 
mark the lesion. The damaged segment of DNA is excised through 5’-incision by the XPF 
endonuclease and 3’-incision by the XPG endonuclease. The DNA gap is filled by DNA 
polymerases δ or ε supported by PCNA and sealed by a DNA ligase, presumably DNA 
ligase I (Kennedy & D'Andrea, 2006; Yu et al., 1999). 
XPD 
The XPD gene (xeroderma pigmentosum group D, also known as ERCC2) encodes a DNA 
helicase involved in nucleotide excision repair pathway. The XPD gene maps to chromosome 
19q13.3 and consists of 23 exons (Wang et al., 2008). Its protein is 761 amino acids in length. 
The XPD protein repairs a wide range of structurally unrelated lesions, such as bulky adducts 
and thymidine dimers (Braithwaite et al., 1999). The DNA repair process and gene 
transcription are coupled via activity of the TFIIH complex, a protein complex with functions 
including transcription, NER, transcription-coupled repair, apoptosis, and cell cycle 
regulation. XPD protein is involved in maintaining the stability of the TFIIH complex. The 
XPD gene product has an ATP-dependent DNA helicase activity (Laine et al, 2007). 
Because of the biological significance of XPD, the XPD Lys751Gln (2251A>C) polymorphism 
has been a common subject of studies in different malignant diseases in the last years. 
Although the XPD 751Gln variant was associated with an increased risk of esophageal 
cancer and acute lymphoid leukemia (Wang et al., 2008) Allan et al. (2004) investigated XPD 
Lys751Gln polymorphism in 341 adult British AML patients and observed that the XPD 
codon 751 polymorphism is an independent prognostic marker for disease-free survival and 
overall survival in elderly AML patients treated with chemotherapy, and specifically that 
the glutamine variant was associated with a poorer prognosis relative to the lysine variant. 
In a pediatric study, Mehta et al. (2006) found no influence of XPD751 genotype on 
susceptibility to de novo AML in children. In another study, Kuptsova-Clarkson et al. (2010) 
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evaluated the role of XPD and XRCC1 gene polymorphic variation in response to induction 
chemotherapy, toxicities and survival in a population of 293 predominantly Caucasian adult 
patients treated for AML. Kuptsova-Clarkson et al. (2010) had reported that in AML, 
variation in the XPD gene may be associated with suboptimal DNA repair activity and may 
thus predispose to therapy-related AML development. In a UK study by Seedhouse et al. 
(2002), therapy-related AML was not associated with XPD genotypes. 
There have been studies of XPD, involved in NER, and survival of patients with AML (Allan 
et al., 2004). In a study of elderly patients with AML conducted by researchers in the United 
Kingdom, modestly increased hazard ratio (HR) of 1.30 and 1.19 were found for disease-free 
and overall survival, respectively, by XPD variant genotypes. However, in a study of  
pediatric patients with  acute myeloid leukemia conducted by the the Children’s Oncology 
Group (Mehta et al., 2006) survival and treatment-related mortality were not associated with 
XPD codon 751 genotypes. 
2.4 Mismatch repair  
DNA mismatch repair (MMR) plays a critical role in maintaining genomic integrity. MMR is 
responsible for correction of mismatched basepairs which occurs through processes 
including misincorporations during DNA replication, formation of heteroduplexes, and 
secondary structure such as imperfect palindromes (Bishop et al., 1985). 
In addition, MMR can also process some types of DNA damage. MMR deficient tumors 
display widespread alterations in simple repetitive DNA sequences, a phenomenon also 
called microsatellite instability; MSI (Li, 2008). The repair mechanism is similar to that of 
excision repair; a patch of nucleotides is removed from one strand, and followed by 
resynthesis and ligation processes. 
There are two types of mismatch repair, long-patch and short-patch which have been found 
in human cells. In short-patch repair system there are three enzymes possessing nicking 
activities specific for mismatch repair; T/G specific (Wiebauer & Jiricny, 1989), A/G specific, 
and all type mismatch nicking enzymes (Yeh et al., 1991). That enzymes have different mode 
of action, but in either an A/G mismatch or a T/G mismatch, it is usually the guanine that 
remains untouched by mismatch specific glycosylases (Wiebauer & Jiricny, 1989). 
Long patch can repair all types of mismatches. Long-patch MMR removes a patch of one of 
the DNA strands from an incision on the to-be-removed strand to 90~170 nucleotides 
beyond the mismatch (Fang & Modrich, 1993; Yu et al., 1999). 
Defects in the MMR pathway significantly increase the mutation frequency and promote 
oncogenesis. It has been documented that defects in MMR genes, are the genetic basis for 
certain types of hereditary and sporadic cancers, including hereditary nonpolyposis 
colorectal cancer (Mao et al., 2008). There are some studies looking at the incidence of MMR 
deficiency (microsatellite instability; MSI) in AML (Mao et al., 2008). Genomic instability in 
AML has led to a search for MSI in AML patients, but the results are quite controversial. 
While several studies have reported MSI in AML (Das-Gupta et al., 2001; Sheikhha et al., 
2002), a study of 132 cases failed to confirm the previous results (Rimsza et al., 2000). 
According to Rimsza et al. (2000) MMR deficiency was associated with all stages of AML, 
but the rate of the deficiency was much higher in patients with refractory and relapsed AML 
than in de novo AML patients, suggesting that the loss of MMR function could contribute to 
the refractory and relapsed disease. 
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2.5 Double Strand Break repair 
Double strand break repair (DSB) is responsible for the repair of double strand DNA breaks. 
DNA double strand breaks represent the most important class of DNA damage because, if 
unrepaired, they can result in a loss of genetic material, chromosome abnormalities and 
possibly cell death. Moreover, the breaks are prone to nuclease attack with subsequent 
destruction (Rufer & Morgan, 1992). Double strand breaks (DSBs) can be produced by 
exogenous agents such as ionizing radiation, some chemotherapeutic drugs, endogenous 
formed reactive oxygen species. When DNA replication forks encounter DNA single strand 
breaks or other types of lesion, it might result in formation of DSBs. In addition, DSBs are 
generated to initiate recombination between homologues chromosomes during meiosis, and 
also during the immunoglobulin class-switch recombination. Repair of DSBs is more 
difficult than other type of DNA damage because there is no undamaged template available 
(Khanna & Jackson, 2001). 
Direct DSBs are mainly repaired by non-homologous end joining (Sargent et al., 1997), 
whereas replication-associated DSBs are repaired by homologous recombination (HR) and 
related replication repair pathways (Iliakis et al., 2004). 
2.5.1 Non-homologous End Joining 
Non homologous end joining (NHEJ) is active in all phases of the cell cycle and is 
considered to be the most important DSB repair pathway in mammalian cells. The NHEJ 
pathway is simpler than HR and requires no complementary template. The protein 
components of NHEJ include the catalytic subunit of DNA protein kinase (DNA-PKCS), the 
two regulatory subunits of the DNA-PK complex Ku70 and Ku80, DNA ligase IV with its 
cofactor XRCC4 (the X-ray cross complementing group 4 protein) and the nuclease artemis 
(Drouet et al., 2005; Khanna & Jackson, 2001). The Ku70/Ku80 (Ku) heterodimer is the first 
protein to bind to the damaged DNA ends. When bound to the DSB, Ku recruits and 
activates DNA-PKcs. These proteins play an important role in DNA DSB repair and will act 
as tumor suppressors. However, either the DNA protein kinase complex, or its three 
subunits individually, can also act as oncogenes, depending on the compartment of the cell 
in which they are expressed and on the cell cycle phase (Gullo et al., 2006). 
XRCC4 
The X-ray cross-complementing group 4 (XRCC4) gene is one of the specific members of the 
NHEJ system. Some of the SNPs of XRCC4 have been found to be associated with the 
susceptibility to different types of cancer. Two single nucleotide polymorphisms (SNPs) of 
XRCC4, one splicing-site polymorphism (SNP14 rs1805377:A4G) and one intronic 
polymorphism (SNP1 rs2075685:G4T), have been studied, and the results are conflicting 
(Allen-Brady et al., 2006; Fu et al., 2003). The protein encoded by XRCC4 consists of 336 
amino acid residues distributed among 8 exons, and has a long helical stem domain 
responsible for multimerization and interaction with DNA ligase IV (Junop et al., 2000). By 
forming a complex with DNA ligase IV and DNA-dependent protein kinase, XRCC4 
functions in the repair of DNA double-strand breaks by non-homologous end joining 
(NHEJ) and the completion of V(D)J recombination events (Hayden et al, 2007). The NHEJ 
pathway is required not only for normal development but also for suppression of tumors. 
Since it is one of the ubiquitous NHEJ components, XRCC4 might be considered as a 
potential tumor suppressor gene in cancer and leukemia. 
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There have been several studies showing that variations of the XRCC4 gene are associated 
with prostate (Chang et al., 2008), gastric (Chiu et al., 2008), and breast cancer (Fu et al., 
2003). Therefore, XRCC4 and the DNA double-strand break repair pathway may serve as a 
common mechanism of early carcinogenesis. In a recent study, Wu et al. (2008) investigated 
the association between XRCC4 gene polymorphisms and oral cancer. Their findings 
suggest that the presence of the A allele of XRCC4 codon 247 was associated with a higher 
susceptibility to oral cancer, and the A allele of XRCC4 codon 247 may be a useful novel 
marker in oral oncology for primary prevention and intervention. 
XRCC5, XRCC6, XRCC7  
A key component of the NHEJ pathway is the DNA-dependent Protein Kinase (DNA-PK), 
which consists of a heterodimeric DNA targeting subunit (i.e., Ku70/Ku80, encoded by 
XRCC6/XRCC5 genes) and a catalytic subunit DNA-PKcs, encoded by XRCC7 gene (Smith 
& Jackson, 1999). 
XRCC5 (X-ray repair cross-complementing 5) is a gene involved in repair of DNA double-
strand breaks. Abnormal expression of the XRCC5 protein is associated with genomic 
instability and an increased incidence of cancers. The XRCC5 gene mapped to chromosome 
2q35, encodes the 80-kDa subunit of the Ku heterodimer protein, the DNA-binding 
component of the DNA-dependent protein kinase. The Ku80 is essential for maintaining 
genomic integrity through its ability to bind DNA double-strand breaks and to facilitate 
repair by the nonhomologous end-joining pathway in mammalian cells (Taccioli et al., 1994). 
XRCC6 (X-ray repair complementing defective repair in Chinese hamster cells 6) is a 
helicase involved in DNA repair and chromatin remodeling. The XRCC6 gene (also called 
Ku70) maps to chromosome 22q13.2-q1. Ku70 plays an important role in the DNA double-
strand breaks repair and maintenance of genomic integrity. Genetic variations within 
human Ku70 have been demonstrated to be associated with increased risk of several types 
of cancers (Wenshan et al., 2011). 
XRCC7 (X-ray repair cross complementing group 7) is located on chromosome 8q12, span 
about 110-180 kb and contains 100 exons. The human XRCC7 gene encodes DNA-PKcs, 
which is recruited to the site of DSBs by the Ku70/Ku80 heterodimer to form an active 
DNA-PK complex (Sipley et al., 1995). The expression of Ku70 and XRCC7 is elevated in 
bladder tumor tissue and head and neck cancer cell lines, respectively (Stronati et al., 2001; 
Sturgis et al., 1999) and Ku70 may function as a caretaker gene for the development of T-cell 
lymphomas (Li et al., 1998). XRCC7 encodes DNA-PKcs, which also may have a caretaker 
role in colon carcinogenesis. Therefore, the variants of the Ku70 and XRCC7 genes could be 
expected to have an effect on DSB repair, and thus, on carcinogenesis. The Ku70 
polymorphism is associated with risk of breast cancer (Fu et al., 2003), and the XRCC7 
polymorphism is associated with risk of glioma (Wang et al., 2004). According to Wang et al. 
(2008) the XRCC7 polymorphism appears to be involved in the etiology of human bladder 
cancer. This data support the notion that the XRCC7 polymorphism is implicated in cancer 
risk. 
Given the crucial roles of the NHEJ pathway in DNA repair (Gullo et al., 2006), it is possible 
that the XRCC5, XRCC6 and XRCC7 variants may modulate the risk of cancer, including 
leukemia. It has been shown that increased NHEJ activity is due to the presence of XRCC5 
and XRCC6 protein, which results in genomic instability in myeloid leukemia cells (Gaymes 
et al., 2002). XRCC5 and XRCC6 may function as a caretaker gene for the development of T-
cell lymphomas, while XRCC7 may have a caretaker role in colon carcinogenesis (Wang et 
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al., 2009). In a recent study, Wang et al. (2009) have investigated the association between the 
X-ray repair cross complementing group XRCC5, XRCC6 and XRCC7 polymorphisms and 
risk of AML in Chinese population. In this case-control study in a southern Chinese 
population three polymorphisms, XRCC5 2R/1R/0R, XRCC6 -61C>G and XRCC7 6721G>T 
were investigated. For the XRCC7 6721G>T polymorphism among AML cases and controls 
no significant association was observed (P=0.68). Significant association was observed 
(P=0.04) for the XRCC6 -61C > G polymorphism. Their analysis revealed that compared 
with the XRCC6 -61CC wild type homozygote, the -61CG heterozygotes had a significant 
43% decreased risk of AML (adjusted OR=0.57; 95% CI=0.35~0.92) and subjects carrying -
61CG/GG variant genotypes had 45% decrease in risk of AML (adjusted OR=0.55; 95% 
CI=0.34~0.89). For the XRCC5 2R/1R/0R polymorphism, Wang et al. (2009) found that 
XRRC5 1R/0R genotype was associated with a 2.60-fold increase in risk of AML (95% 
CI=1.42~5.92) compared with the 2R/2R genotype. They found a significant association 
with the polymorphisms of XRCC5 2R/1R/0R, XRCC6 -61C>G and the risk of AML, but 
there was no evidence for an association between the XRCC7 6721G>T variants and AML. 
2.5.2 Homologous recombination  
Homologous recombination (HR) is one of the main pathways for the repair of DNA double 
strand breaks (DSBs). HR is thought to be particularly important in DNA repair occurring 
during cellular replication (Rollinson et al., 2007). Although HR is indispensable for 
maintaining genome integrity, it must be tightly regulated to avoid harmful outcomes. The 
repair process is complex and involves many proteins working coordinately. Key players 
include MRE11, RAD50, NBS1 (MRN), RAD51, RAD51B, RAD51C, RAD51D, XRCC2, 
XRCC3, RAD52, RAD54 and BRCA2 (Lieberman, 2008). A number of polymorphic genes 
involved in this pathway have been studied in AML. 
Homologous recombination mechanism starts with degradation of the DNA next to the 
double-strand break, leaving single-strand ends. Next the single-strand end of the damaged 
strand invades and binds to its complementary DNA sequence on the homologous duplex. 
This is associated with the displacement of the cross-complementary strand toward the gap 
site, where it serves as a template for gap-filling DNA synthesis. The repair sequence is 
terminated by religation of the repair patches. This mechanism requires the presence of 
undamaged homologous DNA, and increased activity of this repair pathway has been 
observed.  
RAD51 protein catalyzes homologous recombination through its homologous pairing and 
strand exchange activities. RAD52 may modulate these activities through its RAD51-
interacting region. The ability of RAD52 to induce homologous recombination requires its 
binding to the p34 subunit of RPA. This RPA binding domain is at amino acids 221–280. 
Recall that RPA is also involved in NER—this may provide a linkage between these two 
repair systems (Yu Z et al., 1999). 
XRRC3 
The X-ray repair cross-complementing group 3 (XRCC3), codes for a protein participating in 
homologous recombination repair of DNA double-strand breaks. XRCC3 is a member of the 
RAD-51-related protein family. RAD-51-like proteins are known to participate in 
homologous recombination to maintain chromosome stability and repair DNA damage 
(Brenneman et al., 2000). XRCC3-deficient cells demonstrated genetic instability and 
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increased sensitivity to DNA damaging agents (Griffin, 2002). The human XRCC3 gene is 
located on chromosome 14q32.3 and consists of 17870 bases. The protein product of XRCC3 
gene contains 346 amino acids. According to NCBI SNP database, XRCC3 gene has 111 
SNPs. The main polymorphism in this gene involves the change of threonine (Thr) to 
methionine (Met) at codon 241 in exon 7 (Shen et al., 1998). Little is known about the 
functional consequences of this variation, although some studies observed a positive 
relation between the Thr241Met polymorphism and an increased risk for skin (Winsey et al., 
2000), bladder (Matullo et al., 2001), breast (Garcia-Closas et al., 2006) and lung (Jacobsen et 
al., 2004) cancers. 
A meta-analysis of 48 case–control studies, including 24975 cancer patients and 34209 
controls, investigated the associations of the three DNA repair gene XRCC3 polymorphisms 
(Thr241Met; 4541A4G; 17893A4G) with cancer risk (Han et al., 2006). According to this 
meta-analysis individuals carrying the XRCC3 Met/Met genotype have a smaller cancer risk 
compared with the individuals with the Thr/Thr or Thr/Met genotype (OR=1.07; P=0.008; 
95% CI=1.02~1.13) (Han et al., 2006). For A4541G, a significantly increased risk was 
associated with the variant genotypes (G/G+A/G), compared with the wild homozygote 
A/A genotype (OR=1.09; P=0.004; 95% CI, 1.03~1.15). For A17893G, individuals with the 
variant genotypes (G/G+A/G) had a significantly decreased cancer risk, compared with 
individuals with the A/A genotype under a dominant genetic model (OR=0.92; P=0.0004; 
95% CI=0.87~0.96). Han et al. (2006) consider that the XRCC3 could not be a major increased 
risk factor for cancer but it might represent a low-penetrance susceptible gene especially for 
cancer of breast, bladder, head and neck, and non-melanoma skin cancer 
In their study Seedhouse et al. (2004) have observed that the presence of variant XRCC3 
241Met was associated with an increase in the risk of developing therapy-related AML of 
more than 8 fold, whereas the increase in risk for the development of de novo AML was 
nearly 4 fold.  
RAD 51 
The RAD51 gene plays an important role in homologous recombination and in maintaining 
the genetic stability of the cell. In HR, RAD51 interacts with and is stabilized by XRCC3, 
during strand invasion and cross-strand resolution. RAD51 is a central protein in the HR 
repair pathway binding to DNA and promoting ATP-dependent homologous pairing and 
strand transfer reactions.  
The RAD51 gene is located on chromosome 15q15.1 and consists of 36998 bases. The protein 
product of RAD51 has 6 domains, one for DNA binding, one for ATPase activity, and the 
other domains are specific to action of RAD51. According to NCBI SNP database, RAD51 
gene has 296 SNPs. The most important polymorphism identified for RAD51 is G135C SNP 
in 5’ untranslated region. The RAD51 G135C polymorphism is associated with RAD51 
protein over-expression (Richardson et al., 2004). Regarding the role of RAD51 in the 
homologous DNA repair mechanism, several studies have examined the relationship 
between RAD51 G135C polymorphism and risk of certain cancers. However the results from 
these studies are conflicting. Further studies are needed to establish the role of RAD51 
G135C polymorphism in human carcinogenesis. 
Voso et al. (2007) found an increased frequency of the RAD51 135C allele in AML, mainly in 
de novo AML, when compared with controls, but not between therapy-related AML  
(t-AML) and controls. Other reports found increased frequency of the RAD51 135C allele in 
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undamaged homologous DNA, and increased activity of this repair pathway has been 
observed.  
RAD51 protein catalyzes homologous recombination through its homologous pairing and 
strand exchange activities. RAD52 may modulate these activities through its RAD51-
interacting region. The ability of RAD52 to induce homologous recombination requires its 
binding to the p34 subunit of RPA. This RPA binding domain is at amino acids 221–280. 
Recall that RPA is also involved in NER—this may provide a linkage between these two 
repair systems (Yu Z et al., 1999). 
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The X-ray repair cross-complementing group 3 (XRCC3), codes for a protein participating in 
homologous recombination repair of DNA double-strand breaks. XRCC3 is a member of the 
RAD-51-related protein family. RAD-51-like proteins are known to participate in 
homologous recombination to maintain chromosome stability and repair DNA damage 
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product of RAD51 has 6 domains, one for DNA binding, one for ATPase activity, and the 
other domains are specific to action of RAD51. According to NCBI SNP database, RAD51 
gene has 296 SNPs. The most important polymorphism identified for RAD51 is G135C SNP 
in 5’ untranslated region. The RAD51 G135C polymorphism is associated with RAD51 
protein over-expression (Richardson et al., 2004). Regarding the role of RAD51 in the 
homologous DNA repair mechanism, several studies have examined the relationship 
between RAD51 G135C polymorphism and risk of certain cancers. However the results from 
these studies are conflicting. Further studies are needed to establish the role of RAD51 
G135C polymorphism in human carcinogenesis. 
Voso et al. (2007) found an increased frequency of the RAD51 135C allele in AML, mainly in 
de novo AML, when compared with controls, but not between therapy-related AML  
(t-AML) and controls. Other reports found increased frequency of the RAD51 135C allele in 
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t-AML patients compared with controls (Seedhouse et al., 2004), suggesting an effect of 
RAD51 over-expression during leukemogenesis induced by chemotherapy or radiotherapy. 
According to Bhatla et al. (2008) RAD51 gene polymorphism did not influence the outcome 
of AML therapy in the study of de novo AML patients. On the contrary, Liu et al. (2008) 
concluded that RAD51 gene polymorphism was significantly related to response to therapy, 
adverse effects, and prognosis of AML and reported that detection of the RAD51 gene 
polymorphism genotypes may be useful in selecting individual chemotherapy regimens for 
patients with AML. Also, Bolufer et al. (2007) reported that the RAD51 gene polymorphism 
showed significant unfavorable outcome among AML patients. 
In their study, Bathla et al. (2008) observed a doubling of risk of AML in children with a 
RAD51 G135C variant allele and a wild-type XRCC3 Thre241Met genotype. In addition risk 
of AML was significantly increased in children with at least one variant XRCC3 Thr241Met 
allele. In antithesis, risk was not significantly elevated in children with variant alleles at both 
wild-type XRCC3 Thre241Met and RAD51 G135C. Liu et al. (2008) found that XRCC3 gene 
polymorphism was significantly related to response to therapy and prognosis of AML and 
reported that detection of the XRCC3 gene polymorphism genotypes may be useful in 
selecting individual chemotherapy regimens for AML patients. 
2.6 Translesion synthesis 
Translesion synthesis is an important mechanism by which cells replicate past DNA 
damage. The sliding clamp DNA polymerase processivity factors play a central role in this 
process. The clamps are dimeric in bacteria and trimeric in eukaryotes and archaea, raising 
the question of whether more than one polymerase can interact with the clamp 
simultaneously (Lehmann, 2006). 
3. Inherited human disease with leukemia susceptibility  
Several studies have demonstrated that the genes involved in DNA repair and maintenance 
of genome integrity are critically in protecting against mutations that lead to cancer and/or 
inherited human disease (Table 2).  
 
Syndrome Gene(s) involved  Chromosome References 
Fanconi anaemia 
(FA)  
FANC-A to FANC-N  16q24.3  Levitus et al., 2004; 






11q22.3  Savitsky et al., 1995; 




syndrome (NBS)  
NBS1 (Nibrin) 8p21  Digweed et al., 1999; 
Varon et al. 2003 
Bloom syndrome 
(BLM)  
BLM (RECQL3) 15q26.1  Ellis & German, 1996; 
Thompson & Schild, 
2002 
Seckel Syndrome  ATR  3q22-24  Casper et al., 2002;  
Table 2. DNA repair defective syndromes 
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Several of these diseases include an inherent predisposition to hematologic malignancies, 
including AML. The clinical features and molecular characteristics of several of the inherited 
disorders with leukemia risk are described below. 
Fanconi anemia (FA) is a rare disorder with a birth incidence around 3 per million. FA is an 
autosomal recessive and rarely X-linked syndrome which is characterised by congenital 
abnormalities, defective haemopoiesis (bone marrow failure) and a high risk of developing 
AML and certain solid tumours.  
Affected individuals can have mild growth retardation,  hypo- or hyperpigmented areas of 
the skin, skeletal defects including radial limb defects (absent thumb with or without radial 
aplasia), abnormalities of ribs and hips and scoliosis, cardiac and renal malformations, 
genital abnormalities (especially undescended testes, testicular agenesis, hypospadias). 
Other associated anomalies include micropthalmia and developmental delay (Grompe & 
D'Andrea, 2001). The phenotypic abnormalities are variable and there is marked variability 
between affected individuals in the same family (Alter, 1993). 
The Fanconi anemia defect results from biallelic mutation of any one of thirteen known 
Fanconi anemia genes (A, B, C, D1, D2, E, F, G, I, J, L, M, N). The proteins encoded by these 
Fanconi anemia genes cooperate in a common DNA repair pathway, referred to as the 
Fanconi anemia /BRCA pathway. In this pathway, eight of the Fanconi anemia proteins (A, 
B, C, E, F, G, L, M) are assembled into a core complex that functions as an E3 ubiquitin 
ligase. This ligase activates in response to DNA damage from a crosslinking drug, adding a 
76-amino acid moiety onto two other Fanconi proteins, D2 and I. This monoubiquinated 
D2/I complex is translocated into chromatin, where it interacts with the downstream 
Fanconi proteins BRCA2, N, and J. This combination of proteins mediates the DNA repair 
process. After the repair has occurred, there is another enzyme complex, called USP1, which 
removes the ubiquitin and inactivates the pathway. Knocking out any of the proteins in this 
pathway causes FA (D’Andrea, 2010). 
FANCA, located on chromosome 16q24.3, is the most commonly mutated gene and  is 
altered in 60-65% of FA patients (Steensma, 2007). FANCC and G mutations account for 
almost 25%, and FANCE and FANCF for a further 8%. 
Approximately one third of patients homozygous for a Fanconi anemia gene mutation will 
develop a hematologic or solid tumors by the age of 40 years (Kennedy & D'Andrea, 2006). 
Fanconi anemia patients develop predominately myeloid malignancies (the most common 
hematologic maliganancy is AML), although numerous other cancers arise, including 
squamous cell carcinomas of the head and neck or gynecologic system, skin cancers, 
esophageal cancers and liver tumors (Alter, 2003; Rosenberg et al, 2008). 
Fanconi anemia patients have a systemic DNA repair defect that results in a low tolerance 
for DNA damaging chemotherapeutic agents. 
Ataxia–telangiectasia (AT) is a rare autosomal recessive disorder. This human disease is 
characterized by cerebellar degeneration, immunodeficiency, hypogonadism, growth 
retardation, genome instability, extreme sensitivity to radiation and predisposition to cancer 
(Taylor & Byrd, 2005). The disease is caused by homozygous mutations in the gene 
encoding the ATM protein kinase that plays a critical role in DNA damage detection and 
regulates DNA double-strand break repair (Mavrou et al, 2008). The ATM gene is located  
on chromosome 11q23. When ATM is dysfunctional or absent, cells are able to progress 
from G1 to S phase and initiate DNA replication in the presence of DNA damage. 
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t-AML patients compared with controls (Seedhouse et al., 2004), suggesting an effect of 
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of AML was significantly increased in children with at least one variant XRCC3 Thr241Met 
allele. In antithesis, risk was not significantly elevated in children with variant alleles at both 
wild-type XRCC3 Thre241Met and RAD51 G135C. Liu et al. (2008) found that XRCC3 gene 
polymorphism was significantly related to response to therapy and prognosis of AML and 
reported that detection of the XRCC3 gene polymorphism genotypes may be useful in 
selecting individual chemotherapy regimens for AML patients. 
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Translesion synthesis is an important mechanism by which cells replicate past DNA 
damage. The sliding clamp DNA polymerase processivity factors play a central role in this 
process. The clamps are dimeric in bacteria and trimeric in eukaryotes and archaea, raising 
the question of whether more than one polymerase can interact with the clamp 
simultaneously (Lehmann, 2006). 
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Several of these diseases include an inherent predisposition to hematologic malignancies, 
including AML. The clinical features and molecular characteristics of several of the inherited 
disorders with leukemia risk are described below. 
Fanconi anemia (FA) is a rare disorder with a birth incidence around 3 per million. FA is an 
autosomal recessive and rarely X-linked syndrome which is characterised by congenital 
abnormalities, defective haemopoiesis (bone marrow failure) and a high risk of developing 
AML and certain solid tumours.  
Affected individuals can have mild growth retardation,  hypo- or hyperpigmented areas of 
the skin, skeletal defects including radial limb defects (absent thumb with or without radial 
aplasia), abnormalities of ribs and hips and scoliosis, cardiac and renal malformations, 
genital abnormalities (especially undescended testes, testicular agenesis, hypospadias). 
Other associated anomalies include micropthalmia and developmental delay (Grompe & 
D'Andrea, 2001). The phenotypic abnormalities are variable and there is marked variability 
between affected individuals in the same family (Alter, 1993). 
The Fanconi anemia defect results from biallelic mutation of any one of thirteen known 
Fanconi anemia genes (A, B, C, D1, D2, E, F, G, I, J, L, M, N). The proteins encoded by these 
Fanconi anemia genes cooperate in a common DNA repair pathway, referred to as the 
Fanconi anemia /BRCA pathway. In this pathway, eight of the Fanconi anemia proteins (A, 
B, C, E, F, G, L, M) are assembled into a core complex that functions as an E3 ubiquitin 
ligase. This ligase activates in response to DNA damage from a crosslinking drug, adding a 
76-amino acid moiety onto two other Fanconi proteins, D2 and I. This monoubiquinated 
D2/I complex is translocated into chromatin, where it interacts with the downstream 
Fanconi proteins BRCA2, N, and J. This combination of proteins mediates the DNA repair 
process. After the repair has occurred, there is another enzyme complex, called USP1, which 
removes the ubiquitin and inactivates the pathway. Knocking out any of the proteins in this 
pathway causes FA (D’Andrea, 2010). 
FANCA, located on chromosome 16q24.3, is the most commonly mutated gene and  is 
altered in 60-65% of FA patients (Steensma, 2007). FANCC and G mutations account for 
almost 25%, and FANCE and FANCF for a further 8%. 
Approximately one third of patients homozygous for a Fanconi anemia gene mutation will 
develop a hematologic or solid tumors by the age of 40 years (Kennedy & D'Andrea, 2006). 
Fanconi anemia patients develop predominately myeloid malignancies (the most common 
hematologic maliganancy is AML), although numerous other cancers arise, including 
squamous cell carcinomas of the head and neck or gynecologic system, skin cancers, 
esophageal cancers and liver tumors (Alter, 2003; Rosenberg et al, 2008). 
Fanconi anemia patients have a systemic DNA repair defect that results in a low tolerance 
for DNA damaging chemotherapeutic agents. 
Ataxia–telangiectasia (AT) is a rare autosomal recessive disorder. This human disease is 
characterized by cerebellar degeneration, immunodeficiency, hypogonadism, growth 
retardation, genome instability, extreme sensitivity to radiation and predisposition to cancer 
(Taylor & Byrd, 2005). The disease is caused by homozygous mutations in the gene 
encoding the ATM protein kinase that plays a critical role in DNA damage detection and 
regulates DNA double-strand break repair (Mavrou et al, 2008). The ATM gene is located  
on chromosome 11q23. When ATM is dysfunctional or absent, cells are able to progress 
from G1 to S phase and initiate DNA replication in the presence of DNA damage. 
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Approximately one third of AT patients develop cancer, mainly leukemias and lymphomas 
which develop in childhood and are a common cause of death (Ball & Xiao, 2005; Gumy-
Pause et al, 2004). Solid tumors in AT patients are usually adenocarcinoma of the stomach, 
dysgerminoma, gonadoblastoma and medulloblastoma (Mavrou et al, 2008). 
Bloom’s syndrome (BS) is a rare autosomal recessive syndrome of growth retardation, 
telangiectasia manifest by facial erythema, immunodeficiency, and skull abnormalities. BS 
patients also are predisposed to cancer, as they develop mostly leukemias and lymphomas 
in about half of the patients. This disorder is most commonly found in the Ashkenazi Jewish 
population resulting from a founder mutation (Ellis et al, 1998). It is characterised by low 
birth weight, growth deficiency, characteristic facies (long thin face, prominent nose) sun-
sensitivity, immunodeficiency and infertility in males.  
Bloom’s syndrome arise through mutations in both copies of  the BLM gene, which is 
located on chromosome 15 at 15q26.1. This gene encodes a member of the RecQ family of 
DNA helicases (BLM) that is important in maintaining appropriate DNA conformation 
during chromosomal recombination and repair. Together with topoisomerase III, BLM 
resolves Holliday junctions during homologous recombination (HR) by a mechanism called 
double-junction dissolution that is distinct from classical Holliday junction resolution and 
that prevents erroneous exchange of flanking sequences (Steensma, 2007). 
Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder that is most 
commonly found in Eastern Europe. NBS is caused by abnormalities in the NBN gene at 
8p21 (Varon et al, 2003), which encodes the protein NBN (NBS1). Complete loss of this 
polypeptide is lethal. The NBS gene encodes a 95-kDa protein that binds with MRE11 and 
RAD50 to form a nuclease-containing protein complex that appears to be involved in 
homologous and nonhomologous recombination. Clinical features include growth 
retardation, microcephaly, skin findings such as vitiligo and café au lait spots, skeletal 
defects, immunodeficiency and propensity to infection. Radiation hypersensitivity is a 
hallmark of the disease, along with a predisposition to cancer, most notably lymphomas 
(Digweed et al, 1999). The most common cause of death for NBS patients is neoplasia 
(Steensma, 2007). Although the predominant neoplasm is lymphoma, both lymphoid and 
myeloid leukemia have been reported (Resnick et al, 2002). 
Seckel syndrome (SCKL) is a rare autosomal recessive disorder associated with short 
stature, prenatal and postnatal growth retardation, characteristic craniofacial dysmorphism 
(bird-headed face including prominent beaked nose, micrognathia and malformed ears), 
mental deficiency, microcephaly, and skeletal defects (Faivre et al, 2002). Hematological 
abnormalities, including pancytopenia, myelodysplasia and acute myeloid leukemia, have 
been reported in some patients with Seckel syndrome (Chanan-Khan et al, 2003; Hayani et 
al,1994). A gene for  Seckel syndrome was mapped on chromosome 3q22.1-q24. The ataxia-
telancgiectasia and RAD3-related (ATR) gene is mutated in Seckel syndrome, and encodes 
an phosphotidylinositol-3-kinase-like kinase which has distinct, but overlapping functions 
with ATM in co-ordinating the response to DNA damage. ATR is activated by single 
stranded DNA whilst ATM responds to DNA double strand breaks (Casper et al, 2002; 
Steensma, 2007). 
4. Conclusion 
Genetic variations in genes involved in DNA repair may influence both cancer susceptibility 
and treatment response. However, in AML, the relevance of these genetic variations remains 
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to be fully established. There is evidence that some polymorphisms in DNA repair genes 
play a role in carcinogenesis, notably hOGG1 Ser326Cys, XRCC1 Arg194Trp, XRCC3 
Thr241Met, RAD51 G135C and XPD Lys751Gln. Additional studies of these and other DNA 
repair polymorphisms will provide essential information about the relationships between 
the DNA repair mechanisms and risk of AML. 
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Approximately one third of AT patients develop cancer, mainly leukemias and lymphomas 
which develop in childhood and are a common cause of death (Ball & Xiao, 2005; Gumy-
Pause et al, 2004). Solid tumors in AT patients are usually adenocarcinoma of the stomach, 
dysgerminoma, gonadoblastoma and medulloblastoma (Mavrou et al, 2008). 
Bloom’s syndrome (BS) is a rare autosomal recessive syndrome of growth retardation, 
telangiectasia manifest by facial erythema, immunodeficiency, and skull abnormalities. BS 
patients also are predisposed to cancer, as they develop mostly leukemias and lymphomas 
in about half of the patients. This disorder is most commonly found in the Ashkenazi Jewish 
population resulting from a founder mutation (Ellis et al, 1998). It is characterised by low 
birth weight, growth deficiency, characteristic facies (long thin face, prominent nose) sun-
sensitivity, immunodeficiency and infertility in males.  
Bloom’s syndrome arise through mutations in both copies of  the BLM gene, which is 
located on chromosome 15 at 15q26.1. This gene encodes a member of the RecQ family of 
DNA helicases (BLM) that is important in maintaining appropriate DNA conformation 
during chromosomal recombination and repair. Together with topoisomerase III, BLM 
resolves Holliday junctions during homologous recombination (HR) by a mechanism called 
double-junction dissolution that is distinct from classical Holliday junction resolution and 
that prevents erroneous exchange of flanking sequences (Steensma, 2007). 
Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder that is most 
commonly found in Eastern Europe. NBS is caused by abnormalities in the NBN gene at 
8p21 (Varon et al, 2003), which encodes the protein NBN (NBS1). Complete loss of this 
polypeptide is lethal. The NBS gene encodes a 95-kDa protein that binds with MRE11 and 
RAD50 to form a nuclease-containing protein complex that appears to be involved in 
homologous and nonhomologous recombination. Clinical features include growth 
retardation, microcephaly, skin findings such as vitiligo and café au lait spots, skeletal 
defects, immunodeficiency and propensity to infection. Radiation hypersensitivity is a 
hallmark of the disease, along with a predisposition to cancer, most notably lymphomas 
(Digweed et al, 1999). The most common cause of death for NBS patients is neoplasia 
(Steensma, 2007). Although the predominant neoplasm is lymphoma, both lymphoid and 
myeloid leukemia have been reported (Resnick et al, 2002). 
Seckel syndrome (SCKL) is a rare autosomal recessive disorder associated with short 
stature, prenatal and postnatal growth retardation, characteristic craniofacial dysmorphism 
(bird-headed face including prominent beaked nose, micrognathia and malformed ears), 
mental deficiency, microcephaly, and skeletal defects (Faivre et al, 2002). Hematological 
abnormalities, including pancytopenia, myelodysplasia and acute myeloid leukemia, have 
been reported in some patients with Seckel syndrome (Chanan-Khan et al, 2003; Hayani et 
al,1994). A gene for  Seckel syndrome was mapped on chromosome 3q22.1-q24. The ataxia-
telancgiectasia and RAD3-related (ATR) gene is mutated in Seckel syndrome, and encodes 
an phosphotidylinositol-3-kinase-like kinase which has distinct, but overlapping functions 
with ATM in co-ordinating the response to DNA damage. ATR is activated by single 
stranded DNA whilst ATM responds to DNA double strand breaks (Casper et al, 2002; 
Steensma, 2007). 
4. Conclusion 
Genetic variations in genes involved in DNA repair may influence both cancer susceptibility 
and treatment response. However, in AML, the relevance of these genetic variations remains 
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to be fully established. There is evidence that some polymorphisms in DNA repair genes 
play a role in carcinogenesis, notably hOGG1 Ser326Cys, XRCC1 Arg194Trp, XRCC3 
Thr241Met, RAD51 G135C and XPD Lys751Gln. Additional studies of these and other DNA 
repair polymorphisms will provide essential information about the relationships between 
the DNA repair mechanisms and risk of AML. 
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1. Introduction 
Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults 
(American Cancer Society, 2010) however overall survival rate remain poor despite 
advancement in treatment modality.  
Since the last 50 years, systemic chemotherapy has greatly improved outcome in many types 
of cancers. The use of continuous infusion Arabinosylcytosine (Ara-C) combined with 
another agent, usually an anthracycline or anthracenedione, the “3+7” regimen, has been the 
backbone of induction therapy for AML cases (Yates et al., 1973). An attempt to add other 
drugs (Preisler et al., 1987) and intensification of the Ara-C dose (Schiller et al., 1992; Weick 
et al., 1996) to this approach has achieved some degree of success. Currently more work is 
attempted at improving patient outcome by intensifying the doses of anthracyclines 
(Lowenberg et al., 2010a) or by adding targeted therapies like gemtuzumabozogamicin 
(Lowenberg et al., 2010b; Nabhan et al., 2005). 
For consolidation therapy, the use of Ara-C with or without other agents has been 
employed to maintain remission and cure. Allogeneic hematopoietic cell transplantation 
(HCT) based on initial cytogenetic (Cornelissen et al., 2007; Koreth et al., 2009) and 
molecular studies (Castaigne et al., 2004) have been proposed as an alternative 
consolidation therapies. 
Induction therapy aims to produce complete remission (CR) defined as a marrow with 
less than 5% blast, a neutrophil count greater than 1000/mm3 and a platelet count greater 
than 100,000/mm3 (Cheson et al., 2003). Majority of younger patients (65-75%) will 
achieve CR after receiving induction treatment while CR in elderly group is much lower 
(40-50%).  
Patients who do not respond to induction treatment display chemotherapy resistance (Estey 
et al., 1996). In trials done by the Southwest Oncology Group (SWOG), resistant disease was 
found in about 33% (patients younger than 56 ) out of 404 patients’ enrolled into the studies, 
62% for patients in between 56-65 year old, 61% for patients between 66-75 years old and 
57% for age more than 75 year old (Frederick et al., 2006).  
Resistance is also common at relapse (Estey et al., 1996). Relapse itself could be due to 
resistance to treatment in a subgroup of leukaemic cells which survived induction therapy 
despite CR. Patients usually relapse within two to three years after achieving CR. 
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2. Multi-drug resistance protein as a mechanism of drug resistance 
Development of drug resistance is a major problem in AML therapy. It will eventually occur 
in most haematological malignancies treated with chemotherapy. Classically, drug 
resistance is divided into extrinsic and intrinsic (Jean-Pierre et al., 2003). Extrinsic resistance 
(host factors) refers to the inability of the drug to reach the tumour cell. It occurs when the 
bioavailability of the oral form varies from patient to patient like poor absorption resulting 
in low serum levels.  
Intrinsic (cellular) resistance is due to properties of the tumour cell. It can be classified as 
simple resistance, when cells are resistant to only one particular drug, or as multidrug 
resistance (MDR) when cross resistance is observed among chemotherapeutic drugs with 
different biochemical targets. Multidrug resistance is more common than simple resistance 
and it can be due to several mechanisms. The most common pharmacological mechanism 
involved is due to an active efflux of drugs from the tumour cells or enhanced drug 
metabolism which prevented the drug from reaching its target in the nucleus.  
The most important protein described in MDR cells is P-glycoprotein (P-gp), a 
transmembrane energy-dependent drug efflux pump, which is most efficient at transporting 
naturally occurring substances. It is encoded by the MDR1/ABCB1 gene and belongs to a 
superfamily of ABC (ATP binding cassette) transporters. P-gp expression in AML at initial 
presentation has been reported to be 20% to 40% (Motoji T et al., 2000). Increase in P-gp 
expression in leukaemic cells causes reduced intracellular concentration of cytotoxic drugs. 
There are many drugs used in AML that are transported by P-gp including anthracyclines 
and anthracenediones like daunorubicin and mitoxantrone, the vinca alkaloids (vincristine 
and vinblastine) and the epipodophyllotoxins (etoposide and teniposide). 
Other ABC transport proteins that have been implicated in MDR include the multi-drug 
resistance associated proteins (MRP1/ABCC1) and the breast cancer resistance protein 
(BCRP/ABCG2). All these proteins are not unique to drug resistance cells but expressed in 
tissue with excretory and secretory functions. However, many studies have found that 
overexpression of these proteins correlate with poor treatment response (Damiani et al., 
2010; Bendarra et al., 2005). 
A non-ABC protein, found widely expressed in P-gp negative multidrug resistant cancer cell 
termed initially as lung resistance related protein (LRP) and now known as major vault 
protein (MVP) also has been implicated in drug resistance mechanism (Izquierdo et al., 1996; 
Huh et al., 2006). This protein is involved in bidirectional transportation of a variety of 
substrates between nucleus and cytoplasm. It is present in many cells and seems to be 
upregulated in cancer cells and has been found to be an adverse prognostic factor in AML 
(Styczynski et al., 2007). The expression of P-gp (Leith et al., 1999), MRP and LRP in AML 
was also found to correlate with advanced age (>60 years) and high white cell count (van 
delHeuvel et al., 2007). It also correlates with high risk of relapse (Daniela et al., 2007).  
There have been extensive trials conducted on AML therapy to circumvent drug resistance 
like reversion of P-gp, targeted agents against DNA replication and repair, cell cycling and 
apoptosis. 
With the extensive knowledge on P-gp efflux mechanism and its contribution to drug 
resistance in AML, quinine and cyclosporine were tested to reverse the P-gp action. 
However, these substances did not significantly improve the response rate in AML (Eric et 
al., 2003; Solary et al., 1996; Liu et al., 1998; Tallman et al., 1995). Combination of tetrandrine, 
a potent inhibitor of the MDR-1 efflux pump, with induction therapy also showed no 
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significant difference in response between P-gp positive and P-gp negative patients (Wen et 
al., 2006). Nevertheless, an early study revealed by using P-gp reversal modulators, the 
emergence of drug resistance could be prevented (Futscher et al., 1996). However, a recent 
randomized phase III trial involving 302 newly diagnosed AML patients, evaluated the 
effect of P-gp inhibitor valspodar (PSC-833) showed no difference in overall disease survival 
(Jonathan et al., 2010). Similar result was obtained in another phase III randomized trial 
involving poor risk AML patients when valspodar was added in the induction therapy 
(Peter et al., 2004) 
3. Molecular ‘signatures’ in AML 
AML is characterized by a high degree of heterogeneity with respect to chromosome 
abnormalities, gene mutations and expression of multiple genes. The heterogeneous nature 
of AML has significant clinical impact as there are marked differences in survival following 
intensive chemotherapy (explained in detail elsewhere in this book). The World Health 
Organization (WHO) classifies AML by cytogenetics, morphology, immunophenotype and 
clinical features (Swerdlow et al., 2008). Diagnostic karyotype emerges as the most 
significant prognostic factor as determined in multivariable analyses that take into account 
age, type of AML (de novo or secondary) and presenting white blood cell count (WBC), and 
accordingly provides the framework for current risk stratified treatment approaches 
(Grimwade, 2007). Nevertheless as cytogenetic and molecular genetic aberrations are not 
mutually exclusive the expression of downstream target genes that encode proteins 
involved in complex biologic networks are affected (Mrozek et al., 2009) and may alter 
predictability of standard prognostic markers. Microarray genome-wide gene-expression 
profiling (GEP) and microRNA-expression profiling assays have revealed AML signatures 
and may be readily applicable for diagnosis and outcome class prediction in AML (Mrozek 
et al., 2009). Many of the molecules involved are known mediators of signal transduction 
pathways and apoptosis. 
4. Apoptotic molecules in AML 
Apoptosis occurs principally via two separate yet interlinked signaling mechanisms: the 
extrinsic pathway, activated by proapoptotic receptor signals at the cellular surface 
(members of tumor necrosis factor, TNF, family), and the intrinsic pathway (members of 
Bcl-2 family), activated by mitochondrial signals from within the cell. These pathways 
converge through “effector” caspases, which orchestrate the apoptotic program. 
Nevertheless, each requires different initiation caspases to begin the process. The extrinsic 
pathway is activated by engagement of death receptors on the cell membrane. The death 
receptors involved in the extrinsic apoptotic pathway belong to the TNF receptor 
superfamily that include Fas (CD95 or Apo1), TNFR1 (TNF receptor 1), death receptor 3 
(DR3/Wsl-1/APO-3/TRAMP/LARD), death receptor 4 (DR4/TRAIL-R1), death receptor 5 
(DR5/TRAIL-R2) and DR6. These receptors are characterized by an intracellular death 
domain. There are also decoy receptors (i.e. DcR1 and DcR2) that contain no death domain 
or a truncated death domain and can bind ligand but cannot signal. Therefore, these decoy 
receptors function as antagonists to inhibit death ligand/death receptor-induced apoptosis. 
Binding of ligands, such as FasL, tumor necrosis factor-alpha (TNF-alpha) and TNF-related 
apoptosis-inducing ligand (TRAIL) to their respective membrane receptors Fas, TNF-R and 
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TRAIL-R induces trimerization of the receptors and recruitment of adaptor proteins such as 
the Fas-associated death domain (FADD) to the death domain. This then recruits 
procaspase-8 which then leads to the formation of the oligomeric death-induced signaling 
complex (DISC). DISC in turn promotes activation of caspase-8 and a cascade of other 
caspase enzymes that culminates with cell death (reviewed in Elrod and Sun, 2008).  
The intrinsic pathway is triggered by various extracellular and intracellular stresses, 
including growth factor deprivation, DNA damage, oncogene induction, hypoxia and 
cytotoxic drugs. Cellular signals originated by various mechanisms by these different 
stresses converge on a cellular target represented by mitochondria. Mitochondrial 
membrane permeability is controlled by pro-apoptotic (Bax, Bak, Bad, Bid, Bim, Bmf, 
NOXA, PUMA, Bok, Bcl-G, Bfk) and anti-apoptotic (Bcl-2, Bcl-L, Mcl-1, Bcl-w, A1) members 
of the Bcl-2 family, inducing or preventing heterodimerization of pro-apoptotic members. A 
series of biochemical events is induced that lead to damage of the outer mitochondrial 
membrane, with the consequent release of cytochrome c and other pro-apoptotic molecules, 
such as Smac/DIABLO, from the inner membrane into the cytosol enabling the formation of 
the apoptosome, a large molecular complex formed by cytochrome c, apoptotic protease 
activating factor 1 (APAF-1) and caspase-9, and massive activation of caspases. These 
proteins all play crucial roles for cell survival and the loss of any of these proteins causes 
major deregulation of survival of some cell types (reviewed in Ashkenazi and Herbst, 2008). 
Dysregulation of apoptosis plays an important role in the development of a variety of 
human pathologies, including cancer and particularly leukemia. The evasion of 
programmed cell death has been regarded as one of the six essential alterations in cellular 
physiology that dictate the growth of cancer cells and is a hallmark of virtually all cancers. 
Moreover, tumors that have alterations in proteins involved in cell death signaling are very 
frequently resistant to chemotherapy and are difficult to treat with chemotherapeutic agents 
that primarily act by inducing apoptosis (Testa et al., 2007). 
Fas, DR4 and DR5 are generally expressed in both normal and malignant cells. An 
examination of patients with de novo AML revealed Fas was expressed on eight of nine 
(89%) patients tested (Tourneur et al., 2004). Another study showed expression of Fas on 
62% of 29 AML patients (Min et al., 2004). Fas mutation was observed in 4/28 CML cases 
and none of the six AML cases tested (Rozenfeld-Granot et al., 2001). DR4 and DR5 
mutations detected in cancers including chronic myelogenous leukemia were very low (0–
10.6%) (Liu et al., 2005). On the other hand, DR4 and DR5 receptors were positive in 20 
(69%) and 29 (100%) patients, respectively. This study also showed, relapse-free survival 
was significantly prolonged in patients with CD95-positive AML cells compared with 
patients with CD95-negative AML cells (73% versus 38% at 3 years; p = 0.047) using 
univariate analysis (Min et al., 2004). This was however not supported by another study on 
99 AML patients where multivariate analysis showed no correlation with overall survival 
and disease free survival (Brouwer et al., 2001). 
Three ligands (TNF-α, FasL and TRAIL) of the TNF-family and their respective four 
receptors (TNF-R1, Fas, TRAIL-R1 and TRAIL-R2) are potentially important as anti-cancer 
therapeutics. The demonstration that TNF-α selectively kills tumor cells but not normal 
cells, set it up for the first molecules to be studied. Unfortunately, marked pro-inflammatory 
effects precluded its systemic administration (Buzzoni and Butler, 1996). Fas was also 
excluded as agonistic antibodies triggering Fas activation was highly hepatotoxic causing 
death in mouse models (Ogasarawa et al., 1993). In contrast, TRAIL and agonistic anti-
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TRAIL-R1/TRAIL-R2 antibodies appear to be well tolerated in vivo. TRAIL/Apo-2L 
exhibited potent anti-tumor activity and induces little cytotoxic effects in immunodeficient 
mice xenograft models implanted with several human tumor cell lines (Ashkenazi et al., 
1999). However, the in vivo half-life of the TRAIL-ligand is very short (<4 minutes) (Kelley et 
al., 2001). Agonistic TRAIL-R1 and TRAIL-R2 antibodies do not bind to TRAIL decoy 
receptors, TRAIL-R3 and TRAIL-R4, which are frequently expressed on the membrane of 
tumor cells.  
 
 
Fig. 1. Extrinsic and intrinsic pathways in apoptosis (see text for further details).  
Antisense therapies involved the use of sequences of single-stranded DNA to complement and 
bind specific coding regions on mRNA hence forming DNA–mRNA which is then degraded 
by a ribonuclease, therefore gene expression and translation are prevented. Most widely 
studied were with XIAP (X-linked inhibitor of apoptosis) and antiapoptotic proteins Bcl-2.  
Sufficient evidence exists to show that Bcl-2 was overexpressed in AML patients and 
predictive of worst outcome (Campos et al., 1993; Andreef and Konopleva, 2002). It seemed 
conceivable that Bcl-2 downregulation might lower the apoptotic threshold of leukemic cells 
and, through this mechanism, favor response to chemotherapy. Much success has been 
achieved. A phase I study using oblimersen, an antisense to Bcl-2, added during induction 
and then consolidation therapy, in elderly AML patients, induced remission in 14/27 
patients, of which seven relapsed within 12.6 months (Marcucci et al., 2005); In a multicenter 
phase II trial, 12/39 relapsed AML patients treated with oblimersen and gentuzamab (anti-
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CD33) achieved complete remission of which 10/12 survived for more than 6 months 
(Moore et al., 2004). 
XIAP binds and inhibits caspases 3, 7, and 9, mediators of the apoptotic cascade. 
Downregulation of XIAP using multiple approaches (e.g., antisense, RNAi, knock-out 
animals and cell lines, immuno-depletion) in vitro and in vivo conditions resulted in 
increased caspase activation and/or cell death. Antitumor activity was also observed with 
the use of second generation anti-sense compound, AEG35156, in xenograft models of 
cancer (Lacasse et al., 2005) Results from clinical trials however, have been variable. While 
one study on five phase 1 (12–350mg/m2 AEG35156) and eight phase 2 (350 mg/m2 
AEG35156) patients showed increased apoptotic cells and increase response (Bing et al., 
2011) another study on 27 patients randomized to receive high dose Ara-C and idarubicin 
with or without AEG35156 (650 mg) found a lower overall response rate in the group which 
received the anti-XIAP drug (Schimmer et al., 2011).  
The analysis of Mcl-1 protein expression in AML showed great heterogeneity, but the levels 
of the protein do not seem to correlate with response to standard chemotherapy (Kaufmann 
et al., 1998). Bad and Bcl-xL have been shown to be expressed in normal and leukemic 
hematopoietic precursor cells. Immature hematopoietic cells do not express Bcl-2 but do 
express Bcl-xL. CD34 positive cells express Bcl-2, Bcl-xL and Bad. Bcl-2 expression is higher 
on CD34 positive cells than on AML cells. Phosphorylated Bad was expressed in AML 
(Andreef et al., 1999).  
Potential abnormalities of the various initiator caspases in AML have been explored. Levels 
of caspase-8, caspase-2 and caspase-3 are heterogeneous in AML. AML with an immature 
phenotype (i.e., M0 and M1 AML) predominantly express caspase-8L (Mohr et al., 2005).The 
significance of caspases as prognostic indicators in AML are unclear as current reports are 
still controversial may be due to the different format of molecules examined (Svingen et al., 
2000; Estrov et al., 1998; Holleman et al., 2005). 
Expression of pro- and anti-apoptotic molecules continues to be studied in AML to correlate 
its mutated state, expression, activity or methylated state with treatment outcome (Testa et 
al., 2007). At present, the prognostic utility of measurements of pro- and antiapoptotic 
molecules for predicting clinical outcome and response to chemotherapy is uncertain.  
5. Drug modulation of signaling, differentiation and apoptotic pathways 
The study of cancer cell biology in predicting treatment outcome cannot stop at the 
presentation stage as cells continue to be modified by the microenvironment and are 
ultimately subjected to chemotherapy. While remarkable progress have been achieved in 
targeted therapies, for most tumors chemo- or radiotherapy is likely to remain in the near 
future. Both chemo- and radiotherapy are designed to kill cancer cells by damaging nuclear 
DNA. DNA damage triggers the DNA damage response (DDR) which have three critical 
goals: (i) halting cell cycle progression and division to prevent transfer of DNA damage to 
progeny cells; (ii) increasing accessibility of the damage sites to- and engagement of- the 
DNA damage repair machinery, and (iii) triggering apoptosis to exterminate cells whose 
damaged DNA cannot successfully be repaired (reviewed in Darzynkiewicz et al., 2009).  
Chemotherapeutic drugs such as cisplatin, mitomycin, methotrexate, mitoxantrone, 
adriamycin, and bleomycin induce Fas expression in human cancer cells, primarily through 
a p53-dependent mechanism (Muller et al., 1998). Adriamycin, etoposide, Ara-C, cisplatin 
and camptosar were shown to induce the expression of DR4 and DR5 or only DR5 
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expression, through either p53-dependent, or p53-independent mechanisms (Wu et al., 
1997; Guan et al., 2001; Sheikh et al., 1998). Etoposide was shown to induce DR5 expression 
in human acute leukemia cells (Wen et al., 2000). 
To complete induction of cell death, chemotherapeutic drugs have to suppress survival 
mediators in activated signaling pathways. Paclitaxel treatment of transfected MDA MB-435 
human breast carcinoma cell line was observed to downregulate phosphorylated Akt (Klos 
et al., 2003). Nevertheless, chemotherapy induction of cell death is not equal in all cells. 
Adriamycin produced differential responses in Akt phosphorylation and kinase activity in a 
panel of breast cancer cell lines. While MCF7, MDA468 and T47D cells showed a dose 
dependent increase in p-Akt levels; in contrast, SKBR3 and MDA231 cells showed a dose-
dependent decrease and no or minimal change was detected in MDA361, MDA157 and 
BT474 cells (Li et al., 2005). The diversity in response may also be predictive of a 
heterogeneity in treatment outcome. 
Other signaling molecules are activated by chemotherapeutic drugs leading to cell death. 
Ara-C induced apoptosis in HL-60 cell lines through the activation of p38 (Stadheim et al., 
2000). Adriamycin was shown to activate Jnk in a T cell leukemia cell line (Yu et al., 1999). 
Leukemia cell lines (TF-1 and K562) primed for apoptosis were also revealed to stimulate 
Jnk and p38 phosphorylation (Tucker et al., 2004) 
Certain cytokines have apoptotic activity. TNF-alpha and IFN-gamma induced the 
expression of DR5 in a number of cancer cell lines (Meng and El-Deiry, 2000). IFN-gamma 
had differential effect on induction of death receptors in colon carcinoma cell lines. While it 
raised the levels of CD95 membrane 6 – 8-fold, it had no effect on the TRAIL-receptors (DR4, 
DR5, DcR1 and DcR2) (van Geelan et al., 2003). Interferon-alpha was also reported to 
increase DR5 expression in human hepatoma (Shigeno et al., 2003). 
In contrast some cytokines exert protective effect from chemotherapeutic drug induced cell 
death, decreasing the effectiveness of cancer radiotherapy and chemotherapy. Normal 
hematopoietic cells, like other normal cell types, die by the process of apoptosis when 
deprived of viability inducing cytokines that include colony stimulating factors (CSFs) and 
various other cytokines. Induction of apoptosis by cancer chemotherapy such as vincristine, 
adriamycin, methotrexate and Ara-C was suppressed by IL (interleukin)-6, IL-3, 
granulocyte-CSF (G-CSF), granulocyte-monocyte CSF (GM-CSF) and IFN-gamma in 
myeloid leukemia cells (reviewed in Lotem and Sachs, 2002). These cytokines upregulate 
pro-survival molecules such as Bcl-2 [IL-2, IL-3, stem cell factor (SCF), IFN-gamma], Bcl-xL 
[IL-3, IL-6, IL-7, IL15, GM-CSF, IFN-gamma and erythropoietin (EPO)] and other apoptosis 
suppressing genes such as Survivin (Carter et al., 2001), X-linked inhibitor of apoptosis 
protein (XIAP) and cellular inhibitor of apoptosis 2 (cIAP2) (Digicylioglu and Lipton, 2001) 
that are caspase inhibitors and FLICE-like inhibitory protein (FLIP), that may disrupt the 
ability of cell surface molecules such as Fas to activate apoptosis (Kovalovich et al., 2001) 
Some myeloid leukemic cells are autonomous and do not require an exogenous source of 
cytokines for viability (Griffin and Lowenberg,1986), while others do. Thus, it is possible to 
suppress leukemia not only by cytotoxic agents or by induction of terminal differentiation, 
but also by decreasing the in vivo supply of apoptosis suppressing cytokines or the response 
of leukemic cells to these cytokines (reviewed in Sachs, 1996). 
A characteristic abnormality of leukemia cells is that they are blocked at an early stage of 
their development. Myeloid leukemic cells however can be induced to differentiate to non 
dividing mature granulocytes and macrophages by different cytokines, including cytokine 
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independent myeloid leukemic cells that were induced to differentiate with IL-6. Different 
myeloid leukemic clones however have different blocks and ability to undergo 
differentiation by cytokines. Our own work on in vitro cultured AML blasts exhibited 
different degrees of spontaneous apoptosis. Univariate analysis of 13 AML patients 
revealed blasts with lower levels of cell viability after 72h culture was significantly 
correlated with a longer disease free survival . Within a smaller number of samples (n=7) 
we observed blasts with lower levels of cell viability were associated with reduced levels 
CD34 and higher levels of CD16, indicating an increased level of cell differentiation (Maha 
et al., 2008). The observations may indicate an abnormal developmental program in 
leukemic cells which may be reprogrammed epigenetically by appropriate differentiation 
inducing cytokines. Constitutive expression of transcription factors such as c-myc, c-myb 
and E2F1 (Gonda and Metcalf, 1984; Blatt et al., 1992; Melamed et al., 1993) as well as 
others such as the homeobox gene Hox B8 (Hox 2.4) (Blatt et al., 1992) or GATA-1 (Tanaka 
et al., 2000), disrupted the ability of cells to undergo cytokine induced differentiation 
(reviewed in Lotem and Sachs, 2002) 
Cytokines as a differentiation treatment against leukemia however has been disappointing. 
Hematopoietic leukemia cell lines of myeloid origin such as K562, U937, HL-60, CS-1, KG-1, 
MUTZ-3, or ex vivo AML or chronic myeloid leukemia (CML) blasts were modestly 
permissive to induction of in vitro differentiation by EPO, G-CSF, GM-CSF, IL-4, IL-6, SCF, 
or synergistic combinations of several cytokines (Leung et al., 2005; Koss et al., 1996; Goliaei 
et al. 1998; Kamano et al., 1994; Kamijo et al., 1990). A niche for hematopoietic cytokines in 
differentiation therapy exists in the treatment of congenital neutropenia disorder. The 
administration of G-CSF to patients has overcome a block of myeloid differentiation leading 
to a substantial prolongation of their survival (Berliner, 2008). 
Clinically, differentiation therapy has been most successful in acute promyelocytic leukemia 
(APL) using all-trans-retinoic acid (ATRA) as the inducer. This targeted APL cells carrying 
the chromosomal translocation between chromosomes 15 and 17 [t(15;17)(q22;q21)]. 
Subsequently, APL therapy was improved with the combination regimen of ATRA with 
cytotoxic chemotherapy. Currently, complete remission rates of up to 90% to 95% are 
achievable using ATRA/ATO (arsenic trioxide) and anthracycline-based chemotherapy 
(Niu et al., 1999; Soignet et al., 2001; Raffoux et al., 2003; Ghavamzadeh et al., 2006; Mathews 
et al., 2006; Estey et al., 2006; Sanz et al., 2008). 
Another targeted treatment with tyrosine kinase inhibitor (TKI) imatinib for the treatment of 
CMLalso achieved better success. Gefinitib and erlotinib which inhibit the intracellular 
tyrosine kinase activity of epidermal growth factor receptor (EGFR), induce a differentiation 
program in myeloid leukemia cells that corresponds to neutrophil maturation (Stegmaier et 
al., 2005; Boehrer et al., 2008a; Boehrer et al., 2008b). 
These results together emphasize further not only the heterogeneity of leukemias but also 
complexity of host-cancer interaction and its influence on outcome in survival and also 
during induction of cell death. 
6. In vivo drug induced molecular profiles: Potential predictor of drug 
resistance 
The in vivo molecular changes in acute myeloid leukemia cells early after start of 
conventional genotoxic chemotherapy are incompletely understood, and it is not known if 
early molecular modulations reflect clinical response. As increasing evidence is proposing 
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tumor-host mechanisms as important for effective chemotherapy, there is an immediate 
need to investigate these issues in vivo in human cancer (Oyan et al., 2009) 
For that purpose, blasts from patients undergoing chemotherapy were collected as a 
‘natural’ and rich source to study response of these cells to the myriad of signals they were 
subjected to. Even though cells undergo cell death, as white blood cell counts may decline at 
early stages of chemotherapy, very low percentages of apoptotic cells were detected. Oyan 
et al. (2009) comparing treated (‘3+7’, idarubicin + Ara-C ) with untreated AML cells from 
seven patients, observed upregulation of 113 genes (23 of unknown function) at early time 
points (2 – 4 hours) and 108 genes at late time points (18 – 24 hours). Among the 113 genes a 
substantial number (31 genes) were related to the tumor suppressor p53 (Oyan et al., 2009). 
p53 is implicated to affect a variety of cellular processes, the most undisputed roles of p53 
are to induce growth arrest and to induce apoptosis (Bates and Vousden, 1996). p53 is the 
most commonly mutated gene in a variety of human cancers (Greenblatt et al., 1994). In 
AML however, mutations of p53 are rare, occurring in approximately 5% to 10% (Fenaux et 
al., 1992) but in these cases it correlates with worse outcome (Wattel et al., 1994). Wild-type 
p53 appears to change the balance in expression of apoptosis-inducing versus apoptosis-
suppressing genes in favor of the former and thus induce apoptosis. 
In tune with the above, a significant increase in gene expression of the apoptosis facilitators 
PUMA and Bax and a decrease in the Bcl-2 /Bax ratio as well as Bcl-2 /PUMA were 
observed for most of the AML samples. The mRNA profile of three other pro-apoptotic 
mediators Bad , Bak1 and Bim did not change significantly during the first hours, but the 
level of gene expression varied across patients. Altogether five tumor necrosis factor-related 
receptor genes were modulated 2–4 h after induction therapy (Oyan et al., 2009).  
Induction of ligand to death receptor during chemotherapy was also supported by Devemy 
et al. (2001) who observed increased TNF transcripts in treated AML cells. We also studied 
molecular changes in paired AML samples at diagnosis and during chemotherapy ( Ara-C + 
daunorubicin). We showed increased TNF-alpha was significantly higher in chemo-sensitive 
patients. Thus, expression of TNF-alpha early during chemotherapy may be a marker to 
predict good treatment outcome. In chemo-resistant cases, a higher, though not significant, 
percentage of cases expressed IL-1beta and IL-18 (Maha et al., 2009). 
We observed a significantly higher percentage of chemo-responsive AML patients with 
blasts cells increased for the expression of IL-6. This was consistent with Devemy et al (2001) 
who reported that increase of IL-6 transcripts during remission induction therapy of AML 
patients was accompanied by a fall in blood count and bone marrow cellularity. The role of 
cytokines in the induction of cell differentiation is well established. Oyan et al (2009) also 
observed several receptors expressed on monocytic/macrophage lineage cells were 
upregulated, probably related to chemotherapy induced differentiation of the leukemic 
cells. Thus, induction of cytokines expression in drug responsive AML patients may be due 
to induction of cell differentiation.  
Comparing blasts profiles before and during early chemotherapy also revealed upregulation 
of genes potentially involved in interaction between AML blasts and the host 
microenvironment. Chemokine receptors CXCR4 and CX3CR1 were upregulated in the late 
phase after start of chemotherapy indicating intention to home into a microenvironment that 
favours their growth and survival. This supports the hypothesis that the host response in 
chemotherapy is crucial for persistent remission (Oyan et al., 2009). 
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We further examined activation of signaling molecules in AML blasts. Chemotherapy 
increased the percentage of cases showing phosphorylation of the Akt molecules and 
Forkhead transcription factor (FKHR) but no significant differences were observed between 
chemo-resistant and chemo-sensitive cases. We however, observed a significantly higher 
percentage of chemo-resistant cases showing phosphorylation and inactivation of the pro-
apoptotic Bad molecule. A higher percentage of chemo-sensitive cases were phosphorylated 
for p38, and Jnk (Maha et al., 2009). In summary, we were able to show in chemo-sensitive 
cases, chemotherapy stimulated IL-6, induced apoptosis by up-regulating TNF-alpha and 
downregulated phosphorylated Bad. In reverse, in chemo-resistant cases, cells survived by 
maintaining high levels of phosphorylated Bad maybe through protective role of IL-1b and 
IL-18 cytokines (Maha et al., 2009). 
Most anticancer drugs exert their effects by the induction of apoptosis and/or interfering 
with cell cycle progression. Often these drugs give rise to specic patterns of cell death and 
cell cycle arrest that vary according to the drug used and the molecular status of the target 
cell. Simple in vitro methods may aid in this investigation. Drug cytotoxicity and sensitivity 
of individual tumor samples was demonstrated by combining cytochrome c and propidium 
iodide staining of DNA content and detected on flowcytometry. This method elucidated 
mitochondrial resistance mechanisms which may prove useful in identifying the apoptosis-
sensitive cell cycle phase for a given tumor sample/anticancer drug combination. It offers 
the opportunity to design personalized drug regimens and to identify new combined 
treatment modalities (Mohr et al., 2004).  
7. Conclusion 
The heterogeneity in AML continues to elude the best methods to characterize them. 
Genome and proteome-wide analysis has further revealed complexity in the makeup of the 
leukemic cell. The rapid advancement in targeted therapies implied the urgent need for 
alternative therapy and the readiness of the community to embrace it. Nevertheless so far, 
combinatorial medicine still holds out as the best option for successful treatment. If targeted 
therapies remain the way forward it will eventually bank deeply on the ability to identify 
molecular signatures in the individual leading to the establishment of personalized 
medicine. 
In the meantime, the mechanisms in leukemogenesis, drug resistance and relapse remain an 
area of much research. From cell biology to cytogenetics to molecular defects to signaling 
pathways, all have contributed to a better understanding of cancer biology. New knowledge 
in epigenetics and microRNA remain to be elucidated. 
Current diagnostic and prognostication are based on the assumption that the phenotype of 
the leukemic cell is static and thus definitive. There is much evidence that suggest 
otherwise. Activation of oncogenes leads to constitutive expression of signal transduction 
pathways involved in cell survival and anti-apoptotic activities. These pathways are 
multiple and made up of a myriad of molecules that are receptive to the environment. The 
host-cancer microenvironment is a dynamic microcosm of interacting signals and cascading 
molecules that constantly respond to stimuli in the surrounding to find a balance that 
maintains survival. In the course of treatment, blast cells are exposed to DNA damaging 
cytotoxic agents which trigger a gamut of other signaling mediators to exert the opposite 
effect. It would appear that a struggle ensues in which the strength of the victor determines 
whether the blast cell would maintain life or be pushed off-balance and replaced with a new 
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profile signaling cell death. This new phenotype corresponded to a sensitive response to 
chemotherapy. On the other hand, cells may strengthen on pro-survival features which 
corresponded with resistance to chemotherapy. A few reports, including ours, are lending 
support to this hypothesis. 
Unsurprisingly, chemotherapy-induce phenotype is not confined purely to either a survival 
or an apoptosis profile but a complex mix of conflicting signals to survive or die in addition 
to triggers to shut down cell proliferation, induce terminal differentiation or activate 
inflammatory responses. Thus, further elucidation of these profiles would involve 
assignment of each of the modulated molecule to its rightful pathway. 
The immaturity feature in leukemias will undoubtedly be a factor that will further 
compound the heterogeneity in results obtained. An example is the striking correlations 
found between lower Bax/Bcl-2 ratio and higher progenitor marker expression, such as 
CD34, CD117 and CD133 antigens, confirming the link between this apoptotic index and the 
maturation pathways (Del Principe et al., 2005). Attempts to induce cell death by triggering 
death receptors has so far achieved mix results with the use of TNF-alpha, Fas ligands and 
the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (i.e., DR4 and DR5). 
These molecules also selectively kill cancer cells while sparing normal cells (reviewed in 
Elrod and Sun, 2008). These results indicate a preferential expression of specific death 
receptors on different tissues. 
Selection of lab methods for prognostication depends on the ability to identify lineage, 
maturation stages, genetic aberrations and activated signal transduction pathways. This feat 
may include the difficult task of combining surface markers, cytokines (secreted proteins) 
and phosphorylated proteins (unstable intracellular proteins) in the same tube on the same 
platform such as flowcytometry. Furthermore many of these proteins such as TNF-a, IL-6, 
p38 and Jnk have dual function of pro-survival and pro-apoptosis capabilities depending on 
the stimulating conditions cells are exposed to at that period of time. Precise markers will be 
required to differentiate these situations. Altogether, all of these add up to an interesting 
and exciting field of research for the immediate future. 
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combinatorial medicine still holds out as the best option for successful treatment. If targeted 
therapies remain the way forward it will eventually bank deeply on the ability to identify 
molecular signatures in the individual leading to the establishment of personalized 
medicine. 
In the meantime, the mechanisms in leukemogenesis, drug resistance and relapse remain an 
area of much research. From cell biology to cytogenetics to molecular defects to signaling 
pathways, all have contributed to a better understanding of cancer biology. New knowledge 
in epigenetics and microRNA remain to be elucidated. 
Current diagnostic and prognostication are based on the assumption that the phenotype of 
the leukemic cell is static and thus definitive. There is much evidence that suggest 
otherwise. Activation of oncogenes leads to constitutive expression of signal transduction 
pathways involved in cell survival and anti-apoptotic activities. These pathways are 
multiple and made up of a myriad of molecules that are receptive to the environment. The 
host-cancer microenvironment is a dynamic microcosm of interacting signals and cascading 
molecules that constantly respond to stimuli in the surrounding to find a balance that 
maintains survival. In the course of treatment, blast cells are exposed to DNA damaging 
cytotoxic agents which trigger a gamut of other signaling mediators to exert the opposite 
effect. It would appear that a struggle ensues in which the strength of the victor determines 
whether the blast cell would maintain life or be pushed off-balance and replaced with a new 
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profile signaling cell death. This new phenotype corresponded to a sensitive response to 
chemotherapy. On the other hand, cells may strengthen on pro-survival features which 
corresponded with resistance to chemotherapy. A few reports, including ours, are lending 
support to this hypothesis. 
Unsurprisingly, chemotherapy-induce phenotype is not confined purely to either a survival 
or an apoptosis profile but a complex mix of conflicting signals to survive or die in addition 
to triggers to shut down cell proliferation, induce terminal differentiation or activate 
inflammatory responses. Thus, further elucidation of these profiles would involve 
assignment of each of the modulated molecule to its rightful pathway. 
The immaturity feature in leukemias will undoubtedly be a factor that will further 
compound the heterogeneity in results obtained. An example is the striking correlations 
found between lower Bax/Bcl-2 ratio and higher progenitor marker expression, such as 
CD34, CD117 and CD133 antigens, confirming the link between this apoptotic index and the 
maturation pathways (Del Principe et al., 2005). Attempts to induce cell death by triggering 
death receptors has so far achieved mix results with the use of TNF-alpha, Fas ligands and 
the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (i.e., DR4 and DR5). 
These molecules also selectively kill cancer cells while sparing normal cells (reviewed in 
Elrod and Sun, 2008). These results indicate a preferential expression of specific death 
receptors on different tissues. 
Selection of lab methods for prognostication depends on the ability to identify lineage, 
maturation stages, genetic aberrations and activated signal transduction pathways. This feat 
may include the difficult task of combining surface markers, cytokines (secreted proteins) 
and phosphorylated proteins (unstable intracellular proteins) in the same tube on the same 
platform such as flowcytometry. Furthermore many of these proteins such as TNF-a, IL-6, 
p38 and Jnk have dual function of pro-survival and pro-apoptosis capabilities depending on 
the stimulating conditions cells are exposed to at that period of time. Precise markers will be 
required to differentiate these situations. Altogether, all of these add up to an interesting 
and exciting field of research for the immediate future. 
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1. Introduction 
Acute myeloid leukemia (AML) is a cancer wherein dysregulated differentiation, 
uncontrolled growth and inhibition of apoptosis lead to accumulation of immature myeloid 
progenitor cells and progression of oncogenic expression (Lowenberg et al., 1999). AML is 
now seen to be initiated and maintained from a small, self-renewing population of leukemic 
stem cells (LSCs), which give rise to a progeny of more mature and highly cycling 
progenitors (colony forming unit-leukemia, CFU-L). CFU-Ls do not self-renew, however 
they are committed to proliferation and limited differentiation. By doing so, they originate a 
population of blast cells which constitute the majority of leukemic cells in both the bone 
marrow and peripheral blood of patients. The exact phenotype of LSCs is still debated, but 
they are comprised in the CD34+/CD38-/low population (Lane et al., 2009). CD34+/CD38+ 
leukemic cells were unable to initiate leukemia in immunodeficient mice. It should be noted 
that only about 50% of AML are able to initiate leukemia in NOD/SCID mice (Testa et al., 
2007) 
2. Leukemogenesis 
The pathogenesis of leukemia may be explained by two classes of alterations of oncogenic 
genes as a result of chromosomal aberrations. Class I mutations confers a proliferative 
and/or survival advantage to the cells. The current list of known leukemogenic class I 
mutations consists of more than 10 different protein tyrosine kinases (PTK) that undergo 
constitutive activation either by being fused to different N-terminal partner proteins 
providing an oligomerization domain, or by activating mutations such as point mutations in 
their kinase domain or internal tandem repeats (length mutations) in the juxtamembrane 
domain (Flt3, Kit). Most of these alterations are associated with chronic myeloproliferative 
disorders such as chronic myeloid leukemia/chronic myelomonocytic leukemia 
(CML/CMML) or Philadelphia negative myeloproliferative disorders, except activating 
mutations of Flt3 and Kit which are found almost exclusively in acute leukemia. Flt3 ITD 
(internal tandem duplication) mutants constitutively activate MAPK, AKT and STAT5, 
leading to Pim-1 activation and Bcl-xL (B-cell lymphoma) hyperexpression (Minami et al., 
2003; Kim et al., 2005). Extracellular c-Kit mutations resulted in c-Kit receptor 
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hyperactivation in response to Kit ligand, with subsequent strong activation of MAPK and 
PI3K, while codon 816 c-Kit mutations induced constitutive STAT-3 activation and 
upregulation of Bcl-xL and c-myc (Schnittger et al., 2006)). Other class I alterations are gain 
of function mutations of the three main RAS isoforms (N-Ras, Ki-Ras, Ha-Ras) which are 
frequently seen in different myeloid malignancies (Beaupre and Kurzrock, 1999). N-Ras 
mutations lead to increased activity of the Ras pathway, resulting in increased proliferation 
and decreased apoptosis (Testa et al., 2007). Overexpression of class I mutations is generally 
sufficient to transform hematopoietic cells to growth-factor independence in vitro and to 
induce a lethal leukemialike myeloproliferative disorder in mice (Ilaria, 2004). 
(Flt- FMS-Like Tyrosine Kinase 3, STAT- Signal Transducer and Activator of Transcription, 
MAPK-Mitogen-Activated Protein Kinase) 
In contrast to class I mutations, there is a large group of genetic alterations mostly associated 
with acute leukemia, referred to as class II mutations, which impair differentiation of 
hematopoietic cells and subsequent apoptosis but do not directly provide proliferative 
and/or survival advantage. Many of them are loss of function mutations (either through 
fusion formation or point mutations) of transcriptional regulators that are critical for normal 
hematopoietic development and differentiation. Transcription factor fusion genes include 
CBF, RAR, MLL, HOX and CBP while loss of function mutations occur in AML1, CEBP/a, 
PU.1, GATA1 and IKAROS (reviewed in Chalandon and Schwaller, 2005). Via mediators of 
apoptosis, fusion proteins send anti-apoptotic signals that favor the preferential survival of 
leukemic cells:PML/RAR-α or CBF/SMMHC through the p53 pathway and AML1/ETO 
through the Bcl2-related pathway (Klampfer et al., 1996; Britos-bray et al., 1998; Pandolfi, 
2001). PML/RARα fusion protein was also shown to exert an anti-apoptotic activity by 
downmodulating the expression of some death-inducing genes, such as TNF-R1 (Testa et al., 
1998) and TRAIL-R1/-R2 (Ricioni et al., 2005). Nucleophosmin acts as a cellular p53 negative 
regulator to protect hematopoietic cells from stress-induced apoptosis (Lambert and Buckle, 
2006). These mutations are usually not sufficient to mimic the human disease in transgenic 
mice since they do not readily induce a leukemia phenotype. However, after a long latency 
period, signs of myelodysplasia are often seen with a variable propensity to develop an 
immature and clonal hematologic disorder closely resembling human AML (reviewed in 
Chalandon and Schwaller, 2005). Additional mutations, occurring at the level of signal 
transduction molecules (the receptor tyrosine kinases Flt3 or c-Kit, NRas and Ki-Ras), are 
required for the generation of disease (reviewed in Testa et al., 2007). This hypothesis is 
supported by the analysis of unselected blood samples from neonates which showed that 
about 1% have class II genetic alterations that are detectable by PCR (Greaves et al., 2003). 
(CBF-core binding factor, RAR –retinoic acid receptor, MLL-mixed lineage leukemia, HOX-
homeobox, CBP-CREB binding protein, CEBP/a-CCAAT/enhancer binding protein, PML-
promyelocyte leukemia, SMMHC-smooth muscle myosin heavy chain, TRAIL-tumor 
necrosis factor–related apoptosis-inducing ligand) 
In the same light, being a heterogeneous disease, relapsed AML is unlikely to emanate from 
one predominant mechanism; instead, there are likely to be multiple biologic factors at play 
that allow for clinical relapse to occur. These factors likely include multidrug resistance 
proteins, aberrant signal transduction pathways, survival of leukemia stem cells, 
microenvironmental interactions, and immune tolerance. Many conditions in the 
environment select for the development of these target mechanisms, ranging from 
chemotherapeutic modalities, to signal transduction inhibitors, to upregulation of 
antileukemic immune responses (reviewed in Lancet and Karp, 2009) 
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PTK involved Fusion gene Chromosomal 
aberration 
Disease phenotype 
A. Fusion genes    
ABL (9q34)  BCR/ABL t(9;22)(q34;q11) CML 
(ABL1)  TEL/ABL t(9;12)(q34;p13)  Atypical CML 
ARG (1q24)  BCR/ARG t(1;22)(q24;q11)  Atypical CML 
(ABL2)  TEL/ARG t(1;12)(q24;p13) Atypical CML 
PDGFR (5q33)  TEL/PDGFR t(5;12)(q33;p13) CMML, atypical 
CML 
 HIP1/PDGFR t(5;7)(q33;q11) CMML, atypical 
CML 
 RAB5/PDGFR  t(5;17)(q33;p13) CMML, atypical 
CML 
 H4/PDGFR  t(5;10)(q33;q21) CMML,atypical CML 
 Myomegalin/PDGFR  t(1;5)(q23;q33) CMML,atypical CML 
 CEV14/PDGFR  t(5;14)(q33;q32) relapse AML 
 NIN1/PDGFR  t(1;5)(q23;q33) atypical CML 
 HCMOGT/PDGFR t(5;17)(q33;p11)  juvenile CMML 
 TP53BP1/PDGFR  t(5;15)(q33;q22) atypical CML 
PDGFR (4q12) BCR/PDGFR  t(4;22)(q12;q11) Atypical CML 
AK2 (9p24)  BCR/JAK2 t(9;22)(p24;q11) CML, atypical CML 
 TEL/JAK2  t(9;12)(p24;p13) Atypical CML, ALL, 
AML 
 PCM1/JAK2  t(8;9)(p21-22;p23-24) Atypical CML, AML, 
ALL 
TRKC (15q25)  TEL/TRKC t(12;15)(p13;q25) AML 
GFR3 (4p16)  TEL/FGFR3 t(4;12)(p16;p13) AML 
FRK(6q21)  TEL/FRK t(6;12)(q21;p13) AML 
B. Gain of function mutations   
FLT3 (13q12)  ITD (80%), activation loop kinase domain (15%) AML 
KIT (4q12)  JM region, activation loop kinase domain AML 
JAK2 (9p21)  JAK2 V617F mutation 9pLOH PV, ET, 
myelofibrosis 
C. Deregulated expression
FLT3 (13q12)  Overexpression MLL alterations ALL/AML 
CML: chronic myeloid leukemia; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CMML: 
chronic myelomonocytic leukemia; EMS; ITD: internal tandem duplication; JM: juxtamembrane; PV: 
polycythemia vera; ET: essential thrombocythemia; LOH: loss of heterozygosity 
Table 1. Deregulated protein tyrosine kinases in myeloid leukemias (taken from Chalandon 
and Schwaller, 2005) 
3. Signal Transduction Pathways (STP) 
Signal transduction is the primary means by which eukaryotic cells respond to external 
signals from their environment and coordinate complex cellular changes. Extracellular 
signal is transduced into the cell through ligand-receptor binding, followed by the activation 
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of intracellular signaling pathways that involve a series of protein phosphorylation and 
dephosphorylation, protein-protein interaction, and protein-small molecules interaction (Liu 
and Zhou, 2004). Cytokines interact with cell-surface receptors initiating signaling cascades 
that promote cell growth and division, while inhibiting the pathways of apoptotic cell death. 
The JAK/STAT, Raf/ MEK/ERK and PI3K/Akt signaling pathways are activated by a 
variety of cytokines that function to potentiate or inhibit hematopoiesis. These include IL 
(interleukin)-3, IL-7, SCF (stem cell factor), G (granulocyte)-CSF, type I interferons (IFN) and 
TGF- (transforming growth factor)- beta (Steelman et al., 2004). 
The phosphatidylinositol 3-kinase (PI3K) 
PI3K /protein kinase B (Akt)/mammalian target of rapamycin (mTOR) (a family of lipid 
kinases) signaling cascade is crucial to many widely divergent physiological processes 
which include cell cycle progression, transcription, translation, differentiation, apoptosis, 
motility, and metabolism (Yuan and Cantley, 2008). The family of PI3K enzymes 
phosphorylates inositol lipids and comprises three different classes, I, II, and III. 
Phosphorylated phosphatidylinositol 3,4,5trisphosphate [PtdIns (3,4,5)P3] recruits to the 
plasma membrane pleckstrin homology (PH) domain-containing proteins, which include 
phosphoinositide-dependent protein kinase 1 (PDK1) and Akt. The phospholipid products 
of PI3K activate downstream targets, including PDK, Akt and PKC (Palmer et al., 1995; 
Toker et al., 1994; Nakanishi et al., 1993). 
Class I PI3K is further classified as A [activated by receptor tyrosine kinases (RTKs), Ras, 
and G-protein coupled receptors (GPCRs)] and B (activated by GPCRs) subtype. Class IA 
and 1B PI3Ks are heterodimeric enzymes composed of a regulatory and of catalytic subunits 
(Martelli et al., 2010).  
Phosphoinositide-dependent kinase (PDK) 
PDK requires the phospholipid product of PI3K for activation. There are believed to be two 
members of the PDK family – PDK1 and PDK2. Association of Akt with phosphoinositides 
produces a conformational change allowing Ser473 to be phosphorylated by PDK1 (Scheid 
et al., 2002). 
Protein kinase B (Akt) 
Akt is a 57-kDa serine/threonine protein kinase central to cell signaling downstream of 
growth factors, cytokines, and other cellular stimuli. Activated Akt was originally isolated 
from cells of the leukemia and lymphoma prone AKR strain of mice (Staal, 1987). It 
comprises three highly conserved isoforms: Akt1/α, Akt2/β, and Akt3/γ which are 
functionally different (Staal, 1987; Nicolson and Anderson, 2002; Staal et al., 1988). Once Akt 
is recruited at the plasma membrane, its activation loop is phosphorylated on Thr308 by 
PDK1 while the mTOR complex 2 (mTORC2), activated by RTK, phosphorylates Ser473 in 
the Akt COOH-terminus. Full Akt activation requires both phosphorylation steps. Active 
Akt migrates to both the cytosol and the nucleus. Nuclear Akt may fulfill important anti-
apoptotic roles. So far, over 100 Akt substrates have been identified (Manning and Cantley, 
2007). Of these, about 40 which mediate the pleiotropic Akt functions have been 
characterized, including Bad, caspase-9, murine double minute 2 (MDM2), IĸB kinase (IKK) 
α, proline-rich Akt substrate 40-kDa (PRAS40) 40, the Foxo family of Forkhead box-o 
transcription factors, apoptosis signal-regulated kinase 1 [ASK1, a negative regulator of pro-
apoptotic c-Jun N-terminal kinase (JNK)], Raf, p27Kip1, p21Cip1, glycogen synthase kinase 
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3β (GSK3β). Each of these substrates has a key role in the regulation of cell survival and 
proliferation, either directly or through an intermediary.  
The antiapoptotic effects of Akt occur through its phosphorylation of a wide variety of 
targets. The first antiapoptotic target identified was Bad, a member of the Bcl-2 family. 
Phosphorylation of Bad at S136 by Akt allows phosphorylated Bad to interact with 14-3-3 
proteins, promoting cell survival (Datta et al., 1997; Andreeff et al., 1999). Interaction of Bad 
with 14-3-3 proteins inhibits the ability of Bad to interact with Bcl-2 and Bcl-xL. This allows 
Bcl-xL to bind to proapoptotic Bax molecules and prevent the formation of proapoptotic Bax 
homodimers. However, Bad is also phosphorylated on different sites by members of the 
Raf/MEK/ERK (S112) and PKA (S112, S155) pathways.  
In human cells, Akt phosphorylates and inactivates caspase-9. Overexpression of Akt 
inhibits cytochrome c-induced activation of caspase-9 (Cardone et al., 1998). 
Phosphorylation of the Foxo family of transcription factors is also attributed to Akt (Biggs et 
al 1999); Brunet et al., 1999; Rena et al., 1999; Tang et al., 1999).This phosphorylation results 
in forkhead transcription factors translocation to the cytoplasm, thus inhibiting transcription 
of pro-apoptotic genes such as FasL (Brunet et al., 1999). Akt activates transcription of 
antiapoptotic genes through phosphorylation of IKK and regulation of nuclear factor-kappa 
B (NF-kB) (Ozes et al., 1999). Akt also promotes cell survival and cell cycle progression by its 
ability to phosphorylate MDM2 and GSK-3 (Fukumoto et al., 2001; Zhou et al., 2001). Once 
phosphorylated by Akt, MDM2 translocates to the nucleus and interacts with p300. p300 
dissociates from p19ARF, resulting in the degradation of p53 and cell cycle progression. Akt 
phosphorylates GSK-3, inhibiting its activity. The decreased GSK-3 activity increases 
stability ofcatenin and enhances its association with lymphoid enhancer factor/T cell factor 
(LEF/TCF) (Fukumoto et al., 2001). Thecatenin–LEF/TCF complex increases transcription 
of proteins such as cyclin D1 and c-myc, promoting cell cycle progression (Fukumoto et al., 
2001). Clearly, Akt can affect both cell cycle progression and apoptosis (reviewed in 
Steelman et al., 2004). 
MTORC1 is a critical regulator of translation initiation and ribosome biogenesis and plays 
an evolutionarily conserved role in cell growth control (Wullschleger et al., 2006). The 
enhanced sensitivity of cancer cells and mouse tumor models exhibiting oncogenic 
activation of the PI3K-Akt pathway to mTORC1 inhibitors, such as rapamycin, illustrates 
the importance of mTORC1 activation downstream of Akt (Sabatini, 2006). One of the best-
conserved functions of Akt is its role in promoting cell growth (i.e., an increase in cell mass). 
The predominant mechanism appears to be through activation of mTOR complex 1 
(mTORC1 or the mTOR-raptor complex), which is regulated by both nutrients and growth 
factor signaling. mTORC1 signaling integrates environmental clues (growth factors, 
hormones, nutrients, stressors) and information from the cell metabolic status. Thus, 
mTORC1 controls anabolic processes for promoting protein synthesis and cell growth 
(Manning and Cantley, 2007). 
Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT)  
The JAK/STAT pathway consists of three families of genes: the JAK, or Janus family of 
tyrosine kinases, the STAT (signal transducers and activators of transcription) family and 
the CIS/SOCS family, which serves to downregulate the activity of the JAK/STAT pathway 
(Silvennoinen et al., 1993; Kisseleva et al., 2002; Krebs and Hilton, 2002; Fujitani et al., 1997). 
The JAK/STAT pathway involves signaling from the cytokine receptor to the nucleus. JAKs 
are stimulated by activation of a cytokine receptor. Stimulation of JAKs results in STAT 
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The JAK/STAT pathway consists of three families of genes: the JAK, or Janus family of 
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the CIS/SOCS family, which serves to downregulate the activity of the JAK/STAT pathway 
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The JAK/STAT pathway involves signaling from the cytokine receptor to the nucleus. JAKs 
are stimulated by activation of a cytokine receptor. Stimulation of JAKs results in STAT 
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transcription factor activity. JAKs are a family of large tyrosine kinases, having molecular 
weights in the range of 120–140 kDa (1130–1142 aa). Four JAKs (JAK1, JAK2, JAK3 and 
Tyk2) have been identied in mammals. JAK3 expression is limited to hematopoietic cells 
(Steelman et al., 2004). 
The STAT gene family consists of seven proteins (STAT1,STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6). Upregulation of STAT3 is detected with high frequency inhuman 
cancer. STAT3 is activated not only by cytokine receptors, such as the receptor for the IL-6 
family cytokines, but also growth receptor tyrosine kinases, such as the EGFR family 
including Her2/Neu, and non-receptor tyrosine kinases such as Src and Abl(Turkson et al., 
1998), and is also activated in response to stimulation of G-protein-coupled receptors 
(GPCR) (Pelletier et al., 2003). Classically, the receptor stimulation by ligand induces STAT3 
binding to phosphotyrosine residues of receptors through its SH2 domain and its 
phosphorylation on a critical tyr705 residue by the receptor itself, or by associated Janus 
kinase (JAK, Jak1–3, Tyk2) or Src family tyrosine kinases (Yu et al., 2004). 
Ras/Raf/MAPK kinase/extracellular signal-regulated kinase pathway 
(Ras/Raf/MEK/ERK) 
The Ras/Raf/MEK/ERK pathway is a central signal transduction pathway, which transmits 
signals from multiple cell surface receptors to transcription factors in the nucleus (Chang et 
al., 2003a; Chang et al., 2003b; Chang et al., 2003c). This pathway is frequently referred to as 
the MAP kinase pathway as MAPK stands for mitogen-activated protein kinase indicating 
that this pathway can be stimulated by mitogens, cytokines and growth factors. The 
pathway can be activated by Ras stimulating the membrane translocation of Raf. This 
pathway also interacts with many different signal transduction pathways including 
PI3K/Akt and JAK/STAT. 
Ras is a small GTP-binding protein, which is the common upstream molecule of several 
signaling pathways including Raf/MEK/ERK, PI3K/Akt and RalEGF/Ral (Chang et al., 
2003a; Chang et al., 2003b; Chang et al., 2003c). There are three different Ras family 
members: Ha-Ras, Ki-Ras and N-Ras. The Ras proteins show varying abilities to activate the 
Raf/MEK/ERK and PI3K/Akt cascades, as Ki-Ras has been associated with Raf/MEK/ERK 
while Ha-Ras is associated with PI3K/Akt activation. 
The Raf protein family consists of A-Raf, B-Raf and Raf-1, which are involved in the 
regulation of proliferation, differentiation and apoptosis induced after cytokine stimulation 
(Blalock et al., 1999; Mercer et al., 2003; Naumann et al., 1007, Pritchard et al., 1996; Mercer et 
al., 2002).Raf-1 has many effects on the regulation of apoptosis. Some of these effects occur 
at the mitochondrial membrane and are independent of MEK and ERK activity. It was 
observed that overexpression of activated A-Raf abrogates the cytokine dependence of 
hematopoietic cells. Overexpression of B-Raf in Rat-1 cells results in decreased apoptosis 
due to inhibition of caspase activity. Raf-1 has important roles in apoptosis as it 
phosphorylates and inactivates Bad (Wang et al., 1996). Raf-1 phosphorylates and co-
immunoprecipitates with Bcl-2, as well as regulates Bag and Bad expression, in BCR/ABL-
expressing cells (Salomoni et al., 1998). The ability of Raf proteins to phosphorylate MEK1 
varies from B-Raf, Raf-1, A-Raf. The ability of Raf to abrogate cytokine dependency is 
inversely proportional to their MEK1 activity, with A-Raf, Raf-1, B-Raf (McCubrey et al., 
1998; Hoyle et al., 2000). Stimulation of Raf activates MEK1 and ERK resulting in 
phosphorylation of transcription factors, proliferation, and inhibition of apoptosis (Steelman 
et al., 2004).  
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Raf-1 is also phosphorylated by Akt which has been associated with inhibition of Raf-1 
activity (Wojknowski et al., 1997; Rommel et al., 1999). CAMP-dependent protein kinase 
(PKA) inhibits Raf-1 (Wu et al., 1993; Schramm et al., 1994; Dumaz et al., 2002). Protein 
kinase C isoforms (a, b and g) stimulates Raf-1 activity (Sozeri t al., 1992). Raf-1 has been 
postulated to have important roles in cell cycle progression, activation of the p53 and NF-kB 
transcription factors and the prevention of apoptosis (reviewed in Steelman et al., 2004) 
Interactions between the Raf and PI3K/Akt pathways, or crosstalk, is an area of intense 
research Recently, it was demonstrated that it is more effective to inhibit the growth of Raf- 
and MEK1-transformed hematopoietic cells with inhibitors that target both the 
Raf/MEK/ERK and PI3K/Akt pathways (Navolanic et al., 2004). 
MEK 
MEK proteins are the primary downstream targets of Raf. The MEK family of genes consists 
of five genes: MEK1, MEK2, MEK3, MEK4 and MEK5. The structure of MEK consists of an 
amino-terminal negative regulatory domain and a carboxy-terminal MAP kinase-binding 
domain, which is necessary for binding and activation of ERKs (Huang et al., 1995; Tanoue 
et al., 2001; Crews et al., 1992). Deletion of the regulatory MEK1 domain results in 
constitutive MEK1 and ERK activation. Activated MEK1 could abrogate cytokine 
dependency of certain hematopoietic cells. Constitutive activity of MEK1 inhibits NF-kB 
transcription by negatively regulating p38MAPK activity (Carter et al., 2000). 
ERK 
The main physiological substrates of MEK are the members of the ERK (extracellular signal-
regulated kinase) or MAPK (mitogen activated protein kinase) family of genes. The ERK 
family consists of four distinct groups of kinases: ERK, Jun amino terminal kinases 
(JNK1/2/3), p38MAPK (p38 a/b/g/d) and ERK5. In addition, there are ERK3, ERK4, ERK6, 
ERK7 and ERK8 kinases, which while related to ERK1 and ERK2 have different modes of 
activation, and their biochemical roles are not as well characterized. Downstream targets of 
ERK include the p90Rsk kinase and the CREB, c-Myc and other transcription factors. ERK 
and p90Rsk can enter the nucleus to phosphorylate transcription factors which can lead to 
their activation (reviewed in Steelman et al., 2004). 
Nuclear factor kappa B (NFkB) 
Cilloni et al. (2007) have presented a comprehensive review on NF-kB. NF-kB proteins are a 
small group of related and evolutionarily conserved proteins which in mammals consists of 
five members: Rel (c-Rel), RelA/p65, RelB, p50, and p52 (Ghosh et al., 1998; Hayden et al., 
2004).In resting cells, NF-kB proteins arepredominantly cytoplasmic, associating with 
members of the inhibitory IkB family such as IkBa, IkBb and Ikbe (Ghosh et al., 1998).These 
interact with NF-kB through multiple ankyrin repeats and as a result inhibit its DNA 
binding activity. Two NF-kB activation pathways exist; the first is normally triggered in 
response to infections or exposure to pro-inflammatorycytokines that activate the IkB kinase 
(IKK) complex leading to phosphorylation-induced IkB degradation, the other pathway 
leads to selective activation of p52: RelB dimers. This pathway is triggered by certain 
membersof the tumor necrosis factor (TNF)cytokine family through selective activation of 
IKKa by the upstream kinase, NF-kappa B-inducing kinase (NIK).In response to many stimuli 
such as inflammatorycytokines, bacterial lipopolysaccharide, phorbol esters, viral infection or 
stress, IkB are phosphorylated on two critical serine residues (Senftleben et al., 2001).  
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Fig. 1. Signal transduction pathways (refer text for details) 
This modification triggers IkB ubiquitination and destruction via the 26Sproteasome 
degradation machinery. As a consequence, NF-kBis freed to enter the nucleus and 
regulate transcription of over 150 genes encoding cell adhesion molecules, cytokines, 
growth factors, components of the immune systems and anti-apoptotic genes such as FLIP 
(FLICE inhibitory protein), cIAPs (inhibitor of apoptosis), Bcl-2 and Bcl-xL (Aggarwall, 
2004). It is also implicated in the regulation of cell proliferation by controlling D-type 
cyclins (Takebayashi et al., 2003). 
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The three main signaling pathways are kept in check by naturally occurring inhibitors or 
tumor suppressor proteins. For example, the JAK/STAT pathway has the SOCS/CIS family 
of proteins, which serve to limit its effects by a negative feedback pathway. The 
Raf/MEK/ERK pathway can be negatively regulated by the PI3K/Akt cascade as well as 
the MKP1 phosphatase, which inactivates phosphorylated ERK. The PI3K/Akt pathway has 
the PTEN and SHIP phosphatases, which serve to fine-tune its antiapoptotic effects 
(reviewed in Steelman et al., 2004). 
4. Aberrant STP and drug resistance in AML 
Genetic events that give rise to leukemic transformation occur through activation of 
components of receptor tyrosine kinase (RTK) signaling pathways (Liu and Zhou, 2004). 
These include fusion proteins or gene mutations such as seen with activated TEL-JAK, 
STAT5A and BCR-ABL. Transforming activity of oncogenic PTK is mediated by parallel 
activation of several downstream signaling pathways. Final downstream mediators of this 
complex signaling network are phosphoproteins that translocate to the nucleus and act as 
transcriptional regulators activating a distinct group of target genes. The oncogenic activity 
of a given PTK is mediated by several signaling pathways including JAK/STAT, 
Ras/MAPK, PI3K/AKT, or NF-kB.  
Oncogenic activity severs dependence of transformed cell on external stimulation for 
survival. TEL-JAK fusion proteins contain the oligomerization domain of TEL and the 
tyrosine kinase domains of JAK1, JAK2, JAK3, or TYK2. These efficiently substitute for the 
survival and mitogenic signals controlled by IL-3, without concomitant activation of the IL-3 
receptor. STAT5 are constitutively active in TEL-JAK2- and TEL-JAK1-expressing cells 
(Lacronique et al., 2000). The BCR-ABL oncogene produces an activated tyrosine kinase 
fusion protein and gain independence from IL-3 for cell growth (Mandanas et al., 1992). 
Activated forms of Ras, Raf, MEK, PI3K and Akt however, show significant differences in 
the ability to abrogate cytokine dependence (Steelman et al., 2004). 
TEL/JAK2 isoforms, depending on the location of the breakpoints in the JAK2 gene, have 
been described in acute lymphoblastic leukemia of the B-cell type and atypical CML 
(Lacronique et al., 1997). Somatically acquired JAK2 mutation (V617F) was detected in 
472/944 (50%) of patients with Ph-negative chronic myeloproliferative disorders [including 
polycythemia vera (PV), idiopathic myelofibrosis (IMF) and essential thrombocytosis (ET)] 
with predominance in PV (66%) followed by IMF (42%) and ET (26%) (Jones et al., 2005). 
Recent investigation of novel mutations in JAK2 revealed a higher incidence, ~99% and 55% 
in PV and ET, respectively (Tefferi, 2010).  
Flt-3 mediates its proliferative and antiapoptotic effects through several signaling pathways 
including the STAT5, Ras/MAPK and PI3K/AKT pathways. Overexpression of Flt-3 was 
detected in 73% of AML and 78% of ALL patients (Nakao et al., 1996). Flt-3 length mutations 
(internal tandem duplications (ITD) in the juxtamembrane domain) (Nakao et al., 1996), is 
observed in more than 20% of adult and more than 10% of pediatric AML patients harbor an 
Flt-3-ITD (reviewed in Testa et al., 2007). In general, patients with mutant FLT3 show higher 
cell counts and decreased overall survival. Absence of the wild-type allele in patients with 
Flt-3-ITD predicted poor prognosis in 82 adult de novo AML cases with otherwise normal 
cytogenetics who received uniform high-dose therapy. Of the the 23 (28%) patients with 
Flt3-ITD, disease-free survival (DFS) was inferior (P = 0.03), yet overall survival (OS) was 
not different (P = 0.14) (Whitman et al., 2001). In cytogenetic normal AML patients aged > 60 
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years treated on Cancer and Leukemia Group B frontline trials, FLT3-ITD remained 
associated with shorter disease-free survival (P < .001; hazard ratio 2.10) and overall 
survival (P < .001; hazard Ratio 1.97) in multivariable analyses (Whitman et al., 2010). Flt3 
kinase domain point mutants is mutated in about 35% of AML (Stirewalt et al., 2003). In a 
study of 481 patients, FLT3 mutation did not have an impact on event-free survival (EFS) in 
patients with CBF-AML (P = .84) and poor-risk AML (P = .37). However, while event-free 
survival was worse in the FLT3-internal tandem duplication (ITD) group (20 weeks vs 41 
weeks; P < .00,001) this was not observed for the FLT3-tyrosine kinase domain (TKD) point 
mutation group (61 weeks vs 41 weeks; P = .15) (Santos et al., 2011).  
The profiles of signal transduction that correlated with poor response to chemotherapy 
showed potentiated STAT5 and STAT3 phosphorylations as well as attenuated STAT1 
phosphorylation following cytokine stimulation (Irish et al., 2004) 
Ras mutations are frequently observed in certain hematopoietic malignancies including 
myelodysplastic syndromes, juvenile myelomonocytic leukemia and acute myeloid 
leukemia (Bartram et al., 1988; Flotho et al., 1999; Stirewalt et al., 2001). lt has been shown to 
activate both the Raf/MEK/ERK and the PI3K/Akt pathways. Thus, mutations at Ras 
should theoretically activate both pathways simultaneously. Consequence of this activation 
may be the increased expression of growth factors that can potentially further activate this 
cascade by an autocrine loop. Many cytokine and growth factor gene promoters contain 
binding sites for transcription factors (Ets, Elk, Jun, Fos, CREB) whose activities are often 
activated by the Raf/MEK/ERK cascade (reviewed in Steelman et al., 2004). 
There is increasing evidence that activation of the PI3K/AKT signaling pathway leading to 
downstream inactivation of Foxo transcription factors, activation of the mammalian target of 
rapamycin (mTOR), or induction of Skp2 (leading to degradation of the cell cycle inhibitor 
p27), plays a central role in transformation by several mutated PTK such as BCR/ABL, 
mutated FLT3 or KIT (Scheijen et al., 2004; Andreu et al., 2005). Emerging evidence suggests 
that activation of NF-kB involves crosstalk between the PI3K and Ras/MAPK pathways 
(Gelfanov et al., 2001; Kirchner et al., 2003). Several NF-kB target genes, such as 
cIAP1/cIAP2, Bcl-xL, or Mcl-1, are well-known inhibitors of apoptosis that may co-mediate 
the antiapoptotic effect of a constitutively activated PTK (Aichberger et al., 2005).  
Expression of transcription factor fusions like AML1/ETO and PML/RARa in leukemic cells 
leads to induction of several genes associated with WNT signaling (Muller-Tidow et al., 
2004). WNT signaling activation was found in a significant fraction of leukemic blasts from 
patients with AML-M0 (Zheng et al., 2004). 
Other causes of PI3K/Akt/mTOR activation in AML may be the result of several factors, 
including low levels of PP2A, autocrine/paracrine secretion of growth factors such as IGF-1 
and VEGF (reviewed in Martelli et al., 2010). Interactions between leukemic cells and bone 
marrow stromal cells through CXCR4 (a GPCR) which is abundantly expressed on leukemic 
cell surface where it is up-regulated by hypoxic conditions and its physiological ligand, 
(Fierro et al., 2009; Fiegl et al., 2009) CXCL12, produced by stromal cells, (Fiegl et al., 2009; 
Ayala et al., 2009) could result in PI3K/Akt/mTOR activation (Zeng et al., 2009). 
Furthermore, interactions between β1 integrins on AML cells and stromal fibronectin could 
lead to pathway activation, (Matsunaga et al., 2003; Matsunaga et al., 2008) possibly through 
up-regulation of integrin-linked kinase 1 (ILK1) which is involved in Akt phosphorylation 
on Ser473 in a PI3K-dependent manner in AML cells (Tabe et al., 2007). 
PI3K/Akt/ mTOR pathway influences proliferation, survival, and drug resistance of AML 
cells.  
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From 50% to 80% of patients with AML display Akt phosphorylated on either Thr308 or 
Ser473 (or both) (Xu et al., 2003; Min et al., 2003). Univariate analysis of 146 AML patients 
revealed those with low levels of pAKT had somewhat better CR rates (60% versus 50%; 
P=0.21), longer median CR durations (71 versus 32 weeks; P=0.13), and statistically 
significant longer median survival times (59 versus 30 weeks; P=0.02) compared with those 
with high levels of pAKT. In another study, single analysis of Akt phosphorylated at 
threonine 308 (Thr308) and serine 473 (Ser473) showed AktThr308(high) patients had 
significantly shorter overall survival (11 vs 47 months; P=0.01), event-free survival (9 vs 26 
months; P=0.005) and relapse-free survival (10 months vs not reached; P=0.02) than 
Thr308(low) patients. This was not observed for Akt Ser473 (Gallay et al., 2009). Poor 
prognosis of AML patients with elevated PI3K/Akt/mTOR signaling could be also related 
to the fact that this pathway controls the expression of the membrane ATP binding cassette 
(ABC) transporter, multidrug resistance-associated protein 1, associated with a lower 
survival rate (Tazzari et al., 2007; Schaich et al., 2005). Nevertheless, a more recent report has 
highlighted that constitutive activation of PI3K/Akt/mTOR signaling could be a favourable 
prognostic factor in de novo cases of AML. One hypothesis for the lower relapse rate in 
patients with enhanced PI3K/Akt/mTOR signaling is that it could drive immature leukemic 
cells (LSCs and CFU-L) into S phase, thus rendering them more susceptible to 
polychemotherapy (Tamburini et al., 2005) 
The AKT pathway was among the signaling cascades whose simultaneous activation with 
other pathways, such as PKCα and ERK, was found to confer a poor prognosis in AML 
(Altman et al., 2011). Eventhough often mutated in human cancer, MMAC1/PTEN gene are 
infrequent as genetic aberrations in myeloid leukaemia (Aggerholm et al., 2000) 
NF-kB has been found to be activated in CD34+/CD38– blast cells derived from patients 
with de novo AML (Guzman et al., 2001; Baumgartner et al., 2002). Leukemic stem cells 
residing in this population are quiescent or slowly cycling and therefore less sensitive to 
chemotherapy. They are therefore likely to be responsible for disease relapse and represent 
the target for future innovative therapies (Bonnett et al.,1997; Lowenberg et al., 1999; Jordan, 
2002). Activation of NF-kB in leukemia patients has been well documented though NF-kB 
activation is not uniform among AML patients. Forty percent of AML patients evaluated 
presented with increased NF-kB DNA binding activity. These patients are characterized by 
increased white cell counts at diagnosis and increased blast percentages in the bone marrow 
suggesting a link between NF-kB and cell proliferation. In particular, cyclin D1, whose 
expression is regulated by NF-kB. Alternatively, NF-kB action could be due to the induction 
of genes coding for AML growth factors such as GM-CSF or granulocyte colony-stimulating 
factor (G-CSF) (Cilloni et al., 2007). 
The majority of LSCs are quiescent and insensitive to traditional chemotherapeutic drugs. 
This latter feature explains, at least in part, the difficulties in eradicating this cell population 
by conventional polychemotherapy. Thus, novel therapeutic strategies for AML eradication 
should also target LSCs (Misaghian et al., 2009). In AML, aberrant activation of several 
signal transduction pathways strongly enhances the proliferation and survival of both LSCs 
and CFU-Ls (McCubrey et al., 2008; Steelman et al., 2008). Therefore, these signaling 
networks are attractive targets for the development of innovative therapeutic strategies in 
AML (Scholl et al., 2008). 
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Expression of STP proteins is heterogenous and of prognostic value in AML (Kornblau et al., 
2009). These signaling pathways in AML may in the future help rationally select targeted 
therapies in individual patients (Foran, 2010). While current classification schemes have 
prognostic relevance they generally do not alter therapeutic recommendations. As 
knowledge of mutated genes in cancersim proves, our ability to treat patients afflicted with 
certain diseases will increase substantially. The genetic mutation may affect multiple signal 
transduction pathways. Targeting multiple pathways may be more efficacious as this 
approach may suppress or eliminate tumor growth at lower concentrations of the drugs 
than that required to inhibit growth by targeting a single pathway (Steelmanet al., 2004). 
The heterogeneity in AML continues to elude the best methods to characterize them. 
Genome and proteome-wide analysis has further revealed complexity in the makeup of the 
leukemic cell. The rapid advancement in targeted therapies implied the urgent need for 
alternative therapy and the readiness of the community to embrace it. Nevertheless so far, 
combinatorial medicine still holds out as the best option for successful treatment. If targeted 
therapies remain the way forward it will eventually bank deeply on the ability to identify 
molecular signatures in the individual leading to the establishment of personalized 
medicine. 
Novel array technologies enabled the analysis of numerous features at the level of DNA for 
gene copy number variation, mutations, methylation in addition to mRNA transcription and 
regulatory microRNA. Emerging technologies to assess protein expression and 
phosphorylation levels within cells e.g. cytokine and chemokine arrays to assess external 
forces acting on leukemic cells and phosphoproteins in apoptosis, cell-cycle, and signal-
transduction pathways, are highly needed. Protein expression and posttranslational 
modifications, either alone or in concert with other profiling approaches, could provide 
independent or complementary information not captured by transcriptional profiles. Protein 
signature groups, with prognostic information distinct from cytogenetics may reveal 
underlying similarities indistinguishable by cytogenetics (Kornblau et al., 2009). 
Quantitative flow cytometry appears well suited for identifying predictive markers in AML 
patients because it offers obvious advantages over other techniques (western blot, for 
example), including rapidness, a much lower number of cells required to perform the assay, 
and the possibility of identifying different subclones in the leukemic population by 
coimmunostaining with multiple antibodies to surface antigens (Martelli et al., 2010). The 
mechanisms in leukemogenesis, drug resistance and relapse remain an area of much 
research. From cell biology to cytogenetics to molecular defects to signaling pathways, all 
have contributed to a better understanding of the cancer. New knowledge in epigenetics 
and microRNA remain to be elucidated. 
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Expression of STP proteins is heterogenous and of prognostic value in AML (Kornblau et al., 
2009). These signaling pathways in AML may in the future help rationally select targeted 
therapies in individual patients (Foran, 2010). While current classification schemes have 
prognostic relevance they generally do not alter therapeutic recommendations. As 
knowledge of mutated genes in cancersim proves, our ability to treat patients afflicted with 
certain diseases will increase substantially. The genetic mutation may affect multiple signal 
transduction pathways. Targeting multiple pathways may be more efficacious as this 
approach may suppress or eliminate tumor growth at lower concentrations of the drugs 
than that required to inhibit growth by targeting a single pathway (Steelmanet al., 2004). 
The heterogeneity in AML continues to elude the best methods to characterize them. 
Genome and proteome-wide analysis has further revealed complexity in the makeup of the 
leukemic cell. The rapid advancement in targeted therapies implied the urgent need for 
alternative therapy and the readiness of the community to embrace it. Nevertheless so far, 
combinatorial medicine still holds out as the best option for successful treatment. If targeted 
therapies remain the way forward it will eventually bank deeply on the ability to identify 
molecular signatures in the individual leading to the establishment of personalized 
medicine. 
Novel array technologies enabled the analysis of numerous features at the level of DNA for 
gene copy number variation, mutations, methylation in addition to mRNA transcription and 
regulatory microRNA. Emerging technologies to assess protein expression and 
phosphorylation levels within cells e.g. cytokine and chemokine arrays to assess external 
forces acting on leukemic cells and phosphoproteins in apoptosis, cell-cycle, and signal-
transduction pathways, are highly needed. Protein expression and posttranslational 
modifications, either alone or in concert with other profiling approaches, could provide 
independent or complementary information not captured by transcriptional profiles. Protein 
signature groups, with prognostic information distinct from cytogenetics may reveal 
underlying similarities indistinguishable by cytogenetics (Kornblau et al., 2009). 
Quantitative flow cytometry appears well suited for identifying predictive markers in AML 
patients because it offers obvious advantages over other techniques (western blot, for 
example), including rapidness, a much lower number of cells required to perform the assay, 
and the possibility of identifying different subclones in the leukemic population by 
coimmunostaining with multiple antibodies to surface antigens (Martelli et al., 2010). The 
mechanisms in leukemogenesis, drug resistance and relapse remain an area of much 
research. From cell biology to cytogenetics to molecular defects to signaling pathways, all 
have contributed to a better understanding of the cancer. New knowledge in epigenetics 
and microRNA remain to be elucidated. 
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1. Introduction  
Chromosome translocation reflects an abnormality caused by rearrangement of DNA 
fragments between non-homologous chromosomes. These rearrangements can be visualized 
by cytogenetic analysis of affected cells. Non-random chromosomal translocations are 
frequently associated with a variety of cancers, particularly hematological malignancies and 
childhood sarcomas although recent evidence demonstrates that such translocations are also 
common in epithelial tumors (Aplan, 2006; Mitelman et al., 2005). Initially considered as 
random events that get selected, it has become increasingly apparent that chromosomal 
translocations are influenced by cell type, cell stage and genomic context. Most commonly, 
these non-random chromosomal translocations are associated with specific hematopoietic 
cell types. Such chromosomal translocations are commonly used as diagnostic tool and are 
increasingly utilized to guide therapeutic decisions. Although, the mechanism that causes 
chromosomal translocations remains largely unknown, it is commonly accepted that they 
arise from DNA double strand breaks (DSBs) that are misrepaired (Aplan, 2006; Digweed 
and Sperling, 2004; Betti et al., 2003; Povirk, 2006). For a translocation to occur there are 
several mechanistic factors required: First there needs to be at least two DSBs in different 
chromosomes. Second the DSBs must arise close enough both in three-dimensional space 
and in time. Finally, DNA repair pathways must be available to join the two broken DNA 
fragments to form the translocation. It is estimated that everyday a normal cell in our body 
is exposed to approximately 20,000 DNA damaging events (Ames and Shigenaga, 1992). A 
major source of DNA damage is oxygen free radicals; however there are other endogenous 
and exogenous sources of DNA damage such as replication, transcription, and genotoxic 
stress. All of these processes can induce DSBs, but for two DNA fragments to be joined they 
must necessarily come in close proximity of each other (less than 1.3m) (Chen et al., 1996; 
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1. Introduction  
Chromosome translocation reflects an abnormality caused by rearrangement of DNA 
fragments between non-homologous chromosomes. These rearrangements can be visualized 
by cytogenetic analysis of affected cells. Non-random chromosomal translocations are 
frequently associated with a variety of cancers, particularly hematological malignancies and 
childhood sarcomas although recent evidence demonstrates that such translocations are also 
common in epithelial tumors (Aplan, 2006; Mitelman et al., 2005). Initially considered as 
random events that get selected, it has become increasingly apparent that chromosomal 
translocations are influenced by cell type, cell stage and genomic context. Most commonly, 
these non-random chromosomal translocations are associated with specific hematopoietic 
cell types. Such chromosomal translocations are commonly used as diagnostic tool and are 
increasingly utilized to guide therapeutic decisions. Although, the mechanism that causes 
chromosomal translocations remains largely unknown, it is commonly accepted that they 
arise from DNA double strand breaks (DSBs) that are misrepaired (Aplan, 2006; Digweed 
and Sperling, 2004; Betti et al., 2003; Povirk, 2006). For a translocation to occur there are 
several mechanistic factors required: First there needs to be at least two DSBs in different 
chromosomes. Second the DSBs must arise close enough both in three-dimensional space 
and in time. Finally, DNA repair pathways must be available to join the two broken DNA 
fragments to form the translocation. It is estimated that everyday a normal cell in our body 
is exposed to approximately 20,000 DNA damaging events (Ames and Shigenaga, 1992). A 
major source of DNA damage is oxygen free radicals; however there are other endogenous 
and exogenous sources of DNA damage such as replication, transcription, and genotoxic 
stress. All of these processes can induce DSBs, but for two DNA fragments to be joined they 
must necessarily come in close proximity of each other (less than 1.3m) (Chen et al., 1996; 
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Misteli, 2010). These requirements are accommodated in two competing models to explain 
DSBs proximity in the nucleus: the position first and the breakage first (Figure 1). The 
position first model suggests that the DNA regions involved in the translocation are in close 
proximity before DSBs generation. Support for this model comes from the observation that 
translocation frequencies differ among tissues and is paralleled by tissue-specific 
organization of the involved chromosomes (Mitelman et al., 2007). For example, the 
frequency of c-myc translocations to IgH, Ig, or Ig locus in Burkitt’s lymphomas correlates 
with reciprocal distance (Roix et al., 2003). In contrast, the breakage first model proposes 
that DSBs are produced far apart and then move into close proximity to be repaired. In yeast 
for example, independent DNA lesions move and colocalize in repair factories (Lisby et al., 
2003a; Lisby et al., 2003b). In mammalian cells experimental evidence, ranging from no or 
limited movement to an extensive movement and clustering of these DSBs breaks, provides 
support for both models (Kruhlak et al., 2006). 
 
 
Fig. 1. Models for Chromosomal Translocation Formation. In the position first model two 
DSB that are nearby in the nuclei can be erroneously repair and give rise to a chromosomal 
translocation. In the breakage first model two DSB that are far apart in the nuclei are 
brought close together, probably to be repaired, resulting in a translocation. 
In eukaryotic cells, DSBs are repaired by two different repair pathways: homologous 
recombination (HR) and non-homologous end joining (NHEJ) (Figure 2). HR is a relative 
error-free repair pathway that required information from a template sequence to repair 
the damage. This pathway is active during S and G2 phases of the cell cycle when the 
sister chromatid template is easily available and it can also take place during both mitosis 
and meiosis. NHEJ is a template independent DSBs repair mechanism. It is an error-prone 
pathway active throughout the cell cycle and the most commonly used DBSs repair 
pathway in multicellular eukaryotes. NHEJ is subdivided in classical (C-NHEJ) and 
alternate (A-NHEJ). The C-NHEJ is responsible for individual intrachromosomal DSBs 
repair in an homology independent manner, while A-NHEJ works in a micro-homology 
dependent manner, is more error-prone and seems to be the primary pathway responsible 
for the generation of chromosomal translocations (Simsek and Jasin, 2010; Boboila et al., 
2010).  
 




Fig. 2. DNA Double Strand Break Repair Pathways. Schematic representation of the two 
main DNA repair pathways: non homologous end joining (NHEJ) and homologous 
recombination (HR). The key regulatory proteins involved at multiple stages of each 
pathway are indicated. 
Most of the chromosome translocations that have been analyzed to date show no consistent 
homologous sequences at the breakpoints regions. However, several structural features like 
DNase I hypersensitivity, topoisomerase II cleavage sites, DNA fragile sites and matrix or 
scaffold attachment regions (MARs or SARs) often colocalize with the mapped breakpoints. 
These observations suggest that chromatin organization may play a role in generation of 
translocations (Zhang et al., 2002; Strissel et al., 1998; Tanabe et al., 1996; Felix et al., 1995; 
Stanulla et al., 1997; Zhang and Rowley, 2006). Moreover, chromatin organization also has a 
prominent role in DNA repair process and therefore may influence both the selection of a 
DNA repair pathway and the eventual outcome of the DNA repair (Fernandez-Capetillo et 
al., 2004; Verger and Crossley, 2004; Tsukuda et al., 2005; Murr et al., 2006; Falk et al., 2008; 
Falk et al., 2010; Misteli and Soutoglou, 2009). Here we will focus on the current knowledge 
of the role that genomic structural features may have on formation of chromosomal 
translocations. Particularly we will analyze epigenetic marks associated with chromosome 
breakpoint regions and unusual DNA conformations among other structural features that 
may alter genomic structural stability. 
2. Higher-order genome organization and translocations  
The higher order organization of genomes architecture during interphase of the cell cycle 
forms chromosomes territories; which are defined as the nuclear space occupied by the 
DNA of a given chromosome (Cremer and Cremer, 2001; Cremer et al., 2006; Meaburn and 
Misteli, 2007; Misteli, 2007). Individual chromosomes are organized into open and closed 
chromatin domains that occupy different spatial compartments. A similar concept of 
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nonrandom nuclear positioning applies to single loci and may be relevant to their 
translocation potential. For example the BCR and ABL genes, located on chromosomes 9 and 
22, whose translocation leads to formation of a fusion protein involved in leukemia, are 
located in close proximity in normal hematopoietic cells at much higher frequency than 
would be expected based on a random distribution (Lukasova et al., 1997; Neves et al., 1999; 
Bartova et al., 2000). The same is true for the human chromosomes 12 and 16, which are 
frequently translocated in liposarcoma and are found in close proximity in differentiated 
adipocytes (Kuroda et al., 2004). Similarly, the frequency of c-myc translocations to IgH, Ig 
or Ig locus in Burkitt’s lymphomas correlates with reciprocal nuclear distance. However, it 
is important to note that clonal oncogenic translocations in tumors are highly selected and 
therefore cannot be used to unequivocally determine the actual translocation frequency. 
More unbiased examinations may yet reveal translocations between loci that are not 
frequently in close proximity. The proximity of two particular loci within the interphase 
nucleus can be cell-type or tissue-specific. In this context, substantial colocalization of IgH 
and Ig occurs in activated splenic B cells but not in embryonic stem cells or thymocytes 
(Wang et al., 2009). Notably, colocalization with IgH is not a characteristic of the entire 
chromosome 16 on which Ig locus resides. In fact, about 15Mb sequences on either side of 
Ig do not colocalize; therefore, proximity can be determinant in the context of more narrow 
areas around specific genes and not with broad chromosome territories. 
The internal structure of the chromosomal territories is poorly understood but most 
probably is formed by a network of looping chromatin fibers. This relatively open structure 
allows access to gene regulatory factors while simultaneously protect the DNA from the 
continuous attack of damaging agents. Supporting this view, data from several different loci 
involved in genomic rearrangements exhibit an altered chromatin conformation in their 
breakpoint regions. For example, the MLL gene exhibits a strong topoisomerase II cleavage 
site near exon 12 where genomic breakpoint from therapy related AML (t-AML) patients 
and infant leukemia patient with MLL translocation have been mapped. Moreover, the same 
region also exhibit hypersensitivity to DNaseI and is cleaved by S1 and Mung Bean nuclease 
which specifically recognize and cleave single-strand regions in supercoiled DNA (Strissel et 
al., 1998; Felix et al., 1995; Stanulla et al., 1997). These features however are not exclusive to 
MLL gene, as topoisomerase II and DNaseI hypersensitive sites has also been found at the 
breakpoint regions of AF9, BCL, ABL, RUNX1, ETO and CBP among other genes (Greaves, 
1996; Zhang et al., 2002; Strissel et al., 1998; Aplan et al., 1996; Relling et al., 1998; Strick et 
al., 2006; Sperry et al., 1989). However, not all breakpoint regions identified to date for genes 
involved in translocations colocalize with either topoisomeraseII cleavage sites or DHS, 
suggesting that other chromatin structural properties maybe involved in determining the 
location of chromosome breakage.  
3. Chromatin organization and DNA repair 
Higher order chromatin structure is not only important for global susceptibility of DNA 
to damage but may also be relevant for DNA repair. It is well documented that the earliest 
response to a DSB is the phosphorylation of the histone H2A variant histone H2AX on its 
C-terminus. Within seconds of DSB formation, the phosphorylated H2AX is present over 
surrounding regions, spanning thousand to millions of base pairs (Rogakou et al., 1998; 
Rogakou et al., 1999; Leatherbarrow et al., 2006; Kinner et al., 2008). H2AX is not present 
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in lower eukaryote, but the domain that is phosphorylated in response to DSB is present 
in the C-terminus of other H2A-family members like H2A in S. cerevisiae and H2AZ in D. 
melanogaster (Downs et al., 2007). Although loss of H2AX does not abrogate DNA-
damage checkpoints or repair, it impairs the joining of programmed DNA lesions during 
immunoglobulin class-switch recombination. These observations suggest that chromatin 
modifications at a distance are required for bringing together the DNA ends (Petersen et 
al., 2001; Reina-San-Martin et al., 2003). Moreover, failing to rejoin these programmed 
DSB in the absence of H2AX result in frequent chromosomal abnormalities (Franco et al., 
2006; Ramiro et al., 2006). In addition to phosphorylation, H2A is also modified by 
acetylation in its N-terminal tail by NuA4, a histone acetyl transferase (HAT). Acetylation 
seems to be important for the ability of cells to survive after DNA damage (Bird et al., 
2002). 
The findings that DSB induces a rapid local decrease in the density of the chromatin fiber 
(Kruhlak et al., 2006) and that nearby nucleosomes are repositioned (Shim et al., 2007) 
support the idea that ATP-dependent chromatin remodeling factors have an early role in the 
DNA damage response. Indeed, several reports have demonstrated that the ATP-dependent 
chromatin remodeling complexes RSC (Remodels the Structure of Chromatin), SWI/SNF 
(SWItch/Sucrose NonFermenting), INO80 (INOsitol requiring) and SWR (Sick with Rat8 ts) 
are recruited to DSB, although at different time after the DNA damage. The first complex 
recruited to the DSB is RSC, which mobilize the nucleosomes near a DSB to new positions. 
Interestingly, in the absence of RSC the phosphorylation of H2AX is delayed. The other 
three chromatin remodeling complexes, SWI/SNF, INO80 and SWR, are enriched at sites of 
DSB at later times suggesting that they are not required for the initial detection or signaling 
of the DSB, but for the subsequent stages of the repair process. 
Additionally, acetylation of conserved residues in the N-terminal tails of H3 and H4 has 
been found to contribute to both homologous and non-homologous recombination 
processes. For example, in mammalian cells, the TIP60 and the HAT cofactor TRRAP 
(transformation/transcription-domain associated protein) are recruited to sites of DSB, 
where they induce acetylation of H4 and facilitate homologous recombination. Similarly, 
another HAT, MOF (also known as MYST1) contributes to irradiation-induced acetylation of 
H4 at lysine 16 (H4K16). Defects on H3 and H4 acetylation have been linked to sensitivity to 
ionizing radiation and alteration in cell cycle checkpoints (Gupta et al., 2005). Complexes 
catalyzing the reverse process, i.e. histone deacetylation, have been shown to be enriched at 
late times at the DSB regions. If the acetylation of histones in the vicinity of DNA damage 
facilitate the repair process, then it is possible that the role of these histone deacetylase 
complexes might be to restore the chromatin to its original state once the DNA has been 
repaired. 
4. Histone post-translational modifications in chromosomal rearrangements 
The role of histone modifications on genomic rearrangements has been extensively studied 
in the V(D)J recombination process. This assembly process depends on a series of site-
specific recombination reactions that are initiated by DSBs produced by RAG1 and RAG2 
complex (Bassing et al., 2002). Each rearranging gene segment is flanked by a recombination 
signal sequence (RSS). The recombinase complex recognizes pair of compatible RSS, 
introduce DSBs and then channel the reaction products to a DNA repair pathway. Aberrant 
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targeting of RAG proteins can produce chromosomal translocations that are associated with 
many forms of leukemia or lymphoma. In general, genes segments within recombinationally 
active loci are mark by the same histone modifications that characterize transcriptionally 
active genes, i.e. H3 and H4 acetylation as well as H3 trimethylation at lysine 4 (H3K4me3). 
More recently, it has become evident that the predominant effect of these histone 
modifications is to recruit the RAG complex to the RSS. In fact, RAG2 through its PHD 
domain specifically binds to H3K4me3 and mutations that abolish this binding results in 
greatly impaired V(D)J recombination activity (Liu et al., 2007; Matthews et al., 2007). 
Additional support for the epigenetic role on V(D)J recombination comes from the 
observation that in V genes H3 acetylation, although lower than in J genes, exhibit a 
gradient of enrichment that mirrored the rearrangement frequency. Interestingly, a 
reciprocal pattern is observed for the repressive modification H3 dimethylation at lysine 9 
(H3K9me2) (Espinoza and Feeney, 2005; Espinoza and Feeney, 2007). 
H3 trimethylation at lysine 4 (H3K4me3) is also implicated in meiotic recombination. In fact 
PRDM9, a zinc finger protein that catalyze the trimethylation of H3 at lysine 4, has recently 
been identified as a major determinant of sequence-specific meiotic recombination (Cheung 
et al., 2010). 
Another histone modification, H3 methylation at lysine 79 (H3K79me), is associated with 
recombinationally active loci both in yeast and mammalian cell lines (Ng et al., 2003). 
Moreover, overexpression of DOT1L (a H3K79me specific methyltransferase) together with 
genotoxic stress and dihydrotestosterone significantly increases formation of chromosomal 
rearrangement involving the ETS genes, which are a distinguishing feature of prostate 
cancer (Kumar-Sinha et al., 2008; Lin et al., 2009). 
Lin and colleagues (Lin et al., 2009), using prostate cancer as a model to study translocation 
mechanisms, have shown that after irradiation far more translocations are formed in 
androgen treated than in control cells. They also demonstrated that the translocation 
regions, TMPRSS2, ERG and ETV all contain binding sites for the androgen receptor (AR) 
near their breakpoints and that, after treatment with androgen, there is a rapid recruitment 
of AR to these sites. Moreover, AR recruitment induces changes in higher-order chromatin 
structure and epigenetic modifications establishing an open chromatin conformation 
characteristic of transcribed genes. Another consequence of AR binding was the recruitment 
of the activation-induced cytidine deaminase (AID), a key factor in somatic hypermutation 
(SHM) and class switch recombination (CSR) where it contributes to formation of DSB 
during the process of generating antibody diversity. 
Additional data supporting the role of chromatin structure in genomic rearrangements 
comes from the analysis of the mechanisms involved in formation of t(2;5), a chromosomal 
translocation associated with anaplastic large cell lymphoma (ALCL). Mathas et al (Mathas 
et al., 2009) found up-regulation of several genes located near the ALCL translocation 
breakpoint, regardless of the presence of t(2;5) in the tumor. Moreover, their increased 
transcriptional activity promotes cell survival and repression of T-cell specific gene 
expression programs, both characteristics are a hallmark of ALCL (Mathas et al., 2009). 
Interestingly, cells isolated from ALCL patients lacking t(2;5) were more susceptible to form 
the (2;5) translocation than control cells. Together these data suggest that deregulation of 
breakpoint-proximal genes occurs before the formation of translocations and that similar to 
V(D)J recombination, transcriptional activity and altered chromatin structure predispose 
cells to chromosomal translocation. 
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This pattern of highly accessible chromatin structure characterized by H3 and H4 
acetylation is also found at the breakpoint regions of other genes involved in translocations 
like MLL (Khobta et al., 2004), RUNX1 (Stuardo et al., 2009) and ETO (our unpublished 
data). Using chromatin immunoprecipitation assays (ChIPs) we analyzed the chromatin 
structure at intrón 5 of the RUNX1 gene, where all the translocation points for the (8;21) 
translocation has been mapped (Figure 3). Our results demonstrate that chromatin 
organization at intron 5 is completely different in HL-60 hematopoietic cells than in a non-
hematopoietic cell (Stuardo et al., 2009). In fact, two distinct features mark the intron 5 in 
HL-60: a complete lack or significantly reduced levels of histone H1 and an increased 
association of hyperacetylated histone H3. 
 
 
Fig. 3. Diagrammatic representation of the RUNX1 gene. Top panel show the exon-intron 
organization of the gene as well as the two promoters that regulate its expression. Bottom 
panel show a magnification of intron 5 of the RUNX1 gene. The three breakpoint clusters 
(BCR) are indicated as well as the amplification fragments analyzed by ChIP assays  
(purple blocks labeled A-U). Dark gray arrows indicate topoisomerase II sites and light gray 
arrow DNase I hypersensitive site. 
The decreased association of histone H1, may indicate an overall enhanced accessibility and 
hence an increased availability to nucleases or DNA damaging agents. Notably, the region 
where the DNaseI hypersensitive site has been mapped presents one of the lowest rates of 
association of histone H1 in myeloid HL-60 cells (Figure 4, region U). Although the complete 
intron 5 is enriched in acetylated histone H3 (Figure 5), the chromatin organization is not 
homogeneous throughout the intron, suggesting that particular regions of intron 5 may play 
a regulatory role in transcription, subnuclear localization or compaction of the RUNX1 gene. 
Interestingly, the chromatin organization at intron 5 resembles the chromatin structure 
adopted by the V(D)J gene segment. During V(D)J recombination, gene segments encoding 
the variable regions for immunoglobulins and T-cell receptors (TCR) are recombined and 
assembled in a new configuration. The same recombinase is present in both T and B cells, 
however recombination of immunoglobulins loci happens only in B cells while TCR loci 
rearrange only in T cells. Targeting of recombinase activity to specific gene segments is 
controlled largely by changes in chromatin accessibility in a spatio-temporal manner, and 
acetylation of histone tails has been shown to be a key event in this process. In fact, 
acetylation of histone H3 or H4 is elevated in B or T cell type at gene segments that can 
recombine, and reduced at segments that do not undergo recombination (Maes et al., 2006; 
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Maes et al., 2001; McMurry and Krangel, 2000). Moreover, hyperacetylation induced by 
inhibitors of histone deacetylase complexes (HDAC) rescues recombination defects caused 
by the elimination of extracellular signals that induce recombination (Durum et al., 1998). 
These studies suggest that histone hyperacetylation precedes recombination by opening 
chromatin and promoting access to the recombinase. Thus regardless of the molecular 
mechanism involved, it seems that an open chromatin conformation is a common 
requirement for a translocation to take place (Figure 6). 
 
 
Fig. 4. Intron 5 of RUNX1 gene exhibit decreased association of histone H1. Chromatin 
immunoprecipitation assays were performed with formaldehyde cross-linked chromatin 
isolated form HL-60 cells. Real-time PCR amplification of ChIP-DNA is shown as fold 
change over IgG in bar graph for immunoprecipitation with anti H1 antibody. Light gray 
arrow indicates DNaseI hypersensitive site. 
 
 
Fig. 5. Intron 5 of RUNX1 gene is enriched in acetylated histone H3. Chromatin 
immunoprecipitation assays were performed with formaldehyde cross-linked chromatin 
isolated form HL-60 cells. Real-time PCR amplification of ChIP-DNA is shown as fold 
change over IgG for immunoprecipitation with anti acetylated H3 antibody. Light gray 
arrow indicates DNaseI hypersensitive site. 
 




Fig. 6. Summary of chromatin structure and histone modification in the regions involed 
in chromosomal translocation. DSB can occur either in euchromatin or heterochromatin, 
but they must arise close enough both in time and in space to give rise to a chromosomal 
translocation. In both cases the regions surrounding the DSB will exhibit an open chromatin 
conformation either due to its presence in euchromatin or as result of the DNA repair 
process.  
5. DNA conformation  
In addition to the classical B-DNA structure described by Watson and Crick (Watson and 
Crick, 1953), more than 10 different DNA conformations are documented to date. These 
alternative DNA conformations include Z-DNA, hairpins/cruciforms, H-DNA (triplexes), 
slipped DNA and sticky DNA among others (Felsenfeld and RICH, 1957; Wang et al., 1979; 
Lilley, 1980; Panayotatos and Wells, 1981; Lyamichev et al., 1983; Sen and Gilbert, 1988; 
Mirkin, 2008). Several studies have shown that these non-canonical DNA structures affect 
DNA replication and transcription, and contribute to genome instability. For example non-B 
forming sequences located in c-MYC and BCL-2 genes localize with translocation breaking 
points. Studies have demonstrated that the H-DNA structure from the human c-MYC gene 
can induce DSBs in mammalian cells and stimulate genomic instability on mouse 
chromosomes in transgenic mice (Wang et al., 2008). However, the same sequences are not 
mutagenic in bacteria, suggesting a requirement for host-specific trans-acting factors to 
generate genomic instability. 
Palindromic sequences, including palindromic AT-rich repeats (PATRRs), have the potential 
to form stem-loop structures by intrastrand base pairing within single-stranded DNA. In 
fact, PATRRs mapped on chromosome 22q11 and other chromosomes, such as 11q23 and 
17q11, were found to cause non random chromosomal translocation in sperm cells in the 
general population (Kato et al., 2006) as well as in cell culture (Inagaki et al., 2009). 
Polymorphisms within the PATRRs affect the susceptibility to translocation in vitro, with 
longer and more symmetric PATRRs showing a stronger predisposition to translocation 
events (Kato et al., 2006; Kogo et al., 2007; Inagaki et al., 2009). Therefore, it has been 
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proposed that the secondary structures adopted by palindromic DNA induce a greater 
susceptibility to DSBs thus leading to translocations in human (Kurahashi et al., 2000).  
There have also been identified chromosomal fragile sites, which are genomic regions 
especially susceptible to DNA breakage. These fragile sites are non-random specific loci that 
are stable under normal conditions, but under conditions of partial replication stress can 
form visible gaps or breaks in metaphase chromosomes (Durkin and Glover, 2007; Richards, 
2001). Many different studies have established a connection between DNA fragile sites and 
the formation of cancer-specific genome rearrangements. However, only recently there has 
been direct evidence linking breakage at DNA fragile sites to the formation of a cancer 
specific translocation. Using as model RET/PTC rearrangements; which are commonly 
found in the papillary thyroid carcinoma (PTC) and in all cases result in the fusion of the 
tyrosine kinase domain of RET (rearranged in transformation) to the 5’ portion of various 
unrelated genes (Nikiforov, 2008) Gandhi et al (Gandhi et al., 2010) demonstrate that fragile 
site-inducing chemicals can create DNA breaks within the RET/PTC partner genes and 
ultimately lead to the formation of RET/PTC rearrangements. Moreover, aphidicolin 
induced DNA breaks at RET gene were located within intron 11, which is the breakpoint 
cluster region identified in thyroid cells. Clinical studies have shown that two different 
rearrangements, RET/PTC1 and RET/PTC3, are more frequent in sporadic and radiation-
induced tumors respectively (Fenton et al., 2000; Fugazzola et al., 1995; Nikiforov et al., 
1997; Motomura et al., 1998). Interestingly, treatment of cells with aphidicolin (APH), 2-
aminopurine (2-AP) and 5-bromodeoxyuridine (BrdU) resulted in the generation of 
RET/PTC1 but not RET/PTC3 suggesting that sporadic PTC tumors may result from 
breakage at fragile sites. Although no consensus sequence have been identified in the fragile 
sites until now, the majority of them can form highly stable non-B DNA structures. 
6. Concluding remarks  
Traditionally it has been assumed that translocations arise randomly by stochastic DSB and 
that enrichment of particular translocations was result of the survival advantage acquired 
by the cells bearing the translocation. However, more recent results suggest that breaks in 
the genome occur in a nonrandom fashion and that higher-order chromatin organization 
maybe, at least in part, responsible for the formation of recurrent translocations. Although, 
significant progresses have been made in understanding formation of chromosomal 
translocation, particularly in the area of VDJ recombination, many more questions remain 
unanswered. For instance, it is still not known what proteins or pathways are involved in 
formation and maintenance of structure at the breakpoint regions, if these regions have a 
role in some cellular processes and what signaling pathways or environmental conditions 
promote chromosomal translocations. The response to these basic research questions may 
greatly improve diagnostic and therapeutic and may help to develop preventive measures 
for disorders associated with genomic instability such as chromosomal translocations. 
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1. Introduction  
The developing world, Africa included, is witnessing an alarming upsurge of cancer 
incidence. The annual number of new cancer cases is expected to double by 2020 and up to 
70% of the 20 million new cases of cancer predicted to occur yearly will be in the developing 
world (Jones et al., 1999; Ferlay et al., 2003; Yach et al., 2004). 
One startling disparity, however, between cancer in the developing and developed worlds is 
that although the overall incidence of cancer in the developing world is half of that observed 
in the developed world, survival rates in the developing world are often less than one third 
of site-specific cancers in the developed world (Sener et al., 2005). This emphasizes the 
duality of the cancer problem in Africa, for being largely a disease of modern life style, 
occurring against a background of socio-economic disparities and greater burden of 
communicable diseases.  
The study of genetic epidemiology of cancers in Africa hence entails the study of peculiar 
features of gene-environment interaction that may be largely private to Africa. In addition to 
the state of socio-economic underdevelopment that applies almost to the majority of African 
states, there is the plethora of extreme environments, wide range of climatic conditions and 
cultures, but most of all the transition state of the African communities from rural subsistent 
into urban market oriented life style. Furthermore one has to consider the notorious 
prevalence of infectious and non infectious diseases that may have a bearing both on the 
initiation of myeloid leukemia, its prognosis and management, e.g. tuberculosis (Omoti et 
al., 2009), malaria, other chronic infections, sickle cell disease (Ahmed et al., 2008) and 
common adaptive traits that could modulate the course of the disease, as well as the role of 
oncogenic viruses discussed below.  
One interesting example of a potential trade-off between malignancies and parasitic diseases 
is CD36 a multiligand receptor associated with a broad array of physiological processes, 
believed to be under selective pressure from Plasmodium falciparum, and deficient or 
polymorphic in several African populations. The role of CD36 in sickle cell crises and 
cerebral malaria is debatable. As a receptor for thrombospondin 1, CD36 plays a role in the 
regulation of angiogenesis, which may be a therapeutic strategy for controlling the 
dissemination of malignant neoplasm. Moreover, it is commonly expressed on blasts in 
acute monocytic leukemia, megakaryoblastic leukemia, and erythroleukemia (Ge and 
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Elghetany, 2005). However, CD36 negative AML cells could be found especially in those 
populations that usually do not express CD36 (like in several African populations). CD36 
negative cells appeared less susceptible to trombospondin-1 induced apoptosis, which make 
leukemic cells less vulnerable to death through this promising therapeutic strategy (Li et al., 
2003). 
On the other hand, due to the transition state, a number of risk factors believed to represent 
etiologic determinants of leukemia like use of pesticides, radiation etc. are not yet 
commonplace in Africa or at least its rural environment and may explain the differential 
distribution and the focal nature of hematological malignancies in the continent or/and 
individual countries. The potential impact of transition to a modern life style with the 
accompanying risks on the emergence and distribution of these diseases is worth our utmost 
attention. 
Cancers in their complex etiology makes an ideal arena for the classical gene versus 
environment controversy. Those who favor an upper hand for the environment had their 
views strengthened by results of studies showing that people who migrate from one country 
to another generally acquire the cancer rates of the new host country, suggesting that 
environmental or lifestyle factors rather than genetic factors are the key determinants of the 
international variation in cancer rates. As far as Africa is concerned, African Americans´ 
disease data, represent a working model to test the role of changing environment and the 
effect of life style in complex diseases. Interestingly both sides of the argument seem to find 
support. Chronic myeloid leukemia (CML) patients show worse survival for African 
American and Hispanics compared to Americans of European origin (Lee et al., 2009). 
Although the difference in ethnicity data might be argued to reflect socio-economic 
differences, the current advances in genomics enable the implication of particular genomic 
regions and genes that explain the ethnic differences in susceptibility to infectious and 
chronic diseases.  
Environmental determinants also falls short of explaining neither the “focality” of cancer 
types nor the aggressive course of some cancers in Sudan like the breast cancer, a feature 
that has been claimed to exist across Africa and even among African American women 
(reviewed by Morris and Mitchell, 2008). 
Nutritional factors have also been implicated, adding an extra layer of complexity to the 
desperately compound picture of cancer etiology. Data on nutrition is greatly deficient in 
Africa similar to other aspects of genetic epidemiology, although differences in nutritional 
practices and culture may be key in providing vital clues to the contribution of life style. A 
study in China (Zhang et al., 2008), for example, suggested that a higher intake of green tea 
is associated with a reduced risk of adult leukemia. Furthermore, a study by Ross et al. 
which involved 35.221 older women provided evidence that increased vegetable 
consumption may decrease the risk of adult leukemia (Ross et al., 2002). Moreover, AML 
risk was negatively associated with milk intake among women and tea, and positively 
associated among women with beer, wine and beef (Li et al., 2006). A prospective cohort 
study by Ma et al. (2009) showed that smoking and total meat intake were risk factors for 
AML and those who did not drink coffee appeared to have a higher risk of AML.  
Africa is still contains one of the last and few enclaves on the planet to harbor communities 
with distinctive patterns of traditional life styles that once used to characterize human 
existence. Farmers, pastoralists and hunter-gatherers- like societies do preserve their life 
style and culture and often coexist in shared terrains. These communities adopt 
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fundamentally contrasting life styles and their food cultures are different. The significance 
of such disparity to all aspects of health and disease is of interest and the study of potential 
preponderance of these community members to chronic diseases including hematological 
malignancies should be investigated. 
2. Incidence and epidemiology  
The lowest rates of leukemia reported in sub-Saharan Africa probably represent failure of 
diagnosis or reporting to some extent (Davies, 1973; Fleming, 1993 and Parkin et al., 2005). 
We should therefore use caution, when drawing conclusions based on the varying 
prevalence and incidence, as an indication of clustering of cases or an environmental or 
genetic effect, as this may simply be due to the deficiency of statistics in Africa. The 
disparity could also be a reflection of the research milieu and capacity of individual 
countries or research groups, which indeed seem to be the case as most of the current 
reports on leukemia emerges from countries with well established science capacities. 
Even with the scattered and available data, however, the difference from European and 
global trends could be observed as well as the evolution of the problem of leukemia. An 
early report from Uganda found that African children in Uganda showed a great and 
genuine deficiency of leukemia and an excess of solid lympho-reticular tumors (Davies et 
al., 1965). 
In subsequence, the situation seems to change, a study of pediatric leukemia in Cameroon, 
showed that Acute Lymphoblastic Leukemia (ALL) comprised 78.6%, while AML 21.4% of 
all pediatric acute leukemia (Obama et al., 1995). In Egypt, the lymphatic and haemopoietic 
cancer incidence in 2001 have increased approximately 11-fold compared with the incidence 
in 1972. Moreover, the incidence of leukemia among infant less than 5 years increased 
exponentially with a higher incidence among boys (Hosny et al., 2002). In Kenya, leukemia 
in children below the age of 15 years comprised 37% of leukemia in all ages. Childhood 
acute leukemia formed 52.3% of all the acute leukemia. AML and ALL occurred, in almost 
equal proportions 42 % and 46 % respectively (Kasili, 1990). In Ethiopia, a report by 
Shamebo (1990) showed that the commonest type of leukemia was CML 57.8%, acute 
leukemia and chronic lymphatic leukemia (CLL) accounted for 21.1% each. Of the acute 
leukemia, 53.3% were ALL while 46.7% were AML (Shamebo, 1990). A recent study in south 
Nigeria showed that AML comprises 12.3% and CML 23.9% of all leukemia, with a mean 
age at diagnosis of 25.6 years and 35.2 years respectively (Nwannadi et al., 2011). In the last 
25 years in Sudan CML became the predominant cancer in men, while lymphomas 
remained the second most common cancer. In women, breast, cervical and ovarian cancer 
remained the three most common cancers over both time periods, but there was also an 
increase in the incidence of CML among women (Hamad, 2006), the causes of this high 
incidence of CML are not known. 
In Europe AML presents as mainly an adult’s disease with a median age at presentation of 
64 years, accounting for around 30% of all leukemia in adults, and ~18 000 new patients are 
diagnosed in Europe each year, representing ~0.6% of all cancers. The annual incidence rate 
in Europe ranges from two per 100 000/year to four per 100 000/year. In the past decade, 
the trend in overall incidence of AML has generally been stable or slowly increasing in most 
European countries, while most cases of CML occur in adults with a median age at 
presentation around age 60. CML comprises only around 2%–3% of all the leukemia 
diagnosed in patients <20 years of age but the incidence increases with age slowly until the 
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increase in the incidence of CML among women (Hamad, 2006), the causes of this high 
incidence of CML are not known. 
In Europe AML presents as mainly an adult’s disease with a median age at presentation of 
64 years, accounting for around 30% of all leukemia in adults, and ~18 000 new patients are 
diagnosed in Europe each year, representing ~0.6% of all cancers. The annual incidence rate 
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mid-40s, then more rapidly from about one per 1000 000/year in children <10 years to two 
per 100 000 in people in the fifth decade to one per 10 000 at age 80. The disease is more 
common in males. There is no clear evidence of to geographic or ethnic background that 
predisposes to CML; however, in the United States the incidence is slightly higher in 
Caucasians than in Blacks or Hispanics (Lee et al., 2009), and it exhibits a male 
preponderance, in South African Coloured and Black people, and African Americans in 
comparison to whites but the reason for this is unexplained. (Jacobs et al., 1983). 
Furthermore, several reports showed an increased incidence of CML during the first 2 
decades of life in African subjects (Haddock , 1967; Lowe et al., 1971; Lowenthal et al., 1975), 
but other reports by Leibowitz et al., (1976) and Jacobs et al., (1983) disagree with this. 
Jacobs et al. reported that in comparison with Whites and Coloureds, however, the peak 
incidence for Blacks was lower, lying between the 3rd and 4th decades. The peak incidence 
for Coloureds was in the 4th and 5th decades, and that for Whites in the 5th and 6th (Jacobs 
et al., 1983.)  
An interesting study in United Arab Emirate (UAE) found that the rate of AML among UAE 
female nationals was higher than in nationals male and expatriates. The study proposed that 
chemicals in henna dye, which is used to decorate the body, as well as a lack of sunlight 
could be behind the increased incidence (Hassan et al., 2009). Henna is applied in many 
African countries especially Sudan where it is used by vast majority of Sudanese married 
women.  
3. Molecular etiology  
Leukemia in common with other cancers arises from mutations in a single cell, which enable 
the cell to reproduce excessively, emerging as a dominant clone. A large number of different 
mutant genes contribute to leukaemogenesis singly or, more often, in combination and 
many are leukemia sub-type specific (Greaves, 1986). The number of genetic abnormalities is 
believed to reflect the number of genes that control distinct developmental stages of blood 
formation and the multiple routes to clonal dominance. These include changes not only in 
proliferative activity, but in ability to differentiate, in resistance to cell death, in DNA repair 
activity and in general stability of the genes. Whether any particular mutant genes, or hot 
spots' for mutations within a gene, are linked to particular DNA damaging agents is a topic 
of considerable relevance to the molecular epidemiology of cancer in general. For these 
changes to happen some culprit agents has to come into action namely ionizing radiation, 
chemicals such as polycylic hydrocarbons and certain drugs, and viruses. 
The way how these extrinsic factors affect the cell genetically and epigenetically is the core 
of the functional research in cancer. Although multiple risk factors have been linked to the 
development of leukemia, however these known risk factors account for only a small 
number of observed cases. Few epidemiological studies have explored the relation between 
lifestyle, dietary factors and the incidence of adult Leukemia, and almost none has 
addressed the molecular and genetic aspects of these interactions.   
3.1 Role of viruses 
For several reasons pertaining to ecology and the human history in Africa, several 
pathogens have gained access into human genomes through the African gate. This includes 
major parasites, viral and bacterial diseases. It is not coincidence that the first well proven 
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case of viral oncogenesis that of Epstein Barr Virus (EBV) was established in Africa. EBV is a 
highly prevalent infection in the adult population in Africa and has been associated with a 
heterogeneous group of lymphomas, including Burkitt’s lymphoma (especially the endemic 
form in Africa), Hodgkin’s disease, NK, and T malignancies with cytotoxic phenotypes, and 
lymphomas in the immune-compromised patient (congenital immunodeficiency, organ 
transplantation, AIDS). (Rodriguez-Abreu et al., 2007) but not unequivocally with leukemia. 
Of the oncogenic retroviruses, the Human T-cell leukemia virus (HTLV) type-1 and type-2 
have been identified as being related to the development of rare types of leukemia and 
lymphoma. HTLV-1 is endemic in certain areas including central Africa, and is associated 
with the development of adult T-cell leukemia or lymphoma (ATLL), which accounts for 
about half of the lymphoid malignancies in the endemic areas. The virus is transmitted 
mainly from mother to child, especially by breastfeeding. Sexual transmission and blood 
transfusion are minor routes of infection and cell-free blood products are not infectious 
(Rodriguez-Abreu et al., 2007). 
The importance of oncogenic viruses stems not only from their transforming oncogenic 
properties but also from the potential methylating properties of selfish DNA.  
 Environmental determinant including infection with high-risk viruses are necessary but not 
sufficient alone in the development of cancer, as most infections regress without 
intervention. Thus, genetic host factors and cellular immune responses could be potential 
modifiers for the risk of developing cancer. In particular, p53 and Rb are considered as the 
most critical tumor suppressor genes involved in regulating cell division. The 
polymorphism on p53, which encodes either a Proline or an Arginin amino acid residue at 
codon 72, has been reported as a possible risk factor for several cancers including breast and 
cervical cancer in Sudan (Eltahir et al, submitted.).  
3.2 Population and ethnic diversity  
In the last decade the importance of ethnicity, socio-economic and gender differences in 
relation to disease incidence, diagnosis, and prognosis has been realised. Gender and ethnic 
differences in these areas should have a focus in health policy in Africa. A study by Lee et al. 
examined the demographic and clinical features of CML in an ethnically diverse population 
and found that Hispanic patients present with lower risk profile CML and achieve better 
treatment responses compared to non-Hispanic patients. The vast majority of their non-
Hispanic patients were African American or Asian. This study proposed that 
biological/genetic factor can contributes to this observed ethnic differences in disease 
presentation and behavior. Hispanic ethnic group is thought to be the least diverse ethnic 
group, at the opposite site the African descent is the most diverse ethnic group. African 
populations are characterized by greater levels of genetic diversity, extensive population 
substructure, and less linkage disequilibrium (LD) among loci compared to non-African 
populations (Reich et al., 2001; Campbell and Tishkoff, 2008). Due to the long evolutionary 
history in Africa there is more genetic diversity within and between populations in the 
African continent, than between Africans and other peoples in the world (Cavalli-Sforza, 
1997). African populations thus vary considerably in their genes. Moreover Africa shows a 
wide range of environments, climatic, vegetative and zoological. Thus human cancer patters 
are expected to show a similar degree of diversity, the study of which would contribute to 
our understanding of their causes. 
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The majority of cancers as genetic disease of complex nature involve a multiplicity of genetic 
loci that cooperates to make the disease happen (the multiple -hit theory). It is expected that 
such genetic component will be influenced by the genetic background of the population at 
risk. In one of the few studies on a cancer susceptibility genes background mutational 
profile in different populations, Africans were found to harbor more mutations in their 
BRCA2 than populations from the rest of the world (Wagner et al., 1999.) which is expected 
given their larger effective population size. 
Africans also possess a number of genetic adaptations that have evolved in response to 
diverse climates and diets, as well as exposure to infectious disease (Campbell & Tishkoff, 
2008), that diversity may carry great challenge in leukemia presentation and behavior/ 
prognosis and treatment. Moreover, experimental studies using synthetic peptides identical 
to the BCR-ABL fusion region in CML patients region have revealed the capability of 
specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, 
A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individuals 
expressing HLA-A3, B8 or DR4 have a diminished risk for the development of CML in 
Caucasian populations. A statistically significant increase in the frequency of Cw3 and Cw4 
antigens in Caucasians and European CML patients has been reported. Another report in 
Indian population showed that expression of HLA-Cw6 may result in a protective effect on 
CML acquisition (Chhaya, 2006). A study in Chinese population indicated that the 
expression of HLA-A*30, DRB1*07 might imply a protective effect on CML acquisition, 
while B*81 might be associated with CML susceptibility factors in that population (Miao et 
al., 2007). These results suggest that the development of CML is apparently associated with 
HLA phenotypes specific to each population. These data is missed in Africa and we intend 
to investigate this in Sudanese population. 
Common polymorphism like the codon 72 in p53 has been argued to unlikely have major 
genetic effect since polymorphism in loci with major deleterious nature will not be selected 
for to reach such frequencies unless it is a balanced polymorphism. (i.e. selected for under 
the influence of the other allele possessing an favorable adaptive trait). Interestingly It has 
been proposed that the p53 polymorphism at times when the risk of tumors was not a 
Human concern, gave a reproductive leverage by increasing reproductive success (Kang et 
al., 2008). The cost of such trade off will not be visible as long as the conditions that 
predispose for tumors are absent. In fact the derived allele (arginine), almost reached 
fixation in some populations. 
The p53 codon 72 was studied both in normal Sudanese (Bereir et al., 2002) and in the 
distribution of the polymorphism in different cancers in Sudan, (not including leukemia). 
The results show that the different alleles pose different risk ratios in different cancer. The 
Arg allele which is known to be more resistant to cell death was overrepresented breast 
carcinoma patients from different linguistic groups as compared to controls with an Odd 
ratio of 19.44 CI 6.6 – 78.3 P<0.0001. In cervical cancer the homozygous Arg genotype was 
detected in 42.3% (33/78) in cervical cancer patients while the heterozygous arg/pro in 
38.5% (30/78) and only 19.2% (15/78) had the pro/pro genotype, with an allele effect of 2.4 
(CI 1.12 – 5.33, P 0.015). In Burkitt´s lymphoma the opposite seems to be true with a major 
effect from the Pro allele, where the homozygous Arg accounted for only 6.9%, (OR 0.18 CI 
0.02 – 0.89, P= 0.018) while the Arg/Pro was 51.7% and pro/pro 41.4% (OR: 0.57, CI 0.23- 
1.42, P= 0.1). Possibly indicating the different biological pathways of tumorigenesis (Eltahir 
et al., submitted).  
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3.3 Gene and chromosomal rearrangements  
Cancers as a group of diseases display the entire range of inheritance modes from the single 
gene like disorder to the complex inheritance pattern seen in chronic diseases. The paucity 
of genetic investigation in Africa of cancer susceptibility genes and chromosomal 
aberrations linked to cancer, makes the picture even more opaque. The few examples 
discussed above and below demonstrate the great relevance of studying the genetic 
population structure of African populations and establishing the frequencies of the 
individual SNPs, Ins/dels and chromosomal abnormalities associated with diseases that 
may be necessary to define the molecular etiological basis of each cancer. In fact both 
molecular and genetic abnormalities became an important factor for characterising, treating 
and risk stratifying of myeloid leukemia. In 2002 the WHO classification of Myeloid 
Neoplasms showed that AML classification includes specific genetic subcategories; thus, 
determination of genetic features of the neoplastic cells must be performed if possible. Many 
recurring genetic abnormalities in the myeloid neoplasms can be identified by advanced 
molecular and cytogenetic techniques. In the WHO classification, the blast threshold for the 
diagnosis of AML is reduced from 30% to 20% blasts in the blood or marrow. In addition, 
patients with the clonal, recurring cytogenetic abnormalities t(8;21)(q22;q22), 
inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12) should be considered to have 
AML regardless of the blast percentage. On the other hand, according to the WHO 
classification, CML is defined specifically as a myeloproliferative disease that is 
characterized by the invariable presence of the Philadelphia (Ph) chromosome or the BCR-
ABL fusion gene. Although in most cases the diagnosis is easily made from morphologic 
evaluation of the blood smear, confirmation by genetic studies is essential, particularly in 
view of the advent of therapy that targets the BCR-ABL fusion protein (Vardiman et al., 
2002) 
Despite their diagnostic and prognostic values, studies on gene and chromosomal 
rearrangements associated malignancies is greatly lacking on the African continent, and in 
spite of the mandatory genotyping of the BCR-ABL as a prerequisite of administering the 
drug imatinib, in several African countries, there are very few reports on its frequencies. 
Among the few reports on its association with other leukemias, a multi-country study 
comprising 181 children with newly diagnosed ALL were tested in laboratories in India, 
Pakistan, Myanmar, and Sudan, following a common protocol. Across the four countries, 
the ETV6-RUNX1 (TEL-AML1) fusion gene was present in only 5% of cases. All the positive 
samples were from children aged 1 to 10 years, in whom the prevalence of this fusion gene, 
which is associated with good prognosis, was 7.4% (9 out of 121 samples), a much lower rate 
than reported from Western populations. In the 18 ALL cases tested in Sudan, a notable 
excess of MLL-AF4 (17%) and BCR-ABL1 (22%) fusion genes was found (Siddiqui et al., 
2010).  
The significance of studying the frequency of these rearrangements and their relation to 
pathology, is to establish the level of culpability of the molecular events. A study on 
Nigerian breast cancer patients suggest that while BRCA1 genomic rearrangement exists, it 
does not contribute significantly to BRCA1-associated risk in the Nigerian population 
(Zhang et al., 2011). 
Chromosomal translocations in myeloid leukemia yield hybrid RNAs capable of encoding 
fusion chimeric proteins. The unique amino acid sequences found in these oncogenic fusion 
proteins represent true tumor-specific antigens that are potentially immunogenic. Although 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
470 
The majority of cancers as genetic disease of complex nature involve a multiplicity of genetic 
loci that cooperates to make the disease happen (the multiple -hit theory). It is expected that 
such genetic component will be influenced by the genetic background of the population at 
risk. In one of the few studies on a cancer susceptibility genes background mutational 
profile in different populations, Africans were found to harbor more mutations in their 
BRCA2 than populations from the rest of the world (Wagner et al., 1999.) which is expected 
given their larger effective population size. 
Africans also possess a number of genetic adaptations that have evolved in response to 
diverse climates and diets, as well as exposure to infectious disease (Campbell & Tishkoff, 
2008), that diversity may carry great challenge in leukemia presentation and behavior/ 
prognosis and treatment. Moreover, experimental studies using synthetic peptides identical 
to the BCR-ABL fusion region in CML patients region have revealed the capability of 
specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, 
A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individuals 
expressing HLA-A3, B8 or DR4 have a diminished risk for the development of CML in 
Caucasian populations. A statistically significant increase in the frequency of Cw3 and Cw4 
antigens in Caucasians and European CML patients has been reported. Another report in 
Indian population showed that expression of HLA-Cw6 may result in a protective effect on 
CML acquisition (Chhaya, 2006). A study in Chinese population indicated that the 
expression of HLA-A*30, DRB1*07 might imply a protective effect on CML acquisition, 
while B*81 might be associated with CML susceptibility factors in that population (Miao et 
al., 2007). These results suggest that the development of CML is apparently associated with 
HLA phenotypes specific to each population. These data is missed in Africa and we intend 
to investigate this in Sudanese population. 
Common polymorphism like the codon 72 in p53 has been argued to unlikely have major 
genetic effect since polymorphism in loci with major deleterious nature will not be selected 
for to reach such frequencies unless it is a balanced polymorphism. (i.e. selected for under 
the influence of the other allele possessing an favorable adaptive trait). Interestingly It has 
been proposed that the p53 polymorphism at times when the risk of tumors was not a 
Human concern, gave a reproductive leverage by increasing reproductive success (Kang et 
al., 2008). The cost of such trade off will not be visible as long as the conditions that 
predispose for tumors are absent. In fact the derived allele (arginine), almost reached 
fixation in some populations. 
The p53 codon 72 was studied both in normal Sudanese (Bereir et al., 2002) and in the 
distribution of the polymorphism in different cancers in Sudan, (not including leukemia). 
The results show that the different alleles pose different risk ratios in different cancer. The 
Arg allele which is known to be more resistant to cell death was overrepresented breast 
carcinoma patients from different linguistic groups as compared to controls with an Odd 
ratio of 19.44 CI 6.6 – 78.3 P<0.0001. In cervical cancer the homozygous Arg genotype was 
detected in 42.3% (33/78) in cervical cancer patients while the heterozygous arg/pro in 
38.5% (30/78) and only 19.2% (15/78) had the pro/pro genotype, with an allele effect of 2.4 
(CI 1.12 – 5.33, P 0.015). In Burkitt´s lymphoma the opposite seems to be true with a major 
effect from the Pro allele, where the homozygous Arg accounted for only 6.9%, (OR 0.18 CI 
0.02 – 0.89, P= 0.018) while the Arg/Pro was 51.7% and pro/pro 41.4% (OR: 0.57, CI 0.23- 
1.42, P= 0.1). Possibly indicating the different biological pathways of tumorigenesis (Eltahir 
et al., submitted).  
 
Myeloid Leukemia: A Molecular Focus on Etiology and Risk Within Africa 
 
471 
3.3 Gene and chromosomal rearrangements  
Cancers as a group of diseases display the entire range of inheritance modes from the single 
gene like disorder to the complex inheritance pattern seen in chronic diseases. The paucity 
of genetic investigation in Africa of cancer susceptibility genes and chromosomal 
aberrations linked to cancer, makes the picture even more opaque. The few examples 
discussed above and below demonstrate the great relevance of studying the genetic 
population structure of African populations and establishing the frequencies of the 
individual SNPs, Ins/dels and chromosomal abnormalities associated with diseases that 
may be necessary to define the molecular etiological basis of each cancer. In fact both 
molecular and genetic abnormalities became an important factor for characterising, treating 
and risk stratifying of myeloid leukemia. In 2002 the WHO classification of Myeloid 
Neoplasms showed that AML classification includes specific genetic subcategories; thus, 
determination of genetic features of the neoplastic cells must be performed if possible. Many 
recurring genetic abnormalities in the myeloid neoplasms can be identified by advanced 
molecular and cytogenetic techniques. In the WHO classification, the blast threshold for the 
diagnosis of AML is reduced from 30% to 20% blasts in the blood or marrow. In addition, 
patients with the clonal, recurring cytogenetic abnormalities t(8;21)(q22;q22), 
inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12) should be considered to have 
AML regardless of the blast percentage. On the other hand, according to the WHO 
classification, CML is defined specifically as a myeloproliferative disease that is 
characterized by the invariable presence of the Philadelphia (Ph) chromosome or the BCR-
ABL fusion gene. Although in most cases the diagnosis is easily made from morphologic 
evaluation of the blood smear, confirmation by genetic studies is essential, particularly in 
view of the advent of therapy that targets the BCR-ABL fusion protein (Vardiman et al., 
2002) 
Despite their diagnostic and prognostic values, studies on gene and chromosomal 
rearrangements associated malignancies is greatly lacking on the African continent, and in 
spite of the mandatory genotyping of the BCR-ABL as a prerequisite of administering the 
drug imatinib, in several African countries, there are very few reports on its frequencies. 
Among the few reports on its association with other leukemias, a multi-country study 
comprising 181 children with newly diagnosed ALL were tested in laboratories in India, 
Pakistan, Myanmar, and Sudan, following a common protocol. Across the four countries, 
the ETV6-RUNX1 (TEL-AML1) fusion gene was present in only 5% of cases. All the positive 
samples were from children aged 1 to 10 years, in whom the prevalence of this fusion gene, 
which is associated with good prognosis, was 7.4% (9 out of 121 samples), a much lower rate 
than reported from Western populations. In the 18 ALL cases tested in Sudan, a notable 
excess of MLL-AF4 (17%) and BCR-ABL1 (22%) fusion genes was found (Siddiqui et al., 
2010).  
The significance of studying the frequency of these rearrangements and their relation to 
pathology, is to establish the level of culpability of the molecular events. A study on 
Nigerian breast cancer patients suggest that while BRCA1 genomic rearrangement exists, it 
does not contribute significantly to BRCA1-associated risk in the Nigerian population 
(Zhang et al., 2011). 
Chromosomal translocations in myeloid leukemia yield hybrid RNAs capable of encoding 
fusion chimeric proteins. The unique amino acid sequences found in these oncogenic fusion 
proteins represent true tumor-specific antigens that are potentially immunogenic. Although 
 
Myeloid Leukemia – Basic Mechanisms of Leukemogenesis 
 
472 
these leukemia-specific fusion proteins have an intracellular location, they might be 
recognized immunologically by T lymphocytes if peptides derived from the unique 
sequences are capable of presentation by the major histocompatibility complex (MHC) 
molecules on Leukemic cells (Bocchia et al., 1995). The ability of a series of synthetic peptides 
corresponding to the junctional sequences of CML-derived BCR-ABL fusion proteins 
spanning the b3a2 and b2a2 breakpoints to bind to purified class I molecules was studied by 
Bocchia et al. Four peptides derived from b3a2 CML breakpoint bound with high or 
intermediate affinity to HLA A3, A11, and B8. None of the CML b2a2 junctional peptides 
showed affinity of this magnitude for the HLA class I molecules tested. Which draw another 
important conclusion on the significance of the types of BCR-ABL fusion transcripts among 
populations in relation to vaccine development? The frequencies of the types of the fusion 
transcript in Ecuadorian population for example consist of 95% b2a2 (Paz-y-Mino et al., 
2002) indicating that they may not benefit much from such vaccine.  
 Several studies estimated the types of BCR-ABL fusion transcript in CML in different 
populations. The distribution of transcript type has been studied in European and some 
other populations (Eisenberg et al., 1988; Lee et al., 1989) with frequencies for b2a2 and b3a2 
transcripts being roughly of the order of 40% and 55%, and that for co-expression of b3a2 
and b2a2 representing 5% of the cases. A study on an Ecuadorian population, however, 
registered very different frequencies: 5% for b3a2 and 95% for b2a2 (Paz-y-Mino et al., 2002). 
In our report in Sudanese patients ( Osman et al., 2010 ), a frequency of 53.5% and 41.9% for 
b2a2 and b3a2, respectively, was reported, values that are relatively closer to those from a 
Mexican population (Arana- Trejo et al., 2002). This difference in frequencies may be due to 
the genetic differences of the populations. Many Controversial reports about the clinical 
significant of the transcript type in CML were published; however it has a considerable 
importance in the diagnosis and follow up.  
Recently, a polymorphic base in exon 13 of the BCR gene (exon b2 of the major breakpoint 
cluster region) has been identified in the eighth position before the junctional region of BCR-
ABL cDNA. Cytosine replaces thymidine; the corresponding triplets are AAT (T allele) and 
AAC (C allele), respectively, both coding for asparagine. Therefore, this polymorphism has 
no implication in the primary structure of BCR and BCR-ABL proteins. 
Co-expression of b2a2 and b3a2 transcripts has been linked to two polymorphisms, T to C at 
exon 13 and A to G at intron 13 (Meissner et al., 1998; Branford et al., 2002). However, in our 
study by Osman et al. (2010) six PCR products from four patients were sequenced to 
confirm the products of four b2a2 and two b3a2 and one was found to harbor T to C at exon 
13 and expressed only b2a2 transcript which might indicate that this exonic polymorphism 
is not obligatory for co-expression, as reported by Mondal et al. (2006). Moreover, this 
polymorphism has no implication on the primary structure of BCR and BCR-ABL proteins. 
However, since the alteration is located close to the fusion region, it may have a significant 
influence on the annealing of PCR primers, probes for real time PCR, and antisense 
oligonucleotides. This polymorphism could be also a useful marker for the differentiation of 
normal and rearranged BCR alleles in heterozygotes patients and during follow up of 
minimal residual disease. The allele frequency for this SNP varied markedly between 
different world populations, with European attaining intermediate values between African 
and Asians (Table 1)   
The molecular basis of CML is well defined and highly consistent, yet prognosis varies 
considerably. This could reflect the biological diversity occurring in normal populations. 
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Population T allele C allele 
African American 0.55 0.45 
Sub-Saharan African 0.425 0.575 
Asians 0.922 0.078 
Chinese 0.91 0.09 
Japanese 0.98 0.02 
European 0.70 0.30 
Data from NCBI/dbSNP/Short Genetic Variations  
Table 1. The frequencies of T and C alleles of BCR exon 13 SNP in different populations 
andethnic groups  
The study by Gordon et al 2003 suggest that variation among normal individuals may 
contribute to inter patient heterogeneity in CML. Differences in behaviour of haemopoietic 
progenitor cells from different normal individuals may be attributable to genetic diversity or 
other variables. de Haan et al. (2002) concluded that the expression levels of a large number 
of genes might be responsible for controlling stem cell behaviour. These collections of genes 
may be analogous to those responsible for the inter-individual diversity in progenitor cell 
behavior 
In CML, the occurrence of additional specific cytogenetic and molecular changes subsequent 
to the initiation of t(9;22) translocation herald disease progression prior to haematologic and 
clinical manifestation. These events occur in 50 to 80 percent of patients during the 
transition from the chronic phase of the disease to the accelerated and blast phases. Minor 
cytogenetic changes include monosomies of chromosomes 7, 17, and Y; trisomies of 
chromosomes 17 and 21; and translocation t(3;21)(q26;q22) (Mitelman, 1993). Major changes 
include trisomy 8, isochromosome i(17q), trisomy 19, and an extra Ph chromosome (double 
Ph). Trisomy 8 is most common, and isochromosome i(17q) occurs almost exclusively in the 
myeloid type blast phase (Kantarjian et al., 1987; Derderian et al., 1993; Mitelman, 1993). 
Molecular abnormalities may correspond to cytogenetic changes. These include 
abnormalities in p53 (on chromosome 17p13); RB1 (13q14); c-MYC (8q24); p16INK4A (9p21); 
RAS; and AML–EVI-1, a fusion protein resulting from translocation t(3;21) (q26;q22). 
Alterations of p53 (deletions, rearrangements, and mutations) occur in 20 to 30 percent of 
patients with CML in the blast phase (Ahuja et al.,1989) and are associated exclusively with 
myeloid transformation (Stuppia et al., 1997), whereas abnormalities of RB1 are associated 
more with lymphoid transformation, although the association is weaker than it was between 
p53 and myeloid transformation. Mutations of p53 in the progression of CML are associated 
with an aberrant methylation status of CML cells (Guinn et al., 1997). The introduction of a 
methyl group causing transcriptional silencing of the calcitonin gene has been found in the 
transition of chronic-phase CML to blast-phase CML (Malinen et al., 1991). Altered 
methylation was also described within the M-bcr of cells from patients with chronic-phase 
CML (Litz et al., 1996). Up to 50 percent of patients with lymphoid transformation have 
homozygous deletion of p16INK4A (Sill et al., 1995). Alterations of RB1, amplifications of c-
MYC, and mutations of RAS are less frequent (Faderl et al., 1999). 
The genetic variation in Africa is poised to constitute major challenge for diagnosis and 
management. In a world where the diagnosis and prognosis of diseases and particularly 
cancer is increasingly dependent on molecular approaches such diversity might constitute a 
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hurdle for future intervention against cancer in general. The anticancer drug imatinib has 
shown remarkable success in treatment of CML. Though a variety of resistance mechanisms 
can arise, in the majority of patients resistance coincides with reactivation of the tyrosine 
kinase activity of the BCR-ABL fusion oncoprotein. This can result from gene amplification 
and, more importantly, point mutations that disrupt the bind of imatinib to BCR-ABL itself 
(Nardi et al., 2004). Although there are no indication of resistance so far in Sudan (Alkhatib, 
2011), perhaps due to the limited use of the drug, the risk of resistance is proportional to the 
number of mutations that exist within the kinase domain and even outside the domain 
which are expected to be higher in Africa given the increased genetic diversity of African 
populations. The risk of resistance increases with the identification of Novel potential 
signaling pathways associated with drug resistance (Duy et al., 2011). 
The significance of population genetic background extends to diagnostic and prognostic 
markers that may be applied to populations and to individuals. This is expected to form a 
trend in the management of diseases of complex inheritance as we learn more of the 
biological networks in function during diseases and the role of each individual molecule. In 
a study by Elamin et al., (submitted), aimed at developing biomarkers for breast cancer, 
Peroxyredoxin V turned to be a potentially useful marker both as a prognostic and 
treatment marker in Sudanese breast cancer but not among Chinese.  
3.4 Drug metabolizing enzymes  
The drug metabolizing enzymes system has been shown to influence the susceptibility, 
sequel and outcome of cancer treatment. These systems include the Glutathione transferases 
a family member of genes encoding enzymes involved in the metabolism of many chemicals 
and shown to be polymorphic with GSTM1 and GSTT1 being deleted in proportion of 
individuals where in the homozygous state results in a phenotypic absence of the 
corresponding enzyme. These enzymes are considerably important in the detoxification of 
many environmental compounds and reactive oxygen species, and hence may constitute 
important cancer predisposition genes.  
It includes also the cytochrome P450 enzymes one of the best studied for risk association 
with cancer (Aqundez, 2004). The P450 shows conflicting and variable degree of association 
with cancer, possibly reflecting, variation in the role played by these enzymes in 
carcinogenesis and the genetic background of the population.  
 In some populations like those of the Indian subcontinent, the frequencies of homozygous 
3/3 genotype and CYP3A5*3 allele were elevated significantly in the CML group compared 
to controls (χ²=93.15, df=2, p=0.0001) (Sailaja et al., 2010).  
In India also, a statistically significant difference between an AML group and normal control 
was observed in the case of glutathione-S-transferase M1 null (odds ratio 3.25, 95% 
confidence interval 1.9-5.58, P<0.001) and N-acetyl transferase 2*6B (odds ratio 3.04, 95% 
confidence interval 1.79-5.16, P<0.001) genotypes. Combined deficiency of N-acetyl 
transferase 2 and glutathione-S-transferase M1 genes produced an odds ratio of 11.91 (95% 
confidence interval 4.06-34.96, P<0.001). Those with glutathione-S-transferase M1 null 
genotype and N-acetyl transferase 2*6B allele are at increased risk of developing AML, and 
the risk is considerably enhanced in persons with both glutathione-S-transferase M1 and N-
acetyl transferase 2 deficiency (Majumdar et al., 2008). 
Increased risk of AML has also been reported for combined polymorphisms in 
detoxification and DNA repair enzymes (Voso et al., 2007), and patients that achieved 
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complete molecular response following administration of imatinib showed significantly 
(p=0.013) higher in vivo CYP3A activity than patients achieving partial molecular response 
(Green et al., 2010). 
In Sudan impact of the distribution of the GSTM1 and GSTT1 genotype leukemic patients 
was studied in 77 leukemic patients and 107 controls by Tagelsir et al., (Submitted). The 
results suggest that these genotypes could play a role in the development of leukemia 
particularly AML. Statistical analysis showed a significant preponderance of null genotype 
of both genes among pooled cases [GSTM1 OR 3.45 (95% CI, 1.65 - 7.19); P = 0.001] for; 
GSTT1 OR 8.57 (95% CI, 3.68 -19.93); P < 0.0001]. Double null was also higher in patients 
compared to controls (P = 0.01). When the cases were stratified according to the disease 
type, AML showed the highest positive predictive value for both loci (GSTM1 P < 0.0001, 
GSTT1 P < 0.0001), ALL and CLL showed similar patterns for GSTT1 (P = 0.001) while the P-
values for GSTM1 were (0.01) and (0.007) respectively. CML displayed the least positive 
predictive value for GSTM1 (0.02), while for GSTT1 the result was as same as AML (P < 
0.0001). Double null, however, showed only association with AML (P < 0.0001). 
When the distribution of the GSTM1 and GSTT1 null genotypes were compared between 
linguistic groups of the control subjects, different percentages were obtained and GSTT1 
null genotypes was statistically different between the Afro-Asiatic and the Nilo-Saharan 
groups (P = 0.01). Difference in frequencies between Africans population is reported; 
Egyptians 15-29% (Abdel-Rahman, 1996; Hamdy et al., 2003), Tunisians 29% (Hanene et al., 
2007) and Zimbabweans 26% (Masimirembwa, et al., 1998). generally speaking the GSTM1 
frequency (10.3%) is close to sub-Saharan Africa range; Nigerians 22% (Zhao et al., 1994) and 
Zimbabweans 24% (Masimirembwa, et al., 1998). while the previously reported frequency 
from Sudan is 39% (Tiemersma et al., 2001) . Other African populations frequencies are; 
Egyptians 44-55% [Abdel-Rahman, 1996 Hamdy et al., 2003), Tunisians 50% (Hanene et al., 
2007).  
The Tagelsir study suggests an increased risk for leukemia associated with GSTM1 and 
GSTT1 null genotypes and highlights a potential role of genetic make up in leukaemogensis. 
The most statistically significant association for GSTT1 observed for both AML and CML 
may highlight a possible role of GSTT1 enzyme in protection of the myeloid series. Allelic 
variation in the gene encoding the GST isoform theta (GSTT1) enzymes was found to 
modulate the rate of benzene metabolism and excretion (Rossi et al., 1999) as well as 
benzene-induced myelotoxicity (Wan et al., 2002; Chen et al., 2007). AML – which showed 
the strongest association with both genes– comprises a distinct type of leukemia with 
different subtypes and is shown to be to somewhat associated with environmental exposure. 
Epidemiological studies have shown association between AML (M2, M4, and M5) and 
maternal exposure to marijuana and alcohol, and maternal and paternal exposures to 
pesticides, (Buckley et al., 1989; Robison et al., 1989; Severson et al., 1993; Shu et al., 1996). In 
addition to that AML is shown to be associated with exposure to benzene and may arise as 
therapy related complication after treatment of other cancers (Hoffbrand & Pettit, 2001).  
Paradoxically, the presence of these genes could not be excluded as a possible risk factor for 
leukemia as some times these enzymes are involved in bioactivation of some chemicals 
producing more reactive metabolites that could confer threat to the cell. An example of such 
risk in other cancer was found in a study on Chinese population which showed that the 
genotype combination of GSTM1 and GSTT1 double positive confers a 4.2-fold higher risk 
for developing esophageal cancer and a 2.6-fold for esophageal hyperplasia (Lin et al., 1998). 
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Fig. 1. The ladder and lever mechanism towards carcinogenesis. As the cancer cell 
struggles through multiple accumulative genetic events leading to cancer (the ladder), the 
cell will gain the upper hand in its surrounding tissue environment and eventually 
metastasize, it encounters various modifications and modulating effects that vary between 
individuals and communities. The variety of effects and the modifier action is expected to 
be greater in Africa. The up scaling of the ladder requires a lifting effect from the 
Environment (lever).  
 




DNA promoter methylation and histone modification are increasingly recognized as of 
primary importance in carcinogenesis. The two forms of aberrant methylation, 
hypomethylation and hypermethylation, are both well documented features of tumor cells 
(Hanahan and Weinberg, 2000; Jones and Baylin, 2002). The transcriptional silencing of 
tumor suppressor genes via promoter CpG island hypermethylation constitutes a key 
tumorigenic process contributing to all the typical hallmarks of a cancer cell that can result 
from tumor suppressor inactivation. Profiles of tumor suppressor methylation vary 
according to tumor type (Esteller et al., 2001) and each tumor apparently displays a distinct 
‘DNA hypermethylation pattern. 
Recent studies revealed that specific patterns of DNA methylation characterize AML and 
help to distinguish AML subtypes. The contribution of this epigenetic dysregulation to 
leukemogenesis in AML is currently unclear. However, interactions between mutated 
transcription factors and epigenetic networks have already been shown to be partially 
responsible for leukemic transformation, for e.g. in acute promyelocytic leukemia (APL). 
Also, direct mutations in the epigenetic master regulators EZH2 and DNMT3A were 
recently identified in AML and in diseases leading to secondary leukemia ( Schoofs and 
Muller-Tidow, 2011).  
New studies reveal that 20% of individuals with AML harbor somatic mutations in 
DNMT3A (encoding DNA methyltransferase 3A). Although these leukemia have some gene 
expression and DNA methylation changes, a direct link between mutant DNMT3A, 
epigenetic changes and pathogenesis remains to be established. 
The disruption of key protective genes through methylation is not confined to tumor 
suppression, it extends to other vital genes in protection /susceptibility to cancer like drug 
metabolizing enzymes, as been reported for the glutathione-S-transferase P1 gene silencing 
(Karius et al., 2011)   
4. Future directions  
The burden of myeloid leukemia is expected to rise as part of a global trend of increase in 
cancer incidence. In Africa the cost of this rise given the compound problems of health 
systems will be devastating. One pressing need is to challenge the preconception of cancer 
being a disease of the developed societies and show how this image is changing under the 
rapid sweep of “globalization. Even now the limited data available on leukemia indicate 
that the incidence of CML in some African countries may exceed those of the industrialized 
world. The understanding of cancer complex etiology is a prerequisite for successful 
management and control efforts.  
Myeloid leukemia including the chronic subset that behave like a single gene disorder with 
the predominance of the Ph chromosome, posses complex etiology that includes multiple 
steps from environmental switches to inactivation of tumor suppression and other 
guardians of genome integrity and stability and ending with the impact of immune 
competence. Such complexity renders the handling of each of these potential culprits a 
daunting task especially in Africa. Without research into the etiology and genetic 
epidemiology of myeloid leukemia with all possible risk factors considered, including the 
genetic structure of population at risk, individual genetic effects, role of chronic and 
concomitant infections, and the possible trade off between infections and malignancies. For 
 
















Fig. 1. The ladder and lever mechanism towards carcinogenesis. As the cancer cell 
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tumor suppressor genes via promoter CpG island hypermethylation constitutes a key 
tumorigenic process contributing to all the typical hallmarks of a cancer cell that can result 
from tumor suppressor inactivation. Profiles of tumor suppressor methylation vary 
according to tumor type (Esteller et al., 2001) and each tumor apparently displays a distinct 
‘DNA hypermethylation pattern. 
Recent studies revealed that specific patterns of DNA methylation characterize AML and 
help to distinguish AML subtypes. The contribution of this epigenetic dysregulation to 
leukemogenesis in AML is currently unclear. However, interactions between mutated 
transcription factors and epigenetic networks have already been shown to be partially 
responsible for leukemic transformation, for e.g. in acute promyelocytic leukemia (APL). 
Also, direct mutations in the epigenetic master regulators EZH2 and DNMT3A were 
recently identified in AML and in diseases leading to secondary leukemia ( Schoofs and 
Muller-Tidow, 2011).  
New studies reveal that 20% of individuals with AML harbor somatic mutations in 
DNMT3A (encoding DNA methyltransferase 3A). Although these leukemia have some gene 
expression and DNA methylation changes, a direct link between mutant DNMT3A, 
epigenetic changes and pathogenesis remains to be established. 
The disruption of key protective genes through methylation is not confined to tumor 
suppression, it extends to other vital genes in protection /susceptibility to cancer like drug 
metabolizing enzymes, as been reported for the glutathione-S-transferase P1 gene silencing 
(Karius et al., 2011)   
4. Future directions  
The burden of myeloid leukemia is expected to rise as part of a global trend of increase in 
cancer incidence. In Africa the cost of this rise given the compound problems of health 
systems will be devastating. One pressing need is to challenge the preconception of cancer 
being a disease of the developed societies and show how this image is changing under the 
rapid sweep of “globalization. Even now the limited data available on leukemia indicate 
that the incidence of CML in some African countries may exceed those of the industrialized 
world. The understanding of cancer complex etiology is a prerequisite for successful 
management and control efforts.  
Myeloid leukemia including the chronic subset that behave like a single gene disorder with 
the predominance of the Ph chromosome, posses complex etiology that includes multiple 
steps from environmental switches to inactivation of tumor suppression and other 
guardians of genome integrity and stability and ending with the impact of immune 
competence. Such complexity renders the handling of each of these potential culprits a 
daunting task especially in Africa. Without research into the etiology and genetic 
epidemiology of myeloid leukemia with all possible risk factors considered, including the 
genetic structure of population at risk, individual genetic effects, role of chronic and 
concomitant infections, and the possible trade off between infections and malignancies. For 
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diagnosis and management an integrated genomic approach is the way forward. The vision 
for this approach entails an integrated and automated approach to these analyses, bringing 
the possibility of formulating an individualized treatment plan within days of a patient's 
initial presentation. With these expectations comes the hope that such an approach will lead 
to decreased toxicities and prolonged survival for patients (Godley et al., 2011). Such 
integrated approaches are expected to meet challenges pertinent to the peculiarity of African 
genetics.  
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